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3Abstract
Combinations of common germline low-moderate susceptibility alleles may be
responsible for some of the 90% of ovarian cancer (OC) cases not explained by
known risk genes. These alleles may also affect survival of OC patients.
The effects of 34 tagging single nucleotide polymorphisms (tSNPs) from candidate
oncogenes (BRAF, ERBB2, KRAS, NMI and PIK3CA) and 63 tSNPs from
“functionally” relevant genes (AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8,
RGC32, RUVBL1 and STAG3) on the risk and survival of OC sufferers were evaluated
with ~1,800 cases and 3,045 controls. Associations were found between disease risk
and NMI rs11683487 (P-dominant=0.004) and RUVBL1 rs13063604 (P-trend=0.0192).
These associations were not independently validated with additional samples,
however, they remained significant when the results from both stages of genotyping
were combined (P<0.05). Global tests of association with OC risk were significant
for BRAF, ERBB2, CASP5 and RUVBL1 (P-global<0.05). However, there was no
evidence of an excess of significant associations from 340 SNPs investigated with
the admixture maximum likelihood test (P-trend=0.068).
BRAF, FILIP1L, KRAS, RBBP8 and RUVBL1 were also associated with the survival
of all OC cases (P<0.05). When analysis was restricted to the 4 main histological
subtypes of OC, additional associations were identified. Although these results are
of particular interest, they were based on relatively small numbers of samples and
have not been corrected for multiple testing, therefore they should be treated with
4caution. The results from the secondary objective of the project, to evaluate whole
genome amplification (WGA) of DNA and SNP multiplex platforms, are also
described.
To conclude, associations were identified between candidate oncogenes and
functionally relevant genes on the survival and susceptibility of ovarian cancer. The
performance of WGA DNA on SNP multiplex genotyping platforms highlighted the
importance of comparing WGA DNA with corresponding gDNA in order to
ascertain quality of genotyping on the platform.
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Chapter 1: Introduction
1.1: Background
Ovarian cancer is the sixth most common cancer in women worldwide, but the
initiation, progression and metastasis of the disease is still poorly understood (Parkin
et al. 2005). The global incidence of ovarian cancer is approximately 205,000 per
year and the death rate is 125,000 a year. Ovarian cancer is more common in
Northern Europe, North America and other developed areas of the world (Parkin et
al. 2005, Sankaranarayanan and Ferlay 2006). Africa and Asia have the lowest
incidence of the disease (Parkin et al. 2005). The cumulative lifetime risk of ovarian
cancer in the general population is 1% by the age of 70 years, but the risk is higher in
individuals with a family history of breast or ovarian cancer (Sharma et al. 2001).
Individuals with an affected first degree relative have a 3.1% chance of developing
ovarian cancer (Stratton et al. 1998). Aside from age, family history is the strongest
known risk factor for ovarian cancer (Ramus et al. 2007).
1.2: Symptoms and diagnosis of ovarian cancer
Although there are some symptoms associated with ovarian cancer, these symptoms
are usually vague and non-distinct from other conditions such as irritable bowel
syndrome. This can lead to a delay in diagnosing and treating ovarian cancer.
Symptoms of ovarian cancer include a conspicuous abdominal mass, vaginal
bleeding unrelated with menstruation, distended and hard abdomen, and abdominal
pain (Lurie et al. 2009).
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Recently, the “risk of malignancy index” (RMI) has been developed in order to pre-
clinically assess an individual’s risk of cancer, before they are referred to a
gynaecological oncology clinician, if necessary. In ovarian cancer, the combined
results of blood CA-125 levels (the molecular biomarker of ovarian and other
cancers), menopausal status and transvaginal ultrasound results are used to estimate a
woman’s risk of disease before referral to a gynaecological oncologist
(http://info.cancerresearchuk.org/cancerstats/types/ovary/symptoms/?a=5441).
Definitive diagnosis of ovarian cancer is through histological examination of a
suspected tumour.
1.3: Histological pathology of ovarian cancer
Ovarian cancer can occur in the ovarian surface epithelium, germ cells or stroma.
Approximately 90% of ovarian cancer cases are of epithelial origin and of these 90%
are malignant carcinomas (Auersperg et al. 2001, Weiss et al. 1977). There are three
categories of epithelial ovarian cancer: benign cystadenomas, borderline epithelial
ovarian cancer and invasive carcinomas (Scully 1999). Epithelial neoplasms are
believed to arise from the ovarian surface epithelium, benign epithelial inclusion
cysts and cyst-adenomas (Cheng et al. 2004), or in rare cases, from ovarian
endometrial foci. There is also a theory proposing that some cases of ovarian cancer
initiate from the fallopian tube (Dubeau 2008).
1.3.1: Histological subtypes
There are several histological subtypes of invasive epithelial ovarian cancer. The
histological classification of ovarian cancer is reviewed in Kaku et al. (2003) and
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Christie and Oehler (2006). These include serous adenocarcinoma, mucinous
adenocarcinoma, endometrioid adenocarcinoma and clear cell carcinoma
(McCluggage 2008). The serous histological subtype of ovarian cancer is the most
common subtype, occurring in approximately 50% of malignant cases (Koonings et
al. 1989; Seidman et al. 2004). Kooning et al found that there were differences in
the age distributions of histological subtypes. There is conflicting data on whether
the mucinous or the endometrioid is the second most common histological subtype.
Seidman et al found that the frequencies of endometrioid, mucinous and clear cell
ovarian cancer were 6.8%, 6% and 10%, respectively, from a sample of 220 cases
(Seidman et al. 2004). However, Kooning et al established from 180 patients that
the frequencies of endometrioid, mucinous and clear cell histological subtypes were
11%, 9% and 4%, respectively. Each histological subtype has a different underlying
pathogenesis and “natural behaviour” in terms of disease progression. However, it
has been shown that there is an element of subjectivity in the pathological typing of
some samples (McCluggage 2008).
The differences in the underlying pathogenesis and behaviour of the tumours have
led to the suggestion that the histological subtypes of ovarian cancer are different
diseases, rather than different forms of the same disease. This suggestion is
supported by the distinct molecular changes found in the different histological
subtypes of ovarian cancer. KRAS mutations are predominantly found in mucinous
tumours. However, alterations of PTEN and CTNNB1 are found in low grade
endometrioid carcinomas; and BRCA1, BRCA2, TGFBR2 and HNF1B are associated
with the clear cell subtype. The serous subtype can be separated into low and high
grade carcinomas, which correlate with different molecular changes. Whilst
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mutations in TP53, BRCA1 and BRCA2 are associated with high grade serous
carcinomas, mutations in BRAF and KRAS are found in low grade serous tumours
(Christie and Oehler 2006).
1.3.2: Stages of ovarian cancer
Staging of ovarian tumours is the definitive method of confirming ovarian cancer
diagnosis. Staging ovarian cancer involves a pathological examination of the size of
the tumour and whether the tumour has spread. The Fédération Internationale de
Gynécologie et d'Obstétrique (FIGO) staging system is commonly used for this
purpose. There are four major stages of ovarian cancer, and within each stage there
are 3 sub-groups, except stage IV. In stage I (early stage) ovarian cancer the tumour
is confined to either or both ovaries. Stage II comprises of tumours in one or both
ovaries with pelvic extension. Stage III involves ovarian tumour(s) with
microscopically confirmed peritoneal metastases outside of the pelvis and or regional
lymph node metastases. Stage IV, the most advanced, involves distant metastases
(http://info.cancerresearchuk.org/cancerstats/types/ovary/symptoms/?a=5441).
1.3.3: Grading of ovarian cancer
The grade of an ovarian tumour is based on the appearance of the cells under a
microscope. There are 3 grades given to tumours, grade 1 (low-grade) contains well-
differentiated cells, which look similar to normal cells. Grade 1 cells are slow-
growing and are unlikely to spread. Grade 2 cells are moderately differentiated and
appear more abnormal than the low grade cells. Grade 3 cells are poorly
differentiated and fast-growing, with a high likelihood of spreading.
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The stage, grade and histological subtype of the tumour are used for diagnostic
purposes and to provide a prognosis. The pathological information is also used to
evaluate the most appropriate treatment to use.
1.4: Treatment and survival of ovarian cancer patients
The primary treatment for the vast majority of ovarian cancer is surgical removal of
the tumour. However, the full course of treatment is based on the type of ovarian
cancer and also the stage of the tumour. Patients with borderline or low grade stage I
tumours are likely to only require surgery, while those with stages II or III usually
have surgery, followed by adjuvant, platinum-based combination
chemotherapy(Cancer Research UK
http://www.cancerhelp.org.uk/help/default.asp?page=3084). Patients with stage IV
ovarian tumours tend to require more aggressive treatment, if the patient is well
enough. Treatment of stage IV tumours typically involves shrinking the tumour with
chemotherapy before and after debulking surgery. Radiotherapy is also used, in
some cases, to relieve symptoms
(http://www.cancerhelp.org.uk/help/default.asp?page=3084).
The five-year survival rate for ovarian cancer is between 20-30%, which is not
different from around 30 years ago, and overall, 60% of ovarian cancer sufferers die
from their disease (Vanderhyden et al. 2003). The relatively unvarying mortality
rate for ovarian cancer over the past 30 years is a sharp contrast to the mortality rates
of breast and cervical cancer over the same time period (see Figure 1.1). Thus,
although the mortality rates of breast and cervical cancers were greater than that of
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ovarian cancer in 1971, there have been consistent and significant reductions in the
mortality rates for breast and cervical cancers since 1990 and 1976, respectively
(Figure 1.1). As a consequence of these reductions, the mortality rate of cervical
cancer has been less than ovarian cancer since 1988, and in the year 2003 the rate for
cervical cancer was approximately 5 deaths per 100,000 patients compared with 12
per 100,000 for ovarian cancer.
Figure 1.1: Trend of mortality rates for ovarian, breast and cervical cancer (1971-
2003)
Engel and colleagues found 10-year survival rates between 32 and 34% for their
ovarian cancer study participants, who were Caucasians from Germany. They also
reported that despite improvements in the treatment of the disease and better survival
of patients with FIGO stages I and II; the same did not apply to those with FIGO
stages III-IV, and overall, there was no significant increase in the survival rate of
ovarian cancer sufferers (Engel et al. 2002).
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The pathological stage of ovarian tumours at diagnosis has the strongest effect on
survival. Patients with late stage (FIGO III or IV) tumours have lower survival
probabilities and thus worse prognosis, than those with early stage disease. The 5-
year survival rate for ovarian cancer diagnosed in the early stages is greater than
70%. However, only 20% of ovarian cancer sufferers are diagnosed with early stage
disease. In contrast, the 5-year survival rate reduces to approximately 15% for late
stage disease with distant metastases, which affects a third of patients diagnosed
(Cancer Research UK
http://info.cancerresearchuk.org/cancerstats/types/ovary/survival/). Ovarian cancer
is normally diagnosed when the disease is at an advanced stage, at which point, the
prognosis is poor. This contributes to the high mortality from the disease. The age
of the patient at diagnosis is also a determinant of survival. Older patients have
poorer prognosis, compared with younger patients. However, this could be due to
younger patients, despite their illness, being generally healthier than older patients.
1.5: Risk and protective factors of epithelial ovarian cancer
Aside from age, family history is the strongest risk factor for ovarian cancer (Amos
and Struewing 1993). In families with affected individuals, the risk is conferred by
the inheritance of a germline mutation. Other risk factors for ovarian cancer include
early menarche, late menopause, infertility, nulliparity and low parity (Hildreth et al.
1981; Mori et al. 1988; DePasquale et al. 1998). Age has the strongest impact on the
risk of ovarian cancer; as age increases, so does the risk of the disease. Greater than
80% (5,506 out of 6,596) of new ovarian cancer cases diagnosed in the UK in 2006
were at least 50 years old (Cancer Research UK). The age distribution of new
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ovarian cancer cases in the UK are shown in Figure 1.2. Many of these other risk
factors are a result of continuous ovulation, which encompasses early menarche, late
menopause, nulliparity and low parity.
Figure 1.2: Age-distribution of new ovarian cancer cases in 2006 (UK)
N=6,596
There is conflicting evidence for the association between talcum powder use and
ovarian cancer risk. Some studies have found that talcum powder use is associated
with a moderate increase in ovarian cancer risk (Cramer et al. 1999, Gertig et al.
2000, Mills et al. 2004), but meta-analyses have not found a statistically significant
association (Gross and Berg 1995, Huncharek et al. 2003). Studies of menopausal
women on hormone replacement therapy have found that there is an increased risk of
ovarian cancer in women who use oestrogen only treatment for more than 10 years,
but the mechanisms through which the tumours arise are unknown (Folsom et al.
2004, Lacey et al. 2002, Rodriguez et al. 2001). Furthermore, there is also
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conflicting data on whether factors such as consumption of alcohol, coffee, calcium,
lactose, fibre or smoking increase susceptibility to ovarian cancer (Mori et al. 1988;
Whittemore et al. 1988; Cramer 1989).
Use of the oral contraceptive pill is known to be a protective factor against the
development of ovarian cancer (Casagrande et al. 1979; Franceschi et al. 1991). The
oral contraceptive pill prevents ovulation by mimicking the levels of hormones
normally present during pregnancy. Other factors such as high parity, increased
duration of breast feeding, hysterectomy and tubal ligation have also been associated
with reduced risk of the disease (Hildreth et al. 1981; Cramer et al. 1983;
Whittemore et al. 1992; Hankinson et al. 1993).
1.6: Incessant ovulation and ovarian cancer
The ovarian surface epithelium is a monolayer of cells which covers the outside of
the ovary (Vanderhyden et al. 2003) and ovarian cancer is believed to arise as a
result of the continuous rupturing and mitotic repairing of the ovarian surface
epithelium throughout a woman’s life (Auersperg et al. 2001). Humans and
chickens are two of very few animals known to spontaneously develop ovarian
cancer. Fathalla was the first person to suggest a connection between incessant
ovulation and ovarian cancer in women and hens (Fathalla 1971).
Every time mitosis occurs, there is a risk of DNA mutation. During ovulation, a
follicle ruptures, releasing an ovum from the ovary. The ruptured follicle is
subsequently a wound, which must be repaired by mitosis. This knowledge
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combined with the fact that every time mitosis occurs there is a risk of DNA
mutation, suggests a mechanism for the development of neoplasm in the ovaries. It
has been proposed that the constant rupturing and repairing of the wounds on the
ovarian surface throughout a woman’s reproductive life contributes to the lifetime
risk of ovarian cancer.
Ovarian cancer is primarily seen in perimenopausal and postmenopausal women.
Greater than 90% of ovarian cancer cases are seen in women who are over 40 years
old and the average age at which women in the general population are diagnosed is
60 years, and 50 years for familial cases (Holschneider and Berek 2000). This and
other ovarian cancer risk factors, such as high parity, oral contraception use, support
the incessant ovulation theory for the mechanism through which the disease arises
(Casagrande et al. 1979).
1.7: Animal models of ovarian cancer
Little is known about the initiation, progression and metastasis of ovarian cancer
despite research using ascites, primary ovarian tumour cell lines and animal models.
Two varieties of animal models are used: those which spontaneously develop
ovarian cancer (such as hens, some strains of mice, Wistar and Sprague-Dawley rats)
and those which can be induced to develop ovarian cancer (sheep, guinea pig,
rabbits) (Vanderhyden et al. 2003). Animal models used in ovarian cancer research
are reviewed by Vanderhyden et al. (2003). Animal models have been useful in
elucidating; the mechanism through which ovulation occurs, how inclusion cysts
develop and the affects of steroids in vivo, but some of the results are conflicting,
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and the disease is still poorly understood.
Figure 1.3: Accumulation of mutations leading cancer development
(Figure adapted from (Alberts 1994))
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1.8: Genetics of epithelial ovarian cancer
Although the genetics of the initiation, progression and metastasis of ovarian cancer
are poorly characterised, the general development of cancer is better understood.
Normal cells are believed to transform into neoplastic cells after the acquisition of
several mutations. Figure 1.3 shows the schematic progression of a tumour from a
single mutated cell to a clump of mutated cells in a process known as clonal
evolution (Alberts 1994). The mutation of some genes such as BRCA1, BRCA2 and
TP53 have been proposed to lead to genomic instability, where the rate of gene
mutation is accelerated due to the loss of genomic integrity and also the loss of a
cell’s ability to regulate normal cellular processes. The single mutated cell must
have a mutation that gives it a growth advantage over the surrounding cells. The
successive proliferation of the mutated cell and its daughter cells tend to lead to
additional mutations. The clones with mutations for a growth advantage are
continuously selected for and may become malignant.
Although the acquisition of mutations is essential for tumour development, the
accumulation of mutations is not enough to cause cancer. A cell with the
prerequisite genetic changes for cancer must be able to: evade apoptosis and the
host’s immune system; either have an increased rate of cell proliferation, or a
decreased rate of cell death; become insensitive to internal and external inhibitory
signals (i.e. cell-to-cell contact inhibition, anti-growth signals); become self
sufficient in growth signals and either prevent cell differentiation; or promote cell
de-differentiation (Boon 1993, Hanahan and Weinberg 2000). Angiogenesis must
also occur in order for a tumour mass to get sufficient nutrients to grow beyond a
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critical size. Ovarian cancer and other malignancies occur as a result of the
accumulation of genetic alterations and favouring environment for tumour growth.
Two groups of genes which are implicated in ovarian cancer development are
oncogenes and tumour suppressor genes.
1.8.1: Oncogenes
Proto-oncogenes are essential in the normal functioning of cells, particularly in the
regulation of cell division, proliferation, survival, motility and apoptosis. In adults,
proto-oncogenes respond to stimuli from wound sites to repair the damage by
stimulating growth factors. Oncogenes are mutated forms of proto-oncogenes.
Some activating mutations can be within coding regions or regulatory elements.
Proto-oncogenes can also be transformed by amplification of the region. Chemical
carcinogens, ionising radiation, errors in DNA replication and faulty DNA damage
repair can also cause the activating mutations (Balmain et al. 2003). Mutated
oncogenes may still be able to elevate growth factor production and stimulate cell
mitosis, but the activity may be poorly regulated, and this lack of regulation can lead
to the transformation of normal cells into tumour cells (Hogdall et al. 2003a, Rhim
1988). Proto-oncogenes primarily have a dominant effect on cells, therefore the
mutation of a single copy of the gene is sufficient for the gene to become an
oncogene (Aunoble et al. 2000).
A number of oncogenes have been implicated in the development of ovarian cancer.
These oncogenes include AKT2, BCL2, BRAF, CDKN2A, MYC, CSF1R, CTNNB1,
EGFR, ERBB2, FGF3, HRAS, KRAS, MDM2 and PIK3CA.
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BCL2, which is located on chromosome 18q21.3, is involved in inhibiting apoptosis
(White and Gilmore 1996). BCL2 has been found to be over-expressed in 39% of
ovarian tumours (Baekelandt et al. 1999).
The v-raf murine sarcoma viral oncogene homologue B1 (BRAF) is a proto-
oncogene located on chromosome 7q34. The gene encodes a 84.4kDa protein,
which acts as an effecter downstream of KRAS in the RAS-RAF-
mitogen/extracellular signal-regulated kinase (MEK)-extracellular signal regulated
kinase (ERK), and mitogen-activated protein kinase (MAPK) pathway. This
pathway is critical in the transduction of cell growth signals from the cytoplasm into
the nucleus (Russell and McCluggage 2004). Over-expression of BRAF has been
found in ovarian, as well as a variety of other cancers, including melanomas,
colorectal and thyroid cancer (Sieben et al. 2004). Mutations in BRAF in ovarian
cancer have been reported to be as high as 36% (Sieben et al. 2004). However,
according to the Catalogue Of Somatic Mutations In Cancer (COSMIC), a database
from the Sanger Institute which catalogues mutations reported in ovarian and other
malignancies, BRAF is one of the most mutated genes in ovarian cancer, with a
frequency of 12% (www.sanger.ac.uk/genetics/CGP/cosmic/). Activating mutations
of BRAF are more common in early stage ovarian cancer. BRAF mutations are
predominantly found in tumours of the low grade serous histological subtype (Ho et
al. 2001, Sieben et al. 2004). Mutations in BRAF have previously been shown to be
associated with poor survival in patients diagnosed with papillary thyroid cancer and
colon cancer (Abubaker et al. 2007, Samowitz et al. 2005).
Chapter 1: Introduction
36
The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) is located on
chromosome 12p12.1. The proto-oncogene encodes a 21.6 kDa protein, which is
upstream of BRAF in the RAS-RAF-MEK-ERK-MAP kinase pathway (Russell and
McCluggage 2004). Mutations in one of three RAS proto-oncogenes (KRAS, HRAS
or NRAS), which result in the genes becoming activated are found in approximately
25% of human cancers (Gemignani et al. 2003). KRAS, like BRAF, is one of the
most mutated genes found in ovarian cancer tumours and cell lines, with a frequency
of 15% (Forbes et al. 2006). Codons 12 and 13 of the oncogene appear to be
mutation “hotspots”. Mutations in KRAS are predominantly found in mucinous
histological subtype of ovarian cancer (50-68%), however mutations in codons 12
and 13 have also been observed in some non-mucinous ovarian cancers (Cuatrecasas
et al. 1997, Cuatrecasas et al. 1998, Gemignani et al. 2003). Like BRAF, KRAS
mutations tend to be detected in stage 1 tumours (Gemignani et al. 2003, Ho et al.
2001, Sieben et al. 2004). Furthermore, somatic alterations in KRAS have been
associated with poor survival in patients with colorectal, lung and pancreatic cancers
(De Roock et al. 2007, Kim et al. 2008, Lievre et al. 2006).
CDKN2A is a cell cycle control gene on chromosome 9p21.3. CDKN2A induces cell
cycle arrest at G1 and G2/M checkpoints. CDKN2A is mutated in 10% of ovarian
tumours and cell lines (www.sanger.ac.uk/genetics/CGP/cosmic/).
CTNNB1 is located on chromosome 3p22-p21.3 and is involved in cell proliferation.
This gene encodes β-catenin, which is a member of the Wnt signal transduction
pathway. Approximately 30% of endometrioid ovarian carcinomas have CTNNB1
mutations. It has been demonstrated that the β-catenin is normally degraded by
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APC. However, mutant forms are resistant to the degradation, and thus accumulate
in the cytoplasm. β-catenin may form complexes with transcription factors such as
TCF/Lef-1, which translocates into the nucleus and activates transcription of genes,
such as MYC, CCND1 (also known as cyclin D1), C-JUN and FRA-1 (Christie and
Oehler 2006, Schlosshauer et al. 2002).
The v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2 (ERBB2), also
known as human epidermal growth factor receptor-2 (HER-2) and
neuro/glioblastoma derived oncogene homologue (NEU) is a proto-oncogene located
on chromosome 17q21.1. The ERBB2 proto-oncogene encodes a transmembrane
protein, which acts as a growth factor receptor and is involved in cell proliferation
and cell differentiation (Wu et al. 2004). The over-expression of ERBB2 is believed
to cause the transcriptional activation of genes involved in cell proliferation
(Aunoble et al. 2000). Ovarian, breast, prostate, lung, gastrointestinal, kidney, liver
and bladder cancers have been shown to over-express ERBB2 (Wu et al. 2004). For
ovarian cancer, between 20-30% of stage III and IV tumours, primary tumour cells
and cell lines over-express ERBB2 (Hellstrom et al. 2001). Protein expression using
antibody staining on a subset of ovarian tumours from the MALOVA study showed
that 39% of the carcinomas over-expressed ERBB2 (Hogdall et al. 2003). These
findings are indicative of a tumour growth advantage when ERBB2 is over-
expressed (Hellstrom et al. 2001). The variations in ERBB2 expression in the
MALOVA study correlated with survival; where over-expression of ERBB2 was
associated with poor clinical outcome (Hogdall et al. 2003). It has also been found
that ovarian cancer cases homozygous for a polymorphism in ERBB2, I655V, which
results in the production of the valine amino acid instead of isoleucine, have a
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shorter survival period compared with the common homozygotes (who produce the
isoleucine amino acid) (Pinto et al. 2005). Associations between ERBB2 over-
expression in tumours and survival have also been reported for breast and colon
cancers (Fritz et al. 2005).
The catalytic Class IA p110-alpha subunit of phosphatidylinositol 3-kinase (PIK3),
which is known as PIK3CA is located on chromosome 3q26.3. This oncogene is a
lipid kinase, which is involved in the regulation of cell proliferation, adhesion
transformation, survival, apoptosis, and motility (Cantley 2002, Fruman et al. 1998,
Volinia et al. 1994). There are two “hot spots” in which mutations in PIK3CA
cluster – exons 9 and 20. Exon 9 contains the sequence for the helical domain, and
exon 20 encodes the kinase domain. Mutations in these “hot spots” of the gene have
been found in primary tumours and cell lines of cancers such as ovary, breast, lung,
brain, colon and stomach (Muller et al. 2007). Shayesteh et al. initially identified
the over-expression of PIK3CA in 7 out of 9 ovarian carcinoma cell lines. This over-
expression correlated with fluorescent in situ hybridisation (FISH) data, which
showed that PIK3CA was amplified in approximately 58% of the primary ovarian
tumours (Shayesteh et al. 1999). The role of PIK3CA in tumour progression is
reviewed in (Roymans and Slegers 2001, Samuels and Ericson 2006). In addition,
mutations in the gene or over-expression of the gene may be correlated with worse
clinical outcome in patients with ovarian, breast, thyroid, lung and colon cancer
(Abubaker et al. 2007, Kato et al. 2007, Li et al. 2006, Woenckhaus et al. 2007).
MYC is a transcription factor which has a major role in neoplastic transformation.
MYC over-expression caused by gene amplification induces uncontrolled hyper-
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proliferation and occurs in approximately 30% of epithelial ovarian cancers
(Aunoble et al. 2000). Some of the oncogenes and tumour suppressor genes
implicated in ovarian cancer are shown in Table 1.1.
1.8.2: Tumour suppressor genes
Tumour suppressor genes (TSGs) are responsible for the inhibition of cell
proliferation. The inactivation of a TSG results in a decrease in the expression of the
TSG, which may lead to neoplastic growth. It has been proposed that there are two
categories of TSGs: gatekeepers and caretakers. Gatekeepers are genes which act
directly to regulate cell proliferation (Levitt and Hickson 2002). The retinoblastoma
(RB1) and adenomatous polyposis coli (APC) genes are gatekeepers. The normal
RB1 protein represses cell proliferation and also regulates transcription (Classon and
Harlow 2002). Loss of function mutations in both copies of RB1 may result in a
mutated form of the protein being produced, which is incapable of performing its
normal function. Mutations in the RB1 gene can lead to retinoblastoma,
osteosarcoma and small-cell lung cancer (Taya 1997). APC is believed to inhibit the
β-catenin protein, which is involved in the regulation of cell signal transduction,
growth and adhesion (Fearnhead et al. 2002). The loss of these functions can lead to
cells developing the anchorage independent characteristic of cancer cells and
unregulated cell proliferation. Mutations in APC may lead to familial adenomatous
polyposis coli and sporadic colon cancer (Seitz et al. 2003).
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Table 1.1: Oncogenes and tumour suppressor genes involved in ovarian cancer
development
Gene Chromosome Function Mutations (%)
Oncogenes
AKT2 19q13.2
Regulation of cell proliferation. AKT is a major
mediator of survival signals that protect cells
from undergoing apoptosis.
17*
BCL2 12q15
Acts as an ubiquitin ligase promoting
proteasome dependent degradation of p53.
Transcriptional target of p53.
39*
BRAF 7q34 Involved in the transduction of mitogenicsignals from the cell membrane to the nucleus. 12
CDKN2A 9p21.3
Induces cell cycle arrest at G1 and G2/M
checkpoints, blocking them from
phosphorylating RB1 and preventing exit from
G1 phase of the cell cycle. P16-INK4a could
act as a negative regulator of normal cells
proliferation.
10
MYC 8q24.21 Transcription factor. Involved in regulation ofgene expression. 30*
CSF1R 5q32
Receptor. CSF1R activation by CSF1 results in
increased growth, proliferation and
differentiation.
4
ERBB2 17q11.2-q12,17q21.1
Receptor tyrosine kinase. Transmembrane
receptor. 1
KRAS 12p12.1 Involved in the transduction of mitogenicsignals from the cell membrane to the nucleus. 15
PIK3CA 3q26.3 Signal transduction. Activated by growthfactors. 8
Tumour suppressor genes
BRCA1 17q21
Transcription factor. Plays essential role in
DNA repair. Needed for cell arrest after DNA
damage.
3
BRCA2 13q12.3
Transcription factor. Involved in DNA double
strand break repair and homologous
recombination.
2
PTEN 10q23.31
A phosphatase that negatively regulates the
AKT/PKB pathway. Involved in cell cycle
progression and cell survival.
8
TP53 17p13.1 Transcription factor. Induces cell growtharrest/apoptosis. 28
APC 5q21-q22
Antagonist of the Wnt signalling pathway.
Involved in cell migration, cell adhesion,
transcriptional activation, and apoptosis.
9
RB1 13q14.2 Negative regulator of the cell cycle. Regulatestranscription. 10
* over-expressed/amplified.
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Caretaker tumour suppressor genes, such as BRCA1, BRCA2 and TP53, encode
proteins which are involved in the regulation of DNA replication, gene transcription,
DNA repair or cell cycle checkpoints. All of these processes help maintain the
integrity of the genome (Levitt and Hickson 2002). The BRCA1, BRCA2 and TP53
tumour suppressors are important in ovarian and breast cancers. BRCA1 and BRCA2
have many functions within the cell, which include DNA damage repair, DNA
recombination, transcription and cell cycle checkpoint regulation (Venkitaraman
2002). Mutations in BRCA1 and BRCA2 can lead to the accumulation of mutations
within a cell because of the loss of the appropriate DNA repair mechanism. This
allows cells containing mutations to progress through cell cycle checkpoints. The
BRCA1 and BRCA2 genes are very important in familial cases of breast and ovarian
cancer, and their expression is reduced in some sporadic cancers, however mutations
in these genes are relatively low (3% and 2%, respectively) when all ovarian cancers
are considered (www.sanger.ac.uk/genetics/CGP/cosmic/).
PTEN is mutated in 8% of ovarian tumours
(www.sanger.ac.uk/genetics/CGP/cosmic/). The TSG is located on chromosome
10q23.3, which encodes a phosphatase protein that inhibits the AKT/PKB signal
transduction pathway. The protein is involved in cell cycle progression and cell
survival. The expression of the gene can lead to cell cycle arrest, apoptosis and a
reduction of cell motility (Christie and Oehler 2006).
The TP53 protein is crucial for transcription, DNA repair, cell cycle control and
apoptosis (French et al. 2001, Hulla et al. 2001). TP53 is one of the most often
mutated genes in human cancer – over 50% of sporadic tumours have an alteration in
Chapter 1: Introduction
42
the TP53 gene (www-p53.iarc.fr). Twenty-eight per cent of ovarian cancers contain
TP53 mutations (www.sanger.ac.uk/genetics/CGP/cosmic/). TP53 is also the causal
gene of Li-Fraumeni syndrome, which is characterised by an increased susceptibility
to cancers. Mutations in TP53 are predominantly found in the DNA binding domain
of the gene, which disrupts the ability of the protein to bind DNA and activate
transcription (Iwakuma et al. 2005).
1.8.3: Epithelial ovarian cancer and inheritance
Meta-analyses of case-control and cohort studies has demonstrated that an individual
with an affected first degree relative has a 3% risk of developing ovarian cancer
(Stratton et al. 1998). This value is greater than the risk for a woman in the general
population developing ovarian cancer (1%). Since twins, both monozygotic and
dizygotic, generally share the same environment in utero and after birth, twin studies
enable the estimation of the overall contribution of inherited genes to the
development of cancers. Monozygotic twins are genetically identical, and dizygotic
twins share approximately 50% of their segregating genes.
Twins who are concordant for a cancer have a tumour of the same anatomical site. It
can be said that genetics plays an important role in the development of cancer if the
proportion of monozygotic twins concordant for a cancer is greater than that of
dizygotic twins. A twin study published in 2000 compared the concordance of
cancer in monozygotic and dizygotic twins. They found that genetic factors made a
major contribution to susceptibility of cancers such as breast, stomach, lung,
colorectal and prostate as well as ovarian cancer. From Lichtenstein’s study, the
heritability of ovarian cancer was estimated to be 22% (Lichtenstein et al. 2000).
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Approximately 5-10% of ovarian cancer cases are inherited. Familial ovarian cancer
is subdivided into three categories: (i) site specific ovarian cancer, (ii) breast and
ovarian cancer syndrome, and (iii) hereditary non-polyposis colorectal cancer
(HNPCC, also known as Lynch II syndrome) (Prat et al. 2005). Site-specific ovarian
cancer and inherited breast and ovarian cancer syndrome are deemed to be part of the
same disease syndrome spectrum because they are associated with germ-line BRCA1
and BRCA2 mutations (Prat et al. 2005).
Linkage analysis of breast and ovarian cancer families have shown that ovarian
cancer is caused by BRCA1 and BRCA2 in the majority (> 90%) of breast and
ovarian cancer syndrome families with more than 3 affected individuals. It has been
demonstrated that mutations in BRCA1 or BRCA2 co-segregate with the disease
within families. Mutations in the DNA mismatch repair genes, MSH2, MLH1,
PMS1, PMS2 and MSH6/GTBP inherited from HNPCC families account for
approximately 10% of familial cases of ovarian cancer (Sharma et al. 2001).
1.8.4: High risk/high penetrance genes
Mutations in some genes cause a very high risk of developing a cancer. These genes
are known as high risk susceptibility genes, and in cancer, most appear to have a
dominant effect on the development of the cancer. The inheritance of a mutated
form of the high risk gene results in a greater chance of developing the disease.
Normally, the Mendelian dominant mode of inheritance means that the inheritance of
one mutated copy of the causal gene is sufficient to cause the disease in the
offspring. In hereditary cancer, an affected individual usually inherits a mutated
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copy of the gene (such as BRCA1 or BRCA2), this is known as the first hit. The
second copy of the gene is lost by another mechanism, such as somatic mutation,
loss of heterozygosity or methylation (the second hit) (Knudson 1971). These form
the basis of the two-hit hypothesis, which was proposed as a possible explanation of
the development of cancer.
Familial cancers appear at an earlier onset because the affected individuals already
have a mutated gene (first hit), therefore it is assumed that it requires less time to
acquire the second hit compared with sporadic cases, who need to attain both hits
through somatic mutation. The dominant effects of genes on cancer development are
demonstrated by the adenomatous polyposis coli (APC) gene and familial
adenomatous polyposis (FAP) syndrome. FAP is characterised by the presence of
hundreds to thousands of polyps in the colon or rectum before 40 years of age. FAP
is caused by mutations in the APC gene. The children of FAP patients have a 50%
chance of inheriting the mutated gene. Colorectal tumours from FAP patients show
that in addition to the germline mutated copy of the APC gene, somatic mutation
results in the inactivation of the normal gene copy (Fearnhead et al. 2002).
1.8.5: Ovarian cancer and high susceptibility genes
A gene which confers increased susceptibility to ovarian cancer alone has not been
isolated. BRCA1 and BRCA2 are large genes which co-segregate with the majority
of hereditary breast and ovarian cancer. BRCA1 and BRCA2 were both mapped
through linkage analysis of families with breast and ovarian cancer syndrome.
BRCA1 is an 81.09 kb tumour suppressor gene which was mapped to chromosome
17q12-21 in 1994 (Miki et al. 1994). BRCA2 (84.19kb) was mapped to chromosome
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13q12-13 in 1995 and the gene was identified on chromosome 13q12.3 in 1996
(Wooster et al. 1995). BRCA1 and BRCA2 consist of 24 and 28 exons, respectively,
and exon 11 from both genes constitute 60% of their coding DNA sequences (Kote-
Jarai and Eeles 1999).
These two genes account for approximately 45% of epithelial ovarian cancer familial
cases (Ramus et al. 2007). Most cases (approximately 90%) with greater than 3
first-degree relatives with ovarian cancer and breast cancer are due to BRCA1 and
BRCA2 mutations (Pharoah and Ponder 2002). However, there are some large
ovarian cancer families, which are not linked to BRCA1 or BRCA2 (Ramus et al.
2007). Some of the remaining high penetrance familial cases are linked to mutations
in mismatch repair genes in hereditary non-polyposis colorectal cancer (HNPCC)
cases (Lakhani and Flanagan 2002). The mutations and linkage analysis studies are
reviewed in (Pharoah and Ponder 2002, Prat et al. 2005).
Although BRCA1 and BRCA2 germline mutations in breast cancer occur with equal
frequency, BRCA1 mutations are approximately four times more common than
BRCA2 mutations in ovarian cancer (Gayther et al. 1999). BRCA1 mutation carriers
from breast and ovarian cancer families have a greater than 40% lifetime risk of
ovarian cancer, and BRCA2 mutation carriers have a 10% risk of ovarian cancer.
The fact that not all individuals with a BRCA1 or BRCA2 mutation develop ovarian
or breast cancer suggests that the genes are not fully penetrant – a mutation does not
correlate to the development of a malignancy in all mutation-carriers. The
incomplete penetrance of BRCA1 and BRCA2 may be explained by the position of
the mutation within the genes, modifying genes and environmental factors, which
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affect the chances of a BRCA1 and BRCA2 mutation carrier developing ovarian
cancer (Thompson and Easton 2002). It has been demonstrated that BRCA1 and
BRCA2 mutation carriers on long term oral contraceptive pills have a reduced risk of
ovarian cancer (Whittemore et al. 2004).
The diagnosis of cancer is at a younger age for mutation carriers when compared
with non-carriers (Laplace-Marieze et al. 1999, Pharoah and Ponder 2002). There is
also evidence suggesting that BRCA1 mutation carriers are more likely to have
serous adenocarcinoma histological subtype tumours than non-familial cases
(Lakhani and Flanagan 2002, Rubin et al. 1996). Furthermore, there is inconclusive
data for survival in BRCA1 and BRCA2 mutation carriers. Some studies have
reported that BRCA1 and BRCA2 carriers with ovarian cancer have better long-term
survival compared with non-carriers (Boyd et al. 2000; Chetrit et al. 2008).
However, others have demonstrated survival advantage, which were not statistically
significant between BRCA1 and BRCA2 mutation carriers and non-carriers (Pharoah
et al. 1999, Ramus et al. 2001).
To conclude, these high risk susceptibility genes account for approximately 10% of
all ovarian cancer cases (see Figure 1.4). This poses the important question – “is a
proportion of the remaining ovarian cancer cases attributable to moderate or low
penetrance genes?”
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Figure 1.4: Contribution of high-risk susceptibility genes to epithelial ovarian
cancer
HNPCC – genes associated with hereditary non-polyposis colon cancer
1.8.6: Moderate/low penetrance risk susceptibility
Statistical modelling using data from high-risk families and population-based
ovarian cancer cases, have suggested that a dominant or recessive high susceptibility
gene predisposing to ovarian cancer is unlikely (Antoniou et al. 2000). There was no
significant difference between simulation of a hypothetical high risk gene with
BRCA1 and BRCA2 and simulation without the hypothetical gene. The modelling
also showed that common genes with low penetrance or rare alleles with higher risks
were compatible with the observed data. However, the results from simulations of a
model of relatively common alleles with moderate penetrance were inconsistent with
the observed data. These suggest that some of the familial risks could be due to
environmental, or modifying genetic factors (Antoniou et al. 2000).
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1.8.7: Polygenic model of ovarian cancer
Linkage and segregation analysis of non-BRCA1 and -BRCA2 families and
epidemiological modelling have suggested that ovarian cancer may be a polygenic
disease. This polygenic theory is attractive because ovarian cancer, as with other
complex diseases, is likely to be influenced by many genes, as well as environmental
factors. The common variant: common disease hypothesis is correlated with the
polygenic model (Risch, N. and Merikangas 1996; Chakravarti 1999). The
hypothesis proposes that some genetic variants, with moderate effects, become
common over time. These variants may predispose to common diseases and the
combinations of the variants may affect differences in disease susceptibility (Pharoah
et al. 2004).
In light that it is unlikely that there is another high-risk ovarian cancer susceptibility
gene, and twin studies have suggested that genes are more important than shared
environment in ovarian cancer development, it is feasible that polymorphisms of
candidate genes may confer moderate- or low-penetrance susceptibility. This project
aims to evaluate the risks of ovarian cancer associated with common genetic
polymorphisms of candidate genes.
1.9: Linkage and case-control studies
Linkage analysis led to the discovery of mutations in BRCA1 and BRCA2 in breast
and ovarian cancer syndrome families. However, linkage analysis and segregation
analyses have not been successful in identifying other high-risk ovarian cancer
susceptibility genes. Genetic susceptibility association studies involve the
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comparison of the frequencies of candidate susceptibility variants in ovarian cancer
cases with matched (by age, ethnicity, area of residence, sometimes socio-ecomonic
status, parity, oral contraceptive use and other epidemiological factors depending on
the number of study participants), unaffected controls to ascertain whether there are
significant differences between cases and controls. Association studies can also be
used to identify genetic factors which may influence response to treatment or overall
survival from the disease. In survival association studies, comparisons are made
between the frequencies of the genetic variables of individuals still alive, and those
who have died, within a specified period of time.
As ovarian cancer has late onset and poor survival, there are insufficient numbers of
older members of pedigrees to perform associations with families. Thus, case-
controls association studies have greater statistical power than familial association
studies to detect ovarian cancer susceptibility variants with moderate effects.
Statistical power refers to the probability of rejecting a false null hypothesis. As
statistical power increases, the likelihood of obtaining a false negative result (type II
error) decreases, therefore increasing the chance of finding a true association. Type I
error is the rejection of the null hypothesis due to chance findings. For example, the
5% significance level suggests that there is a 5 in 100 probability of obtaining a
positive result by chance.
1.9.1: Single nucleotide polymorphisms
A single nucleotide polymorphism (SNP) is variation at a single base in a DNA
sequence, which occurs with a frequency of ≥ 1% in the population. SNPs with
allele frequencies greater than 5% are called common polymorphisms. SNPs are the
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most abundant polymorphisms in humans, with approximately 10 million variants in
the human genome (Sobrino et al. 2005). The vast majority of SNPs are bi-allelic,
which means there are two variants for the particular SNP, with one copy inherited
from each parent (Doris 2002), see Figure 1.5.
Figure 1.5: A single nucleotide polymorphism and it’s po
Between 3-5% of the human genome encode proteins, therefore
SNPs are in non-coding regions of the genome, such as the intr
genes or in regions without open reading frames. SNPs within
genes are of particular interest because there is a greater chance
in a variation of the biological function of the protein either by
the protein, or the binding of the protein. A SNP can be coding
Coding SNPs are located in the exons of genes and can be transHomozygous for A
Genotype: AAHeterozygous for SNP
Genotype: AGHomozygous for G
Genotype: GG50
ssible genotypes
the majority of
ons of genes, between
coding regions of
that they may result
altering the folding of
or non-coding.
cribed into amino
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acids. Coding SNPs can be synonymous or non-synonymous. The alleles of a
synonymous SNP result in the same amino acid being produced, due to the
redundancy of amino acid codons. However, non-synonymous SNPs result in
different amino acids being produced. These are known as missense SNPs. The
amino acids translated from missense SNPs may have different charges, which may
affect protein folding and binding, and subsequently the function of the protein.
Another type of non-synonymous SNP exists, nonsense SNPs – these result in one of
the alleles encoding a STOP codon, which may lead to a truncated protein being
produced, if at all. However, most nonsense SNPs are mutations rather than
polymorphisms.
SNPs in the untranslated regions (UTR) 5’ or 3’ of genes are also of interest. SNPs
in the 5’ UTR may contain sequences involved in promoting translation initiation.
5’ UTRs often contain binding sites for proteins which may influence mRNA
stability or translation. SNPs in 3’ UTR may also be part of sequences for binding
sites for proteins involved in mRNA stability or location of proteins within the cell.
Within a population, the frequencies of the alleles may be different; however the
proportions of the genotypes add up to one in a population in Hardy-Weinberg
equilibrium (HWE) (this is discussed below). The more frequent allele is known as
the common or major allele, and the less frequent is the rare/minor allele. As shown
in Figure 1.6, the allele frequencies of a SNP may be different within different
populations. These differences in the allele frequencies between different
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populations highlight the importance of ascertaining the ethnicity of study
participants and stratifying populations during analysis.
Figure 1.6: Different allele and genotype frequencies in different populations
1.9.2: Hardy-Weinberg equilibrium
The Hardy-Weinberg principle states that allele and genotype frequencies at an
autosomal locus within an infinitely large population will reach equilibrium in a
single generation where there is random mating, and there are no selective pressures,
mutations, migration/emigration or random genetic drift or flow. The Hardy-
Weinberg method has been demonstrated to be robust when estimating the allele
frequencies of SNPs which are not “physiologically meaningful”, such as the
polymorphisms which encode the ABO blood groups, enzymes and DNA markers
(Elston et al. 2002). The term “physiologically meaningful” refers to the fact that,
Chapter 1: Introduction
53
for example, blood performs the same function, regardless of the ABO group. It
must be taken into consideration that despite the same function being performed,
there are differences which prevent the transfer of blood from an individual with
blood group A or B to a person whose blood group is O. The Hardy-Weinberg
method is robust despite the fact that the chances of any population being able to
meet all the conditions of the Hardy-Weinberg principle at any one time are very
small. HWE is extensively used because the statistical power of detecting deviation
from the HWE within large populations is also very small as a result of minute
deviations (Chakraborty and Rao 1972; Elston et al. 2002).
If a bi-allelic SNP is considered, where the common allele is denoted by “A”, the
rare allele by “a”, with allele frequencies p and q, respectively; when a population is
in HWE, the frequency of “A” is p; the frequency of “a” is q, and p+q=1. The
Punnett square below shows how genotypes can be derived from parents
heterozygous at a SNP.
Punnett square for Hardy-Weinberg equilibrium (HWE)
Female gametes
A (p) a (q)
A (p) AA (p2) Aa (pq)Male
gametes a (q) Aa (pq) aa (q2)
Therefore, if a population is in equilibrium, the frequencies the genotypes would be:
AA (common homozygotes) = p2;
Aa (rare homozygotes) = q2;
Aa (heterozygotes) = 2pq.
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1.9.3: Linkage disequilibrium
Linkage disequilibrium (LD) is the non-random association of alleles at two or more
loci. Neighbouring SNPs tend to be in LD – the SNPs are correlated with each
other. The term “tag” is sometimes used to describe the correlation between SNPs
with the same or similar minor allele frequencies (MAF). The correlation between
neighbouring SNPs makes it unnecessary to genotype all the SNPs within a gene or
chromosomal locus in order to test for association with disease. SNP tagging is
described in detail in section 1.9.8 on page 60. There are two main ways of
measuring LD between SNPs: disequilibrium coefficient (r2), and normalised
measure of Lewontin (D’). r2 is a measure of the statistical correlation between two
loci. For example, at two bi-allelic SNP loci on the same chromosome, if the
common and rare alleles of the first locus are denoted as A and a, respectively, and
the alleles of the second locus is B and b. When r2 is used to calculate the LD
between the alleles, the allele frequencies for A, a, B and b, are written as πA, πa, πB
and πb, respectively, and the frequencies of the haplotypes (the combinations of the
alleles of the two loci) are πAB, πAb, πaB and πab. Then
bBaA
BAABr


2
2 )( 

(Pritchard and Przeworski 2001)
D’ is derived from D, which measures the deviation of the frequencies of alleles or
haplotypes from the equilibrium state. Therefore, D is calculated by subtraction the
expected allele frequency from the observed frequency. For haplotype frequencies
D=πABπab-πAbπaB
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D is significantly greater than 0 when there is LD between alleles. D’ is the absolute
ratio of D compared with its minimum value, when D<0, or its maximum value,
when D≥0. D’ is calculated by:


BA
DD

'
(Devlin and Risch 1995). When two loci are in complete LD, r2=1 and D’=1, and
both r2 and D’ tends towards 0 as the degree of correlation decreases; “0”
corresponds to no LD/correlation. r2 and D’ can be calculated in terms of each other
and allele frequencies, and r2 can be calculated from D by the equation:
bBaA
D

2
2r 
(Hedrick and Kumar 2001). r2 is more commonly used in genetic association studies
because it is inversely correlated to the sample size needed, given a fixed genetic
effect. Therefore, the genotypes of a SNP can be predicted from a genotyped SNP
with an r2 ≥0.8 correlation. An r2 ≥0.8 suggests a ≥80% correlation between the
SNPs.
1.9.4: The International HapMap Project
The International HapMap Project records genetic variants, genotypes and
sequences of 30 sets of (2 parents and an adult child) trios of Yoruba people from
Ibadan, Nigeria; 30 trios of north and west European descent – from the Centre
d'Etude du Polymorphisme Humain (CEPH) research in the United States of
America; 45 unrelated individuals from Beijing, China; and 45 unrelated individuals
from Tokyo, Japan. The results are freely available to researchers and they may be
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used as a reference for genetic association studies. The project aims to identify and
record all differences and similarities within the subjects in the project
(www.hapmap.org).
1.10: Association study approaches
The vast majority of association studies in ovarian cancer have been conducted on
candidate genes from pathways which have been implicated in neoplastic
transformation, such as mismatch repair, cell cycle control and oestrogen pathways
(Gayther et al. 2007, Goodman J. E. et al. 2000, Goodman M. T. et al. 2001b, Song
et al. 2006a, Song et al. 2006b, Spurdle et al. 2000). Table 1.2 shows some
significant genetic association studies in ovarian cancer.
1.10.1: Functional SNP, candidate gene approach
The first association studies in ovarian cancer were conducted on single nucleotide
polymorphisms (SNPs), with variants which result in different amino acids. It was
believed that association studies of these functional SNPs would be successful in
identifying ovarian cancer susceptibility genes. However, the approach was not as
successful as expected and resulted in the identification of an association with a
variant (I31 allele of F31I) of STK-15, a putative oncogene (Dicioccio et al. 2004).
This approach was also used in a study which found that the V108M polymorphism
of the catechol-O-methyltransferase (COMT) gene was not associated with ovarian
cancer risk (Goodman, J. E. et al. 2000).
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Table 1.2: Published susceptibility association studies on ovarian cancer (positive results)
Gene SNP No.cases No. controls OR (95% CI) P-value
Study
approach Population Reference
P53 A72Arg 51 30 4.16 0.0058 a Greek (Agorastos et al. 2004)
CYP1A1
Ile
CYP1A1*3
Val
117 202 6.08 (3.73–10.95) <1x10-3 a Turkey (Aktas et al. 2002)
BRCA2 N372H 1121 2643 1.36 (1.04–1.77) 0.03 a UK, Australia (Auranen et al. 2003)
XRCC2 R188H 1600 4241 0.3 (0.1-0.9) 0.003 a Caucasian (Denmark,UK, USA) (Auranen et al. 2005)
XRCC3 rs1799796 1600 4241 0.08 (0.7–0.9) 0.049 a Caucasian (Denmark,UK, USA) (Auranen et al. 2005)
GST GSTM1null 293 219 1.54 (1.06–2.14) 0.025 a UK (Baxter et al. 2001)
PGR +331G/A 973 802 0.46 (0.09-0.97) - a White American,Australian (Berchuck et al. 2004)
STK15 F31I 1821 2467 1.17 (1.02-1.35) 0.03 a Caucasian (Denmark,UK, USA) (Dicioccio et al. 2004)
MLH1 G>A nt-93 899 931 1.5 (1.3–1.9) 5x10-5 a Canadian mixed (Harley et al. 2008)
TGFBR1 TGFBR1*6A 1155 983 1.53 (1.07-2.17) 0.017 a
Italy, Jamaica, UK,
USA (Kaklamani et al. 2003)
PgR +331G/A(rs10895068
)
490 534 1.68 (1.09–2.59) - a USA - mixed (Risch, H. A. et al. 2006)
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Gene SNP No.cases No. controls OR (95% CI) P-value
Study
approach Population Reference
EPHX Tyr113His 545 287 0.38 (0.17–0.87) - a Australia (Spurdle et al. 2001)
PGR V660L 987 1034 0.70 (0.57-0.85) - a White USA (Terry et al. 2005)
FSHR Thr307Ala 202 266 2.60 (1.56–4.34) <0.0005 a China (Yang et al. 2006)
FSHR Asn680Ser 202 266 2.89 (1.73–4.84) <0.0005 a China (Yang et al. 2006)
BRCA1 Q356R 312 401 0.9 (0.5-1.4) 0.64 a Caucasian, AfricanAmerican (Wenham et al. 2003)
CYP17 A2 200 241 1.86 (1.26-2.75)* 0.002 a/b Caucasian (Garner et al. 2002)
CYP1B1 V432L 129 144 3.8 (1.2-11.4) 0.005 a/b White, Asian,Hawaiian
(Goodman, M. T. et al.
2001a)
XRCC2 R188H 1600 4241 0.3 (0.1-0.9) - b Caucasian (Denmark,UK, USA) (Auranen et al. 2005)
VDR rs7975232 72 148 2.8 (1.2–7.0) 0.02 b USA Caucasian (Lurie et al. 2007)
VDR rs10735810 72 148 2.5 (1.3–4.8) 0.04 b USA Caucasian (Lurie et al. 2007)
SOD2 Val-9ala 125 193 2.1 (1.1–4.0) 0.04 b USA - mixed (Olson et al. 2004)
VDR rs11568820 94 173 0.5 (0.3–0.9) 0.03 b USA Japanese Lurie et al. 2007)
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Gene SNP No.cases No. controls OR (95% CI) P-value
Study
approach Population Reference
RB1 rs2854344 1514 2415 0.73 (0.61-0.89) 0.0009 b/c Caucasian (Denmark,UK, USA) (Song et al. 2006b)
RB1 rs4151620 1514 2415 0.19 (0.07-0.53 0.00005 b/c Caucasian (Denmark,UK, USA) (Song et al. 2006b)
SHMT1 rs9909104 829 941 1.2 (1.0–1.4) 0.02 c USA Caucasian (Kelemen et al. 2008)
PMS2 rs7797466 1531 2570 1.17 (1.03–1.33) 0.013 c Caucasian (Denmark,UK, USA) (Song et al. 2006a)
CDKN1B rs2066827 4526 6913 0.93 (0.87-0.995) 0.036 d
Caucasian, African
American, Asian,
Hawaiian
(Gayther et al. 2007)
CDKN2A rs3731257 4526 6913 0.91 (0.85-0.98) 0.008 d
Caucasian, African
American, Asian,
Hawaiian
(Gayther et al. 2007)
PgR rs1042838 7614 651† 1.17 (1.01–1.36) 0.036 d USA – mixed, UK,Denmark (Pearce et al. 2008)
AURKA rs2273535 4624 8113 1.12 (1.01–1.24) 0.03 d Caucasian – Denmark,UK, USA (Ramus et al. 2008a)
RB1 rs2854344 4624 8113 0.87 (0.76–0.98) 0.025 d Caucasian – Denmark,UK, USA (Ramus et al. 2008a)
9p22 rs3814113 4487 7021 0.82 (0.79-0.86) 5.1 x 10-19 e Caucasian – Denmark,UK, USA, Australia
(Song et al. 2009b)
-; P-value not given; a: functional SNP, candidate gene; b: functional SNP, candidate pathway; c: tSNPs, candidate pathway; d: consortium; e: genome-wide, consortium;
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1.10.2: Functional SNP, candidate pathways approach
The functional SNP approach was then used on candidate genes from molecular
pathways which were believed to be involved in ovarian cancer development.
Auranen et al (2005) conducted an association study on genes (BRCA1, NBS1,
RAD51, RAD52, XRCC2 and XBCC3) involved in the DNA double strand break
repair pathways. They found evidence for a decrease in ovarian cancer risk with the
rare variants in XRCC2 and XRCC3 (R188H and rs1799796, respectively) (Auranen
et al. 2005). Associations between ovarian cancer risk and genes involved in steroid
hormone metabolism and catecholestrogen formation have also been investigated.
Individuals who carried the leucine allele for the V432L polymorphism in CYP1B1
had an increased risk of ovarian cancer (Goodman, M. T. et al. 2001b).
1.10.3: Tagging SNPs, candidate pathways approach
The next SNP association study approach involved the use of tagging SNPs (tSNPs)
from candidate genes within a pathway. The tagging SNP approach takes advantage
of the LD between neighbouring SNPs. SNPs in complete LD (r2=1) are said to tag
each other. Therefore, the genotype of a SNP which is tagged by another can be
determined from the genotype of the tagging SNP (if they have the same minor allele
frequencies [MAF]). SNPs which are in strong LD are inherited together, but their
polymorphisms may have different MAF. The pairwise correlation coeffiecient (r2p)
is the best way to measure how well a SNP tags another SNP. r2p takes into account
the loss of power incurred by using the tSNP as a marker, rather than as the causal
SNP. r2s is a measure of how well a haplotype of tSNPs tags a single SNP that is
inefficiently tagged by single SNPs (Song et al. 2006a). The SNP which is
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genotyped is known as the tagging SNP (tSNP). Figure 1.7 shows the principle of
tagging SNPs.
(a)
(b)
(c)
(d)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
1 4 5 12 16 18 24
2 8 16 23 25
1 1661
Figure 1.7: Principles of tagging SNPs
(a) This hypothetical gene contains 25 SNPs. (b) SNPs of the same colour are correlated, thus tag
each other, (c) therefore only 1 SNP needs to be genotyped to gain information about all the SNPs it
tags. (d) Therefore only 5 SNPs in the gene need to be genotyped in order to acquire information
about all 25 SNPs in the gene.
The correlation between two SNPs is measured by r2. Normally an r2 of 0.8 is
chosen, which means there is at least 80% correlation between the tSNP and all the
SNPs it tags. This approach ensures that not all 10 million SNPs need to be
genotyped in order to ascertain the genotypes of each SNP. Only approximately
500,000 tSNPs need to be genotyped to gain information about the remaining 9.5
million variants. The tSNP may be a marker of the causative SNP. This approach
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was used to evaluate associations between MLH1, MLH3, MSH2, MSH6, PMS1 and
PMS2 from the mismatch repair pathway and ovarian cancer. The rare alleles of
MSH6 (rs3136245) and MSH3 (rs6151662) were associated with a decrease in
ovarian cancer risk, and PMS2 (rs7797466) was associated with an increase in
ovarian cancer risk (Song et al. 2006a). This approach has also been used to identify
a positive association between a variant in SHMT1, a member of the one-carbon
transfer pathway, and an increase in ovarian cancer susceptibility (Kelemen et al.
2008).
1.10.4: Consortium approach
The consortia approach is currently the most popular strategy for genetic association
studies in ovarian cancer research. This approach allows staged genotyping designs
in a multi-centre collaboration. The initial stage is the genotyping of the tSNPs from
the candidate genes by a group or a small number of groups within a consortium.
Positive associations are genotyped by the remaining groups within the consortium
to validate or refute the findings of the initial stage of research. This approach gives
more statistical power to a study, reducing type I error.
The Ovarian Cancer Associations Consortium (OCAC) is a multinational consortium
which co-ordinates ovarian cancer research. The group ensures that research is not
duplicated unnecessarily and allows easy sharing of data. At present, the OCAC
consists of 20 groups, which have published a two-stage study on candidate genes
from the cell cycle control pathway (Gayther et al. 2007). In the first stage of the
study, 88 tSNPs in 13 genes were genotyped in three study populations (MALOVA,
SEARCH and GEOCS [previously FROC], also known as Stanford) consisting of
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approximately 1,500 cases and 2,500 controls. There were 13 statistically significant
associations found between the variants and ovarian cancer. Approximately 50% of
the significant SNPs conferred an increased risk of ovarian cancer. Stage 2 of the
study involved the genotyping of the five most significant tSNPs from stage 1 on
approximately 2,000 cases and 3,200 controls by the remaining groups within the
OCAC. The five most significant tSNPs from stage 1 were not significant with the
stage 2 samples alone. There were only significant associations between ovarian
cancer risk and the rare variants from CDKN2A (rs3731257) and CDKN1B
(rs2066827) SNPs when the data from stages 1 and 2 were pooled (Gayther et al.
2007).
The consortium approach has also been used in other studies: seven best candidates
from publication (Ramus et al. 2008), progesterone receptor (Pearce et al. 2008).
These studies have highlighted the importance of validating results in larger studies.
The lack of replication of statistically significant associations independently in later
stages/studies suggests that the initial associations may have been chance findings.
The larger sample sizes from consortia also allow stratification of samples by
histology, race, grade, stage etc. for further analysis. Another advantage of this
approach is that negative results can also be confirmed with additional samples.
1.10.5: Genome-wide, consortium approach
Genome-wide association studies have proved to be a success in the identification of
genes which may be associated with ovarian, breast, colon and prostate cancer risks
(Easton et al. 2007, Song et al. 2009, Thomas et al. 2008, Yeager et al. 2007, Zanke
et al. 2007). In genome-wide association studies, the tagging SNP approach is used
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to genotype evenly distributed SNPs within the genome and evaluate the effect of the
genotyped tSNPs on disease risk. These studies tend to use a staged-design,
whereby highly significant associations are further assessed in succeeding stages
with additional studies. The data from the different stages are combined to increase
the statistical power of detecting associations.
Genome-wide association studies have also been used in the investigation of
susceptibility genes in other complex disorders such as diabetes and heart disease
(Cupples et al. 2007, Sladek et al. 2007). Some of the results from these studies
have been highly significant. In the breast cancer genome-wide association study, an
association was found between a variant in FGFR2 (a fibroblast growth factor
receptor) and an increase in breast cancer risk, P=2x10-76 (Easton et al. 2007).
Genome-wide association studies involve the genotyping of thousands of SNPs
throughout the human genome and performing association analyses on the SNPs
genotyped.
Recently, the OCAC has published results from genome-wide association studies of
ovarian cancer. The study also used the consortia approach in a 3-stage design. In
the first stage 507,094 SNPs were genotyped in 1,817 invasive epithelial ovarian
cancer cases and 2,353 unaffected controls. The 22,790 top ranked significantly
associated polymorphisms were genotyped in an additional 4,274 ovarian cancer
cases and 4,809 controls. Moreover, stage 3 involved genotyping the most
significant SNPs from stage 2 in a further 2,670 cases and 4,668 controls. The data
from all three stages were combined to increase the power of the study. The rare
allele of the most significant SNP, rs3814113, was associated with a reduced risk of
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ovarian cancer (combined stage 1-3 OR=0.82 (0.79-0.86), Ptrend = 5.1 x 10-19) (Song
et al. 2009c).
1.11: Survival analysis
There is substantial evidence showing that cancer patients have different responses
to the same treatment (McGuire et al. 1996; Piccart et al. 2000), and chemotherapy
resistance remains a very important issue; chemotherapy resistance is reviewed by
(Lage and Denkert 2007). There have also been reports suggesting that
chemotherapy resistance may be affected by germline genetic variation (Marsh 2005,
Villafranca et al. 2001). These findings indicate that it is feasible that genetic
polymorphisms may influence a patient’s response to treatment, and thus survival
from the disease. The effects may be attributed to polymorphisms in genes encoding
drug targets, drug-metabolising enzymes and/or drug transporters (Pinto et al. 2005).
Molecular markers such as ERBB2 and TYMS have been identified for predicting
overall survival after diagnosis of cancer ERBB2-positive breast cancer, and serous
ovarian cancer (Hsu et al. 2004; Piccart-Gebhart et al. 2005; Romond et al. 2005).
Although there have been improvements in the response to adjuvant chemotherapy,
the majority of ovarian cancer patients go into remission, developing recurrent
disease. Some of these recurrent cases are drug-resistant (Bristow et al. 2002).
Differences in survival of ovarian cancer patients have been found between BRCA1
and BRCA2 mutation carriers and non-mutation carriers (Chetrit et al. 2008, Tan et
al. 2008). There are also publications, including findings from this project, on the
effects of common genetic polymorphisms from candidate genes in mismatch repair
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and cell cycle control pathways; and combinations of variants in the vascular
endothelial growth factor (EGF) gene (Hefler et al. 2007, Mann et al. 2008, Nagle et
al. 2007, Quaye et al. 2009, Quaye et al. 2008, Song et al. 2008). All of these
results suggest that it is feasible that common genetic variants may affect survival
from ovarian cancer.
As well as establishing associations between genetic polymorphisms and
susceptibility to developing a disease, association studies can also be used to identify
genetic variants that may influence survival from the disease. To do this, follow-up
data is required to ascertain the vital statistics of the patients recruited into a study
over a period of time (usually over 10 years). Although participating patients may
die from other causes, such as heart failure, stroke etc, many are likely to die from
ovarian cancer. It is also likely that the sufferers would eventually die from the
disease, particularly because many cases are diagnosed in the advanced stages of
disease.
In survival analyses, the frequencies of genotypes are compared between the patients
which have, unfortunately, died and those still alive over a time period. Variants of
SNPs are said to be associated with survival if a statistically significant difference is
observed between the frequencies of the genotypes/alleles within the groups of
survivors and those who die over the time period. Survival is measured by the
hazard ratio (HR), which essentially, is a measure of the risk of death, based on the
individual’s genotype. Survival analyses using genetic polymorphisms as variables
have the potential of identifying genotypes which may predict a patient’s survival
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over a period of time. This has the potential of becoming a prognostic tool and may
also be used for identifying suitable individuals for targeted therapy.
Survival analysis may also be used to establish response to therapy or overall clinical
outcome. The former could potentially be used for targeted treatment, and the latter
for prognostic purposes. There are studies which have investigated and, in some
instances, identified associations between SNPs and response to treatment,
progression-free survival and overall clinical outcome.
Associations have been found between variants of genes such as ABCB1, ERCC1
and IL8 and response to treatment. ABCB1 is a transporter protein, which is
involved in multi-drug resistance. Associations have been found between variants of
ABCB1 in the tumour DNA of ovarian cancer cases and response to paclitaxel and
carboplatin (Green et al. 2008). Associations between progression-free survival and
ovarian cancer patients and polymorphisms of ABCB1 in germline DNA have also
been reported (Johnatty et al. 2008). Similar associations have been observed
between ECCR1 and response to platinum-based treatment (with tumour and
germline DNA) and progression-free survival (Krivak et al. 2008). ECCR1 is a
component of the nucleotide excision repair pathway. The gene is involved in the
repair of DNA lesions, such as those caused by ultraviolet light and electrophilic
compounds. Cisplatin, a platinum-based chemotherapy agent which is used to treat
many different types of cancer, including ovarian cancer, is an electrophilic
compound. The drug results in the cross-linking of DNA, which consequently
triggers the apoptosis pathway.
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Although the findings of these publications are of interest, the results should be
treated with caution since many of the findings are based on small numbers of
samples (<200) (Green et al. 2006; Kang et al. 2006; Saldivar et al. 2007; Green et
al. 2008; Schultheis et al. 2008; Steffensen et al. 2008). Some of the publications
reporting significant findings between a common polymorphism and response to
treatment or survival are listed in Table 1.3 (page 69).
Survival association studies have also been conducted on the effect of common
polymorphism on overall survival from ovarian cancer (Dhar et al. 1999; Spurdle et
al. 2001; Hefler et al. 2003; Hogdall et al. 2003; Li et al. 2005; Pinto et al. 2005;
Beeghly et al. 2006; Gadducci et al. 2006; Green et al. 2006; Higashi et al. 2006;
Kang et al. 2006; Obata et al. 2006; Santos et al. 2006; Six et al. 2006; Hefler et al.
2007; Nagle et al. 2007a; Nagle et al. 2007b; Mann et al. 2008; Song et al. 2008),
with some statistically significant results (Dhar et al. 1999; Hefler et al. 2003;
Hogdall et al. 2003; Li et al. 2005; Pinto et al. 2005; Beeghly et al. 2006; Green et
al. 2006; Higashi et al. 2006; Obata et al. 2006; Santos et al. 2006; Six et al. 2006;
Nagle et al. 2007a; Nagle et al. 2007b; Mann et al. 2008; Song et al. 2008). Some of
these are shown in Table 1.3.
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Table 1.3: Response to treatment and clinical outcome publications (significant SNPs)
Gene SNP No. cases HR/response rates P-value Treatment/ Population Reference/ source ofDNA
Response to treatment
IL-8 T251A 53 AA* (19%); AT*(0%); vs TT* (50%) 0.006
Cyclophosphamide &
bevacizumab
USA: 45 Caucasian, 8
other (Schultheis et al. 2008)
ERCC1 Codon 118 SNP 159 TT* (44%), CT*(41%), CC* (15%) 0.045 Platinum-based Danish (Steffensen et al. 2008)
ERCC1 Asn118Asn 60 OR=0.17 (0.04-0.74) 0.018 Platinum-taxane Korean (Kang et al. 2006)§
Progression-free survival
CXCR2 C+785T 53
(CC*, CT*) –
7.4months vs (TT*)-
3.7 months
0.026 Cyclophosphamide &bevacizumab
USA: 45 Caucasian, 8
other (Schultheis et al. 2008)
ABCB1 2677 G>T/A 914 0.7 (0.46-1.04) 0.039 Paclitaxel & carboplatin,docetaxel Australia (Johnatty et al. 2008)
ERCC1 C8092A 233 1.44 (1.06-1.94) 0.018 Paclitaxel & cisplatin USA: 214 Caucasian; 19other (Krivak et al. 2008)
XP XPG 146 (GG*) 8.3 months vs24.6 months 0.006 Carboplatin
USA: 135 Caucasian, 21
other (Saldivar et al. 2007)
Overall survival
ERCC1 C8092A 233 1.5 (1.07-2.09) 0.018 Cisplatin & paclitaxel USA: 214 Caucasian; 19other (Krivak et al. 2008)
VEFG
Haplotype of
_634C/C,
_1154G/G,
_2578C/C)
563 2.1 (1.1-3.9) 0.02 Platinum-based Austria, Germany (Hefler et al. 2007)
TP53 codon 72 114 HR>1 0.011 Cisplatinum & paclitaxel Portugal (Santos et al. 2006)
PMS2 rs2228006 1473 0.84 (0.71–0.99) 0.04± Unknown Caucasian UK, USA,Denmark (Mann et al. 2008)
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Gene SNP No. cases HR/response rates P-value Treatment/ Population Reference/ source ofDNA
CCND2
rs3217933;
rs3217901;
rs3217862
1,488
1,489
1,480
1.16 (1.03-1.31)
1.14 (1.02-1.27)
0.85 (0.73-1.00)
0.02
0.024
0.043
Unknown Caucasian UK, USA,Denmark (Song et al. 2008)
CCNE1 rs3218038 1,489 1.39 (1.04-1.85) 0.033 Unknown Caucasian UK, USA,Denmark (Song et al. 2008)
CYP17 5’ UTR C allele 454 1.30 (1.02– 1.68) 0.04 Platinum based Australian (Nagle et al. 2007a)
GSTP1 Ile105Val 448 0.77 (0.61–0.99) 0.04 Platinum based Australian (Nagle et al. 2007a)
VDR FokI 101 0.18 (0.005-0.61) 0.006 Paclitaxel & carboplatin, Japan (Tamez et al. 2009)§
HR – hazard ratio; mo – months; § - based on tumour DNA; *Genotype; ± No longer significant after adjusting for prognostic factors, however the effect became more
pronounced.
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1.12: The admixture maximum likelihood test
To date, there has been limited success in identifying germline variants associated
with ovarian cancer predisposition. Many of the statistically significant associations
are based on relatively small numbers of samples, where the statistical power to
detect true positives is reduced. Furthermore, very few of the published results are
corrected for multiple testing. One possible reason for the lack of multiple testing
correction is that there is a lack of agreement on the most suitable test to use,
because of the correlation between many of the polymorphisms evaluated within a
project. This increasingly important issue has resulted in much discussion and
investigation in the most appropriate method for assessing and correcting for this
“experiment-wise” type I error.
The need for correction for experiment-wise type I error has led to a proposal of a
global null hypothesis of no associations between any of the genetic variants from a
project, and an alternative hypothesis that there are true positive significant
associations between the SNPs and disease risk. A number of methods have been
proposed with the aim of testing whether the null hypothesis can be rejected. The
simple Bonferroni correction for multiple testing only performed best when there
were only three statistically significant SNPs or 5% of the total number of SNPs
tested, whichever is smaller (Pharoah et al. 2007, Tyrer et al. 2006).
Some of the proposed methods for testing the global significance of association
studies include those described in (Hoh et al. 2001; Schaid et al. 2005), as well as
the improved Bonferroni procedure (Simes 1986), truncated product (Zaykin et al.
2002), ranked truncated product of P-values (Dudbridge and Koeleman 2003). The
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admixture likelihood (AML) test is a method that was created in order to assess
whether there are statistically significant differences between the proportion of
significant SNPs from a group/selection genotyped, and that which would be
expected by chance (Tyrer et al. 2006).
The AML method has been tested against many of the tests currently available for
controlling for multiple testing over a variety of scenarios for the alternative
hypothesis, and it was found to have the same or improved statistical power than all
the other methods tested (rank truncated product, unrestricted maximum likelihood,
restricted space maximum likelihood, most significant SNP, Global χ2, Best subset
χ
2) ((Tyrer et al. 2006), (Pharoah et al. 2007)). The AML test has already been used
on genotyping data from breast cancer association studies. In the study, the 710
common polymorphisms of 117 candidate genes were evaluated with AML to
establish the global association between the variants and susceptibility to breast
cancer (Pharoah et al. 2007). The test found that although the effects of individual
SNPs are likely to be small, there were some variants which are associated with risk
of breast cancer (Pharoah et al. 2007). The AML method will be used to evaluate
whether a statistically significant proportion of SNPs were found to be associated
with ovarian cancer risk from genotyping data spanning the past few years, and the
effect size of these associations.
1.13: DNA amplification and genotyping platforms
Along with the evolution of the approaches used in genetic association studies of
ovarian cancer, there have been developments in genotyping platforms. Genotyping
platforms are used to ascertain the genotype of an individual. Although TaqMan®
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and other single SNP genotyping platforms are still popular with research groups,
there is an increasing need for multiplex genotyping platforms to be used. Multiplex
platforms enable the genotyping of more than one SNP in a single reaction. The
multiplex levels currently available differ widely from 12-plex (up to 12 SNPs
genotyped in a single reaction) up to 96-plexes and more. The advent of the chip
genotyping technology also allows thousands of SNPs to be genotyped in a single
reaction. However, chip genotyping technology is only ever likely to be used for
genome-wide association studies or evaluation of whole chromosomes due to the
number of SNPs which can be analysed from a single reaction. The SNP multiplex
genotyping technique offers the potential of reducing the time, amount of reagents
and money spent on genotyping, and in some instances, the quantity of DNA used.
1.13.1: Whole genome amplification
The number of SNPs genotyped has increased exponentially as new approaches are
designed. This has highlighted the importance of addressing the issue of limited
amount of DNA from study individuals and the increasing number of SNPs from
candidate genes which need to be genotyped. Whole genome amplification of DNA
samples and SNP multiplex genotyping platforms are possible solutions for these
problems. Whole genome amplification (WGA) methods are used to replicate the
genome of an individual by varying magnitudes, depending on the method used.
The WGA technique offers the potential of producing limitless quantities of DNA
from research participants – if the re-amplification claims of some WGA products
are to be believed. However there have been conflicting reports of the accuracy of
the replication of some WGA methods.
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Many research groups have reported complete, or near complete (>99%)
concordance between non-amplified genomic material and the corresponding, whole
genome-amplified DNA (Jasmine et al. 2008, Pan et al. 2008, Sorensen et al. 2007).
However, others have found discordances between the non-amplified and amplified
DNA (Pinard et al. 2006, Talseth-Palmer et al. 2008). These discordances have
predominantly been a result of preferential amplification of some alleles at
heterozygous loci. The fidelity of the replication of the DNA needs to be assessed
due to the small effects expected in low-moderate risk models. There are two major
types of WGA techniques, polymerase chain reaction (PCR)-based, and multiple
strand displacement.
1.13.1.1. PCR-based whole genome amplification
PCR-based WGA involves the amplification of the genome, using the PCR process,
with primers which will result in the amplification of the whole genome, rather than
small regions. There are several PCR-based WGA methods commercially available;
Primer Extension Preamplification (PEP, (Zhang et al. 1992)), GenomePlex (Sigma-
Aldrich®) and Degenerate Oligonucleotide PCR (DOP-PCR, (Telenius et al. 1992))
are such methods. PEP uses 15-mer random primers and the Taq polymerase, at low
annealing temperature (to ensure low stringency binding to genomic sites). DOP-
PCR is fairly similar to PEP, however there are some essential differences. Semi-
degenerate oligonucleotide primers (for example ACG TGC GAG NNN NNN NNN
GCT CAT) and a higher PCR annealing temperature is utilised in the DOP-PCR
process. The Taq polymerase is also used in DOP-PCR. Taq is known to produce
short fragments of amplified material (approximately 3 kilobases [kb]), which is
suitable for SNP genotyping studies, however, not for all DNA analysis protocols.
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GenomePlex® is also a PCR-based WGA method, however, the genomic DNA is
converted to an OmniPlex® Library. The OmniPlex Library consists of fragmented
DNA, whose flanking regions have been converted to PCR-amplifiable units. The
library is amplified with universal primers. The method is said to generate 5-10ug of
amplified DNA from nanogram quantities of template DNA (Sigma-Aldrich). The
GenomePlex process is illustrated in Figure 1.8.
Figure 1.8: Schematic diagram of whole genome amplification with GenomePlex
1.13.1.2. Multiple displacement amplification
Whole genome amplification methods such as GenomiPhi™ (GE Healthcare, UK)
and REPLI-g™ (Qiagen, UK) come under the multiple displacement amplification
category of WGA. Both methods are based on the process illustrated in Figure 1.9.
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GenomiPhi and REPLI-g use random hexamers and the bacteriophage Phi29 (φ29)
DNA polymerase, which has 3’ to 5’ exonuclease proofreading activity. The φ29
polymerase does not detach from the template during the amplification process, and
is thus, capable of producing amplified DNA that is up to 100kb in length. The
major differences between GenomiPhi and REPLI-g are that the former uses heat to
denature the template DNA, and the latter uses alkaline denaturation. The methods
also differ in the quantities of amplified material produced. REPLI-g, apparently
Binding of primers to template DNA
Polymerisation begins
Polymerisation continues
Strand displacement
Binding of new primers to newly
formed DNA
Polymerisation from new DNA strands
Figure 1.9: Schematic diagram of multiple strand displacement
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generates up to 45μg of amplified DNA material, however GenomiPhi generates
between 4-7μg of product.
1.13.2: SNP multiplex genotyping platforms
SNP multiplex genotyping methods allow the use of relatively low concentrations of
DNA for the genotyping of more than one polymorphism, usually greater than 12
SNPs, in single reactions. The use of SNP multiplex genotyping platforms should
drastically reduce the time required for laboratory work and the amount of DNA
used for the number of SNPs per reaction. There are various ways in which the
genotypes of multiple polymorphisms can be ascertained from a single reaction.
These include fluorescence, mass and micro-arrays.
There are increasing numbers of multiplex genotyping platforms, such as SNPstream
(microarray), SNPlex (fluorescence and mass, see Figure 1.10), OpenArray
(microarray), iPLEX (mass), Illumina GoldenPath (microarray) and Fluidigm
(microarray). Figure 1.10 shows the binding of a PCR product of a fluorescently
tagged allele and a mass modifier which will enable the distinction of different SNPs
in a SNPlex reaction. The ZipCode sequence ensures the binding of the PCR
product of interest to the complementary ZipChute sequence on the hybridisation
plate before the genotype is determined. The performances of the multiplex
genotyping platforms need to be assessed to determine the suitability of the available
DNA. Therefore, the performance of DNA amplified with four WGA methods:
Genomeplex, GenomiPhi, primer extension PCR (PEP) and REPLI-g will be
investigated on TaqMan and SNP multiplex genotyping platforms (iPLEX,
OpenArray and SNPlex).
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Figure 1.10: The binding of biotinylated amplicons to streptavidin-coated SNPlex
hybridisation plate
Probes and linkers are linked together by phosphorylation. Blue- genome equivalent regions, red-
universal reverse priming site, green-universal PCR priming site. After this step, the unbound probes,
and bottom parts of linkers are enzymatically digested. The ligated probes and linkers are PCR
amplified with biotin tagged universal primers. The products from this are denatured, the supernatant,
containing the linker-probe, are removed. Leaving the biotinylated amplicons to bind with
streptavidin-coated plates.
1.14: Project aims
The aims of this project are:
1. To determine if there is an effect of common variants and haplotypes of
candidate oncogenes on the risk of invasive epithelial ovarian cancer.
2. To determine if there is an effect of common variants and haplotypes of
functional candidate genes (associated with neoplastic suppression of ovarian
cancer cell lines) on predisposition to ovarian cancer.
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3. To use the admixture maximum likelihood test to assess if a significant
number of associations have been found from ovarian cancer association
studies.
4. To evaluate the effect of tSNPs and haplotypes from candidate oncogenes on
all-cause mortality of ovarian cancer patients.
5. To investigate the effect of tSNPs and haplotypes in a series of “functional”
candidates identified from in vitro studies on all-cause survival of ovarian
cancer patients.
6. To evaluate the ease of use and quality of whole genome amplification
methods.
7. To evaluate the performance of non-amplified and whole amplified DNA on
multiplex SNP genotyping platforms.
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Chapter 2: Materials and Methods
2.1: Introduction
This chapter will describe the materials and methods used in this research. All the
samples analysed were Caucasians who were either healthy, unaffected controls or
individuals diagnosed with invasive epithelial ovarian cancer.
2.1.1: Ethics Statement
The collection and genetic analysis of all samples was approved by local review
boards and ethics committees, and informed written consent was obtained from all
study participants.
2.2: Study individuals
Thirteen population-based case control ovarian cancer sample series were used in the
analyses, totalling 6,245 cases and 8,787 controls. These studies comprised of
residents of the United Kingdom (SEARCH and UKOPS); Australia (AUS);
Denmark (MALOVA); Germany (GER, BAVARIA), Poland (POCS, also known as
JAC), and the United States of America (GEOCS, USC, DOVE, HOPE, NCOCS and
HAWAII). Although many of the sample sets included non-Caucasian individuals,
only the genotypes of non-Hispanic Caucasian samples of North European descent
were analysed. This decision was taken because there are some significant
differences in the allele frequencies of some SNPs within different ethnicities, and
some variants are polymorphic in some ethnicities, but not others. The analysis of
genotypes of only Caucasian minimises population stratification. This was discussed
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in chapter 1. Follow-up data was only available for the GEOCS, MALOVA,
SEARCH and UKOPS studies. The DOVE, HOPE, AUSTRALIA, JAC, BAV,
GER, HAW and NCOCS studies were only used in the validation of statistically
significant findings from stage 1 genotyping results.
The Genetic Epidemiology Ovarian Cancer Study (GEOCS, formerly known as
FROC and Stanford) comprised of 327 cases and 429 controls. The cases were
invasive epithelial ovarian cancer patients aged between 20 and 64 years, who were
diagnosed with the disease between 1997-2002, from Alameda, Contra Costa, Marin,
San Francisco, San Mateo and Santa Clara of the Greater Bay Area of San Francisco,
USA. The affected individuals were all prevalent cases, therefore, they were
recruited into the study after the cancer was diagnosed. The controls were recruited
into the GEOCS study through random-digit dial identification from the same towns
and cities of the Greater Bay Area Cancer Registry San Francisco as the cases. The
controls were age (5-year categories) and ethnicity matched with the cases. The
DNA from the study participants was extracted from blood samples and exfoliated
buccal cells from mouthwash rinses with the Puregene Kit (Gentra Systems,
Minneapolis, MN), (Lum and Le Marchand 1998). The vital status information of
the GEOCS cases was obtained from the Greater Bay Cancer Registry, San
Francisco twice during the study. The most current follow-up occurred in 2004.
Computerised hospital tumour registry data or medical records were used for
updated vital status by cancer registry staff. The state’s death index was also used to
follow the vital status of patients. There was a lag time of approximately 18 months
with the state’s death index. 147 deaths have occurred to date (45%). The majority
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of the genotyping was on DNA that had been whole genome amplified with primer
extension pre-amplification (PEP).
The Malignant Ovarian Cancer prediction study (MALOVA) contained 1221
controls and 446 cases from Denmark. The criteria for cases were women aged
between 30 and 80 years, who were diagnosed with an invasive epithelial ovarian
tumour over the December 1994 and May 1999 time period. Cases were recruited
from 18 hospitals from the municipalities of Copenhagen, Frederiksborg, and
counties within Copenhagen, Frederiksborg, Roskilde, Western Sealand, Storstrøm,
Funen, Southern Jutland and Northern Jutland. All the cases were recruited into the
study at surgery before diagnosis of the disease, therefore they are said to be incident
cases. Follow-up to establish the patients’ vital statistics occurred until 2003.
Individuals living in Denmark have a unique personal identification number which
was used to identify patients who were alive, as well as those who had died or
emigrated. The cause of death of those who died during follow-up was determined
by matching medical records with a Danish Hospital Reference System. Currently,
there have been 301 (67%) deaths. Unaffected controls were obtained from the
general female population within the same areas as the cases and the age range was
also 30-80 years. Genomic DNA from both cases and controls were extracted from
pre-operative blood samples by Whatman International Ltd with chloroform protocol
(Ely, UK).
The UK SEARCH ovarian cancer study (SEARCH), consisted of 1,215cases of
ovarian cancer and 1,229 controls from an ongoing, population-based ovarian cancer
case-control study covering the regions served by the East Anglia and West
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Midlands cancer registries in the UK. The cases were younger than 70 years from
East Anglia, West Midlands and Trent regions of England. Prevalent cases
diagnosed between 1991 and 1998, of which there were 284 participants, were
recruited for the study. The incident cases were recruited from 1998 onwards.
Active follow-up was conducted at 3 and 5 years after diagnosis, and then at 5-year
intervals by the Eastern and West Midlands cancer registries. The latest update was
on 31th August 2007. Follow-up involved searching hospital information systems for
recent visits and contacting general practitioners for the patient’s vital status if a
recent visit had not occurred. There were 230 (27%) deaths at the time of analysis.
Healthy individuals, aged between 45 and 74 years, from the EPIC-Norfolk
constituent of the European Prospective Investigation of Cancer (EPIC) cohort of
25,000 people were recruited as controls. The controls were from the same
geographical region as the cases. The blood DNA of study participants was
extracted by Whatman International Ltd.
The participants of the United Kingdom Ovarian Population Study (UKOPS) were
recruited from the UK. There were 691 cases and 1,051 controls. The cases were
recruited from 10 major Gynaecological Oncology National Health Service centres
in England (University College London Hospital, East Kent, Gateshead, Southend,
Bristol, Middlesbrough, Manchester and Portsmouth), Wales (North Wales) and
Northern Ireland (Belfast), from 2006 onwards. The UKOPS controls, aged 50-76
years from the general population, were apparently healthy postmenopausal females
who were recruited into the United Kingdom Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS) study. However, 75 of the cases were identified through the
UKCTOCS study. DNA was extracted with the chloroform extraction method
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(Sambrook and Russell 2001). The control women were followed up for cancers
through the Office of National Statistics. The most current follow-up for the
UKCTOCS samples was June 2008, and in August 2008 for the remaining samples.
Survival data was available for 401 of the cases at the time of analysis. Of these
cases, 148 were diagnosed with ovarian cancer after recruitment into the study, and
the remaining were prevalent cases. At the time of analysis, there were 83 deaths
(21%) out of the 391 cases with complete follow-up data.
The University of Southern California/Los Angeles County case-control studies of
ovarian cancer (USC), from the USA, consisted of 434 ovarian cancer cases and 584
healthy controls, aged between 18-84 years. Recruitment began in 1993 and is
ongoing as part of a larger study, known as the Los Angeles County Case-Control
Studies of Ovarian Cancer (LAC-CCOC). The cases were identified from the
Surveillance, Epidemiology, and End Results (SEER) registry. Unaffected study
participants (controls) were matched with the cases in terms of age, race, socio-
economic status, parity, oral contraceptive use, geographical residence and other
ovarian cancer risk factors, however only non-Hispanic Whites were analysed in this
study. DNA was extracted from blood lymphocytes with the chloroform extraction
(Sambrook and Russell 2001) process or the Qiagen Blood Kit (Qiagen, Chatsworth,
CA, USA). The DNA samples were sent to Molecular Staging, Inc. (New Haven,
CT, USA) for whole genome amplification with RepliG™. There was no follow-up
for this study.
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Table 2.1: Ovarian cancer case-control populations used in study
Cases Controls
Population*
Total Age(years)
Part.~n
rate (%) Ascertainment Total
Age
(years)
Part.~n
rate (%) Ascertainment
MALOVA
(Denmark) 446 35-79 79
Incident cases diagnosed 1994 -1999
from municipalities of Copenhagen &
Frederiksberg & surrounding counties.
1,221 35-79 67
Random selection of females from the
computerized Central Population
Register.
SEARCH
(UK)
847
(368)§ 21-74 69
Cases from East Anglian, West Midlands
& Trent regions of England. Prevalent
cases diagnosed 1991-1998; incident
cases diagnosed 1998 onwards.
1,229 39-77 84
Selected from the EPIC-Norfolk cohort
of 25000 individuals based in the same
geographical regions as the cases.
GEOCS
(USA) 327 23-64 75
Consecutive cases diagnosed from 1997-
2002 in Greater Bay Area Cancer
Registry San Francisco. 429 19-66 75
Random-digit dial identification from
study area. Frequency matched to cases
for race/ethnicity & 5 year age group.
USC
(USA) 197 18-84 73
Rapid case ascertainment through Los
Angeles Cancer Surveillance program
from 1999-2004.
224 21-78 73
Neighbourhood recruited controls,
frequency matched to cases for age &
ethnicity from 1993-2004.
UKOPS
(UK)
506
(185)§ 35-86 86
Cases from 10 gynaecological oncology
National Health Service centres
throughout the UK, from January 2006
onwards.
595
(467)§ 50-76 97
Apparently healthy postmenopausal
women from the general population
participating in the UKCTOCS.
Followed up for cancers through the
Office of National Statistics.
DOVE
(USA) 584 35-74 75
Cases diagnosed with primary invasive
ovarian cancer between 2002-2005 from
a 13-county area of Western Washington
state.
716 35-74 82
Random-digit dial identification from
study area. Frequency matched to cases
for race/ethnicity & 5 year age group.
BAV
(Germany) 228 25-81
Hospital based study from Erlangen,
Northern Bavaria, Germany, Recruitment
from May 2002 to August 2008.
234 24-86
Random selected woman from
Erlangen, Northern Bavaria, Germany
Recruitment from May 2002 to August
2008.
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Cases Controls
Population*
Total Age(years)
Part.~n
rate (%) Ascertainment Total
Age
(years)
Part.~n
rate (%) Ascertainment
GER
(Germany) 218 21-74 58
Incident cases diagnosed 1993 -1996
from two study areas in southern
Germany and identified through frequent
monitoring of hospitals serving the study
areas.
416 23-75 51
Two controls per case matched by age
and recruitment area were selected from
a random sample of the general female
population in study area selected using
population registries
POCS
(Poland) 603 23-82 80
Cases diagnosed with epithelial ovarian
cancer in five gynaecological oncology
centres in Poland; between 1998 and
2006.
593 24-74 90
Healthy women from the general
population were randomly selected and
matched to cases with the same year of
birth and geographical region.
NCOCS
(USA) 622 20-74 70
Identified from 48 counties within
Northern California 747 22-75 63
Controls identified from same
region. Frequency matched to cases for
age and race.
HAWAII
(USA) 70 18-84 66
Rapid case ascertainment through
Hawaii Tumour Registry. 158 27-86 69
Randomly selected from Hawaii
Department of Health Annual
Survey of the representatives
households.
AUS
(Australia) 768 19-79 84
Comprised of Cancer registries of New
South Wales and Victoria. Recruited
through surgical treatment centres
throughout Australia.
1,122 19-79 47
Randomly selected from
Commonwealth electoral roll.
Frequency matched for age and
geographical region.
HOPE
(USA) 276 25-80 69
Variable source including physician
offices cancer registries & pathology
databases from counties of Western PA
Eastern OH & Western NY.
636 25-80 81
Identified in same regions as cases.
Frequency matched for age & ethnicity.
All participants undergo home
interviews.
Total 6,245 8,787
§ - additional samples used in validation of functional candidates results. Part.~n - participation.
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Diseases of the Ovary and their Evaluation (DOVE) study, also from the USA, is
part of the SEER registry. There were 584 cases aged between 35-74 years,
diagnosed with primary invasive ovarian cancer between 2002 and 2005 from a
thirteen-county area of western Washington State. Controls were selected through
random digit dialling. There were 716 controls who were matched to the age groups,
race/ethnicity and area of residence as the cases. DNA of the cases and controls was
isolated from blood or buccal cell samples.
The Hormones and ovarian cancer prediction study (HOPE) from the USA, recruited
study participants from the counties of western Pennsylvania, eastern Ohio and
western New York. The 276 invasive epithelial ovarian cancer cases were identified
from a variety of sources including physicians’ offices, cancer registries and
pathology databases from the study region. Both cases and controls were individuals
aged between 25 and 80 years. The 636 controls were recruited from the same cities
as the cases. The controls were frequency matched for age. The case-control
population sets are summarised in Table 2.1.
The Australian (AUS) case-control samples series comprised of sample collections
from the Australian Cancer Study (ACS) and the Australian Ovarian Cancer Study
(AOCS). There were a total of 768 cases and 1,122 controls when the two studies
were amalgamated. The controls of both studies were randomly selected from
Commonwealth electoral roll, and age- and geographical region-matched to the
cases. The controls were aged between 19 and 81 at the time of recruitment.
Participant recruitment occurred between 2002 and 2005 for ACS, and 2002-2006
for AOCS.
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The cases from the ACS study were recruited from Cancer registries of New South
Wales and Victoria; and the cases from the AOCS study were recruited from surgical
treatment centres in Australia, and also cancer registries of Queensland, and South
and West Australia. Age range of cases was 23-80 years.
The 603 invasive epithelial ovarian cancer cases from the Poland Ovarian Cancer
Study (POCS), previously known as JAC, were recruited between 1998 and 2006,
from five gynaecological oncology centres from four cities (Szczecin, Opole, Poznan
and Rzeszów) in Poland. There was a participation rate of 80% among the ovarian
cancer sufferers approached. The controls (593 individuals) of the study comprised
of randomly selected healthy women from the general population. There was a 90%
participation rate among the controls. The controls were matched to the cases by
geographical region of residence and the year of birth.
The BAVARIA study consisted of 234 unaffected controls and 228 women
diagnosed with invasive epithelial ovarian cancer. The patients were recruited from
May 2002 to August 2008 from hospitals within Erlangen, of Northern Bavaria,
Germany. The apparently healthy controls, aged between 24 and 86 years, were
randomly selected from the same geographical area as the cases in the same time
period.
German Ovarian cancer study (GER) consisted of 416 healthy controls (58%
participation rate), and 218 individuals with ovarian cancer. Incident cases of
ovarian cancer, diagnosed in individuals aged between 20 and 75 years were
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recruited from two study areas in southern Germany. The cases were recruited from
1993 to 1996 through frequent monitoring of hospitals within the study areas.
Controls from the general population were matched, 2:1 with the cases, for age and
area of residence. The controls were randomly selected from population registries.
Confirmed cases of primary epithelial ovarian cancer from the Hawaii Ovarian
Cancer Study (HAWAII) were recruited from residents of Oahu. The 70 affected
participants were diagnosed between 1 June 1993 and 30 June 1999 in the major
hospitals of Oahu. The 158 controls of the study comprised of unaffected women
from the general population of Oahu. Controls were selected from lists of women
who had been interviewed by the Health Surveillance Program of the Hawaii
Department of Health. Participants of the Health Care Financing Administration of
Oahu aged 65 years or older were randomly selected as potential controls. The
controls were ethnicity and 5-year age matched with the cases in order to help
minimise selection/ascertainment bias. DNA was extracted from peripheral blood
leukocytes by SDS/proteinase K treatment and phenol/chloroform extraction. All
the participants analysed in the study were Caucasian. There were 70 cases and 158
controls. These samples were only used in the stage 2, validation studies.
The North Carolina Ovarian Cancer Study (NCOCS) samples used comprised of 622
cases and 747 controls, all of whom were Caucasian. Eligible cases were recruited
from a 48-county area of North Carolina. Rapid case ascertainment was used to
identify potential study participants from the North Carolina Central Cancer
Registry. This registry contains information on cancer sufferers from the general
population of the state. Patients with primary ovarian cancer aged between 20 and
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74 years from the 48 counties within North Carolina fulfilled the study entry criteria.
List assisted random dialling was used to identify population-based controls from the
same 48-county region as the cases. The controls were also ethnicity and 5-year age
matched with the cases. The DNA was extracted using the PureGene DNA isolation
protocol.
2.3: Gene and tagging SNP selection of candidate oncogenes
Various oncogenes have been implicated in the development of ovarian cancer; these
include AKT2, BCL2, BRAF, CMYC, CTNNB1, ERBB2, KIT, KRAS, MUC1, MUC2
and PIK3CA. SNP genotyping data on the Centre d'Etude du Polymorphisme
Humain (CEPH) population for AKT2, BCL2, BRAF, CMYC, CTNNB1, ERBB2,
KIT, KRAS, MUC1, MUC2, NMI and PIK3CA were downloaded from The
International HapMap Project, Data Release 20/phase II Jan06. NMI is not an
oncogene, but was accidentally selected as a result of the information being
displayed when CMYC, an alias of MYC, was entered as a search term in HapMap.
There was genotyping data available for only two common SNP (minor allele
frequency ≥0.05) for MYC, so this oncogene was excluded from further evaluation.
The genotyping data downloaded for these genes was CAU, which is a reference for
Caucasians of north European populations. The gene selection process is discussed
in chapter 3.
The reference genotyping data from HapMap was used to select a group of SNPs
from each gene (with minor allele frequency [MAF] of at least 5%), which could
subsequently be tagged. To do this, the genotype information was imported into
Haploview version 3.32 (Barrett et al. 2005) and Tagger (de Bakker et al. 2005).
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Haploview is a programme which was designed primarily for haplotype analysis.
The programme can be used to perform: linkage disequilibrim (LD) and haplotype
block analyses; haplotype population frequency estimation; single SNP and
haplotype association tests; and permutation testing for association significance.
Tagger contains an algorithm which performs tagging SNP (tSNP) selection. Tagger
is able to produce a list of tSNPs by initially selecting a set of SNPs which are to be
captured through the tagging approach.
The LD between a pair of SNPs is established so that SNPs which are in strong LD
capture each other, and therefore only one tSNP needs to be genotyped. This
tagging approach is known as the pair-wise method for SNP selection. It is possible
that a SNP is in strong LD with several SNPs. This SNP is selected to be the tSNP
and it is said to capture all the SNPs it tags.
Aggressive tagging is another method of tSNP selection. The initial stage of
aggressive tagging is the same as that of pair-wise tagging. The additional steps
include using multi-marker/SNP tests to try to capture SNPs which could not be
tagged by other SNPs with the pair-wise approach. Multi-marker tests are used
because in some instances, a combination of markers is in stronger LD with a SNP
than another single SNP. The software then “peels back” the tSNP list by replacing
some of the tSNPs with multi-marker SNPs. Haploview and Tagger have several
options which can be changed by the user, and thus a user is able to select tSNPs
based on a criterion.
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Haploview and Tagger were used to select tSNPs that capture common genetic
variation (minor allele frequency ≥ 5%) from the candidate genes, and putative
regulatory regions up and down stream of the gene (within 5kb), with a minimum
squared correlation of 0.8 (r2 ≥ 0.8). r2 ≥ 0.8 means that there is at least 80%
correlation between the genotype tSNP and the SNPs that it tags. The quality of the
HapMap data was also ascertained and only SNPs with sufficiently good quality data
were selected for tagging. The selection criteria for good quality data was based on
≥80% genotyping data of the CEPH participants for each common polymorphism.
The other criteria for SNP selection were for the Hardy-Weinberg equilibrium p-
value to be greater than 0.01, the minimum percentage of non-missing genotypes for
each SNP (of the HapMap data) to be ≥ 80% and the maximum number of
Mendelian inheritance errors in the HapMap CEPH trios to be no greater than 1.
The 2-3 multi-marker (aggressive) tagging option of Tagger was used to select
tSNPs.
If a selected tSNP failed assay design or genotyping, an alternative tSNP was chosen
where possible. The sequences for the SNPs were obtained from the National Center
for Biotechnology Information (NCBI) SNP database, dbSNP,
(http://www.ncbi.nlm.nih.gov/SNP/) and were used for SNP pooling and primer
design.
2.4: Microcell-mediated chromosome transfer of chromosome 18
The microcell-mediated chromosome transfer of chromosome 18 (MMCT-18) in
vitro and in vivo experiments were performed by Dr Dimitra Dafou. Details of the
experimental procedure of the MMCT of chromosome 18 can be found in (Dafou et
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al. 2008). Briefly, donor mouse A9 cells containing normal human chromosome 18
were micronucleated with 48 hours of colcemid. The human chromosome was
tagged with selectable fusion gene marker, hygromycin phosphotransferase.
Polyethylene glycol was used to fuse the donor cells to the endometrioid TOV21G,
and the clear cell TOV112D, ovarian cancer cell lines. This procedure is
summarised in Figure 2.1. Microcells containing the human chromosome were
selected with hygromycin B. TOV21G and TOV112D hybrid clones were isolated
and expanded after 2-3 weeks of culture.
Figure 2.1: Schematic diagram of microcell-mediated chromosome transfer (MMCT)
(printed with permission from Dr Dimitra Dafou). *Hybrid cells contained an extra copy or a
fragment of normal human chromosome 18. The clones showed in vivo and in vitro characteristics
suggesting their phenotype was reverting back to that of non-neoplastic cells.
colcemid
48h
Donor
cell Micronuclei
Tumour
cell
Fusion
Hybrid
cell
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The tumourigenicity of the resulting recipient: donor hybrid clones were assessed
using in vitro and in vivo assays. Fluorescence in situ hybridisation (FISH) was also
used to visualise the incorporated chromosomes in the hybrid clones.
Microsatellite analysis and array comparative genomic hybridisation were used to
evaluate the regions of chromosome 18 which were transferred into the hybrid
clones. The whole chromosome was transferred into the TOV21G cell line hybrids,
however only the chromosomal region 18p11.21 – 18q11.2 was transferred into the
TOV112D hybrids. Two hybrid clones from each cell line (18G1 and 18G5 from
TOV21G, and clones18D22 and 18D23 from TOV112D) were selected based on
their phenotypic characteristics - in vivo and in vitro tumour suppression.
The Applied Biosystems 32K gene expression array platform (Applied Biosystems)
was used to evaluate the global gene expression levels of each parental ovarian
cancer cell line and their corresponding “reverted” hybrids in triplicate. The Spotfire
DecisionSiteTM software for functional genomics (Spotfire AB, Goteborg, Sweden)
and R version 1.9.1. were used to assess the fold change in gene expression between
each hybrid and their parental cell line in the 32,878 probes of 29,098 genes. The
corresponding P-values for the fold changes in gene expression were evaluated with
an analysis of variance (ANOVA) test. The pooled data from both hybrids of each
of the cell lines were also analysed using Spotfire DecisionSite(TM) and R software.
2.5: Gene and tagging SNP selection of “functional” candidate genes
Candidate genes were selected based on significant differential expression between
MMCT-18 hybrids and the parental ovarian cancer cell lines. Genes with
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concordant and consistent expression fold changes (up or down regulation following
the insertion of the normal human chromosome 18), within the two hybrid clones,
were selected. Genes with consistent expression changes between the TOV21G and
TOV112D were also selected for a master-list. The master-list of the candidate
genes selected based on consistent fold changes in expression between parental and
the hybrids, and statistically significant P-values for the fold changes, is given in
Appendix I. The candidate gene selection process is described in detail in Chapter 3.
2.6: Selection of genes tagging SNPs analysed with admixture
maximum likelihood test
The admixture maximum likelihood (AML) test involved the evaluation of
genotyping data of 3 population-based studies (GEOCS [327 cases, 429 controls],
MALOVA [446 cases, 1,221 controls] and SEARCH [847 cases, 1,229 controls]).
The results of the associations from the genotyping data had previously been
reported in (Dicioccio et al. 2004; Auranen et al. 2005; Song et al. 2006a; Song et
al. 2006b; Gayther et al. 2007; Song et al. 2007; Ghoussaini et al. 2008; Quaye et al.
2009). Over the course of the last 6 years, there have been developments in SNP
association studies. The rationale and approaches used in SNP selection have also
changed. The limited success in finding strongly associated genes with ovarian
cancer development has also lead to new approaches being used to identify candidate
genes.
Candidate gene selection for ovarian cancer associations studies have predominantly
been based on biological pathways that are predicted to be involved in ovarian
carcinogenesis. These pathways include DNA double strand break repair, DNA
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mismatch repair and cell cycle control. Coding SNPs from the DNA double strand
repair (BRCA1, NBS1, RAD51, RAD52, XRCC2 and XRCC3 genes) and cell cycle
control (STK15 gene) pathways were selected in the earliest studies. The alleles of
these functional SNPs resulted in different amino acids being produced. These
variants were selected because it was biologically plausible that they would be
directly involved in altering protein function through the folding and binding of the
protein. These changes would be expected to affect ovarian cancer development or
susceptibility if there was a significant association.
The LD between SNPs was advantageously used in the tagging SNP approach of
candidate genes from the DNA mismatch repair pathway, and all subsequent
candidate genes (from cell cycle and oncogene pathways and MMCT-18). The
tagging approach enabled the genotyping of smaller numbers of SNPs from genes,
which would provide genotyping data for a greater number of SNPs overall.
Oncogenes and tumour suppressor genes which were known or predicted to be
involved in ovarian cancer development were also selected for associations studies.
Candidate genes were also selected based on differential expression of cancer
parental cell lines and their suppressed, non-neoplastic normal chromosome 18
hybrids (from the functional MMCT-18 study). The genes selected from the
MMCT-18 study were the only genes chosen based on putative, functionally relevant
candidate genes for ovarian cancer aetiology through in vitro and in vivo assays.
Furthermore, candidate SNPs validated by OCAC were selected because they had
been found to be significantly associated with ovarian cancer in other population-
based studies (from other members of the Ovarian Cancer Association Consortium
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[OCAC]) or associated with breast cancer (identified by the Breast Cancer
Association Consortium- [BCAC]).
2.7: Laboratory work
The vast majority of the experiments were conducted in the laboratories at
University College London. Due to the collaborative nature of the studies, some of
the genotyping was also conducted at Strangeways Research Laboratory at the
University of Cambridge (GEOCS and SEARCH for all SNPs except MMCT and
some oncogenes), University of Southern California (HOPE, DOVE, NCOCS) and
Australia (AUS).
The MALOVA samples were normalised to 50ng/ul with distilled water into deep-
well plates with the 8-span liquid handling (LiHa) arm of the Tecan Freedom EVO®
workstation (Tecan, Reading, UK). LiHa accurately distributes low volumes with
the aid of pinch valves. Filter tips were used to minimise contamination. The LiHa
and TeMO®, a 96-head multi-channel pipette, were used to dilute some of the
50ng/ul DNA to 2ng/ul. The TeMO was also used to dispense 5ul of the 2ng/ul DNA
to 384-well, barcoded PCR plates. Barcoded plates were used for ease of tracking
the DNA plates (and sample).
2.8: Whole genome amplification methods
Ninety-five MALOVA control samples and one non-template test control (NTC)
were whole genome amplified with GenomePlexTM, GenomiPhiTM, primer extension
pre-amplification (PEP) and REPLI-gTM. The starting concentrations of DNA
amplified with GenomePlex™, GenomiPhi™ and REPLI-g was 100ng of DNA.
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20ng of DNA was used for PEP amplification. All amplification reactions were
performed manually in 96-well PCR plates.
2.8.1: Whole genome amplification with GenomePlex
100ng of 95 MALOVA samples were amplified with the GenomePlex® Whole
Genome Amplification (WGA2) kit 2 (Sigma, Poole, Dorset, UK). 2μL of 50ng/μL
DNA was diluted with 8μL distilled water and fragmented at 95oC for 4 minutes. An
OmniPlex library mix, containing 2μL of 1x Library Preparation Buffer and 1μL of
the Library Stabilization Solution were added to each sample. The mixture was
subsequently incubated for 2 minutes at 95oC. The mixture was cooled on ice and
1μL of Library Preparation Enzyme was added. The DNA-library solution was
incubated for the following conditions: 16oC for 20 minutes, 24oC for 20 minutes,
37oC for 20 minutes, 75oC for 5 minutes and cooled to 4oC. A mixture containing
7.5μL of 10x Amplification Master Mix, 47.5μL of nuclease-free water and 5μL of
WGA DNA polymerase was added to each sample. The mixture was thermocycled
for 95oC for 3 mins, 14 cycles (of 94oC for 15 secs and 65oC of 5 mins); and cooled
to 4oC.
A working stock of the amplified material at the concentration of 2ng/μl was stored
at 4oC, and the original and 20ng/μl stock were stored at -20oC.
2.8.2: Whole genome amplification with GenomiPhi
The GenomiPhi DNA amplification kit (GE Healthcare, Bucks, UK) was also used
to amplify the 95 MALOVA DNA samples. The DNA (2μL of 50ng/μL) was
denatured at 95oC for 3 minutes. An amplification mix containing 9μL of
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GenomiPhi reaction buffer and 1μL of the GenomiPhi φ29 enzyme was added to
each sample. The DNA-amplification mixture was incubated at 30oC for 16 hours.
The reaction was heat inactivated at 65oC for 10 minutes and cooled to 4oC.
2.8.3: Whole genome amplification with PEP
For each primer extension pre-amplification (PEP) reaction, 10ul of 2ng/µL of the 95
MALOVA samples were amplified in 50μL final volume reactions. The 40μL PCR
reaction for each sample consisted of 22.75μL water, 5μL of 10x PEP buffer (1.5nM
Mg), 2μL of 25nM magnesium, 5μL of 2nM dNTP, 5μL of 2000μM PEP N15-mer
(5’ NNN NNN NNN NNN NNN 3’), and 0.25μL Qiagen Taq polymerase. The PCR
master-mix containing the PCR components were added to the DNA samples, and
subsequently thermocycled for the following conditions: activation of the enzyme
for 3 minutes at 94oC, 50 cycles of (94oC for 3 mins, 37oC for 2 mins, 37oC to 55oC
[RAMP at 10 seconds per oC], 55oC for 4 mins), incubated at 72oC for 5 mins and
cooled to 4oC.
2.8.4: Whole genome amplification with REPLI-g
100ng of 95 MALOVA samples were amplified with REPLI-g Midi Kit (Qiagen,
West Sussex, UK). 500µL of Solution A was prepared with 40μL 5M potassium
hydroxide (KOH) and 10μL of 0.5M ethylenediamine tetra-acetic acid (EDTA)
(pH8) which had been diluted in 450μL deionised water. 280µL of denaturing
buffer was made up with 35μL Solution A and 245μL nuclease-free water. 560μL of
neutralisation buffer was prepared with 56μL Solution B and 504μL nuclease-free
water.
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0.5μL of tris-EDTA (TE) was added to 2μL of 50ng/μL DNA sample. 3μL of
denaturation buffer was added to the DNA. This denaturing mixture was mixed,
spun and incubated at room temperature for 3 minutes. 5μL of the neutralisation
buffer was mixed into the samples to neutralise the denaturing reaction. A 40μL
master-mix, containing 32.4μL nuclease-free water, 15μL 4x REPLI-g buffer and
0.6μL REPLI-g DNA polymerase, was added to each 10μL denatured and
neutralised DNA solution. These solutions were mixed, pulse centrifuged and
incubated at 30oC for 16 hours. The amplification reaction was inactivated by
incubating the plate at 65oC for 3 minutes. The amplified DNA was cooled to 4oC.
The DNA of an additional 95 samples were amplified with REPLI-g by a colleague,
Mr Mark Cox, to further investigate concordance of the amplified DNA.
2.9: DNA quantification with PicoGreen
The whole genome amplified DNA were quantified with Quant-iT™ PicoGreen®
dsDNA assay (Molecular Probes, Invitrogen, Paisley, UK). A 200-fold dilution of
the concentrated DMSO solution (from the PicoGreen kit) was made with TE in a
plastic container in a dark room. Calf thymus DNA (Sigma) was diluted to generate
a high-range size standard which would be used to extrapolate the concentration of
the sample DNA. 100μL of the calf thymus stock (1μg/mL) was diluted with 900μL
of TE, to make a concentration of 100μg/mL. 84μL of TE was added to 16μL of the
100μg/mL DNA to make a concentration of 16μg/mL. A 1:5 dilution of the
16μg/mL DNA was made with 100μL of the 16μg/mL DNA and 400μL of TE (to
make a DNA concentration of 3.2μg/mL. Serial dilutions of the DNA were made
using 200μL DNA and 200μL TE as indicated below, starting with 3.2μ/mL:
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Volume of TE (µL) Volume of calf DNA
(µL)
Calf DNA concentration
(μg/mL)
0 200 3.2
200 200 1.6
200 200 0.8
200 200 0.4
200 200 0.2
200 200 0.1
200 200 0.05
200 0 0
(The 1.6μg /mL DNA was made by mixing 200μL of the 3.2μg/mL DNA with
200μL of TE. The 0.8μg/mL DNA concentration was made by mixing 200ul of the
1.6μg/mL DNA with 200ul TE. Etcetera…).
50μL of the diluted PicoGreen was added to 50μl of the diluted calf thymus DNA
(standard) in triplicate in a black plate. 5ul of each WGA DNA sample was diluted
with 45ul TE and 50ul of diluted PicoGreen was added the black plate. The Tecan
Genios plate reader was used to measure the DNA concentration and the data was
analysed with the Magellan software (Tecan, Dorset, UK).
2.10: Genotyping platforms
The ninety-five MALOVA samples which were whole genome amplified with
GenomePlex, GenomiPhi, PEP and REPLI-g, and their corresponding non-amplified
genomic DNA were genotyped with TaqMan®, iPLEX®, SNPlex® and TaqMan®
OpenArray.
2.10.1: TaqMan® genotyping
For each 5μL TaqMan (Applied Biosystems, Warrington, UK) genotyping reaction,
a master-mix containing 2.44μL distilled water, 2.5μl Applied Biosystem’s SNP
Chapter 2: Materials & methods
102
genotyping master-mix, and 0.06μL 80x Custom Assay-by-Design TaqMan probe
(Applied Biosystems), was added to 10ng of DNA. TaqMan genotyping reactions
for oncogene and MMCT-18 tSNPs were conducted at half volume (2.5μL);
appropriate adjustments were made to the volumes of reaction components used.
Normally a large mastermix was made which contained enough reaction mix for the
samples being genotyped. The 5μL or 2.5μL reaction mix was dispensed into the
appropriate wells of the dried DNA plates with the liquid handling (LiHa) arm of the
Tecan Evo 200 robot. The DNA – master-mix solution was thermocyled for the
following conditions: activation at 95oC for 10 mins, annealed/extended for 40
cycles of (95oC for 15 seconds, 60oC for 1 min), and cooled to 4oC. All
thermocycling was performed on Auto-Lid Dual 384-well GeneAmp® PCR System
9700 instruments and end reaction products were read on the 7900HT Fast Real-
Time PCR System using the Sequence Detection Software. Although the vast
majority of Applied Biosystems TaqMan assay clustered well with the annealing
temperature at 60oC, some required different temperatures. Therefore, each TaqMan
assay was tested (with 95 DNA samples and an NTC) with the annealing
temperature at 60oC, before whole population sets were genotyped. An additional 5-
10 anneal extend PCR cycles were performed if the clusters were sub-optimal. If
this failed, or the assay did not produce distinct clusters for the genotypes, the probe
test was repeated with annealing temperature of 54oC.
2.10.2: iPLEX genotyping
The MassARRAY iPLEX SNP multiplex genotyping platform was used to genotype
whole genome amplified samples, and genomic GEOCS, MALOVA and SEARCH
samples for the oncogene study, and iPLEX Gold was used to genotype MALOVA,
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SEARCH and UKOPS for the MMCT-18 study. iPLEX Gold is an upgrade to the
iPLEX system. The only real difference between the platforms are the multiplex
levels. While up to 29 SNPs can be genotyped with the iPLEX assay in a single
reaction, up to 40 SNPs can be assayed with the upgrade. iPLEX Gold has a wider
mass range from which alleles/SNPs can be detected. The GEOCS and SEARCH
samples were air-dried genomic samples, which had been plated a year prior to the
lab work. Wet MALOVA DNA was used in the iPLEX runs. Desalted forward,
reverse and extend primers for the iPLEX panels were manufactured by Metabion
(Martinsried, Germany). The PCR with the forward and reverse primers were
performed at UCL with the Tecan robot, and all post-PCR processing was conducted
at Sequenom Europe in Hamburg, Germany, by the author.
A primer mix, comprising of 120μL of 500nM of each of the forward and reverse
primers of all the SNPs were combined, resulting in a final concentration of 100nM
in each 5μL reaction. A dNTP mix was also prepared with equal amounts (400μL)
of 100nM dATP, dCTP, dGTP and dTTP. A PCR cocktail containing the following
for each sample: (1.85μL distilled Milli-Q water, 0.625μL of PCR buffer with 10X
magnesium chloride [MgCl2], 0.325μL of 25mM MgCl2, 0.1μL of 25mM dNTP mix,
1μL of primer mix [500nM of each primer], and 0.1μL of 5U/μL Hotstar Taq® DNA
polymerase enzyme), was prepared and added to 10ng of DNA.
In a thermocycler, the reaction mixture was activated at 94oC for 15 mins, cycled 45
times (at 94oC for 20 secs, 56oC for 30 secs, 72oC for 60 secs), and inactivated at
72oC for 60 secs. Unincorporated dNTPs in the PCR amplification mixture were
dephosphorylated with a shrimp alkaline phospatase (SAP) cleaning step. This
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involved incubating the PCR-amplified mixtures with 2μL of SAP mix (which
comprised of 1.53μL distilled Milli-Q water, 0.17μL of 10x SAP buffer and 0.3μL of
1U/μL SAP enzyme for each sample). The incubation steps were 37oC for 20
minutes and 85oC for 5 minutes. The dephosphorylated mixture was then cooled to
4oC. The SAP cleaning was necessary in order to prevent the remaining dNTPs
being incorporated in the primer extension reactions, which could subsequently
result in contamination peaks being present in the results.
The extend primers were pooled into four groups according to the mass of the extend
primers. The signal-to-noise ratios of the extend primers decrease with increasing
extend primer mass, therefore these adjustments in extend primer concentrations
were required in order to equilibrate the signal-to-noise ratios of the extend primers
of different masses. The extend primers were arranged into increasing masses, and
the primers were split into 4 groups. Therefore, lower mass primers were grouped
with other low mass primers and high mass primers were grouped with other high
mass primers. The final concentration of the lowest mass primers was half of those
in the highest mass group. Thus an extend primer mix was prepared whereby the
final concentrations of the group 1 extend primers (lowest mass) was 0.625μM,
group 2 was 0.833μM, group 3 was 1.042μM, and group 4 (highest mass) was
1.25μM.
An iPLEX reaction mix was made up of (for each sample): 0.755μL distilled water,
0.2μL of 10X iPLEX buffer, 0.2μL of iPLEX termination mix, 0.804μl of the extend
primer mix and 0.041μL of the iPLEX enzyme. 2μL of this cocktail was added to
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each sample. The mixture was mixed and covered with adhesive seal. This was
subsequently cycled for the following PCR conditions:
40 CYCLESHOLD Hold 5 cycles HOLD HOLD
94oC
30 secs
94oC
5 seconds
52oC
5 secs
80oC
5 secs
72oC
3 mins
4oC
15 mins
The iPLEX reaction products were desalted by adding 25μL of water and 6mg of
Clean resin (using a dimple plate). A nano-dispenser was used to dispense the
iPLEX reaction products onto a 384-element SpectroCHIP bioarray. The
SpectroCHIPs were read on Bruker™ Autoflex, a matrix-assisted laser
desorption/ionization time of flight (MALDI-TOF) mass spectrometer.
2.10.3: SNPlex genotyping
SNPlex is a 48-plex SNP genotyping method from Applied Biosystems. The
genomic and amplified DNA were genotyped on two separate occasions on the
SNPlex platform. The first run was manually performed at UCL by the author and
Applied Biosystems’ SNPlex technical expert. The SNP pass rates from this run
were very poor, therefore the experiments were repeated by another Applied
Biosystems’ SNPlex technical expert at their laboratory in Warrington, UK. The
results of the second run are discussed in this work.
50ng of the genomic MALOVA DNA and 100ng of the corresponding whole
genome amplified products were genotyped with the SNPlex platform. To fragment
the genomic DNA, 2.5μL of the 20ng/μL stock plate was dispensed into a 384 well
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plate and incubated at 95oC for 5 minutes. The samples were dried down after DNA
fragmentation. The whole genome amplified products, which did not require
fragmentation, were also air-dried. The fluorescent probes and linkers were
phosporylated with the following mixture: for each samples, 0.1μL pooled SNPlex
ligation probes, 0.05μL of 48-plex SNPlex universal linkers, 0.125μL of nuclease-
free water, 0.05μL of 10x SNPlex kinase buffer, 0.025μL of SNPlex kinase, 0.1μL of
5x SNPlex enhancer, and 0.05μL 10x dATP. This mixture, known as the SNPlex
Ligation probe pool, was incubated at 37oC for 1 hour. The activated probe pool was
diluted 1:1 with 0.1xTE of pH8.
The ligation reaction was performed with the oligonucleotide ligation assay (OLA)
and the activated SNPlex ligation probe pool. The OLA was prepare on ice, and
consisted, for each sample, of 3.422μL of nuclease-free water, 0.5μL of SNPlex
ligation buffer, 0.025μL of SNPlex ligase, 0.053μL AmpErase® UNG. The 4μL
OLA master-mix and 1μL of the activated SNPlex ligation probe pool was added to
each DNA sample. The DNA plate containing the ligation reaction mixture was
covered with an adhesive cover and incubated at 4oC for 10 mins, placed on a
thermocycler which was at 90oC. The plate was thermocycled for the following
conditions: 3 mins at 90oC; 30 cycles of the 3 step (15 secs at 90oC, 30 secs at 60oC,
30 secs at 51oC with 2% RAMP); incubated for 10 mins at 99oC, and cooled to 4oC.
The ligation product was purified by exonuclease digestion. To do this, a 2x
exonuclease master-mix was prepared on ice. For each sample, the master-mix
contained 4.2μL nuclease-free water, 0.5μL of 10x SNPlex exonuclease buffer,
0.2μL of SNPlex lambda exonuclease, 0.1μL of SNPlex exonuclease I. 5μL of the
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master-mix was added to each sample, the sample plate was covered, vortexed, and
pulse spun. The plate was transferred to a thermocycler at 37oC, and incubated at
37oC for 90 mins, 80oC for 10 min and cooled to 4oC. The exonuclease reaction
product was diluted with 15μL nuclease-free water.
The PCR master-mix was prepared with 2.42μL of nuclease-free water, 5μL of 2x
SNPlex amplification master-mix and 0.5μL of 20x SNPlex amplification primers.
7.92μL of the PCR master-mix was added to each well of a new 384-well plate, and
2.08μL of the diluted exonuclease reaction product was also added to the plate. The
plate was covered, pulse spun and thermocycled for: 95oC for 10 mins, 30 cycles of
95oC for 15 and 63oC for 1min, and then cooled to 4oC.
A 1:10 dilution of the Wash Buffer was made with deionised water. The wells of the
Hybridization Plate were washed three times with 100μL of diluted Wash Buffer.
17.491μL of the SNPlex Hybridisation binding buffer was diluted with 0.009μL of
the positive hybridisation control. This was subsequently added to the SNPlex
hybridisation plate. The PCR products were bound to the hybridisation plate by
transferring 1.5μL from each well of the diluted PCR product to the Hybridisation
Plate and incubating at room temperature on a rotary shaker for 1 hour. In this
reaction, the biotinylated amplicons from the PCR products are bound to the
streptavidin coat on the hybridisation plate. The plate was centrifugated at
1000RPM for 1min, the supernatant was removed, and the plate was washed three
times with 100μL of diluted SNPlex Wash buffer. 50μL of 0.1N sodium hydroxide
(NaOH) was added to each sample in the hybridisation plate, the plate was covered
and incubated for 30 mins on a rotary shaker at room temperature.
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The hybridisation plate was removed from the rotary shaker, spun at 1000RMP for 1
min, and the supernatant was removed. The hybridisation plate was washed five
times with diluted 100μL SNPlex hybridisation wash buffer. An incubation oven
was equilibrated to 37oC. A hybridisation master-mix was prepared with 0.05μL of
SNPlex ZipChute mix, 11.25μL of SNPlex Denaturant and 13.7μL of SNPlex
ZipChute dilution buffer for each sample. 25μL of hybridisation master-mix was
added to each sample in the hybridisation plate. The plate was covered and incubated
at 37oC on a rotary shaker for 1 hour.
A sample loading mix was prepared, which contained, for each sample, 0.59μL of
SNPlex size standard and 16.91μL of SNPlex sample loading reagent. The
hybridisation plate was briefly spun and the supernatant was removed. The plate
was washed four times with 100μL of diluted hybridisation buffer. The plate was
spun upside down at 100RPM for 1 min on a stack of paper towels. 17.5μL of
SNPlex sample loading mix was added to each well of the hybridisation plate. The
plate was covered and incubated at 37oC for 30 mins. 7.5μL of the products in the
hybridisation plate was transferred to a new 384-well optical reaction plate. The
plate was read on the Applied Biosystem 3730xl DNA Analyzer. The results were
analysed with GeneMapper 4.0 software. The manufacturer default settings were
used to analyse the data.
2.10.4: OpenArray genotyping
The TaqMan® OpenArray™ genotyping system is another mid-range genotyping
platform from Applied Biosystems. The 32-plex format was used for these
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experiments, with which up to 96 samples can be genotyped on a single OpenArray
Genotyping plate. However, 16-, 64-, 128-, 192- and 256-plex formats are also
available for 144, 48, 24, 16 and 12 samples, respectively. Each OpenArray
genotyping plate consists of 48 subarrays and each subarray is comprised of 64
through-holes. The hydrophobic and hydrophilic coatings ensure that the through-
holes can retain 33nL reaction volume. The OpenArray genotyping plates were
manufactured with the 32 TaqMan SNP assays, with an assay in each through-hole.
2ul of TaqMan® OpenArray™ Master-Mix was mixed with each well of a 384-well
PCR sample plate (1ul of 50ng/μL genomic DNA or 2ul of 50ng/μL of WGA-DNA).
The master-mix-DNA solutions were transferred from the sample plate to the
OpenArray Genotyping plates. To do this, the sample plate was divided into eight
different sections, consisting of 12-well by 4-well areas as shown in Figure 2.2.
Plate guides were used to ensure that the appropriate sections of the sample plate
were transferred to the OpenArray plate. The plate guide was placed over the
sample plate. A tip block was placed over the appropriate section of the plate guide.
OpenArray Loader tips were placed into each whole of the tip block. The tip block,
with the loader tips inserted, was slid up and down approximately 50 times until the
tips were filled to 1mm above the bottom edge of the tip block.
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Figure 2.2: Sections of the OpenArray sample plate
Each OpenArray sample plate section contains 48 wells.
The samples in the loader tips were transferred to the OpenArray plate with the auto
loader. The loaded OpenArray plate was placed into an OpenArray genotyping case,
which was filled with immersion fluid. The genotyping case was sealed with glue on
the OpenArray case sealing station. The genotyping case was cleaned and placed in
the Bio-Rad thermal cycler for the following conditions:
Step Temperature and Time
RAMP 0.8oC/ second to 95.5oC
Hold 91.0oC for 10:00 mins
0.5oC/s RAMP to 51.0oC
Hold 51.0oC for 23s
0.8oC/s RAMP to 53.5oC
Hold 53.5oC for 30s
0.8oC/s RAMP to 54.5oC
Hold 54.5oC for 13s
0.8oC/s to 97.0oC
Hold 97.0oC to 22s
0.8oC/s RAMP to 92.0oC
ANNEALING &
EXTENDING:
50 CYCLES
Hold 92.0oC for 7s
Hold 20oC for 5 mins
Hold 4oC for Forever
s - seconds, mins - minutes
The genotyping case was “imaged” with the OpenArray™ NT Imager software. The
genotypes were manually called after training by Applied Biosystems OpenArray
technical expert.
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2.11: Sequencing
DNA sequencing of 95 MALOVA cases amplified with REPLI-g was performed
with the help of Mark Cox. The samples were sequenced for two regions of BRCA1,
316705 (exon 11), and 316700 (exon 13), in order to further investigate discordances
between the genomic control DNA and corresponding REPLI-g DNA.
10ng of the amplified DNA was sequenced using the BRCA1 (v1) Variant SeqR kit
(Applied Biosystems). 95-well plates were used. For each sample, a reaction mix
containing: 5μL of 2x AmpliTaq Gold® Master mix, 1.6 μL of 50% UltraPure™
Glycerol, 1.0μL (0.6μM/μL) of Forward VariantSEQr RSA primer, 1.0μL (0.6
μM/μL) of Reverse VariantSEQr™ RSA primer, and 1μL of distilled water, was
prepared. 10µl of the reaction mix was added to each sample. The plates were
covered, vortexed, pulse centrifuged and thermocycled on AB9700 cyclers. The
PCR cycling conditions were: heat activation at 96ºC for 5 min, followed by 40
cycles of 94ºC for 30 sec, 60ºC for 45 sec, and 72ºC for 45 sec; final extension of
72ºC for 10 min, and cooled to 4ºC. The PCR reactions products were cleaned by
adding 2μL of ExoSAP-IT® (USB Corporation), and incubating at 37ºC for 30 min
followed by heat inactivation at 80ºC for 15 min.
The forward Sequencing Master Mix contains the M13 Forward primer and the
reverse contains the M13 Reverse primer. The forward and reverse sequencing
reaction mix was then prepared by mixing 4μL of BigDye® Terminator Mix v1.1
with 1μL of 3.2pmol/μL M13 forward or reverse primer, 3μL of deionised water.
8μL of the sequencing mix was added to 2μL of the PCR product. The sequencing
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mixture was thermocycled at 96 ºC for 1 min, 25 cycles of 96 ºC for 10 sec, 50 ºC
for 5 sec, and 60 ºC for 4 min, then cooled to 4 ºC. The sequencing reaction was
cleaned-up by mixing 2.5μL of 125mM EDTA and 30μL of 100% ethanol with the
sequencing products, and incubating at room temperature for 15 min. The DNA
plate was subsequently centrifuged at 2500xg for 30 min at 4oC. The supernatant
was removed, 30 μL of 70% ethanol was added to each sample, and the plate was
centrifuged upside-down at 1650xg for 15 min at 4oC. The supernatant was
removed, the plate was left to air dry, and the pellet was re-suspended in 10μL of Hi-
Dye Formamide. The sequences were analysed (after performing electrophoresis on
the 3730xl DNA Analyzer with POP-7™) with SeqScape® v2.5 software (Applied
Biosystems).
2.12: Genotyping quality control
All genotyping for the association studies was conducted in 384-well plate format.
Each plate contained at least one non-template negative test control (NTC) and
twelve duplicate samples, which accounted for 3% of the total proportion of
samples. Studies were excluded from analysis if the concordance between the
duplicate samples was less than 98%. Genotyping of sample plates were either
repeated, where possible, or excluded from analysis if the NTCs failed. For the
oncogene and the BCAC, mismatch repair, cell cycle control, DNA repair pathways
of the AML method, studies with call rates less than 90% were excluded from
analysis. For the MMCT-18 study, and OCAC genotyping SNPs, the OCAC
genotyping quality control guidelines were used. These guidelines encompassed the
above, with the addition that 384-well DNA sample plates with call rates less than
90% were to be excluded from analysis.
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2.13: Statistical methods
All statistical analysis was performed on the STATA version 8.2 statistical package
(College Station, TX, www.stata.com).
2.13.1: Genetic Susceptibility
Due to the lack of apparent drive for evolution in humans, it is expected that
populations within their respective ethnic groups are in Hardy-Weinberg equilibrium
(HWE). Therefore, deviation from HWE was assessed in controls for each study
population for each assay using standard 2 test. The 2 test measures the extent to
which observed values differ from the expected proportion of genotypes (Norman
and Streiner, 2008).  For each population set, χ2 (1 degree of freedom) was used to
assess deviations from genotype frequencies of the control subjects from those
expected under Hardy-Weinberg equilibrium (HWE). For the polymorphisms
analysed from the oncogene and the BCAC, mismatch repair, cell cycle control,
DNA repair pathways, sample sets which were significantly out of HWE (P<0.05),
had genotype clustering was evaluated and sample sets with good quality clustering
were included in the analysis. For the genotyping data from the MMCT-18
candidate genes, the sample sets were excluded from analysis if they deviated from
HWE at P<10-4.
Logistic regression is a statistical model, which can be used for predicting the
probability of the occurrence of an event, taking into account risk factors, for
example, the chance of a person having a heart attack is dependent on their age, sex
and body mass index. In genetic association studies, logistic regression is used to
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produce a model to predict the probability that an individual will be affected by
ovarian cancer, given their genotype. This is done by using the genotyping results
to determine the frequency of each genotype in the cases and the controls and
comparing the frequencies to ascertain whether there are significant differences
between cases and controls for each genotype.
Associations between invasive epithelial ovarian cancer and each SNP were assessed
using two tests; the one-degree of freedom Cochran–Armitage trend test and the
general two-degrees of freedom χ2 test (heterogeneity test).  The χ2 test for trend was
stratified by study to account for any differences within the sample sets.
Unconditional logistic regression was used to assess the relationship between each
tSNP and risk of ovarian cancer for each population set, then the pooled samples
(stratified by study) with the primary test of association being a test for trend (P-
trend). The dependent variable (outcome/risk of ovarian cancer), can be estimated
with the logistic regression model, which is generally written as:
ln(ODDS)= KK  ....22110
which can be re-written, this study, as:
Ln(risk of being affected) = setsamplegenotypeercept _int  
A “Do-file”, which contains a file with a list of commands for STATA to run when
requested, was used to analysing groups of SNPs. However, the same results could
be obtained by using the following STATA commands:
 xi:logistic status i.set i.SNP
 est sto A
 xi:logistic status i.set if(SNP!=.)
 lrtest A
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The above commands are comprised of unconditional logistic regression with terms
for disease status (whether case or control) and sample set with and without a term
for genotype-study interaction. The likelihood ratio test (lrtest) assesses the fit of the
model with genotypes nested within a model without a term for genotypes. The P-
value <0.05 suggests that the null hypothesis that there is no association between the
genotypes and risk of disease should be rejected.
Homogeneity between the samples sets was also assessed to ensure there were no
statistically significant differences in the distribution of genotypes within the
different population set. Homogeneity between studies was tested with likelihood
ratio tests to compare the logistic regression models with and without a genotype-
stratus interaction term. Statistically significant (P<0.05) heterogeneity between
sample sets was usually caused by a study with different minor allele frequency for a
particular polymorphism. Should this arise, the study would be excluded and the test
for homogeneity repeated. If there was still statistically significant heterogeneity
between studies, the genotyping data for the polymorphism would be excluded.
Trend tests are used for categorical data analysis. In genetic association studies,
affected status is categorical (an individual is a case or a control); the genotypes are
also categorical and ordered – for example, if the common allele at a SNP site is
denoted as “A” and the rare allele is “a”, an individual is either homozygous for the
common allele (AA), heterozygous (Aa) or homozygous for the rare allele (aa). The
odds ratio (OR) is the ratio of the odds of an event (developing ovarian cancer)
occurring in one group (homozygotes of the common allele [y]) compared with to
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the odds of the same event occurring in another group (heterozygous [z]). The OR
can be calculated with the formula
)1/(
)1(
zz
yyOR



Which can be simplified to:
)1(
)1(
yz
zyOR



(Elston et al. 2002).
The ovarian cancer risks associated with being a heterozygote or a rare homozygote
were estimated as OR with associated 95% confidence intervals by unconditional
logistic regression with the common homozygote as the baseline comparator.
2.13.2:Haplotype definition and analysis
The confidence interval option (Gabriel et al. 2002) of the Haploview programme
was used, with some minor adjustments to include adjacent SNPs, to define the
haplotype blocks of the candidate genes. However, the cumulative frequency of the
common haplotypes was maintain at >90%. Only tSNPs successfully genotyped
were used to define the haplotype blocks, using the HapMap reference genotyping
data. Quality control checks were performed on the haplotype frequencies per study,
based on the genotype data.
The TagSNPs programme (Stram et al. 2003) was used to model multi-marker
haplotypes from aggressive SNP tagging and also haplotypes of each gene when
haplotype analysis was performed. TagSNPs implements an expectation-substitution
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approach to account for the uncertainty caused by the unphased genotype data
(Stram et al. 2003). The programme outputs estimates of the haplotype dosages for
each haplotype for each individual, and logistic regression is performed on the
estimates.
The genotyping data for nominally significant tSNPs were modelled with the log-
additive, co-dominant, dominant and recessive genetic models and compared with
likelihood ratio tests to ascertain the genetic model of best fit. This analysis was
only conducted with associations between a SNP and ovarian cancer overall (not
with histological subtypes).
The aetiology of ovarian cancer is very heterogeneous, and it has been demonstrated
that mutation in particular genes are predominantly found in specific histological
subtypes of the disease (Christie and Oehler 2006). Due to this heterogeneity,
analysis was also restricted to the major histological subtypes of ovarian cancer
(serous, endometrioid, mucinous and clear cell). Univariate unconditional logistic
regression was used to test for associations of the germline polymorphisms and
haplotypes of the candidate genes. The global effects of haplotypes of each gene or
haplotype block were assessed with logistic regression and likelihood ratio tests.
Models with and without the multiplicative effects of the haplotypes (minus the most
common haplotype) were evaluated.
2.13.3: Admixture maximum likelihood test
The admixture maximum likelihood (AML) test is a method which was created for
assessing the overall evidence for an excess of statistically significant associations
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between the genetic polymorphisms and risk of diseases (such as breast or ovarian
cancer) in case-control studies (Tyrer et al. 2006). The AML test was used to this
effect with the genotyping data from candidate genes from DNA repair, mismatch
repair, cell cycle control, oncogenes associated with ovarian cancer, differentially
expressed genes from in vitro functional experiments, and candidate SNPs from the
OCAC.
The AML method concurrently estimates the proportion of underlying false
hypotheses, as well as testing the global null hypothesis of no association between
the polymorphisms and risk of disease. The method does this by formulating the
alternative hypothesis based on the probability (α) that a given SNP is associated
with disease and the estimated effect size of the polymorphism.  The calculated χ
2
statistic of a SNP associated with disease is distributed, asymptotically, as a non-
central χ
2 distribution with the usual degrees of freedom and a non-centrality
parameter, η. 
The non-centrality parameter, which is closely related to the contribution of the SNP
to the genetic variance of the trait, is a measure of the size of effect of the
polymorphism. The AML method assumes that the non-centrality parameter for all
variants is the same, in order to make the model more parsimonious. Thus, the non-
centrality parameter will be estimated. However, this is required because power will
increase if the non-centrality parameter is the same for associated SNPs, as fewer
parameters need to be optimised.
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If η is assumed to be the same for each associated SNP, then α and η can be 
estimated by maximum likelihood, and a test of the null hypothesis, of no
association, can then be obtained as a likelihood ratio test. In the instances where
some variants were correlated, as many of the polymorphisms are in these studies,
the same procedure can generate pseudo-maximum likelihood estimates, as if the
germline variants are not correlated. The statistical significance of the AML test can
then be determined by simulation testing. One thousand permutations were used to
ascertain the significance of the AML test based on the ovarian cancer genotyping
data.
The genomic control method for adjusting for cryptic population stratification was
used on all polymorphisms analysed. Population stratification refers to the
differences with in populations which may lead to false positive associations
between genes or polymorphisms and disease risk. The genomic control approach,
which is described in Devlin et al. (2001), estimates and takes into consideration the
“over dispersion” of statistics used to evaluate association when there is population
stratification. The genomic control approach involves estimating and taking into
account the degree of over-dispersion caused by population stratification, by
analysing polymorphisms, including some associated with disease risk, throughout
the genome (Devlin et al. 2001).
Genotyping data from breast cancer case-control samples from the genome-wide
association study (Easton et al. 2007; Hunter et al. 2007) were used to estimate the
degree of over-dispersion of statistics, also known as inflation test statistic (Pharoah
et al. 2007). The genotyping data consisted of 280 randomly selected, unlinked
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polymorphisms from 4,037 breast cases and 4,012 controls. A more conservative
inflation statistic (10%), than the one estimated from the genomic controls for the
breast cancer study was used to adjust the P-trend for cryptic population
stratification.
2.13.4: Survival analysis
There was a variable time between diagnosis and patient recruitment, therefore
subjects were only considered to be at risk from the date of recruitment (blood
draw). This provides an unbiased estimate of the relative hazard, provided that the
proportional hazard assumption is not violated. The assumptions of proportional
hazard are that the hazard ratios are constant over time and the hazard ratios are
proportional within the different genotype groups across time. The survival period
was defined as starting at date of blood draw.
All-cause mortality was the only end-point collected; censoring was at the date a
participant was last known to be alive or at 10 years after diagnosis if the participant
was still alive. Log-log survival curves were used to check that the assumptions of
proportional hazards were met. The primary tests were likelihood ratio test for trend
(1 degree of freedom), based on the number of rare alleles carried.
The Cox regression for survival analysis, stratified by study, was used to estimate the
hazard ratio (HR) per rare allele carried. The Cox regression for survival analysis
(also known as proportional-hazards regression) models the effect of variables
(genotypes), over the time an event (death) takes to occur, or within a specified time
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period. The model produces estimates of hazard ratios for the explanatory variables
(genotypes).
The STATA commands for performing Cox regression survival analyses are as
follows:
 stset yearoutcome, failure(outcome) enter(yearenter) exit(time 10)
 xi:stcox SNP i.study
the first command informs STATA of the names of the appropriate variable names
which are essential for performing survival analysis (for example information
regarding whether an event (death/”failure”) has occurred can be found from the
“outcome” variable; yearenter=([date of blood draw] – [date of diagnosis])/365.25;
yearoutcome = ([date last seen or date of death] – [date of diagnosis])/365.25).
Survival over 10 years was investigated. The second command runs the Cox
regression test on the selected SNP, stratified by study.
The hazard ratios of all variables were adjusted for prognostic factors; age at
diagnosis, tumour stage, tumour grade and histological subtype, where survival
modelling showed that the prognostic factor significantly affected chances of
survival. The inclusion of these prognostic factors in the survival models is known
as multivariate survival analysis. These factors (age at diagnosis, tumour stage,
tumour grade and histological subtype) are known to affect patient survival. The
adjustments were made in order to observe whether the association remained after
adjustments for known prognostic factors.
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Univariate Cox regression analysis, stratified by study, was also used when the
genotyping data was restricted to the four major histological subtypes of epithelial
ovarian cancer (serous, endometrioid, mucinous and clear cell) to determine if the
tSNPs were associated with survival in individuals with the particular histology.
Clinical factors such as age, tumour stage and grade are known to affect survival.
Therefore, they must be adjusted for in order to ascertain whether statistically
significant associations were attributable to the SNP, and not to the clinical factors.
The effects of clinical factors are discussed in more detail in Chapter 3. The effects
of the clinical factors were tested with:
 xi: stcox i.agegroup i.grade i.stage i.set
the dummy variables generated by the command (for statistically associated factors)
could be saved by renaming the variable name. For example:
 rename _Istage_2 stage2
Multivariate survival analysis was performed with terms for the statistically
associated clinical factors. For example:
 xi:stcox SNP stage2 i.study
As with the susceptibility analysis, the TagSNPs programme was used to estimate
haplotype dosages of each individual, for the survival analysis. The haplotype dose
was based on the maximum likelihood of haplotypes of the candidates. Cox
regression analysis, stratified by study, was also used to assess the effect of each
haplotype dose on survival. In the STATA command, the name of the SNP was
replaced with the name of the haplotype to assess its affect.
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2.13.5: Kaplan-Meier survival estimates
Kaplan-Meier survival estimates are used to plot survival curves in order to illustrate
survival over a period of time of the different groups (of genotypes, or clinical
factors) being analysed and compared. The graphs can be generated in STATA with
the command:
 xi: sts graph, by(var)
(var refers to variable, such as genotype, age at diagnosis, tumour histology, grade or
stage).
The Kaplan-Meier survival estimator of the survival function at time t (or the
probability of surviving up to time t) is calculated by the following formula:
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Ŝ(t) is the survival function at time t
ni corresponds to the number "at risk" just prior to time ti,
and di, the number of deaths at time ti (Hosmer et al. 2008).
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Chapter 3: Results - The effects of common
SNPs and haplotypes variants of oncogenes and
functional candidate genes on the risk of
ovarian cancer
3.1: Introduction
Hypothesis:
Common germline genetic variants in candidate genes connected with ovarian cancer
development can influence the risk of epithelial ovarian cancer.
Aims:
(1) To determine if there is an effect of common variants and haplotypes of
candidate oncogenes on the risk of invasive epithelial ovarian cancer.
(2) To determine if there is an effect of common variants and haplotypes of
functional candidate genes (associated with neoplastic suppression of ovarian cancer
cell lines) on predisposition to ovarian cancer.
(3) To use the admixture maximum likelihood test to assess if a significant number
of associations have been found from ovarian cancer association studies.
Objectives:
(1) To use two-tailed unconditional logistic regression analysis to evaluate
associations between common variants and haplotypes in 2 sets of candidate genes
(oncogenes: BRAF, ERBB2, KRAS, NMI and PIK3CA; and functional candidates:
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AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3)
and risk of invasive epithelial ovarian cancer.
(2) To investigate associations between the variant and haplotypes of these genes on
the 4 major ovarian cancer histological subtypes: serous, endometrioid, mucinous
and clear cell.
(3) To use the admixture maximum likelihood experiment-wise test for association
to evaluate the overall evidence of association between 340 common variants (in 74
genes and 10 regions without known genes or open reading frames) and risk of
ovarian cancer.
3.2: Investigation of the effect of candidate oncogenes on risk of
ovarian cancer
Oncogenes, such as MYC, KRAS, BRAF and ERBB2 have been shown to be mutated
or amplified in ovarian tumours. However, it is not known whether germline
variants of the normal copies of these genes may predict a woman’s risk of ovarian
cancer. The following describes the selection of candidate oncogenes and the results
of the analyses of the common polymorphisms and haplotypes of the genes on
ovarian cancer risk.
3.2.1: Candidate oncogene and tSNP selection
The aim of the candidate oncogene selection was to find genes, with implications in
ovarian cancer development, which would fit into a single iPLEX SNP multiplex
genotyping run, and the minimum numbers of tSNPs remaining for genotyping by
the TaqMan platform. The iPLEX genotyping platform can genotype up to 27
variants in a single reaction. Furthermore, the cost of genotyping with the TaqMan
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platform increased with rising numbers of tSNPs which required genotyping with the
platform, therefore, the number of SNPs which could not be genotyped on iPLEX
had to be kept to a minimum. It became apparent that although BCL2 and KIT were
good candidate oncogenes for the study, too many tSNPs, 86 and 30, respectively,
would need to be genotyped in order to genotype enough SNPs to gain genotyping
data for the whole genes. Therefore, they were excluded from the selection. There
was only 1 tSNP for MUC1 (and 2 tSNPs for MYC), which suggested that the genes
were either insufficiently tagged or there was not enough genotyping data available
from HapMap for efficient tagging. Therefore, these genes were also excluded.
Table 3.1 shows the number of tSNPs for all the candidate genes initially selected for
tagging.
Table 3.1: Number of tagging SNPs of candidate oncogenes
Gene Total SNPs No. criteria SNPs No. tSNPs
AKT2 33 17 4
BCL2 374 170 86 Excluded
BRAF 158 75 9
CTNNB1 88 22 11
ERBB2 16 6 3
KIT 147 71 30 Excluded
KRAS 59 46 11
MDM2 50 10 5
MUC1 3 1 1 Excluded
MUC2 17 14 10
MYC 15 2 2 Excluded
NMI* 45 25 6
PIK3CA 53 36 11
Criteria SNPs – Minor allele frequency ≥0.05; HWE > 0.01; * NMI was erroneously selected from
HapMap due to its interaction with MYC – its data is presented under CMYC, an alias of MYC. The
mistake was not realised until the samples had been genotyped with iPLEX.
The National Center for Biotechnology Information (NCBI) Single Nucleotide
Polymorphism website www.ncbi.nlm.nih.gov/projects/SNP/, also known as dbSNP,
was used to find the Fasta sequence of each tSNP of AKT2, MUC2, BRAF, KRAS,
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NMI, PIK3CA, MDM2, ERBB2 and CTNNB1. The iPLEX Assay Design software
was used to design panels based on four different combinations of candidate
oncogenes (see Table 3.2).
Table 3.2: SNP panels from iPLEX assay design software
Gene No. tSNPs inpanel
No. tSNPs not in
panel Total
Panel 1
ERBB2 2 1 3
KRAS 7 4 11
NMI 6 - 6
PIK3CA 11 11
Panel 2
BRAF 8 2 10
ERBB2 3 - 3
KRAS 7 4 11
NMI 7 2 9
Panel 3
BRAF 6 3 9
ERBB2 3 0 3
KRAS 8 3 11
NM 5 1 6
PIK3CA 5 6 11
Panel 4
ERBB2 2 1 3
MDM2 3 2 5
MUC2 7 3 10
KRAS 5 6 11
BRAF 5 5 10
Panel – refers to iPLEX panel.
The best iPLEX assay design pool, Panel 3, contained tSNPs of BRAF, NMI,
ERBB2, KRAS and PIK3CA, which were also considered to be good candidates due
to their known or predicted involvement in ovarian cancer development. Therefore,
Panel 3 was selected for genotyping. The iPLEX assay pool comprised of 27 tSNPs.
The best panel (with the most important genes and minimum number of tSNPs
which would have to genotyped with TaqMan) was chosen.
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3.2.2: Oncogenes - Samples and methods
The stage 1 samples consisted of GEOCS, MALOVA, SEARCH, UKOPS and USC
(A) series of population-based studies. Stage 2 samples, comprising of the DOVE,
HOPE and USC (B) studies, were used for the validation of significant findings from
stage 1. The numbers of samples for each study are listed in Table 3.3.
Table 3.3: Samples used in oncogene study
Histology
Study Controls Total cases
Serous Endometrioid Mucinous Clear cell
GEOCS 429 327 166 47 29 23
MALOVA 1221 446 275 56 43 33
SEARCH 855 730 254 130 94 62
UKOPS 271 116 65 20 10 12
USC (A) 224 197 115 22 16 8
Total stage 1 3000 1816 875 275 192 138
DOVE 716 584 303 86 18 30
HOPE 636 276 157 39 13 21
USC (B) 360 237 161 33 19 14
Total stage 2 1792 1097 621 158 50 65
Total stages
1 & 2 4713 2913 1496 433 242 203
All study individuals included in the analysis were non-Hispanic Whites.
In total, 40 tSNPs were selected to tag the common germline variants of the
candidate oncogenes (BRAF, ERBB2, KRAS, NMI and PIK3CA). A combination of
iPLEX and TaqMan were used to genotype the first stage samples, and only Taqman
was used to genotype second stage samples. Whole genome amplified samples were
also genotyped on iPLEX – the results for these and problems with the iPLEX
platform are discussed in Chapter 5.
Chapter 3: Results - susceptibility
129
3.2.3: Quality control
There were 12 duplicate samples per 384-well plate. Studies with less than 98%
concordance between the total number of duplicate samples were excluded from
analysis. Sample sets which had a call rate <90% for a SNP were also excluded
from analysis. There were no studies which were out of Hardy-Weinberg
equilibrium.
Of the 27 tSNPs genotyped on iPLEX, 2 (rs10842513 and rs6944385) failed quality
control due to failed assays (failed PCR) and one was monomorphic (rs11047917).
The GEOCS study performed extremely poorly on iPLEX, with only 5 tSNPs from
the panel achieving call rates greater than 90%. The reason for the poor call rates
may have been due to degraded non-amplified DNA, which had been plated and
dried a year prior to the experimental work. These samples were used because the
iPLEX manufacturers, Sequenom, advised the use of non-amplified DNA for the
study, and these were the only remaining non-amplified DNA for GEOCS.
Consequently, the iPLEX genotyping results from the GEOCS sample set were
excluded from analysis.
TaqMan assays of all polymorphisms not genotyped on iPLEX were manufactured,
where possible and GEOCS, UKOPS and USC (A) were genotyped with the
TaqMan platform. Of the 40 tSNPs required to be genotyped in order to get full
gene coverage, 34 were successfully genotyped with iPLEX and TaqMan. The six
remaining tagging variants had either failed assay design, manufacture or probe
testing and could not be efficiently genotyped by any other polymorphism.
Chapter 3: Results - susceptibility
130
3.2.4: Associations between candidate genes and ovarian cancer risk
Two-tailed unconditional logistic regression was used to determine the effect of
common variants, and haplotypes of the oncogenes on risk of ovarian cancer. A
SNP or haplotype is said to be associated with ovarian cancer susceptibility when
there is a significant difference in the frequency of genotypes or haplotypes between
cases and controls. Two-tailed unconditional logistic regression was used because
no assumptions were made about the effect of the tSNP or haplotype prior to
analysis – i.e. no assumptions were made about whether a SNP/haplotype would
increase or decrease predisposition to ovarian cancer.
Odds ratios are used as a measure of the effect of the variant or haplotype on the risk
of disease. An odds ratio <1 corresponds to a reduced risk of disease, and odds
ratios >1 - increased risk. The genetics and histological pathology of ovarian cancer
suggest different aetiologies for the histological subtypes of the disease. In order to
establish the effects of the candidate oncogenes on the risk of serous, endometrioid,
mucinous and clear cell subtypes, the logistic regression analysis was restricted to
these particular subtypes. The results from these tests are below. The results
reported below are of the stage 1, unless otherwise stated. All reported P-values are
2-tailed. The numbers of samples for each genotype group are shown in Appendices
II-A and II-B for the oncogene and MMCT-18 candidate genes, respectively, and the
genotype and haplotype-specific risks for all oncogenes are shown in Appendices
III-A to III-J.
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Initially, the associations between the risk of ovarian cancer and the common
variants of candidate genes were assessed with all ovarian cancer cases pooled. The
statistically significant association from this analysis was validated with addition
samples.
There was no evidence of association between risk of ovarian cancer and common
variants of BRAF, ERBB2, KRAS and PIK3CA when all cases were combined (Table
3.4). The rare allele of a tSNP in NMI (rs11683487) showed evidence of association
with reduced risk of ovarian cancer (heterozygous odds ratio [OR] with 95%
confidence intervals [CI] 0.80 [95% CI 0.69-0.93] homozygous OR 0.87 [0.71-1.02],
P = 0.038). The HetOR is the odds ratio for individuals heterozygous for the variant,
and HomOR is the odds ratio for individuals homozygous for the rare allele. Both
HetOR and HomOR are compared with the homozygotes of the common allele. The
association is a result of the rare allele of NMI rs11683487 being more frequent in
the controls (46.3%) compared to cases (43.9%). There were 1,464 cases and 2,564
controls successfully genotyped for this SNP.
The genetic model of best fit for the NMI rs11683487 tSNP was a dominant model
(rare allele carriers vs common allele homozygotes) because the odds ratios were
similar in the heterozygotes and rare homozygotes. The similarity of the odds ratios
of the heterozygotes and rare homozygotes suggested that this was a result of either a
single or 2 copies of the rare allele. When the heterozygotes and rare homozygotes
were grouped for analysis, the odds ratio for the dominant model was OR=0.81
(0.71- 0.94), P=0.004 for all cases analysed.
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Table 3.4: Genotype-specific risks of pooled stage 1 oncogene data
Gene SNP name Cases Controls MAF HetOR§ HomOR§ P-Trend
rs10487888 1680 2694 0.47 1.09 (0.93 - 1.28) 1.02 (0.86 - 1.22) 0.9
rs1733832 1159 2043 0.06 1.08 (0.86 - 1.36) 3.39 (0.96 - 11.89) 0.2
rs1267622 1751 2880 0.24 0.99 (0.87 - 1.12) 0.97 (0.75 - 1.26) 0.79
rs13241719 1602 2488 0.31 0.98 (0.85 - 1.12) 0.86 (0.69 - 1.08) 0.27
rs17695623 1744 2901 0.07 0.97 (0.81 - 1.16) 1.14 (0.52 - 2.46) 0.86
rs17161747 1771 2909 0.5 1.13 (0.93 - 1.38) 1.29 (0.57 - 2.93) 0.18
rs17623382 1764 2900 0.12 1.01 (0.87 - 1.17) 1.01 (0.61 - 1.66) 0.9
rs6944385 1758 2893 0.14 1.14 (0.99 - 1.32) 0.99 (0.66 - 1.50) 0.14
BRAF
rs1267622,
rs6944385; AA 1786 2948 0.76 1.02 (0.79 - 1.33) 1.04 (0.80 - 1.34) 0.77
rs2952155 1667 2678 0.24 1.01 (0.89 - 1.15) 1.11 (0.84 - 1.47) 0.57
rs2952156 1766 2912 0.29 0.97 (0.86 - 1.10) 1.15 (0.89 - 1.49) 0.74ERBB2
rs1801200 1766 2916 0.22 1.04 (0.92 - 1.19) 1.01 (0.77 - 1.31) 0.64
rs12305513 1788 2934 0.1 0.87 (0.74 - 1.03) 0.71 (0.38 - 1.31) 0.053
rs12822857 1751 2901 0.47 1.01 (0.88 - 1.17) 0.94 (0.80 - 1.12) 0.53
rs10842508 1776 2935 0.25 0.97 (0.86 - 1.10) 0.95 (0.73 - 1.22) 0.57
rs12579073 1765 2900 0.48 0.97 (0.84 - 1.12) 0.92 (0.78 - 1.09) 0.36
rs10842513 1770 2878 0.09 1.03 (0.87 - 1.21) 0.93 (0.50 - 1.74) 0.86
rs4623993 1748 2892 0.16 0.96 (0.83 - 1.10) 1.13 (0.77 - 1.67) 0.85
rs6487464 1763 2895 0.38 1.04 (0.91 - 1.18) 0.99 (0.82 - 1.19) 0.94
rs10842514 1757 2886 0.44 0.98 (0.86 - 1.13) 1.08 (0.91 - 1.29) 0.42
rs11047917 1476 2456 0.06 0.92 (0.75 - 1.14) 1.62 (0.57 - 4.57) 0.71
rs4623993,
rs12579073;
TC
1717 2818 0.1 0.96 (0.80 - 1.15) 0.94 (0.56 - 1.57) 0.63
rs12822857,
rs10842508;
AC
1730 2857 0.23 0.99 (0.87 - 1.13) 1.04 (0.80 - 1.36) 0.93
rs12822857,
rs10842514;
GT
1715 2806 0.4 1.04 (0.91 - 1.20) 1.12 (0.94 - 1.34) 0.23
KRAS
rs12822857,
rs12579073,
rs6487464;
GAC
1689 2746 0.39 1.04 (0.89 - 1.21) 1.06 (0.88 - 1.29) 0.51
rs394884 1708 2852 0.15 1.01 (0.88 - 1.17) 1.40 (0.84 - 2.32) 0.47
rs11551174 1159 2040 0.06 0.96 (0.76 - 1.23) 1.23 (0.45 - 3.38) 0.92
rs289831 1665 2718 0.13 1.05 (0.91 - 1.22) 1.08 (0.61 - 1.89) 0.48
rs3771886 1764 2927 0.41 1.03 (0.90 - 1.18) 1.19 (1.00 - 1.42) 0.075
rs11683487 1464 2564 0.46 0.80 (0.69 - 0.93) 0.87 (0.71 - 1.02) 0.038
NMI
rs2113509 1776 2944 0.13 1.05 (0.91 - 1.21) 1.16 (0.68 - 1.97) 0.42
rs2865084 1164 2046 0.06 1.14 (0.89 - 1.45) 0.43 (0.37 - 0.50) 0.29
rs7621329 1749 2818 0.16 0.99 (0.86 - 1.13) 1.23 (0.86 - 1.77) 0.64
rs1517586 1739 2908 0.1 0.98 (0.83 - 1.15) 0.77 (0.42 - 1.40) 0.54
rs2699905 1741 2855 0.27 1.01 (0.88 - 1.15) 0.89 (0.71 - 1.11) 0.49
rs7641889 1779 2939 0.07 0.89 (0.74 - 1.07) 1.28 (0.58 - 2.84) 0.38
rs7651265 1794 2883 0.1 0.89 (0.76 - 1.04) 1.58 (0.89 - 2.80) 0.54
rs7640662 1765 2916 0.15 1.02 (0.89 - 1.17) 0.85 (0.57 - 1.27) 0.86
PIK3CA
rs2677760 1762 2925 0.49 1.01 (0.87 - 1.16) 1.04 (0.88 - 1.23) 0.67
MAF – minor allele frequency; Het: heterozygous; Hom – homozygous; OR= odds ratio (with associated 95%
confidence intervals in parentheses); § compared with common homozygous; Emboldened tSNP, and P-values
are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross 1.
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Validation of association with NMI rs11683487 association
The association found between the rare allele of NMI rs11683487 and a decrease in
the risk of invasive epithelial ovarian cancer was further investigated by performing
a second stage of genotyping. Three additional populations from the USA (USC B);
DOVE and HOPE), which comprised of an extra 1,097 cases and 1,712 controls
were used in this second stage. There was no evidence of association between the
rare allele of NMI rs11683487 and risk of ovarian cancer with the stage 2 samples
alone (dominant model: OR= 0.01 [0.85-1.20]; Pdominant=0.92). When the data from
both stages was subsequently combined and analysed with unconditional logistic
regression the association with rs11683487 was weaker, but still statistically
significant (OR= 0.89 [0.80– 0.99]; Pdominant =0.0317; Table 3.5).
Table 3.5: The effect of NMI rs11683487 on the risk of ovarian cancer in
Stages 1 & 2 cases
Dominant model
Stage Controls Cases
OR§ (95% CI) P-value
1 2564 1464 0.81 (0.71-0.94) 0.004
2 1712 1097 0.01 (0.85-1.2) 0.92
1 & 2 4276 2561 0.87 (0.8-0.99) 0.0317
OR – odds ratio; CI – confidence interval; § compared with common homozygous; Emboldened
tSNP, and P-values are statistically associated with susceptibility; emboldened OR are statistically
significant or do not cross 1.
The forest plot in Figure 3.3 shows the effect size and the corresponding confidence
intervals of the variant per study and stage(s). Forest plots are plotted on the natural
logarithmic scale with the odds ratio represented by the diamond, the corresponding
95% confidence intervals shown as the horizontal lines, and no effect on risk
symbolised by a vertical line. Odds ratios left of the vertical line (<1) imply a
decrease in odds ratio, therefore protective effect of the rare variant, and those on the
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right (>1) – increased risk of disease. Statistically significant associations have
confidence intervals not crossing the vertical line.
The NMI SNP rs11683487 tags eight other SNPs with r2 > 0.8 (rs3854012,
rs3771882, rs4665150, rs1048135, rs11730, rs13004590, rs12987765 and
rs17798290). rs11683487 tags rs1048135 with an r2=1 (perfectly correlated).
rs1048135 is a non-synonymous coding SNP and the rare (G) allele codes for a
leucine instead of serine. The programme PMut (Ferrer-Costa et al. 2005), predicted
that the rare allele (coding for leucine) had a pathological significance score of 3/10
and was classed as ‘damaging’ using the SIFT programme (Ng and Henikoff 2001;
Ng and Henikoff 2002) . The bioinformatics tool, PupaSNP
(http://pupasuite.bioinfo.cipf.es/) (Conde et al. 2006; Reumers et al. 2007) also
suggested that this allele may disrupt the binding of exonic splicing enhancers. In
addition, PupaSNP indicated that rs11683487 and rs11730 may have transcription
and translation regulatory functions, and that rs11730 may affect exon splicing.
Combinations of SNPs, in a haplotype, have also been suggested ble to affect an
individual’s disease risk. A haplotype is a combination of alleles at multiple loci on
the same chromosome, which are transmitted as a single unit (haplotype block). A
haplotype block comprises a region of a chromosome which is unlikely to undergo
recombination. Figure 3.2 shows the two haplotype blocks of KRAS, which was the
only oncogene with more than 1 haplotype block. The variants shown in the figure
were those genotyped in this study.
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Figure 3.1: Forest plots of tSNP rs11683487 in the NMI gene in ovarian cancer
case-control populations
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In the haplotype analysis, the frequencies of the haplotypes in cases and healthy
controls are compared to ascertain whether there is statistically significant
difference. A common haplotype occurs in a population with a frequency of ≥5%.
In haplotype analysis, these common haplotypes were analysed as an individual
entity, and the rare haplotypes were grouped. The overall effect of the gene on
disease risk was also assessed in the global analysis.
Haplotype block 1 of KRAS comprised of 3 tagging variants, spanning 6 kilobases
(kb), and haplotype block 2 consisted of the 6 tSNPs over 20kb. It is important to
note that the variants shown in the haplotypes are tagging SNPs, and therefore
encompass 50 common SNPs captured with r2=0.8 in the KRAS gene, (see Figure
3.2).
There were 4 common haplotypes of KRAS block 1, and 11 of haplotype block 2
(Figure 3.3). Within each representation of haplotype, the common allele is denoted
by “0”, and the rare by “1”. The most frequent haplotype of KRAS block 1, h100,
includes the rare allele of rs12305513, and the common alleles of rs12822857 and
rs10842508, respectively. The “h” in front of the alleles represents “haplotype”, and
is used to distinguish between haplotypes and other strings of “0” and “1” which
may occur in a document.
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Figure 3.2: Haplotype blocks of KRAS SNPs genotyped
(a) Haplotypes blocks based on genotyped KRAS tSNPs; (b) the total number of SNPs in the
haplotypes (captured by the tSNPs); colour scheme: standard (D’/LOD) – white (D’<1, LOD<2),
shades of pink/red (D’<1, LOD≥2), blue (D’=1, LOD<2) and bright red (D’=1, LOD≥2),
numbers shown in sqares (LD values) are based on D’.
Block 1 Block 2
Block 1 Block 2
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Figure 3.3: Common haplotypes of KRAS
“0” – common allele of SNP; “1” – rare allele.
Associations between haplotypes of the oncogenes and risk of ovarian cancer were
also evaluated. There was no evidence of association between risk of ovarian cancer
and haplotypes of KRAS and PIK3CA (Table 3.6).
Statistically significant associations were found between common haplotypes of
BRAF, ERBB2 and NMI and risk of ovarian cancer at the 5% significance level. The
h00001 haplotype of NMI correlated with a decreased risk of ovarian cancer
(OR=0.91 [0.84-0.99], P=0.0276). Another haplotype of NMI, h00010, was also
marginally associated with the risk of ovarian cancer (P=0.043; Table 3.6).
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Table 3.6: Haplotype analysis results for BRAF, ERBB2, KRAS, NMI and PIK3CA
Gene Haplotype Freq (%)in controls OR (95% CI) P-value
Global P-
value
h10000000 21.5 1.07 (0.97-1.19) 0.182
h10010000 19.4 0.88 (0.76-1.01) 0.07
h00000000 17.3 0.90 (0.78-1.04) 0.15
h10010010 11.8 0.96 (0.82-1.12) 0.57
h00100000 10.3 0.81 (0.68-0.95) 0.012
h00101001 6.8 0.94 (0.78-1.13) 0.49
h01100001 6.1 1.15 (0.95-1.39) 0.14
BRAF
h00000100 5.2 1.08 (0.88-1.31) 0.48
0.005
h000 53.6 0.95 (0.87-1.04) 0.284
h110 16.3 1.19 (1.03-1.37) 0.016
h001 16 1.17 (1.02-1.34) 0.022
h010 6.6 0.99 (0.82-1.20) 0.9
ERBB2
h111 6.5 0.84 (0.68-1.05) 0.12
0.034
h100 52.1 1.02 (0.94-1.11) 0.66
h000 22.8 1.00 (0.9 – 1.11) 0.99
h001 15.1 1.03 (0.91 – 1.16) 0.67
KRAS
haplotype
block 1
h101 9.5 0.89 (0.77 – 1.04) 0.15
0.16
h000010 30.6 1.04 (0.95-1.15) 0.389
h100010 12.9 1.00 (0.85-1.17) 0.98
h100100 11.9 1.03 (0.88-1.19) 0.75
h101100 10.6 0.98 (0.84-1.14) 0.77
h010000 5.5 1.01 (0.82-1.25) 0.91
h000100 5.4 0.92 (0.73-1.18) 0.52
h100000 5.4 0.81 (0.65-1.01) 0.06
h001100 4.7 0.96 (0.74-1.24) 0.74
h100101 4.3 0.82 (0.64-1.05) 0.11
h110000 3.2 0.94 (0.70-1.27) 0.69
KRAS haplotype
block 2
h000000 3.1 0.89 (0.64-1.23) 0.48
0.56
h00001 45.9 0.91 (0.84-0.99) 0.027
h00010 33.7 1.11 (1.003-1.22) 0.043
h10100 11.8 1.09 (0.95-1.25) 0.22
NMI
h01010 5.7 1.05 (0.84-1.3) 0.67
0.26
h00000001 48.2 1.02 (0.93-1.11) 0.713
h00010010 14.8 1.01 (0.89-1.14) 0.91
h00000000 10.2 0.94 (0.81-1.09) 0.39
h00110000 9.7 0.98 (0.84-1.14) 0.79
h01001100 6.6 0.94 (0.79-1.12) 0.5
h01000100 4 1.02 (0.82-1.28) 0.84
PIK3CA
h11000000 3.9 1.20 (0.97-1.48) 0.102
0.69
OR - odds ratio, CI - confidence interval; SNP order in haplotypes is 5’ to 3’ of the genes – BRAF: rs10487888,
rs1733832, rs1267622, rs13241719, rs17695623, rs17161747, rs17623382, rs6944385; ERBB2: rs2952155,
rs2952156, rs1801200; KRAS (block 1): rs12305513, rs12822857, rs10842508; KRAS (block 2): rs12579073,
rs10842513, rs4623993, rs6487464, rs10842514, rs11047917; NMI: rs394884, rs11551174, rs289831,
rs3771886, rs11683487; PIK3CA: rs2865084, rs7621329, rs1517586, rs2699905, rs7641889, rs7651265,
rs7640662, rs2677760.
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Although no associations were found between the tSNPs of BRAF and ERBB2,
correlations were found with the combinations of tSNPs from these oncogenes and
risk of ovarian cancer. There was an association between the h00100000 haplotype
of BRAF and a reduced risk of all ovarian cancer cases (OR=0.81 [0.68- 0.95],
P=0.012). Statistically significant ERBB2 haplotype-effects were observed with the
risk of ovarian cancer. Both associated haplotypes, h001 and h110, correlated with
an increase in ovarian cancer risk when all cases were analysed (OR=1.17[1.02-
1.34], P=0.022; and (OR=1.19 [1.03-1.37], P=0.016), respectively. The fact that
both h110 and h001 were associated with an increased risk of ovarian cancer could
not be explained because there was no common allele which could explain the
associations found with h110 and h001; the haplotypes contained opposite alleles at
all loci. HapMap genotype data was used to investigation whether these haplotypes
shared a common untagged variant, however, this was without success. Globally,
haplotypes of BRAF and ERBB2 were associated with ovarian cancer susceptibility
(P=0.005; and P=0.034, respectively).
Ovarian cancer is known to be heterogeneous, and the aetiologies of the four major
histological subtypes are believed to be through different pathways. It is, therefore,
of considerable interest to evaluate the effect of the oncogene variants and
haplotypes on the risk of the serous, mucinous, endometrioid and clear cell
histological subtypes of ovarian cancer. It is important to treat the results with
caution because the numbers of the individual histological subtypes are far less than
when all cases are grouped; therefore the power to detect true positive associations is
reduced. The power to detect an association with the recessive, dominant and co-
dominant genetic models with 3,000 controls, 875 serous ovarian cancer cases for a
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SNP with MAF=0.46 and an effect size of 1.2 at the 5% significance level are 40%,
55% and 92%, respectively. Serous is the most common histological subtype,
therefore the power to detect associations for the remaining common subtypes are
further reduced. The results will be described on a gene-by-gene basis.
The association between the rare allele of NMI rs11683487 and reduced risk of
ovarian cancer remained when the analysis was restricted to the serous and mucinous
subtypes from the stage 1 data; (HetOR=0.81 [0.67-0.98], HomOR=0.80 [0.63-1.01],
P=0.0377; HetOR=0.67 [0.47-0.96], HomOR=0.62 [0.39-0.99], P=0.0269)
respectively. However, the associations were not as significant as for all cases -
Table 3.7. As with all cases, the associations were not independently validated in
with the stage 2 data, however the association with the mucinous subtype remained
when the results from stages 1 and 2 were pooled.
The associations observed between the h00001 and h00010 haplotypes of NMI and
risk of ovarian cancer also remained when the analysis was restricted to the serous
subtype (see Table 3.8). The effect size was these associations were marginally
stronger; however the significance was reduced, suggesting these are likely to be
false positives. None the less, all of the associations found with the NMI haplotypes
were supported by the single tSNP findings with NMI rs11683487, which was in the
last position of the haplotype.
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Table 3.7: The effect of NMI rs11683487 on the risk of ovarian cancer in Stages 1 &
2 cases
Dominant model
Stage Controls Cases Histology
OR§ (95% CI) P-value
1464 All 0.81 (0.71-0.94) 0.004
713 Serous 0.8 (0.67-0.95) 0.0112Stage 1 2564
154 Mucinous 0.81 (0.68-0.96) 0.0163
1097 All 0.01 (0.85-1.2) 0.92
711 Serous 1.02 (0.84-1.25) 0.8319Stage 2 1712
50 Mucinous 1.38 (0.73-2.62) 0.314
2561 All 0.87 (0.8-0.99) 0.0317
1424 Serous 0.89 (0.78-1.02) 0.0824Stages 1 & 2 4276
204 Mucinous 0.84 (0.71-0.99) 0.0419
MAF – minor allele frequency; OR – odds ratio; CI – confidence interval; § compared with common
homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with
susceptibility; emboldened OR are statistically significant or do not cross 1.
Table 3.8: Haplotype analysis results for NMI (P<0.05)
Haplotype Freq (%) Histology OR (95% CI) P-value Global P-value
All 0.91 (0.84-0.99) 0.0276
Serous 0.89 (0.8-1) 0.048
Endometrioid 1.05 (0.87-1.25) 0.631
Mucinous 0.84 (0.68-1.05) 0.128
h00001 45.9
Clear cell 0.96 (0.74-1.23) 0.729
All 1.11 (1-1.22) 0.043
Serous 1.13 (1.01-1.28) 0.041
Endometrioid 0.9 (0.74-1.1) 0.305
Mucinous 1.11 (0.88-1.4) 0.361
h00010 33.7
Clear cell 0.97 (0.74-1.28) 0.832
0.26
OR - odds ratio, CI - confidence interval; in the haplotypes, †: ‘0’= common allele and ‘1’= rare allele;
SNP order in haplotypes is 5’ to 3’ of the gene : rs394884, rs11551174, rs289831, rs3771886,
rs11683487.
Associations between KRAS and ovarian cancer susceptibility
When the effects of KRAS common variants and haplotypes on ovarian cancer risk
were assessed, there was evidence suggesting that 3 variants of KRAS were
associated with risk of the mucinous histological subtype of invasive epithelial
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ovarian cancer. The frequency of the rare allele of rs10842514 was significantly
greater in cases of mucinous subtype compared to healthy controls. The minor allele
frequency (MAF) of the rare allele, “T”, of the variant in the controls was 0.44,
however, 0.54 the cases. The rare allele of rs10842514 was associated with a 2.02-
fold increase in the risk of the mucinous subtype (heterozygous odds ratio [OR] with
95% confidence intervals [CI] =1.13 [95% CI 0.78-1.64], homozygous OR=2.02
[1.35-3.01], P-trend = 6x10-4), see Table 3.9. This tSNP is in intron 2 of KRAS, and
to date, it does not tag any other SNP within or flanking KRAS. The association was
not found with other subtypes of ovarian cancer or all subtypes combined, therefore
if the association is true positive, it is unique to the mucinous subtype.
An association was also found between the mucinous histological subtype and two
other polymorphisms of KRAS. Those homozygous for the rare allele of rs12822857
had a reduced risk of mucinous ovarian cancer. The heterozygous genotype of
rs6487464 was also associated with a 0.61-fold reduction in the risk of the subtype in
individuals heterozygous for the tSNP; see Table 3.9. However, it is still unknown
how mutations or variation of KRAS may result in the mucinous subtype. The results
for all the tSNPs genotyped for KRAS can be found in Appendix III-E.
The associations between these variants and risk of mucinous subtype of ovarian
cancer are of particular interest because mutations in KRAS have previously been
reported to be associated with this subtype. Gemignani et al found that of 22
mucinous ovarian carcinomas, 50% had mutations in the KRAS oncogene, compared
with 4 (5%) of 82 non-mucinous tumours (Gemignani et al, 2003).
Chapter 3: Results - susceptibility
144
Table 3.9: Genotype-specific risks of KRAS tSNPs (P<0.05)
Gene tSNP MAF Controls Cases Histology HetOR (95% CI)* HomOR (95% CI)* P-trend
1751 All 1.01 (0.88-1.17) 0.94 (0.80-1.12) 0.5281
835 Serous 1.08 (0.90-1.30) 0.97 (0.78-1.20) 0.8167
268 Endometrioid 0.99 (0.73-1.33) 1.06 (0.75-1.50) 0.7605
187 Mucinous 0.74 (0.53-1.04) 0.63 (0.41-0.96) 0.0232
rs12822857 0.47 2901
132 Clear cell 1.14 (0.75-1.74) 1.04 (0.63-1.72) 0.8398
1763 All 1.04 (0.91-1.18) 0.99 (0.82-1.19) 0.9408
836 Serous 1.09 (0.92-1.29) 0.98 (0.77-1.24) 0.8783
269 Endometrioid 1.13 (0.86-1.5) 1.15 (0.79-1.67 0.3878
192 Mucinous 0.61 (0.44-0.85) 0.76 (0.50-1.18) 0.0379
rs6487464 0.38 2895
136 Clear cell 1.02 (0.70-1.48) 0.95 (0.56-1.61) 0.8918
1757 All 0.98 (0.86-1.13) 1.08 (0.91-1.29) 0.4153
835 Serous 1.04 (0.87-1.24) 1.09 (0.88-1.36) 0.4379
269 Endometrioid 0.85 (0.64-1.13) 0.97 (0.68-1.38) 0.7294
188 Mucinous 1.13 (0.78-1.64) 2.02 (1.35-3.01) 0.0006
KRAS
rs10842514 0.44 2886
134 Clear cell 0.95 (0.64-1.40) 0.79 (0.47-1.33) 0.4026
MAF: minor allele frequency; Cons: controls; Het: heterozygous; Hom: homozygous; OR: odds ratio; CI: confidence interval, *
compared with common homozygote. Enboldened OR and P-trend values are statistically significant.
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Table 3.10: Haplotype analysis results for KRAS (P<0.05)
Gene/
block Haplotype
Freq
(%) Histology OR (95% CI) P-value
All 1.04 (0.95-1.15) 0.389
Serous 1.07 (0.94-1.21) 0.306
Endometrioid 0.99 (0.81-1.21) 0.916
Mucinous 1.3 (1.03-1.64) 0.025
h000010 30.6
Clear cell 0.79 (0.59-1.06) 0.121
All 0.89 (0.64-1.23) 0.48
Serous 1.08 (0.75-1.58) 0.67
Endometrioid 0.36 (0.14-0.92) 0.033
Mucinous 0.3 (0.09-0.99) 0.049
KRAS
haplotype
block 2
h000000 3.1
Clear cell 0.61 (0.21-1.78) 0.365
OR - odds ratio, CI - confidence interval, In the haplotypes, †: ‘0’= common allele and ‘1’= rare allele;
SNP order in haplotypes is 5’ to 3’ of the genes –KRAS (block 2): rs12579073, rs10842513,
rs4623993, rs6487464, rs10842514, rs11047917
When the frequencies of the haplotypes of KRAS haplotype block 1 and 2 were
compared between cases and controls, statistically significant differences were found
between 2 haplotypes of KRAS block 2 and the risk of the mucinous subtype of
ovarian cancer. The h000010 haplotype of KRAS block 2 was associated with a 1.3-
fold increase in the risk of the mucinous subtype (OR=1.3 (1.03-1.64), P=0.025.
Conversely, the h000000 haplotype of the same block was associated with a
decreased risk of the subtype, OR=0.3 (0.09-0.99), P=0.049. The associations
between h000010 and h000000 and risk of mucinous ovarian cancer are supported
by the presence of the common allele of rs6487464 in the fourth position of the
haplotype, and the rare allele of rs10842514 in the fifth position. This is because the
rare allele of rs6487464 was associated with reduced risk, and the rare allele of
rs10842514 with increased risk. However, this haplotype is not the only one with
this combination of alleles of rs6487464 and rs10842514. Assuming that the
association found between the rare allele of rs10842514 and increased risk of the
mucinous subtype is a true positive, it is feasible that the associations between the
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h000000 and h000010 haplotypes of KRAS block 2 were due, primarily to the alleles
of rs10842514.
Analysis of the effect of haplotype on disease risk can sometimes elucidate
associations which could not be identified through individual SNP analysis. It is
believed that the combinations of alleles, rather than individual variant may affect
disease risk. Such an association was found between the h000000 haplotype of
KRAS and reduced risk of endometrioid ovarian cancer. This association was also
found with the mucinous histological subtype. The association between h000000
and risk of the endometrioid subtype was marginally more significant than the
mucinous subtype (OR=0.36 [0.14-0.92], P=0.033), with similar odds ratio (Table
3.10 – page 145). See Appendix III-F for the results for all the common and
combined rare haplotypes of KRAS.
Associations between BRAF and ovarian cancer susceptibility
There was evidence suggesting that three variants of BRAF also influenced the risk
of mucinous histological subtype of invasive epithelial ovarian cancer. The rare
alleles of two of the variants, rs1267622 and rs17695623, were associated with a
decreased risk of the subtype (see Table 3.11). The rare allele of BRAF rs10487888,
conversely, was associated with an increased risk of the subtype; HetOR=1.32 (0.86-
2.03), HomOR=1.61 (1.03-2.53), P=0.0357 (Table 3.11). The associations with
these variant were also unique to the subtype. The results for all the BRAF common
variants can be found in Appendix III-A.
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There were 8 common (haplotype frequency >5% in control samples) BRAF
haplotypes (see Appendix III-A). Analysis showed that a haplotype with a 6.8%
frequency was associated with a reduced risk of mucinous ovarian cancer (OR=0.54
[0.31-0.93], P=0.027). The BRAF tSNPs, rs10487888, rs1267622 and rs17695623
are in the first, third and eighth positions, respectively, of the haplotype. rs10487888
tags rs1267622 with r2=0.318, and rs17695623 with r2=0.097; and rs1267622 and
rs17695623 tag each other with r2=0.306.
The haplotype showing significant association with mucinous ovarian cancer
contained the common allele of rs10487888, and the rare alleles of rs1267622 and
rs17695623, both of which were associated with decreased risk (Table 3.11), which
may explain the association. The combination of the alleles supported a reduction in
risk of the mucinous subtype. However, this combination of alleles of the above
variants also occurred in another haplotype of BRAF (h01100001), which had an
odds ratio of less than 1, but was not significantly associated with risk of mucinous
ovarian cancer (OR=0.93 [0.58-1.48], P=0.76); Table 3.12.
There was an association between the h00100000 haplotype of BRAF and a reduced
risk of all ovarian cancer cases (OR=0.81 [0.68- 0.95], P=0.012). The association
with this haplotype, which occurred at a frequency of 10.3% in controls, remained
when analysis was restricted to serous only cases – OR=0.8 (0.66-0.98), P=0.028 -
Table 3.12. Although there were no other statistically significant associations of this
haplotype and the other histological subtypes of ovarian cancer, the odds ratios for
endometrioid, mucinous and clear cell histological subtypes were similar to that of
serous (Table 3.12).
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Table 3.11: Genotype-specific risks of common BRAF tSNPs (P<0.05)
Gene tSNP MAF Controls Cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
1680 All 1.09 (0.93-1.28) 1.02 (0.86-1.22) 0.902
804 Serous 1.21 (0.99-1.49) 1.09 (0.87-1.37) 0.5747
251 Endometriod 0.84 (0.61-1.17) 0.88 (0.61-1.25) 0.5007
180 Mucinous 1.32 (0.86-2.03) 1.61 (1.03-2.53) 0.0357
rs10487888 0.47 2694
125 Clear cell 1.04 (0.66-1.64) 0.88 (0.52-1.48) 0.5947
1751 All 0.99 (0.87-1.12) 0.97 (0.75-1.26) 0.7894
831 Serous 1.04 (0.88-1.22) 0.90 (0.64-1.26) 0.9055
268 Endometriod 0.76 (0.58-1.01) 1.06 (0.63-1.77) 0.2725
187 Mucinous 0.67 (0.48-0.94) 0.71 (0.35-1.43) 0.0278
rs1267622 0.24 2880
135 Clear cell 1.24 (0.87-1.78) 1.12 (0.53-2.37) 0.3392
1744 All 0.97 (0.81-1.16) 1.14 (0.52-2.46) 0.8642
829 Serous 1.04 (0.83-1.31) 1.19 (0.45-3.10) 0.6437
264 Endometriod 0.99 (0.68-1.45) 0.63 (0.08-4.85) 0.8421
186 Mucinous 0.47 (0.26-0.86) 0.79 (0.10-6.08) 0.0191
BRAF
rs17695623 0.07 2901
135 Clear cell 1.25 (0.78-2.03) 1.37 (0.18-10.56) 0.3393
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common homozygous;
Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross 1.
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Table 3.12: Haplotype analysis results for BRAF (P<0.05)
Gene Haplotype Freq(%) Histology OR
± (95% CI)† P-value
All 0.88 (0.76-1.01) 0.07
Serous 0.99 (0.86-1.15) 0.921
Endometrioid 1.04 (0.82-1.31) 0.769
Mucinous 0.92 (0.69-1.22) 0.547
h10010000 19.4
Clear cell 0.67 (0.46-0.97) 0.033
All 0.81 (0.68-0.95) 0.012
Serous 0.8 (0.66-0.98) 0.028
Endometrioid 0.88 (0.64-1.21) 0.439
Mucinous 0.87 (0.59-1.27) 0.463
h00100000 10.3
Clear cell 0.86 (0.55-1.34) 0.508
All 0.94 (0.78-1.13) 0.49
Serous 1.09 (0.88-1.35) 0.444
Endometrioid 0.99 (0.69-1.42) 0.947
Mucinous 0.54 (0.31-0.93) 0.027
BRAF
h00101001 6.8
Clear cell 1.36 (0.87-2.11) 0.175
OR - odds ratio; CI - confidence interval; in the haplotypes, ‘0’= common allele and ‘1’= rare allele; SNP
order in haplotypes is 5’ to 3’ of the genes – BRAF: rs10487888, rs1733832, rs1267622, rs13241719,
rs17695623, rs17161747, rs17623382, rs6944385.
Another haplotype of BRAF, h10010000, was associated with a reduced risk of the
clear cell subtype – OR=0.67 (0.46-0.97), P=0.033. The combined rare haplotypes
of BRAF were also associated with a decrease in the risk of serous ovarian cancer
(P=0.038; see Table 3.12), however the frequency of the combined rare haplotype
was less than 1. Therefore only a small number of samples with the rare haplotypes
would have had a reduced risk of the subtype, if the association is a true positive.
Associations between ERBB2 and ovarian cancer susceptibility
Of the 3 common tagging variants of ERRB2 genotyped, there was evidence of
association between rs1801200 and risk of the endometrioid subtype of ovarian
cancer. The rare allele of ERBB2 rs1801200 was associated with an increased risk of
endometrioid disease (HetOR=1.16 [0.88-1.52], HomOR=1.71 [1.05-2.76],
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P=0.0389; Table 3.13). This variant was not statistically associated with all cases or
the other subtypes of ovarian cancer. The heterozygous risk for clear cell cases was
OR=1.51, and the confidence intervals did not cross 1, (1.05-2.17), however this
correlation was not statistically significant, although the P-value was close to
significance at the 5% level (P=0.0564). The results of the ERBB2 variants are in
Appendix III-C.
The ERBB2 rs1801200 polymorphism is a non-synonymous coding SNP. The “A”
allele, which is the major form of the SNP, encodes isoleucine, while the “G” allele
encodes valine. The polymorphism is conserved in mice and the sequence is also
predicted to be an exonic splicing enhancer.
Statistically significant ERBB2 haplotype-effects were observed with the risk of
ovarian cancer – see Appendix III-D for the results of all the ERBB2 haplotypes.
h001 and h110, which were associated with the risk of all subtypes combined were
also clear cell and mucinous subtypes, respectively, see Table 3.14.
The ERBB2 variant which was associated with ovarian cancer risk, rs1801200, was
in the last position of the haplotypes. The fact that both h110 and h001 were
associated with an increase in risk of ovarian cancer could not be explained by this
variant because it would suggest that the 2 different alleles both result in increased
risk of disease. The other loci of the haplotype also contained opposite alleles,
therefore, there was no common allele which could explain the associations found
with h110 and h001.
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Table 3.13: Genotype-specific risks of common ERBB2 tSNPs (P<0.05)
Gene tSNP MAF Controls Cases Histology HetOR§ (95% CI) HomOR§ (95% CI) P-Trend
1766 All 1.04 (0.92-1.19) 1.01 (0.77-1.31) 0.6401
847 Serous 1.04 (0.88-1.22) 0.86 (0.60-1.23) 0.8257
263 Endometriod 1.16 (0.88-1.52) 1.71 (1.05-2.76) 0.0389
188 Mucinous 0.79 (0.57-1.11) 0.82 (0.41-1.66) 0.2007
ERBB2 rs1801200 0.22 2916
134 Clear cell 1.51 (1.05-2.17) 1.30 (0.61-2.76) 0.0564
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common homozygous; Emboldened
tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross 1.
Table 3.14: Haplotype analysis results for ERBB2 (P<0.05)
Gene Haplotype Freq (%) Histology OR± (95% CI)† P-value*
All 1.19 (1.03-1.37) 0.016
Serous 1 (0.85-1.19) 0.964
Endometrioid 1 (0.75-1.34) 0.982
Mucinous 1.39 (1.02-1.9) 0.036
h110 16.3
Clear cell 0.94 (0.63-1.4) 0.752
All 1.17 (1.02-1.34) 0.022
Serous 1.08 (0.92-1.27) 0.329
Endometrioid 1.25 (0.97-1.62) 0.079
Mucinous 0.88 (0.63-1.23) 0.466
ERBB2
h001 16
Clear cell 1.6 (1.15-2.21) 0.005
OR - odds ratio, CI -confidence interval; in the haplotypes: ‘0’= common allele and ‘1’= rare allele; SNP order in haplotypes: rs2952155, rs2952156,
rs1801200.
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Both the size of the effect and the significance between the h001 haplotype of
ERBB2 and increased risk of ovarian cancer became stronger when analysis was
restricted to the clear cell subtype only (OR=1.6 [1.15-2.21], P=0.005). The
mucinous subtype was associated with the other significant haplotype, h110,
OR=1.39 (1.02-1.9), P=0.036 (see Table 3.14).
Associations between PIK3CA and ovarian cancer susceptibility
There was no evidence of association between tSNPs PIK3CA and susceptibility to
invasive epithelial ovarian cancer when all the cases of stage 1 samples were
analysed (see Appendix III-I). However, a statistically significant association was
found between the rare allele of rs2865084 and risk of the endometrioid subtype
when analysis was restricted to this subtype, – HetOR=1.6 (1.03-2.5), HomOR=0.3
(0.22-0.42), P=0.0344; Table 3.15. Interestingly, for all but the clear cell subtype,
there was a suggestion that the heterozygotes for the tSNP had an increased risk of
disease, however all rare homozygotes had a reduced risk of the disease (the
confidence interval did not cross 1) – Appendix III-I. The odds ratios for all cases
and the all individual subtypes did not cross 1, which suggest an association with
rare homozygosity of the variant despite P>0.05 for all but the endometrioid samples
– see Table 3.15. PIK3CA rs2865084 tags 4 other SNPs. All of these SNPs are
intronic, however they are all conserved. rs2865084 is in a transcription factor
binding site, upstream of the gene. Analysis of the PIK3CA haplotypes showed that
the h11000000 haplotype was associated with a marginally increased risk of the
endometrioid subtype (P<0.05, Table 3.16). However, corrections for multiple
testing would attenuate the association. The odds ratios for all the PIK3CA
haplotypes are shown in Appendix III-J.
Chapter 3: Results - susceptibility
153
Table 3.15: Genotype-specific risks of common PIK3CA tSNPs (P<0.05)
Gene tSNP MAF Controls Cases Histology HetOR§ (95% CI) HomOR§ (95% CI) P-Trend
1164 All 1.14 (0.89-1.45) 0.43 (0.37-0.50) 0.294
525 Serous 1.13 (0.83-1.55) 0.77 (0.63-0.93) 0.428
183 Endometrioid 1.60 (1.03-2.50) 0.30 (0.22-0.42) 0.034
135 Mucinous 1.32 (0.77-2.25) 0.32 (0.22-0.46) 0.309
PIK3CA rs2865084 0.06 2046
95 Clear cell 0.51 (0.21-1.28) 0.37 (0.24-0.57) 0.147
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with
common homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR
are statistically significant or do not cross 1.
Table 3.16: Haplotype analysis results for PIK3CA (P<0.05)
OR - odds ratio; CI - confidence interval, Freq=frequency in controls; In the haplotypes, ‘0’= common allele and ‘1’= rare allele; SNP order
in haplotypes is 5’ to 3’ of PIK3CA: rs2865084, rs7621329, rs1517586, rs2699905, rs7641889, rs7651265, rs7640662, rs2677760.
Gene Haplotype Freq (%) Histology OR (95% CI) P-value GlobalP-value
All 1.20 (0.97-1.48) 0.102
Serous 1.29 (0.99-1.67) 0.055
Endometrioid 1.49 (1-2.22) 0.049
Mucinous 1.07 (0.63-1.82) 0.795
PIK3CA h11000000 3.9
Clear cell 0.91 (0.47-1.79) 0.793
0.69
Chapter 3: Results - susceptibility
154
3.3: The Effect of tagging SNPs and haplotypes of functional
candidate genes on risk of ovarian cancer
Deletions on chromosomes 4, 5, 6, 13, 14, 15 and 18 have frequently been observed
in primary ovarian cancer cell lines with the metaphase comparative genomic
hybridisation procedure. There is also strong evidence from in vitro assays
suggesting that the incorporation of a normal chromosome 18 into 2 ovarian cancer
cancer cell lines can lead to the suppression of the neoplastic phenotype (Dafou et al.
2009). The micro-cell mediated chromosome transfer of a normal chromosome 18
(MMCT-18) has also been demonstrated to result in the suppression of the
tumourigenic phenotype in prostate and pancreatic cancer cell lines (Padalecki et al.
2001; Lefter et al. 2002; Gagnon et al. 2006). These observations suggest that
chromosome 18 harbours tumour suppressor genes which may contribute to these
suppressions (Lefter et al. 2004; Dafou et al. 2009).
Although there has been some degree of success in identifying germline
polymorphisms associated with ovarian cancer predisposition with the candidate
gene approach, almost all associations have been borderline significant with small
effect sizes. It is possible that the limited success may be because the candidate gene
selection process is usually based on a predicted function or mutations found in
tumours rather than on “functional” evidence. The microcell-mediated chromosome
transfer (MMCT) technique was used in the hope of identifying putative functionally
relevant genes involved in ovarian cancer aetiology.
The MMCT method was used to transfer normal human chromosome 18 (MMCT-
18) into ovarian cancer cell lines. In vitro and in vivo assays were used to ascertain
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the effect of the transferred chromosome on the neoplastic phenotype of the resultant
recipient/donor hybrids. Differences in gene expression were assessed between the
parental cancer cell lines, and the neoplastically suppressed hybrid cells, in order to
establish if the incorporation of chromosome 18 resulted in a phenotypic change
which could be correlated to biological and/or molecular function.
3.3.1: Gene and tSNP selection of functional candidate genes
The global differential gene expression results from the micro-cell mediated
chromosome 18 transfer (MMCT-18) were obtained for each cell line containing
columns for: gene ID, probe ID, gene name, cytoband, fold change (hybrid/parental),
log2 of the fold change and P-value. Although the gene expression results were not
validated with quantitative (Q)-PCR, the experiments were conducted in triplicate
and the results corrected for multiple testing. The gene lists contained data on
32,878 probes for 32,000 genes; there was more than 1 probe for some genes due to
different transcripts for the genes being available. Genes from all chromosomes
were analysed because genes have dynamic interactions with others throughout the
whole genome. It is feasible that although a gene on chromosome 18 may not
directly affect tumourigenicity, the gene may interact with or regulate other genes
which may have an effect on the suppression of tumour growth.
For the selection of candidate genes, the gene list from the parental and hybrid cell
lines of TOV112D was combined with the gene list from TOV21G expression data,
matching gene and probe IDs. A simple colour scheme was created for fold change
for easy visualisation and data sorting. Green corresponded to down-regulation of
gene expression in hybrids in comparison with their respective parental cell line, and
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red for up-regulation of gene expression of hybrids. Probes with missing data for
both cell lines were excluded. Genes with inconsistent fold change directions within
and between cell lines were also excluded. For probes where there were missing
data for 1 of the parental/hybrid cell lines, the data from the other parental/hybrid
trio was used. Gene lists were created for genes which were:
 up-regulated in the hybrids of both cell lines (62 genes);
 down-regulated in the hybrids of both cell lines (993 genes);
 up-regulated in TOV21G hybrids (264 genes);
 down-regulated in TOV21G hybrids (1089 genes);
 up-regulated in TOV112D hybrids (72 genes);
 down-regulated in TOV112D hybrids (312 genes);
 up-regulated in TOV21G hybrids chromosome 18 only (31 genes);
 down-regulated in TOV21G hybrids chromosome 18 only (44 genes);
 up-regulated in TOV112D hybrids chromosome 18 only (24 genes);
 down-regulated in TOV112D hybrids chromosome 18 only (53 genes);
 up-regulated in TOV112D hybrids chromosome 18 break-point region (5
genes);
 down-regulated in TOV112D hybrids chromosome 18 break-point region (8
genes).
Figure 3.4 shows a flow chart of the candidate gene selection process.
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Figure 3.4: Flow chart of functional candidate gene selection
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The genes from these lists were ranked by p-values and differential gene expression
fold change. From the gene lists with concordant fold change in both cell-lines, the
top 30 ranking P-values and fold changes from both cell lines were selected for the
master list. From the other gene lists, the top 15 ranking genes according to P-value
and fold change were selected for the master list. There were 192 genes in the
master list (Appendix I), of which there were some genes that were duplicated from
the different lists. The gene size and functions for the genes in the master list were
obtained from Entrez Gene (http://www.ncbi.nlm.nih.gov/sites/entrez) and
Genecards (http://genecards.org/). The genes were subsequently tagged as described
in Chapter 2.
The master list was narrowed down by excluding genes with less than one common
variant (MAF ≥ 0.05) per 2kb of gene; less than 3 tagging SNPs (tSNPs); greater
than 20 tSNPs. Genes were excluded from selection if the function of the gene was
unknown. Genes with inconsistent fold change data (i.e. up-regulated in one hybrid,
but down-regulated in the other hybrid of the same cell-line) were also discarded.
This resulted in the exclusion of 107 genes/probes from the master list. Many genes
from those excluded would have been very interesting to study (such as APOBEC3C,
TUBA1, HIF1A, ANXA13, DIO2, C20orf100, LIX1, C18orf34, GAMP, TPM3,
DNAJB1, HEY1, SERINC2, RARB, RCDHB2, EPS15L2, SLC38A6 and MAPT) – see
Appendix I for the functions of these genes.
Genes were then selected based on their function and role in ovarian and other
malignancies, using literature searches and Oncomine (http://www.oncomine.org/).
The hypothesis was that common variants and haplotypes of differentially expressed
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candidate genes selected based on in vitro and in vivo functional evidence may affect
a woman’s risk of ovarian cancer.
At least 1 candidate gene was selected from each gene list. The genes selected from
each list were: one from “down-regulated in TOV112D hybrids” (RGC32 [FC=3,
P=1.79x10-6]); two from “up-regulated in TOV112D hybrids” (FILIP1L [FC=4.9,
P=3.44x10-5], AXIN2 [FC=5.2, P=0.0027]); one from “down-regulated in the
TOV21G hybrids” (SQSTM1 [FC=109.9, P=1.29x10-5]); two from “up-regulated in
TOV21G hybrids” (CASP5 [FC=6.9, P=1.7x10-3], STAG3 [FC=8.6, P=6.4x10-5);
two from “down-regulated in both cell lines” (RUVBL1 [TOV21G: FC=46.7,
P=2.22x10-6; TOV112D: FC=2, P=9.49x10-6], SFRS9 [TOV21G: FC=76.9,
P=0.0028; TOV112D: FC=4.3, P=0.0019]); three from “up-regulated in both cell-
lines” (AIFM2 [TOV21G: FC=3.4, P=0.0014; TOV112D: FC=1.8, P=0.003], AKTIP
[TOV21G: FC=5.7, P=0.006; TOV112D: FC=3, P=0.0067], EIF4B [TOV21G:
FC=8.8, P=0.09; TOV112D: FC=4, P=0.0014]); and one from “chromosome 18, up-
regulated in TOV112D” (RBBP8 [FC=2.9, P=0.023]).
iPLEX Gold Assay Design software was used to create multiplex panels with the
tSNPs from these genes. The candidate genes selected for genotyping were based on
the multiplex levels within two panels, how many SNPs from each gene were
included in the panel; the rankings of the gene within the lists; and the function of
the gene. The candidate genes selected from the MMCT gene expression results for
iPLEX Gold genotyping were AIFM2, AKTIP, AXIN2, CASP5, EIF4B, FILIP1L,
RBBP8, RGC32, RUVBL1, SFRS9, SQSTM1 and STAG3 (see Table 3.17).
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Table 3.17: Candidate “functional” genes from MMCT-18 study
Regulation
in hybrids Gene Cytoband Function Size (bp)
No.
SNPs tSNPs
Down in
TOV112D
hybrids
RGC32 13q14.11
Cell cycle progression regulation.
Induced by p53 in response to
DNA damage.
13,323 17 8
FILIP1L 3q12.1 Down regulated in ovarian cancer. 281,369 135 8
Up in
TOV112D
hybrids
AXIN2 17q23-q24
Inhibitor of β-catenin in the Wnt
signalling pathway. In region of
LOH in breast & other cancers.
33,084 14 12
CASP5 11q22.2-q22.3
Regulation of apoptosis. 14,729 17 9Up in
TOV21G
hybrids STAG3 7q22.1 Component of cohesin complex.Chromosome segregation. 43,764 28 3
Down in
TOV21G
hybrids
SQSTM1 5q35
May be involved in cell
differentiation, apoptosis, immune
response and regulation of K(+)
channels
17,181 15 10
RUVBL1 3q21
Interacts with MYC. Forms a
complex which may be involved in
cell growth.
42,857 29 7Down in
TOV112D
& TOV21G
hybrids SFRS9 12q24.31
Plays a role in constitutive splicing
and can modulate the selection of
alternative splice sites.
8,087 5 3
AIFM2 10q22.1
TP53-induced apoptosis.
Overexpression has been shown to
induce apoptosis.
34,711 17 13
AKTIP 16q12.2
Apoptosis. Protein interacts
directly with PKB/Akt and
modulates PKB activity by
enhancing the phosphorylation of
PKB's regulatory sites.
11,978 7 4
Up in
TOV112D
& TOV21G
hybrids
EIF4B 12q13.13 Translation initiation factor. 35,770 40 8
Chr18 up in
TOV112D
hybrids
RBBP8 18q11.2
RB1 binding protein. Believed to
modulate the functions of BRCA1
in transcriptional regulation, DNA
repair, and/or cell cycle checkpoint
control. Has been proposed that
this gene may be a tumour
suppressor acting in the same
pathway as BRCA1.
93,155 39 4
SNP selection criteria: minor allele frequency ≥ 0.05, Hardy-Weinberg equilibrium p-value ≥ 0.01
using HapMap Data Release 22.
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The sequences of the tagging SNP of the differentially expressed candidate genes
were formatted for the iPLEX Gold Assay design software, in differing gene
combinations to assess the most efficient multiplexes for panels. The assay panel
design chosen contained the most interesting candidate genes in terms of known
function (AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and
STAG3), would result in 10 tSNPs in total being genotyped by TaqMan if all the
polymorphisms were successfully genotyped on the iPLEX Gold system. The
functions of the candidate genes that were chosen for the association study are
summarised in Table 3.17. The panel also contained assays for BRCA1 (rs799917)
and BRCA2 (rs144848) SNPs, which had been genotyped and sequenced. These
variants were used for quality control purposes. The panel selected comprised of a
27-plex and 33-plex.
3.3.2: MMCT-18 samples and methods
Due to the poor performance of the GEOCS samples on the iPLEX platform in the
oncogene study, it was excluded from the stage 1 set of samples. More SEARCH
and UKOPS samples were available for stage 1 than for the oncogene study.
Additional SEARCH cases and UKOPS cases and controls were also available for
stage 2 validation. These extra samples came from ongoing participant recruitment
and preparation of samples. The sample sets used in this “functional” study are
shown in Table 3.18. The histological subtype data for BAVARIA and the new
SEARCH and UKOPS cases are currently not available.
Three different populations were used in stage 1 of this study. These populations
consisted of: (1) The Danish MALOVA study; (2) The UK SEARCH study; (3) the
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UKOPS study from the UK. In total, there were 1,799 invasive epithelial ovarian
cancer cases and 3,045 unaffected controls in this series. Stage 2 samples were used
to validate findings from stage 1. See Table 3.18 for the numbers of cases and
controls genotyped from each population set.
Table 3.18: Ovarian cancer case-control populations included in functional study
Study Controls Total cases Serous Endometrioid Mucinous Clear cell
MALOVA 1221 446 275 56 43 33
SEARCH 1229 847 328 138 104 83
UKOPS 595 506 246 84 48 49
Total stage 1 3045 1799 849 278 195 165
AUS 1122 768 464 105 27 50
BAV 234 228 Unknown Unknown Unknown Unknown
DOVE 716 584 303 86 18 30
GEOCS 429 327 166 47 29 23
GER 416 218 103 21 21 6
HAWAII 158 70 36 11 2 6
HOPE 603 280 159 40 13 21
JAC 593 603 300 62 49 12
NCOCS 747 622 242 50 33 22
USC 546 391 161 33 19 14
UKO-P2 467 553 Unknown Unknown Unknown Unknown
Total stage 2 6031 4590 1934 455 211 184
Total stages
1 & 2 9076 6389 2783 733 406 349
The stage 2 samples comprised of case-control studies from Australia (AUS),
Germany (BAVARIA; and GER), Poland (JAC), the United Kingdom (UKO (B) -
consisting of 368 SEARCH cases; and 185 UKOPS cases and 467 controls), and the
United States of America (DOVE; GEOCS; HAWAII; HOPE; NCOCS and USC).
A total of 68 tSNP were identified from the nine candidate genes. Of these, five
tSNPs (AIFM2 rs2271695; AXIN2 rs2240308 and rs4128941; RGC32 rs3783197;
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and RUVBL1 rs13091198) failed assay design, manufacture, probe testing or QC.
Therefore, the stage 1 samples were successfully genotyped with 63 tSNPs from
AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3
with a combination of iPLEX Gold and Taqman SNP genotyping platforms.
Overall 95% of the candidate genes were covered by the tSNPs which were
successfully genotyped (288 variants covered by the genotyped tSNPs out of a total
303 variants).
3.3.3: Ovarian cancer risks associated with common genetic variation in
functional candidate genes
The genotype distributions for the tagging SNPs of the MMCT-18 candidate genes
are tabulated in Appendix II-B. The results of the logistic regression are shown in
Appendix IV-A to IV-R.
When the effects of the common variants of the MMCT-18 candidate genes on
predisposition of ovarian cancer were assessed, there was no evidence of association
with AIFM2, AKTIP, FILIP1L, RBBP8, RGC32 and STAG3. A tSNP from AXIN2,
CASP5 and RUVBL1 were associated with risk of ovarian cancer. The rare allele of
AXIN2 rs11079571 was associated with an increase in ovarian cancer risk
(HetOR=1.23 [1-1.51], HomOR=1.73 [0.99-3.01], P=0.0383). The rare allele of
CASP5 rs518604 was associated with an increase in ovarian cancer risk; (HetOR=
1.39 [1.06-1.81], HomOR=1.44 [1.05-1.97], P=0.0124), Table 3.19. This association
remained when analysis was restricted to serous only cases.
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Table 3.19: Genotype-specific risks of MMCT-18 candidate genes
All subtypes Serous subtype
Gene tSNP MAF Controls All cases Serouscases HetOR HomOR P-trend HetOR HomOR P-trend
rs2394655 0.04 2924 1751 827 1.01 (0.80-1.27) 1.37 (0.42-4.42) 0.7773 1.12 (0.84-1.49) 1.03 (0.21-5.04) 0.4297
rs7908957 0.13 2873 1719 817 0.92 (0.79-1.07) 1.13 (0.73-1.75) 0.5342 0.91 (0.75-1.11) 0.91 (0.50-1.67) 0.3812
rs1053495 0.08 2704 1697 790 0.97 (0.81-1.16) 0.72 (0.35-1.51) 0.457 0.96 (0.75-1.21) 0.88 (0.35-2.18) 0.6293
rs2894111 0.28 2861 1770 835 0.99 (0.87-1.13) 0.93 (0.74-1.16) 0.5545 1.02 (0.87-1.20) 0.86 (0.64-1.17) 0.5896
rs2394656 0.19 1703 913 506 0.96 (0.80-1.15) 0.85 (0.55-1.34) 0.4114 0.93 (0.75-1.17) 0.85 (0.50-1.47) 0.3965
rs6480440 0.23 1140 422 556 1.01 (0.79-1.29) 0.88 (0.55-1.42) 0.7992 1.07 (0.80-1.43) 0.75 (0.40-1.39) 0.8126
rs2280201 0.12 1783 1313 261 1.05 (0.88-1.25) 0.96 (0.53-1.71) 0.59 1.11 (0.88-1.40) 0.97 (0.44-2.12) 0.5089
rs10999147 0.08 2395 1285 600 1.25 (1.03-1.51) 0.48 (0.16-1.47) 0.2055 1.13 (0.88-1.46) 0.79 (0.23-2.75) 0.6396
rs3750772 0.05 2944 1743 831 1.02 (0.83-1.24) 2.28 (0.86-6.04) 0.54 1.12 (0.88-1.44) 3.43 (1.23-9.58) 0.1043
rs4295944 0.41 1784 1335 567 0.98 (0.83-1.15) 1.09 (0.88-1.34) 0.4913 0.95 (0.77-1.18) 1.11 (0.84-1.46) 0.6042
rs2394644 0.12 1685 1324 561 1.05 (0.88-1.26) 1.03 (0.60-1.79) 0.5245 1.02 (0.80-1.29) 1.11 (0.55-2.25) 0.7103
AIFM2
rs10999152 0.17 2610 1618 760 1.14 (0.99-1.32) 0.96 (0.68-1.36) 0.2066 1.17 (0.98-1.40) 1.01 (0.65-1.57) 0.2171
rs9931702 0.44 1722 917 506 0.96 (0.80-1.16) 1.01 (0.80-1.27) 0.9734 1.10 (0.87-1.38) 1.12 (0.85-1.50) 0.4039
rs17801966 0.14 1469 828 450 1.06 (0.87-1.31) 0.74 (0.38-1.46) 0.9282 1.14 (0.89-1.46) 0.90 (0.40-2.00) 0.4718
rs7189819 0.32 2923 1745 825 0.93 (0.82-1.06) 0.92 (0.75-1.14) 0.2796 0.99 (0.84-1.17) 1.02 (0.78-1.33) 0.867
AKTIP
rs3743772 0.06 1093 413 256 0.90 (0.62-1.32) 2.02 (0.32-12.59) 0.6778 1.12 (0.73-1.72) 1.72 (0.17-17.14) 0.6424
rs11868547 0.49 1717 919 509 0.93 (0.76-1.13) 1.02 (0.81-1.29) 0.8178 0.92 (0.72-1.17) 0.99 (0.74-1.31) 0.9949
rs7591 0.37 2881 1779 838 1.09 (0.96-1.24) 1.05 (0.87-1.27) 0.4234 1.19 (1.01-1.41) 1.11 (0.87-1.41) 0.1463
rs4074947 0.2 2898 1775 840 1.16 (1.02-1.32) 0.92 (0.67-1.24) 0.2189 1.21 (1.03-1.43) 0.76 (0.50-1.16) 0.323
rs7210356 0.11 2974 1777 838 1.01 (0.87-1.17) 0.97 (0.56-1.69) 0.8864 1.09 (0.90-1.32) 1.08 (0.54-2.14) 0.3518
rs11655966 0.26 1779 1301 552 0.92 (0.79-1.07) 1.07 (0.80-1.44) 0.9064 0.99 (0.81-1.22) 1.10 (0.74-1.63) 0.6218
AXIN2
rs4541111 0.49 1770 1297 554 1.09 (0.91-1.30) 0.97 (0.78-1.19) 0.806 1.10 (0.87-1.40) 1.03 (0.78-1.36) 0.755
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rs4791171 0.28 2109 1185 539 1.08 (0.92-1.25) 1.19 (0.92-1.55) 0.1238 1.05 (0.86-1.29) 1.23 (0.88-1.73) 0.2499
rs11079571 0.15 1206 839 326 1.23 (1.00-1.51) 1.73 (0.99-3.01) 0.0383 1.22 (0.92-1.63) 1.74 (0.84-3.63) 0.1127
rs3923087 0.21 2910 1780 843 1.05 (0.93-1.20) 1.26 (0.95-1.68) 0.1545 1.05 (0.89-1.24) 1.10 (0.75-1.60) 0.4525
rs3923086 0.41 2935 1753 833 0.91 (0.80-1.04) 1.07 (0.90-1.27) 0.813 0.84 (0.71-1.00) 1.02 (0.81-1.27) 0.6828
rs518604 0.44 1195 438 270 1.39 (1.06-1.81) 1.44 (1.05-1.97) 0.0124 1.36 (0.98-1.88) 1.45 (0.99-2.11) 0.0313
rs523104 0.47 1199 824 320 1.03 (0.83-1.29) 1.07 (0.82-1.39) 0.7689 0.86 (0.65-1.16) 0.80 (0.55-1.15) 0.1294
rs3181328 0.09 1206 829 319 0.95 (0.73-1.23) 1.16 (0.50-2.72) 0.7779 0.93 (0.65-1.33) 0.68 (0.18-2.64) 0.7345
rs17446518 0.12 1177 803 311 0.88 (0.69-1.12) 1.28 (0.54-3.02) 0.5052 0.87 (0.63-1.22) 1.01 (0.28-3.69) 0.5292
rs9651713 0.11 2898 1730 819 0.99 (0.85-1.15) 1.22 (0.70-2.13) 0.836 0.96 (0.78-1.17) 1.55 (0.81-2.96) 0.8167
rs3181175 0.18 2379 1282 597 0.96 (0.83-1.12) 1.23 (0.83-1.82) 0.9331 0.93 (0.76-1.13) 1.34 (0.82-2.19) 0.9482
rs3181174 0.08 2962 1780 840 0.96 (0.80-1.14) 1.21 (0.55-2.65) 0.7967 1.09 (0.88-1.36) 1.12 (0.41-3.09) 0.4061
rs2282657 0.35 1478 852 462 1.08 (0.90-1.30) 0.89 (0.67-1.20) 0.7645 1.16 (0.92-1.45) 1.11 (0.78-1.56) 0.3615
CASP5
rs507879 0.54 2839 1768 835 1.02 (0.87-1.20) 1.00 (0.84-1.19) 0.9144 1.09 (0.89-1.34) 1.00 (0.79-1.26) 0.8497
rs796977 0.33 1166 437 269 1.07 (0.84-1.35) 1.33 (0.94-1.89) 0.1458 0.98 (0.74-1.31) 1.25 (0.83-1.90) 0.4593
rs793477 0.13 2646 1653 771 1.02 (0.88-1.18) 0.88 (0.53-1.43) 0.9373 1.11 (0.92-1.35) 1.08 (0.59-1.99) 0.3224
rs793446 0.4 2947 1773 838 1.05 (0.92-1.20) 1.11 (0.93-1.32) 0.3207 0.95 (0.80-1.13) 1.07 (0.86-1.34) 0.842
rs3921767 0.07 2859 1773 840 1.00 (0.84-1.20) 0.69 (0.29-1.61) 0.6908 0.90 (0.71-1.15) 0.19 (0.03-1.43) 0.1194
rs17338680 0.11 2989 1786 574 1.06 (0.91-1.24) 0.77 (0.46-1.28) 0.985 0.88 (0.69-1.14) 0.98 (0.44-2.20) 0.3051
rs9864437 0.22 2972 1786 843 0.98 (0.86-1.12) 1.18 (0.91-1.53) 0.6077 0.96 (0.81-1.14) 1.47 (1.08-2.01) 0.2249
rs6788750 0.41 2532 1414 710 0.98 (0.84-1.13) 0.96 (0.79-1.17) 0.7028 1.07 (0.88-1.29) 1.12 (0.88-1.44) 0.3295
FILIP1L
rs12494994 0.17 2347 1273 594 1.14 (0.98-1.33) 0.88 (0.59-1.33) 0.433 0.95 (0.78-1.17) 0.52 (0.27-0.99) 0.097
rs7239066 0.11 2366 1272 594 0.80 (0.67-0.96) 1.05 (0.57-1.95) 0.0645 0.99 (0.79-1.23) 1.18 (0.55-2.53) 0.7647
rs11082221 0.04 2937 1748 826 1.12 (0.89-1.41) 1.13 (0.31-4.07) 0.2974 1.17 (0.88-1.57) 0.55 (0.07-4.59) 0.3355
rs4474794 0.37 2895 1764 829 0.94 (0.82-1.07) 0.88 (0.72-1.06) 0.2066 0.83 (0.70-0.98) 0.80 (0.63-1.03) 0.0323
RBBP8
rs9304261 0.24 888 346 215 1.07 (0.82-1.40) 0.67 (0.38-1.17) 0.5163 1.08 (0.79-1.49) 0.37 (0.16-0.88) 0.2176
RGC32 rs10467472 0.13 2887 1769 839 0.99 (0.86-1.15) 1.05 (0.68-1.64) 0.9822 0.91 (0.75-1.10) 0.74 (0.39-1.41) 0.2126
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rs3783194 0.11 2723 1690 788 1.02 (0.88-1.19) 1.03 (0.57-1.89) 0.8873 0.89 (0.72-1.09) 0.70 (0.29-1.69) 0.1363
rs11618371 0.1 2959 1771 835 1.01 (0.87-1.18) 1.31 (0.74-2.32) 0.5158 1.03 (0.85-1.26) 1.33 (0.66-2.70) 0.4921
rs9532824 0.08 2892 1782 841 0.96 (0.81-1.15) 0.47 (0.19-1.16) 0.3412 0.94 (0.74-1.18) 0.46 (0.14-1.54) 0.3245
rs995845 0.26 2365 1274 595 1.01 (0.87-1.16) 1.09 (0.82-1.45) 0.8121 0.89 (0.74-1.09) 1.06 (0.73-1.52) 0.4695
rs9594551 0.15 2863 1766 833 1.01 (0.88-1.16) 1.10 (0.74-1.65) 0.611 1.09 (0.91-1.29) 0.97 (0.56-1.65) 0.4095
rs975590 0.24 2940 1749 828 1.02 (0.90-1.16) 0.89 (0.68-1.17) 0.8348 1.03 (0.87-1.21) 0.84 (0.59-1.21) 0.7862
rs9860614 0.11 2966 1777 839 1.05 (0.90-1.22) 1.44 (0.89-2.31) 0.2094 1.16 (0.96-1.40) 1.03 (0.52-2.02) 0.1425
rs13063604 0.23 1724 1266 537 1.14 (0.97-1.34) 1.39 (1.02-1.89) 0.0192 1.42 (1.15-1.74) 1.63 (1.10-2.42) 0.0002
rs3732402 0.38 2382 1280 596 1.20 (1.03-1.40) 1.06 (0.85-1.31) 0.207 1.35 (1.10-1.64) 1.14 (0.86-1.52) 0.0677
rs7650365 0.49 2672 1645 769 1.08 (0.93-1.26) 0.86 (0.72-1.03) 0.1081 0.97 (0.80-1.17) 0.74 (0.58-0.93) 0.009
rs4857836 0.27 2993 1787 845 1.05 (0.93-1.19) 0.97 (0.76-1.23) 0.8219 1.11 (0.95-1.31) 1.04 (0.77-1.41) 0.3458
RUVBL1
rs9821568 0.15 2911 1733 820 0.97 (0.84-1.11) 0.93 (0.63-1.37) 0.5613 0.99 (0.82-1.18) 0.57 (0.31-1.06) 0.2966
rs11762932 0.22 2965 1787 846 1.03 (0.90-1.17) 1.06 (0.80-1.40) 0.6327 1.03 (0.88-1.22) 1.06 (0.74-1.52) 0.6639
rs2246713 0.49 1765 1295 549 0.97 (0.81-1.15) 0.96 (0.78-1.19) 0.6593 0.95 (0.75-1.20) 0.87 (0.66-1.16) 0.2436STAG3
rs1637001 0.28 2967 1784 843 0.86 (0.76-0.98) 0.92 (0.73-1.16) 0.0692 0.84 (0.71-0.99) 0.77 (0.56-1.05) 0.0177
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common homozygous;
Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not
cross 1.
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The confidence intervals of both the heterozygous and homozygous odds ratios of
CASP5 rs518604 crossed 1, however the lower confidence intervals were close to 1
(HetOR=1.36 [0.98-1.88], HomOR=1.45 [0.99-2.11], P=0.0313; Table 3.19). The
AXIN2 rs11079571 and CASP5 rs518604 were only successfully genotyped for 839
cases and 1,206 controls, and 438 cases and 1,195 controls, respectively with the
iPLEX Gold platform. TaqMan assays of the variants failed to produce callable
genotype clusters, therefore the associations could not be further investigated with
the remaining stage 1 and stage 2 samples. Neither AXIN2 nor CASP5 variants were
tagged by any other SNP with r2≥0.8, therefore it was not possible to manufacture
Taqman assays of SNPs in LD. Due to the relatively small numbers of samples
successfully genotyped for these variants and the borderline significance of the P-
values, there is a possibility that the associations are chance findings.
The rare allele of RUVBL1 rs13063604 was also associated with an increased risk of
ovarian cancer; HetOR=1.14 (0.97-1.34), and the HomOR=1.39 (1.02-1.89),
P=0.0192. This association became stronger when the analysis was restricted to the
serous histological subtype (P=0.0002). There was also evidence suggesting that the
rare allele of RUVBL1, rs7650365, was associated with a decreased risk of the serous
subtype (Table 3.20).
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Table 3.20: Genotype-specific risks of variants of RUVBL1 (P<0.05)
Gene tSNP MAF Controls Cases Histology HetOR (95% CI)* HomOR (95% CI)* P-trend
1266 All 1.14 (0.97-1.34) 1.39 (1.02-1.89) 0.0192
537 Serous 1.42 (1.15-1.74) 1.63 (1.10-2.42) 0.0002
207 Endometrioid 0.74 (0.53-1.04) 1.29 (0.73-2.31) 0.3904
143 Mucinous 0.95 (0.64-1.41) 1.39 (0.69-2.83) 0.5473
rs13063604 0.25 1724
124 Clear cell 1.22 (0.83-1.80) 1.07 (0.48-2.40) 0.4113
1645 All 1.08 (0.93-1.26) 0.86 (0.72-1.03) 0.1081
769 Serous 0.97 (0.80-1.17) 0.74 (0.58-0.93) 0.009
256 Endometrioid 1.12 (0.83-1.53) 0.74 (0.50-1.09) 0.1777
175 Mucinous 1.04 (0.70-1.53) 1.25 (0.81-1.93) 0.371
rs7650365 0.46 2672
155 Clear cell 1.08 (0.73-1.60) 0.93 (0.58-1.48) 0.7821
1733 All 0.97 (0.84-1.11) 0.93 (0.63-1.37) 0.5613
820 Serous 0.99 (0.82-1.18) 0.57 (0.31-1.06) 0.2966
269 Endometrioid 1.14 (0.86-1.52) 2.09 (1.16-3.78) 0.0286
186 Mucinous 0.86 (0.60-1.23) 0.62 (0.19-2.00) 0.1981
RUVBL1
rs9821568 0.15 2911
161 Clear cell 0.68 (0.45-1.02) 0.85 (0.30-2.38) 0.0967
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common
homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically
significant or do not cross 1.
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Validation of RUVBL1 results
The two SNPs with the strongest associations with ovarian cancer risk (RUVBL1
rs13063604 and rs7650365) were genotyped in additional stage 2 samples, which
included a total of 2,636 cases and 6,164 controls. Stage 2 comprised of samples
from AUS, BAVARIA, DOVE, GEOCS, GER, HAW, HOPE, JAC, NCOCS, UKO-
P2 (UKOPS cases and controls, and SEARCH cases) and USC. The associations
with risk of the serous subtype were not validated in the stage 2 samples alone
(P>0.05; refer to Table 3.21). The association between increased risk of serous
ovarian cancer and the rare allele of rs13063604 HetOR=1.13 (1.00-1.27), HomOR=
1.22 (0.9-1.56), P=0.0191 remained statistically significant after combining stages 1
and 2 genotyping data. The rs13063604 variant tags nine other SNPs. Two of these,
rs1057220 and rs1057156, are located in the 3’ untranslated region (3’UTR), and
they are predicted to be exonic splicing enhancers.
The association between the rare allele of rs7650365 and reduced risk of the serous
subtype was no longer statistically significant after stages 1 and 2 were combined
(HetOR=0.94 [0.86-1.04), HomOR=0.92 [0.82-1.03), P=0.142); Table 3.21.
The rare allele of RBBP8 rs4474794 was found to be associated with a decrease in
risk of serous histological subtype when logistic regression analysis was restricted to
the subtype, HetOR=0.83 (0.70-0.98), HomOR=0.80 (0.63-1.03), P=0.0323;
Appendix IV-L. The rs4474794 tSNP tags 17 other variants with r2≥0.8. Five of
these SNPs are conserved in mice, however, all of the SNPs are intronic, and there
are no known functions which could explain the association.
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Table 3.21: Genotype-specific risks of RUVBL1 rs13063604 and rs7650365 (by genotyping stage)
tSNP Study Controls Cases Histology HetOR* (95% CI) HomOR* (95% CI) P-trend
Stage 1 1724 1266 1.14 (0.97-1.34) 1.39 (1.02-1.89) 0.019
Stage 2 2639 1915 1.04 (0.92-1.18) 1.09 (0.85-1.41) 0.402
Stage 1 & 2 4363 3181
All
1.08 (0.98-1.19) 1.19 (0.98-1.45) 0.033
Stage 1 1724 537 1.42 (1.15-1.74) 1.63 (1.10-2.42) 0.0002
Stage 2 2639 1218 1.00 (0.86-1.16) 1.05 (0.77-1.42) 0.83
rs13063604
Stage 1 & 2 4363 1755
Serous
1.13 (1.00-1.27) 1.22 (0.96-1.56) 0.019
Stage 1 2672 1645 1.08 (0.93-1.26) 0.86 (0.72-1.03) 0.11
Stage 2 5885 4437 0.97 (0.88-1.06) 0.97 (0.87-1.09) 0.624
Stage 1 & 2 8778 6129
All
1.02 (0.94-1.1) 0.96 (0.87-1.05) 0.404
Stage 1 2672 769 0.97 (0.80-1.17) 0.74 (0.58-0.93) 0.009
Stage 2 5885 2534 0.94 (0.84-1.05) 0.99 (0.87-1.13) 0.858
rs7650365
Stage 1 & 2 8778 3303
Serous
0.94 (0.86-1.04) 0.92 (0.82-1.03) 0.142
Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; * compared with common homozygous; Emboldened tSNP and
histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross 1.
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Figure 3.5: Forest plots of RUVBL1 rs7650365 (serous subtype)
The genotype- and haplotype-specific results of STAG3 are shown in Appendix IV-Q
and V-R. The rare allele of rs1637001 was associated with a reduced risk of the
serous histological subtype (HetOR=0.84 (0.71-0.99), HomOR=0.77 (0.56-1.05),
P=0.0177). The heterozygous odd ratio for rs1637001 for all histological subtypes
correlated to a decrease in the risk of ovarian cancer, HetOR=0.86 (0.76-0.98),
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HomOR=0.92 (0.73-1.16), P=0.0692. However, the correlation was not statistically
significant.
Associations were also found with the haplotypes of AXIN2, CASP5 and RUVBL1
and ovarian cancer susceptibility – see Table 3.22. The h1111 haplotype of AXIN2
block 2 was associated with an increased risk of ovarian cancer - OR=1.21 (1.03-
1.42), P=0.023. This association was also found when analysis was restricted to the
serous subtype (OR=1.19 [1.01-1.39], P=0.037) – Appendix IV-F. The rs11079571
variant, which was associated with disease risk, was in the second position of the
haplotypes of this block (AXIN2 block 2). The association between the rare allele of
rs11079571 and increased risk of ovarian cancer was consistent with the correlation
of the h1111 haplotype of AXIN2 block 2 and increased risk of ovarian cancer. No
other common haplotypes of AXIN2 block 2 contained the rare allele of rs11079571
(see Appendix IV-F).
The h000 haplotype of CASP5 block 1, which contained rs518604 in the first
position, was associated with a reduced risk of ovarian cancer, OR=0.72 (0.56-0.94),
P=0.015. Conversely, the h100 haplotype of the same block was associated with an
increased risk of ovarian cancer of all subtypes, OR=1.13 (1.03-1.24), P=0.012;
Table 3.22. The associations were consistent with the effects of the rs518604 alleles.
When the global effects of CASP5 haplotype block 1 on ovarian cancer susceptibility
were investigated, a highly significant association was found, P=8.43x10-6.
Although no individual haplotype of RUVBL1 was found to be associated with the
risk of ovarian cancer, RUVBL1 haplotypes were globally associated with ovarian
cancer predisposition, P=0.0016.
Chapter 3: Results - susceptibility
173
Table 3.22: MMCT-18 susceptibility - haplotype results (all subtypes)
Gene/haplotype
block Haplotype Freq (%) OR (95% CI) P-value
Global P-
value
h0000000 70 1.04 (0.9-1.2) 0.60
h0001011 7 1.22 (0.94-1.59) 0.13
h0001100 4 0.8 (0.54-1.17) 0.24
AIFM2 block 1
h1111110 4 1 (0.71-1.42) 1.00
0.93
h00000 36 0.92 (0.83-1.02) 0.12
h00001 4 1.06 (0.83-1.35) 0.67
h00011 7 1.12 (0.92-1.36) 0.25
AIFM2 block 2
h00100 39 1.01 (0.91-1.11) 0.86
0.80
h0000 55 1.01 (0.88-1.16) 0.90
h1010 30 1 (0.86-1.16) 1.00
h1100 8 0.97 (0.75-1.25) 0.80
AKTIP
h1101 6 1 (0.75-1.33) 1.00
0.37
h000001 15 0.9 (0.77-1.04) 0.15
h010011 6 0.9 (0.72-1.12) 0.36
h010111 11 1.05 (0.89-1.23) 0.58
h011001 10 1.15 (0.98-1.36) 0.08
h011010 4 0.96 (0.73-1.26) 0.75
h011011 6 1.08 (0.87-1.33) 0.49
AXIN2 block 1
h100000 45 1.03 (0.93-1.13) 0.60
0.19
h0000 53 0.98 (0.87-1.1) 0.75
h0001 15 0.93 (0.79-1.11) 0.43
h1001 6 0.98 (0.77-1.26) 0.87
h1011 7 1.06 (0.86-1.3) 0.60
AXIN2 block 2
h1111 13 1.21 (1.03-1.42) 0.023
0.085
h001 10 0.9 (0.77-1.06) 0.22
h010 44 0.99 (0.9-1.09) 0.79CASP5 block 1
h100 43 1.13 (1.03-1.24) 0.012
8.4 x10-6
h000000 10 0.87 (0.71-1.07) 0.18
h000001 49 1.02 (0.9-1.14) 0.77
h000010 13 1.1 (0.93-1.3) 0.29
h001110 7 0.97 (0.77-1.22) 0.79
h011010 10 1.15 (0.95-1.39) 0.16
CASP5 block 2
h100001 5 1.01 (0.82-1.26) 0.90
0.25
h00000 46 0.95 (0.84-1.08) 0.45
h00110 7 0.94 (0.74-1.2) 0.62
h01000 12 0.97 (0.79-1.19) 0.78
h10100 23 1.08 (0.93-1.24) 0.31
FILIP1L block
1
h10101 11 1.11 (0.91-1.35) 0.29
0.59
h000 19 0.94 (0.83-1.08) 0.38
h001 17 1.04 (0.92-1.17) 0.56
FILIP1L block
2
h010 41 0.98 (0.88-1.08) 0.64
0.76
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Gene/haplotype
block Haplotype Freq (%) OR (95% CI) P-value
Global P-
value
h100 23 1.04 (0.93-1.16) 0.53
h0000 62 1.12 (0.98-1.27) 0.09
h0010 02 0.88 (0.71-1.1) 0.27
h0011 23 0.92 (0.8-1.07) 0.27
RBBP8
h1010 7 0.83 (0.64-1.07) 0.15
0.64
h0000000 42 0.98 (0.89-1.08) 0.67
h0000011 5 0.93 (0.74-1.17) 0.54
h0000100 10 1.04 (0.89-1.21) 0.61
h0001001 7 0.92 (0.75-1.12) 0.41
h0010011 8 1.1 (0.93-1.31) 0.28
h0100100 11 1.01 (0.87-1.18) 0.85
RGC32
h1000000 8 1 (0.84-1.2) 0.96
0.63
h000000 13 0.91 (0.77-1.07) 0.25
h000100 48 0.96 (0.86-1.07) 0.49
h001011 15 0.98 (0.84-1.15) 0.83
h011010 12 1.15 (0.97-1.36) 0.11
RUVBL1
h111000 10 1.17 (0.99-1.4) 0.07
0.0016
h000 51 1.06 (0.96-1.16) 0.26
h011 27 0.94 (0.85-1.05) 0.29STAG3
h110 21 1.03 (0.92-1.16) 0.63
0.098
Freq – frequency; OR – odds ratio; CI – confidence interval; SNP order in haplotypes is 5’ to 3’ of the genes –
AIFM2 (block 1): rs2394655, rs7908957, rs1053495, rs2894111, rs2394656, rs6480440, rs2280201. AIFM2
(block 2): rs10999147, rs3750772, rs4295944, rs2394644, rs10999152. ATKIP: rs9931702, rs17801966,
rs7189819, rs3743772. AXIN2 (block 1): rs11868547, rs7591, rs4074947, rs7210356, rs11655966, rs4541111.
AXIN2 (block 2): rs4791171, rs11079571, rs3923087, rs3923086. CASP5 (block 1): rs518604, rs523104,
rs3181328. CASP5 (block 2): rs17446518, rs9651713, rs3181175, rs3181174, rs2282657, rs507879. FILIP1L
(block 1): rs796977, rs793477, rs793446, rs3921767, rs17338680. FILIP1L (block 2): rs9864437, rs6788750,
rs12494994. RBBP8: rs7239066, rs11082221, rs4474794, rs9304261. RGC32: rs10467472, rs3783194,
rs11618371, rs9532824, rs995845, rs9594551, rs975590. RUVBL1: rs9860614, rs13063604, rs3732402,
rs7650365, rs4857836, rs9821568. STAG3: rs11762932, rs2246713, rs1637001.
Associations between the MMCT-18 candidates and risk of the major
histological subtypes of ovarian cancer
As shown with the candidate oncogenes, statistically significant associations may be
found between candidate genes and the histological subtypes of ovarian cancer,
which may not be detected with the analysis of all samples. However, the results
should be treated with caution as the numbers of samples are further reduced. The
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following describes statistically significant associations with tables of the results of
all subtypes combined and individually.
Associations between AIFM2 and ovarian cancer susceptibility
A haplotype of AIFM2 block 2 was associated with the risk of mucinous ovarian
cancer (Table 3.23). The h00100 of AIFM2 block 2 was associated with an
increased risk of the subtype, OR=1.26 (1.02-1.55), P=0.034. See Appendix IV-B
for the logistic regression results for all the common AIFM2 haplotypes.
Table 3.23: Haplotype-specific results of AIFM2 (P<0.05)
Haplotype
block Haplotype
Freq
(%) Histology OR (95% CI) P-value
Global
P-value
All 1.01 (0.91-1.11) 0.856
Serous 1.02 (0.91-1.14) 0.702
Endometrioid 0.96 (0.8-1.15) 0.637
Mucinous 1.26 (1.02-1.55) 0.034
AIFM2
haplotype
block 2
h00100 39
Clear cell 0.91 (0.72-1.15) 0.437
0.7949
SNP order in haplotypes is 5’ to 3’ of the gene – haplotype block 2: rs10999147, rs3750772, rs4295944,
rs2394644, rs10999152.
Association between RGC32 and ovarian cancer susceptibility
The only association between risk of ovarian cancer and RGC32 was with a common
variant with a minor allele frequency of 0.11. The rare allele of rs3783194 was
associated with a 1.5-fold increase in the risk of the clear cell histological subtype –
HetOR=1.5 (1.04-2.17), HomOR=1.99 (0.59-6.7), P=0.0206; see Table 3.24.
Currently, it is not known if this variant tags any other SNPs in the gene or the
regulatory regions up- or downstream of the gene. See Appendix IV-M for the
results for the other common tSNPs of this gene.
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There was also evidence of an association between a haplotype of RGC32,
h0100100, and increased risk of clear cell ovarian cancer (OR=1.53 [1.11-2.11],
P=0.01), see Table 3.25. This haplotype comprised of the rare allele of RGC32
rs3783194, which was associated with an increase risk of clear cell ovarian cancer in
the second position, thus lending support to the association with the h0100100
haplotype. No other common haplotype contained the rare allele of rs378319.
Associations between RBBP8 and ovarian cancer susceptibility
In addition to the association between the RBBP8 rs4474794 variant and a decrease
in risk of serous histological subtype, the h0000 haplotype of the gene was
associated with a marginal increase in the risk of the subtype – OR=1.13 (1.01-1.27),
P=0.032. These haplotype-specific associations were concordant with the tSNP
findings. The results for all tSNPs and haplotypes of RBBP8 are shown in
Appendices IV-K and IV-L, respectively.
Associations between AXIN2 and ovarian cancer susceptibility
As well as the association between h1111, of AXIN2 haplotype block 2 and
increased risk of ovarian cancer in general – OR=1.21 (1.03-1.42), P=0.023. This
association was also found when analysis was restricted to the serous subtype
(OR=1.19 [1.01-1.39], P=0.037) – see Table 3.26. The rs11079571 variant, which
was associated with disease risk, was in the second position of the haplotypes of this
block (AXIN2 block 2). The association between the rare allele of rs11079571 and
increased risk of ovarian cancer was consistent with the correlation of the h1111
haplotype of AXIN2 block 2 and increased risk of ovarian cancer. The rare allele of
rs11079571 was not present in any other common haplotype (Appendix IV-F).
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Table 3.24: Genotype-specific risks of RGC32 (P<0.05)
Gene tSNP MAF Controls Cases Histology HetOR (95% CI)* HomOR (95% CI)* P-trend
1690 All 1.02 (0.88-1.19) 1.03 (0.57-1.89) 0.8873
788 Serous 0.89 (0.72-1.09) 0.70 (0.29-1.69) 0.1363
264 Endometrioid 1.13 (0.83-1.54) 1.50 (0.51-4.36) 0.4304
184 Mucinous 1.09 (0.75-1.59) 1.08 (0.25-4.66) 0.7964
RGC32 rs3783194 0.11 2723
155 Clear cell 1.50 (1.04-2.17) 1.99 (0.59-6.70) 0.0206
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common
homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically
significant or do not cross 1.
Table 3.25: Haplotype-specific results of RGC32 (P<0.05)
Gene Haplotype Freq (%) Histology OR (95% CI) P-value GlobalP-value
All 1.01 (0.87-1.18) 0.851
Serous 0.89 (0.74-1.07) 0.212
Endometrioid 1.02 (0.76-1.36) 0.89
Mucinous 1.01 (0.72-1.41) 0.962
RGC32 h0100100 10.8
Clear cell 1.53 (1.11-2.11) 0.01
0.6294
SNP order in haplotypes is 5’ to 3’ of the gene: rs10467472, rs3783194, rs11618371, rs9532824, rs995845, rs9594551, rs975590.
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Statistically significant associations were also found with 2 haplotypes of AXIN2
block 1, which had opposing effects on the risk of the serous histological subtype.
The h000001 haplotype was associated with a reduced risk of the disease, OR=0.81
(0.68-0.97), P=0.018, (see Table 3.26). However, the h011001 haplotype of AXIN2
block 1 was associated with an increased risk of the serous subtype (OR=1.21 [1.01-
1.45], P=0.041). The results of the remaining haplotypes are shown in Appendix IV-
F.
Associations between FILIP1L and ovarian cancer susceptibility
Although there was no evidence suggesting that a common variant of FILIP1L was
associated with overall risk of ovarian cancer, statistically significant associations
were found when the analysis was restricted to the endometrioid and mucinous
histological subtypes. These associations were found with 3 variants of the gene,
rs793446, rs17338680 and rs12494994, of which the rare alleles of all the variants
were associated with increased risk of the endometrioid histological subtype (see
Table 3.27 on page 181). The risks associated with carrying at least 1 of the rare
alleles of rs793446, rs17338680 or rs12494994 ranged from 1.36 (for the rs793446
tSNP) to 1.71 (for rs17338680) for the endometrioid histological subtype (Table
3.27). The rs12494994 variant had the strongest association; HetOR=1.48 (1.08-
2.04), HomOR=2.16 (1.13-4.12), P=0.0024. The heterozygous genotype of
rs12494994 was also correlated with a 1.57-fold increase in the risk of the mucinous
histological subtype, however, the connection was not statistically significant
(P=0.2574). See Appendix IV-I for the genotype-specific results for all FILIP1L
variants.
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Table 3.26: Haplotype-specific risks of common AXIN2 (P<0.05)
Gene/haplotype
block Haplotype Freq (%) Histology OR (95% CI) P-value
Global
P-value
All 0.9 (0.77-1.04) 0.148
Serous 0.81 (0.68-0.97) 0.018
Endometrioid 0.95 (0.73-1.24) 0.7
Mucinous 1.08 (0.8-1.46) 0.632
h000001 14.6
Clear cell 0.97 (0.7-1.36) 0.868
All 1.15 (0.98-1.36) 0.082
Serous 1.21 (1.01-1.45) 0.041
Endometrioid 1.16 (0.87-1.54) 0.312
Mucinous 1.22 (0.87-1.7) 0.246
AXIN2 haplotype
block 1
h011001 10.4
Clear cell 0.86 (0.57-1.29) 0.458
0.185
All 1.21 (1.03-1.42) 0.023
Serous 1.19 (1.01-1.39) 0.037
Endometrioid 1.08 (0.83-1.4) 0.572
Mucinous 1.13 (0.83-1.53) 0.434
AXIN2 haplotype
block h1111 12.8
Clear cell 0.96 (0.68-1.36) 0.838
0.0847
SNP order in haplotypes is 5’ to 3’ of the genes –AXIN2 haplotype block 1: rs11868547, rs7591, rs4074947, rs7210356, rs11655966,
rs4541111. AXIN2 haplotype block 2: rs4791171, rs11079571, rs3923087, rs3923086.
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The correlation between rs793446 and rs17338680 (which are both in intron 4 of
the gene) is r2=0.173; rs793446 and rs12494994 is r2=0.407; and rs17338680 and
rs12494994 (intron 1) is r2=0.404. The rs793446 variant tags 28 other SNPs with
r20.8; rs17338680 tags 6 other SNPs and rs12494994 tags 11 other variants with 
r20.8.  All of these SNPs are in the introns of the gene, and approximately 70% of 
them are conserved in mice.
Associations were also found between risk of endometrioid ovarian cancer and
haplotypes of FILIP1L, see Table 3.28 for the significant associations, and
Appendix IV-J for all results. FILIP1L comprises 2 haplotype blocks. The h10101
haplotype of haplotype block 1 had the strongest association with disease risk, with
a 1.56-fold increase in odds; OR=1.56 (1.22-2.01), P=5.01x10-4. The haplotype,
which had a frequency of 10.7%, contained the rare alleles of rs793446 and
rs17338680 in the third and last positions of the haplotype, respectively. The rare
alleles of the variants were associated with an increased risk of endometrioid
ovarian cancer, thus, the haplotype result was supported by the individual common
tSNP findings.
There was also evidence suggesting a statistically significant association between a
variant of FILIP1L haplotype block 2 and risk of the endometrioid subtype. The
h001 haplotype was associated with an increased risk of the subtype; OR=1.37
(1.1-1.69), P=0.004 (see Table 3.28). This association was also supported by the
individual SNP results - the rare allele of rs12494994, which was correlated to
increased risk of the endometrioid histological subtype which was in the last
position of the haplotype.
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Table 3.27: Genotype-specific risks of common FILIP1L variants (P<0.05)
Gene tSNP MAF Controls Cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
1773 All 1.05 (0.92-1.20) 1.11 (0.93-1.32) 0.3207
838 Serous 0.95 (0.80-1.13) 1.07 (0.86-1.34) 0.842
274 Endometrioid 1.36 (1.02-1.81) 1.52 (1.05-2.20) 0.0262
194 Mucinous 1.14 (0.82-1.58) 0.93 (0.58-1.48) 0.8885
rs793446 0.41 2947
164 Clear cell 1.05 (0.74-1.50) 1.11 (0.69-1.77) 0.6725
1786 All 1.06 (0.91-1.24) 0.77 (0.46-1.28) 0.985
574 Serous 0.88 (0.69-1.14) 0.98 (0.44-2.20) 0.3051
221 Endometrioid 1.71 (1.24-2.36) 0.79 (0.19-3.39) 0.0073
196 Mucinous 1.23 (0.86-1.76) 0.35 (0.05-2.58) 0.7109
rs17338680 0.11 2989
133 Clear cell 1.04 (0.67-1.63) 1.12 (0.26-4.81) 0.8406
1273 All 1.14 (0.98-1.33) 0.88 (0.59-1.33) 0.433
594 Serous 0.95 (0.78-1.17) 0.52 (0.27-0.99) 0.097
193 Endometrioid 1.48 (1.08-2.04) 2.16 (1.13-4.12) 0.0024
145 Mucinous 1.57 (1.10-2.25) 0.25 (0.03-1.83) 0.2574
FILIP1L
rs12494994 0.18 2347
113 Clear cell 1.20 (0.79-1.82) 1.69 (0.71-4.03) 0.1986
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common
homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically
significant or do not cross 1.
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Table 3.28: Haplotype-specific risks of FILIP1L (P<0.05)
Gene/hap
block Haplotype Freq (%) Histology OR (95% CI) P-value
Global
P-value
All 1.11 (0.91-1.35) 0.29
Serous 0.94 (0.78-1.13) 0.514
Endometrioid 1.56 (1.22-2.01) 5.01x10-4
Mucinous 1.09 (0.78-1.51) 0.617
FILIP1L
haplotype
block 1
h10101 10.7
Clear cell 1.25 (0.89-1.75) 0.204
0.5938
All 1.04 (0.92-1.17) 0.562
Serous 0.88 (0.76-1.02) 0.092
Endometrioid 1.37 (1.1-1.69) 0.004
Mucinous 1.03 (0.79-1.36) 0.815
FILIP1L
haplotype
block 2
h001 17.1
Clear cell 1.17 (0.88-1.56) 0.269
0.7565
SNP order in haplotypes is 5’ to 3’ of the gene –FILIP1L (block 1): rs796977, rs793477, rs793446,
rs3921767, rs17338680. FILIP1L (block 2): rs9864437, rs6788750, rs12494994.
Table 3.29: Haplotype-specific risks of STAG3 (P<0.05)
Gene Haplotype Freq (%) Histology OR (95% CI) P-value GlobalP-value
All 1.06 (0.96-1.16) 0.257
Serous 1.12 (1.01-1.25) 0.039
Endometrioid 1.06 (0.89-1.27) 0.523
Mucinous 0.97 (0.79-1.2) 0.805
h000 50.7
Clear cell 1 (0.8-1.25) 0.996
All 0.94 (0.85-1.05) 0.29
Serous 0.88 (0.78-1) 0.046
Endometrioid 0.89 (0.73-1.09) 0.251
Mucinous 1.22 (0.97-1.53) 0.084
STAG3
h011 26.8
Clear cell 0.89 (0.69-1.16) 0.401
0.0979
Freq – frequency; OR – odds ratio; CI – confidence interval; SNP order in haplotypes is 5’ to 3’ of
the gene: rs11762932, rs2246713, rs1637001.
The STAG3 rs1637001 variant was in the last position of a haplotype block
comprising the 3 tSNPs genotyped. Associations were found between the serous
histological subtype and two haplotypes of STAG3, Table 3.29. The h000 haplotype
was associated with a marginal, 1.12-fold, increase in the risk of serous ovarian
cancer (OR=1.12 [1.01-1.25], P=0.039). Conversely, the h011 haplotype was
associated with a reduced risk of the serous subtype (0.88 [0.78-1], P=0.046). This
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association was also supported by the association between the rare allele of
rs1637001 tSNP (in the last position of the haplotype) and the decrease in risk of
serous ovarian cancer. The rs1637001 polymorphism tags 17 other variants with
r2≥0.8. Three of these SNPs, rs1623264, rs1727134 and rs1727128, are located in
transcription factor binding sites. Several of the other polymorphisms may be
involved in splicing.
Associations between AKTIP and ovarian cancer susceptibility
There was evidence of an association between the AKTIP gene and ovarian cancer
susceptibility. The rare allele of rs718919 was associated with risk of the mucinous
and clear cell histological subtypes. The associated risks were: HetOR=0.87 (0.64-
1.19), HomOR=0.42 (0.21-0.84), P=0.0247 for the mucinous subtype; and
HetOR=0.62 (0.44-0.87), HomOR=0.78 (0.45-1.35), P=0.0412 for the clear cell
(Table 3.30). See Appendix IV-C for the genotype-specific susceptibility results of
all the common variants of AKTIP. A haplotype of AKTIP, h1010, was also
associated with a 0.73- and 0.77-fold decrease in the risk of both the mucinous and
the clear cell subtypes, respectively (see Table 3.31). rs718919, the rare allele of
which was associated with a reduced risk of mucinous and clear cell subtypes, was in
the third position of the haplotype. These associations were concordant with each
other. An additional association was found with the h1101 haplotype of AKTIP and
the serous subtype. The h1101 haplotype was associated with increased risk of the
serous subtype (OR=1.29 [1.01-1.66], P=0.044). Although the correlations were not
statistically significant, with the exception of the mucinous subtype, the odds ratios
for all cases of ovarian cancer, the endometrioid and clear cell subtypes were greater
than 1 (see Table 3.31).
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Table 3.30: Genotype-specific risks of an AKTIP tSNP (P<0.05)
Gene tSNP MAF Controls Cases Histology HetOR (95% CI)* HomOR (95% CI)* P-trend
1745 All 0.93 (0.82-1.06) 0.92 (0.75-1.14) 0.2796
825 Serous 0.99 (0.84-1.17) 1.02 (0.78-1.33) 0.867
271 Endometrioid 0.95 (0.73-1.24) 1.06 (0.69-1.61) 0.9177
186 Mucinous 0.87 (0.64-1.19) 0.42 (0.21-0.84) 0.0247
AKTIP rs7189819 0.3 2923
163 Clear cell 0.62 (0.44-0.87) 0.78 (0.45-1.35) 0.0412
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common
homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically
significant or do not cross 1.
Table 3.31: Haplotype-specific risks for AKTIP (P<0.05)
Gene Haplotype Freq (%) Histology OR (95% CI) P-value GlobalP-value
All 1 (0.86-1.16) 0.996
Serous 0.99 (0.88-1.11) 0.858
Endometrioid 0.97 (0.8-1.18) 0.766
Mucinous 0.73 (0.58-0.94) 0.013
h1010 30.4
Clear cell 0.77 (0.59-1) 0.047
All 1 (0.75-1.33) 0.999
Serous 1.29 (1.01-1.66) 0.044
Endometrioid 1.02 (0.65-1.59) 0.927
Mucinous 0.94 (0.54-1.65) 0.835
AKTIP
h1101 5.7
Clear cell 1.37 (0.82-2.3) 0.227
0.3703
SNP order in haplotypes is 5’ to 3’ of the genes –ATKIP: rs9931702, rs17801966, rs7189819, rs3743772.
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3.4: Admixture Maximum Likelihood test results
A large number of statistical tests are involved in the analysis of genetic association
studies, however multiple testing corrections such as the Bonferoni correction are
too stringent and do not take into account the correlation between SNPs. It has been
suggested that the adjustment for “experiment-wise” type I error is more appropriate
method for testing the global null hypothesis of no association within an experiment.
These methods evaluate whether a greater than expected proportion of statistically
significant associations are detect within an experiment. The admixture maximum
likelihood (AML) test is a reportedly robust method for testing the global null
hypothesis. The AML test simultaneously estimates the proportion of associated
SNPs and their effect size. The AML test was used to evaluate the SNP genotyping
data from 12 previous ovarian cancer case-control association studies for global
evidence of associations between 340 SNPs from 84 genes and 10 chromosomal
regions and the risk of the disease. The test was used to establish whether there was
a statistically significant difference in the proportion of associations found from
genetic susceptibility association studies of ovarian cancer and that which would
have been found by chance.
3.4.1: Samples and methods
Genotyping data of 340 SNPs from three population-based case-control study series
were analysed with the admixture maximum likelihood test. The studies comprised
of up to 1,491 invasive epithelial ovarian cancer cases and 3,145 healthy controls
from the GEOCS, MALOVA and SEARCH sample sets. The vast majority (>250)
of the SNPs were tagging SNPs identified from 84 candidate genes from pathways,
such as the cell cycle control, mismatch repair, DNA repair, oncogene and
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differentially expressed genes with described functions from functional studies
(microcell-mediated chromosome 18 transfer [MMCT-18) group), which have been
implicated with ovarian cancer development.
Candidate SNPs from 10 different regions on chromosomes 2, 3, 5, 8, 11, 12 and 17
were also analysed. These variants had originally been selected for validation from
the Ovarian Cancer Association Consortium (OCAC), Breast Cancer Association
Consortium (BCAC) or the breast cancer genome-wide association study due to
associations with breast or ovarian cancer. Associations between individual SNPs
and ovarian cancer risk with unconditional logistic regression, and the heterogeneity
and trend test. The admixture maximum likelihood test was used on groups of SNPs
to determine whether the proportion of associations found were greater than that
which would be expected.
All variants analysed were allocated into a group based on known or putative
function, or the research consortia from which the candidate SNP had come. There
were a total of 7 groups – BCAC (16 SNPs), cell cycle control (101 tSNPs), DNA
repair (28 SNPs), mismatch repair (43 tSNPs), MMCT (consisting of differentially
expressed genes from functional tumour suppression experiments- 63 tSNPs),
OCAC (55 SNPs) and ovarian cancer oncogenes (34 tSNPs). The genotype
distribution for all SNPs analysed are shown in Appendix II-B.
3.4.2: Logistic regression results (unadjusted)
When the trend model was used to test for association, 22 (6.5%) of the 340 SNPs
were significantly associated with ovarian cancer risk at the 5% level, and 5 SNPs
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(1.5%) were significant at the 1% level. Of the 5 most significant SNPs with the
trend model, two variants were from the BCAC group (rs2107425 on chromosome
11p15.5 and rs3817198 of LSP1), another two were from the cell cycle group
(CDKN1B rs2066827 and CDK6 rs8) one SNP was from the OCAC group (ESR1
rs9322336).
Adjustments for population stratification by genomic control were made in order to
ensure that the associations found were due to the variants analysed, rather than
underlying structure of the population. Logistic regression analyses were also
stratified by sample sets to account for population stratification. Following
adjustments of genomic controls for population stratification, 18 (5.3%) of the 340
variants were now statistically significant at the 5% level. This was a reduction of 4
SNPs compared to the unadjusted findings. The same number of SNPs (5 [1.5%])
were significant at the 1% level, after adjustments for population stratification (Table
3.32).
After analysis with the heterogeneity test, 17 (5%) of the SNPs were significant at
the 5% level, 6 SNPs (1.8%) were significant at the 1% level, and one at the 0.001%
significance level. After adjusting for population stratification, 15 of the 17 SNPs
significantly associated with ovarian cancer risk at the 5% level, remained
significant. One of the 6 SNPs, significant at the 1% level with the heterogeneity
test, was no longer significant, thus 5 (1.5%) SNPs remained significant at the 1%
level. The only SNP, which reached 0.001% level of significance, remained at the
same level after adjustments for population stratification.
Chapter 3: Results - susceptibility
188
Both the heterogeneity and trend tests detected associations between the same 9
SNPs and risk of epithelial ovarian cancer. Although there was a slight attenuation
in the P-values after adjustments for population stratification, the significant
associations remained. The unadjusted and adjusted trend test results for each SNP
are shown in Appendix VI. The results of the trend test are illustrated in Figure 3.6
as a quantile-quantile (Q-Q) plot. Q-Q plots are probability plots used for comparing
2 probability distributions. In order for the probability distributions to be compared,
the quantiles of the distributions are plotted against each other.
The Q-Q plot in Figure 3.6 shows the ordered observed trend test statistics plotted
against the expected trend χ2 results given the rank. The line of equivalence is the
straight line through the plot. This line is used as a reference for no difference
between the observed and expected χ2 values, given the rank. Deviation from the
line of equivalence suggests differences between the observed and expected χ2
values. In Figure 3.6, the plots of both the unadjusted and adjusted trend test results
suggested that a greater proportion of associations were found than expected. In the
Q-Q plot shown in Figure 3.6, the plot followed the line of equivalence for the first
240 SNPs, and then started to deviate. This indicates that a modest number of SNPs
were associated with ovarian cancer risk.
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Table 3.32: AML - SNPs with significant associations (trend test for association)
Group Genelocation SNP MAF Controls Cases
HetOR‡
(95% CI)
HomOR‡
(95% CI)
Unadjust
P-het*
Adjust. P-
het§
Unadjusted
P-trend
Adjusted
P-trend§
BCAC 11p15.5 rs2107425 0.32 1460 2463 0.71 (0.62-0.82) 0.88 (0.70-1.10) 1.28x10-5 2.17x10-5 0.0012 0.0019
OCAC ESR1 rs9322336 0.23 1453 2464 0.81 (0.70-0.93) 0.73 (0.52-1.02) 0.005 0.006 0.0013 0.0021
BCAC LSP1 rs3817198 0.3 1457 2435 1.16 (1.01-1.34) 1.40 (1.11-1.75) 0.006 0.009 0.0016 0.0026
Cell cycle CDKN1B rs2066827 0.26 1481 2484 0.88 (0.77-1.01) 0.68 (0.51-0.90) 0.011 0.019 0.0035 0.0053
Cell cycle CDK6 rs8 0.21 1473 2481 1.17 (1.02-1.35) 1.44 (1.04-1.99) 0.015 0.013 0.0039 0.0059
Mismatch PMS2 rs7797466 0.18 1305 1968 1.18 (1.01-1.38) 1.38 (0.96-2.00) 0.039 0.044 0.0108 0.0142
Cell cycle CCND1 rs603965 0.44 1476 2464 1.06 (0.91-1.23) 1.28 (1.06-1.55) 0.027 0.032 0.013 0.0178
MMCT-18 RUVBL1 rs13063604 0.22 564 785 1.23 (0.98-1.56) 1.54 (1.00-2.39) 0.0556 0.058 0.016 0.0181
OCAC PGR rs1042838 0.14 1424 2408 1.25 (1.07-1.46) 1.09 (0.73-1.64) 0.019 0.023 0.0161 0.0215
Cell cycle CCND1 rs7178 0.07 1480 2491 1.24 (1.04-1.49) 1.24 (0.50-3.04) 0.063 0.072 0.021 0.0278
OCAC IL18 rs1834481 0.25 1449 2435 0.89 (0.77-1.02) 0.77 (0.59-1.01) 0.074 0.083 0.0227 0.0295
Cell cycle CCND1 rs602652 0.46 1468 2493 1.13 (0.97-1.32) 1.24 (1.03-1.49) 0.074 0.084 0.0235 0.0307
OCAC IGF2 rs4320932 0.2 1473 2402 0.84 (0.73-0.97) 0.86 (0.60-1.22) 0.0529 0.061 0.0243 0.0314
MMCT-18 CASP5 rs518604 0.44 1041 2029 1.11 (0.93-1.33) 1.27 (1.02-1.58) 0.0987 0.072 0.032 0.0387
Cell cycle CCND1 rs3212879 0.49 1472 2491 0.85 (0.73-0.99) 0.82 (0.68-0.99) 0.063 0.108 0.0321 0.0409
DNA XRCC2 rs3218536 0.08 1337 1787 0.88 (0.72-1.08) 0.23 (0.07-0.79) 0.014 0.017 0.0364 0.0439
Cell cycle CCND1 rs3212891 0.46 1475 2476 0.86 (0.74-1.00) 0.83 (0.69-1.00) 0.082 0.092 0.0376 0.0472
Mismatch PMS1 rs256563 0.12 1456 2446 2.50 (0.99-6.33) 2.15 (0.84-5.48) 0.0435 0.134 0.04 0.05
BCAC 8q24.21 rs10808556 0.4 1462 2453 1.15 (0.99-1.33) 1.20 (0.99-1.46) 0.1071 0.119 0.0446 0.0552
Cell cycle CDKN2A rs3731257 0.26 1480 2476 0.89 (0.78-1.03) 0.80 (0.60-1.07) 0.1345 0.148 0.0451 0.056
Cell cycle CCNE1 rs3218036 0.31 1476 2481 1.07 (0.93-1.23) 1.27 (1.01-1.59) 0.1126 0.125 0.0458 0.0567
OCAC IGF2 rs1003483 0.49 1459 2407 1.20 (1.02-1.40) 1.20 (1.00-1.44) 0.0611 0.07 0.0473 0.0581
‡ compared with common homozygous; HetOR – heterozygous odds ratio, HomOR – homozygous odds ratio; CI – confidence interval; *P-heterogeneity; § Adjusted for
population stratification.
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Figure 3.6: Quantile-quantile plot of the univariate trend test results
Chapter 3: Results - susceptibility
191
3.4.3: AML results (adjusted for population stratification)
The genomic control method for adjusting for cryptic population stratification was
used on the variants analysed. Genotyping data from breast cancer case-control
samples from the genome-wide association study (Easton et al. 2007; Hunter et al.
2007) were used to estimate the degree of over-dispersion of statistics, also known as
inflation test statistic (Pharoah et al. 2007). The results from the breast cancer were
used to estimate the level of stratification within Caucasian populations. A more
conservative inflation statistic of 10%, was used to adjust the P-trend for cryptic
population stratification.
Eight of the 22 SNPs that were statistically significant at the 5% level with the trend
test belonged to the mitotic cell cycle control pathway group (Table 3.32). This
group consisted of 101 SNPs from 15 genes, which have been demonstrated to be
involved in the regulation of progression through the cell cycle. The most
significant tSNP in the cell cycle group was rs2066827 in the cyclin-dependent
kinase inhibitor 1B (CDKN1B) gene. The rare allele of this SNP was associated with
a decrease in the risk of ovarian cancer (HetOR=0.88 [0.77-1.01], HomOR=0.68
(0.51-0.9), adjusted (for population stratification) P-het=0.019, adjusted P-
trend=0.0059. The rs2066827 variant (the fourth most significant SNP with the
trend model) is a missense SNP located in exon 1 of CDKN1B. The common allele
encodes a valine amino acid, and the rare allele, which has a frequency of 26%,
glycine.
Five variants from the 55 SNPs in the OCAC group were significant at the 5% level
after adjustments for population stratification. The most significant SNP from the
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OCAC group, rs9322336, was from the oestrogen receptor gene (ESR1). This
variant was the second most significant of the SNPs analysed with the trend test, and
the third most significant with the heterogeneity test. The rare allele of this variant
was also associated with a reduced risk of ovarian cancer – HetOR= 0.81 (0.70-
0.93), HomOR=0.73 (0.52-1.02), adjusted P-trend=0.0021.
Three of the most significant SNPs were from the BCAC group, which comprised
the 16 variants which were identified from genome wide association studies to be
strongly associated with breast cancer risk. One of these variants, rs2107425, was
associated with a decrease in risk of ovarian cancer (hetOR=0.71 [0.62-0.82],
HomOR=0.88 [0.70-1.10], adjusted P-trend=0.0019). rs2107425 is located on
chromosome 11p15.5 in a region with no known genes or open reading frame. This
variant had the strongest association with ovarian cancer risk, with both the trend
and heterogeneity models – and the p-value for the heterogeneity test reached a level
of significance deemed to provide definitive evidence of association (P<1x10-4) in
case-control association studies, however, not enough for genome-wide significance
(P<1x10-7).
Two variants from the functional candidate genes (of 63 SNPs) and the DNA
mismatch repair pathway (of 43) groups were also statistically significant. The most
significant SNP from the functional candidate group was the intronic rs13063604 in
the RUVBL1 gene on chromosome 3. RUVBL1 rs13063604 was associated in an
increased risk of ovarian cancer with the trend model (HetOR=1.23 (0.98-1.56),
HomOR=1.54 (1.00-2.39), adjusted P-het=0.058, P-trend=0.0181. Incidentally an
association was also found with this SNP with 1,755 serous histological subtype
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cases and 4,363 controls from 7 different population based case-control series
including SEARCH (DOVE, GEOCS, HOPE, JAC, UKOPS and USC). A single
variant from XRCC2 gene of the DNA double strand break repair pathway group (28
SNPs), rs3218536, was also among the significant associations with the trend test,
with a correlation with a reduction in ovarian cancer risk (HetOR=0.88 [0.72-1.08],
HomOR=0.23 [0.07-0.79], adjusted P-het=0.017, adjusted P-trend=0.0439.
Of the 15 associations identified with the heterogeneity test at the 5% significance
level after adjustments for population stratification, 2 variants were from the BCAC
group, 7 were from the cell cycle control pathway, one from the DNA repair
pathway, two from the mismatch repair pathway, two from the MMCT-18 functional
group, two from the OCAC and one from the oncogene pathway (of 34 tSNPs).
Seven of the associations found with the heterogeneity test were not identified with
the trend test.
The AML method was used to test for association of the SNPs according to
functional group, biological pathway or genotyping group. There was evidence
suggesting that the breast cancer associated group of SNPs, identified by genome
wide association studies, was significantly associated with ovarian cancer risk (P-
trend = 0.0028; adjusted P-trend = 0.0059). The statistically significant findings
suggest that there were a greater number of variants observed to be associated with
ovarian cancer risk, than that would have been expected by chance.
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Table 3.33: AML experiment-wise test results for genotyping groups
Pathway /
Group
Genes/
regions‡
No.
SNPs
LR P-trend of
most
significant
SNP*
AML P-
het*
AML P-
trend*
Reference with original single
SNP analysis using logistic
regression
BCAC† 5 (5§) 16 0.0012 0.0003 0.0028 (Song et al. 2009a)
OCAC† 36 (6§) 55 0.0014 0.863 0.806 (Palmieri et al. 2008; Pearce etal. 2008; Ramus et al. 2008b)
MMCT-18 9 63 0.016 0.609 0.468 (Notaridou et al. 2010)
Cell cycle
control 15 101 0.0035 0.274 0.225
(Dicioccio et al. 2004; Song et
al. 2006b; Gayther et al. 2007)
Mismatch repair 7 43 0.0106 0.706 0.702 (Song et al. 2006a)
DNA repair 7 28 0.0374 0.366 0.444 (Auranen et al. 2005; Song etal. 2007)
Ovarian Cancer
Oncogenes 5 34 0.0671 0.524 0.528 (Quaye et al. 2009)
Total 84 (10) 340 0.051 0.068
*Based on GEOCS, MALOVA and SEARCH genotypes; ‡ SNPs in regions with no known genes or
open reading frames are in parenthesis;† candidate genes identified from the Breast Cancer
Association Consortium (BCAC) and Ovarian Cancer Association Consortium (OCAC); § different
SNPs from 8q24.21 were genotyped in both BCAC and OCAC sets; LR – logistic regression; AML –
admixture maximum likelihood; het – heterogeneity.
There was no evidence that there were a significant proportion of variants from the
remaining groups (cell cycle control, DNA repair, mismatch repair, MMCT-18,
OCAC and ovarian cancer oncogenes) associated with ovarian cancer risk than that
which would have been expected by chance. When the genotyping data from all
groups were combined and analysed, the AML experiment-wise test for association
was not significant for either the heterogeneity test (P=0.051) or the trend test
(P=0.068). This suggests that there is a trend towards a proportion of the SNPs
evaluated being associated with disease, however this is not statistically significant,
and the effect sizes were too small to detect for individual SNPs. Table 3.33 shows
the results of the AML experiment-wise tests summarised for the complete set of
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SNPs categorised according to functional group, biological pathway or genotyping
group.
3.5: Summary
The effects of 34 tSNPs of BRAF, ERBB2, KRAS, NMI and PIK3CA on
susceptibility of ovarian cancer were evaluated with 1,816 invasive epithelial ovarian
cancer cases and 3,000 unaffected controls. There was evidence of association
between risk of ovarian cancer and all the candidate genes. Three tSNPs of both
BRAF and KRAS were associated with the risk of the mucinous histological subtype.
The associations between the mucinous subtype and BRAF and KRAS also extended
to haplotypes of these oncogenes. These findings are of particular interest because
KRAS and, to a lesser extent, BRAF mutations are predominantly found in mucinous
ovarian tumours, and these mutations are early events in the development of the
disease. Moremover, a haplotype of BRAF, h00100000, was associated with a
decrease in the risk all subtypes of ovarian cancer. This association remained when
the analysis was restricted to the serous subtype.
Common polymorphic variants of ERBB2 (non-synonymous coding SNP,
rs1801200) and PIK3CA (rs2865084) were marginally associated with risk of the
endometrioid subtype. There was also evidence suggesting that two haplotypes of
ERBB2, h110 and h001, which had opposite alleles at every position, were
associated with increased risk of ovarian cancer (all subtypes). These associations
may be caused by an unknown polymorphism which tags both haplotypes.
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Furthermore, the haplotypes of BRAF and ERBB2 were globally associated with
ovarian cancer susceptibility, (P=0.005 and P=0.034, respectively).
A statistically significant association was found between the rs11683487 variant of
NMI and ovarian cancer. This SNP was associated with serous and endometrioid
subtypes when the analysis was restricted to the histological subtypes. The finding
was not replicated with additional 1,097 cases and 1,712 controls in stage 2.
However, when the genotyping data from both stages of the study were combined,
the association with all histological subtypes, and the mucinous subtype remained.
Two haplotypes of NMI were also associated with all subtypes combined. There
results were also found when analysis was restricted to the serous subtype.
The effects of 63 tSNPs and haplotypes of candidate genes (from differentially
expressed genes with described function from in vitro neoplastic suppression
studies) on the risk of ovarian cancer were analysed with 1,799 ovarian cancer cases
and 3,045 controls. There was evidence of association between ovarian cancer
susceptibility and all of the differentially expressed genes (AIFM2, AKTIP, AXIN2,
CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3). A common variant of
AXIN2 (11079571), CASP5 (rs518604) and RUVBL1 (rs13063604) were associated
with the risk of ovarian cancer when it is considered as a single disease. The
TaqMan probes for the CASP5 and AXIN2 SNPs failed probe testing, therefore they
could not be validated with additional samples.
The association between the rare allele of CASP5 rs518604 and increased risk of
ovarian cancer remained when analysis was restricted to the serous subtype. The
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CASP5 block 1 haplotypes, h100 and h000, were also associated with the risk of
ovarian cancer (P=0.012 and P=0.015, respectively). h100 and h010 of CASP5
haplotype block 1 were also associated with the risk of the serous subtype. The
haplotypes of CASP5 block 1 were globally, strongly, associated with the risk of
ovarian cancer (P=8.43x10-6).
RUVBL1 rs13063604 was not independently validated with the stage 2 samples
(4,590 cases and 6,031 controls) alone, however, the association remained
statistically significant when the genotyping data from stages 1 and 2 were combined
(P=0.033). rs13063604 and another tSNP of RUVBL1, rs7650365, were associated
with risk of the serous subtype with stage 1 samples, P=0.002 and P=0.009,
respectively. Neither of these associations were independently validated with stage
2 samples and only the association between the rare allele of rs13063604 and
increased risk of the serous subtype remained when the data from the 2 genotyping
stages were combined (HetOR=1.13 [1-1.27], HomOR=1.22 [0.96-1.56], P=0.019).
Two haplotypes of RUVBL1 were also associated with the risk of the serous subtype,
and globally, the haplotypes of RUVBL1 were associated with ovarian cancer
susceptibility (P=0.0016).
Associations were also found between the risk of the serous histological subtype of
ovarian cancer and common a variant of RBBP8 and STAG3, and haplotypes of
AKTIP, AXIN2, as well as RBBP8 and STAG3. Interestingly, associations were
found between three tSNPs and two haplotypes of FILIP1L and the risk of
endometrioid ovarian cancer. The tSNPs and the SNPs they tag were intronic, and
some were conserved in mice. A common tagging variant of AKTIP was associated
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with risk of mucinous and clear cell histological subtypes. There was also evidence
of association between a haplotype of AKTIP and risk of serous ovarian cancer.
Another haplotype of AKTIP was associated with reduced susceptibility to mucinous
and clear cell disease.
Although many of the associations appear to be of great interest, it is important to
take into consideration that the results are based on relatively small samples,
particulary when the analyses were restricted to the histological subtypes. Many
statistical tests were performed in the analyses, however, there was no correction for
multiple testing, which may render many, if not, all associations statistically
significant. Nonetheless, the tagging approach of genetic associations attempts to
identify markers, rather than the causal genetic locus.
The admixture test (AML) was used to establish whether there was a statistically
significant difference in the proportion of associations found from genetic
susceptibility association studies of ovarian cancer and that which would have been
found by chance. A modest number of SNPs were associated with predisposition of
ovarian cancer. When the AML method was used to evaluate SNPs which were
grouped according to their proposed function, biological pathway or validation
study, only the BCAC group was statistically significant for an excess of positive
associations. The SNPs within this group were those which were highly associated
with risk of breast cancer. Three (19%) out of 16 tSNPs in the BCAC group were
significantly associated with risk of ovarian cancer. The experiment-wise test of the
340 SNPs analysed was not significant (P=0.068).
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Chapter 4: Results - Common germline
variants in candidate ovarian cancer genes and
survival of patients with invasive epithelial
ovarian cancer
4.1: Introduction
Hypothesis:
Common germline genetic variants in candidate genes associated with ovarian
cancer development can influence the clinical outcome (survival) of patients
diagnosed with invasive epithelial ovarian cancer.
Aims:
(1) To evaluate the effect of tSNPs and haplotypes from candidate oncogenes on all-
cause mortality of ovarian cancer patients.
(2) To investigate the effect of tSNPs and haplotypes in a series of “functional”
candidates identified from in vitro studies on all-cause survival of ovarian cancer
patients.
Objectives
(1) To assess the effects of common germline genetic variants and haplotypes of
candidate oncogenes and functional genes on clinical outcome of ovarian cancer
patients using univariate Cox regression survival analysis.
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(2) To evaluate the effects of the common germline variants and haplotypes in
candidate genes on overall survival after restricting the analysis to the major
histological subtypes of ovarian cancer (serous, endometrioid, mucinous and clear
cell).
(3) To examine the effects of other prognostic factors such as age at diagnosis,
tumour histological subtype, grade and stage on clinical outcome.
(4) To investigate the effects of the common genetic variants and haplotypes of
candidate genes, after adjustments for confounding prognostic factors, on clinical
outcome (using multivariate Cox regression survival analysis).
The effects of overall survival for tSNPs and haplotypes of candidate oncogenes and
a series of functional candidate genes identified from in vitro modelling studies in
patients with ovarian cancer over a 10 year period were investigated. The oncogenes
(BRAF, ERBB2, KRAS, NMI and PIK3CA) and functional candidates (AIFM2,
AKTIP, AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3) were
selected because of their putative role in ovarian cancer development.
Cox regression survival analysis was used to establish the effects of the genetic
variants and haplotypes on all-cause mortality in ovarian cancer patients. Cox
regression survival analysis was also used to evaluate the effects of clinical,
prognostic factors on patient survival in order to make appropriate adjustments for
these potentially confounding factors. Clinical factors which were found to be
significantly associated with all cause mortality were adjusted for all common
variants and haplotypes, in order to determine if true associations with the genetic
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factors existed. Survival analysis was performed on a total of 2,021 invasive
epithelial ovarian cancer cases.
4.2: Survival analyses of variants and haplotypes of candidate
oncogenes
Thirty-four tSNPs identified in the candidate oncogenes (BRAF, ERBB2, KRAS, NMI
and PIK3CA) were genotyped in a total of 1,572 invasive epithelial ovarian cancer
cases from 4 population-based series: GEOCS (327 cases), MALOVA (445 cases),
SEARCH (708 cases) and UKOPS (92 cases). Together, these cohorts included a
total of 662 deaths in 6,467 person-years at risk. The time at risk was calculated by
the summation of the time (years) from entry into the study until an individual died
or was censored from the study. The effects of the tSNPs on all-cause mortality
were investigated using Cox regression survival analysis. All reported values are
based on likelihood ratio test for trend (1 degree of freedom).
4.2.1:Univariate survival analysis results of BRAF
There was evidence of a statistically significant association between a common
genetic variant of BRAF, rs6944385, and all-cause mortality of ovarian cancer
patients, with the univariate survival model. The univariate survival model
contained terms for the common variant, stratified by population set because there
were significant differences in the survival of patients in the different data sets. The
rare allele of rs6944385 was associated with poor survival (per-rare allele hazard
ratio (HR) =1.19 (95% confidence interval 1.03-1.38, P=0.021). The rare allele of
the tSNP resulted in a 1.19-fold increase in mortality, compared with the common
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allele. This suggested that the addition of a rare allele increases the hazard ratio by
1.19. Thus for the additive model, heterozygotes have an increased hazard of 1.19,
and rare homozygotes have a 2.38-fold increase in hazard, compared with common
homozygotes. The hazard ratio measures the effect of the explanatory factor (allele)
on the risk (hazard) of death.
Figure 4.1: Kaplan-Meier survival estimates of BRAF rs6944385 (all cases)
Numbers following the keys are individuals still at risk after 10 years.
Figure 4.1 shows the plot of the Kaplan-Meier survival estimates of the different
genotypes of BRAF rs6944385 over a 10-year period. Kaplan-Meier survival
estimates were used to illustrate the survival function of ovarian cancer patients
grouped according to their genotype for a particular tSNP. The survivor curves are
step functions that decrease (step-down) at the time points when patients die (Everitt
and Palmer 2005). The figure clearly shows a worse survival associated with rare
HR=1.19 (1.03-1.38), P=0.021
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homozygotes of rs6944385 compared with common homozygotes and
heterozygotes. Half of the patients homozygous for the rare allele of rs6944385
survived for 2.5 years after diagnosis, which was approximately 1.5 years less than
the survival of the common homozygotes and heterozygotes.
The association observed with the BRAF rs6944385 variant and survival of all
histological subtypes combined was more significant, with increased hazard when
analysis was restricted to the clear cell histological subtype. The rare variant of
rs6944385 was associated with a 2.2-fold increase in mortality compared with the
common allele, HR=2.22 (1.18-4.17), P=0.014, see Table 4.1.
Table 4.1: Univariate Cox regression results of BRAF rs6944385, by histology
Univariate
Gene tSNP MAF Histology Cases
HR (95% CI) P-value
All 1758 1.19 (1.03-1.38) 0.021
Serous 840 0.97 (0.79-1.2) 0.804
Endometrioid 268 1.31 (0.84-2.07) 0.235
Mucinous 187 0.83 (0.4-1.73) 0.614
BRAF rs6944385 0.14
Clear cell 124 2.22 (1.18-4.17) 0.014
HR - Hazard ratio; CI - confidence interval; MAF- minor allele frequency; Emboldened histology
names are statistically associated with survival; emboldened HR are statistically significant.
Although associations may not be found with individual tSNPs, different
combinations of SNPs forming haplotypes may affect survival from ovarian cancer.
When the effects of the BRAF haplotypes on survival from ovarian cancer were
evaluated, none of the common haplotypes of BRAF were statistically associated
with survival from ovarian cancer. However, the 95% confidence intervals of all
histological subtypes of the h01100001 haplotype did not cross 1, HR=1.21 (1-1.46),
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P=0.055. This suggests that the haplotype may be marginally correlated with
increased mortality of ovarian cancer.
4.2.2: Univariate survival analysis results of KRAS
When Cox regression survival analysis was used to assess the effect of KRAS
variants on the survival from ovarian cancer, a statistically significant association
was found between a common tSNP, rs10842513, and all-cause mortality of serous
histological subtype cases. The rare allele of rs10842513 was associated with poor
survival (HR=1.38 (1.09-1.75), P=0.008), see Table 4.2. Although, this variant was
not statistically associated with increased mortality of patients with clear cell ovarian
cancer, the 95% confidence interval did not cross 1, which suggests a marginal
correlation (Table 4.2).
Table 4.2: Univariate Cox regression results of common tSNPs of KRAS (P<0.05)
Univariate
Gene tSNP MAF Histology Cases
HR (95% CI) P-value
All 1770 1.18 (0.98-1.42) 0.08
Serous 846 1.38 (1.09-1.75) 0.008
Endometrioid 271 1.19 (0.67-2.1) 0.552
Mucinous 187 0.7 (0.29-1.69) 0.432
rs10842513 0.09
Clear cell 132 2.02 (1-4.1) 0.052
All 1748 0.93 (0.8-1.09) 0.378
Serous 834 0.89 (0.73-1.08) 0.236
Endometrioid 242 0.83 (0.51-1.36) 0.463
Mucinous 187 1.79 (1.02-3.15) 0.044
KRAS
rs4623993 0.16
Clear cell 136 0.93 (0.46-1.89) 0.835
HR - Hazard ratio; CI - confidence interval; MAF- minor allele frequency; Emboldened histologies
are statistically associated with survival; emboldened HR are statistically significant or the CI does
not cross 1.
Another variant of KRAS, rs4623993, was associated with survival of mucinous
cases. The rare allele of KRAS rs4623993 was associated with poor survival of
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individuals with mucinous ovarian cancer, HR=1.79 (1.02-3.15), P=0.044 (see Table
4.2).
The effect of both rs10842513 and rs4623993 on the mucinous subtype, although not
statistically significant for the previous tSNP, was the opposite of the other
histological subtypes (see Table 4.2). This difference in the ratios was also found
with another tSNP of KRAS, rs4623993, which was significantly associated with the
increased risk of the mucinous subtype. These marked differences between
mucinous disease and the other subtypes may be a result of putative involvement of
the KRAS gene in the development of mucinous ovarian cancer.
Table 4.3: Univariate Cox regression results of KRAS haplotypes (P<0.05)
Univariate
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value
All 1.27 (0.99-1.62) 0.056
Serous 1.69 (1.21-2.36) 0.002
Endometrioid 1.21 (0.59-2.48) 0.599
Mucinous 0.66 (0.17-2.55) 0.55
h010000 5.9
Clear cell 2.81 (0.95-8.33) 0.062
All 1.02 (0.79-1.31) 0.902
Serous 0.87 (0.62-1.21) 0.411
Endometrioid 0.99 (0.44-2.18) 0.971
Mucinous 3.24 (1.55-6.74) 0.002
h001100 3.7
Clear cell 2.42 (0.6-9.66) 0.212
All 1.26 (0.87-1.82) 0.219
Serous 0.96 (0.61-1.53) 0.872
Endometrioid 2.47 (0.84-7.23) 0.099
Mucinous 6.59 (1.37-31.62) 0.018
KRAS
haplotype
block 2
h000000 2.6
Clear cell 1.53 (0.32-7.36) 0.593
†: ‘0’= common allele and ‘1’= rare allele; HR - Hazard ratio; CI - confidence interval; Emboldened
HR are statistically significant or the CI does not cross 1; Emboldened haplotypes are statistically
significant; SNP order in haplotypes (5’ to 3’ of the genes) –KRAS - block 2: rs12579073,
rs10842513, rs4623993, rs6487464, rs10842514, rs11047917.
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Statistically significant associations were found between 3 haplotypes of KRAS
block 2 and survival of patients with serous and mucinous histological subtypes of
ovarian cancers. The h010000 haplotype, which has a frequency of 5.9%, was
associated with poor survival of serous cases (HR=1.69 [1.21-2.36], P=0.002), see
Table 4.3. This association was supported by the tSNP results – the rare allele of
KRAS rs10842513, which was associated with poor survival of patients with serous
ovarian cancer, was in the second position of the KRAS haplotype block 2.
The other 2 haplotypes of KRAS block 2, h001100 and h000000, were also
associated with poor survival, however, of the mucinous histological subtype in
these instances, (see Table 4.3). These associations were concordant with the
univariate analysis results of KRAS rs4623993 (third position of the KRAS haplotype
block 2), which was associated with survival from mucinous disease.
4.2.3:Univariate survival analysis results of PIK3CA
An association was found between a tSNP and haplotype of PIK3CA when the
effects of the gene on survival were evaluated. The rare allele of PIK3CA rs7651265
was associated with poor survival of clear cell ovarian cancer cases – HR=2.25
(1.06-4.79), P=0.035, see Table 4.4. The h11000000 haplotype of PIK3CA was also
associated with poor survival from the endometrioid subtype, HR=2.19 (1.1-4.37),
P=0.026 (Table 4.5).
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Table 4.4: Univariate Cox regression results of PIK3CA rs7651265 (by histology)
Univariate
Gene tSNP MAF Histology Cases
HR (95% CI) P-value
All 1794 1.07 (0.9-1.26) 0.449
Serous 828 1.05 (0.85-1.29) 0.678
Endometrioid 267 0.97 (0.56-1.67) 0.913
Mucinous 189 1.66 (0.79-3.46) 0.179
PIK3CA rs7651265 0.1
Clear cell 135 2.25 (1.06-4.79) 0.035
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; Emboldened histologies are
statistically associated with survival; emboldened HR are statistically significant.
Table 4.5: Univariate Cox regression results of a PIK3CA haplotype (by histology)
Univariate
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value
All 1.1 (0.86-1.42) 0.444
Serous 1.06 (0.78-1.45) 0.701
Endometrioid 2.19 (1.1-4.37) 0.026
Mucinous 0.76 (0.24-2.46) 0.651
PIK3CA h11000000 4.9
Clear cell 0.38 (0.04-3.48) 0.394
†: ‘0’= common allele and ‘1’= rare allele; HR - Hazard ratio; CI - confidence interval; Emboldened
HR are statistically significant or the CI does not cross 1; Emboldened histologies are statistically
significant; SNP order in haplotypes is 5’ to 3’ of PIK3CA: rs2865084, rs7621329, rs1517586,
rs2699905, rs7641889, rs7651265, rs7640662, rs2677760.
4.2.3: The influence of clinical prognostic factors on survival
Clinical factors such as age at diagnosis, tumour histological subtype, grade and
stage are known to influence survival from ovarian cancer. Therefore, these factors
are used clinically to predict a patient’s chances of survival. It is possible that these
prognostic factors confound the results from the univariate analyses, either by
masking statistically significant associations, or creating false positive associations.
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Cox regression survival analysis was used to ascertain the effects of the prognostic
factors on the samples within the dataset. As expected, statistically significant
associations were found between survival from ovarian cancer and all the prognostic
factors (age at diagnosis, tumour histological subtype, grade and stage). Cox
regression survival modelling showed that survival from ovarian cancer decreased
with increasing age; those between aged between 50 and 59 years had a 1.67 fold
increase in all-cause mortality (HR=1.67 (1.01-2.77), P=0.047 compared with those
aged less than 40 years. Individuals in the greater than 60 years age group had the
worse survival, compared with the under 40 year olds (see Table 4.6).
Figure 4.2 shows the Kaplan-Meier survival curves for the prognostic factors.
Individuals with mucinous, endometrioid or clear cell histological subtypes of
invasive epithelial ovarian cancer survived for longer than those with the serous
subtype (see Table 4.6).
Tumour grades 2 (moderately differentiated tumour) and 3 (poorly differentiated,
more malignant tumour) were also significantly associated with poor survival
(HR=1.47 (1.11-1.96), P=0.008; HR=1.6 (1.21-2.11), P=0.001, respectively).
Advanced stage tumours, which comprised of tumours that have spread to lymph
nodes or metastasised to distant locations, had the strongest effect on survival from
ovarian cancer (HR=4.08 (3.15-5.29), P=1.57x10-26) when compared with localised,
early stage tumours. The Cox regression survival analysis results for the clinical
factors are summarised in Table 4.6.
The samples analysed included both incident cases (patients recruited into their
respective studies before diagnosis of the ovarian cancer) and prevalent cases
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(sufferers recruited after diagnosis of disease). There was potential survival bias
between incident and prevalent cases because prevalent cases are likely to have
received treatment before recruitment into the studies, and individuals with poor
chances of survival would have died before recruitment. It was thus expected that
incident cases would have poor survival compared with prevalent cases. Although
the Kaplan-Meier curves showed that incident cases had a slightly higher mortality
rate compared with prevalent cases, the difference in mortality was not statistically
significant (HR=1.04 [0.66-1.63], P=0.871).
Table 4.6: Results of univariate Cox regression survival analysis of clinical
prognostic factors (oncogene dataset)
Prognostic
factor No. cases HR (95% CI) P-value
5-year
survival rate
10-year
survival rate
Histological subtype
Serous 735 (47%) 1 40% 30%
Endometrioid 249 (16%) 0.4 (0.3-0.52) 2.56x10-11 70% 65%
Mucinous 170 (11%) 0.4 (0.29-0.56) 9.29x10-8 60% 63%
Clear cell 126 (6%) 0.4 (0.28-0.59) 1.75x10-6 65% 60%
Age at diagnosis (years)
< 40 100 (6%) 1 75% 63%
40-49 306 (19%) 1.49 (0.88-2.52) 0.137 60% 48%
50-59 586 (37%) 1.67 (1.01-2.77) 0.047 50% 43%
≥ 60 580 (37%) 2.26 (1.37-3.73) 0.002 38% 30%
Tumour grade*
1 260 (17%) 1 68% 60%
2 398 (25%) 1.47 (1.11-1.96) 0.008 52% 40%
3 540 (34%) 1.6 (1.21-2.11) 0.001 38% 30%
Tumour stage
Localised 531 (34%) 1 80% 68%
Advanced§ 736 (47%) 4.08 (3.15-5.29) 1.57x10-26 28% 18%
N=1,572; HR – hazard ratio; CI – confidence interval; * Tumour grades (1= well differentiated – low
grade; 2= moderately differentiated; 3= poorly differentiated (high grade). § spread to regional lymph
nodes or distant metastases; emboldened prognostic factors are significantly associated with survival
from ovarian cancer.
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Figure 4.2: Kaplan-Meier survival curves
by (a) histological subtype; (b) age-group at diagnosis; (c) tumour grade; (d) tumour stage; numbers following the keys are individuals still at risk
after 10 years.
(a) (b)
(c) (d)
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4.2.4: Multivariate survival analysis results of oncogene variants
The results of all variants were adjusted for the prognostic factors which were
significantly associated with survival from ovarian cancer (age at diagnosis ≥ 50
years; mucinous, endometrioid and clear cell histological subtypes; tumour grades 2
and 3; and advanced stage disease). The statistical modelling of the survival data,
with adjustments for confounding (clinical prognostic) factors is known as
multivariate analysis. The results of the univariate and multivariate survival analysis
for the common tagging polymorphisms and haplotypes of the candidate oncogenes
are tabulated in Appendices VII-A to VII-J.
There was no evidence of association between the common genetic variants or
haplotype of ERBB2 or NMI. The univariate and multivariate Cox regression
analysis results for ERBB2 and NMI are shown in Appendices VII-C to VII-D, and
VII-G to VII-H, respectively. The associations found in the univariate survival
analysis of the PIK3CA variants or haplotypes were no longer statistically significant
after adjustments for prognostic factors. The survival results of the tSNPs and
haplotypes can be found in Appendix VII-I and VII-J, respectively.
4.2.5: Multivariate survival analysis results of BRAF oncogene
When multivariate Cox regression survival analysis was used to assess the effects of
the common variants of candidate oncogenes on survival from epithelial ovarian
cancer, the association between the rare allele of BRAF rs6944385 and all-cause
survival of all subtypes combined became stronger – adjusted (for prognostic
factors) per-rare allele HR=1.25 (1.05-1.5), P=0.013. However, the association of
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the variant with the clear cell histological subtype was no longer significant (see
Table 4.7). The univariate and multivariate Cox regression survival results for all
the common variants and haplotypes of the BRAF oncogene are shown in Appendix
VII-A and VII-B, respectively.
Additional associations, which were not identified with the univariate analyses, were
found between all-cause survival and variants of BRAF. The rare allele of BRAF
rs1267622 was associated with poor survival of ovarian cancer patients (adjusted
HR=1.19 (1.03-1.38), P=0.02). The rare allele of BRAF rs13241719 and the AA
haplotype of rs1267622:rs6944385 were associated with better survival of all
histological subtypes combined in the multivariate analyses (adjusted HR=0.79
(0.67-0.93), P=0.004; and adjusted HR=0.84 (0.72-0.97), P=0.018, respectively).
The rs13241719 variant was also associated with the serous histological subtype
when the analysis was restricted to the individual subtypes (see Table 4.7).
The BRAF variants rs1267622, rs13241719 and rs6944385 are correlated. The r2
between BRAF rs1267622 and rs13241719 is 0.116; rs1267622 and rs6944385 -
r2=0.339; and rs13241719 and rs6944385 - r2=0.039. A likelihood ratio test was
performed with and without terms for the three BRAF variants, adjusted for the
prognostic factors. This test was used to evaluate whether a model with all three
variants was statistically significant, compared with a model without the variants.
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Table 4.7: Univariate and multivariate Cox regression results of BRAF tSNPs, by histology
Univariate* Multivariate*§
Gene tSNP MAF Histology Cases
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)‡
All 1751 1.12 (0.99-1.27) 0.077 1.19 (1.03-1.38) 0.02 6
Serous 831 1.03 (0.87-1.22) 0.727 1.2 (1-1.4) 0.134 17
Endometrioid 268 1.07 (0.72-1.59) 0.733 1.1 (0.71-1.71) 0.655 3
Mucinous 187 1.08 (0.64-1.82) 0.764 0.89 (0.54-1.49) 0.663 18
rs1267622 0.23
Clear cell 123 1.27 (0.7-2.3) 0.429 1 (0.51-1.98) 0.997 21
All 1602 0.97 (0.85-1.1) 0.606 0.79 (0.67-0.93) 0.004 19
Serous 733 0.94 (0.79-1.12) 0.507 0.8 (0.6-0.9) 0.006 15
Endometrioid 246 0.77 (0.49-1.21) 0.258 0.79 (0.48-1.29) 0.339 3
Mucinous 176 0.99 (0.58-1.69) 0.98 1.05 (0.63-1.74) 0.852 6
rs13241719 0.31
Clear cell 135 1.12 (0.59-2.15) 0.723 1.4 (0.64-3.06) 0.404 25
All 1758 1.19 (1.03-1.38) 0.021 1.25 (1.05-1.5) 0.013 5
Serous 840 0.97 (0.79-1.2) 0.804 1.1 (0.9-1.3) 0.516 13
Endometrioid 268 1.31 (0.84-2.07) 0.235 1.43 (0.87-2.35) 0.156 9
Mucinous 187 0.83 (0.4-1.73) 0.614 0.76 (0.36-1.62) 0.477 8
rs6944385 0.14
Clear cell 124 2.22 (1.18-4.17) 0.014 1.93 (0.95-3.92) 0.07 13
All 1786 0.89 (0.79-1.01) 0.076 0.84 (0.72-0.97) 0.018 6
Serous 724 0.97 (0.82-1.14) 0.708 0.9 (0.7-1) 0.115 7
Endometrioid 246 0.9 (0.61-1.34) 0.611 0.87 (0.57-1.34) 0.532 3
Mucinous 169 0.94 (0.56-1.58) 0.82 1.18 (0.7-1.98) 0.528 26
BRAF
rs1267622,
rs6944385; AA 76
†
Clear cell 126 0.79 (0.44-1.43) 0.434 1 (0.51-1.98) 0.999 27
* stratified by study; HR - Hazard ratio; CI - confidence interval; MAF- minor allele frequency; † Haplotype frequency; § adjusted for prognostic factors (histology
[where appropriate], age, stage and grade);‡: difference in HR after multivariate analysis – values ≥ 10: prognostic factors were confounding. Emboldened tSNP
names are statistically associated with survival after adjustments; emboldened HR are statistically significant or the CI does not cross 1.
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Table 4.8: Univariate and multivariate Cox regression results of BRAF haplotypes (P<0.05)
Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.95 (0.81-1.1) 0.493 0.8 (0.66-0.95) 0.014 16
Serous 0.95 (0.79-1.16) 0.633 1.1 (0.9-1.4) 0.415 16
Endometrioid 0.88 (0.54-1.42) 0.591 0.88 (0.53-1.48) 0.629 0
Mucinous 0.63 (0.31-1.28) 0.204 0.62 (0.32-1.23) 0.173 2
h10010000 18.8
Clear cell 1.38 (0.61-3.08) 0.438 2.38 (0.92-6.15) 0.074 72
All 1.1 (0.94-1.3) 0.238 1 (0.83-1.21) 0.96 9
Serous 1.12 (0.91-1.37) 0.296 0.8 (0.6-1) 0.037 29
Endometrioid 0.74 (0.36-1.5) 0.401 0.74 (0.36-1.54) 0.425 0
Mucinous 1.5 (0.81-2.8) 0.199 1.91 (0.96-3.78) 0.065 27
h10010010 12.2
Clear cell 0.79 (0.35-1.75) 0.557 0.62 (0.23-1.7) 0.351 22
All 1.21 (1-1.46) 0.055 1.43 (1.14-1.8) 0.002 18
Serous 1.1 (0.85-1.42) 0.483 0.9 (0.7-1.3) 0.636 18
Endometrioid 1.3 (0.71-2.4) 0.393 2.04 (1.05-3.99) 0.036 57
Mucinous 0.81 (0.33-1.99) 0.652 0.9 (0.38-2.1) 0.804 11
BRAF
h01100001 7.1
Clear cell 1.86 (0.84-4.13) 0.127 1.92 (0.74-4.96) 0.179 3
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; HR: Hazard ratio; CI: confidence interval; Emboldened HR are statistically significant or the CI does not
cross 1; Emboldened haplotypes are statistically significant after adjustments for clinical factors; SNP order in haplotypes is 5’ to 3’ of the genes – BRAF: rs10487888, rs1733832,
rs1267622, rs13241719, rs17695623, rs17161747, rs17623382, rs6944385;
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The likelihood ratio test including all three tSNPs, adjusted for prognostic factors,
was statistically significant (P=0.0147), however, when forward stepwise regression
procedure was used, only rs13241719 was retained in the final model (P=0.009).
The forward stepwise regression procedure involved the modelling of the variants
(rs1267622, rs13241719 and rs6944385), one-by-one, and retaining the tSNP which
was statistically significant (rs13241719 in this instance). The prognostic factors
were included in the model because the association between rs1267622 and
rs13241719 were found with the multivariate survival analysis.
BRAF rs1267622 tags rs4726020 with r2 =1. According to Pupasuite, both SNPs are
intronic and the dbSNP database showed rs1267622 is in intron 3 of the oncogene,
and rs4726020 is in intron 1. rs13241719 (intron 2) is not known to tag any other
SNP within BRAF. rs6944385 (intron 1) tags rs9648716 (intron 1) with r2=1. None
of these SNPs are predicted to have functions that could explain their association
with survival from ovarian cancer.
The correlation between the h01100001 haplotype of BRAF and all-cause mortality
of the combined subtypes of ovarian cancer cases became statistically significant
after adjustments for the prognostic factors, adjusted HR=1.43 (1.14-1.8), P=0.002,
(see Table 4.8). This haplotype was also associated with poor survival, when
analysis was restricted to the endometrioid histological subtype. The haplotype was
associated with a 2.04-fold increase in hazard of the endometrioid subtype – Table
4.8. These results were confounded by the clinical prognostic factors, by at least
18%.
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Figure 4.3: tSNPs in BRAF haplotype block
Colour scheme: standard (D’/LOD) – white (D’<1, LOD<2), shades of pink/red (D’<1, LOD≥2), blue (D’=1,
LOD<2) and bright red (D’=1, LOD≥2), numbers shown in squares (LD values) are based on D’.
Two other, previously undetected, associations were found between haplotypes of
BRAF and survival from ovarian cancer after adjustments for prognostic factors.
The h10010000 haplotype was associated with improved survival of all histological
subtypes (adjusted HR=0.8 [0.66-0.95], P=0.014; Table 4.8). There was also
evidence suggesting that this haplotype was associated with improved survival of
serous cases, when the Cox regression survival analysis was restricted to the
histological subtype – Table 4.8. This association was supported by the multivariate
result of BRAF rs13241719, which was in the fourth position of the haplotype
(Figure 4.3).
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4.2.6: Multivariate survival analysis results of KRAS oncogene
An association was found between the rs10842513 variant of KRAS and poor
survival of ovarian cancer, after adjustments for the clinical prognostic factors (Table
4.9). A statistically significant association was also found with this variant and the
serous histological subtype in the univariate analysis (see Table 4.9). Although the
association with the serous subtype was no longer statistically significant, the 95%
confidence interval did not cross 1.
The difference between the hazard ratios of the univariate and multivariate analyses
of the serous subtype for the rs10842513 variant were not significant (<10%),
therefore the hazard ratio was not confounded by the prognostic factors. The
rs10842513 SNP, which is located in intron 2 of KRAS, is not known to tag another
SNP within the oncogene. Although the SNP is currently not predicted to have a
“function”, it is conserved in mice.
The h001100 haplotype of KRAS block 2 remained significantly associated with
reduced survival of sufferers with the mucinous subtype (adjusted HR=2.74 [1.27-
5.9], P=0.01). The h100010 haplotype of block 2 was also associated with poor
survival of mucinous disease – see Table 4.10. This association was found after
adjustments for the prognostic factors had been made.
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Table 4.9: Univariate and multivariate survival results of KRAS rs10842513
Univariate Multivariate§
Gene tSNP MAF Histology Cases
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1770 1.18 (0.98-1.42) 0.08 1.25 (1.01-1.55) 0.039 6
Serous 846 1.38 (1.09-1.75) 0.008 1.3 (1-1.6) 0.091 6
Endometrioid 271 1.19 (0.67-2.1) 0.552 1.47 (0.79-2.74) 0.227 24
Mucinous 187 0.7 (0.29-1.69) 0.432 0.74 (0.29-1.87) 0.521 6
KRAS rs10842513 0.09
Clear cell 132 2.02 (1-4.1) 0.052 1.71 (0.81-3.58) 0.156 15
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; § adjusted for prognostic factors (histology, age, stage and grade, where appropriate); emboldened HR are
statistically significant or the CI does not cross 1.
Table 4.10: Univariate and multivariate survival results of KRAS haplotype block 2 (P<0.05)
Univariate Multivariate§
Gene Haplotype† Freq(%) Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.96 (0.83-1.12) 0.625 0.95 (0.81-1.12) 0.556 1
Serous 0.9 (0.74-1.08) 0.255 0.9 (0.6-1.3) 0.479 0
Endometrioid 0.86 (0.51-1.45) 0.571 0.82 (0.47-1.43) 0.481 5
Mucinous 1.32 (0.79-2.22) 0.288 1.79 (1.03-3.13) 0.04 36
h100010 10.7
Clear cell 0.95 (0.47-1.91) 0.881 0.87 (0.39-1.93) 0.723 8
All 1.02 (0.79-1.31) 0.902 1.05 (0.79-1.41) 0.722 3
Serous 0.87 (0.62-1.21) 0.411 1.1 (0.8-1.5) 0.631 26
Endometrioid 0.99 (0.44-2.18) 0.971 1.21 (0.52-2.82) 0.652 22
Mucinous 3.24 (1.55-6.74) 0.002 2.74 (1.27-5.9) 0.01 15
KRAS
haplotype
block 2
h001100 3.7
Clear cell 2.42 (0.6-9.66) 0.212 3.42 (0.65-18) 0.146 41
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; HR: Hazard ratio; CI: confidence interval; Emboldened HR are statistically significant or the CI does not
cross 1; SNP order in haplotypes is 5’ to 3’ of the genes –KRAS haplotype block 2: rs12579073, rs10842513, rs4623993, rs6487464, rs10842514, rs11047917.
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4.3: Survival analyses of variants and haplotypes of functional
candidates
Sixty-three tSNPs from nine differentially expressed genes (AIFM2, AKTIP, AXIN2,
CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3) selected from the
microcell-mediated transfer of chromosome 18 (MMCT-18) into two ovarian cancer
cell-lines were genotyped with the MALOVA (446 cases), SEARCH (847 cases) and
UKOPS (401 cases) population-based sample sets. There were 617 deaths in 5,885
person-years at risk. Cox regression survival analysis was used to ascertain the
effect of the tSNPs and haplotypes of the functional candidates on the survival of
ovarian cancer patients.
4.3.1: Association between clinical prognostic factors and survival for
“functional” candidate genes
The results from the survival analysis of tSNPs and haplotypes of candidate
oncogenes demonstrated that the adjustment for clinical prognostic factors was
critical in determining associations which were not confounded by prognostic
factors. Therefore, Cox regression survival analysis was used to assess the effects of
the prognostic factors (age at diagnosis, tumour histological subtype, grade and
stage) on survival from ovarian cancer of individuals from the MALOVA, SEARCH
and UKOPS population-based studies used in this analysis. The results of the effect
of the prognostic factors on survival from ovarian cancer are summarised in Table
4.11.
Chapter 4: Results - survival
220
Table 4.11: Cox regression survival analysis results of clinical prognostic factors
(MMCT-18 dataset)
Prognostic factor No. cases (%) HR (95% CI) P-value
Histological subtype
Serous 796 (47%) Reference
Mucinous 185 (11%) 1.15 (0.78-1.69) 0.49
Endometrioid 262 (16%) 0.79 (0.57-1.09) 0.148
Clear cell 153 (9%) 0.75 (0.44-1.26) 0.278
Age at diagnosis (years)
< 40 72 (4%) Reference
40-49 270 (16%) 1.41 (0.66-3) 0.37
50-59 636 (38%) 1.79 (0.87-3.68) 0.115
≥ 60 716 (42%) 2.44 (1.19-4.97) 0.014
Tumour grade*
1 250 (15%) Reference
2 400 (24%) 1.36 (1.01-1.82) 0.041
3 518 (31%) 1.38 (1.04-1.85) 0.028
Tumour stage§
Localised 492 (29%) Reference
Advanced§ 744 (44%) 3.99 (3.01-5.02) 4.04x10-22
N=1,694; * 1= well differentiated – low grade, 2= moderately differentiated - medium grade, 3=
poorly differentiated (high grade); § spread to regional lymph nodes or distant metastases;
emboldened prognostic factors are significantly associated with survival from ovarian cancer.
Contrary to the findings with the samples analysed in the oncogene study, there were
no statistically significant associations between survival from ovarian cancer and
tumour histological subtypes (P>0.05). This may have been as a result of the
absence of the GEOCS and additional samples in the SEARCH and UKOPS sample
populations. Individuals in the > 60 years old age group had a significantly
increased mortality rate compared with those in the <40 years age group (HR=2.44
[1.19-4.97], P=0.014). There were statistically significant differences in the
mortality of individuals with low grade tumours and those with intermediate and
high grade tumours (HR=1.36 [1.01-1.82], P=0.041; HR=1.38 [1.04-1.85], P=0.028,
respectively). In concordance with the samples in the oncogene study, advanced
stage disease had the biggest effect on survival from ovarian cancer, with an
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approximately 4-fold increase in mortality compared with localised, early stage
disease (HR=3.99 (3.01-5.02), P=4.04x10-22).
4.3.2: Effect of “functional” candidate ovarian cancer genes on survival of
ovarian cancer patients
Univariate and multivariate Cox regression survival analysis results for all common
variants and haplotypes of this series of functional candidate genes (AIFM2, AKTIP,
AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3) are tabulated in
Appendix VIII-A to VIII-R.
There was no evidence of association between survival from ovarian cancer and the
common tSNPs or haplotypes of AKTIP, AXIN2 or STAG3. However, associations
were found between survival from clear cell, and endometrioid ovarian cancers and
the combined rare haplotypes of AKTIP and STAG3, respectively (Appendix VIII-D,
and VIII-R, respectively).
Multivariate survival analysis results of AIFM2
After adjustments for the prognostic factors, two variants of AIFM2 were
significantly associated with survival from histological subtypes of invasive
epithelial ovarian cancer. The rare allele of AIFM2 rs2394655 was associated with
increased mortality of patients with the mucinous subtype (adjusted per-rare allele
HR=3.05 [1.03-8.98], P=0.043). This association was also found with the univariate
survival analysis (see Table 4.12). The rare allele of AIFM2 rs2280201 was
associated with poor survival of the endometrioid subtype, adjusted HR=2.03 (1.13-
3.65), P=0.018.
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Associations were also found between haplotypes of AIFM2 and survival of ovarian
cancer cases. The associations were found with both haplotype block of AIFM2.
The h0001011 haplotype of AIFM2 block 1 was associated with increased mortality
of endometrioid patients after adjustments for prognostic factors (adjusted HR=2.76
[1.36-5.59], P=0.005). The variant of AIFM2, rs2280201, was in the last position of
haplotype block 1. The rare allele of this variant was associated with poor survival of
endometrioid cases, and thus supports the findings of the haplotype analysis. The
h01011 haplotype of AIFM2 block 2 was also associated with poor survival of
endometrioid cases, adjusted HR=5.31 (2.04-13.8), P=0.001, see Table 4.13.
There was evidence suggesting that the h1111110 haplotype of AIFM2 block 1 was
associated with increased mortality of mucinous patients (adjusted HR=3.02 (1.02-
8.91), P=0.045; Table 4.13). This association was supported by the single variant
results. The rare allele of rs2394655, which was associated with poor survival, was
the first position of the haplotype. The rs2394655 variant is not known to tag
another SNP. The variant, which is conserved in mice, is located in the 3’
untranslated region of the gene, and it is predicted to be an exonic splicing enhancer.
Furthermore, the h00001 haplotype of AIFM2 block 2 was associated with poor
survival of those with clear cell disease, adjusted HR=2.29 (1.23-4.28), P=0.009; see
Table 4.13.
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Table 4.12: Univariate and multivariate survival results of AIFM2 tSNPs (P<0.05)
Univariate Multivariate§
Gene tSNP MAF Histology Cases
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1751 1.04 (0.78-1.39) 0.788 1 (0.72-1.4) 0.986 4
Serous 827 0.97 (0.68-1.39) 0.878 0.91 (0.61-1.36) 0.652 6
Endometrioid 269 0.22 (0.03-1.56) 0.129 0.32 (0.04-2.35) 0.262 45
Mucinous 189 4.88 (1.96-12.15) 0.001 3.05 (1.03-8.98) 0.043 38
rs2394655 0.04
Clear cell 150 1.08 (0.55-2.11) 0.824 1.27 (0.6-2.73) 0.532 18
All 1313 0.93 (0.77-1.11) 0.392 0.95 (0.77-1.17) 0.617 2
Serous 556 0.81 (0.63-1.03) 0.08 0.87 (0.66-1.13) 0.296 7
Endometrioid 216 1.44 (0.84-2.45) 0.182 2.03 (1.13-3.65) 0.018 41
Mucinous 146 0.93 (0.49-1.78) 0.833 2.02 (0.96-4.24) 0.065 117
AIFM2
rs2280201 0.12
Clear cell 150 1.01 (0.71-1.45) 0.94 0.86 (0.56-1.33) 0.496 15
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; § adjusted for prognostic factors (histology, age, stage and grade, where appropriate);
Emboldened histological subtypes - variants are statistically associated with survival after adjustments; emboldened HR are statistically significant or the CI
does not cross 1.
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Table 4.13: Effects of AIFM2 haplotypes on survival from ovarian cancer (P<0.05)
Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.90 (0.71-1.13) 0.348 1 (0.77-1.3) 0.98 11
Serous 0.80 (0.60-1.08) 0.149 0.86 (0.62-1.19) 0.352 7
Endometrioid 1.51 (0.81-2.8) 0.191 2.76 (1.36-5.59) 0.005 83
Mucinous 0.88 (0.37-2.12) 0.776 1.98 (0.69-5.7) 0.204 125
h0001011 7
Clear cell 0.87 (0.52-1.47) 0.602 0.86 (0.48-1.56) 0.626 1
All 1.02 (0.76-1.38) 0.879 0.99 (0.7-1.41) 0.957 3
Serous 0.91 (0.62-1.32) 0.612 0.82 (0.53-1.27) 0.379 10
Endometrioid 0.34 (0.07-1.71) 0.191 0.5 (0.1-2.58) 0.408 47
Mucinous 4.87 (1.95-12.17) 0.001 3.02 (1.02-8.91) 0.045 38
AIFM2
haplotype
block 1
h1111110 4
Clear cell 1.15 (0.58-2.27) 0.69 1.57 (0.71-3.48) 0.27 37
All 1.07 (0.79-1.45) 0.651 1.21 (0.86-1.71) 0.279 13
Serous 1.18 (0.79-1.75) 0.414 1.37 (0.89-2.11) 0.155 16
Endometrioid 0.27 (0.05-1.34) 0.11 0.33 (0.07-1.51) 0.153 22
Mucinous 0.47 (0.11-1.97) 0.304 1.31 (0.29-5.91) 0.725 179
h00001 4
Clear cell 1.77 (1-3.12) 0.05 2.29 (1.23-4.28) 0.009 29
All 0.93 (0.64-1.35) 0.702 1.16 (0.77-1.74) 0.476 25
Serous 0.73 (0.45-1.17) 0.188 1.04 (0.63-1.73) 0.879 42
Endometrioid 2.74 (1.07-7.04) 0.036 5.31 (2.04-13.8) 0.001 94
Mucinous - - - - -
AIFM2
haplotype
block 2
h01011 2
Clear cell 1 (0.43-2.36) 0.992 0.62 (0.22-1.73) 0.36 38
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, haplotype block 1: rs2394655, rs7908957,
rs1053495, rs2894111, rs2394656, rs6480440, rs2280201; haplotype block 2: rs10999147, rs3750772, rs4295944, rs2394644, rs10999152.
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Multivariate survival analysis results of CASP5
An association between the rare allele of CASP5 rs2282657 and reduced mortality of
clear cell patients became stronger after adjustments in the multivariate analysis,
adjusted HR=0.68 (0.48-0.96), P=0.029, see Table 4.14. The CASP5 rs2282657
variant, an intronic SNP, tags 2 other intronic SNPs, all of which are conserved in
mice.
The h000011 haplotype of CASP5 block 2 remained associated with reduced
mortality of clear cell patients after adjustments for prognostic factors, adjusted
HR=0.57 (0.34-0.97), P=0.037; see Table 4.15. This association is concordant with
the presence of the rare allele of CASP5 rs2282657, in the fifth position of the
haplotype block, which was associated with improved survival of clear cell cases.
The combined rare haplotypes of CASP5 block 1 were also associated with poor
survival of all histological subtypes (P=8.85x10-5), and the serous and clear cell
subtypes when the multivariate analysis was restricted to the subtypes (see Appendix
VIII-H). Despite the strength of the association with all histological subtypes, the
combined rare haplotypes have a frequency of 4%, and it is not possible to
definitively ascertain the haplotype responsible for the association. However, if the
causative haplotype was found, only a very small number of cases are likely to carry
the haplotype.
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Table 4.14: Effect of CASP5 rs2282657 on survival from ovarian cancer
Univariate Multivariate§
Gene tSNP MAF Histology Cases
HR (95% CI) P-value HR (95% CI) P-value
Diff HR (%)
All 852 0.94 (0.83-1.06) 0.329 0.94 (0.81-1.09) 0.442 0
Serous 462 1.10 (0.95-1.28) 0.216 1.12 (0.93-1.34) 0.247 2
Endometrioid 128 0.82 (0.55-1.22) 0.327 0.78 (0.5-1.2) 0.254 5
Mucinous 80 0.75 (0.47-1.19) 0.224 0.92 (0.57-1.48) 0.735 23
CASP5 rs2282657 0.35
Clear cell 73 0.76 (0.57-1) 0.049 0.68 (0.48-0.96) 0.029 11
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are
statistically associated with survival; emboldened HR are statistically significant.
Table 4.15: Univaraite and multivariate survival results of CASP5 haplotype (P<0.05)
Univariate Multivariate§Haplotype
block Haplotype
† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1.02 (0.87-1.20) 0.821 1.01 (0.83-1.23) 0.916 1
Serous 1.11 (0.91-1.35) 0.298 1.08 (0.86-1.36) 0.493 3
Endometrioid 1.05 (0.63-1.77) 0.847 1.17 (0.66-2.07) 0.583 11
Mucinous 1.69 (0.92-3.1) 0.089 1.64 (0.85-3.15) 0.139 3
CASP5
(haplotype
block 2)
h000011 13
Clear cell 0.62 (0.4-0.97) 0.034 0.57 (0.34-0.97) 0.037 8
Freq – frequency; HR – hazard ratio; CI – confidence interval; †: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in
haplotypes, 5’ to 3’, CASP5 haplotype block 2: rs17446518, rs9651713, rs3181175, rs3181174, rs2282657, rs507879.
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Multivariate survival analysis results of RGC32
There was also evidence of an association between poor survival from the serous
histological subtype and the rare allele of RGC32 rs3783194 (adjusted HR=1.44
(1.12-1.86), P=0.005); Table 4.16. This SNP is located in intron 2 of the gene, and
to date, it is not known if it tags another variant. The rare allele of another genetic
variant of RGC32, rs995845, was also associated with poor survival of endometrioid
patients after using the multivariate Cox regression survival analysis (adjusted
HR=1.8 (1.03-3.14), P=0.039); see Appendix VIII-M.
Despite the associations found between the common genetic variants of RGC32 and
survival from ovarian cancer, no statistically significant associations were found
between common haplotypes of the gene, and survival from the disease. The results
of the haplotype-specific effects are given in Appendix VIII-N.
Multivariate survival analysis results of FILIP1L
When multivariate Cox regression survival analysis was used to determine the
effects of common tSNPs from FILIP1L on survival of ovarian cancer patients,
statistically significant associations were found with two variants. The rare allele of
FILIP1L rs3921767 was associated with poor survival of ovarian cancer patients
regardless of the histology of the tumour, adjusted (for prognostic factors) per-rare
allele HR=1.39 (1.07-1.81), P=0.014 - Table 4.17.
Chapter 4: Results - survival
228
Table 4.16: Univariate and multivariate survival results of RGC32 tSNPs (P<0.05)
Univariate Multivariate§
Gene tSNP MAF Histology Cases
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1690 0.95 (0.79-1.14) 0.567 1.11 (0.9-1.36) 0.342 17
Serous 788 1.11 (0.88-1.41) 0.359 1.44 (1.12-1.86) 0.005 30
Endometrioid 264 1.09 (0.65-1.84) 0.742 1.12 (0.61-2.05) 0.713 3
Mucinous 184 0.63 (0.29-1.35) 0.232 0.64 (0.24-1.73) 0.38 2
rs3783194 0.11
Clear cell 155 0.81 (0.55-1.19) 0.282 0.76 (0.5-1.16) 0.202 6
All 1274 0.96 (0.85-1.08) 0.488 1.13 (0.93-1.38) 0.218 18
Serous 595 1.03 (0.88-1.21) 0.682 1.25 (0.97-1.61) 0.082 21
Endometrioid 193 1.55 (0.93-2.6) 0.093 1.8 (1.03-3.14) 0.039 16
Mucinous 146 1.09 (0.58-2.03) 0.797 0.75 (0.36-1.54) 0.43 31
RGC32
rs995845 0.2
Clear cell 112 0.94 (0.66-1.34) 0.716 1.04 (0.69-1.56) 0.851 11
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; § adjusted for prognostic factors (histology, age, stage and grade, where
appropriate); Emboldened histological subtypes - variants are statistically associated with survival after adjustments; emboldened HR are
statistically significant or the CI does not cross 1.
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Conversely, the rare allele of FILIP1L rs9864437 was associated with better survival
of mucinous cases alone (adjusted HR=0.46 (0.23-0.91), P=0.027), see Table 4.17.
An additional association was found between the rare allele of another tSNP of
FILIP1L, rs793446, and reduced mortality of mucinous cases, adjusted HR=0.57
(0.33-0.99), P=0.046. See Appendix VIII-I and VIII-J for the univariate and
multivariate Cox regression analysis results for all common variants and haplotypes,
respectively, of FILIP1L.
Analysis of the effects of the haplotypes of FILIP1L on survival from ovarian cancer
also showed statistically significant associations. A total of 4 haplotypes of FILIP1L
were associated with survival from ovarian cancer, 2 from haplotype block 1, and the
other 2 from block 2. The h00110 haplotype of FILIP1L block 1 was associated
with reduced mortality, of all histological subtypes, after adjustments for prognostic
factors, adjusted HR=1.36 (1.04-1.77), P=0.024 (Table 4.18). The association with
h00110 haplotype of FILIP1L block 1 was supported by the effect of the rare allele
of the rs3921767 variant, which was in the fourth position of the haplotype.
The remaining 3 FILIP1L haplotypes were all associated with survival of patients
with the mucinous subtype. One of these haplotypes was from block 1 of the gene,
and the other 2 were from haplotype block 2. The h10100 haplotype of FILIP1L
block 1, which had a frequency of 21%, was associated with reduced mortality
(adjusted HR=0.44 (0.21-0.9), P=0.024) – see Table 4.18 for the Cox regression
survival analysis results for the combined and individual subtypes for this haplotype.
This association was also in concordance with the single variant results. The rare
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allele of rs793446, which was correlated with reduced mortality, was in the third
position of FILIP1L haplotype block 1.
As shown in Table 4.18, the 2 haplotypes of FILIP1L block 2, h000 and h100, had
opposing effects on survival from the mucinous subtype. The h000 haplotype was
associated with poor survival of mucinous cases (adjusted HR=1.96 [1.15-3.33],
P=0.013). Conversely, h100 of the same haplotype block was associated with
reduced mortality (adjusted HR=0.46 [0.23-0.91], P=0.026). These associations
were also supported by the single variant results (FILIP1L rs9864437 was in the first
position of the block 2 haplotypes).
Multivariate survival analysis results of RBBP8
There was evidence suggesting that the rare alleles of two tSNPs of RBBP8,
rs4474794 and rs9304261, were associated with better survival of ovarian cancer
(adjusted HR=0.86 (0.74-0.99), P=0.034; adjusted HR=0.83 (0.7-0.99), P=0.038),
respectively - Table 4.19. The Kaplan-Meier survival curves for these two variants
are shown in Figure 4.4.
The association between the RBBP8 tSNPs and survival from ovarian cancer was
also identified in the univariate analysis. RBBP8 rs4474794 and rs9304261 are
correlated with r2=0.56. RBBP8 rs4474794 was retained in the final model after the
forward stepwise regression (P=0.035). An interaction between rs4474794 and
rs9304261 was statistically significant (adjusted HR=0.95 (0.9-0.99), P=0.036), and
the likelihood ratio test of this interaction was also significant (P=0.031).
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Table 4.17: Univariate and multivariate survival results of FILIP1L tSNPs (P<0.05)
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1773 All 0.96 (0.85-1.07) 0.461 1.04 (0.9-1.19) 0.628 8
838 Serous 1.02 (0.88-1.18) 0.816 1.08 (0.91-1.28) 0.399 6
274 Endometrioid 1.08 (0.74-1.59) 0.69 1.15 (0.77-1.71) 0.501 6
194 Mucinous 0.65 (0.41-1.03) 0.065 0.57 (0.33-0.99) 0.046 12
rs793446 0.41
164 Clear cell 0.97 (0.76-1.25) 0.83 0.99 (0.74-1.32) 0.932 2
1773 All 1.03 (0.83-1.29) 0.786 1.39 (1.07-1.81) 0.014 35
840 Serous 0.98 (0.71-1.34) 0.895 1.28 (0.89-1.84) 0.186 31
276 Endometrioid 0.99 (0.5-1.93) 0.967 1.23 (0.59-2.57) 0.576 24
191 Mucinous 1.03 (0.45-2.34) 0.949 1.09 (0.44-2.73) 0.849 6
rs3921767 0.07
166 Clear cell 1.29 (0.88-1.89) 0.196 1.59 (0.99-2.58) 0.057 23
1786 All 0.96 (0.84-1.09) 0.515 0.93 (0.8-1.09) 0.366 3
843 Serous 1.03 (0.88-1.20) 0.708 1 (0.84-1.2) 0.964 3
278 Endometrioid 1.07 (0.69-1.68) 0.752 0.97 (0.6-1.57) 0.892 9
195 Mucinous 0.45 (0.25-0.82) 0.009 0.46 (0.23-0.91) 0.027 2
FILIP1L
rs9864437 0.22
165 Clear cell 0.89 (0.66-1.2) 0.455 0.87 (0.63-1.2) 0.396 2
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; § adjusted for prognostic factors (histology, age, stage and grade, where appropriate);
Emboldened histological subtypes - variants are statistically associated with survival after adjustments; emboldened HR are statistically significant or the CI does not
cross 1.
Chapter 4: Results - survival
232
Table 4.18: Univariate and multivariate survival results of FILIP1L haplotype block 2 (P<0.05)
Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.96 (0.84-1.09) 0.52 0.94 (0.8-1.1) 0.424 2
Serous 1.03 (0.89-1.21) 0.667 0.94 (0.67-1.31) 0.697 9
Endometrioid 1.12 (0.71-1.78) 0.618 1 (0.61-1.63) 0.998 11
Mucinous 0.42 (0.22-0.78) 0.006 0.44 (0.21-0.9) 0.024 5
h10100 21
Clear cell 0.88 (0.65-1.19) 0.419 0.88 (0.64-1.22) 0.447 0
All 1.02 (0.81-1.27) 0.871 1.36 (1.04-1.77) 0.024 33
Serous 0.95 (0.69-1.30) 0.742 1.22 (0.85-1.76) 0.283 28
Endometrioid 1 (0.5-2) 0.996 1.22 (0.58-2.55) 0.604 22
Mucinous 1.01 (0.44-2.31) 0.977 1.08 (0.43-2.69) 0.877 7
FILIP1L
(haplotype
block 1)
h00110 7
Clear cell 1.29 (0.88-1.89) 0.197 1.61 (0.99-2.6) 0.053 25
All 0.96 (0.84-1.09) 0.506 0.94 (0.8-1.09) 0.42 2
Serous 1.03 (0.89-1.21) 0.668 0.92 (0.77-1.1) 0.371 11
Endometrioid 1.08 (0.69-1.69) 0.727 0.97 (0.6-1.57) 0.902 10
Mucinous 0.45 (0.25-0.82) 0.009 0.46 (0.23-0.91) 0.026 2
h100 22
Clear cell 0.88 (0.65-1.18) 0.385 0.87 (0.63-1.21) 0.407 1
All 1.10 (0.94-1.28) 0.223 1.11 (0.92-1.33) 0.292 1
Serous 1.07 (0.87-1.31) 0.506 0.64 (0.26-1.55) 0.321 40
Endometrioid 0.87 (0.53-1.44) 0.594 0.98 (0.59-1.64) 0.946 13
Mucinous 1.72 (1.09-2.72) 0.019 1.96 (1.15-3.33) 0.013 14
FILIP1L
(haplotype
block 2)
h000 19
Clear cell 1.13 (0.82-1.58) 0.456 1.09 (0.74-1.6) 0.664 4
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, FILIP1L -block 1: rs796977, rs793477,
rs793446, rs3921767, rs17338680. FILIP1L - block 2: rs9864437, rs6788750, rs12494994.
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Figure 4.4: Kaplan-Meier survival estimates of RBBP8 (a) rs4474794; (b) rs9304261
(all subtypes combined)
Numbers following the keys are individuals still at risk after 10 years.
HR=0.85 (0.75-0.95), P=0.007
Adjusted HR=0.86 (0.74-0.99), P=0.034
HR=0.83 (0.71-0.95), P=0.009
Adjusted HR=0.83 (0.7-0.99), P=0.038
409
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Table 4.19 Univariate and multivariate survival results of RBBP8 tSNPs (P<0.05)
Univariate Multivariate§
Gene tSNP MAF Histology Cases
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1764 0.85 (0.75-0.95) 0.007 0.86 (0.74-0.99) 0.034 1
Serous 829 0.88 (0.75-1.02) 0.098 0.85 (0.71-1.01) 0.065 3
Endometrioid 271 0.8 (0.53-1.19) 0.265 0.86 (0.56-1.31) 0.479 7
Mucinous 193 0.67 (0.42-1.05) 0.079 0.83 (0.51-1.36) 0.465 24
rs4474794 0.36
Clear cell 165 0.91 (0.71-1.18) 0.484 0.98 (0.73-1.32) 0.899 8
All 346 0.83 (0.71-0.95) 0.009 0.83 (0.7-0.99) 0.038 0
Serous 215 0.87 (0.72-1.05) 0.143 0.82 (0.66-1.02) 0.073 6
Endometrioid 44 0.87 (0.56-1.35) 0.536 0.99 (0.62-1.6) 0.982 14
Mucinous 33 0.61 (0.35-1.05) 0.074 0.81 (0.44-1.49) 0.497 33
RBBP8
rs9304261 0.22
Clear cell 21 0.84 (0.62-1.13) 0.242 0.86 (0.61-1.22) 0.401 2
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; § adjusted for prognostic factors (histology, age, stage and grade,
where appropriate); Emboldened histological subtypes - variants are statistically associated with survival after adjustments; emboldened HR are
statistically significant or the CI does not cross 1.
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Table 4.20: Univariate and multivariate survival results of RBBP8 haplotypes (P<0.05)
Univariate Multivariate§
Gene Haplotype† Freq(%) Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1.16 (1.03-1.31) 0.015 1.17 (1.01-1.34) 0.032 1
Serous 1.12 (0.97-1.30) 0.134 0.02 (0-27735) 0.589 98
Endometrioid 1.26 (0.85-1.86) 0.257 1.15 (0.76-1.75) 0.511 9
Mucinous 1.57 (1-2.47) 0.05 1.22 (0.75-2) 0.422 22
h0000 62
Clear cell 1.06 (0.83-1.35) 0.659 1 (0.75-1.32) 0.98 6
All 0.81 (0.71-0.94) 0.005 0.82 (0.69-0.98) 0.029 1
Serous 0.84 (0.70-1.02) 0.079 0.99 (0.53-1.85) 0.976 18
Endometrioid 0.83 (0.53-1.3) 0.422 0.94 (0.58-1.52) 0.789 13
Mucinous 0.64 (0.37-1.08) 0.096 0.86 (0.48-1.53) 0.614 34
h0011 23
Clear cell 0.85 (0.64-1.13) 0.261 0.87 (0.63-1.22) 0.429 2
All 0.60 (0.39-0.93) 0.022 0.75 (0.45-1.25) 0.275 25
Serous 0.75 (0.41-1.36) 0.347 1.2 (1.01-1.42) 0.041 60
Endometrioid 0.35 (0.08-1.56) 0.169 0.54 (0.12-2.46) 0.429 54
Mucinous 0.56 (0.13-2.31) 0.419 1.03 (0.15-7.23) 0.976 84
RBBP8
h0010 3
Clear cell 0.7 (0.31-1.58) 0.388 0.78 (0.28-2.18) 0.637 11
†: ‘0’= common allele and ‘1’= rare allele; Freq – frequency; HR – hazard ratio; CI – confidence interval; §: adjusted for clinical factors; SNP order
in haplotypes, 5’ to 3’, RBBP8: rs7239066, rs11082221, rs4474794, rs9304261.
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As shown in Table 4.19, the univariate Cox regression survival analysis also
detected the associations between survival and the tSNPs of RBBP8 (rs4474794 and
rs9304261). As well as being associated with better survival from ovarian cancer
overall, the rare allele of rs4474794 was also significantly associated with a
decreased risk of serous ovarian cancer. The rs4474794 variant and the 17 SNPs it
tags were intronic, with no predicted functions.
Two haplotypes of RBBP8, h0000 and h0011, had opposing effects on survival of
the patients. The h0000 haplotype was associated with poor survival (adjusted
HR=1.17 (1.01-1.34), P=0.032). However, the h0011 haplotype of RBBP8 was
associated with improved survival from the disease, adjusted HR=0.82 (0.69-0.98),
P=0.029. These associations were also identified with the univariate analyses, and
were supported by the tSNP results (see Table 4.20). The variants of RBBP8,
rs4474794 and rs9304261, which were shown to affect survival from ovarian cancer,
were in the third and fourth positions, respectively, of the haplotypes.
The association between the h0000 haplotype of RBBP8 and poor survival of all
ovarian cancer patients was also found when multivariate analysis was restricted to
serous only samples (adjusted for prognostic factors HR=1.2 (1.01-1.42), P=0.041).
Although, the association between reduced mortality and the h0011 haplotype of
RBBP8 was attenuated after restriction to the serous subtype, the confidence interval
did not cross 1 (adjusted HR=0.81 (0.65-1), P=0.054); Table 4.20.
Chapter 4: Results - survival
237
Table 4.21: Cox regresssion results of RUVBL1 rs4857836
Univariate Multivariate§
Gene tSNP MAF Histology Cases
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1787 0.98 (0.86-1.12) 0.758 0.81 (0.67-0.98) 0.03 17
Serous 845 1.01 (0.86-1.19) 0.879 0.75 (0.59-0.95) 0.018 26
Endometrioid 278 1.12 (0.67-1.88) 0.66 0.92 (0.52-1.61) 0.762 18
Mucinous 195 0.8 (0.42-1.55) 0.513 0.9 (0.42-1.95) 0.797 13
RUVBL1 rs4857836 0.2
Clear cell 165 0.97 (0.68-1.38) 0.863 0.84 (0.55-1.28) 0.406 13
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically
associated with survival; emboldened HR are statistically significant.
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However, rs9304261, which is downstream of the gene, is currently known to tag 14
SNPs with r2>0.8, half of these are conserved in mice. One of these SNPs,
rs930910, is upstream of the gene in a transcription factor binding site. Another of
the tagged SNPs, rs1902921, has a predicted triplex-forming sequence.
4.3.3:Multivariate survival analysis results of RUVBL1
When multivariate Cox regression survival analysis was used to determine the
effects of common tSNPs and haplotypes from the RUVBL1 gene, statistically
significant associations were found between survival and a tSNP and 2 haplotypes
and survival from ovarian cancer. The rare allele of RUVBL1 rs4857836 was
associated with reduced mortality of all cases, adjusted HR=0.81 (0.67-0.98),
P=0.03. The size of the effect of the variant and the significance increased when the
analysis was restricted to the serous only histological cases (see Table 4.21). The
rs4857836 variant was not significantly associated with survival from the other
major histological subtypes of ovarian cancer when the analysis was restricted (to the
subtypes). However, similarly to the serous and all subtypes, the hazard ratios for
the individual subtypes (endometrioid, mucinous and clear cell) were less than 1 (see
Table 4.21).
4.4: Summary
Cox regression survival analysis of a model with terms for all of the prognostic
factors showed that although all of the factors significantly affected survival from
ovarian cancer, there were of varying effect sizes. Advanced tumour stage had the
strongest effect on survival, with a four times increased hazard ratio compared with
localised early stage disease.
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Multivariate survival analysis with terms for prognostic factors suggested that the
results of univariate analyses (with genotypes as the only explanatory variable) may
have been masked by the unaccounted clinical factors. When multivariate Cox
regression survival analysis was used to evaluate the affect of tSNPs and haplotypes
of candidate oncogenes on the survival of 1,572 invasive epithelial ovarian cancer
cases, associations were found between BRAF and KRAS and clinical outcome of
invasive epithelial ovarian cancer patients. Three common tagging variants of BRAF
(rs1267622, rs13241719 and rs6944385), and the AA haplotype of rs1267622 and
rs6944385 influenced survival of all cases. When the analysis was restricted to the
histological subtypes, an association was found between the survival of serous cases
and the rs13241719 polymorphism. Associations were also found between
haplotypes of BRAF (h10010000 and h01100001) and survival of all cases. The
h01100001 haplotype was also associated with poor survival of endometrioid
patients. Furthermore, an additional haplotype of BRAF, h10010010, was associated
with improved survival of serous cases. The rare allele of KRAS rs10842513 and
two haplotypes of the oncogene were associated with poor survival of all ovarian
cancer cases.
Multivariate Cox regression survival analysis was also used to evaluate the affects of
candidate genes selected from in vitro tumour suppression studies on the clinical
outcome of ~1,700 ovarian cancer patients. Associations were identified between a
polymorphism (rs2280201) and 2 haplotypes (h0001011 of haplotype block 1 and
h01011 of haplotype block 2) of AIFM2 and survival of endometrioid cases,
P=0.018, P=0.005 and P=0.001, respectively. This gene was also associated with the
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survival of those with mucinous and clear cell ovarian cancer. Moreover, the rare
allele of a variant, and haplotypes of CASP5 were associated with increased survival
of patients of clear cell ovarian cancer.
FILIP1L, RUVBL1 and RBBP8 influenced the clinical of individuals with epithelial
ovarian cancer. A common variant and haplotype of FILIP1L were associated with
the survival of all cases of ovarian cancer combined. Two tSNPs and haplotypes of
FILIP1L were associated with the survival of mucinous as well. The rare allele of
RUVBL1 rs4857836 was associated with longer survival of all hstological subtypes
of the disease. This association became stronger when the analysis was restricted to
the serous subtype. The rare alleles of RBBP8 rs4474794 and rs9304261 were
marginally associated with improved survival of all subtypes (P=0.034 and P=0.038,
respectively). Two haplotypes of RBBP8 were also associated with the clinical
outcome of all cases. Furthermore, another hapltoyep of RBBP8 was associated with
poor survival of patients with the serous subtype.
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Chapter 5: Results
Evaluating whole genome amplification
methods and SNP multiplex genotyping
platforms
5.1: Introduction
Aims:
(1) To evaluate the ease of use and quality of whole genome amplification methods.
(2) To evaluate the performance of non-amplified and whole amplified DNA on
multiplex SNP genotyping platforms.
Objectives:
(1) To assess the call rates and concordance of non-amplified, genomic DNA and
whole genome amplified DNA.
(2) To evaluate the performance of multiplex SNP genotyping platforms with
genomic and whole genome amplified DNA.
(3) To examine the SNP pass rates, call rates and concordance between genomic and
amplified DNA.
5.2: Whole genome amplification
Whole genome amplification methods are used to increase the amount of DNA
available for research, and some types of diagnoses (ie preimplantation diagnostics).
A whole genome amplification method which produces good quality amplified
DNA, that generates good call rates and consistent, accurate genotypes could be used
instead of the limited, non-amplified genomic DNA. In order to evaluate the
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magnitude of DNA amplification, quality of genotype calls, and concordance
between genotypes of the whole genome amplified samples and non-amplified
genomic samples, 95 samples were amplified with GenomePlexTM, GenomiPhi, PEP
and RepliGTM. PEP is a random 15-mer method of PCR-based DNA amplification.
This method and GenomePlex uses the Taq polymerase enzyme for extension.
GenomiPhi uses the Phi29 (Φ29) DNA polymerase, and REPLI-g uses a modified
Φ29 enzyme. GenomePlex is a PCR-based method, which generates a library from
the template DNA and subsequently amplifies the library. PEP amplification has
been used to amplify GEOCS and SEARCH study samples for several years and all
Taqman assays with samples from those two studies were performed with PEP-
amplified samples. Although 100ng of starting DNA was used for GenomePlex,
GenomiPhi and RepliG amplification, 20ng, the recommended amount, was used for
PEP. The focus of the research was primarily on the GenomePlex, GenomiPhi and
RepliGTM methods.
5.2.1: Comparison of the ease of use of whole genome amplification methods
In terms of ease of the amplification procedure, GenomiPhi was the simplest. The
protocol involved adding the amplification mix and enzyme to the DNA and two
incubation steps. The PEP protocol was also very easy to perform, with only a PCR
reaction following the addition of the reaction mixture to the template DNA. The
GenomePlex method was the most time consuming of the four amplification
methods during the preparation steps (Table 5.1). There were three separate stages
involving addition of reagents followed by incubation steps. This contrasted with
only 1 stage each for GenomiPhi, PEP and REPLI-g. PEP was the only protocol
without a separate denaturing DNA step. Overall, GenomePlex required the least
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amount of time to perform the whole procedure. There was an insufficient amount
of the Library preparation enzyme in the GenomePlex amplification kit, therefore
five samples could not be successfully amplified with the method. In total 90
samples were amplified with the GenomePlex method. It is possible that some of the
enzyme may have evaporated during the pipetting into the sample mixture, because a
master-mix was not made with the enzyme and only 1μl was to be aliquotted into the
samples.
Table 5.1: Comparison of whole genome amplification methods
GenomePlex GenomiPhi PEP REPLI-g
Pattern Thermal
cycling
Isothermal Thermal
cycling
Isothermal
Ease of
performance Least easy Easiest Moderate Moderate
Time required 6 hours 17 hours 13 hours 17 hours
Template DNA
concentration used 100ng 100ng 100ng 100ng
Amplified DNA
yield 9μg 15μg 1.6μg 189μg
Fold increase 90 150 80 1894
The REPLI-g-amplified samples were the most difficult to pipette after
amplification, before the DNA of each sample was quantified. This was because
some samples were very viscous. As a consequence, a 1 in 10 dilution was needed
prior to DNA quantification.
5.2.2: Quantities of whole genome amplified products
PICO-green was used to evaluate the amount of DNA produced by each whole
genome amplification method. As shown in Table 5.2, the REPLI-g method
produced the greatest increase in amplified DNA, with an average yield of
approximately 190μg. This approximated to 1890-fold increase overall, in the
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quantity of DNA with this method. However, there was also a very large range in
the quantities of DNA produced, from 53μg to 579μg total yield with a standard
deviation of 110. The standard deviations for the total yield for the other methods
were less than 4. The fold increases in DNA quantities after GenomePlex and PEP
amplification were relatively similar (90 and 80, respectively). The average total
yield produced for GenomiPhi-amplified samples was 15μg, which was a 150-fold
increase in the amount of DNA.
Table 5.2: Average fold increase in DNA quantities after WGA
GenomePlex GenomiPhi PEP REPLI-g
Template DNA
concentration
used
100ng 100ng 20ng 100ng
Amplified DNA
yield 9μg 15μg 1.6μg 189μg
Fold increase 90 150 80 1894
Standard
deviation 2.2 3.5 1.9 109.7
The yields of GenomiPhi and REPLI-g exceeded that which was expected for the
method. This may have been due to the increased amount of input template DNA
than suggested by the protocol (10ng). 100ng of template DNA was used in order to
reduce the likelihood of allele dropout. Approximately double the expected amount
of amplified DNA was generated by the GenomiPhi method, and more than 4 times
by REPLI-g.
5.3: Comparison of SNP multiplex genotyping platforms
There were advantages and disadvantages for the procedures of all of the SNP
multiplex genotyping platforms tested (iPLEX, OpenArray and SNPlex). This
makes it difficult to say which platform was easiest to use. One of the biggest
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advantages that OpenArray had over SNPlex and iPLEX was that any combination
of SNPs could be included in a panel. The panels of SNPs for each iPLEX and
SNPlex reaction needed to the designed to ensure reactions could not occur between
the reaction products and the allele/SNP masses, so that they could be differentiated
from each other. The ease of use of the SNP multiplexing platforms are summarised
in Table 5.3.
5.3.1:OpenArray
Overall, the OpenArray platform was the most straight-forward to use after the
transfer of the samples on to the TaqMan OpenArray plates. However, the transfer
of the samples onto the plate was labour intensive and could not be automated with
robotics. This process, thus had an increased chance of operator error. Before the
transfer of the samples, each 384-well sample plate was divided into eight sections,
as illustrated in Figure 2.2, and only one section, comprised of 48 samples, could be
transferred at any one time. Two different plate guides, (one for plate areas 1, 3, 6
and 8, and the other for plate areas 2, 4, 5 and 7) were needed for transferring the
samples from the sample plate on to the TaqMan OpenArray plate. Furthermore,
only 96 samples could fit onto an OpenArray plate, therefore, five plates were
required for genotyping the GenomePlex, GenomiPhi, PEP and REPLI-g products,
and the corresponding genomic DNA.
There is no easy way of tracking the sample plates or sections after the samples have
been transferred onto the OpenArray plates – the manual suggested writing the
barcodes on the plates before transferring the samples. This created another area
where operator error could occur. The serial number of the OpenArray plate also
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had to be manually entered into the software before performing the imaging run.
Again, there was potential for operator error when entering the OpenArray plate
serial number.
Figure 5.1: The transfer of sections of sample plates to an OpenArray plate
Each OpenArray sample plate section contains 48 wells, and each OpenArray plate can hold 96
samples when the 32-plex option is used. Normally the 4 sections of a sample plate are transferred to
an OpenArray plate.
The OpenArray SNP Genotyping analysis software was reasonably easy to use.
Sample well positions were included in the sample information files which were
needed for the plate “set-up” files prior to imaging. However, the OpenArray SNP
Genotyping Analysis software neither displayed, nor outputted the well positions of
samples, which made it difficult to ascertain areas of the sample plates which failed
genotyping.
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Table 5.3: Ease of use of SNP multiplex genotyping platforms
iPLEX OpenArray SNPlex
Company Sequenom Applied Biosystems Applied Biosystems
Multiplex level tested 27 32 48
Panel design SNPs must work inpanel Any SNP combination
SNPs must work in
panel
DNA required (ng) 10 125 50-100
DNA per SNP (ng) 0.34 3.91 1.04-2.08
Total no. samples/plate 384 96 384
Type of procedure Extensive post-PCRprocessing
Extensive sample
preparation
Extensive post-PCR
processing
SNP/allele detection MALDI-TOF Fluorescence Mass and fluorescence
Experiment time 2 days 2 days 3 days
Ease of procedure Easiest Least easy Moderately easy
Ease of analysis Easiest Moderately easy Least easy
SNP pass rate
(gDNA)* 24 (100%)
§ 32 (100%) 29 (60%)
* Overall rate for non-amplified genomic DNA only. § Three SNPs with insufficient extend primers
failed.
Applied Biosystems recommended manually calling the genotypes on OpenArray.
The advantage of using the OpenArray genotyping software was that it allowed the
importing and analysis of multiple OpenArray plates in the same “genotyping
project”. This compensated for having to manually call the genotypes, and also
allowed the analysis of multiple plates, provided there was minimal plate-to-plate
variation in genotyping quality. The OCAC quality control guidelines required that
at least 95 ovarian cancer samples were placed on each 384-well plate in order to
eliminate any possible case/control genotyping bias. However, the sample
information file, and the fact that only 96 samples could be genotyped on a 32-plex
format, which would make it impossible to conform to the guidelines for genotyping
studies. Adjustments to incorporate the OCAC guidelines would involve re-
organisation of all sample plates layouts and the corresponding templates used for
quality control purposes.
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Figure 5.2: OpenArray cluster (auto-call)
Dots: Blue – homozygotes for FAM allele; green – heterozygotes; red – homozygotes for VIC allele;
black – undetermined genotype; purple circle – sample could not be given a user call without another
VIC homozygote becoming “uncalled”, however a user call (to undetermined) could be made for the
genotype circled in yellow.
Despite the manual calling, there was a considerable amount of automation in the
calling when “cluster centre” and exclusion bars were used. There were instances
when some samples could not be called with the cluster centre and exclusion bars,
without a logical reason (as demonstrated in Figure 5.2). The “Draw” function of the
OpenArray genotyping analysis software was supposedly available for modifying the
genotype cluster shapes. However, the genotype calling from the Draw function
could not be exported, which rendered the function useless.
5.3.2: SNPlex
The SNPlex genotyping platform was a fairly standard procedure. Although the
procedure was carried out manually, the vast majority of the steps could be
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automated with liquid handling robotics. However, there was a risk of
contamination, and/or operator error with the extensive post-PCR process.
Manual calls could not be made per se, with the GeneMapper software. The
clustering parameters could be modified in order to make the callings more, or less
stringent. The quality of the experiments could be evaluated by checking the allelic
ladders, and the software had an internal quality control that failed assays with call
rates less than 80%, therefore it was not possible to find the exact call rates, or
genotypes of poor performing assays.
5.3.2:iPLEX
The iPLEX genotyping platform was the preferred SNP multiplex genotyping
platform. The platform performed the least level of multiplexing level compared
with SNPlex and OpenArray, however all steps of the protocol were highly
automatable, and relatively simple to perform. One of the few problems with the
iPLEX procedure was the use of a dimple plate for transferring Clean Resin into the
diluted extend products. There was a chance that less than 6mg of Clean resin was
dispensed into each well of the dimple plate, as the method used is not particularly
accurate. There was also a risk that the sample and dimple plates did not completely
align when the resin was transferred to the sample plate, so small amounts of resin
may not have entered the wells of the sample plate.
The iPLEX genotype analysis software, TyperAnalyzer, was very user-friendly and
relatively easy to use. It was possible to find an approximate call rate for each SNP
prior to data output, and colour coding of the “traffic light” plot indicates the overall
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performance of each sample. Although auto-calling function of the software was
fairly accurate, user (manual) calls could also be made. The software gave a
“Status” for each genotype, either ”conservative”, ”moderate”, “aggressive”, “low
probability”, “bad spectrum”, “user” or “No-alleles”. User-calls could be made for
clear and distinct genotype clusters, like that shown in Figure 5.3.
Perfect clustering Possible user calls
Figure 5.3: Examples of iPLEX clustering
Green triangle – homozygotes of high mass allele; yellow squares – heterozygote; blue triangle –
homozygote of low mass allele; red dots – uncalled genotypes; (a) auto-call did not call the sample
because the spectra was noisy, however, it was clear that the genotype was homozygous for the high
mass allele; (b) samples were not auto-called because the allele peak heights were not equal, but the
peaks were high enough to call them heterozygous.
The spectrum of each reaction could be viewed to determine the reason behind the
auto-caller not calling some samples, and whether the genotype could be manually
called. Examples of spectra of genotypes giving conservative, aggressive and user
calls statuses are shown in Figure 5.4. Genotypes with conservative or moderate call
status were considered accurate, and those with bad spectra or no-alleles were
considered as failed assays. However the software automatically assigned genotypes
for those conservatively, moderately or aggressively called.
(a)
(b)
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concordance. The average call rate for the genomic DNA was 97%. Samples
amplified with PEP had the highest call rates, averaging 100% for the 4 TaqMan
SNPs genotyped. GenomePlex also had excellent call rates, which averaged 98%.
The call rates of GenomiPhi were not as good as GenomePlex, but they were all
greater than 90% (averaging 93%). Although REPLI-g amplification produced the
greatest yield of amplified DNA, it had the poorest call rate on the Taqman
genotyping platform.
The highest call rate for the REPLI-g-amplified DNA genotyped on TaqMan was
87%, and the average call rate for the assays combined was 82%, which is below the
level accepted by the Ovarian Cancer Association Consortium (OCAC). Refer to
Appendix IX-A for the individual call rates and concordance of the WGA samples
compared with non-amplified genomic DNA genotyped on the TaqMan platform.
REPLI-g amplified DNA also produced the worst clusters, as shown in Figure 5.5,
which explains the poor call rates.
No discordances were found between the genotypes of genomic DNA and
GenomePlex, GenomiPhi and PEP-amplified DNA on TaqMan. It should be taken
into consideration that only a small number of assays were tested. However, the
SNPs genotyped on TaqMan had high minor allele frequencies (MAFs). A total of
four discordances between the genotype of genomic DNA samples and their
corresponding REPLI-g-amplified DNA were found on TaqMan (for rs602652,
rs3217869 and rs10487888). However, the concordance levels were >98% for two
of the polymorphisms, therefore the genotyping results for these (rs602652 and
rs3217869) were acceptable under quality control (QC). The genomic DNA was
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homozygous for the rare allele of rs602652; however, the corresponding REPLI-g
amplified DNA was homozygous for the common allele of the SNP. This
discordance, is known as a “miscall” and cannot be explained by unequal
amplification of the alleles.
Genomic DNA REPLI-g-amplified DNA
Figure 5.5: Clustering of genomic and corresponding REPLI-g-amplified samples
with rs602652
Clusters: blue – common homozygous; green – heterozygous; red – rare homozygous; black x – failed
reactions; black square – non-template control.
Miscall discordances consist of the genotype of the genomic DNA being
homozygous for an allele of a SNP, and the corresponding WGA DNA being
homozygous for the other allele, or heterozygous for the same SNP as demonstrated
in Figure 5.6. The other type of discordance is known as “allele-drop”, which
involves the loss of an allele in the WGA DNA (when the genomic DNA is
Failed PCRs
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heterozygous), suggesting unequal amplification of an allele at a heterozygous locus
(see Figure 5.6). This type of discordance was found with rs10487888.
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Sample 1 Sample 2 Sample 3
Fragment 316705
(rs16941)
Fragment 316700
(rs1060915)
Genomic DNA
REPLI-g DNA
Genomic DNA
REPLI-g DNA
Equal amplification
of alleles
Unequal amplification
of alleles
Unequal amplification
of alleles
Figure 5.7: Unequal amplification of REPLI-g amplified DNA
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Figure 5.7 shows electropherograms of gDNA and corresponding sequences for
REPLI-g amplified DNA with equal and unequal amplification of alleles. The green,
blue, black and red peaks of the electropherograms correspond to bases A, C, G and
T, respectively. Overlapping peaks are heterozygous genotypes. The SNPs are in
LD (r2=1) and have a minor allele frequency of 0.35. There was 97% concordance
between the genotypes of genomic and REPLI-g DNA for the SNPs. There were 44
heterozygous individuals for these SNPs and 3 of them (6.8%) showed unequal
amplification of the linked alleles of the polymorphisms.
5.5: The performance of genomic and amplified DNA on SNP
multiplex genotyping platforms
The next aim of the study was to investigate the performance of the whole genome
amplified products on SNP multiplex genotyping platforms. In order to execute this
aim, the WGA DNA and their matching genomic DNA were genotyped on iPLEX,
SNPlex and OpenArray. The resultant call rates and concordances were evaluated.
Assays which failed were excluded from all, but the SNP pass rate calculation.
5.5.1:Call rates
The 95 non-amplified genomic DNA samples and their corresponding GenomePlex,
GenomiPhi, PEP and REPLI-g-amplified DNA were genotyped on the iPLEX
genotyping platform with a 27-plex panel. The performances of the genomic and
WGA DNA on the platform were assessed by calculating the SNP pass rate (the
number of SNPs from the panel which produced callable genotype clusters), and the
per SNP assay call rates (the number of samples successfully assigned a genotype).
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From the 27-plex panel, three assays (rs6944385, rs10842514 and rs10252135) with
insufficient amounts of extend primers, consistently failed for all the WGA products
and the genomic DNA. The auto-calls from the iPLEX TyperAnalyzer software
were evaluated. The call rates per assay/SNP are shown in Appendix IX-B. Refer to
Table 5.4 for the summary of the call rates from iPLEX genotyping.
Overall, the GenomePlex, GenomiPhi and RepliG genotypes had call rates >95% for
more assays (23 tSNPs each) than the genomic DNA (17 tSNPs). PEP-amplified
DNA had the poorest call rates with only 10 assays with call rates greater than 90%
and an average of call rate of 89%, see Table 5.4. The average call rates for the
genomic and GenomePlex, GenomiPhi and RepliG-amplified samples were >95%.
Table 5.4: iPLEX call rates by DNA amplification method
Call rate (%) Genomic GenomePlex§ GenomiPhi PEP REPLI-g
<80 1 0 0 9 0
80-89 1 1 1 5 1
90-94 5 0 0 2 0
≥95 17 23 23 8 23
Mean 97% 99% 99% 81%* 99%
The 3 assays which failed for all amplification methods and gDNA were not included in the analysis;. § n=90,
there were 95 samples for all other methods.
5.5.2:Concordance rates from iPLEX genotyping
The fidelity of the amplification methods were assessed with the iPLEX platform by
comparing the genotypes of genomic DNA with the matching WGA DNA.
GenomiPhi results had the lowest level of discordance. There were only 2
discordances in the 1,872 genotypes called in both the GenomiPhi-amplified DNA
and their corresponding genomic DNA. This averaged to a concordance rate of
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99.9%. The greatest level of discordance was found between PEP-amplified DNA
and their corresponding genomic DNA (1.62%).
Table 5.5: Overall discordance per WGA method on iPLEX platform
GenomePlex GenomiPhi PEP REPLI-g
Total genotypes 1872 1998 1423 1972
Total discordant 5 2 23 20
No. discord SNPs 4 2 7 13
Discordance (%) 0.3 0.1 1.6 1
As shown in Table 5.5, when the overall discordance per WGA method is
considered, none of the methods resulted in discordance greater than or equal to 2%.
Therefore all the WGA methods would have passed the OCAC quality control
criteria for the concordance between duplicates.
When the discordances per assay were considered, only the genotypes of GenomiPhi
DNA were acceptable in terms of discordance rates (<2%) for the 24 SNPs. The
discordance rates of the SNPs genotyped on iPLEX are shown in Appendix IX-C.
Of the 19 SNPs successfully genotyped with PEP-amplified DNA, 4 assays were
discordant for > 2% of the samples. The highest discordance rate was 19% for
rs3771886 for the PEP DNA, however the call rate was very poor (32%). The
second highest level of discordance (13%) for the PEP samples was for the for the
rs10487888 SNP, which had a call rate of 85% (see Appendix IX-C). Discordances
were not restricted to SNPs with poor call rates, refer to Appendices IX-B and IX-C.
The call rates of the genomic and PEP DNAs for rs1801200 was 98%, however, 2%
of the genotypes were discordant. Furthermore, 8 of the 13 SNPs with discordances
were REPLI-g DNA with call rates >95%. The greatest number of SNPs with
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discordances was found with the REPLI-g-amplified DNA (13 out of 22 SNPs
[~60%]). Of these, 7 SNPs were discordant for ≥2% of genotypes (see Appendix
IX-C). Moreover, only one assay (rs17623382) had a call rate <90% (REPLI-g vs
genomic DNA). Discordances were found between genomic DNA GenomePlex for
four of the SNPs. However, only one (rs11551174) was discordant for >2% of the
genotypes (see Appendix IX-C). Of the 4 assays genotyped with GenomePlex-
amplified DNA, there was one, with call rate >90%, with >2% discordance.
GenomiPhi-amplified DNA were the only one which did not have discordances >2%
for any of the assays; see Appendix IX-C.
All of the discordances found with GenomePlex DNA were allele dropouts except
one of the rs11551174 discordances, where the genomic DNA was homozygous for
the “G” allele and the amplified sample was heterozygous for the SNP. The PEP
DNA failed for this assay. The other WGA DNA genotypes (GenomiPhi and
REPLI-g) were also heterozygous for the SNP, which suggests that the genomic
DNA was incorrect. The genomic DNA was discordant for all WGA DNA for
another SNP, rs17623382, which also indicates that the genomic DNA was incorrect.
When the genotypes of these two SNPs for the particular sample are excluded, there
are no longer discordances with GenomiPhi DNA on the iPLEX platform. The vast
majority of the discordances with PEP and REPLI-g DNA were allele dropouts,
suggesting unequal amplification of the alleles (refer to Table5.6).
Chapter 5: WGA & SNP multiplexing
260
Table 5.6: Types of discordances found with iPLEX (by WGA method)
GenomePlex GenomiPhi PEP REPLI-g
SNP
Dropout Miscall Dropout Miscall Dropout Miscall Dropout Miscall
rs10487888 0 0 0 0 9 2 1 1
rs11047917 0 0 0 0 1 0 2 0
rs11551174 1 1* 0 1* 0 0 1 1*
rs12305513 0 0 0 0 1 0 1 0
rs12822857 0 0 0 0 Failed 1 0
rs17623382 1* 0 1* 0 Failed 1* 1
rs1801200 1 0 0 0 0 2 1 0
rs2161841 0 0 0 0 1 0 0 0
rs2699905 1 0 0 0 1 0 1 1
rs2952155 0 0 0 0 0 0 1 0
rs3771882 0 0 0 0 0 0 1 0
rs3771886 0 0 0 0 6 0 1 0
rs3854012 0 0 0 0 0 0 1 0
rs4623993 0 0 0 0 0 0 1 0
Total 4 (3) 1 (0) 1 (0) 1 (0) 19 4 14 (13) 4 (3)
Dropout – Genotype of genomic DNA is heterozygous. Miscall – genotype of genomic DNA is homozygote for an allele. * Genomic DNA appeared to be incorrect; Total
discordance in parenthesis are the totals when the incorrect genomic results are excluded.
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5.5.3:Assays with discordances in more than one amplification method
At least one DNA sample amplified with GenomePlex and REPLI-g was also
discordant for the assays with discordances in the GenomiPhi-amplified DNA.
There was also at least one discordant REPLI-g-amplified DNA sample with each
assay that had a discordant genotype for the GenomePlex-amplified DNA.
The discordances found with GenomePLEX-amplified samples on the iPLEX
genotyping platform occurred in different samples – each sample was only
discordant for 1 SNP. rs11551174 was the only SNP with discordance in more than
1 sample. No sample was discordant in more than 1 WGA method. However, three
and four samples amplified with PEP and REPLI-g, respectively, were discordant for
2 or more assays. This suggests that there may have been either a problem with the
amplification of these samples with the WGA method, or with the genotyping of the
individual samples.
5.5.4:The performance of gDNA and WGA-DNA on SNPlex
The automatically assigned genotypes of the genomic and WGA-DNA from the
SNPlex platform were analysed with the GeneMapper software. No assays were
successfully genotyped with the PEP-amplified DNA on the platform. However, it
is worth noting that the GeneMapper software automatically fails samples which fail
for >80 of the SNPs, and also if the per assay call rate is below 80%. Therefore, it
was not possible to find the exact call rates of the assays which failed the internal
quality control criteria. The REPLI-g DNA had the highest SNP pass rate (73%) and
aside from PEP DNA samples, GenomiPhi had the lowest SNP pass rate; see Table
5.7. Twenty-nine SNPs were successfully genotyped with genomic DNA, and there
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was an average genotype call rate of 97% for these SNPs. In comparison, the
GenomiPhi DNA, which performed badly on SNPlex, had the lowest average call
rate of 85%. The SNP pass and call rates are summarised in Table 5.7; the
individual SNP call rates for the genomic and WGA DNA from the SNPlex
genotyping are tabulated in Appendix IX-D.
All but 1 of the SNPs which passed the GeneMapper internal QC had SNP genotype
call rates >95% for the genomic DNA. GenomePlex was the only amplification
method with SNPs with call rates >95 on SNPlex. However, this comprised only 2
out of the 13 SNPs which passed genotyping on SNPlex (see Table 5.7).
Table 5.7: SNPlex assay pass rates (by WGA method)
Genomic Genomeplex GenomiPhi PEP REPLI-g
SNP pass rates
DNA conc (ng/ìL) 50 100 100 100 100
No. SNPs passed 29 13 9 0 35
% SNPs passed 60.4 27.1 18.8 0.0 72.9
No. of calls 2647 1147 722 0 3010
Call rates*
<80% 19 39 35 48 13
80-89% 0 0 9 0 3
90-94% 1 11 0 0 32
>95% 28 2 0 0 0
Mean 97% 94% 85% Fail 91%
gDNA – genomic DNA; conc – concentration; the call rates for all assays genotyped with PEP amplified DNA
were less than 80%; * based on SNPs with >80% call rate (pass).
5.5.5:Concordance between gDNA and WGA-DNA on SNPlex
When the concordance between genomic DNA and the WGA-DNA genotyped on
SNPlex was evaluated, there was evidence of discordances between the genomic
DNA and the corresponding amplified DNA for all the WGA methods. Overall,
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DNA amplified with GenomePlex appeared to have the greatest proportion of
discordant genotypes, when the autocall genotypes from the SNPlex platform were
analysed. There were 217 discordance samples from those with genotypes for both
genomic DNA and the amplified DNA out of 699 genotypes. This accounted for
31% of the genotypes. This contrasted sharply with the discordances found with the
GenomiPhi and REPLI-g-amplified DNA 0.7% and 3.6%, respectively.
Upon inspection of the genotype clusters of the assays for the genomic DNA and
WGA-DNA, it became apparent that some assays which were deemed as good
quality, were indeed failed assays. rs751340, rs2286216, rs927221 and rs1713423
failed to produce callable clusters for GenomePlex-amplified DNA. The clusters of
rs751340, rs2286216 and rs1713423 for all the samples are shown in Figure 5.8.
However, the GeneMapper software assigned genotypes to the samples, resulting in
approximately a third of GenomePlex-amplified DNA samples (61%) being
discordant for these variants alone (see Appendix IX-E). Figure 5.8 shows some of
these clusters with poor quality and miscalled clustering.
When the failed assays were excluded, the overall concordance rates were 98%, 99%
and 96% for GenomePlex, GenomiPhi and REPLI-g, respectively. See Appendix
IX-E for the discordance rates for each SNP. Of the assays which passed for both
gDNA and WGA-DNA, >98% concordance was observed for 2 assays out of 8
genotyped in both genomic and GenomePlex, 8 of 9 assays with GenomiPhi, and 3
of the 25 assays with REPLI-g-amplified DNA (see Appendix IX-E).
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All five discordances of the GenomiPhi amplified DNA were allele dropouts
(heterozygous for genomic DNA, homozygous for the WGA-DNA). Of the 7
discordances found between the GenomePlex-amplified DNA and genomic DNA,
only 2 were allele dropouts (see Appendix IX-E), and the 4 of the remaining
discordances were miscalls of the same SNP (rs1419755). Refer to Appendix IX-F
for the types of discordances for the successfully genotyped SNPs. Only 25 (33%)
of the REPLI-g discordances were allele dropouts (see Appendix IX-F), the
remaining discordances were miscalls. However, some of these may be attributable
to inadequate genotype calling of the GeneMapper software.
A sample amplified with GenomePlex was discordant for 2 assays on the SNPlex
platform. Although, there were 76 discordances with REPLI-g DNA on SNPlex,
these occurred with 10 samples. The discordances did not correlate with
amplification yield. Of the 10 REPLI-g-amplified samples with discordances, only 2
samples were discordance for a single assay. The other 8 REPLI-g-amplified
samples were discordant for at least 3 assays each. Thus, these 8 samples were
discordant in 74 instances. There were 4 instances when the same discordances
were found with GenomiPhi and REPLI-g DNA and on each occasion, the
discordance was an allele dropout. There is a possibility that the same alleles were
preferentially amplified with both GenomiPhi and REPLI-g methods at the 4 loci,
however, due to the poor quality genotypes from the SNPlex platform, it is more
likely that either the genomic or WGA genotypes were incorrect.
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Figure 5.8: Discrepant auto-calling
of SNPlex platform
(a-d) Clusters top left to right: GenomiPhi,
PEP, and REPLI-g; bottom L to R:
GenomePlex and genomic DNA.
(a) rs751340
(b) rs2286216
(c) rs1861606
(d) rs1713423
Clusters: blue – homozygous for allele 1;
green – heterozygous; red – homozygous
for allele 2; black square – non-template
test control; black “x” – failed genotyping.
(a) (b)
(c) (d)
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5.5.6:The performance of gDNA and WGA-DNA on OpenArray
The samples amplified with GenomePlex, GenomiPhi, PEP and REPLI-g, and their
corresponding genomic DNA were genotyped with a 32-assay panel on the Open
array multiplex genotyping platform. The samples were initially prepared manually.
The genotyping was performed with Applied Biosystems’ staff. The technical
representative for the platform recommended manually calling the genotypes on the
TaqMan OpenArray™ SNP Genotyping Analysis Software.
As on SNPlex, the PEP-amplified DNA failed to produce callable clusters on the
OpenArray platform. Refer to Appendix IX-G for the call rates for each assay for
the genomic, and GenomePlex, GenomiPhi and REPLI-g. There were callable
clusters for all the assays with the genomic DNA, however, 10, 4 and 3 SNPs failed
for GenomePlex, GenomiPhi and REPLI-g amplified DNA, respectively. As shown
in Table 5.8, all but one of the SNPs had call rates >90% for the genomic DNA, with
an average call rate of 97%. However, none of the SNPs genotyped with amplified
DNA resulted in average call rates >90% (see Table 5.8).
Table 5.8: OpenArray call rates*
Call rate (%) Genomic GenomePlex GenomiPhi REPLI-g
<80 0 10 5 10
80-89 1 14 13 22
90-94 2 7 14 0
 95 29 1 0 0
Average 97% 88% 89% 82%
N=93 *based on manually called SNPs)
When the overall concordance rates between genomic DNA, and their corresponding
whole genome amplified DNA were assessed, again, samples amplified with REPLI-
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g had the lowest concordance (92.7%). The overall concordance for GenomePlex
and GenomiPhi was 97.1% for 1,693 and 2,270 genotypes, respectively. Therefore,
none of the overall concordance rates for the amplification methods met the OCAC
criteria of ≥98%; (see Appendix IX-H for the discordance rate for each assay).
Only 5 SNPs out of the 21 successfully genotyped OpenArray SNPs had
concordance rates >98 for the GeomePlex amplified DNA. Again, DNA amplified
with GenomiPhi were concordance for >98% of genotypes, for the highest
proportion of SNPs (12/29 variants). As with iPLEX and SNPlex, REPLI-g
amplified DNA resulted in the highest proportion of SNPs with discordance rates
>2%. Of the 29 polymorphisms successfully genotyped with REPLI-g DNA, only 2
assays had acceptable concordance rates (see Appendix IX-H).
As observed with iPLEX and SNPlex, there were both allele dropouts and miscall
discordances between the genomic DNA and the matching amplified DNA on the
OpenArray platform; refer to Appendix IX-I for the number of each type of
discordance per SNP. However, for all of the WGA methods, the majority of
discordances were miscalls, which suggests there was a serious problem with using
DNA amplified with PEP, GenomePlex, GenomiPhi or REPLI-g WGA on this
platform. The total numbers of allele dropouts and miscalls for the WGA products
which were successfully genotyped on OpenArray are shown below:
GenomePlex GenomiPhi REPLI-g
Dropout Miscall Dropout Miscall Dropout Miscall
12 38 15 51 72 85
There were several occasions (18) when the genomic DNA was homozygous for an
allele, and the corresponding genotypes of the WGA DNA samples heterozygous for
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all WGA methods. This occurred with 15 different assays, and 9 different samples,
and suggests that some, if not all, of the genomic genotypes may be incorrect.
5.5.7: Reproducibility of the OpenArray genotyping data
Twelve duplicates of the WGA DNA and their corresponding genomic DNA were
genotyped on OpenArray and compared with each other in order to ascertain
reproducibility of genotyping data from the OpenArray platform. No discordances
were found between the GenomePlex-amplified duplicates; but this method had the
lowest SNP pass rate (59%). The concordance rates between the duplicates (by
WGA method) are tabulated in Appendix IX-J. When all genotypes were
considered, acceptable levels of discordance (<2%) were found with the genomic,
GenomePlex and GenomiPhi DNA; see Table 5.9.
Table 5.9: Reproducibility of genotypes from OpenArray platform
Genomic GenomePlex GenomiPhi REPLI-g
No. SNPs 29 19 27 26
No. genotypes 316 206 299 253
Average call rate 90.8% 90.4% 95.8% 81.1%
Discordance 5 (1.6%) 0 (0%) 2 (0.7%) 20 (7.9%)
The discordances in the duplicated genomic DNA were with 5 different SNPs. Due
to the small numbers of duplicates assessed, each discordant pair will reduce the
concordance rate by at least 8%. Again, REPLI-g had the greatest amount of
discordances with 20 discordances out of 253 genotypes (8%, see Table 5.9). These
REPLI-g discordances occurred in 14 SNPs, therefore the duplicates were
concordant for only 12 SNPs.
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5.5.8:Comparison of rs10487888 genotypes from iPLEX and OpenArray
One of the assays genotyped on OpenArray, rs10487888, was also genotyped with
iPLEX Gold with genomic DNA. Comparisons of the genotyping results of the
gDNA and WGA samples were made.
There was 100% concordance between genomic DNA genotyped on iPLEX Gold
and GenomePlex and GenomiPhi DNA genotyped on OpenArray. However, 2
discordances were found between the genomic DNA which was genotyped on both
platforms and 4 with REPLI-g (Table 5.10). All but 1 of the discordances found
were allele dropouts in the OpenArray genotypes.
Table 5.10: Comparison of iPLEX Gold with OpenArray genotypes for rs10487888
Genomic GenomePlex GenomiPhi REPLI-g
No. samples called 89 83 90 89
Call rate 95.7% 90.2% 97.8% 96.7%
No. discordant 2 0 0 4
Concordance 97.8% 100 100 95.5%
Applied Biosystems recommended manually calling the genotypes, however this is
time consuming, particularly as the number of SNPs and samples increases.
Although auto-calling is able to correctly assign genotypes, based on clustering in
some instances, there were also gross miscallings in others (see Figure 5.9).
Of the auto-called genomic DNA assays, 10 (31%) of the SNPs with callable clusters
were incorrectly called. Two assays with poor clustering were auto-called when they
should not have been. The systematic miscalling also occurred with WGA samples.
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Correct auto-calling
Assay 8
Incorrect auto-calling (below)
rs28665122 rs12722489
rs2066845 rs1050152
Figure 5.9: Examples of auto-calling with OpenArray Genotype Analysis software
Dots: Red – homozygous for VIC allele; green – heterozygous; blue – homozygous for FAM allele;
black – uncalled; black dot with circle – non-template test control.
Chapter 5: WGA & SNP multiplexing
271
A meeting was conducted with Applied Biosytems staff to discuss the results from
the OpenArray platform. During the meeting it became apparent that, as with the
test runs on SNPlex, the OpenArray platform was still in its developmental stages.
Although the company claims to have genotyped a great number of SNPs (>100) on
the platform, only 20 samples were used in each experiment. The use of such small
numbers of samples makes it difficult to gauge the quality of clusters, and also to
assess reproducibility. Applied Biosystems suggested genotyping some of the SNPs
with the same genomic samples on the TaqMan platform.
During the meeting it also became clear that the technical staff did not have faith in
the SNPlex platform. The poor performance of the samples on the SNPlex and
OpenArray platforms with SNPs which had been validated and optimised by Applied
Biosystems, and the lack of explanation for the inadequate auto-calling, as well as
low genotyping pass rates, makes OpenArray (and SNPlex) unsuitable for high-
throughput genotyping with the research samples used.
5.6: Direct comparison of the multiplexing methods
As shown in Table 5.11, iPLEX genotypes produced the best average call rates and
the fewest discordances of the SNP multiplex genotyping platforms. Aside from the
genotypes from iPLEX, the REPLI-g amplified DNA always produced the most
discordances, possibly due to over-amplification of the DNA, see Table 5.12. The
OpenArray genotyping system was the worst performing platform in terms of
genotyping call rate and discordances. On OpenArray, only GenomePlex DNA had
an average call rate >90. None of the WGA methods had average concordances
>98%. Moreover, most of the miscall discordances were identified on OpenArray,
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and SNPlex platforms (see Table 5.12). When the criteria of 90% call rate and <2%
discordance are taken into consideration, only 1 SNP, each for the GenomePlex-
amplified DNA would fulfil both call rate and discordance on the SNPlex and
OpenArray platforms, despite the relatively high numbers of SNPs genotyped (see
Table 5.13). However, the criteria were fulfilled for 20 and 21 SNPs for
GenomePlex and GenomiPhi-amplified DNA, respectively.
Table 5.11: Average call rate and discordances for each method
gDNA
(n=95)
GenomePlex
(n=90)
GenomiPhi
(n=95)
PEP
(n=95)
REPLI-g
(n=95)
Call rate Callrate Dis
Call
rate Dis
Call
rate Dis
Call
rate Dis
Taqman
(n=5) 97 97 0 94 0 97 0 82 1
iPLEX
(n=22) 97 99 0 99 0 81 2 99 1
SNPlex
(n=29) 96 94 2 84 1 Fail Fail 90 4
Open
Array
(n=32)
95 91 3 87 3 Fail Fail 80 7
Dis – discordance; call rates and discordances (%); Bold pass call ≤90% and discordance ≥2%.
Table 5.12: Types of discordances identified with each WGA method and platform
GenomePlex
(n=90)
GenomiPhi
(n=95)
PEP
(n=95)
REPLI-g
(n=95)
No.
SNPs
passed
Drop
out
Miss-
call
Drop
out
Miss-
call
Drop
out
Miss-
call
Drop
out
Miss-
call
TaqMan 5 0 0 0 0 0 0 1 3
iPLEX 24 4 1 1 1 19 4 14 4
SNPlex 29 2 5 5 0 Fail Fail 25 51
Open
Array 32 12 38 15 51 Fail Fail 72 85
Number of assays passed for genomic DNA samples
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Table 5.13: Number of SNPs with call rates ≥90% and discordances <2% for each
method
gDNA
(n=95)*
GenomePlex
(n=90)
GenomiPhi
(n=95)
PEP
(n=95)
REPLI-g
(n=95)
Taqman
(n=5) 5 5 5 5 0
iplex
(n=22) 21 20 21 9 14
SNPlex
(n=29) 29 1 0 Fail 0
Open Array
(n=32) 22 1 0 Fail 0
* call rates only
5.7: Genotyping on iPLEX gold system
The iPLEX Gold platform, which is an upgraded version of iPLEX, is highly
automated and accurately advertises high through-put genotyping. The only major
difference between iPLEX and iPLEX Gold is the number of SNPs which can be
genotyped in a single reaction, up to 29 and up to 40, respectively. This upgrade was
achieved by increasing the mass range in which alleles/SNPs can be detected by the
mass spectrometer. The work flow is the same as that of iPLEX - straightforward
and simple to follow.
The automated genotype calling of iPLEX and iPLEX Gold was correct for the
majority of genotypes, however an error was found with SNP rs3783197 (see Figure
5.10). The TyperAnalyzer software had obviously called the genotypes based on the
peaks of the mass spectra, however, the plot clearly shows that there is an increase in
the high mass molecules, resulting in a shift of the blue cluster (common
homozygous). A similar shift was observed for rs6788750, however the shift was
not as pronounced as it was for rs3783197.
Chapter 5: WGA & SNP multiplexing
274
Figure 5.10: Shift in clusters on iPLEX clusters
The concordance between genomic and WGA amplified DNA on the iPLEX
platform, was overall, acceptable for all WGA methods. Comparison of genotypes
of the 95 samples from iPLEX and TaqMan were also concordant for rs17623382
and rs3771886. Acceptable concordance and call rates were found for MALOVA
and SEARCH DNA with the iPLEX method with the variants from the candidate
oncogenes.
However, there were instances where the NTCs failed QC. These genotypes may
have been caused by primer dimers in the reactions, or as a result of poor desalting
during the cleaning step. This is of great concern because it suggests that a genotype
could be attained for a low concentration DNA sample, which would, otherwise,
have failed. There was no correlation between failed NTCs and the assigned
genotypes. The failed NTCs occurred with some, not all SNPs, which suggests the
locus of the SNP may also affect whether an NTC fails.
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There were also instances on both iPLEX and iPLEX Gold, when common SNPs,
with minor allele frequencies >0.05, appeared to be monomorphic. On iPLEX Gold,
the rs2271695, which has a MAF=5.8% in Caucasian population, only had one
cluster. The rs17695623 polymorphism, MAF=0.125, also appeared to be
monomorphic, according to the platform. A TaqMan assay of this SNP produced 3
clusters. A possible explanation for this may be that there was insufficient
differences between the masses of the extend primers for the alleles of the
polymorphism. Poor de-salting may also explain the lack of mass separation.
Despite the common SNPs, which are classed as monomorphic on the iPLEX
platform, and the failed NTCs, acceptable call rates and concordances were found
with the vast majority of SNPs. The quality of the genotyping with iPLEX Gold was
not as good as iPLEX. The intensity of the allele peaks were not as high as those
from the iPLEX reactions, and there were worrying levels of discordances and poor
call rates were found with tSNPs from the MMCT-18 candidate genes with iPLEX
Gold. However, these may have been due to a sub-optimal run.
In spite of acceptable call rates, discordance rates greater than 2% were observed
between duplicate genomic DNA samples on the iPLEX Gold platform for two
tSNPs, rs523104 and rs7650365. TaqMan assays of these SNPs were manufactured,
and used to genotype MALOVA, SERACH and UKOPS population series. When
the genotypes from iPLEX Gold and TaqMan were compared, discordance rates of
6.1% (241/3,924 calls) for rs523104, and 5.8% (256/4,417 calls) for rs7650365 were
found. The genotypes from TaqMan were reproducible, however, do to high costs,
the iPLEX experiments could not be repeated. It is likely that the high proportion of
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“aggressive calling” caused by poor cluster quality may have been responsible for
some of the discordances identified with the iPLEX Gold genotypes for the two
SNPs.
Genotyping data for some of the SNPs genotyped on iPLEX Gold was also available
from the Illumina Infinium 610K array. The Infinium 610K array platform was used
to genotype the SNPs analysed for the ovarian cancer genome-wide association
studies (Song et al. 2009a) Comparisons were made between genotyping from
iPLEX Gold, TaqMan and Infinium SNPs for the MMCT-18 candidate SNPs, where
possible.
Genotype data was available for rs523104 and rs7650365 was available from the
Infinium platform, as well iPLEX Gold and TaqMan. The genotypes were
compared. Of the samples genotyped on all three platforms, the discordance rates
are summarised below:
Discordances
Comparison
rs523104 rs7650365
Infinium vs iPLEX Gold 58/1092 (5.3%) 88/1231 (7.1%)
Infinium vs TaqMan 24/1275 (1.9%) 15/1262 (1.9%)
iPLEX Gold vs TaqMan 64/1063 (6%) 75/1169 (6%)
There were discordances between the genotypes from iPLEX, Infinium and TaqMan.
However, the lowest discordance rates were between genotypes from Infinium and
TaqMan for both rs523104 and rs7650365. Despite these discordances between
Infinium and TaqMan, the rates were just under 2% for both SNPs. Although the
call rate for UKOPS samples with rs7650365 on iPLEX Gold was 94%, and there
were no discordances between the 47 successfully genotyped pairs of duplicate
genomic DNA, discordance rates of >2% were found when the genotypes of
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Infinium and iPLEX Gold, and Infinium and Taqman were compared, see Table
5.15.
The distributions of the genotypes are shown in Table 5.14 and Table 5.15, for
rs523104 and rs7650365, respectively. The discordances of rs523104 are
predominantly in UKOPS samples, and rs7650365 in SEARCH samples.
Interestingly, 22 (55%) of the discordances between genotypes from iPLEX Gold
and Infinium were common homozygotes according to the Infinium genotypes of
SEARCH samples, and heterozygous by iPLEX Gold. A similar distribution was
found between the rs523104 genotypes by iPLEX Gold and TaqMan, with 59% of
the discordances being heterozygous for the later platform and common homozygous
for the Taqman platform; Table 5.14.
Disproportional distributions of the discordances were also found between genotypes
of rs7650365 from different genotyping platforms. 97% of the discordances
consisted of rare homozygotes from iPLEX and heterozygotes from the Infinium or
Taqman platforms.
Additional discordances were found when data from iPLEX Gold and Infinium, for
other variants were compared. The discordances ranged from 0 to 2.4%, when
SEARCH and UKOPS genotypes were combined, see Table 5.16. Appendix IX-K
shows the discordance rates for SEARCH and UKOPS, separately for the SNPs
listed in Table 5.16. It can be seen in Appendix IX-K that most of the discordances
were with UKOPS DNA samples. Furthermore, discordances (3% of 1334
genotypes) were also found between TaqMan and Infinium genotypes for rs2894111.
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Table 5.14: Distribution of discordances of rs523104 (Infinium vs iPLEX Gold vs
Taqman)
Call SEARCH UKOPS
Infinium iPLEX No. Discord (%)* No. Discord (%)*
GG CG 22 (55%) 11 (27.5%)
GG CC 1 (2.5%) 2 (5%)
CG GG 1 (2.5%) 8 (20%)
CG CC 15 (37.5%) 10 (25%)
CC GG 0 (0%) 2 (5%)
CC CG 1 (2.5%) 7 (17.5%)
Total 40/638 (6.3%) 40/454 (8.8%)
Infinium TaqMan
GG CG 1 (16.7%) 4 (22.2%)
GG CC 0 (0%) 3 (16.7%)
CG GG 1 (16.7%) 3 (16.7%)
CG CC 3 (50%) 4 (22.2%)
CC GG 0 (0%) 3 (16.7%)
CC CG 1 (16.7%) 1 (5.6%)
Total 6/813 (0.74%) 18/462 (3.9%)
iPLEX TaqMan
GG CG 1 (2.9%) 5 (16.7%)
GG CC 0 (0%) 1 (3.3%)
CG GG 20 (58.8%) 7 (23.3%)
CG CC 0 (0%) 9 (30%)
CC GG 1 (2.9%) 1 (3.3%)
CC CG 12 (35.3%) 7 (23.3%)
Total 34/620 (5.5%) 30/443 (9.3%)
Discord: * % of discordances; iPLEX- iPLEX Gold
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Table 5.15: Distribution of discordances of rs7650365 (Infinium vs iPLEX Gold vs
Taqman)
Call SEARCH UKOPS
Infinium iPLEX No. Discord (%)* No. Discord (%)*
AA AG 2 (2.8%) 2 (11.8%)
AA GG 0 (0%) 3 (17.7%)
AG AA 0 (0%) 6 (35.3%)
AG GG 69 (97.2%) 3 (22.2%)
GG AA 0 (0%) 2 (17.7%)
GG AG 0 (0%) 1 (5.9%)
Total 71/765 (9.23%) 17/466 (3.6%)
Infinium TaqMan
AA AG 1 (33.3%) 1 (8.3%)
AA GG 0 (0%) 3 (25%)
AG AA 1 (33.3%) 4 (33.3%)
AG GG 1 (33.3%) 1 (8.3%)
GG AA 0 (0%) 2 (16.7%)
GG AG 0 (0%) 1 (8.3%)
Total 3/810 (0.37%) 12/452 (2.7%)
iPLEX TaqMan
AA AG 0 (0%) 2 (33.3%)
AA GG 0 (0%) 0 (0%)
AG AA 2 (2.9%) 2 (33.3%)
AG GG 0 (0%) 0 (0%)
GG AA 0 (0%) 0 (0%)
GG AG 67 (97.1%) 2 (33.3%)
Total 69/742 (9.3%) 6/427 (1.4%)
Discord: *% of discordances; iPLEX- iPLEX Gold
The quality of the iPLEX Gold genotyping was investigated further by comparing
the genomic DNA genotypes of BRCA1 rs799917 from sequencing of 467 samples
and the corresponding iPLEX Gold results. Of the 442 samples successfully
genotyped with sequencing and iPLEX Gold, there were 3 discordances (0.68%).
The fact that some NTCs were automatically assigned genotypes with high
confidence on the iPLEX and iPLEX gold platforms was of particular concern
because samples which may have otherwise failed genotyping may appear to have
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been successfully genotyped. The randomness of the genotypes of the failed NTCs
also suggests that these artefacts of the platform may be locus or mass dependent.
Table 5.16: Discordances between iPLEX Gold and Infinium
SNP Total no. ofgenotypes
No. of
discordances
Discordance
%
rs6788750 962 19 2.0
rs7650365 1263 16 1.3
rs2280201 1292 7 0.5
rs2394644 1302 8 0.6
rs3181175 834 4 0.5
rs3783194 1321 10 0.8
rs3923086 1291 23 1.8
rs793477 1285 21 1.6
rs12494994 829 1 0.1
rs9860614 1321 15 1.1
rs10999147 1322 6 0.5
rs3181328 1284 8 0.6
rs2282657 1321 15 1.1
rs7189819 1286 31 2.4
rs4541111 1274 20 1.6
rs4791171 828 1 0.1
A possible explanation of the discordances with the iPLEX Gold genotyping
platform could be due to inadequate desalting of the extend products (single base
extension products). No two alleles for an iPLEX assay are within 15Daltons (Da)
of each other. The inadequate desalting of samples can cause the formation of
sodium and potassium adducts, which are 22Da and 38Da, respectively. The
presence of adducts in the nano-dispensed single extension products may make
accurate heterozygote allele discrimination, particularly for A/C (24Da) and C/G
(40Da) SNPs, difficult. Adducts usually have smaller peak areas than allele peaks.
However, it is likely that some of the peaks of the adducts were assigned genotypes
because of low peaks of the sample genotypes. Evaluation of the SEARCH
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genotyping plates showed that desalting of the single base extensions were
suboptimal.
The comparison of TaqMan vs iPLEX Gold vs Infinium genotyping platforms
showed that there may be discordances in genotypes from different genotyping
platforms of the same samples and assays. These discordances were sometimes
observed even when the genotyping data passed quality control criteria. This
worrying issue should be taken into consideration when different genotyping
platforms are used for a study. The OCAC minimise the problem by ensuring that
the same CEPH samples are genotyped for the same SNP(s) at all the genotyping
centres and the genotype results are compared with each other and the results from
HapMap.
5.8: Summary
Ninety-five DNA samples were amplified with GenomePlex, GenomiPhi, PEP and
REPLI-g. The resulting amplified products were genotyped on TaqMan, and SNP
multiplex genotyping platforms (iPLEX, OpenArray and SNPlex). The DNA
amplification procedures were simple for all of the methods. Of the WGA methods,
REPLI-g produced the greatest amount of amplified DNA. The iPLEX was the most
automatable and straight-forward SNP multiplex genotyping platform, compared
with OpenArray and SNPlex. The iPLEX platform also produced the most
concordant results when comparisons were made between the genotypes of the
amplified DNA and their corresponding genomic DNA.
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Although there was ~1,800 fold increase of the amount of DNA with the REPLI-g
method, the products also resulted in the highest rates of discordances on iPLEX,
SNPlex and OpenArray multiplex SNP genotyping platforms, as well as on TaqMan.
It is possible that unequal and over- amplification of the DNA was responsible for
some, if not all of these discordances. Despite excellent genotype call rates and
concordance on TaqMan, PEP-amplified DNA performed badly on all of the
multiplex genotyping platforms tested. GenomePlex and GenomiPhi –amplified
DNA gave the best results, in terms of SNP pass rates, genotype call rates and
concordance with non-amplified DNA. Disproportionate amounts of miscall
discordances were found with OpenArray and SNPlex platforms. These
discordances cannot be explained by unequal amplification of the DNA alone, and
they suggest problems with the multiplexing platforms. GenomePlex and
GenomiPhi genotyped on iPLEX was the best combination of WGA method and
SNP multiplex platform identified with the evaluations.
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Although ovarian cancer is relatively rare, globally, it is the seventh most common
cause of cancer death amongst women, with ~125,000 deaths a year worldwide.
This is because the disease is usually diagnosed in the advanced stages, when the
chances of survival are drastically reduced. Despite the poor survival rate, the
aetiology of ovarian cancer is still poorly understood and the known genetic causes
are responsible for approximately 10% of all cases. Several moderate predisposition
genes, and multiple low risk (low penetrance) genes may account for some of the
remaining cases which are not explained by the known susceptibility genes. The
work presented in this thesis aimed to investigate this hypothesis.
This thesis reports the results from investigations of candidate genes which may
affect ovarian cancer susceptibility with a case-control association study design; and
the influence of these candidate genes on survival of ovarian cancer patients with
multivariate Cox regression survival analysis. The performance of possible solutions
to the issues of limited amounts of DNA from study participants and the increasing
numbers of SNPs genotyped for association studies, respectively, were also
investigated.
The effect of oncogene common germline SNP variants and haplotypes on
ovarian cancer susceptibility
The activation of proto-oncogenes through somatic mutation is a common feature of
cancer. These mutations may result in un-regulated proliferation of cells, leading to
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a neoplastic phenotype (Rhim 1988; Croce 2008). The activation of different
oncogenes have been demonstrated to cause the development of different types of
cancer. For example, mutations in the MYC gene are linked to the development of
chondrosarcoma and osteosarcoma (Castresana et al. 1992; Ladanyi et al. 1993).
Oncogenes, such as BRAF, ERBB2, KRAS and PIK3CA, among others are crucial in
the development of malignancies, and have been shown to be mutated in ovarian
cancer (Shayesteh et al. 1999; Hellstrom et al. 2001; Gemignani et al. 2003; Sieben
et al. 2004).
The alteration of the oncogenes in ovarian cancer leads to the question of whether
germline common polymorphisms or combinations of alleles (haplotypes) of these
oncogenes may predispose some women to developing ovarian cancer and/or affect a
sufferer’s chances of survival. In order to attempt to answer this question, thirty-four
tagging SNPs (tSNPs) from BRAF, ERBB2, KRAS, NMI and PIK3CA were
genotyped in five different population-based case-control series. Logistic regression
was used to evaluate associations between the tSNPs and haplotypes of the candidate
oncogenes and the risk of developing ovarian cancer, or survival from the disease.
When all cases were combined, and ovarian cancer was treated as a single disease,
there was evidence of association between a tSNP of NMI, rs11683487, and risk of
ovarian cancer. The rare allele of the polymorphism, which has a minor allele
frequency (MAF) of 0.46, was associated with a reduced risk of the disease. Even
though the association between NMI rs11683487 and risk of ovarian cancer was not
validated with an additional 1,097 cases and 1,712 unaffected controls, the
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association was marginally significant when the data from stages 1 and 2 of
genotyping were combined to increase the statistical power of the study (P-
dominant=0.0419). The association remained when analysis was restricted to the serous
and mucinous histological subtypes of ovarian cancer. The rs11683487 variant tags
8 other SNPs with r2≥0.8. One of these, rs1048135, is a non-synonymous coding
SNP. The rare, G, allele of rs1048135 codes for a leucine instead of serine. The
PMut (http://mmb2.pcb.ub.es:8080/PMut/ ) (Ferrer-Costa et al. 2005) and SIFT
(http://sift.jcvi.org/ ) (Ng and Henikoff 2001) programmes classified the rare variant
of this SNP as having “pathological significance”, and “damaging”, respectively.
Another bioinformatics programme, PupaSuite (http://pupasuite.bioinfo.cipf.es/)
(Conde et al. 2006; Reumers et al. 2008), also suggested that the rare allele of
rs1048135 may disrupt the binding of exonic splicing enhancers. This disruption
may result in alternative splicing of the gene. PupaSuite also predicted that the
rs11683487 variant and another of the tagged polymorphisms, rs11730, may
influence the regulation of transcription and translation, and that rs11730 may affect
exon splicing.
The NMI gene, which was erroneously chosen as a candidate due to its interaction
with MYC, may be important in ovarian cancer development. NMI interacts with the
NMYC, MYC, MAX and FOS oncogenes and has been shown to form a complex with
MYC and BRCA1 (Li, H. et al. 2002). This complex has been demonstrated to
inhibit the MYC-induced human telomerase reverse transcriptase gene (hTERT)
promoter activity in breast cancer (Li, H. et al. 2002). The formation of this NMI-
MYC-BRCA1 complex suggests that NMI may be involved in breast and ovarian
cancers.
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Ovarian cancer is a very heterogeneous disease and it has been suggested that the
different histological subtypes are in fact different diseases of the ovary and should
be treated as such. There is evidence in support of this suggestion: certain genetic
alterations are found predominantly in particular histological subtypes of ovarian
cancer (Christie and Oehler 2006). Of note is the high proportion of KRAS
mutations in mucinous ovarian tumours (Cuatrecasas et al. 1997; Gemignani et al.
2003). There is also a correlation between germline mutations of BRCA1 and
BRCA2 with the susceptibility of the serous histology of ovarian cancer (Lakhani et
al. 2004).
The numbers of ovarian cancer cases of the 4 major histological subtypes,
particularly that of endometrioid, mucinous and clear cell subtypes were small and
there was insufficient statistical power to accurately detect associations. However,
due to the compelling evidence for the heterogeneity of ovarian cancer, and the
associations of some genes with specific histological subtypes, it was worth
evaluating the effect of the candidate oncogenes on the risk of the 4 major
histological subtypes of ovarian cancer. The identification of potential associations
could be validated by consortia, such as the Ovarian Cancer Association Consortium
(OCAC).
Although there was no evidence of association between the polymorphisms of BRAF
and predisposition to ovarian cancer when all cases were considered, statistically
significant associations were detected when the analysis was restricted to the
mucinous histological subtype. Three tSNPs of BRAF (rs10487888, rs1267622 and
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rs1769623) were associated with susceptibility of the mucinous subtype (P-trend <
0.05). These tSNPs were intronic polymorphisms, which tagged other intronic
variants. To date, these associated SNPs and the SNPs they tag are not known (or
predicted) to be functional. When PupaSuite PupaSNP
(http://pupasuite.bioinfo.cipf.es/) was used to evaluate the predicted functions of
these SNPs, the sequences of a BRAF variant, rs9640168, which correlated with
rs10487888 (r2=0.934), suggested that it was located in putative triplex forming
sequences. Triple helices are long sequences containing only purines or only
pyrimidines in a given strand that have the potential to form additional hydrogen
bonds with functional groups of the major groove of a DNA double helix, resulting
in a triple helical structure. Triple helices may cause replication blocking,
subsequently leading to DNA recombination and mutation (Guntaka et al. 2003;
Patel et al. 2004). Many of the other polymorphisms are conserved in mice.
There was evidence of an association between a haplotype, h10010000, of BRAF and
reduced risk of clear cell ovarian cancer. Furthermore BRAF haplotypes were
globally associated with predisposition to ovarian cancer (P=0.005).
Associations were also identified between KRAS and predisposition to the mucinous
histological subtype of ovarian cancer. rs6487464 and rs10842514 of KRAS were
associated with susceptibility of the mucinous subtype (P-trend < 0.05). Although
the associations were found with a limited number of samples, they are of particular
interest because KRAS mutations are found in 34% of mucinous ovarian adenomas
and carcinomas (COSMIC, http://www.sanger.ac.uk/genetics/CGP/cosmic/), and the
mutations have been shown to be early events in ovarian cancer development.
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Haplotypes (h000010 and h00000) KRAS block 2 were associated with susceptibility
of mucinous ovarian cancer. These haplotypes comprised of the SNPs which were
associated with risk.
BRAF and KRAS are components of the mitogen-activated protein kinase (MAPK)
pathway. The MAPK pathway transmits signals for processes such as cell
proliferation and cell survival from the cytoplasm to the nucleus (Hingorani et al.
2003). The pathway is activated by growth stimulating signals (Pohl et al. 2005),
and mutations in BRAF or KRAS lead to the continuous activation of the MAPK.
The activation of the MAPK pathway activates downstream cellular targets,
including both cellular and nuclear proteins (Pohl et al. 2005). It has been
demonstrated that the inhibition of the mitogen/extracellular signal-reguated kinase
(MEK) pathway, a downstream effector of the MAPK pathway in cell lines with
BRAF or KRAS mutations, results in the suppression of cell growth and promotion of
apoptosis (Hingorani et al. 2003). It is conceivable then, that a functional germline
variant in either of these genes could influence a multitude of downstream targets
that may affect the biological and clinical characteristics of ovarian cancers.
The rare allele of a variant of ERBB2, rs1801200, with MAF=0.22, was associated
with increased risk of endometrioid ovarian cancer. Another group has published an
association between the rare allele of rs1801200 and an increased risk of
endometrioid ovarian cancer (Pinto et al. 2005). This independent validation of the
result found with this work is of great importance and it would be of interest to
establish if the amalgamation of the data would increase the statistical significance of
the association. This polymorphism, also known as I655V, is a non-synonymous
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coding, and the rare allele, “G”, codes for valine, instead of isoleucine. The amino
acid change was predicted to be tolerated with a score of 0.75 by SIFT
(http://sift.jcvi.org/www/SIFT_seq_submit2.html). rs1801200 is also conserved in
mice and is predicted to enhance exonic splicing. The coding variant is located in
the region of the gene which is involved in the dimerisation and activation of the
ERBB2 receptor. Fleishman’s group demonstrated that the rare allele of the variant
destabilises the active dimmer formation (Fleishman et al. 2002). The rs1801200
polymorphism has also been associated with the risk of breast cancer (Montgomery
et al. 2005; Rutter et al. 2003). However other studies have not been able to
replicate this result (Benusiglio et al. 2005).
Two haplotypes of ERBB2, h110 and h001, were associated with increased risk of
ovarian cancer. The fact that the haplotypes contain the opposite allele at each SNP
loci is surprising. There was nothing from HapMap genotyping data to suggest that
these putative susceptibility haplotypes shared an untagged common variant,
however, it is feasible that an unknown or rare polymorphism tags both haplotypes.
There was evidence suggesting that the global test of haplotype effect was also
significant for the ERBB2 gene (P-global=0.034).
ERBB2 is involved in cell proliferation and cell differentiation (Wu, Y. et al. 2004),
and is over-expressed in approximately 40% of ovarian tumours (Hogdall et al.
2003). This suggests that the over-expression of ERBB2 leads to tumour growth
advantage (Hellstrom et al. 2001). Although the association identified with the risk
of ovarian cancer and this gene was marginal, and corrections for multiple testing
would render the association insignificant, it is likely that the amplification of the
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gene is more important in predicting disease risk, rather than a SNP, which would
not indicate the amplification of the gene. Although no statistically significant
associations were found between ERBB2 and survival from ovarian cancer with this
project, over-expression of the oncogene has been correlated with poor survival of
MALOVA samples in another study (Hogdall et al. 2003). An association has also
been previously published between the rare allele of the polymorphism which was
associated with increased risk of endometrioid ovarian cancer, rs1801200, and poor
survival of cases (Pinto et al. 2005). However, this association was not replicated
with this study.
A borderline association was also found between the rare allele of PIK3CA
rs2865084 and decreased risk of endometrioid ovarian cancer. This SNP is upstream
of the gene, and is predicted to generate a new transcription factor binding site. A
new transcription binding site has the potential of affecting the transcription of the
gene.
The effect of “functional” common germline SNP variants and haplotypes on
ovarian cancer susceptibility
Although there has been some success in the identification of ovarian cancer
predisposition variants through the candidate pathway/candidate gene approach, it is
clear that other ways of identifying genes which affect ovarian cancer susceptibility
and survival are needed. To this effect, a functional approach (micro-cell mediated
chromosome transfer) was used to identify differentially expressed genes, which
may be involved in the development of ovarian neoplasm, from an in vitro model of
ovarian cancer suppression. Nine candidate genes with described functions were
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selected from differential expression data of the parental ovarian cancer cell lines
and their corresponding hybrid clones (which had incorporated normal human
chromosome 18). The associations between 63 tSNPs from nine candidate
differentially expressed “functional” genes (AIFM2, AKTIP, AXIN2, CASP5,
FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3) and susceptibility of invasive
epithelial ovarian cancer were evaluated.
An association was found between the rare allele of a variant of CASP5, rs518604,
and predisposition to ovarian cancer. This association became stronger when the
analysis was restricted to the serous histological subtype. However, the results could
not be validated with additional samples because TaqMan assays for this SNP and
those it tags, could not be successfully manufactured. Associations were also found
between the risk of ovarian cancer and haplotypes of CASP5. The associations with
the CASP5 haplotypes were supported by the individual SNP finding. The global
test for association of haplotype effect on ovarian cancer predisposition was highly
significant for CASP5 (8.43x10-6). This was the only association which reached the
level of significance suggested for case-control genetic association studies (P<10-5)
(Thomas et al. 2005). The involvement of CASP5 in apoptosis and inflammation
makes it a plausible ovarian cancer susceptibility gene, despite the small numbers of
samples analysed.
The rare allele of RUVBL1 rs13063604 tSNP correlated with an increased risk of all
histological subtypes of ovarian cancer. This association became stronger when
analysis was restricted to the serous subtype (P=0.002). The rare allele of another
RUVBL1 SNP, rs7650365, had the opposite effect on serous ovarian cancer
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(P=0.009). Up to additional 2,636 cases and 6,164 controls were genotyped with
assays of rs13063604 and rs7650365, for a second genotyping stage of the study, to
ascertain if the significant finding was reproducible. The associations were not
validated with the stage 2 samples alone, however when the data from the two stages
were combined, the association between rs13063604 and ovarian cancer remained.
This polymorphism tags 9 other variants with r2≥0.8. Two of them, rs1057220 and
rs1057156, which are tagged with r2=1, are located in the 3’ untranslated region of
the gene and they are predicted to be exonic splicing enhancers. Globally, RUVBL1
haplotypes also had a significant effect on the risk of ovarian cancer (P=0.0016).
RUVBL1 (also known as pontin), was down-regulated in the reverted hybrids of both
cancer cell lines, and thus up-regulated in the parental neoplastic ovarian cancer cell
lines. Although, to date, there are few publications reporting the over-expression of
RUVBL1 in malignancies, data from the Oncomine database
(http://www.oncomine.org) shows over-expression of the gene in breast, colon,
bladder, liver and other malignancies (Dehan et al. 2007; Lauscher et al. 2007;
Rousseau et al. 2007; Huber et al. 2008; Haurie et al. 2009). If the associations from
this research are true, then they could be attributed to its interactions with other
genes which are implicated in cancer. RUVBL1 interacts with the transcriptional
activation domain of MYC and also β-catenin (Bauer et al. 1998; Wood et al. 2000).
RUVBL1 is necessary for Tip60 activity, which is involved in DNA damage repair
(Jha et al. 2008). Venteicher and colleagues demonstrated that RUVBL1 interacts
with the human telomerase reverse transcriptase (hTERT) and is involved in the
assembly and function of the telomerase complex; and the abrogation of RUVBL1
expression has been shown to induce premature senescence (Venteicher et al. 2008).
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Furthermore, RUVBL1 is a component of the NuA4 histone acetyltransferase
complex, which may activate the transcription of cell growth, DNA repair and
apoptosis genes (Jha et al. 2008).
The rare alleles of three FILIP1L polymorphisms, rs793446, rs17338680 and
rs12494994, were associated with increased risk of the endometrioid histological
subtype. However, no functions were identified for these SNPs or those they tag,
other than the conservation of many of the SNP sequences in mice.
FILIPL1, which is located on chromosome 3q12.1, was up-regulated in the hybrids
of TOV112D, and thus down-regulated in the malignant parental cell line. The
FILIP1L gene has also been reported to be down-regulated in ovarian cancer by
another group (Mok et al. 1994), which support the results from the gene expression
data of the MMCT-18 TOV112D hybrid clones. The FILIP1L gene is also
conserved in yeast, and although little is known about the gene, it has been shown to
be implicated in a variety of cellular functions (Hwang and Murray 1997). It has
been shown that although FILIP1L was present in normal ovarian surface epithelial
cells, it was predominantly absent from the cell lines tested (Mok et al. 1994). The
gene is part of a subunit, Doc1p/Apc10, which is involved in substrate recognition
by anaphase-promoting co-activator complexes (Passmore et al. 2003). Tandle’s
group showed that FILIP1L may be involved in mediating some of the effects of the
pro-inflammatory cytokine endothelial monocyte activating polypeptide-II (Tandle
et al. 2005). There is also evidence suggesting that the FILIP1L protein is down-
regulated in human prostate cancer cell lines and it may be involved in the regulation
of senescence (Schwarze et al. 2002).
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In 2009, the results from the ovarian cancer genome wide association study (GWAS)
were published by the Ovarian Cancer Association Consortium. Virtually all of the
UKOPS and SEARCH cases used in these projects were also analysed in the GWAS,
along the cases from 5 other UK-based ovarian cancer studies, totalling 1,890 cases
and 2,353 controls. 14 tSNPs genotyped in the oncogene study were also analysed
in the GWAS, however, none of them were associated with ovarian cancer risk at the
genome-wide significance level (P≤ 5x10-8).
Despite the lack of association of the candidate oncogenes at the genome-wide
significance level, some similarities were identified between the results of the
GWAS and candidate gene studies. Of these, NMI rs11683487, which was
nominally associated with ovarian cancer risk, had relatively similar odds ratio and
P-values in the 2 approaches (candidate gene result: HetOR = 0.80 (0.69-0.93)
HomOR= 0.87 (0.71-1.02), P= 0.0379; GWAS per rare allele: OR=0.86, P=0.027).
However, this is indicative of no association for this variant when both experiments
are taken into consideration.
From the MMCT-18 study, no similarities were identified between the results of the
nominally significant associations from this project and those from the first stage
GWAS data when all histological subtypes were analysed. However, when the
analysis was restricted to the serous histological subtype, similarities were found
with CASP5 rs518604 (candidate gene result: HetOR= 1.36 (0.98-1.88), HomOR=
1.45 (0.99-2.11), P=0.0313; GWAS per rare allele: OR=1.12, P=0.047) and
rs523104 (candidate gene result: HetOR= 0.86 (0.65-1.16), HomOR= 0.80 (0.55-
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1.15), P= 0.1294; GWAS per rare allele OR=1.12, P=0.044), and FILIP1L
rs12494994 (candidate gene result: HetOR= 0.95 (0.78-1.17, HomOR = 0.52 (0.27-
0.99), P=0.097; GWAS per rare allele OR=0.84, P=0.02). CASP5 rs518604 is
currently being investigated further with additional samples. Although FILIP1L
rs12494994 was not associated with the serous ovarian cancer susceptibility in the
candidate gene approach, the homozygous odds ratio did not cross 1. Incidentally,
the rare allele of FILIP1L rs12494994 was associated with an increased risk of the
endometrioid histological subtype (P=0.0024) with the candidate gene data.
The ovarian cancer GWAS was a 3-staged experimental design which further
investigated the most statistically significant associations from the previous stage,
using samples from the UK, Australia, USA, Denmark, Poland, Germany and
Canada. It is likely that the discrepancies in the associations identified with the
candidate gene approach and GWAS could be due to the samples used; SEARCH
and UKOPS are the only studies common to both approaches. Although none of the
SNPs analysed in this project reached genome-wide significance, only a limited
number of the SNPs evaluated with the candidate gene approach were also analysed
with the GWAS. However, the results from both the candidate gene and GWAS
suggest that there is strong no evidence for association between the tSNPs analysed
in this project and the risk of ovarian cancer. The 12 strongest associations from the
GWAS, with P<10-8, were all located on chromosome 9p22.2 (Song et al. 2009).
Eight of these SNPs were in BCN2, a DNA-binding zinc finger protein, and the
remaining SNPs were within 45kb upstream of the gene. BCN2 would not have been
an obvious candidate for an ovarian cancer association study because there is very
little evidence to suggest its involvement in the development of the disease.
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However, this finding strongly suggests that the germline common variants of genes
which have been demonstrated to be important in the initiation and development of
cancer may not be useful in predicting an individual’s disease risk.
rs3814113, the strongest associated SNP from the ovarian cancer GWAS, was 44kb
from BCN2, the nearest gene, with per rare allele OR of 0.79 (0.75-0.84),
P=2.47x10-17. The identification of strongly associated SNPs in so-called gene-
deserts have also been observed in the GWAS for other diseases, which suggests
genes already implicated in the development of disease may not necessarily be the
best predictors of disease risk. However, it is possible that rare SNPs and/or copy
number variants may also be associated with disease risk. Ovarian cancer is a
complex heterogeneous disease which arises through various genetic and genetic
factors. Therefore interactions between genes and the environment should,
ultimately, be considered when evaluating a woman’s risk of the disease.
Global evaluation of associations with admixture maximum likelihood method
Numerous statistically significant associations have been identified between
candidate genes and ovarian cancer risk and survival over the past decade; however,
it is not known if an excess of significant associations were identified compared to
the proportion which would be expected by chance (Goodman et al. 2001; Song et
al. 2006; Gayther et al. 2007; Harley et al. 2008; Kelemen et al. 2008; Ramus et al.
2008). The admixture maximum likelihood (AML) approach was used to evaluate
the overall evidence of excess of positive associations with SNP genotyping data for
340 SNPs in 94 candidate genes or chromosomal regions. The polymorphisms were
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genotyped in approximately 1,500 cases and 3,100 unaffected controls from three
population-based ovarian cancer case-control series.
Twenty-two out of the 340 SNPs analysed with the AML test were significantly
associated (P-trend<0.05) with ovarian cancer risk. This number was reduced to 18
polymorphisms when the results were adjusted for population stratification. The 3
most significant SNPs had adjusted (for population stratification) P-values <0.003.
These SNPs were rs2107425 (adjusted P=0.0019) from chromosome 11p15.5,
rs9322336 (adjusted P=0.0021) from the oestrogen receptor (ESR1) gene and
rs3817198 (adjusted P=0.0026) from the lymphocyte-specific protein 1 (LSP1) gene.
The most strongly associated SNP was from the BCAC group of SNPs which is
located on chromosome 11p15.5, in a region which does not contain genes or open
reading frames. The 11p15.5 region, despite the lack of genes, loss of heterogeneity
of this locus has been observed, and it is said to contain tumour suppressive
properties malignancies and is associates with breast, lung, bladder and stomach
cancers (Viel et al. 1992; Gudmundsson et al. 1995; Shaw and Knowles 1995; Baffa
et al. 1996; Bepler et al. 1998; Karnik et al. 1998; Xu et al. 2001). rs2107425 was
chosen as a candidate SNP due to its strong association with breast cancer
susceptibility. This association was identified from the breast cancer genome-wide
association study (Easton et al. 2007). This SNP tags another, rs2251375, with r2=1,
which is located in a region that is conserved in mice. ESR1 rs9322336, which is in
the second intron of the gene, is not known to tag any other common SNP. The
ESR1 gene encodes a ligand activated transcription factor, which is able to bind
hormones and DNA. The gene is associated with ovarian and breast cancers (Imura
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et al. 2006; Dunning et al. 2009). The third most significant SNP from the analysis,
rs3817198 of the LSP1 gene, was also identified from the breast cancer association
genome-wide association study and chosen because of its strong association with the
risk of breast cancer (Easton et al. 2007).
It is likely that the associations would no longer be statistically significant after
adjustments for multiple corrections. It may be more appropriate to assess the
experiment-wise significance of either subsets of polymorphisms investigated, or the
totality of all SNPs analysed. The AML test was used to this effect on subsets of
SNPs based on their function, or their genotyping group.
There was no evidence for an overall association between common genetic variation
in the 94 candidate genes or regions and risk of ovarian cancer, when the genotyping
data was analysed with AML, P-trend=0.068. There was evidence of a statistically
significant association between tSNPs identified from the breast cancer genome-
wide association study and evidence of an excess of positive associations over the
proportion expected by chance from this group of 16 common variants (P=0.0028).
Although the AML did not identify an excess of statistically significant associations,
the associations found should not be disregarded. The associations are very modest,
and should be treated with caution, however, there is evidence that the SNPs (or the
chromosomal regions in which they are located) are associated with the risk of other
cancers.
Chapter 6: Discussion & conclusions
299
Effects of germline variants and haplotypes of candidate oncogenes on survival
of ovarian cancer cases
Comparisons between the univariate and multivariate results of all the tSNPs and
haplotypes demonstrated the importance of performing the multivariate analysis with
adjustments for prognostic factors such as age at diagnosis, tumour histology, grade
and stage for all genetic variants being investigated. Prognostic factors that had a
statistically significant affect on survival can mask the influences of the SNPs, which
can result in types I and II statistical errors. This was demonstrated with the tSNP of
RUVBL1, rs4857836. The rare allele of the common variant was not significantly
associated with survival with the univariate Cox regression analysis (per-rare allele
hazard ratio [HR]=0.98 [0.86-1.12], P=0.758), however there was evidence of
association between the rare allele of rs4857836 and better survival after adjustments
for the prognostic factors (adjusted HR=0.8 [0.67-0.98], P=0.003). Conversely, the
opposite was also observed, where the results of the univariate analysis was
significant (KRAS haplotype block 2 h010000, HR=1.69 (1.21-2.36), P=0.002); but
the association was no longer significant after adjustments for prognostic factors
(adjusted HR=0.9 (0.6-1.13), P=0.523). There were 17% and 47% differences
between the hazard ratios of the univariate and multivariate analysis results for
rs4857836 and haplotype h010000, respectively, which is substantial.
These findings suggest, although associations may be identified with the univatiate
Cox regression analysis, correction for prognostic factors is required for all the
variants analysed in order to ascertain more accurate associations between the
genetic variants and survival from the disease. Numerous publications, including
work from this thesis, have reported survival analysis results in ovarian and other
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malignancies with adjustments for prognostic factors of only the variants found to be
associated with survival from the univariate analysis (Mann et al. 2008; Quaye et al.
2008; Koessler et al. 2009; Quaye et al. 2009; Udler et al. 2009). However, it is
likely that some associations were overlooked by not conducting multivariate Cox
regression survival analysis of all the polymorphisms analysed.
The multivariate survival analysis of the oncogene variants showed that associations
between BRAF polymorphisms and ovarian cancer were not restricted to
predisposition to ovarian cancer. Correlations were also found between haplotypes
and tSNPs of BRAF and all-cause survival of patients with ovarian cancer. Contrary
to the susceptibility results, the associations were observed when all ovarian cancer
cases were combined. Although the rare allele of BRAF rs1267622, was associated
with a reduced risk of mucinous subtype, it was also associated with poor survival of
all ovarian cancer cases combined. These associations suggest that although the
common variant may influence the risk of only the mucinous subtype, the tSNP may
also be useful for predicting the survival of ovarian cancer patients, regardless of the
ovarian tumour histological subtype. There was also evidence of an association
between BRAF h10010000 and better survival of all cases combined (P=0.014).
This haplotype was also associated with a reduction in the rest risk of clear cell
ovarian cancer.
Although no statistically significant associations were found between ERBB2 and
survival from ovarian cancer with this project, over-expression of the oncogene has
been correlated with poor survival of MALOVA samples in another study (Hogdall
et al. 2003). An association has also been previously published between the rare
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allele of the polymorphism which was associated with increased risk of endometrioid
ovarian cancer, rs1801200, and poor survival of cases (Pinto et al. 2005). However,
this association was not replicated in this study. Subtle differences in the genetics or
lifestyle of the Portuguese population used in the Pinto study and the research
presented in this thesis may explain the lack of validation of Pinto’s group’s study.
Alternatively, the result from the Pinto paper may have been a false positive; there
were a total of 129 ovarian cancer patients included in the Pinto study in comparison
with 1,766 cases genotyped for rs1801200 in this study.
Effects of germline variants and haplotypes of “functional” candidates on
survival of ovarian cancer cases
When the effects of the MMCT-18 common genetic variants on survival of ovarian
cancer patients were evaluated, associations were identified with various candidate
genes which correlated with suppression of the tumourigenic phenotype. Of note,
the rare alleles of two tSNPs of RBBP8, rs4474794 and rs9304261, were associated
with better survival of all ovarian cancer patients after adjustments for prognostic
factors. Incidentally, the rare allele of rs4474794 was also associated with reduced
risk of serous ovarian cancer. Haplotypes of RBBP8 were also associated with the
risk of ovarian cancer.
The RBBP8 protein, which is also known as CtBP-interacting protein (CtIP), has
been shown to interact with the retinoblastoma protein and the BRCA protein C-
terminal region domains of the BRCA1 gene and a variety of other proteins which are
involved in the regulation of the cell cycle and transcription (Fusco et al. 1998;
Meloni et al. 1999; Li, S. et al. 2000; Zheng et al. 2000). Chen et al have suggested
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that a complex containing RBBP8, BRCA1 and MRN is cell-cycle dependent and is
involved in the activation of homologous recombination double strand DNA repair
in the S and G2 phases of the cell cycle (Sartori et al. 2007; Chen et al. 2008). There
is also evidence suggesting that the RBBP8 protein is resistant to DNA double strand
break-inducing agents (Sartori et al. 2007). Furthermore, the expression of RBBP8
has been shown to be elevated in the majority of oestrogen receptor alpha (ER)
positive breast cancer cell lines. However, this gene was down-regulated in the
TOV112D cell line. Nonetheless, the over-expression of the gene is associated with
patient response to neoadjuvant endocrine therapy (Wu, M. et al. 2007). Moreover,
it was been demonstrated that tamoxifen resistance in breast cancer cells is conferred
through the silencing of the RBBP8 gene (Wu, M. et al. 2007).
rs793446 and two other polymorphisms (rs3921767 and rs9864437) of FILIP1L
were also associated with ovarian cancer survival. However, the rs793446 and
rs9864437 were associated with survival from mucinous ovarian cancer. There was
no striking functional evidence to explain the observed associations between ovarian
cancer susceptibility and survival. However the fact that many of the sequences of
the tagged SNPs were conserved in mice suggests that the region containing the gene
may be functionally important. Furthermore, it has been demonstrated that when the
FILIP1L protein is over-expressed in endothelial cells, there is an increase in
apoptosis and inhibition of cell proliferation and migration (Au et al. 2002; Passmore
et al. 2003).
Another polymorphism of RUVBL1, rs4857836, which tags 2 other SNPs
(rs4857837 and rs7641133), was associated with survival from ovarian cancer;
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adjusted (for prognostic factors) HR=0.81 (0.67-0.98), P=0.03. This association
became stronger when the analysis was restricted to the serous subtype, adjusted
HR= 0.75 (0.59-0.95), P=0.018.
There was a 5-fold and 7-fold increase in the expression of FILIP1L, and RBBP8,
respectively, in TOV112D+18 hybrid cell lines, compared to parental cancer cell
lines. This suggested that the genes behave like tumour suppressor genes. There
was an average 25-fold decrease in the expression of RUVBL1 in both TOV21G+18
and TOV112D+18 hybrid cell lines compared with parental cancer cell lines,
suggesting the gene behaves like an oncogene. Although the gene expression
changes for FILIP1L, RBBP8 and RUVBL1 are likely to be attributed, either directly
or indirectly, to the transfer of chromosome 18 into the hybrid cell lines, RBBP8 was
the only one located on the transferred chromosome. Fluorescence in situ
hybridization analysis showed that RBBP8 was on the 10Mb fragment of human
chromosome 18 that was transferred into the TOV112D cells, rather than the whole
chromosome. The gene expression data has shown that the RBBP8 gene had the
greatest fold increase in expression compared to the other genes in the transferred
region (Quaye et al. 2009).
The rare allele of another variant of CASP5, rs2282657, was associated with better
survival of clear cell ovarian cancer patients. The sequence of the SNP indicates that
it is located within a splice site of the gene. CASP5 was up-regulated in the hybrid
clones showing suppressed (reverted) neoplastic phenotype, therefore, it was down-
regulated in the parental ovarian cancer cell line (TOV21G). CASP5 is involved in
apoptosis and inflammation signaling (Eckhart et al. 2006), the protein is a
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component of the NALP1 inflammasome, and it is involved in the maturation and
secretion of interleukin-1β following simulation by lipopolysaccharide, when it is
part of this complex (Martinon et al. 2002).The expression of CASP5 is also
regulated by interferon-γ (Lin et al. 2000). Mutations in this gene have been
observed in leukaemia, lymphoma and colon cancer (Takeuchi et al. 2003). CASP5
is also of interest because it forms a complex with MYC and MAX oncogenes and has
been demonstrated to cleave MAX, which is important for cell growth,
differentiation and apoptosis (Krippner-Heidenreich et al. 2001). CASP5 also
appears to be a target gene in the microsatellite mutator pathway for cancer (Offman
et al. 2005).
Whole genome DNA amplification and multiplex SNP genotyping platforms
The final topic of this thesis was whole genome amplification and SNP multiplex
genotyping platforms. The concentration of DNA available for research from each
patient is limited. The relative rarity and devastating effects of ovarian cancer makes
it difficult to recruit ovarian cancer patients for studies. Whole genome
amplification (WGA) is a method through which DNA concentrations can be
increased. The use of WGA amplified DNA has the potential of increasing the
numbers of samples available for research because more DNA from cumulatively
increasing numbers of study participants would substantially increase the statistical
power of genetic association studies.
The number of common genetic polymorphisms within the human genome and the
numbers of these SNPs from candidate genes, which need to be evaluated, make the
single SNP reactions labourious and unappealing. This is especially so because of
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the availability of SNP multiplex genotyping platforms. Four WGA methods,
GenomePlex, GenomiPhi, PEP and REPLI-g were used to amplify 95 samples; and
the performance of the WGA products and their performance was evaluated with
three SNP multiplex genotyping platforms, iPLEX, SNPlex and OpenArray.
REPLI-g generated the greatest amount of amplified material and PEP, the lowest
fold increase in amplified DNA. PEP-amplified DNA performed poorly on all of the
SNP multiplex genotyping platforms evaluated. REPLI-g DNA were the only
products with average call rates <90% on TaqMan genotyping platform. The call
rates for the genomic DNA were generally higher than those of the amplified DNA.
Of the SNP multiplex genotyping platforms tested, iPLEX generated the best quality
genotyping results. However, there are issues with failed non-template negative test
controls, which seems to be an artefact of the platform. This could result in a sample
with low concentration apparently yielding an incorrect genotype. A small
proportion of common SNPs genotyped on iPLEX appear to be monomorphic
despite MAF>0.05. The reason behind this is still unclear. It is possible that
contaminating salt adducts prevent the discrimination of genotypes of the SNP.
Discordances were found between genomic DNA and matching amplified products
from all of the WGA methods. However, fewer discordances were identified with
the GenomePlex and GenomiPhi amplified DNA. GenomePlex and GenomiPhi
appeared to provide the best balance between quantity of amplified DNA and
performance on SNP multiplexing platforms.
Chapter 6: Discussion & conclusions
306
Other studies have reported similar findings of lower call rates of amplified DNA
and discordances between WGA DNA and genomic DNA (Tranah et al. 2003;
Bergen et al. 2005; Berthier-Schaad et al. 2007; Moore et al. 2007; Cunningham et
al. 2008; Xing et al. 2008).
Although discordances between genotypes of the amplified DNA and non-amplified
genomic DNA were observed with every WGA method on all of the SNP multiplex
genotyping platforms, the vast majority were found with REPLI-g-amplified DNA.
When PEP-amplified DNA is not considered, genotypes of the WGA DNA from the
iPLEX platform were the most concordant with those of the corresponding non-
amplified genomic DNA. None of the amplification products had an average
discordance rates ≥2% on the iPLEX platform, however the average discordance
rates ranged from 1% (for GenomiPhi-DNA on SNPlex) to 7% (REPLI-g on
OpenArray) for the other 2 multiplex platforms investigated. These results, like
many reported in the literature, are misleading because they are not indicative of the
discordances for each polymorphism genotyped. Cunningham’s group reported a
>99% average concordance rate between WGA and their corresponding genomic
DNA when they were genotyped on the Illumina GoldenGate BeadArray platform,
however, only 1 (0.9%) of the 116 pairs of WGA and genomic DNA was
concordant for all the 1,536 SNPs successfully genotyped (Cunningham et al. 2008).
Although the majority of discordances, both allele dropout and miscall were found
between REPLI-g amplified DNA and genomic DNA, other researchers have not
found this. Xing et al. report “excellent” (overall 98.7%) concordance between
genomic and matching REPLI-g DNA based on genotyping data from the
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Affymetrix 250K array platform, however, the genotypes are of 4 individuals, which
is too small a number to accurately ascertain the performance of WGA DNA (Xing
et al. 2008). Another study reported 100% concordance between genomic DNA and
the corresponding DNA amplified with DOP-PCR, ligation-mediated PCR and a
strand displacement amplification method, for the 10 SNPs genotyped, however,
again, only 4 samples were analysed (Lee et al. 2008).
Talseth-Palmer et al. have demonstrated gains and losses of GenomePlex and
GenomiPhi amplified DNA with array comparative genomic hybridisation,
compared with genomic DNA. They also report that the discordances appear to be
random and are not reproducible (Talseth-Palmer et al. 2008). The results from the
OpenArray platform, which was the only genotyping platform where the
reproducibility of the genotyping was assessed, also suggested that there is a lack
reproducibility of the genotyping results in both genomic and amplified DNA on the
platform.
Limitations
The studies within this project had differing statistical powers to detect associations.
Where all ovarian cancer cases were analysed, there was 97% power at the 5%
significance level to detect a co-dominant allele with a minor allele frequency of 0.3
that confers an odds ratio of 1.2, and 96% power to detect a dominant allele with a
minor allele frequency of 0.1 that confers an odds ratio of 1.3. However, statistical
power depends on the sample size, the minor allele frequency, the risks conferred,
and the genetic model. Therefore, the statistical power to detect associations when
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analysis was restricted to the histological subtypes of ovarian cancer was greatly
reduced.
It is possible that some associations were missed because some tSNPs from the
candidate genes could not genotyped such as BRAF (1 tSNP not genotyped), KRAS
(2 tSNPs), PIK3CA (3 tSNPs), AIFM2 (1tSNP), AXIN2 (2 tSNPs), RGC32 (1 tSNP)
and RUVBL1 (1 tSNP).
The findings reported should be treated with caution because they could be chance
findings. The results have not been adjusted for multiple testing, which may
diminish the vast majority of the associations found. Unfortunately, associations
between germline genetic variants and other clinical features of disease, such as
disease recurrence, and response and resistance of chemotherapy could not be
assessed in this project. This is because the data for the collections are
epidemiological, rather than clinical. Therefore there is no access to the clinical
information, other than the ones mentioned.
Genomic controls from a breast cancer study were used to estimate the inflation of
the test statistic used to adjust for cryptic population stratification. It is possible that
the stratification observed in the breast cancer study was not a true reflection of that
from the samples analysed with the admixture maximum likelihood test. Although,
a very conservative inflation test of 10% was used to adjust the results, it is
nonetheless, possible that the value is an over-estimation, or under-estimation for the
ovarian cancer studies. The test statistics from the ovarian cancer GWAS showed
that there were marginal increases in the estimated inflation factor (λ1000=1.026) with
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the stage 1 samples which were exclusively Caucasian Britons and λ1000=1.005 with
the European, Australian and North American non-Hispanic Caucasians (Song et al.
2009b). Therefore the 1.1 inflation factor used to adjust for cryptic population
stratifications in this thesis was likely to be a gross over-estimation.
It is also believed that the use of prevalent samples in the survival analysis may be a
weakness of the study. However, Cox regression survival analysis of the follow-up
data showed that, although the prevalent samples appeared to have better survival
than incident cases, the difference was not statistically significant (P>0.05). Left
truncation of the data was also used in the analysis, which controlled for any bias of
the hazard ratio estimates which may have arisen. Although, as a result of smaller
events (deaths) occurring with prevalent samples, the exclusion of prevalent samples
would reduce the overall sample size and number of events. Therefore the inclusion
of prevalent samples increases the statistical power to detect associations. The
inclusion of prevalent samples may also be considered as a form of adjustment, as
they may generate more conservative associations. Azzato et al. (2009) have also
reported that they did not find significant bias in the hazard ratios of incident and
prevalent cases of breast cancer when survival analysis, with left truncation, was
conducted on data on clinical stage, histopathological grade and oestrogen receptor.
The analysis of data based on all-cause mortality, rather than mortality from ovarian
cancer is another limitation of this study. It is likely that some of the affect
participants die or will die from causes other than ovarian cancer. However, this
issue it not of great importance as the vast majority of the cases, will sadly die from
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ovarian cancer. The small number of patients who die from other causes should be
too small to greatly affect the results.
The numbers of histological subtypes of epithelial ovarian cancer, which include
serous, endometrioid, mucinous and clear cell, are limited, as was the power to
detect association with a reasonable degree of confidence. However, the results from
the susceptibility and survival analyses re-affirms the heterogeneity of ovarian
cancer aetiology. The results were in concordance with mutational analyses, which
have found that mutations of some genes are restricted to particular histological
subtypes of ovarian cancer. This is particularly true when the susceptibility and
survival results for candidate genes such as BRAF, KRAS and FILIP1L are
considered. These results need to be validated with additional samples.
The results from these studies provide proof of principle for the theory that SNPs
may influence predisposition and the survival outcome of ovarian cancer. Ultimately
highly significant SNPs with strong effects may be used clinically to predict a
woman’s risk of ovarian cancer, or survival from the disease. However, the vast
majority of associations identified by these studies have been limited to marginal
significance, which are considerably less than the P-value suggested for candidate
gene association studies (P=10-4).
The additional limitations of this study and others of ovarian cancer susceptibility are
the fact that the sizes of the effects have generally been <2, which suggest that the
findings from these studies are unlikely to be translated and implemented to the
clinical setting. None-the-less, the genes which have been selected for the
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ovarian cancer genetic research.
Moreover, although SNP genotyping data from the HapMap Project is invaluable to
SNP and haplotype association studies, the research is ongoing and is not immune
from error. HapMap data from Release 20 for the BRAF oncogene suggested that
one of the tSNPs genotyped, rs1267622, tagged rs7384384 with r2=1. However,
recent data releases from HapMap no longer include rs7384384, and dbSNP gives
the error message:
This message suggests that both rs numbers were assigned to the same SNP. The
policy in these instances is to keep the lower rs number and “retire” the higher
number. There have also been a few occasions when HapMap has announced errors
with its data. For example:
an
“This snp_id was merged into rs4726020
refSNP cluster id(rs): rs7384384 is an invalid snp_id value.
Note that rs# is not contiguous due to user withdraws and merging of clusters.”“2008-02-21: Incorrect position for merged SNPs in rel #23
The position of ~24,500 SNPs was inadvertently entered incorrectly in
HapMap release #23 bulk files (genotypes and frequencies). A complete list
of affected SNPs can be found here. Errors are being corrected and new
genotypes and frequency files will be made available shortly under HapMap311
d
release #23a.”
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Files with errors have been removed from public view and will be replaced
with correct files. Nonetheless, the files continue to be under scrutiny. An
official announcement will be made when these files are officially approved312
ese announcements highlight the importance of regularly visiting the HapMap
bsite for such updates, and also conducting validation studies in order to confirm
associations identified.
new release of HapMap SNP genotying data, Release 21, became available after
completion of the genotyping of the samples with the oncogene probes. The
cogenes selected for the study were re-tagged with the more up-to-date data to
tablish the efficiency of the tagging based on the tSNPs successfully genotyped.
shown in Appendix Y, although there was data available for more SNPs (“All
Ps” in the appendix table) for all of the genes, with the exception of ERBB2
hich had a tagging efficiency reduced, from 100% to 80% with the new data) the
ging efficiency of the tSNP from the other genes remained unchanged. Moreover,
overall tagging efficiency of all the genes combined stayed at 94%.
ture work
e advent of genome-wide association studies has led to the usefulness of the
ndidate gene approach of genetic association studies being questioned. This is
ely to be due to the limited success of the approach. These questions are of
rticular importance since some of the most significant associations found from the
east and ovarian cancer genome-wide association studies were located at regions
for general use.”
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without genes or open reading frames. To date, the only possible explanation for the
associations may be that of long-range regulation. Fine-mapping is a technique in
which the SNPs tagged by the significant tSNP and other neighbouring SNPs are
genotyped in order to elucidate the individual SNP responsible for the association. It
is expected that the P-value and effect (odds ratio) would be greatest at the “causal”
polymorphism. Similar results can also be obtained through sequencing the
region(s) significantly associated with ovarian cancer susceptibility or survival.
It is feasible that the fine-mapping technique could be used to find “causal” SNPs
from the positive associations found from these and other studies. However, all the
results need to be corrected for multiple testing and validated before such a step is
taken. The validation of some of the findings could increase the power to detect
associations. It would be of great interest to run the AML method on all genotyping
data, restricted by histological subtype, to evaluate the overall evidence of positive
associations over the proportion expected by chance.
There were insufficient numbers of samples for investigating gene-gene or gene-
environment interactions. However, it would be of great interest to conduct these
analyses as the SNPs are unlikely to cause ovarian cancer without interacting with
other factors. Therefore these tests should be considered in the future. Stronger,
more significant associations may be found if the analyses of these interactions were
performed.
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Conclusions
In conclusion, 34 tSNPs of four oncogenes (BRAF, ERBB2, KRAS and PIK3CA) and
a putative oncogene (NMI), and 63 tSNPS from 9 differentially expressed genes
(AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3)
from in vitro neoplastic suppression experiments were genotyped in invasive ovarian
cancer case-control series. Associations were identified between polymorphisms and
haplotypes of NMI, CASP5, and RUVBL1 and disease risk when ovarian cancer is
considered as a single disease. Additional associations were found with many of the
other genes when analysis was restricted to the histological subtypes of ovarian
cancer. Of note, associations were found between mucinous ovarian cancer
susceptibility and survival and haplotypes and variants of BRAF and KRAS; and risk
of endometrioid disease and variants of FILIP1L.
Associations were also identified between RBBP8, RUVBL1 and FILIP1L and
clinical outcome of ovarian cancer patients. Additional associations were found
when the survival analyses were restricted to the major histological subtypes of
ovarian cancer. Although the results should be treated with caution, they should be
further investigated. The identification of strongly associated polymorphisms
candidate genes could used for targeted screening of individuals at high risk of
ovarian cancer, the prediction of response to therapy or prognosis, and/or more
effective treatment.
The genotyping of GenomePlex and GenomiPhi amplified DNA on the iPLEX
system was the best combination of WGA method and SNP multiplex genotyping
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platform. However, these results should be confirmed with replication of the
investigations.
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Appendix I: MMCT-18 master-list
List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Down in
hybrids
TOV112D
C20orf100 20q13.12 1 4 153,449 167 60
TOX high mobility group box family
member 2. Granulosa cell HMG box
protein. Putative transcriptional
activator involved in the
hypothalamo-pituitary-gonadal
system.
Down in
hybrids
TOV112D
FAM19A5 22q13.32 2 8 269,793 216 83
Family with sequence similarity 19
(chemokine (C-C motif)-like),
member A5. Unknown function.
Down in
hybrids
TOV112D
PDGFRL 8p22-p21.3 3 91 65,917 124 56
Platelet-derived growth factor
receptor-like. Mutations in gene, or
deletion of a chromosomal segment
containing this gene, are associated
with sporadic hepatocellular
carcinomas, colorectal cancers, and
non-small cell lung cancers. May
function as tumour suppressor.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Down in
hybrids
TOV112D
DIO2 14q24.2-q24.3 4 1 14,656 13 5 Deiodinase, iodothyronine, type II.
Down in
hybrids
TOV112D
RGC32 13q14.11 5 80 13,323 17 8
Believed to regulate cell cycle
progression. Induced by p53 in
response to DNA damage, or by
sublytic levels of complement
system proteins that result in
activation of the cell cycle.
Down in
hybrids
TOV112D
APCDD1 18p11.22 6 14 34,154 42 13
Adenomatosis polyposis coli down-
regulated 1. May play a role in
colorectal tumorigenesis. May be a
developmental target gene of the
Wnt/β-catenin pathway
Down in
hybrids
TOV112D
SLITRK6 13q31.1 7 55 6,561 5 4
SLIT and NTRK-like family,
member 6. SLITRKs are expressed
predominantly in neural tissues and
have neurite-modulating activity.
Down in
hybrids
TOV112D
TCBA1 6q21 8 19 1,021,734 1093 279
Na+/K+ transporting ATPase
interacting 2. T-cell lymphoma
breakpoint associated target 1.
Down in
hybrids
TOV112D
CXXC4 4q22-q24 9 11 26,485 5 3 CXXC finger 4. May be in the Wntreceptor signalling pathway.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Down in
hybrids
TOV112D
CLEC11A 19q13.3 10 13 2,376 None Unknown function.
Down in
hybrids
TOV112D
MME 3q25.1-q25.2 15 9 104,033 83 35
Membrane metallo-endopeptidase.
Gene encodes a common acute
lymphocytic leukemia antigen that is
an important cell surface marker in
the diagnosis of human acute
lymphocytic leukemia (ALL). This
protein is present on leukemic cells
of pre-B phenotype, which represent
85% of cases of ALL. Also found on
variety of normal tissues.
Down in
hybrids
TOV112D
EN1 2q13-q21 17 2 5,993 1 1
Engrailed homeobox 1. Homeobox-
containing genes are believed to be
involved in controlling development.
The human engrailed homologs 1
and 2 encode homeodomain-
containing proteins and have been
implicated in the control of pattern
formation during development of the
central nervous system.
Down in
hybrids
TOV112D
C21orf94 21q21.3 19 7 9,572 14 9 Uncharacterized protein
Down in
hybrids
TOV112D
ARMCX2 Xq21.33-q22.2 22 5 4,609 2 2
Armadillo repeat containing, X-
linked 2. Arm protein lost in
epithelial cancers. Gene encodes a
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
member of the ALEX family of
proteins and may play a role in
tumour suppression. The encoded
protein contains a potential N-
terminal transmembrane domain and
a single Armadillo (arm) repeat.
Other proteins containing the arm
repeat are involved in development,
maintenance of tissue integrity, and
tumorigenesis.
Down in
hybrids
TOV112D
CRABP1 15q24 28 3 7,878 2 2
Cellular retinoic acid binding protein
1. Cellular retinoic acid-binding
protein is assumed to play an
important role in retinoic acid-
mediated differentiation and
proliferation processes.
Down in
hybrids
TOV112D
MAB21L1 13q13 38 6 2,511 1 1
Mab-21-like 1 (C. elegans). This
gene is similar to the MAB-21 cell
fate-determining gene found in C.
elegans. May be involved in eye and
cerebellum development, and it has
been proposed that expansion of a
trinucleotide repeat region in the 5'
UTR may play a role in a variety of
psychiatric disorders.
Down in
hybrids
TOV112D
CSN3 4q21.1 46 10 8,838 20 7 Casein kappa.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Up in
hybrids
TOV112D
ANKFN1 17q23.2 1 7 329,171 261 51
Ankyrin-repeat and fibronectin type
III domain containing 1. Unknown
function.
Up in
hybrids
TOV112D
CDH12 5p14-p13 2 13 1,102,756 792 133
Cadherin 12. Gene encodes an
integral membrane protein that
mediates calcium-dependent cell-cell
adhesion.
Up in
hybrids
TOV112D
CXCL14 5q31 3 10 8,594 11 6 Chemokine (C-X-C motif) ligand 14.
Up in
hybrids
TOV112D
LIX1 5q15 4 2 51,002 36 7 Lix1 homolog (mouse). Limbexpression 1. Unknown function
Up in
hybrids
TOV112D
C18orf34 18q12.1 5 5 Hypothetical protein
Up in
hybrids
TOV112D
PRAC 17q21 6 6 801 1 1
This gene is reported to be
specifically expressed in prostate,
rectum and distal colon. Sequence
analysis suggests that it may play a
regulatory role in the nucleus.
Up in
hybrids
TOV112D
FILIP1L (DOC1) 3q12.1 7 9 281,369 135 8
Filament A interacting protein 1-
like. GPBP-interacting protein 90;
down-regulated in ovarian cancer 1.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Up in
hybrids
TOV112D
GNAT3 7q21.11 8 18 53,255 Not inhapmap
Guanine nucleotide binding protein,
alpha transducing 3.
Up in
hybrids
TOV112D
OLFM3 1p22 9 16 194,456 250 69
Olfactomedin 3. Expressed in brain
and retina; may be a candidate gene
for disorders involving the anterior
segment of the eye and the retina.
Up in
hybrids
TOV112D
TAIP-2 2q24.3 10 29 211,055 86 21
Family with sequence similarity 130,
member A2. TGF beta induced
apotosis protein.
Up in
hybrids
TOV112D
NELL2 12q13.11-q13.12 13 4 368,073 319 49
NEL-like 2 (chicken). Neural
epidermal growth factor-like 2.
Gene encodes a cytoplasmic protein
that contains epidermal growth
factor (EGF) -like repeats. The
encoded heterotrimeric protein may
be involved in cell growth regulation
and differentiation.
Up in
hybrids
TOV112D
AXIN2 17q23-q24 19 8 33,084 14 12
Axin 2 (conductin, axil). Inhibitor β-
catenin in the Wnt signalling
pathway. In region of frequent loss
of heterozygosity in breast cancer,
neuroblastoma, and other tumors.
Mutations in this gene have been
associated with colorectal cancer
with defective mismatch repair.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Up in
hybrids
TOV112D
PSMAL 11q14.3 22 1 66,834 17 4 Growth-inhibiting protein 26.
Up in
hybrids
TOV112D
STMN2 8q21.13 24 3 54,996 86 24
Stathmin-like 2. May play a role in
neuronal differentiation, and in
modulating membrane interaction
with the cytoskeleton during neurite
outgrowth
Up in
hybrid
TOV21G
C1orf116 1q32.1 1 28 14,226 5 5 Specifically androgen-regulatedprotein. Unknown function
Up in
hybrid
TOV21G
C11orf17 11p15.3 2 120 8,925 10 4
Breast cancer associated gene 3;
koyt binding protein 1; koyt binding
protein 2; koyt binding protein 3;
protein kinase A-interacting protein
1.
Up in
hybrid
TOV21G
STAG3 7q22.1 3 31 43,764 28 3
Stromal antigen 3. Encoded protein
is a component of the cohesion
complex during chromosome
segregation.
Up in
hybrid
TOV21G
RLN1 9p24.1 4 50 4,904 8 3 Relaxin 1. Unknown function.
Up in
hybrid
TOV21G
VTCN1 1p13.1 5 35 67,347 54 22
V-set domain containing T cell
activation inhibitor 1. Expressed on
the surface of antigen-presenting
cells and interact with ligands on T
lymphocytes.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Up in
hybrid
TOV21G
CASP5 11q22.2-q22.3 6 40 14,729 17 9
Caspase 5. Sequential activation of
caspases plays a central role in the
execution-phase of cell apoptosis.
Overexpression of the active form of
this enzyme induces apoptosis in
fibroblasts. Max, a central
component of the Myc/Max/Mad
transcription regulation network
important for cell growth,
differentiation, and apoptosis, is
cleaved by this protein. Target gene
in the microsatellite mutator pathway
for cancer.
Up in
hybrid
TOV21G
STK17A 7p12-p14 7 103 42,996 34 11
Gene encodes an autophosphorylated
nuclear protein which acts as a
positive regulator of apoptosis.
Up in
hybrid
TOV21G
CXorf6 Xq28 8 86 68,729 87 35
Hypothetical protein. Putative DNA
binding protein, expressed in skeletal
muscle, brain, heart. May be
involved in gonadal function.
Up in
hybrid
TOV21G
F2 11p11-q12 9 12 20,300 13 4
Coagulation factor II (thrombin).
Involved in first step of the
coagulation cascade which
ultimately results in the stemming of
blood loss. Also plays a role in
maintaining vascular integrity during
development and postnatal life.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Up in
hybrid
TOV21G
C10orf33 10q24.2 10 61 31,619 88 9 Oxidoreductase activity.
Up in
hybrid
TOV21G
ANXA13 8q24.13 16 5 56,613 98 40
Annexin A13. May play a role in the
regulation of cellular growth and in
signal transduction pathways.
Up in
hybrid
TOV21G
FLJ20701 2q36.3 25 2 247,291 339 85
Phosphotyrosine interaction domain
containing 1. Increases proliferation
of preadipocytes.
Up in
hybrid
TOV21G
SLC17A2 6p21.3 28 8 17,857 24 7
Solute carrier family 17 (sodium
phosphate), member 2. May be
involved in actively transporting
phosphate into cells.
Up in
hybrid
TOV21G
MPL 1p34 31 9 16,660 3 1
Myeloproliferative leukemia virus
oncogene. Encodes a transmembrane
domain. Important in megakaryocyte
and platelet formation.
Up in
hybrid
TOV21G
WDR78 1p31.2 51 7 112,002 77 23 Unknown function
Up in
hybrid
TOV21G
PRDM14 8p21-p12 65 6 19,542 16 14
PRDM14 mRNA is overexpressed in
about 2/3 of breast cancers;
moreover, immunohistochemical
analysis showed that expression of
PRDM14 protein is also up-
regulated. Regulation of
transcription.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Up in
hybrid
TOV21G
PNOC 8p21 70 10 26,219 49 12
Prepronociceptin. Protein in part of
the neuropeptide signalling pathway.
May be involved in neuronal
differentiation and development.
Up in
hybrid
TOV21G
LOC400942 2p25.1 84 3 Not inHapmap
Hypothetical protein. Unknown
function.
Up in
hybrid
TOV21G
C14orf110 14q32.33 114 4 4,163 Not inHapmap
Hypothetical protein. Unknown
function.
Up in
hybrid
TOV21G
LOC283677 15q24.1 120 1 116,832 32 9 Hypothetical protein. Unknownfunction.
Down in
hybrid
TOV21G
HIF1A 14q21-q24 1 12 52,737 16 6 Hypoxia-inducible factor 1.Transcription factor.
Down in
hybrid
TOV21G
IPO7 11p15.4 2 330 60,871 20 6
Importin 7. RAN binding protein 7.
The importin-α/β complex and the
GTPase Ran mediate nuclear import
of proteins.
Down in
hybrid
TOV21G
KIAA0895 7p14.1 3 48 65,863 Hypothetical protein. Unknownfunction.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Down in
hybrid
TOV21G
HPS6 10q24.32 4 183 2,648 2 2
Hermansky-Pudlak syndrome 6. This
intronless gene encodes a protein
that may play a role in organelle
biogenesis associated with
melanosomes, platelet dense
granules, and lysosomes.
Down in
hybrid
TOV21G
FBXW5 9q34.3 5 28 4,286 1 1
F-box and WD repeat domain
containing 5. The F-box proteins
constitute one of the four subunits of
ubiquitin protein ligase complex,
which function in phosphorylation-
dependent ubiquitination.
Down in
hybrid
TOV21G
APOBEC3C 22q13.1-q13.2 6 3 18,110 6 3
Apolipoprotein B mRNA editing
enzyme, catalytic polypeptide-like
3C. May be RNA editing enzymes
and have roles in growth or cell
cycle control.
Down in
hybrid
TOV21G
BCAR1 16q22-q23 7 64 22,575 17 7
Breast cancer anti-estrogen
resistance 1. Docking protein which
plays a central coordinating role for
signalling related to cell adhesion.
Implicated in induction of cell
migration. Overexpression confers
antiestrogen resistance on breast
cancer cells.
Down in
hybrid
TOV21G
CTPS2 Xp22 8 182 124,937 31 10
Cytidine 5'-triphosphate synthetase
2. Cancer cells that exhibit increased
cell proliferation also exhibit an
increased activity of this encoded
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
protein.
Down in
hybrid
TOV21G
LOC130951 2p13.1 9 286 Hypothetical protein. Unknownfunction
Down in
hybrid
TOV21G
NMT1 17q21.31 10 34 47,704 41 10
N-myristoyltransferase 1. Adds a
myristoyl group to the N-terminal
glycine residue of certain cellular
and viral proteins
Down in
hybrid
TOV21G
DDIT4 10pter-q26.12 13 10 2,120 1 1 DNA-damage-inducible transcript 4.
Down in
hybrid
TOV21G
SQSTM1 5q35 44 9 17,181 15 10
Sequestosome 1. Paget disease of
bone 3. May be involved in cell
differentiation, apoptosis, immune
response and regulation of K(+)
channels.
Down in
hybrid
TOV21G
PDZK1IP1 1p33 77 6 7,455 1 1
PDZK1 interacting protein 1.
Epithelial protein up-regulated in
carcinoma.
Down in
hybrid
TOV21G
TUBA1 2q35 106 1 4,205 4 1
Encodes an α-tubulin, a major
component of microtubules.
Microtubules of the eukaryotic
cytoskeleton perform essential and
diverse functions. Highly conserved.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Down in
hybrid
TOV21G
IL6 7p21 151 8 6,113 10 4 Interleukin 6. Involved in theregulation of immune response.
Down in
hybrid
TOV21G
NNMT 11q23.1 236 7 54,685 13 7
Nicotinamide N-methyltransferase.
Protein is involved in the
metabolism of drugs and xenobiotic
compounds by the liver.
Down in
hybrid
TOV21G
CXCL1 4q21 261 4 14,276 1 1
Chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating
activity, alpha). Oncogene involved
in regulation of cell trafficking of
leukocytes. Also play fundamental
roles in the development,
homeostasis, and function of the
immune system, and have effects on
cells of the central nervous system as
well as on endothelial cells involved
in angiogenesis or angiostasis.
Down in
hybrid
TOV21G
PPP1CA 11q13 332 5 3,750 1 1
Protein phosphatase 1, catalytic
subunit, alpha isoform. Encoded
protein is one of the three catalytic
subunits of protein phosphatase 1
(PP1). PP1 is a serine/threonine
specific protein phosphatase known
to be involved in the regulation of a
variety of cellular processes, such as
cell division, glycogen metabolism,
muscle contractility, protein
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
synthesis, and HIV-1 viral
transcription.
Down in
hybrid
TOV21G
SPP1 4q21-q25 456 2 7,766 10 4
Secreted phosphoprotein 1. May be
involved in cell-matrix interaction.
Sequence suggests that the protein
acts as a cytokine involved in
enhancing production of interferon-γ 
and interleukin-12 and reducing
production of interleukin-10 and is
essential in the pathway that leads to
type I immunity.
Up in
hybrids both
lines
RARB 3p24 11 22 25 2 423,531 245 102
Retinoic acid receptor-β. This
receptor controls cell function by
directly regulating gene expression.
Up in
hybrids both
lines
PRO1843 12q13.13 42 9 9 3 35,770 40 8
Eukaryotic translation initiation
factor 4B. Required for the binding
of mRNA to ribosomes.
Up in
hybrids both
lines
HEY1 8q21 15 16 16 4 3,760 2 2
Hairy/enhancer-of-split related with
YRPW motif 1. Transcriptional
repressors. Implicated in Notch
signaling pathway; and nervous
system development.
Up in
hybrids both
lines
AKTIP (FTS) 16q12.2 18 14 15 6 11,978 7 4
AKT interacting protein. Fused toes
homolog. Regulates apoptosis.
This protein interacts directly with
serine/threonine kinase protein
kinase B (PKB)/Akt and modulates
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
PKB activity by enhancing the
phosphorylation of PKB's regulatory
sites.
Up in
hybrids both
lines
IGHM 14q32.33 43 46 28 7 4,285 Not inhapmap
Immunoglobulin heavy constant mu.
Protein has transmembrane receptor
activity, which is implicated in
activation of MAPK activity.
Up in
hybrids both
lines
NMB 15q22-qter 44 24 11 8 3,442 7 4
neuromedin B. Stimulates smooth
muscle contraction in a manner
similar to that of bombesin. hormone
activity. signal transduction.
neuropeptide signaling pathway.
cell-cell signalling.
Up in
hybrids both
lines
MRPL46 15q24-q25 12 23 44 9 7,910 1 1
Encoded a subunit of mammalian
mitochondrial ribosomal proteins,
which help in protein synthesis
within the mitochondrion.
Up in
hybrids both
lines
SERINC2 1p35.1 19 27 22 10 25,113 8 3 Serine incorporator 2. Positiveregulation of transferase activity.
Up in
hybrids both
lines
PCDHB2 5q31 2 29 19 12 2,745 1 1
Protocadherin β 2. Specific functions
are unknown but they most likely
play a critical role in the
establishment and function of
specific cell-cell neural connections.
Up in
hybrids both
lines
KRT8L2 3q25.33 39 15 4 13 1,688 Not onhapmap
keratin 8 pseudogene 12. Unknown
function.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Up in
hybrids both
lines
SP110 2q37.1 8 20 33 14 51,036 87 29
SP110 nuclear body protein. The
protein can function as an activator
of gene transcription and may serve
as a nuclear hormone receptor
coactivator. May also be involved in
ribosome biogenesis and induction
of myeloid cell differentiation.
Up in
hybrids both
lines
EPS15L2 7p12.3 16 25 18 15 2,046 Not onhapmap
Epidermal growth factor receptor
pathway substrate 15-like 2. Pseudo
gene. Unknown function.
Up in
hybrids both
lines
EPHX2 8p21-p12 7 35 24 16 53,860 50 11
Epoxide hydrolase 2, cytoplasmic.
Plays role in xenobiotic metabolism
by degrading potentially toxic
epoxides.
Up in
hybrids both
lines
LOC92689 4p14 40 21 29 18 77,923 100 24
Family with sequence similarity 114,
member A1. Nervous system over-
expressed protein. May play a role in
neuronal cell development (By
similarity). Hypothetical protein.
Up in
hybrids both
lines
SRGAP1 12q14.2 25 58 14 19 299,033 170 60
SLIT-ROBO Rho GTPase activating
protein 1. Together with CDC42
seems to be involved in the pathway
mediating the repulsive signalling of
Robo and Slit proteins in neuronal
migration.
Up in
hybrids both
lines
FLJ10826 16q12.2 28 1 57 20 27,588
2-oxoglutarate and iron-dependent
oxygenase domain containing 1.
Hypothetical protein. Unknown
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
function.
Up in
hybrids both
lines
SLC38A6 14q23.1 1 18 20 21 102,550 22 5 Solute carrier family 38, member 6.
Up in
hybrids both
lines
AIFM2 (AMID) 10q22.1 10 11 27 23 34,711 17 13
Apoptosis-inducing factor,
mitochondrion-associated, 2.
Induction of apoptosis. Induced by
tumour suppressor protein p53 in
colon cancer cells. Down-regulated
in a wide range of human tumours.
Up in
hybrids both
lines
PLXNA1 3q21.3 38 51 2 24 48,730 16 9
Plexin A1. Plays a role in axon
guidance, invasive growth and cell
migration.
Up in
hybrids both
lines
LHX6 9q33.2 35 52 3 26 26,221 21 12
LIM homeobox 6. The encoded
protein may function as a
transcriptional regulator and may be
involved in the control of
differentiation and development of
neural and lymphoid cells.
Up in
hybrids both
lines
IL4 5q31.1 26 47 8 28 8,995 15 3 Interleukin 4. Regulation of B cellproliferation.
Up in
hybrids both
lines
MAPT 17q21.1 3 13 17 30 133,923 188 27
Microtubule-associated protein tau.
Promotes microtubule assembly and
stability, and might be involved in
the establishment and maintenance
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
of neuronal polarity.
Up in
hybrids both
lines
C20orf6 20p12.1 30 12 39 34 70,563 70 14
ESF1, nucleolar pre-rRNA
processing protein, homolog (S.
cerevisiae). May constitute a novel
regulatory system for basal
transcription. Negatively regulates
ABT1 (By similarity). Transcription.
regulation of transcription, DNA-
dependent.
Up in
hybrids both
lines
FLJ22662 12p13.1 6 2 30 35 64,196 41 13 Hypothetical protein. Unknownfunction.
Up in
hybrids both
lines
TMEM45A 3q12.2 27 19 10 51 84,822 77 14 Transmembrane protein 45A.Unknown function
Down in
hybrids both
cell lines
TPM3 1q21.2 19 87 7 9 35,776 11 6
Tropomyosin 3. Gene encodes a
member of the tropomyosin family
of actin-binding proteins involved in
the contractile system of striated and
smooth muscles and the cytoskeleton
of non-muscle cells.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Down in
hybrids both
cell lines
SFRS9 12q24.31 91 68 8 11 8,087 5 3
Splicing factor, arginine/serine-rich
9. Plays a role in constitutive
splicing and can modulate the
selection of alternative splice sites.
Down in
hybrids both
cell lines
RUVBL1 3q21 8 7 10 67 42,857 29 7
Interacts with MYC. Forms a
complex which may be required for
the activation of transcriptional
programs associated with oncogene
and proto-oncogene mediated
growth induction, tumor suppressor
mediated growth arrest and
replicative senescence, apoptosis,
and DNA repair.
Down in
hybrids both
cell lines
GAMT 19p13.3 15 124 14 5 4,464 0 0
Guanidinoacetate N-
methyltransferase. Converts
guanidoacetate to creatine. Important
in creatine biosynthetic process.
Down in
hybrids both
cell lines
DNAJB1 19p13.2 7 71 18 29 3,619 6 4
DnaJ (Hsp40) homolog, subfamily
B, member 1. Interacts with HSP70
and can stimulate its ATPase
activity.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Down in
hybrids both
cell lines
SIP1 14q13 26 9 26 75 22,689 10 4
Survival of motor neuron protein
interacting protein 1. The SMN
complex plays an essential role in
spliceosomal snRNP assembly in the
cytoplasm and is required for pre-
mRNA splicing in the nucleus.
Down in
hybrids both
cell lines
DKFZP686A10121 7q21.13 20 26 59 79 44,329 70 10
GTP-binding protein 10 (putative).
Hypothetical protein. Unknown
function.
Down in
hybrids both
cell lines
BTG3 21q21.1-q21.2 21 23 104 64 19,294 5 3
BTG family, member 3. Regulation
of progression through mitotic cell
cycle. Putatively involved in
neurogenesis in the central nervous
system.
Down in
hybrids both
cell lines
CTSL 9q21-q22 16 18 105 66 5,874 3 2
Cathepsin L1. Encoded protein plays
a major role in intracellular protein
catabolism.
CHR18
TOV21G
down in
hybrids
ZNF532 18q21.32 1 21 123,648 73 28
Zinc finger protein 532. Nucleic acid
binding activity. Transcription
activity.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
TOV21G
down in
hybrids
ACAA2 18q21.1 2 3 30,376 26 8
Acetyl-Coenzyme A acyltransferase
2. Catalyses the last step of the
mitochondrial fatty acid beta-
oxidation spiral.
CHR18
TOV21G
down in
hybrids
RALBP1 18p11.3 3 6 63,106 47 15
RalA binding protein 1. Can catalyse
transport of glutathione conjugates
and xenobiotics, and may contribute
to the multidrug resistance
phenomenon. Serves as a scaffold
protein that brings together proteins
forming an endocytotic complex
during interphase and also with
CDC2 to switch off endocytosis.
CHR18
TOV21G
down in
hybrids
RAB31 18p11.3 4 15 154,284 174 85
RAB31, member RAS oncogene
family. Predominantly expressed in
melanocytes. Signal transduction.
Small GTPase mediated signal
transduction.
CHR18
TOV21G
down in
hybrids
C18orf55 18q22.3 5 8 10,445 14 3
TIM21-like protein, mitochondrial
precursor. May participate in the
translocation of transit peptide-
containing proteins across the
mitochondrial inner membrane (By
similarity). Hypothetical protein.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
TOV21G
down in
hybrids
KNTC2 18p11.32 6 9 45,055 63 11
NDC80 homolog, kinetochore
complex component (S. cerevisiae).
Mitotic sister chromatid segregation.
Spindle organization and biogenesis.
Vesicle-mediated transport.
Phosphoinositide-mediated
signalling.
CHR18
TOV21G
down in
hybrids
CCDC5 18q21.1 7 27 24,002 12 6
Coiled-coil domain containing 5
(spindle associated). Regulator of
spindle function and integrity during
the metaphase-anaphase transition.
CHR18
TOV21G
down in
hybrids
LAMA1 18p11.31 8 10 175,929 246 104
Laminin, α 1. Mediates the
attachment, migration and
organization of cells into tissues
during embryonic development.
CHR18
TOV21G
down in
hybrids
ATP5A1 18q12-q21 9 1 20,090 15 4
ATP synthase, H+ transporting,
mitochondrial F1 complex, alpha
subunit 1, cardiac muscle. This gene
encodes a subunit of mitochondrial
ATP synthase. Involved in ATP
biosynthetic process.
CHR18
TOV21G
down in
hybrids
DYM 18q12-q21.1 10 7 416,908 237 47
Dymeclin. Protein is involved in
normal skeletal development and
brain function.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
TOV21G
down in
hybrids
ENOSF1 18p11.32 11 25 38,729 68 16
Enolase superfamily member 1.
catalytic activity. transferase
activity.
CHR18
TOV21G
down in
hybrids
PQLC1 18q23 12 22 49,131 22 9 PQ loop repeat containing 1.Unknown function.
CHR18
TOV21G
down in
hybrids
LPIN2 18p11.31 13 14 94,954 81 21 Lipin 2. Unknown function.
CHR18
TOV21G
down in
hybrids
SMAD4 18q21.1 14 32 54,803 20 3
SMAD family member 4. Common
mediator of signal transduction by
TGF-beta (transforming growth
factor) superfamily; May act as a
tumor suppressor. Negative
regulation of cell proliferation.
CHR18
TOV21G
down in
hybrids
DSG2 18q12.1 15 12 48,686 51 9
Desmoglein 2. Component of
intercellular desmosome junctions.
Involved in the interaction of plaque
proteins and intermediate filaments
mediating cell-cell adhesion.
CHR18
TOV21G
down in
hybrids
MRLC2 18p11.31 16 2 16,160 12 3
Myosin regulatory light chain
MRLC2. Plays an important role in
regulation of both smooth muscle
and non-muscle cell contractile
activity.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
TOV21G
down in
hybrids
RPL17 18q21 19 13 4,053 5 4
Ribosomal protein L17. This gene
encodes a ribosomal protein that is a
component of the 60S subunit.
Amino acid translation.
CHR18
TOV21G
down in
hybrids
NDUFV2 18p11.31-p11.2 21 4 31,632 22 7
NADH dehydrogenase (ubiquinone)
flavoprotein 2, 24kDa. NADH
dehydrogenase (ubiquinone) activity.
CHR18
TOV21G
down in
hybrids
C18orf10 18q12.2 26 11 33,125 28 8 Hypothetical protein. Unknownfunction
CHR18
TOV21G
down in
hybrids
RPL17 18q21 27 5 Same as above
CHR18
TOV21G up
in hybrids
SDCCAG33 18q22.3 1 19 79,171 79 30
Tee-shirt zinc finger homeobox 1.
May be involved in transcriptional
regulation of developmental
processes.
CHR18
TOV21G up
in hybrids
C18orf22 18q23 2 17 12,035 12 5 rRNA processing. Hypotheticalprotein. Unknown function.
CHR18
TOV21G up
in hybrids
TCF4 18q21.1 3 1 408,217 183 62
Transcription factor-4
(immunoglobulin transcription
factor-2). Transcription factor that
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
binds to the immunoglobulin
enchancer Mu-E5/KE5-motif.
CHR18
TOV21G up
in hybrids
KIAA1632 18q12.3 4 6 119,732 87 14 Hypothetical protein. Unknownfunction
CHR18
TOV21G up
in hybrids
KIAA1012 18q12.1 5 21 113,167 66 11
May play a role in vesicular
transport from endoplasmic
reticulum to Golgi.
CHR18
TOV21G up
in hybrids
MYO5B 18q21 6 7 372,284 519 108 Motor activity. Actin, calmodulinand nucleotide binding protein.
CHR18
TOV21G up
in hybrids
EMILIN2 18p11.3 7 5 67,063 57 39
Elastin microfibril interfacer 2. May
be responsible for anchoring smooth
muscle cells to elastic fibres,
formation of elastic fibres and vessel
assembly regulation.
CHR18
TOV21G up
in hybrids
RALBP1 18p11.3 8 9 Same as above
CHR18
TOV21G up
in hybrids
CYB5 18q23 9 24 38,695 52 9
Cytochrome b5 type A
(microsomal). A membrane bound
hemoprotein which functions as an
electron carrier
CHR18
TOV21G up
in hybrids
RALBP1 18p11.3 10 22 Same as above
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
TOV21G up
in hybrids
ZNF396 18q12 11 16 10,641 13 4
Zinc finger protein 396. Isoforms 1
and 2 act as DNA-dependent
transcriptional repressors.
CHR18
TOV21G up
in hybrids
C18orf12 18q21.1 12 10 Unknown Not onhapmap
Hypothetical protein. Unknown
function.
CHR18
TOV21G up
in hybrids
BCL2 18q21.33|18q21.3 13 12 196,783 189 66
B-cell CLL/lymphoma 2. Regulation
of progression through cell cycle and
apoptosis.
CHR18
TOV21G up
in hybrids
ONECUT2 18q21.1-q21.2 14 3 55,613 67 13
One cut homeobox 2.
Transcriptional activator of target
genes, which include genes involved
in melanocyte and hepatocyte
differentiation.
CHR18
TOV21G up
in hybrids
EPB41L3 18p11.32 15 2 238,253 115 32
Erythrocyte membrane protein band
4.1-like 3. Differentially expressed
in adenocarcinoma of the lung.
Critical growth regulator in the
pathogenesis of meningiomas.
CHR18
TOV21G up
in hybrids
NAPG 18p11.22 16 11 24,342 26 3
N-ethylmaleimide-sensitive factor
attachment protein γ. Required for 
vesicular transport between the
endoplasmic reticulum and the Golgi
apparatus.
CHR18
TOV21G up
in hybrids
TWSG1 18p11.3 18 15 67,568 46 12
Twisted gastrulation homolog 1.
May be involved in dorsoventral axis
formation.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
TOV21G up
in hybrids
LIPG 18q21.1 19 4 30,852 17 8
Lipase, endothelial. The protein
encoded by this gene has substantial
phospholipase activity and may be
involved in lipoprotein metabolism
and vascular biology.
CHR18
TOV21G up
in hybrids
SLC14A2 18q12.1-q21.1 21 8 68,307 88 29
Solute carrier family 14 (urea
transporter), member 2. Mediates
urea transport in kidney.
CHR18
TOV21G up
in hybrids
FBXO15 18q22.3 22 13 74,345 81 9 F-box protein 15. Involved in theubiquitin cycle.
CHR18
TOV21G up
in hybrids
FAM59A 18q12.1 23 14 202,985 165 34 Family with sequence similarity 59,member A. Unknown function.
CHR18 Up
in hybrids
TOV112D
C18orf34 18q12.1 1 2 503,097 334 34
Hypothetical protein. DNA
unwinding during replication (by
similarity. DNA topological change
CHR18 Up
in hybrids
TOV112D
SLC39A6 18q12.2 2 7 20,007 29 7
Solute carrier family 39 (zinc
transporter), member 6. Zinc ion
transporter.
CHR18 Up
in hybrids
TOV112D
NOL4 18q12 3 5 372,458 210 66 Nucleolar protein 4. Transition metalion binding activity.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18 Up
in hybrids
TOV112D
KNTC2 18p11.32 4 4 Same as above
CHR18 Up
in hybrids
TOV112D
IMPACT 18q11.2-q12.1 5 18 26,811 29 8
Impact homolog (mouse). Involved
in ubiquitin cycle and protein
modification process.
CHR18 Up
in hybrids
TOV112D
CCDC5 18q21.1 6 16 Same as above
CHR18 Up
in hybrids
TOV112D
C18orf51 18q22.3 7 1 22,217 35 14 Hypothetical protein. Unknownfunction
CHR18 Up
in hybrids
TOV112D
LOC390773|RPL17 18q21 8 22 Same as above
CHR18 Up
in hybrids
TOV112D
KIAA0863 18q23 9 17 31,318 34 6
ADNP homeobox 2. May be
involved in transcriptional
regulation.
CHR18 Up
in hybrids
TOV112D
NDUFV2 18p11.31-p11.2 10 8 Same as above
CHR18 Up
in hybrids
TOV112D
PTPN2 18p11.3-p11.2 11 14 98,855 48 13
Protein tyrosine phosphatase, non-
receptor type 2. The protein
encoded is member of the protein
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
tyrosine phosphatase (PTP) family.
PTPs are known to regulate a variety
of cellular processes including cell
growth, differentiation, mitotic
cycle, and oncogenic transformation.
CHR18 Up
in hybrids
TOV112D
RBBP8 18q11.2 12 3 93,155 39 4
Retinoblastoma binding protein 8.
The protein a ubiquitously expressed
nuclear protein. Found among
several proteins that bind directly to
retinoblastoma protein, which
regulates cell proliferation. This
protein complexes with
transcriptional co-repressor CTBP. It
is also associated with BRCA1 and
is thought to modulate the functions
of BRCA1 in transcriptional
regulation, DNA repair, and/or cell
cycle checkpoint control. It is
suggested that this gene may itself be
a tumour suppressor acting in the
same pathway as BRCA1.
CHR18 Up
in hybrids
TOV112D
RAB31 18p11.3 13 10 Same as above
CHR18 Up
in hybrids
TOV112D
RPL17 18q21 14 6 Same as above
Appendices
360
List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18 Up
in hybrids
TOV112D
C18orf49 18q21.33 15 13 unknown Not inhapmap
Hypothetical protein. Unknown
function.
CHR18 Up
in hybrids
TOV112D
MIB1 18q11.2 17 15 129,369 31 10
Mindbomb homolog 1. Regulates the
Delta-mediated Notch signaling by
ubiquitinating the intracellular
domain of Delta, leading to
endocytosis of Delta receptors.
CHR18 Up
in hybrids
TOV112D
MRLC2 18p11.31 20 9 Same as above
CHR18 Up
in hybrids
TOV112D
OSBPL1A 18q11.1 21 12 235,782 158 69
Oxysterol binding protein-like 1A.
This gene encodes a member of the
oxysterol-binding protein (OSBP)
family, a group of intracellular lipid
receptors.
CHR18 Up
in hybrids
TOV112D
DYM 18q12-q21.1 23 11 Same as above
CHR18
Down in
hybrids
TOV112D
CDH2 18q11.2 1 1 226,257 303 59
Cadherin 2, type 1, N-cadherin
(neuronal). Encoded protein is a
calcium dependent cell-cell adhesion
glycoprotein. The protein functions
during gastrulation and is required
for establishment of left-right
asymmetry. May be involved in
neuronal recognition mechanism.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
Down in
hybrids
TOV112D
COLEC12 18pter-p11.3 5 2 181,334 288 127
Protein is a scavenger receptor, a cell
surface glycoprotein that can bind to
carbohydrate antigens on
microorganisms facilitating their
recognition and removal. May also
participate in removing oxidatively
damaged or apoptotic cells.
phosphate transport.
CHR18
Down in
hybrids
TOV112D
APCDD1 18p11.22 3 3 34,070 55 16
Adenomatosis polyposis coli down-
regulated 1. May play a role in
colorectal tumorigenesis. May be a
developmental target gene of the
Wnt/β-catenin pathway
CHR18
Down in
hybrids
TOV112D
FAM38B 18p11.22 4 4 26,965 39 13 Family with sequence similarity 38,member B. Unknown function
CHR18
Down in
hybrids
TOV112D
EPB41L3 18p11.32 11 5 Same as above
CHR18
Down in
hybrids
TOV112D
LOC284214 18p11.31 19 6 unknown Not inhapmap
Hypothetical protein. Unknown
function
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
Down in
hybrids
TOV112D
FHOD3 18q12 27 7 482,317 527 141
Formin homology 2 domain
containing 3. Involved in actin
cytoskeleton organization and
biogenesis.
CHR18
Down in
hybrids
TOV112D
KATNAL2 18q21.1 14 8 100,877 51 14 Katanin p60 subunit A-like 2. ATPbinding activity.
CHR18
Down in
hybrids
TOV112D
EPB41L3 18p11.32 20 9 Same as above
CHR18
Down in
hybrids
TOV112D
ZNF532 18q21.32 40 10 Same as above
CHR18
Down in
hybrids
TOV112D
PMAIP1 18q21.32 16 11 4,301 3 3
Phorbol-12-myristate-13-acetate-
induced protein 1. Adult T cell
leukemia-derived PMA-responsive.
CHR18
Down in
hybrids
TOV112D
P15RS 18q12.2 24 12 77,729 41 10
Cyclin-dependent kinase 2B-
inhibitor-related protein. May act as
a negative regulator of cyclin D1
(CCND1) and cyclin E (CCNE1) in
the cell cycle. Up-regulated in cells
overexpressing CDKN2B.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
Down in
hybrids
TOV112D
SMCHD1 18p11.32 15 13 148,281 Not onHapmap
Structural maintenance of
chromosomes flexible hinge domain
containing 1.
CHR18
Down in
hybrids
TOV112D
C18orf17 18q11.2 33 14 140,255 38 20 Hypothetical protein. Unknownfunction
CHR18
Down in
hybrids
TOV112D
NEDD4L 18q21 2 15 353,592 446 116
Neural precursor cell expressed,
developmentally down-regulated 4-
like. Unknown function
CHR18
Down in
hybrids
TOV112D
DSC3 18q12.1 13 19 51,659 84 27
Desmocollin 3. The protein encoded
by this gene is a calcium-dependent
glycoprotein. Found primarily in
epithelial cells, they are required for
cell adhesion and desmosome
formation.
CHR18
Down in
hybrids
TOV112D
PHLPP 18q21.33 7 23 264,933 146 46
PH domain and leucine rich repeat
protein phosphatise. Protein
regulates the balance between cell
survival and apoptosis. May act as a
negative regulator of K-Ras
signalling in the membrane rafts.
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
CHR18
Down in
hybrids
TOV112D
TGIF 18p11.3 8 24 46,338 37 19
TGFB-induced factor homeobox 1.
The protein is an active
transcriptional co-repressor of
SMAD2 and may participate in the
transmission of nuclear signals
during development and in the adult.
Negative regulation of transcription
from RNA polymerase II promoter.
CHR18
Down in
hybrids
TOV112D
YES1 18p11.31-p11.21 10 27 90,740 52 17
V-yes-1 Yamaguchi sarcoma viral
oncogene homolog 1. This gene is
the cellular homolog of the
Yamaguchi sarcoma virus oncogene.
The encoded protein has tyrosine
kinase activity and belongs to the src
family of proteins.
CHR18
Down in
hybrids
TOV112D
YES1 18p11.31-p11.21 6 33 Same as above
CHR18
Down in
hybrids
TOV112D
LOC441805 18p11.32 9 40 Gene record has been discontinued.
CHR18
Down in
hybrids
TOV112D
PTPN2 18p11.3-p11.2 12 51 Same as above
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List Gene Cytoband
21G pval
hybrid
rank
112D pval
hybrid
rank
21G FC*
hybrid
rank
112D FC*
hybrid
rank
Gene
Size (bp)
No.
Criteria
SNPs§
No.
tSNPs Function
Breakpoint
region
TOV112D
OSBPL1A 18q11.1 21 12 Same as above
Breakpoint
region
TOV112D
RBBP8 18q11.2 12 3 93,154 40 4 Same as above
Breakpoint
region
TOV112D
SNRPD1 18q11.2 16 20 18,108 5 1
Small nuclear ribonucleoprotein D1
polypeptide 16kDa. Sm-D
autoantigen. Protein may act as a
charged protein scaffold to promote
SNRNP assembly or strengthen
SNRNP-SNRNP interactions with
RNA.
Breakpoint
region
TOV112D
MIB1 18q11.2 17 15 129,369 31 10 Same as above.
Breakpoint
region
TOV112D
ZNF521 18q11.2 19 19 290,226 220 65
Zinc finger protein 521.
Transcription factor involved in
regulation of transcription.
Breakpoint
region
TOV112D
IMPACT 18q11.2-q12.1 5 18 26,810 29 8
Highly conserved. Unknown
function
* FC - expresion fold change between hybrids and parental; § Criteria SNPs - minor allele frequency ≥ 0.05; Hardy-Weinberg ≥ 0.01
Ranks of differential gene expression of hybrid clones over parental expression: 21G – TOV21G, 112D – TOV112D, pval – P-value,
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Appendix II-A: Genotype distributions of tagging SNPs in BRAF, ERBB2, KRAS, NMI and PIK3CA (by study)
Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
GEOCS 88 157 72 317 98 205 114 417
MALOVA 92 219 132 443 274 582 352 1208
SEARCH 124 372 221 717 173 419 262 854
BRAF rs10487888
USC 57 86 50 193 67 90 58 215
MALOVA 377 58 3 438 1047 150 3 1200
BRAF rs1733832
SEARCH 629 78 4 711 754 88 1 843
GEOCS 174 111 26 311 250 141 21 412
MALOVA 268 151 17 436 681 427 75 1183
SEARCH 416 258 34 708 497 312 43 852
UKOPS 54 35 8 97 129 82 13 224
BRAF rs1267622
USC 106 64 18 188 117 69 23 209
GEOCS 166 124 26 316 202 178 39 419
MALOVA 126 120 28 274 370 322 73 765
SEARCH 316 333 63 712 374 370 108 852
UKOPS 54 31 15 100 112 101 25 238
BRAF rs13241719
USC 106 68 16 190 118 80 16 214
GEOCS 282 30 3 315 364 42 2 408
MALOVA 367 53 1 421 1024 165 5 1194
SEARCH 598 99 3 700 713 105 7 825
UKOPS 86 17 0 103 216 36 0 252
BRAF rs17695623
USC 176 15 4 195 191 30 1 222
BRAF rs17161747 GEOCS 282 34 4 320 373 41 5 419
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Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
MALOVA 371 64 4 439 1065 132 0 1197
SEARCH 647 66 0 713 771 76 4 851
UKOPS 92 5 1 98 215 18 2 235
USC 173 15 2 190 187 18 2 207
GEOCS 239 71 12 322 326 84 8 418
MALOVA 322 111 7 440 884 282 23 1189
SEARCH 526 175 10 711 651 185 17 853
UKOPS 65 26 3 94 169 50 6 225
BRAF rs10281173
USC 140 41 7 188 155 57 8 220
GEOCS 255 62 3 320 318 98 5 421
MALOVA 331 89 12 432 917 234 17 1168
SEARCH 542 163 7 712 646 188 16 850
UKOPS 78 17 1 96 189 46 5 240
BRAF rs17623382
USC 149 41 3 193 179 40 2 221
GEOCS 237 74 12 323 325 86 8 419
MALOVA 318 112 6 436 888 284 24 1196
SEARCH 524 177 10 711 646 185 18 849
UKOPS 61 28 3 92 161 49 5 215
BRAF rs6944385
USC 138 42 6 186 150 55 9 214
GEOCS 182 112 14 308 239 136 29 404
MALOVA 263 159 21 443 700 458 49 1207
SEARCH 391 272 50 713 485 322 44 851
ERBB2 rs2952155
USC 105 78 10 193 117 88 11 216
ERBB2 rs2952156 GEOCS 152 162 0 314 194 219 0 413
Appendices
368
Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
MALOVA 216 186 41 443 581 536 90 1207
SEARCH 323 316 75 714 405 365 83 853
UKOPS 48 49 0 97 94 129 1 224
USC 83 104 0 187 92 124 0 216
GEOCS 190 97 16 303 245 120 19 384
MALOVA 255 162 26 443 695 427 84 1206
SEARCH 408 259 43 710 507 297 40 844
UKOPS 71 31 3 105 159 85 19 263
ERBB2 rs1801200
USC 123 61 10 194 146 64 9 219
GEOCS 267 49 7 323 340 78 3 421
MALOVA 363 78 2 443 990 201 7 1198
SEARCH 599 112 5 716 682 157 14 853
UKOPS 89 13 0 102 205 45 2 252
KRAS rs12305513
USC 158 32 2 192 166 40 5 211
GEOCS 97 147 75 319 127 202 89 418
MALOVA 109 218 110 437 298 599 288 1185
SEARCH 211 347 150 708 250 395 198 843
UKOPS 32 56 16 104 69 122 56 247
KRAS rs12822857
USC 57 75 40 172 65 86 57 208
GEOCS 199 102 21 322 239 157 25 421
MALOVA 247 164 27 438 670 460 65 1195
SEARCH 403 269 43 715 491 304 58 853
KRAS rs10842508
UKOPS 65 33 6 104 146 88 15 249
Appendices
369
Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
USC 107 68 11 186 121 78 18 217
GEOCS 91 150 80 321 113 213 94 420
MALOVA 117 216 104 437 305 586 287 1178
SEARCH 203 343 157 703 237 401 206 844
UKOPS 28 53 19 100 62 126 49 237
KRAS rs12579073
USC 58 91 44 193 62 100 59 221
GEOCS 274 46 4 324 346 74 3 423
MALOVA 362 69 2 433 937 200 15 1152
SEARCH 591 115 5 711 720 121 5 846
UKOPS 78 22 0 100 197 41 4 242
KRAS rs10842513
USC 155 31 5 191 185 29 2 216
GEOCS 238 68 9 315 289 118 6 413
MALOVA 312 115 11 438 841 325 27 1193
SEARCH 496 186 19 701 615 203 19 837
UKOPS 63 26 2 91 161 59 8 228
KRAS rs4623993
USC 147 41 5 193 153 60 7 220
GEOCS 130 141 52 323 171 185 66 422
MALOVA 150 212 73 435 409 563 201 1173
SEARCH 280 324 107 711 343 383 127 853
UKOPS 34 46 9 89 94 108 30 232
KRAS rs6487464
USC 79 87 28 194 85 95 35 215
GEOCS 97 157 67 321 134 195 88 417KRAS rs10842514
MALOVA 144 201 87 432 386 577 208 1171
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Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
SEARCH 213 333 171 717 253 421 178 852
UKOPS 29 48 19 96 77 110 48 235
USC 60 84 37 181 67 97 46 210
GEOCS 271 41 2 314 365 41 1 407
MALOVA 386 54 3 443 1052 147 5 1204KRAS rs11047917
SEARCH 645 62 2 709 741 102 2 845
GEOCS 216 85 3 304 281 110 8 399
MALOVA 321 99 5 425 909 245 11 1165
SEARCH 507 170 8 685 620 198 8 826
UKOPS 69 28 3 100 171 80 3 254
NMI rs394884
USC 132 41 10 183 141 64 4 209
MALOVA 394 41 1 436 1048 141 5 1194
NMI rs11551174
SEARCH 629 78 6 713 762 80 4 846
GEOCS 231 83 3 317 300 107 10 417
MALOVA 328 85 6 419 955 222 15 1192
SEARCH 545 158 9 712 668 176 7 851
UKOPS 69 22 0 91 106 45 0 151
NMI rs289831
USC 84 29 2 115 78 29 1 108
GEOCS 98 166 56 320 164 187 69 420
MALOVA 146 199 92 437 384 584 229 1197
SEARCH 250 327 129 706 294 420 134 848
UKOPS 29 51 21 101 99 120 30 249
NMI rs3771886
USC 66 84 39 189 70 100 43 213
NMI rs11683487 GEOCS 91 123 56 270 111 170 83 364
Appendices
371
Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
MALOVA 140 192 83 415 356 549 257 1162
SEARCH 162 204 124 490 164 321 138 623
UKOPS 32 46 12 90 45 113 40 198
USC 66 87 41 194 78 96 44 218
GEOCS 237 82 2 321 300 106 13 419
MALOVA 340 91 7 438 957 231 14 1202
SEARCH 548 156 9 713 666 174 6 846
UKOPS 75 28 1 104 189 68 1 258
NMI rs2113509
USC 141 44 4 189 162 56 1 219
MALOVA 393 48 0 441 1083 115 0 1198
PIK3CA rs2865084
SEARCH 630 79 0 709 758 83 0 841
GEOCS 211 103 10 324 293 116 10 419
MALOVA 311 114 15 440 814 318 30 1162
SEARCH 487 195 19 701 583 237 23 843
UKOPS 65 14 5 84 130 46 4 180
PIK3CA rs7621329
USC 129 55 6 190 147 62 6 215
GEOCS 243 64 3 310 337 61 7 405
MALOVA 351 71 4 426 956 215 13 1184
SEARCH 580 109 7 696 697 141 7 845
UKOPS 85 14 2 101 209 39 6 254
PIK3CA rs1517586
USC 165 30 0 195 176 41 3 220
GEOCS 157 113 25 295 231 124 37 392
MALOVA 264 144 32 440 658 440 103 1201
PIK3CA rs2699905
SEARCH 392 248 70 710 487 288 72 847
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Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
UKOPS 50 34 8 92 117 53 30 200
USC 126 57 10 193 118 75 23 216
GEOCS 277 46 0 323 360 56 3 419
MALOVA 393 43 3 439 1044 144 8 1196
SEARCH 627 82 6 715 731 115 2 848
UKOPS 87 12 1 100 231 27 1 259
PIK3CA rs7641889
USC 168 22 1 191 192 24 1 217
GEOCS 257 52 3 312 314 82 5 401
MALOVA 348 80 6 434 932 235 15 1182
SEARCH 568 128 12 708 657 186 5 848
UKOPS 79 14 2 95 205 34 0 239
PIK3CA rs7651265
USC 145 43 1 189 179 33 1 213
GEOCS 223 98 1 322 312 102 9 423
MALOVA 335 94 11 440 857 320 26 1203
SEARCH 493 200 19 712 619 202 25 846
UKOPS 65 20 2 87 164 53 10 227
PIK3CA rs7640662
USC 149 39 5 193 155 58 4 217
GEOCS 91 165 59 315 100 203 104 407
MALOVA 98 218 115 431 315 605 268 1188
SEARCH 209 322 179 710 230 416 201 847
UKOPS 23 56 21 100 67 122 72 261
PIK3CA rs2677760
USC 45 104 46 195 62 116 44 222
AA – common homozygous; Aa – heterozygous; aa – rare homozygous;
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Appendix II-B: Genotype distributions of tSNPs in AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8,
RGC32, RUVBL1 and STAG3
Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
MALOVA 406 34 1 441 1053 91 5 1149
SEARCH 768 59 1 828 1123 85 0 1208AIFM2 rs2394655
UKOPS 443 36 3 482 526 39 2 567
MALOVA 352 78 8 438 862 246 19 1127
SEARCH 612 175 20 807 883 275 21 1179AIFM2 rs7908957
UKOPS 363 103 8 474 443 113 11 567
MALOVA 308 42 1 351 767 124 8 899
SEARCH 727 109 7 843 1046 163 11 1220AIFM2 rs1053495
UKOPS 430 70 3 503 504 77 4 585
MALOVA 234 179 30 443 589 405 91 1085
SEARCH 437 333 70 840 600 505 108 1213AIFM2 rs2894111
UKOPS 253 194 40 487 297 223 43 563
MALOVA 303 125 12 440 746 351 37 1134
AIFM2 rs2394656
UKOPS 310 143 20 473 376 167 26 569
AIFM2 rs6480440 MALOVA 259 138 25 422 697 368 75 1140
MALOVA 342 94 6 442 928 212 22 1162
SEARCH 631 187 13 831 925 260 23 1208AIFM2 rs2280201
UKOPS 372 101 9 482 451 118 6 575
MALOVA 373 65 2 440 1017 152 4 1173
SEARCH 695 148 2 845 1032 178 12 1222AIFM2 rs10999147
UKOPS 418 77 5 500 488 78 9 575
MALOVA 383 57 3 443 1043 129 5 1177AIFM2 rs3750772
SEARCH 740 72 3 815 1059 128 3 1190
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Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
UKOPS 435 47 3 485 529 48 0 577
MALOVA 160 198 81 439 423 533 217 1173
SEARCH 284 400 158 842 404 602 204 1210AIFM2 rs4295944
UKOPS 164 238 91 493 201 269 104 574
SEARCH 635 183 14 832 863 231 22 1116
AIFM2 rs2394644
UKOPS 373 108 11 492 438 122 9 569
MALOVA 221 105 14 340 602 241 32 875
SEARCH 535 239 23 797 806 322 41 1169AIFM2 rs10999152
UKOPS 329 135 17 481 401 143 22 566
MALOVA 145 211 85 441 362 553 235 1150
AKTIP rs9931702
UKOPS 149 224 103 476 183 278 111 572
MALOVA 265 78 5 348 670 214 14 898
AKTIP rs17801966
UKOPS 344 128 8 480 426 130 15 571
MALOVA 212 182 45 439 557 471 124 1152
SEARCH 398 354 73 825 538 536 126 1200AKTIP rs7189819
UKOPS 236 190 55 481 275 242 54 571
AKTIP rs3743772 MALOVA 371 40 2 413 971 119 3 1093
MALOVA 114 204 118 436 268 578 298 1144
SEARCH 185 314 141 640 293 456 238 987AXIN2 rs11868547
UKOPS 127 249 107 483 160 297 116 573
MALOVA 175 196 70 441 492 524 157 1173
SEARCH 308 412 117 837 446 512 168 1126AXIN2 rs7591
UKOPS 194 239 68 501 219 277 86 582
MALOVA 274 143 22 439 721 345 43 1109
SEARCH 508 303 27 838 775 383 55 1213AXIN2 rs4074947
UKOPS 297 181 20 498 356 188 32 576
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Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
MALOVA 348 90 2 440 934 225 18 1177
SEARCH 658 173 12 843 972 235 13 1220AXIN2 rs7210356
UKOPS 395 92 7 494 447 125 5 577
SEARCH 448 312 66 826 648 475 83 1206
AXIN2 rs11655966
UKOPS 272 173 30 475 313 228 32 573
SEARCH 203 430 191 824 332 574 296 1202
AXIN2 rs4541111
UKOPS 132 234 107 473 141 289 138 568
MALOVA 173 136 36 345 475 352 69 896
AXIN2 rs4791171
SEARCH 412 351 77 840 619 491 103 1213
AXIN2 rs11079571 SEARCH 573 238 28 839 869 310 27 1206
MALOVA 285 138 17 440 757 332 40 1129
SEARCH 498 289 49 836 741 417 50 1208AXIN2 rs3923087
UKOPS 295 180 29 504 338 203 32 573
MALOVA 171 208 64 443 422 570 165 1157
SEARCH 274 392 160 826 409 585 211 1205AXIN2 rs3923086
UKOPS 166 216 102 484 175 296 102 573
MALOVA 105 225 108 438 369 568 258 1195
CASP5 rs518604
SEARCH 262 411 158 831 375 628 201 1204
CASP5 rs523104 SEARCH 223 424 177 824 330 617 252 1199
MALOVA 365 75 2 442 933 193 22 1148
SEARCH 702 116 11 829 1013 179 14 1206CASP5 rs3181328
UKOPS 398 78 1 477 491 71 9 571
SEARCH 647 146 10 803 930 235 12 1177
CASP5 rs17446518
UKOPS 360 106 22 488 451 97 26 574
MALOVA 363 73 4 440 936 197 9 1142CASP5 rs9651713
SEARCH 634 173 11 818 943 235 11 1189
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Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
UKOPS 367 97 8 472 427 130 10 567
MALOVA 298 128 13 439 774 359 31 1164
CASP5 rs3181175
SEARCH 554 257 32 843 800 379 36 1215
MALOVA 370 68 3 441 986 179 9 1174
SEARCH 729 103 4 836 1036 165 6 1207CASP5 rs3181174
UKOPS 436 63 4 503 508 72 1 581
MALOVA 131 183 37 351 363 416 119 898
SEARCH 363 366 114 843 510 586 123 1219CASP5 rs2282657
UKOPS 214 234 52 500 241 274 65 580
MALOVA 90 236 115 441 235 570 324 1129
SEARCH 167 407 251 825 239 609 346 1194CASP5 rs507879
UKOPS 104 251 147 502 110 249 157 516
MALOVA 188 188 61 437 541 488 137 1166
SEARCH 622 190 13 825 912 261 26 1199FILIP1L rs796977
UKOPS 362 108 8 478 436 123 9 568
MALOVA 145 205 88 438 407 536 216 1159
SEARCH 292 415 135 842 438 582 196 1216FILIP1L rs793446
UKOPS 180 233 80 493 213 274 85 572
MALOVA 379 59 1 439 958 151 6 1115
SEARCH 718 114 4 836 1062 148 9 1219FILIP1L rs3921767
UKOPS 444 51 3 498 453 69 3 525
MALOVA 349 81 9 439 954 200 30 1184
SEARCH 677 162 5 844 979 225 17 1221FILIP1L rs17338680
UKOPS 390 105 8 503 460 116 8 584
MALOVA 265 135 39 439 685 415 66 1166FILIP1L rs9864437
SEARCH 507 300 38 845 739 418 64 1221
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Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
UKOPS 312 161 29 502 372 184 29 585
MALOVA 161 212 67 440 418 534 192 1144
SEARCH 165 241 88 494 270 402 146 818FILIP1L rs6788750
UKOPS 161 239 80 480 186 291 93 570
MALOVA 294 121 19 434 781 314 40 1135
FILIP1L rs12494994
SEARCH 562 260 17 839 845 324 43 1212
MALOVA 352 83 8 443 889 255 15 1159
SEARCH 674 146 9 829 942 251 14 1207RBBP8 rs7239066
UKOPS 365 111 5 481 469 99 6 574
MALOVA 403 37 2 442 1058 96 3 1157
SEARCH 777 50 1 828 1134 72 2 1208RBBP8 rs11082221
UKOPS 432 45 1 478 534 37 1 572
MALOVA 187 197 51 435 444 507 155 1106
SEARCH 342 378 115 835 479 571 165 1215RBBP8 rs4474794
UKOPS 201 229 64 494 230 261 83 574
RBBP8 rs9304261 MALOVA 207 122 17 346 531 291 66 888
MALOVA 344 90 9 443 853 228 18 1099
SEARCH 628 193 16 837 914 282 23 1219RGC32 rs10467472
UKOPS 367 112 10 489 426 131 12 569
MALOVA 272 71 6 349 728 184 8 920
SEARCH 662 171 11 844 951 254 13 1218RGC32 rs3783194
UKOPS 394 102 1 497 465 112 8 585
MALOVA 349 83 8 440 956 201 11 1168
SEARCH 664 168 9 841 971 233 11 1215RGC32 rs11618371
UKOPS 403 82 5 490 459 110 7 576
RGC32 rs9532824 MALOVA 383 59 2 444 929 161 11 1101
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Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
SEARCH 720 119 2 841 1037 178 8 1223
UKOPS 437 58 2 497 506 58 4 568
MALOVA 230 171 35 436 636 451 76 1163
RGC32 rs995845
SEARCH 468 317 53 838 657 467 78 1202
MALOVA 306 120 14 440 771 291 22 1084
SEARCH 630 194 14 838 912 286 21 1219RGC32 rs9594551
UKOPS 339 135 14 488 396 145 19 560
MALOVA 252 169 19 440 658 449 62 1169
SEARCH 474 304 46 824 700 424 72 1196RGC32 rs975590
UKOPS 287 171 27 485 343 196 36 575
MALOVA 341 86 7 434 895 253 22 1170
SEARCH 649 175 19 843 973 233 13 1219RUVBL1 rs9860614
UKOPS 386 107 7 500 457 114 6 577
SEARCH 450 283 55 788 709 383 63 1155
RUVBL1 rs13063604
UKOPS 266 176 36 478 333 202 34 569
MALOVA 163 218 57 438 450 544 171 1165
RUVBL1 rs3732402
SEARCH 290 425 127 842 478 559 180 1217
MALOVA 88 185 76 349 242 423 233 898
SEARCH 206 445 168 819 313 594 297 1204RUVBL1 rs7650365
UKOPS 141 222 114 477 151 270 149 570
MALOVA 237 180 25 442 658 462 69 1189
SEARCH 443 341 60 844 648 482 90 1220RUVBL1 rs4857836
UKOPS 264 195 42 501 306 226 52 584
MALOVA 321 114 5 440 855 271 20 1146
SEARCH 604 190 22 816 866 301 30 1197RUVBL1 rs9821568
UKOPS 344 117 16 477 397 152 19 568
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Number of cases Number of controls
Gene tSNP Study
AA Aa aa Total AA Aa aa Total
MALOVA 266 146 28 440 705 396 64 1165
SEARCH 518 287 39 844 753 412 55 1220STAG3 rs11762932
UKOPS 304 179 20 503 362 192 26 580
SEARCH 218 415 189 822 290 621 286 1197
STAG3 rs2246713
UKOPS 123 248 102 473 162 285 121 568
MALOVA 263 148 29 440 608 472 87 1167
SEARCH 451 324 68 843 612 505 99 1216STAG3 rs1637001
UKOPS 269 193 39 501 321 222 41 584
AA – common homozygous; Aa – heterozygous; aa – rare homozygous;
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Appendix III-A: Genotype specific ratios of BRAF tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR
§ (95% CI) HomOR§ (95% CI) P-trend
1680 All 1.09 (0.93-1.28) 1.02 (0.86-1.22) 0.902
804 Serous 1.21 (0.99-1.49) 1.09 (0.87-1.37) 0.5747
251 Endometrioid 0.84 (0.61-1.17) 0.88 (0.61-1.25) 0.5007
180 Mucinous 1.32 (0.86-2.03) 1.61 (1.03-2.53) 0.0357
BRAF rs10487888 0.47 2694
125 Clear cell 1.04 (0.66-1.64) 0.88 (0.52-1.48) 0.5947
1159 All 1.08 (0.86-1.36) 3.39 (0.96-11.89) 0.1985
525 Serous 1.15 (0.86-1.53) 2.99 (0.66-13.46) 0.1847
182 Endometrioid 1.25 (0.79-1.98) 3.18 (0.33-30.71) 0.2301
135 Mucinous 0.58 (0.29-1.16) 15.23 (3.16-73.29) 0.9086
BRAF rs1733832 0.06 2043
95 Clear cell 1.18 (0.63-2.20) 5.89 (0.62-55.68) 0.335
1751 All 0.99 (0.87-1.12) 0.97 (0.75-1.26) 0.7894
831 Serous 1.04 (0.88-1.22) 0.90 (0.64-1.26) 0.9055
268 Endometrioid 0.76 (0.58-1.01) 1.06 (0.63-1.77) 0.2725
187 Mucinous 0.67 (0.48-0.94) 0.71 (0.35-1.43) 0.0278
BRAF rs1267622 0.24 2880
135 Clear cell 1.24 (0.87-1.78) 1.12 (0.53-2.37) 0.3392
1602 All 0.98 (0.85-1.12) 0.86 (0.69-1.08) 0.2715
733 Serous 1.01 (0.85-1.20) 0.91 (0.68-1.23) 0.7063
246 Endometrioid 0.93 (0.70-1.23) 0.88 (0.56-1.39) 0.5238
176 Mucinous 1.14 (0.82-1.58) 0.98 (0.57-1.67) 0.7484
BRAF rs13241719 0.31 2488
123 Clear cell 0.79 (0.54-1.16) 0.57 (0.28-1.16) 0.0734
1744 All 0.97 (0.81-1.16) 1.14 (0.52-2.46) 0.8642BRAF rs17695623 0.07 2901
829 Serous 1.04 (0.83-1.31) 1.19 (0.45-3.10) 0.6437
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Gene tSNP MAF No.controls
No.
cases Histology HetOR
§ (95% CI) HomOR§ (95% CI) P-trend
264 Endometrioid 0.99 (0.68-1.45) 0.63 (0.08-4.85) 0.8421
186 Mucinous 0.47 (0.26-0.86) 0.79 (0.10-6.08) 0.0191
135 Clear cell 1.25 (0.78-2.03) 1.37 (0.18-10.56) 0.3393
1771 All 1.13 (0.93-1.38) 1.29 (0.57-2.93) 0.1802
847 Serous 1.04 (0.80-1.34) 1.43 (0.53-3.82) 0.5816
272 Endometrioid 1.03 (0.67-1.58) 2.85 (0.91-8.91) 0.3223
191 Mucinous 1.14 (0.70-1.84) 0.96 (0.12-7.47) 0.6521
BRAF rs17161747 0.5 2909
132 Clear cell 1.42 (0.84-2.41) 1.55 (0.20-12.12) 0.1738
1764 All 1.01 (0.87-1.17) 1.01 (0.61-1.66) 0.9035
841 Serous 0.97 (0.80-1.18) 0.98 (0.51-1.86) 0.7935
270 Endometrioid 0.87 (0.64-1.20) 0.22 (0.03-1.62) 0.1391
186 Mucinous 1.08 (0.76-1.55) 1.74 (0.67-4.51) 0.3566
BRAF rs17623382 0.12 2900
134 Clear cell 0.90 (0.58-1.40) 1.86 (0.65-5.30) 0.8512
1758 All 1.14 (0.99-1.32) 0.99 (0.66-1.50) 0.1407
840 Serous 1.25 (1.05-1.50) 0.78 (0.44-1.38) 0.114
268 Endometrioid 0.98 (0.72-1.33) 1.18 (0.53-2.62) 0.9193
187 Mucinous 0.63 (0.42-0.95) 0.88 (0.31-2.47) 0.057
BRAF rs6944385 0.14 2893
133 Clear cell 1.41 (0.96-2.09) 1.54 (0.54-4.34) 0.0691
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common homozygous;
Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross 1.
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Appendix III-B: Haplotype-specific risks of BRAF on ovarian cancer
susceptibility
Gene Haplotype Freq (%) Histology OR (95% CI) P-value
All 1.07 (0.97-1.19) 0.182
Serous 1.07 (0.93-1.24) 0.325
Endometrioid 1 (0.8-1.27) 0.966
Mucinous 1.28 (0.99-1.66) 0.059
BRAF h10000000 21.5
Clear cell 1.24 (0.91-1.69) 0.174
All 0.88 (0.76-1.01) 0.07
Serous 0.99 (0.86-1.15) 0.921
Endometrioid 1.04 (0.82-1.31) 0.769
Mucinous 0.92 (0.69-1.22) 0.547
BRAF h10010000 19.4
Clear cell 0.67 (0.46-0.97) 0.033
All 0.90 (0.78-1.04) 0.15
Serous 0.96 (0.83-1.12) 0.605
Endometrioid 1.06 (0.84-1.35) 0.612
Mucinous 0.98 (0.73-1.31) 0.881
BRAF h00000000 17.3
Clear cell 0.83 (0.57-1.19) 0.303
All 0.96 (0.82-1.12) 0.57
Serous 1.01 (0.85-1.2) 0.931
Endometrioid 0.87 (0.65-1.17) 0.36
Mucinous 1.19 (0.87-1.62) 0.282
BRAF h10010010 11.8
Clear cell 1.03 (0.7-1.51) 0.895
All 0.81 (0.68-0.95) 0.012
Serous 0.8 (0.66-0.98) 0.028
Endometrioid 0.88 (0.64-1.21) 0.439
Mucinous 0.87 (0.59-1.27) 0.463
BRAF h00100000 10.3
Clear cell 0.86 (0.55-1.34) 0.508
All 0.94 (0.78-1.13) 0.49
Serous 1.09 (0.88-1.35) 0.444
Endometrioid 0.99 (0.69-1.42) 0.947
Mucinous 0.54 (0.31-0.93) 0.027
BRAF h00101001 6.8
Clear cell 1.36 (0.87-2.11) 0.175
All 1.15 (0.95-1.39) 0.14
Serous 1.2 (0.97-1.5) 0.095
Endometrioid 1.17 (0.81-1.69) 0.398
Mucinous 0.93 (0.58-1.48) 0.76
BRAF h01100001 6.1
Clear cell 1.32 (0.81-2.16) 0.262
All 1.08 (0.88-1.31) 0.48
Serous 1.11 (0.88-1.4) 0.382
Endometrioid 1.17 (0.81-1.69) 0.405
Mucinous 1.11 (0.7-1.75) 0.661
BRAF h00000100 5.2
Clear cell 1.36 (0.84-2.22) 0.213
All 0.6 (0.4-0.91) 0.007
Serous 0.52 (0.28-0.97) 0.038
Endometrioid 0.52 (0.17-1.61) 0.258
Mucinous 0.87 (0.38-1.99) 0.748
BRAF Rare 0.6
Clear cell 0.73 (0.2-2.62) 0.626
OR - odds ratio, CI - confidence interval; SNP order in haplotype (5’ to 3’) – rs10487888, rs1733832,
rs1267622, rs13241719, rs17695623, rs17161747, rs17623382, rs6944385.
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Appendix III-C: Genotype specific risks of ERBB2 tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR
§ (95% CI) HomOR§ (95% CI) P-trend
1667 All 1.01 (0.89-1.15) 1.11 (0.84-1.47) 0.5745
795 Serous 0.93 (0.79-1.10) 0.97 (0.67-1.40) 0.4832
250 Endometrioid 1.06 (0.81-1.40) 1.26 (0.73-2.20) 0.4297
177 Mucinous 1.32 (0.96-1.81) 1.11 (0.54-2.27) 0.175
ERBB2 rs2952155 0.24 2678
126 Clear cell 0.95 (0.65-1.39) 1.20 (0.56-2.55) 0.9093
1766 All 0.97 (0.86-1.10) 1.15 (0.89-1.49) 0.7416
840 Serous 0.92 (0.79-1.08) 1.24 (0.90-1.72) 0.8924
269 Endometrioid 0.95 (0.73-1.23) 1.05 (0.61-1.78) 0.8719
186 Mucinous 1.25 (0.92-1.71) 0.81 (0.39-1.65) 0.5535
ERBB2 rs2952156 0.29 2912
135 Clear cell 0.89 (0.63-1.28) 0.89 (0.41-1.90) 0.5537
1766 All 1.04 (0.92-1.19) 1.01 (0.77-1.31) 0.6401
847 Serous 1.04 (0.88-1.22) 0.86 (0.60-1.23) 0.8257
263 Endometrioid 1.16 (0.88-1.52) 1.71 (1.05-2.76) 0.0389
188 Mucinous 0.79 (0.57-1.11) 0.82 (0.41-1.66) 0.2007
ERBB2 rs1801200 0.22 2916
134 Clear cell 1.51 (1.05-2.17) 1.30 (0.61-2.76) 0.0564
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common
homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are
statistically significant or do not cross 1.
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Appendix III-D: Haplotype-specific risks of ERBB2 on ovarian cancer
susceptibility
Gene Haplotype Freq (%) Histology OR (95% CI) P-value
All 0.95 (0.87-1.04) 0.284
Serous 0.99 (0.88-1.11) 0.808
Endometrioid 0.85 (0.7-1.04) 0.108
Mucinous 1.03 (0.82-1.3) 0.792
ERBB2 h000 53.6
Clear cell 0.87 (0.67-1.15) 0.331
All 1.19 (1.03-1.37) 0.016
Serous 1 (0.85-1.19) 0.964
Endometrioid 1 (0.75-1.34) 0.982
Mucinous 1.39 (1.02-1.9) 0.036
ERBB2 h110 16.3
Clear cell 0.94 (0.63-1.4) 0.752
All 1.17 (1.02-1.34) 0.022
Serous 1.08 (0.92-1.27) 0.329
Endometrioid 1.25 (0.97-1.62) 0.079
Mucinous 0.88 (0.63-1.23) 0.466
ERBB2 h001 16
Clear cell 1.6 (1.15-2.21) 0.005
All 0.99 (0.82-1.20) 0.9
Serous 1.1 (0.87-1.38) 0.435
Endometrioid 0.86 (0.57-1.3) 0.474
Mucinous 0.63 (0.37-1.1) 0.102
ERBB2 h010 6.6
Clear cell 0.65 (0.34-1.24) 0.193
All 0.84 (0.68-1.05) 0.12
Serous 0.85 (0.64-1.14) 0.275
Endometrioid 1.36 (0.89-2.06) 0.151
Mucinous 0.85 (0.48-1.48) 0.563
ERBB2 h111 6.5
Clear cell 0.85 (0.44-1.64) 0.626
All 0.7 (0.43-1.15) 0.157
Serous 0.46 (0.23-0.95) 0.035
Endometrioid 1.14 (0.48-2.74) 0.761
Mucinous 0.61 (0.14-2.63) 0.507
ERBB2 Rare 5.6
Clear cell 0.93 (0.22-3.92) 0.923
OR - odds ratio, CI - confidence interval; SNP order in haplotype (5’ to 3’) - rs2952155, rs2952156,
rs1801200.
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Appendix III-E: Genotype specific ratios of KRAS tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR
§ (95% CI) HomOR§ (95% CI) P-trend
1788 All 0.87 (0.74-1.03) 0.71 (0.38-1.31) 0.0526
852 Serous 0.86 (0.70-1.06) 0.89 (0.42-1.89) 0.1677
272 Endometrioid 0.75 (0.53-1.07) 0.83 (0.25-2.76) 0.1342
189 Mucinous 0.89 (0.6-1.33) 1.22 (0.36-4.06) 0.7436
KRAS rs12305513 0.1 2934
136 Clear cell 1.06 (0.69-1.65) 0.61 (0.08-4.56) 0.9825
1751 All 1.01 (0.88-1.17) 0.94 (0.80-1.12) 0.5281
835 Serous 1.08 (0.90-1.30) 0.97 (0.78-1.20) 0.8167
268 Endometrioid 0.99 (0.73-1.33) 1.06 (0.75-1.50) 0.7605
187 Mucinous 0.74 (0.53-1.04) 0.63 (0.41-0.96) 0.0232
KRAS rs12822857 0.47 2901
132 Clear cell 1.14 (0.75-1.74) 1.04 (0.63-1.72) 0.8398
1776 All 0.97 (0.86-1.10) 0.95 (0.73-1.22) 0.5789
841 Serous 0.95 (0.81-1.12) 1.03 (0.74-1.41) 0.7882
273 Endometrioid 1.05 (0.80-1.37) 1.26 (0.77-2.05) 0.4115
190 Mucinous 0.93 (0.68-1.27) 0.46 (0.20-1.06) 0.1345
KRAS rs10842508 0.25 2935
136 Clear cell 0.93 (0.64-1.34) 1.12 (0.57-2.21) 0.9696
1765 All 0.97 (0.84-1.12) 0.92 (0.78-1.09) 0.3591
836 Serous 1.01 (0.84-1.22) 0.88 (0.70-1.10) 0.2746
269 Endometrioid 0.95 (0.70-1.28) 1.02 (0.72-1.44) 0.9418
190 Mucinous 0.72 (0.51-1.01) 0.74 (0.49-1.10) 0.1074
KRAS rs12579073 0.48 2900
135 Clear cell 1.29 (0.84-2.01) 1.32 (0.80-2.18) 0.2772
1770 All 1.03 (0.87-1.21) 0.93 (0.50-1.74) 0.8581
846 Serous 0.91 (0.74-1.13) 0.91 (0.41-2.01) 0.4011
KRAS rs10842513 0.09 2878
271 Endometrioid 1.28 (0.93-1.77) 0.86 (0.20-3.67) 0.2085
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Gene tSNP MAF No.controls
No.
cases Histology HetOR
§ (95% CI) HomOR§ (95% CI) P-trend
187 Mucinous 1.04 (0.69-1.57) 0.62 (0.08-4.66) 0.9898
137 Clear cell 1.26 (0.81-1.95) 1.77 (0.41-7.57) 0.2217
1748 All 0.96 (0.83-1.10) 1.13 (0.77-1.67) 0.845
834 Serous 0.93 (0.77-1.11) 1.06 (0.64-1.76) 0.5753
268 Endometrioid 1.17 (0.88-1.53) 1.21 (0.54-2.69) 0.2623
187 Mucinous 0.73 (0.50-1.06) 1.07 (0.42-2.72) 0.2037
KRAS rs4623993 0.16 2892
132 Clear cell 0.80 (0.52-1.23) 2.55 (1.18-5.50) 0.5715
1763 All 1.04 (0.91-1.18) 0.99 (0.82-1.19) 0.9408
836 Serous 1.09 (0.92-1.29) 0.98 (0.77-1.24) 0.8783
269 Endometrioid 1.13 (0.86-1.5) 1.15 (0.79-1.67 0.3878
192 Mucinous 0.61 (0.44-0.85) 0.76 (0.50-1.18) 0.0379
KRAS rs6487464 0.38 2895
136 Clear cell 1.02 (0.70-1.48) 0.95 (0.56-1.61) 0.8918
1757 All 0.98 (0.86-1.13) 1.08 (0.91-1.29) 0.4153
835 Serous 1.04 (0.87-1.24) 1.09 (0.88-1.36) 0.4379
269 Endometrioid 0.85 (0.64-1.13) 0.97 (0.68-1.38) 0.7294
188 Mucinous 1.13 (0.78-1.64) 2.02 (1.35-3.01) 0.0006
KRAS rs10842514 0.44 2886
134 Clear cell 0.95 (0.64-1.40) 0.79 (0.47-1.33) 0.4026
1476 All 0.92 (0.75-1.14) 1.62 (0.57-4.57) 0.7116
685 Serous 0.99 (0.76-1.29) 1.91 (0.57-6.40) 0.7757
231 Endometrioid 0.68 (0.42-1.11) 1.4 (0.17-11.64) 0.171
163 Mucinous 0.76 (0.44-1.32) 1.97 (0.24-16.40) 0.4739
KRAS rs11047917 0.06 2456
118 Clear cell 1.20 (0.69-2.06) 2.87 (0.35-23.69) 0.354
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common
homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically
significant or do not cross 1.
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Appendix III-F: Haplotype-specific risks of KRAS on ovarian cancer
susceptibility
Gene/
haplotype
block
Haplotype Freq (%) Histology OR (95% CI) P-value
All 1.02 (0.94-1.11) 0.66
Serous 1.01 (0.9-1.12) 0.894
Endometrioid 0.92 (0.77-1.1) 0.366
Mucinous 1.23 (0.99-1.52) 0.061
KRAS
haplotype
block 1
h100 52.1
Clear cell 0.97 (0.76-1.24) 0.81
All 1.00 (0.9 – 1.11) 0.99
Serous 1.03 (0.9-1.18) 0.643
Endometrioid 1.04 (0.84-1.29) 0.736
Mucinous 0.92 (0.71-1.2) 0.53
KRAS
haplotype
block 1
h000 22.8
Clear cell 1.13 (0.84-1.52) 0.406
All 1.03 (0.91 – 1.16) 0.67
Serous 1.04 (0.89-1.22) 0.591
Endometrioid 1.25 (0.98-1.59) 0.068
Mucinous 0.79 (0.57-1.09) 0.152
KRAS
haplotype
block 1
h001 15.1
Clear cell 0.98 (0.69-1.4) 0.917
All 0.89 (0.77 – 1.04) 0.15
Serous 0.88 (0.72-1.07) 0.195
Endometrioid 0.85 (0.62-1.18) 0.329
Mucinous 0.9 (0.62-1.31) 0.584
KRAS
haplotype
block 1
h101 9.5
Clear cell 0.9 (0.58-1.4) 0.652
All 0.43 (0.17-1.06) 0.0465
Serous 0.54 (0.19-1.55) 0.253
Endometrioid 0.53 (0.08-3.74) 0.527
Mucinous 0.7 (0.09-5.2) 0.724
KRAS
haplotype
block 1
Rare 0.1
Clear cell 0.02 (0-19174) 0.587
All 1.04 (0.95-1.15) 0.389
Serous 1.07 (0.94-1.21) 0.306
Endometrioid 0.99 (0.81-1.21) 0.916
Mucinous 1.3 (1.03-1.64) 0.025
KRAS
haplotype
block 2
h000010 30.6
Clear cell 0.79 (0.59-1.06) 0.121
All 1.00 (0.85-1.17) 0.98
Serous 0.97 (0.82-1.16) 0.772
Endometrioid 1 (0.72-1.37) 0.979
Mucinous 1.37 (0.99-1.89) 0.058
KRAS
haplotype
block 2
h100010 12.9
Clear cell 1.07 (0.71-1.62) 0.74
All 1.03 (0.88-1.19) 0.75
Serous 1.08 (0.9-1.3) 0.381
Endometrioid 1.16 (0.88-1.53) 0.301
Mucinous 0.78 (0.54-1.13) 0.195
KRAS
haplotype
block 2
h100100 11.9
Clear cell 0.87 (0.57-1.33) 0.521
All 0.98 (0.84-1.14) 0.77
Serous 0.96 (0.8-1.16) 0.703
KRAS
haplotype
block 2
h101100 10.6
Endometrioid 1.15 (0.86-1.53) 0.337
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Gene/
haplotype
block
Haplotype Freq (%) Histology OR (95% CI) P-value
Mucinous 0.75 (0.51-1.1) 0.143
Clear cell 1.21 (0.82-1.79) 0.326
All 1.01 (0.82-1.25) 0.91
Serous 0.92 (0.7-1.2) 0.526
Endometrioid 1.11 (0.74-1.66) 0.629
Mucinous 0.78 (0.45-1.35) 0.375
KRAS
haplotype
block 2
h010000 5.5
Clear cell 1.36 (0.8-2.29) 0.254
All 0.92 (0.73-1.18) 0.52
Serous 0.91 (0.68-1.2) 0.487
Endometrioid 1.09 (0.66-1.82) 0.731
Mucinous 1.09 (0.61-1.95) 0.775
KRAS
haplotype
block 2
h000100 5.4
Clear cell 1.13 (0.59-2.16) 0.708
All 0.81 (0.65-1.01) 0.06
Serous 0.8 (0.6-1.07) 0.136
Endometrioid 0.68 (0.42-1.11) 0.123
Mucinous 0.61 (0.33-1.12) 0.11
KRAS
haplotype
block 2
h100000 5.4
Clear cell 1.07 (0.6-1.92) 0.817
All 0.96 (0.74-1.24) 0.74
Serous 0.95 (0.7-1.29) 0.759
Endometrioid 1 (0.57-1.78) 0.988
Mucinous 1.15 (0.62-2.12) 0.664
KRAS
haplotype
block 2
h001100 4.7
Clear cell 0.66 (0.26-1.65) 0.369
All 0.82 (0.64-1.05) 0.11
Serous 0.92 (0.66-1.27) 0.616
Endometrioid 0.82 (0.48-1.38) 0.45
Mucinous 0.94 (0.53-1.69) 0.845
KRAS
haplotype
block 2
h100101 4.3
Clear cell 1.33 (0.71-2.46) 0.371
All 0.94 (0.70-1.27) 0.69
Serous 0.78 (0.53-1.16) 0.224
Endometrioid 1.16 (0.63-2.16) 0.633
Mucinous 1.12 (0.54-2.35) 0.761
KRAS
haplotype
block 2
h110000 3.2
Clear cell 1.68 (0.84-3.36) 0.139
All 0.89 (0.64-1.23) 0.48
Serous 1.08 (0.75-1.58) 0.67
Endometrioid 0.36 (0.14-0.92) 0.033
Mucinous 0.3 (0.09-0.99) 0.049
KRAS
haplotype
block 2
h000000 3.1
Clear cell 0.61 (0.21-1.78) 0.365
All 1.27 (0.93-1.73) 0.131
Serous 1.55 (1.09-2.2) 0.014
Endometrioid 0.93 (0.42-2.07) 0.861
Mucinous 0.83 (0.31-2.23) 0.712
KRAS
haplotype
block 2
Rare 1.7
Clear cell 1.14 (0.44-2.96) 0.793
OR - odds ratio, CI - confidence interval; SNP order in haplotype (5’ to 3’) haplotype block 1 -
rs12305513, rs12822857, rs10842508; haplotype block 2 - rs12579073, rs10842513, rs4623993,
rs6487464, rs10842514, rs11047917.
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Appendix III-G: Genotype specific risks of NMI tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR
§ (95% CI) HomOR§ (95% CI) P-trend
1708 All 1.01 (0.88-1.17) 1.40 (0.84-2.32) 0.474
809 Serous 0.98 (0.81-1.18) 1.56 (0.85-2.87) 0.6587
260 Endometrioid 1.01 (0.75-1.36) 1.97 (0.81-4.82) 0.4804
184 Mucinous 0.98 (0.69-1.39) 0.45 (0.06-3.31) 0.6601
NMI rs394884 0.15 2852
129 Clear cell 1.26 (0.85-1.86) 0.68 (0.09-5.03) 0.3847
1159 All 0.96 (0.76-1.23) 1.23 (0.45-3.38) 0.9163
524 Serous 0.90 (0.65-1.24) 1.23 (0.33-4.58) 0.6308
185 Endometrioid 1.25 (0.78-1.99) 1.18 (0.14-9.63) 0.3592
133 Mucinous 1.05 (0.59-1.87) 1.61 (0.20-13.17) 0.7416
NMI rs11551174 0.06 2040
95 Clear cell 0.69 (0.31-1.51) 2.41 (0.30-19.70) 0.608
1665 All 1.05 (0.91-1.22) 1.08 (0.61-1.89) 0.4843
792 Serous 1.04 (0.86-1.27) 1.47 (0.78-2.79) 0.3594
258 Endometrioid 1.13 (0.84-1.53) 1.07 (0.32-3.58) 0.4472
176 Mucinous 0.89 (0.61-1.31) 0.48 (0.06-3.53) 0.4077
NMI rs289831 0.13 2718
132 Clear cell 1.23 (0.82-1.84) 0.71 (0.09-5.26) 0.448
1764 All 1.03 (0.90-1.18) 1.19 (1.00-1.42) 0.0753
843 Serous 1.10 (0.92-1.31) 1.25 (1.00-1.56) 0.0546
266 Endometrioid 0.85 (0.65-1.12) 0.85 (0.58-1.24) 0.2876
191 Mucinous 1.02 (0.73-1.43) 1.51 (1.01-2.27) 0.0747
NMI rs3771886 0.41 2927
132 Clear cell 0.92 (0.62-1.35) 0.90 (0.53-1.53) 0.6514
1464 All 0.80 (0.69-0.93) 0.87 (0.71-1.02) 0.0379
713 Serous 0.81 (0.67-0.98) 0.80 (0.63-1.01) 0.0377
NMI rs11683487 0.46 2564
227 Endometrioid 0.82 (0.59-1.13) 1.09 (0.75-1.57) 0.7567
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Gene tSNP MAF No.controls
No.
cases Histology HetOR
§ (95% CI) HomOR§ (95% CI) P-trend
154 Mucinous 0.67 (0.47-0.96) 0.62 (0.39-0.99) 0.0269
107 Clear cell 0.97 (0.62-1.52) 0.90 (0.52-1.57) 0.7186
1776 All 1.05 (0.91-1.21) 1.16 (0.68-1.97) 0.4222
843 Serous 1.03 (0.86-1.25) 1.37 (0.73-2.57) 0.457
272 Endometrioid 1.21 (0.91-1.62) 1.02 (0.31-3.38) 0.2417
190 Mucinous 0.90 (0.62-1.31) 1.38 (0.42-4.61) 0.8066
NMI rs2113509 0.13 2944
138 Clear cell 1.21 (0.81-1.79) 0.65 (0.09-4.82) 0.5121
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common
homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are
statistically significant or do not cross 1.
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Appendix III-H: Haplotype-specific risks of NMI on ovarian cancer
susceptibility
Gene Haplotype Freq (%) Histology OR (95% CI) P-value
All 0.91 (0.84-0.99) 0.027
Serous 0.89 (0.8-1) 0.048
Endometrioid 1.05 (0.87-1.25) 0.631
Mucinous 0.84 (0.68-1.05) 0.128
NMI h00001 45.9
Clear cell 0.96 (0.74-1.23) 0.729
All 1.11 (1.003-1.22) 0.043
Serous 1.13 (1.01-1.28) 0.041
Endometrioid 0.9 (0.74-1.1) 0.305
Mucinous 1.11 (0.88-1.4) 0.361
NMI h00010 33.7
Clear cell 0.97 (0.74-1.28) 0.832
All 1.09 (0.95-1.25) 0.22
Serous 1.04 (0.87-1.23) 0.686
Endometrioid 1.14 (0.87-1.5) 0.346
Mucinous 1 (0.71-1.4) 0.979
NMI h10100 11.8
Clear cell 1.06 (0.72-1.57) 0.774
All 1.05 (0.84-1.3) 0.67
Serous 0.98 (0.73-1.32) 0.915
Endometrioid 1.01 (0.63-1.63) 0.951
Mucinous 1.23 (0.75-2.03) 0.418
NMI h01010 5.7
Clear cell 0.85 (0.43-1.69) 0.643
All 1.11 (0.87-1.43) 0.399
Serous 0.94 (0.66-1.33) 0.713
Endometrioid 0.85 (0.47-1.56) 0.607
Mucinous 1.4 (0.78-2.51) 0.257
NMI Rare 1.9
Clear cell 1.7 (0.9-3.19) 0.101
OR - odds ratio, CI - confidence interval; SNP order in haplotype (5’ to 3’) - rs394884, rs11551174,
rs289831, rs3771886, rs11683487.
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Appendix III-I: Genotype specific risks of PIK3CA tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR
§ (95% CI) HomOR§ (95% CI) P-trend
1164 All 1.14 (0.89-1.45) 0.43 (0.37-0.50) 0.294
525 Serous 1.13 (0.83-1.55) 0.77 (0.63-0.93) 0.4279
183 Endometrioid 1.60 (1.03-2.50) 0.30 (0.22-0.42) 0.0344
135 Mucinous 1.32 (0.77-2.25) 0.32 (0.22-0.46) 0.3093
PIK3CA rs2865084 0.06 2046
95 Clear cell 0.51 (0.21-1.28) 0.37 (0.24-0.57) 0.1465
1749 All 0.99 (0.86-1.13) 1.23 (0.86-1.77) 0.6387
834 Serous 1.04 (0.88-1.24) 1.59 (1.04-2.43) 0.1222
268 Endometrioid 0.95 (0.71-1.27) 1.44 (0.73-2.87) 0.7763
186 Mucinous 0.90 (0.64-1.27) 0.39 (0.09-1.60) 0.2353
PIK3CA rs7621329 0.16 2818
135 Clear cell 1.05 (0.71-1.54) 0.57 (0.14-2.37) 0.826
1739 All 0.98 (0.83-1.15) 0.77 (0.42-1.40) 0.5448
827 Serous 0.98 (0.79-1.20) 0.78 (0.36-1.70) 0.6412
267 Endometrioid 0.90 (0.64-1.28) 0.62 (0.15-2.61) 0.4212
183 Mucinous 1.16 (0.79-1.71) 0.49 (0.07-3.64) 0.7202
PIK3CA rs1517586 0.1 2908
134 Clear cell 0.82 (0.50-1.35) 1.22 (0.29-5.16) 0.5886
1741 All 1.01 (0.88-1.15) 0.89 (0.71-1.11) 0.4877
825 Serous 1.00 (0.84-1.18) 0.84 (0.63-1.13) 0.4006
266 Endometrioid 0.97 (0.73-1.28) 1.08 (0.70-1.67) 0.8835
184 Mucinous 1.09 (0.80-1.50) 0.72 (0.39-1.33) 0.65
PIK3CA rs2699905 0.27 2855
135 Clear cell 1.02 (0.70-1.48) 1.04 (0.57-1.90) 0.893
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Gene tSNP MAF No.controls
No.
cases Histology HetOR
§ (95% CI) HomOR§ (95% CI) P-trend
1779 All 0.89 (0.74-1.07) 1.28 (0.58-2.84) 0.377
845 Serous 0.90 (0.71-1.14) 2.22 (0.96-5.14) 0.989
273 Endometrioid 0.75 (0.50-1.14) 0.78 (0.10-6.05) 0.1854
192 Mucinous 0.88 (0.56-1.40) 1.14 (0.15-8.78) 0.655
PIK3CA rs7641889 0.07 2939
136 Clear cell 1.04 (0.63-1.74) 1.68 (0.22-12.93) 0.741
1794 All 0.89 (0.76-1.04) 1.58 (0.89-2.80) 0.5447
828 Serous 0.89 (0.73-1.09) 2.08 (1.09-3.98) 0.9988
267 Endometrioid 0.90 (0.65-1.24) 1.80 (0.61-5.31) 0.8684
189 Mucinous 0.89 (0.61-1.30) 0.63 (0.08-4.69) 0.4749
PIK3CA rs7651265 0.1 2883
136 Clear cell 0.98 (0.64-1.51) 0.90 (0.12-6.78) 0.9072
1765 All 1.02 (0.89-1.17) 0.85 (0.57-1.27) 0.8572
842 Serous 0.99 (0.83-1.18) 0.58 (0.31-1.07) 0.3077
268 Endometrioid 1.15 (0.87-1.54) 1.46 (0.74-2.91) 0.1748
188 Mucinous 1.02 (0.73-1.44) 0.61 (0.19-1.96) 0.7189
PIK3CA rs7640662 0.15 2916
135 Clear cell 1.04 (0.69-1.55) 1.41 (0.55-3.58) 0.5889
1762 All 1.01 (0.87-1.16) 1.04 (0.88-1.23) 0.663
836 Serous 0.92 (0.76-1.10) 0.96 (0.77-1.19) 0.6718
268 Endometrioid 1.08 (0.80-1.47) 1.02 (0.71-1.46) 0.9136
189 Mucinous 1.29 (0.89-1.89) 1.37 (0.89-2.11) 0.1488
PIK3CA rs2677760 0.49 2925
134 Clear cell 1.03 (0.68-1.56) 0.90 (0.55-1.49) 0.7044
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common homozygous; Emboldened
tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross 1.
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Appendix III-J: Haplotype-specific risks of PIK3CA on ovarian cancer
susceptibility
Gene Haplotype Freq (%) Histology OR (95% CI) P-value
All 1.02 (0.93-1.11) 0.713
Serous 0.99 (0.89-1.11) 0.866
Endometrioid 1.01 (0.84-1.21) 0.914
Mucinous 1.17 (0.95-1.45) 0.146
PIK3CA h00000001 48.2
Clear cell 0.98 (0.76-1.26) 0.871
All 1.01 (0.89-1.14) 0.91
Serous 0.95 (0.81-1.11) 0.543
Endometrioid 1.13 (0.89-1.45) 0.31
Mucinous 0.93 (0.69-1.26) 0.649
PIK3CA h00010010 14.8
Clear cell 1.08 (0.77-1.51) 0.67
All 0.94 (0.81-1.09) 0.39
Serous 1 (0.83-1.2) 0.996
Endometrioid 0.82 (0.59-1.13) 0.223
Mucinous 0.85 (0.59-1.25) 0.414
PIK3CA h00000000 10.2
Clear cell 1.1 (0.73-1.65) 0.657
All 0.98 (0.84-1.14) 0.79
Serous 0.97 (0.81-1.17) 0.782
Endometrioid 0.86 (0.63-1.19) 0.374
Mucinous 1.08 (0.76-1.53) 0.664
PIK3CA h00110000 9.7
Clear cell 0.89 (0.58-1.38) 0.612
All 0.94 (0.79-1.12) 0.5
Serous 0.98 (0.79-1.23) 0.881
Endometrioid 0.84 (0.57-1.24) 0.372
Mucinous 0.81 (0.51-1.29) 0.369
PIK3CA h01001100 6.6
Clear cell 1.02 (0.62-1.68) 0.932
All 1.02 (0.82-1.28) 0.84
Serous 1.06 (0.8-1.4) 0.698
Endometrioid 0.98 (0.61-1.58) 0.932
Mucinous 0.82 (0.45-1.5) 0.522
PIK3CA h01000100 4
Clear cell 1.17 (0.63-2.16) 0.625
All 1.20 (0.97-1.48) 0.102
Serous 1.29 (0.99-1.67) 0.055
Endometrioid 1.49 (1-2.22) 0.049
Mucinous 1.07 (0.63-1.82) 0.795
PIK3CA h11000000 3.9
Clear cell 0.91 (0.47-1.79) 0.793
All 0.94 (0.73-1.21) 0.633
Serous 0.96 (0.69-1.33) 0.795
Endometrioid 1.07 (0.68-1.68) 0.786
Mucinous 0.66 (0.27-1.58) 0.345
PIK3CA Rare 1.6
Clear cell 0.71 (0.27-1.9) 0.499
OR - odds ratio, CI - confidence interval; SNP order in haplotype (5’ to 3’) – rs2865084, rs7621329,
rs1517586, rs2699905, rs7641889, rs7651265, rs7640662, rs2677760.
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Appendix IV-A: Genotype specific ratios of AIFM2 tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
1751 All 1.01 (0.80-1.27) 1.37 (0.42-4.42) 0.7773
827 Serous 1.12 (0.84-1.49) 1.03 (0.21-5.04) 0.4297
269 Endometrioid 0.65 (0.36-1.16) 2.21 (0.26-18.68) 0.2592
189 Mucinous 1.11 (0.64-1.94) 4.09 (0.48-35.13) 0.4945
AIFM2 rs2394655 0.04 2924
164 Clear cell 1.53 (0.90-2.58) 3.71 (0.44-31.65) 0.064
1719 All 0.92 (0.79-1.07) 1.13 (0.73-1.75) 0.5342
817 Serous 0.91 (0.75-1.11) 0.91 (0.50-1.67) 0.3812
264 Endometrioid 0.71 (0.50-1.00) 2.06 (1.01-4.18) 0.5702
184 Mucinous 1.03 (0.71-1.48) 1.84 (0.75-4.49) 0.4123
AIFM2 rs7908957 0.13 2873
159 Clear cell 1.21 (0.84-1.76) 1.05 (0.32-3.44) 0.3951
1697 All 0.97 (0.81-1.16) 0.72 (0.35-1.51) 0.457
790 Serous 0.96 (0.75-1.21) 0.88 (0.35-2.18) 0.6293
267 Endometrioid 0.64 (0.41-0.98) 0.84 (0.19-3.65) 0.0622
185 Mucinous 1.11 (0.71-1.71) 0.52 (0.06-4.13) 0.9899
AIFM2 rs1053495 0.07 2704
156 Clear cell 1.38 (0.89-2.12) 1.51 (0.35-6.57) 0.1241
1770 All 0.99 (0.87-1.13) 0.93 (0.74-1.16) 0.5545
835 Serous 1.02 (0.87-1.20) 0.86 (0.64-1.17) 0.5896
276 Endometrioid 0.87 (0.67-1.14) 1.26 (0.82-1.94) 0.8942
192 Mucinous 1.04 (0.76-1.42) 1.03 (0.59-1.80) 0.8834
AIFM2 rs2894111 0.28 2861
164 Clear cell 1.13 (0.81-1.57) 1.27 (0.73-2.22) 0.3776
913 All 0.96 (0.80-1.15) 0.85 (0.55-1.34) 0.4114
506 Serous 0.93 (0.75-1.17) 0.85 (0.50-1.47) 0.3965
AIFM2 rs2394656 0.19 1703
136 Endometrioid 0.91 (0.61-1.35) 0.87 (0.33-2.26) 0.5861
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Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
85 Mucinous 1.11 (0.69-1.77) 0.58 (0.14-2.44) 0.9529
78 Clear cell 1.13 (0.69-1.86) 0.99 (0.30-3.31) 0.7857
422 All 1.01 (0.79-1.29) 0.88 (0.55-1.42) 0.7992
261 Serous 1.07 (0.80-1.43) 0.75 (0.40-1.39) 0.8126
56 Endometrioid 0.66 (0.35-1.27) 1.50 (0.61-3.69) 0.9252
42 Mucinous 1.20 (0.62-2.33) 1.56 (0.52-4.64) 0.3371
AIFM2 rs6480440 0.24 1140
28 Clear cell 1.14 (0.52-2.53) 0.55 (0.07-4.17) 0.8263
1313 All 1.05 (0.88-1.25) 0.96 (0.53-1.71) 0.59
556 Serous 1.11 (0.88-1.40) 0.97 (0.44-2.12) 0.5089
216 Endometrioid 1.03 (0.73-1.47) 1.72 (0.67-4.42) 0.3743
195 Mucinous 1.03 (0.67-1.60) 1.01 (0.24-4.32) 0.9688
AIFM2 rs2280201 0.12 1783
164 Clear cell 1.39 (0.97-1.99) 0.40 (0.05-2.93) 0.2643
1285 All 1.25 (1.03-1.51) 0.48 (0.16-1.47) 0.2055
600 Serous 1.13 (0.88-1.46) 0.79 (0.23-2.75) 0.6396
277 Endometrioid 1.07 (0.75-1.52) 0.37 (0.05-2.74) 0.8708
194 Mucinous 0.87 (0.56-1.36) 1.17 (0.27-5.02) 0.606
AIFM2 rs10999147 0.09 2395
165 Clear cell 1.43 (0.95-2.15) 0.64 (0.09-4.81) 0.2092
1743 All 1.02 (0.83-1.24) 2.28 (0.86-6.04) 0.54
831 Serous 1.12 (0.88-1.44) 3.43 (1.23-9.58) 0.1043
266 Endometrioid 1.14 (0.76-1.71) 2.63 (0.32-21.75) 0.4623
186 Mucinous 0.81 (0.47-1.41) 3.02 (0.36-25.58) 0.5111
AIFM2 rs3750772 0.06 2944
163 Clear cell 1.07 (0.63-1.80) 2.96 (0.36-24.53) 0.6195
1335 All 0.98 (0.83-1.15) 1.09 (0.88-1.34) 0.4913
567 Serous 0.95 (0.77-1.18) 1.11 (0.84-1.46) 0.6042
220 Endometrioid 0.87 (0.64-1.20) 0.88 (0.57-1.35) 0.3373
AIFM2 rs4295944 0.42 1784
149 Mucinous 1.18 (0.78-1.79) 1.50 (0.90-2.50) 0.1196
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Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
133 Clear cell 0.81 (0.55-1.20) 0.86 (0.51-1.44) 0.413
1324 All 1.05 (0.88-1.26) 1.03 (0.60-1.79) 0.5245
561 Serous 1.02 (0.80-1.29) 1.11 (0.55-2.25) 0.7103
218 Endometrioid 1.13 (0.80-1.59) 1.64 (0.67-4.03) 0.1308
149 Mucinous 0.64 (0.39-1.06) 0.42 (0.06-3.15) 0.0727
AIFM2 rs2394644 0.13 1685
133 Clear cell 1.45 (0.97-2.16) 1.44 (0.43-4.83) 0.073
1618 All 1.14 (0.99-1.32) 0.96 (0.68-1.36) 0.2066
760 Serous 1.17 (0.98-1.40) 1.01 (0.65-1.57) 0.2171
251 Endometrioid 1.18 (0.88-1.58) 1.51 (0.82-2.78) 0.0767
170 Mucinous 0.83 (0.57-1.20) 0.50 (0.15-1.61) 0.1659
AIFM2 rs10999152 0.18 2610
153 Clear cell 1.46 (1.03-2.08) 1.22 (0.52-2.87) 0.0666
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with
common homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR
are statistically significant or do not cross 1.
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Appendix IV-B: Haplotype-specific risks of AIFM2 on ovarian cancer
susceptibility
Gene
(haplotype
Haplotype Freq (%) Histology OR (95% CI) P-value
All 1.04 (0.9-1.2) 0.602
Serous 1.05 (0.93-1.18) 0.465
Endometrioid 0.99 (0.82-1.2) 0.941
Mucinous 1 (0.8-1.24) 0.966
AIFM2
(haplotype
block 1)
h0000000 69.8
Clear cell 0.95 (0.75-1.21) 0.672
All 1.22 (0.94-1.59) 0.13
Serous 1.11 (0.9-1.37) 0.348
Endometrioid 1.15 (0.82-1.61) 0.418
Mucinous 1.25 (0.85-1.84) 0.253
AIFM2
(haplotype
block 1)
h0001011 6.5
Clear cell 1.44 (0.97-2.14) 0.073
All 1 (0.71-1.42) 0.997
Serous 1.11 (0.84-1.47) 0.458
Endometrioid 0.74 (0.43-1.27) 0.272
Mucinous 1.11 (0.64-1.9) 0.714
AIFM2
(haplotype
block 1)
h1111110 4.2
Clear cell 1.5 (0.89-2.51) 0.127
All 0.8 (0.54-1.17) 0.241
Serous 0.91 (0.67-1.24) 0.537
Endometrioid 1.16 (0.74-1.83) 0.511
Mucinous 0.97 (0.55-1.72) 0.919
AIFM2
(haplotype
block 1)
h0001100 3.5
Clear cell 0.88 (0.46-1.66) 0.689
All 0.98 (0.66-1.46) 0.929
Serous 1.02 (0.74-1.42) 0.885
Endometrioid 1.09 (0.65-1.8) 0.751
Mucinous 0.76 (0.38-1.52) 0.43
AIFM2
(haplotype
block 1)
h0001010 2.8
Clear cell 0.76 (0.36-1.59) 0.463
All 1.06 (0.7-1.6) 0.801
Serous 1 (0.72-1.38) 0.976
Endometrioid 1.12 (0.69-1.83) 0.646
Mucinous 1.22 (0.7-2.13) 0.481
AIFM2
(haplotype
block 1)
h0101111 2.8
Clear cell 0.8 (0.39-1.65) 0.544
All 0.79 (0.5-1.24) 0.309
Serous 0.8 (0.57-1.11) 0.184
Endometrioid 0.69 (0.38-1.24) 0.209
Mucinous 1.21 (0.71-2.09) 0.481
AIFM2
(haplotype
block 1)
h0111110 2.8
Clear cell 1.35 (0.78-2.35) 0.289
All 0.98 (0.62-1.55) 0.926
Serous 0.84 (0.67-1.05) 0.128
Endometrioid 1 (0.71-1.4) 0.993
Mucinous 0.68 (0.42-1.08) 0.101
AIFM2
(haplotype
block 1)
Rare 1
Clear cell 0.65 (0.39-1.09) 0.104
All 1.01 (0.91-1.11) 0.856
Serous 1.02 (0.91-1.14) 0.702
Endometrioid 0.96 (0.8-1.15) 0.637
Mucinous 1.26 (1.02-1.55) 0.034
AIFM2
(haplotype
block 2)
h00100 39
Clear cell 0.91 (0.72-1.15) 0.437
All 0.92 (0.83-1.02) 0.119
Serous 0.92 (0.82-1.04) 0.197
Endometrioid 1.01 (0.84-1.22) 0.907
Mucinous 0.94 (0.75-1.18) 0.6
AIFM2
(haplotype
block 2)
h00000 36.3
Clear cell 0.99 (0.78-1.26) 0.939
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Gene
(haplotype
Haplotype Freq (%) Histology OR (95% CI) P-value
All 1.12 (0.92-1.36) 0.253
Serous 1.11 (0.89-1.39) 0.359
Endometrioid 1.18 (0.83-1.68) 0.346
Mucinous 0.77 (0.47-1.26) 0.294
AIFM2
(haplotype
block 2)
h00011 6.7
Clear cell 1.3 (0.84-2) 0.24
All 1.06 (0.83-1.35) 0.665
Serous 0.97 (0.73-1.3) 0.849
Endometrioid 1.05 (0.67-1.67) 0.823
Mucinous 1.12 (0.66-1.91) 0.675
AIFM2
(haplotype
block 2)
h00001 4.1
Clear cell 1.13 (0.63-2.02) 0.686
All 1.15 (0.84-1.58) 0.387
Serous 1.18 (0.83-1.67) 0.352
Endometrioid 0.73 (0.37-1.42) 0.351
Mucinous 1.11 (0.56-2.17) 0.719
AIFM2
(haplotype
block 2)
h10000 3.2
Clear cell 1.14 (0.55-2.35) 0.719
All 0.98 (0.68-1.4) 0.895
Serous 1.01 (0.65-1.56) 0.97
Endometrioid 0.64 (0.29-1.44) 0.286
Mucinous 0.41 (0.13-1.26) 0.119
AIFM2
(haplotype
block 2)
h10011 2.3
Clear cell 1.1 (0.47-2.54) 0.833
All 1.1 (0.8-1.53) 0.551
Serous 1.33 (0.93-1.9) 0.112
Endometrioid 1.53 (0.88-2.65) 0.129
Mucinous 0.66 (0.27-1.62) 0.362
AIFM2
(haplotype
block 2)
h01011 2.2
Clear cell 0.81 (0.32-2.03) 0.65
All 1.33 (0.92-1.93) 0.126
Serous 1.06 (0.68-1.65) 0.792
Endometrioid 1.43 (0.76-2.68) 0.263
Mucinous 1.24 (0.57-2.67) 0.591
AIFM2
(haplotype
block 2)
h10100 2.2
Clear cell 0.83 (0.31-2.22) 0.709
All 0.61 (0.19-2) 0.418
Serous 1.05 (0.79-1.4) 0.732
Endometrioid 1.04 (0.65-1.65) 0.88
Mucinous 0.67 (0.35-1.31) 0.246
AIFM2
(haplotype
block 2)
Rare 0.3
Clear cell 1.43 (0.84-2.42) 0.183
SNP order in haplotypes is 5’ to 3’ of AIFM2 (block 1): rs2394655, rs7908957, rs1053495,
rs2894111, rs2394656, rs6480440, rs2280201. AIFM2 (block 2): rs10999147, rs3750772,
rs4295944, rs2394644, rs10999152.
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Appendix IV-C: Genotype specific ratios of AKTIP tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
917 All 0.96 (0.80-1.16) 1.01 (0.80-1.27) 0.9734
506 Serous 1.10 (0.87-1.38) 1.12 (0.85-1.50) 0.4039
137 Endometrioid 0.89 (0.59-1.34) 1.06 (0.65-1.73) 0.8928
86 Mucinous 0.83 (0.52-1.34) 0.58 (0.29-1.14) 0.1045
AKTIP rs9931702 0.44 1722
79 Clear cell 0.52 (0.31-0.88) 0.72 (0.39-1.34) 0.1424
828 All 1.06 (0.87-1.31) 0.74 (0.38-1.46) 0.9282
450 Serous 1.14 (0.89-1.46) 0.90 (0.40-2.00) 0.4718
125 Endometrioid 0.81 (0.50-1.31) 0.96 (0.28-3.35) 0.3441
75 Mucinous 1.05 (0.61-1.83) 0.58 (0.08-4.37) 0.8683
AKTIP rs17801966 0.15 1469
78 Clear cell 1.13 (0.66-1.91) 0.58 (0.08-4.40) 0.9369
1745 All 0.93 (0.82-1.06) 0.92 (0.75-1.14) 0.2796
825 Serous 0.99 (0.84-1.17) 1.02 (0.78-1.33) 0.867
271 Endometrioid 0.95 (0.73-1.24) 1.06 (0.69-1.61) 0.9177
186 Mucinous 0.87 (0.64-1.19) 0.42 (0.21-0.84) 0.0247
AKTIP rs7189819 0.3 2923
163 Clear cell 0.62 (0.44-0.87) 0.78 (0.45-1.35) 0.0412
413 All 0.90 (0.62-1.32) 2.02 (0.32-12.59) 0.6778
256 Serous 1.12 (0.73-1.72) 1.72 (0.17-17.14) 0.6424
54 Endometrioid 0.67 (0.24-1.90) 11.42 (1.04-125.41) 0.9435
43 Mucinous 0.41 (0.10-1.71) 8.79 (0.86-89.58) 0.6759
AKTIP rs3743772 0.07 1093
26 Clear cell 0.34 (0.05-2.55) 22.33 (1.82-273.37) 0.9875
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common homozygous;
Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross 1.
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Appendix IV-D: Haplotype-specific risks of AKTIP on ovarian cancer
susceptibility
Gene Haplotype Freq (%) Histology OR (95% CI) P-value
All 1.01 (0.88-1.16) 0.9
Serous 0.92 (0.83-1.03) 0.153
Endometrioid 1.04 (0.87-1.25) 0.634
Mucinous 1.2 (0.97-1.49) 0.086
AKTIP h0000 54.7
Clear cell 1.13 (0.9-1.41) 0.299
All 1 (0.86-1.16) 0.996
Serous 0.99 (0.88-1.11) 0.858
Endometrioid 0.97 (0.8-1.18) 0.766
Mucinous 0.73 (0.58-0.94) 0.013
AKTIP h1010 30.4
Clear cell 0.77 (0.59-1) 0.047
All 0.97 (0.75-1.25) 0.804
Serous 0.93 (0.76-1.15) 0.524
Endometrioid 0.77 (0.54-1.11) 0.158
Mucinous 0.86 (0.57-1.29) 0.46
AKTIP h1100 7.9
Clear cell 0.97 (0.63-1.49) 0.891
All 1 (0.75-1.33) 0.999
Serous 1.29 (1.01-1.66) 0.044
Endometrioid 1.02 (0.65-1.59) 0.927
Mucinous 0.94 (0.54-1.65) 0.835
AKTIP h1101 5.7
Clear cell 1.37 (0.82-2.3) 0.227
All 73.28 (0.84-6372.38) 0.059
Serous 1.8 (1.3-2.49) 3.71x10-4
Endometrioid 1.53 (0.93-2.52) 0.093
Mucinous 2.27 (1.39-3.71) 0.001
AKTIP Rare 0.02
Clear cell 1.52 (0.81-2.86) 0.19
SNP order in haplotypes is 5’ to 3’ of ATKIP: rs9931702, rs17801966, rs7189819, rs3743772.
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Appendix IV-E: Genotype specific ratios of AXIN2 tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.
controls
No.
cases
Histology HetOR (95% CI) HomOR (95% CI) P-trend
919 All 0.93 (0.76-1.13) 1.02 (0.81-1.29) 0.8178
509 Serous 0.92 (0.72-1.17) 0.99 (0.74-1.31) 0.9949
136 Endometrioid 0.87 (0.56-1.35) 1.21 (0.75-1.97) 0.4357
85 Mucinous 0.91 (0.54-1.55) 0.95 (0.51-1.77) 0.89
AXIN2 rs11868547 0.48 1717
81 Clear cell 0.81 (0.47-1.38) 1.06 (0.57-1.96) 0.9215
1779 All 1.09 (0.96-1.24) 1.05 (0.87-1.27) 0.4234
838 Serous 1.19 (1.01-1.41) 1.11 (0.87-1.41) 0.1463
277 Endometrioid 0.80 (0.61-1.06) 1.04 (0.72-1.50) 0.6889
195 Mucinous 1.29 (0.93-1.77) 0.80 (0.48-1.32) 0.9404
AXIN2 rs7591 0.38 2881
165 Clear cell 0.84 (0.59-1.18) 1.05 (0.66-1.66) 0.8548
1775 All 1.16 (1.02-1.32) 0.92 (0.67-1.24) 0.2189
840 Serous 1.21 (1.03-1.43) 0.76 (0.50-1.16) 0.323
276 Endometrioid 1.10 (0.84-1.44) 1.20 (0.68-2.11) 0.4121
192 Mucinous 1.03 (0.75-1.43) 0.96 (0.45-2.01) 0.948
AXIN2 rs4074947 0.22 2898
163 Clear cell 1.02 (0.72-1.44) 1.20 (0.59-2.44) 0.6962
1777 All 1.01 (0.87-1.17) 0.97 (0.56-1.69) 0.8864
838 Serous 1.09 (0.90-1.32) 1.08 (0.54-2.14) 0.3518
277 Endometrioid 0.88 (0.64-1.22) 1.09 (0.33-3.61) 0.5776
193 Mucinous 1.05 (0.73-1.52) 1.19 (0.34-4.20) 0.5978
AXIN2 rs7210356 0.11 2974
165 Clear cell 0.71 (0.46-1.10) 1.54 (0.46-5.13) 0.3368
1301 All 0.92 (0.79-1.07) 1.07 (0.80-1.44) 0.9064
552 Serous 0.99 (0.81-1.22) 1.10 (0.74-1.63) 0.6218
213 Endometrioid 0.84 (0.61-1.15) 1.35 (0.79-2.28) 0.865
144 Mucinous 0.95 (0.66-1.39) 0.40 (0.15-1.07) 0.4605
AXIN2 rs11655966 0.27 1779
130 Clear cell 0.78 (0.53-1.15) 1.30 (0.68-2.47) 0.8989
1297 All 1.09 (0.91-1.30) 0.97 (0.78-1.19) 0.806AXIN2 rs4541111 0.48 1770
554 Serous 1.10 (0.87-1.40) 1.03 (0.78-1.36) 0.755
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Gene tSNP MAF No.
controls
No.
cases
Histology HetOR (95% CI) HomOR (95% CI) P-trend
214 Endometrioid 0.93 (0.65-1.31) 1.04 (0.70-1.55) 0.894
141 Mucinous 1.32 (0.85-2.04) 0.64 (0.36-1.15) 0.3682
128 Clear cell 0.92 (0.60-1.39) 0.77 (0.46-1.28) 0.3251
1185 All 1.08 (0.92-1.25) 1.19 (0.92-1.55) 0.1238
539 Serous 1.05 (0.86-1.29) 1.23 (0.88-1.73) 0.2499
180 Endometrioid 1.04 (0.75-1.45) 1.30 (0.76-2.20) 0.3845
133 Mucinous 1.37 (0.94-2.00) 1.07 (0.54-2.11) 0.2561
AXIN2 rs4791171 0.3 2109
111 Clear cell 0.88 (0.58-1.32) 1.01 (0.50-2.01) 0.7639
839 All 1.23 (1.00-1.51) 1.73 (0.99-3.01) 0.0383
326 Serous 1.22 (0.92-1.63) 1.74 (0.84-3.63) 0.1127
137 Endometrioid 1.05 (0.69-1.59) 2.32 (0.92-5.87) 0.3712
104 Mucinous 1.03 (0.63-1.69) 1.77 (0.54-5.80) 0.5048
AXIN2 rs11079571 0.17 1206
83 Clear cell 1.54 (0.95-2.50) 2.00 (0.58-6.89) 0.0625
1780 All 1.05 (0.93-1.20) 1.26 (0.95-1.68) 0.1545
843 Serous 1.05 (0.89-1.24) 1.10 (0.75-1.60) 0.4525
275 Endometrioid 0.96 (0.73-1.26) 1.68 (1.02-2.79) 0.3043
193 Mucinous 1.03 (0.75-1.42) 1.17 (0.59-2.32) 0.657
AXIN2 rs3923087 0.22 2910
164 Clear cell 0.84 (0.59-1.20) 1.60 (0.85-3.00) 0.8136
1753 All 0.91 (0.80-1.04) 1.07 (0.90-1.27) 0.813
833 Serous 0.84 (0.71-1.00) 1.02 (0.81-1.27) 0.6828
267 Endometrioid 0.89 (0.67-1.18) 1.02 (0.71-1.47) 0.9432
188 Mucinous 1.18 (0.83-1.66) 1.22 (0.78-1.90) 0.2639
AXIN2 rs3923086 0.42 2935
163 Clear cell 0.81 (0.57-1.16) 1.00 (0.64-1.57) 0.793
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with
common homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility;
emboldened OR are statistically significant or do not cross 1.
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Appendix IV-F: Haplotype-specific risks of AXIN2 on ovarian cancer
susceptibility
Gene/
haplotype
block
Haplotype Freq (%) Histology OR (95% CI) P-value
All 1.03 (0.93-1.13) 0.599
Serous 1.01 (0.9-1.12) 0.907
Endometrioid 1.09 (0.92-1.3) 0.316
Mucinous 0.95 (0.77-1.17) 0.639
AXIN2
(haplotype
block 1)
h100000 44.9
Clear cell 1.06 (0.85-1.32) 0.6
All 0.9 (0.77-1.04) 0.148
Serous 0.81 (0.68-0.97) 0.018
Endometrioid 0.95 (0.73-1.24) 0.7
Mucinous 1.08 (0.8-1.46) 0.632
AXIN2
(haplotype
block 1)
h000001 14.6
Clear cell 0.97 (0.7-1.36) 0.868
All 1.05 (0.89-1.23) 0.58
Serous 1.07 (0.9-1.28) 0.421
Endometrioid 0.89 (0.65-1.2) 0.431
Mucinous 1.13 (0.81-1.57) 0.471
AXIN2
(haplotype
block 1)
h010111 10.7
Clear cell 0.85 (0.57-1.26) 0.414
All 1.15 (0.98-1.36) 0.082
Serous 1.21 (1.01-1.45) 0.041
Endometrioid 1.16 (0.87-1.54) 0.312
Mucinous 1.22 (0.87-1.7) 0.246
AXIN2
(haplotype
block 1)
h011001 10.4
Clear cell 0.86 (0.57-1.29) 0.458
All 1.08 (0.87-1.33) 0.49
Serous 1.03 (0.81-1.31) 0.803
Endometrioid 1.37 (0.97-1.92) 0.075
Mucinous 0.66 (0.39-1.14) 0.137
AXIN2
(haplotype
block 1)
h011011 6
Clear cell 1.2 (0.76-1.89) 0.433
All 0.9 (0.72-1.12) 0.355
Serous 1.08 (0.85-1.37) 0.547
Endometrioid 0.86 (0.57-1.31) 0.495
Mucinous 0.86 (0.53-1.41) 0.553
AXIN2
(haplotype
block 1)
h010011 5.5
Clear cell 1.01 (0.61-1.66) 0.984
All 0.96 (0.73-1.26) 0.751
Serous 0.96 (0.71-1.3) 0.797
Endometrioid 0.7 (0.4-1.23) 0.216
Mucinous 1.03 (0.58-1.82) 0.916
AXIN2
(haplotype
block 1)
h011010 3.5
Clear cell 1.38 (0.8-2.4) 0.251
All 0.83 (0.49-1.41) 0.488
Serous 0.86 (0.67-1.11) 0.249
Endometrioid 0.58 (0.35-0.96) 0.033
AXIN2
(haplotype
block 1)
Rare 0.8
Mucinous 0.97 (0.61-1.53) 0.887
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Gene/
haplotype
block
Haplotype Freq (%) Histology OR (95% CI) P-value
Clear cell 0.85 (0.5-1.44) 0.546
All 0.98 (0.87-1.1) 0.75
Serous 1.03 (0.92-1.15) 0.637
Endometrioid 1.02 (0.85-1.22) 0.833
Mucinous 0.93 (0.75-1.15) 0.48
AXIN2
(haplotype
block 2)
h0000 53.4
Clear cell 1.04 (0.82-1.3) 0.767
All 0.93 (0.79-1.11) 0.431
Serous 0.89 (0.75-1.05) 0.167
Endometrioid 0.85 (0.64-1.12) 0.24
Mucinous 1.23 (0.92-1.65) 0.157
AXIN2
(haplotype
block 2)
h0001 14.5
Clear cell 1.06 (0.76-1.47) 0.744
All 1.21 (1.03-1.42) 0.023
Serous 1.19 (1.01-1.39) 0.037
Endometrioid 1.08 (0.83-1.4) 0.572
Mucinous 1.13 (0.83-1.53) 0.434
AXIN2
(haplotype
block 2)
h1111 12.8
Clear cell 0.96 (0.68-1.36) 0.838
All 1.06 (0.86-1.3) 0.596
Serous 0.95 (0.76-1.19) 0.656
Endometrioid 1.28 (0.93-1.77) 0.134
Mucinous 0.83 (0.53-1.31) 0.43
AXIN2
(haplotype
block 2)
h1011 7
Clear cell 1.2 (0.79-1.83) 0.395
All 0.98 (0.77-1.26) 0.873
Serous 0.92 (0.73-1.17) 0.508
Endometrioid 0.95 (0.64-1.4) 0.78
Mucinous 0.98 (0.63-1.54) 0.943
AXIN2
(haplotype
block 2)
h1001 5.8
Clear cell 0.74 (0.43-1.27) 0.27
All 0.84 (0.59-1.21) 0.355
Serous 0.91 (0.61-1.35) 0.638
Endometrioid 0.7 (0.34-1.44) 0.327
Mucinous 0.78 (0.35-1.75) 0.549
AXIN2
(haplotype
block 2)
h1000 2.7
Clear cell 0.6 (0.22-1.62) 0.314
All 1.67 (0.59-4.69) 0.332
Serous 0.91 (0.69-1.21) 0.511
Endometrioid 0.92 (0.58-1.45) 0.708
Mucinous 0.88 (0.51-1.53) 0.649
AXIN2
(haplotype
block 2)
Rare 0.1
Clear cell 1 (0.57-1.74) 0.992
SNP order in haplotypes is 5’ to 3’ of AXIN2 (block 1): rs11868547, rs7591, rs4074947,
rs7210356, rs11655966, rs4541111. AXIN2 (block 2): rs4791171, rs11079571, rs3923087,
rs3923086.
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Appendix IV-G: Genotype specific ratios of CASP5 tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
438 All 1.39 (1.06-1.81) 1.44 (1.05-1.97) 0.0124
270 Serous 1.36 (0.98-1.88) 1.45 (0.99-2.11) 0.0313
56 Endometrioid 1.12 (0.58-2.15) 1.40 (0.67-2.92) 0.3451
42 Mucinous 1.45 (0.65-3.22) 2.00 (0.84-4.77) 0.0958
CASP5 rs518604 0.46 1195
32 Clear cell 1.63 (0.71-3.73) 0.72 (0.21-2.42) 0.8022
824 All 1.03 (0.83-1.29) 1.07 (0.82-1.39) 0.7689
320 Serous 0.86 (0.65-1.16) 0.80 (0.55-1.15) 0.1294
131 Endometrioid 1.24 (0.78-1.97) 1.45 (0.84-2.48) 0.0826
102 Mucinous 1.00 (0.60-1.66) 0.87 (0.46-1.66) 0.8518
CASP5 rs523104 0.46 1199
81 Clear cell 1.01 (0.60-1.71) 0.81 (0.40-1.60) 0.5623
829 All 0.95 (0.73-1.23) 1.16 (0.50-2.72) 0.7779
319 Serous 0.93 (0.65-1.33) 0.68 (0.18-2.64) 0.7345
273 Endometrioid 0.85 (0.59-1.24) 0.54 (0.13-2.25) 0.2291
102 Mucinous 0.97 (0.52-1.80) 3.90 (1.06-14.34) 0.5649
CASP5 rs3181328 0.09 1206
83 Clear cell 1.10 (0.60-2.00) 1.12 (0.14-8.75) 0.6481
803 All 0.88 (0.69-1.12) 1.28 (0.54-3.02) 0.5052
311 Serous 0.87 (0.63-1.22) 1.01 (0.28-3.69) 0.5292
130 Endometrioid 0.81 (0.50-1.33) 0.79 (0.10-6.24) 0.3787
97 Mucinous 1.15 (0.66-1.99) 4.12 (1.10-15.36) 0.2146
CASP5 rs17446518 0.11 1177
81 Clear cell 0.70 (0.37-1.32) 1.20 (0.15-9.47) 0.3467
1730 All 0.99 (0.85-1.15) 1.22 (0.70-2.13) 0.836
819 Serous 0.96 (0.78-1.17) 1.55 (0.81-2.96) 0.8167
269 Endometrioid 1.16 (0.86-1.58) 1.80 (0.68-4.77) 0.2196
CASP5 rs9651713 0.11 2898
183 Mucinous 0.86 (0.57-1.28) 1.10 (0.26-4.69) 0.4883
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Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
162 Clear cell 1.09 (0.74-1.61) 1.13 (0.27-4.83) 0.6561
1282 All 0.96 (0.83-1.12) 1.23 (0.83-1.82) 0.9331
597 Serous 0.93 (0.76-1.13) 1.34 (0.82-2.19) 0.9482
194 Endometrioid 1.01 (0.73-1.39) 1.66 (0.80-3.44) 0.4992
147 Mucinous 1.05 (0.73-1.51) 0.72 (0.22-2.37) 0.8575
CASP5 rs3181175 0.19 2379
115 Clear cell 0.98 (0.65-1.48) 1.19 (0.42-3.37) 0.9266
1780 All 0.96 (0.80-1.14) 1.21 (0.55-2.65) 0.7967
840 Serous 1.09 (0.88-1.36) 1.12 (0.41-3.09) 0.4061
278 Endometrioid 0.82 (0.56-1.21) 0.83 (0.11-6.43) 0.3188
195 Mucinous 0.87 (0.56-1.37) 1.11 (0.14-8.64) 0.6099
CASP5 rs3181174 0.07 2962
165 Clear cell 0.64 (0.37-1.10) 1.20 (0.16-9.26) 0.151
852 All 1.08 (0.90-1.30) 0.89 (0.67-1.20) 0.7645
462 Serous 1.16 (0.92-1.45) 1.11 (0.78-1.56) 0.3615
128 Endometrioid 1.12 (0.76-1.66) 0.87 (0.45-1.69) 0.7802
80 Mucinous 1.02 (0.64-1.64) 0.63 (0.26-1.52) 0.4369
CASP5 rs2282657 0.35 1478
73 Clear cell 1.06 (0.65-1.73) 0.35 (0.11-1.18) 0.1926
1768 All 1.02 (0.87-1.20) 1.00 (0.84-1.19) 0.9144
835 Serous 1.09 (0.89-1.34) 1.00 (0.79-1.26) 0.8497
276 Endometrioid 0.99 (0.72-1.36) 0.83 (0.58-1.20) 0.2713
194 Mucinous 0.84 (0.57-1.23) 1.01 (0.67-1.53) 0.7951
CASP5 rs507879 0.46 2839
164 Clear cell 1.05 (0.70-1.60) 0.97 (0.61-1.54) 0.8762
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common
homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are
statistically significant or do not cross 1.
Appendices
408
Appendix IV-H: Haplotype-specific risks of CASP5 on ovarian cancer
susceptibility
Gene/
haplotype
block
Haplotype Freq (%) Histology OR (95% CI) P-value
All 0.99 (0.9-1.09) 0.79
Serous 0.89 (0.79-0.99) 0.033
Endometrioid 1.07 (0.89-1.28) 0.475
Mucinous 0.82 (0.66-1.01) 0.068
CASP5
(haplotype
block 1)
h010 43.8
Clear cell 1.02 (0.81-1.29) 0.836
All 1.13 (1.03-1.24) 0.012
Serous 1.2 (1.08-1.35) 0.001
Endometrioid 1.1 (0.92-1.32) 0.289
Mucinous 1.18 (0.95-1.46) 0.126
CASP5
(haplotype
block 1)
h100 43.3
Clear cell 1 (0.79-1.26) 0.983
All 0.9 (0.77-1.06) 0.215
Serous 0.92 (0.76-1.12) 0.421
Endometrioid 0.74 (0.53-1.06) 0.098
Mucinous 1.13 (0.8-1.6) 0.476
CASP5
(haplotype
block 1)
h001 9.8
Clear cell 0.94 (0.63-1.41) 0.764
All 0.72 (0.56-0.94) 0.015
Serous 0.91 (0.59-1.4) 0.653
Endometrioid 0.77 (0.37-1.59) 0.477
Mucinous 0.84 (0.36-1.99) 0.697
CASP5
(haplotype
block 1)
h000 2.3
Clear cell 1.32 (0.65-2.71) 0.443
All 0.74 (0.54-1.02) 0.069
Serous 0.65 (0.41-1.02) 0.061
Endometrioid 0.37 (0.14-1.01) 0.052
Mucinous 1.16 (0.6-2.24) 0.653
CASP5
(haplotype
block 1)
h110 0.8
Clear cell 0.46 (0.14-1.48) 0.193
All 1.02 (0.9-1.14) 0.768
Serous 1.01 (0.9-1.13) 0.904
Endometrioid 0.96 (0.8-1.15) 0.628
Mucinous 1.01 (0.81-1.25) 0.952
CASP5
(haplotype
block 2)
h000001 48.7
Clear cell 1.03 (0.82-1.3) 0.791
All 1.1 (0.93-1.3) 0.285
Serous 1.07 (0.91-1.26) 0.43
Endometrioid 1.28 (0.99-1.64) 0.059
Mucinous 1.05 (0.77-1.44) 0.752
CASP5
(haplotype
block 2)
h000010 12.8
Clear cell 1.17 (0.84-1.63) 0.348
All 0.87 (0.71-1.07) 0.179
Serous 0.9 (0.74-1.1) 0.319
Endometrioid 1.01 (0.75-1.38) 0.931
CASP5
(haplotype
block 2)
h000000 10.1
Mucinous 0.98 (0.68-1.42) 0.931
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Gene/
haplotype
block
Haplotype Freq (%) Histology OR (95% CI) P-value
Clear cell 0.98 (0.66-1.46) 0.923
All 1.15 (0.95-1.39) 0.162
Serous 1.02 (0.85-1.23) 0.833
Endometrioid 1.28 (0.97-1.69) 0.076
Mucinous 0.9 (0.63-1.31) 0.593
CASP5
(haplotype
block 2)
h011010 9.6
Clear cell 1.17 (0.82-1.68) 0.393
All 0.97 (0.77-1.22) 0.787
Serous 1.1 (0.88-1.37) 0.396
Endometrioid 0.82 (0.56-1.22) 0.335
Mucinous 0.79 (0.49-1.27) 0.331
CASP5
(haplotype
block 2)
h001110 6.5
Clear cell 0.76 (0.45-1.28) 0.305
All 1.01 (0.82-1.26) 0.902
Serous 0.97 (0.75-1.26) 0.821
Endometrioid 0.77 (0.48-1.22) 0.27
Mucinous 1.12 (0.69-1.8) 0.651
CASP5
(haplotype
block 2)
h100001 5.2
Clear cell 0.76 (0.42-1.39) 0.38
All 1.07 (0.79-1.45) 0.663
Serous 0.88 (0.57-1.34) 0.548
Endometrioid 0.79 (0.39-1.61) 0.517
Mucinous 1.39 (0.7-2.76) 0.343
CASP5
(haplotype
block 2)
h100010 2.6
Clear cell 0.72 (0.28-1.82) 0.485
All 0.28 (0.12-0.69) 0.005
Serous 0.84 (0.6-1.17) 0.293
Endometrioid 0.45 (0.22-0.89) 0.022
Mucinous 1.1 (0.62-1.95) 0.742
CASP5
(haplotype
block 2)
Rare 0.9
Clear cell 0.75 (0.36-1.55) 0.433
SNP order in haplotypes is 5’ to 3’ of CASP5 (block 1): rs518604, rs523104, rs3181328. CASP5
(block 2): rs17446518, rs9651713, rs3181175, rs3181174, rs2282657, rs507879.
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Appendix IV-I: Genotype specific ratios of FILIP1L tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
437 All 1.07 (0.84-1.35) 1.33 (0.94-1.89) 0.1458
269 Serous 0.98 (0.74-1.31) 1.25 (0.83-1.90) 0.4593
56 Endometrioid 1.67 (0.93-3.02) 1.51 (0.62-3.68) 0.1545
43 Mucinous 1.20 (0.62-2.34) 1.77 (0.72-4.38) 0.2813
FILIP1L rs796977 0.33 1166
31 Clear cell 0.93 (0.42-2.03) 1.38 (0.49-3.91) 0.6504
1653 All 1.02 (0.88-1.18) 0.88 (0.53-1.43) 0.9373
771 Serous 1.11 (0.92-1.35) 1.08 (0.59-1.99) 0.3224
257 Endometrioid 0.92 (0.67-1.27) 0.60 (0.18-1.97) 0.4293
175 Mucinous 1.16 (0.80-1.67) 0.66 (0.16-2.76) 0.8392
FILIP1L rs793477 0.13 2646
155 Clear cell 1.04 (0.70-1.54) 1.79 (0.69-4.61) 0.4497
1773 All 1.05 (0.92-1.20) 1.11 (0.93-1.32) 0.3207
838 Serous 0.95 (0.80-1.13) 1.07 (0.86-1.34) 0.842
274 Endometrioid 1.36 (1.02-1.81) 1.52 (1.05-2.20) 0.0262
194 Mucinous 1.14 (0.82-1.58) 0.93 (0.58-1.48) 0.8885
FILIP1L rs793446 0.41 2947
164 Clear cell 1.05 (0.74-1.50) 1.11 (0.69-1.77) 0.6725
1773 All 1.00 (0.84-1.20) 0.69 (0.29-1.61) 0.6908
840 Serous 0.90 (0.71-1.15) 0.19 (0.03-1.43) 0.1194
276 Endometrioid 1.09 (0.75-1.57) 1.16 (0.26-5.15) 0.6936
191 Mucinous 1.12 (0.72-1.73) 0.90 (0.12-6.92) 0.7966
FILIP1L rs3921767 0.07 2859
166 Clear cell 1.00 (0.62-1.61) 1.94 (0.44-8.55) 0.7117
1786 All 1.06 (0.91-1.24) 0.77 (0.46-1.28) 0.985
574 Serous 0.88 (0.69-1.14) 0.98 (0.44-2.20) 0.3051
FILIP1L rs17338680 0.11 2989
221 Endometrioid 1.71 (1.24-2.36) 0.79 (0.19-3.39) 0.0073
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Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
196 Mucinous 1.23 (0.86-1.76) 0.35 (0.05-2.58) 0.7109
133 Clear cell 1.04 (0.67-1.63) 1.12 (0.26-4.81) 0.8406
1786 All 0.98 (0.86-1.12) 1.18 (0.91-1.53) 0.6077
843 Serous 0.96 (0.81-1.14) 1.47 (1.08-2.01) 0.2249
278 Endometrioid 1.05 (0.80-1.37) 0.86 (0.47-1.59) 0.8102
195 Mucinous 0.99 (0.72-1.36) 0.91 (0.45-1.85) 0.782
FILIP1L rs9864437 0.22 2972
165 Clear cell 0.81 (0.57-1.15) 0.98 (0.49-1.98) 0.3807
1414 All 0.98 (0.84-1.13) 0.96 (0.79-1.17) 0.7028
710 Serous 1.07 (0.88-1.29) 1.12 (0.88-1.44) 0.3295
226 Endometrioid 0.84 (0.62-1.14) 0.72 (0.47-1.11) 0.1277
140 Mucinous 1.01 (0.69-1.48) 0.86 (0.50-1.46) 0.6811
FILIP1L rs6788750 0.41 2532
131 Clear cell 0.91 (0.61-1.35) 1.15 (0.70-1.89) 0.7396
1273 All 1.14 (0.98-1.33) 0.88 (0.59-1.33) 0.433
594 Serous 0.95 (0.78-1.17) 0.52 (0.27-0.99) 0.097
193 Endometrioid 1.48 (1.08-2.04) 2.16 (1.13-4.12) 0.0024
145 Mucinous 1.57 (1.10-2.25) 0.25 (0.03-1.83) 0.2574
FILIP1L rs12494994 0.18 2347
113 Clear cell 1.20 (0.79-1.82) 1.69 (0.71-4.03) 0.1986
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common homozygous;
Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross 1.
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Appendix IV-J: Haplotype-specific risks of FILIP1L on ovarian
cancer susceptibility
Gene/
haplotype
block
Haplotype Freq (%) Histology OR (95% CI) P-value
All 0.95 (0.84-1.08) 0.445
Serous 0.97 (0.87-1.08) 0.572
Endometrioid 0.86 (0.72-1.03) 0.092
Mucinous 0.98 (0.79-1.2) 0.823
FILIP1L
(haplotype
block 1)
h00000 46.1
Clear cell 0.9 (0.71-1.13) 0.351
All 1.08 (0.93-1.24) 0.311
Serous 1.12 (0.98-1.27) 0.087
Endometrioid 1 (0.81-1.24) 0.972
Mucinous 1 (0.78-1.29) 1
FILIP1L
(haplotype
block 1)
h10100 22.5
Clear cell 0.88 (0.67-1.17) 0.39
All 0.97 (0.79-1.19) 0.782
Serous 1.08 (0.91-1.27) 0.383
Endometrioid 0.93 (0.71-1.23) 0.62
Mucinous 1.1 (0.81-1.49) 0.527
FILIP1L
(haplotype
block 1)
h01000 11.5
Clear cell 1.17 (0.85-1.6) 0.347
All 1.11 (0.91-1.35) 0.29
Serous 0.94 (0.78-1.13) 0.514
Endometrioid 1.56 (1.22-2.01) 5.01x10-4
Mucinous 1.09 (0.78-1.51) 0.617
FILIP1L
(haplotype
block 1)
h10101 10.7
Clear cell 1.25 (0.89-1.75) 0.204
All 0.94 (0.74-1.2) 0.617
Serous 0.83 (0.66-1.04) 0.111
Endometrioid 1.05 (0.75-1.47) 0.791
Mucinous 1.05 (0.7-1.56) 0.819
FILIP1L
(haplotype
block 1)
h00110 7.4
Clear cell 1.06 (0.69-1.63) 0.779
All 0.34 (0.11-1.03) 0.056
Serous 0.81 (0.53-1.25) 0.345
Endometrioid 0.61 (0.27-1.36) 0.226
Mucinous 0.15 (0.02-1.01) 0.051
FILIP1L
(haplotype
block 1)
Rare 0.4
Clear cell 1.11 (0.53-2.33) 0.784
All 0.98 (0.88-1.08) 0.644
Serous 1.08 (0.96-1.2) 0.197
Endometrioid 0.83 (0.69-1) 0.053
Mucinous 0.96 (0.77-1.18) 0.672
FILIP1L
(haplotype
block 2)
h010 41
Clear cell 1.03 (0.82-1.29) 0.823
All 1.04 (0.93-1.16) 0.528
Serous 1.09 (0.96-1.24) 0.167
Endometrioid 0.98 (0.79-1.22) 0.877
FILIP1L
(haplotype
block 2)
h100 22.6
Mucinous 0.99 (0.77-1.27) 0.952
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Gene/
haplotype
block
Haplotype Freq (%) Histology OR (95% CI) P-value
Clear cell 0.9 (0.69-1.19) 0.473
All 0.94 (0.83-1.08) 0.383
Serous 0.9 (0.78-1.04) 0.16
Endometrioid 0.98 (0.78-1.23) 0.873
Mucinous 1.07 (0.82-1.38) 0.615
FILIP1L
(haplotype
block 2)
h000 18.9
Clear cell 0.93 (0.7-1.25) 0.649
All 1.04 (0.92-1.17) 0.562
Serous 0.88 (0.76-1.02) 0.092
Endometrioid 1.37 (1.1-1.69) 0.004
Mucinous 1.03 (0.79-1.36) 0.815
FILIP1L
(haplotype
block 2)
h001 17.1
Clear cell 1.17 (0.88-1.56) 0.269
SNP order in haplotypes is 5’ to 3’ of FILIP1L (block 1): rs796977, rs793477, rs793446,
rs3921767, rs17338680. FILIP1L (block 2): rs9864437, rs6788750, rs12494994.
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Appendix IV-K: Genotype specific ratios of RBBP8 tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
1272 All 0.80 (0.67-0.96) 1.05 (0.57-1.95) 0.0645
594 Serous 0.99 (0.79-1.23) 1.18 (0.55-2.53) 0.7647
188 Endometrioid 0.70 (0.47-1.06) 0.74 (0.17-3.18) 0.1083
144 Mucinous 0.60 (0.37-0.97) 0.88 (0.20-3.92) 0.1098
RBBP8 rs7239066 0.11 2366
115 Clear cell 0.64 (0.38-1.09) 1.31 (0.30-5.64) 0.2167
1748 All 1.12 (0.89-1.41) 1.13 (0.31-4.07) 0.2974
826 Serous 1.17 (0.88-1.57) 0.55 (0.07-4.59) 0.3355
271 Endometrioid 1.27 (0.80-2.02) 1.56 (0.18-13.31) 0.2858
188 Mucinous 1.38 (0.81-2.36) 1.92 (0.22-16.89) 0.1282
RBBP8 rs11082221 0.04 2937
165 Clear cell 1.10 (0.60-2.02) 3.56 (0.40-31.29) 0.4888
1764 All 0.94 (0.82-1.07) 0.88 (0.72-1.06) 0.2066
829 Serous 0.83 (0.70-0.98) 0.80 (0.63-1.03) 0.0323
271 Endometrioid 1.16 (0.88-1.52) 1.03 (0.69-1.53) 0.5615
193 Mucinous 1.11 (0.81-1.53) 0.97 (0.60-1.57) 0.8372
RBBP8 rs4474794 0.36 2895
165 Clear cell 1.03 (0.73-1.46) 1.27 (0.80-2.01) 0.3447
346 All 1.07 (0.82-1.40) 0.67 (0.38-1.17) 0.5163
215 Serous 1.08 (0.79-1.49) 0.37 (0.16-0.88) 0.2176
44 Endometrioid 1.34 (0.71-2.52) 0.67 (0.15-2.91) 0.8077
33 Mucinous 1.26 (0.59-2.69) 1.90 (0.62-5.83) 0.2486
RBBP8 rs9304261 0.22 888
21 Clear cell 0.58 (0.19-1.83) 3.22 (1.09-9.46) 0.1763
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common homozygous;
Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross
1.
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Appendix IV-L: Haplotype-specific risks of RBBP8 on ovarian cancer
susceptibility
Gene Haplotype Freq (%) Histology OR (95% CI) P-value
All 1.12 (0.98-1.27) 0.092
Serous 1.13 (1.01-1.27) 0.032
Endometrioid 0.99 (0.83-1.19) 0.932
Mucinous 0.98 (0.8-1.21) 0.865
RBBP8 h0000 62.3
Clear cell 0.91 (0.72-1.13) 0.389
All 0.92 (0.8-1.07) 0.273
Serous 0.88 (0.77-1) 0.051
Endometrioid 0.99 (0.81-1.22) 0.958
Mucinous 1.05 (0.83-1.34) 0.667
RBBP8 h0011 23
Clear cell 1.11 (0.86-1.43) 0.415
All 0.83 (0.64-1.07) 0.147
Serous 0.93 (0.75-1.16) 0.542
Endometrioid 1.02 (0.72-1.45) 0.891
Mucinous 0.76 (0.48-1.2) 0.235
RBBP8 h1010 7.2
Clear cell 1.07 (0.7-1.65) 0.742
All 1.16 (0.85-1.58) 0.338
Serous 1.2 (0.9-1.59) 0.211
Endometrioid 1.11 (0.69-1.78) 0.66
Mucinous 1.32 (0.79-2.22) 0.284
RBBP8 h1110 4.4
Clear cell 1.1 (0.61-2.01) 0.745
All 0.88 (0.71-1.1) 0.266
Serous 0.77 (0.53-1.11) 0.156
Endometrioid 1.18 (0.73-1.91) 0.502
Mucinous 1.15 (0.65-2.03) 0.624
RBBP8 h0010 2
Clear cell 1.05 (0.56-2) 0.873
All 0.74 (0.25-2.15) 0.579
Serous 0.85 (0.52-1.39) 0.517
Endometrioid 0.52 (0.19-1.38) 0.189
Mucinous 0.74 (0.28-1.92) 0.532
RBBP8 Rare 0.1
Clear cell 0.64 (0.21-1.99) 0.441
SNP order in haplotypes is 5’ to 3’ of RBBP8: rs7239066, rs11082221, rs4474794, rs9304261.
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Appendix IV-M: Genotype specific ratios of RGC32 tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
1769 All 0.99 (0.86-1.15) 1.05 (0.68-1.64) 0.9822
839 Serous 0.91 (0.75-1.10) 0.74 (0.39-1.41) 0.2126
273 Endometrioid 1.04 (0.77-1.40) 0.62 (0.19-2.02) 0.8091
191 Mucinous 0.88 (0.61-1.27) 1.69 (0.70-4.06) 0.9293
RGC32 rs10467472 0.13 2887
164 Clear cell 0.98 (0.67-1.44) 1.97 (0.82-4.71) 0.4683
1690 All 1.02 (0.88-1.19) 1.03 (0.57-1.89) 0.8873
788 Serous 0.89 (0.72-1.09) 0.70 (0.29-1.69) 0.1363
264 Endometrioid 1.13 (0.83-1.54) 1.50 (0.51-4.36) 0.4304
184 Mucinous 1.09 (0.75-1.59) 1.08 (0.25-4.66) 0.7964
RGC32 rs3783194 0.11 2723
155 Clear cell 1.50 (1.04-2.17) 1.99 (0.59-6.70) 0.0206
1771 All 1.01 (0.87-1.18) 1.31 (0.74-2.32) 0.5158
835 Serous 1.03 (0.85-1.26) 1.33 (0.66-2.70) 0.4921
275 Endometrioid 0.95 (0.69-1.32) 1.48 (0.51-4.31) 0.9104
193 Mucinous 1.03 (0.71-1.51) 0.55 (0.07-4.09) 0.871
RGC32 rs11618371 0.11 2959
164 Clear cell 1.12 (0.76-1.66) 1.31 (0.31-5.62) 0.4759
1782 All 0.96 (0.81-1.15) 0.47 (0.19-1.16) 0.3412
841 Serous 0.94 (0.74-1.18) 0.46 (0.14-1.54) 0.3245
276 Endometrioid 1.22 (0.86-1.72) 0.54 (0.07-4.07) 0.4241
196 Mucinous 1.23 (0.82-1.83) 0.93 (0.12-7.06) 0.288
RGC32 rs9532824 0.07 2892
164 Clear cell 0.94 (0.58-1.50) 0.82 (0.11-6.13) 0.7749
1274 All 1.01 (0.87-1.16) 1.09 (0.82-1.45) 0.8121
595 Serous 0.89 (0.74-1.09) 1.06 (0.73-1.52) 0.4695
RGC32 rs995845 0.2 2365
193 Endometrioid 0.99 (0.73-1.36) 1.04 (0.56-1.90) 0.9679
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Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
146 Mucinous 0.98 (0.69-1.40) 0.93 (0.45-1.92) 0.8142
112 Clear cell 1.41 (0.95-2.10) 1.45 (0.70-3.03) 0.1034
1766 All 1.01 (0.88-1.16) 1.10 (0.74-1.65) 0.611
833 Serous 1.09 (0.91-1.29) 0.97 (0.56-1.65) 0.4095
275 Endometrioid 1.02 (0.77-1.36) 0.78 (0.31-1.99) 0.9957
193 Mucinous 0.95 (0.67-1.34) 0.46 (0.11-1.90) 0.5421
RGC32 rs9594551 0.15 2863
163 Clear cell 1.03 (0.72-1.49) 0.82 (0.25-2.66) 0.9809
1749 All 1.02 (0.90-1.16) 0.89 (0.68-1.17) 0.8348
828 Serous 1.03 (0.87-1.21) 0.84 (0.59-1.21) 0.7862
268 Endometrioid 1.08 (0.83-1.41) 1.03 (0.60-1.78) 0.5433
188 Mucinous 1.11 (0.81-1.51) 0.65 (0.30-1.44) 0.9566
RGC32 rs975590 0.23 2940
161 Clear cell 1.08 (0.78-1.51) 0.41 (0.15-1.12) 0.465
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with
common homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened
OR are statistically significant or do not cross 1.
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Appendix IV-N: Haplotype-specific risks of RGC32 on ovarian cancer
susceptibility
Gene Haplotype Freq (%) Histology OR (95% CI) P-value
All 0.98 (0.89-1.08) 0.674
Serous 1.11 (0.99-1.25) 0.063
Endometrioid 0.93 (0.78-1.13) 0.478
Mucinous 1.07 (0.86-1.33) 0.549
RGC32 h0000000 41.5
Clear cell 0.89 (0.7-1.12) 0.32
All 1.01 (0.87-1.18) 0.851
Serous 0.89 (0.74-1.07) 0.212
Endometrioid 1.02 (0.76-1.36) 0.89
Mucinous 1.01 (0.72-1.41) 0.962
RGC32 h0100100 10.8
Clear cell 1.53 (1.11-2.11) 0.01
All 1.04 (0.89-1.21) 0.608
Serous 1.09 (0.91-1.3) 0.352
Endometrioid 0.97 (0.72-1.31) 0.826
Mucinous 0.8 (0.55-1.17) 0.25
RGC32 h0000100 10.4
Clear cell 0.78 (0.52-1.18) 0.239
All 1 (0.84-1.2) 0.957
Serous 0.92 (0.74-1.15) 0.466
Endometrioid 1.12 (0.8-1.56) 0.511
Mucinous 1.11 (0.75-1.64) 0.603
RGC32 h1000000 8.1
Clear cell 1.11 (0.73-1.69) 0.635
All 1.1 (0.93-1.31) 0.278
Serous 1.15 (0.95-1.4) 0.146
Endometrioid 0.98 (0.7-1.36) 0.892
Mucinous 0.87 (0.58-1.32) 0.521
RGC32 h0010011 7.8
Clear cell 1.15 (0.78-1.71) 0.478
All 0.92 (0.75-1.12) 0.405
Serous 0.92 (0.73-1.16) 0.501
Endometrioid 1.15 (0.81-1.63) 0.433
Mucinous 1.16 (0.77-1.75) 0.484
RGC32 h0001001 6.7
Clear cell 0.94 (0.58-1.53) 0.816
All 0.93 (0.74-1.17) 0.54
Serous 0.97 (0.75-1.26) 0.829
Endometrioid 0.96 (0.63-1.47) 0.849
Mucinous 0.66 (0.37-1.19) 0.169
RGC32 h0000011 4.9
Clear cell 0.85 (0.49-1.51) 0.587
All 0.99 (0.79-1.26) 0.958
Serous 0.9 (0.67-1.22) 0.502
Endometrioid 0.83 (0.51-1.36) 0.458
RGC32 h1000100 4.1
Mucinous 1.03 (0.61-1.75) 0.905
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Gene Haplotype Freq (%) Histology OR (95% CI) P-value
Clear cell 1.24 (0.73-2.1) 0.429
All 1.15 (0.66-2.02) 0.621
Serous 0.61 (0.42-0.89) 0.009
Endometrioid 0.8 (0.46-1.39) 0.428
Mucinous 0.7 (0.34-1.41) 0.317
RGC32 Rare 0.8
Clear cell 0.74 (0.35-1.55) 0.422
SNP order in haplotypes is 5’ to 3’ of RGC32: rs10467472, rs3783194, rs11618371, rs9532824,
rs995845, rs9594551, rs975590.
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Appendix IV-O: Genotype specific ratios of RUVBL1 tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
1777 All 1.05 (0.90-1.22) 1.44 (0.89-2.31) 0.2094
839 Serous 1.16 (0.96-1.40) 1.03 (0.52-2.02) 0.1425
276 Endometrioid 0.90 (0.65-1.24) 1.76 (0.72-4.27) 0.9619
193 Mucinous 0.85 (0.58-1.25) 1.73 (0.59-5.11) 0.8531
RUVBL1 rs9860614 0.12 2966
162 Clear cell 0.85 (0.56-1.29) 1.97 (0.69-5.67) 0.983
1266 All 1.14 (0.97-1.34) 1.39 (1.02-1.89) 0.0192
537 Serous 1.42 (1.15-1.74) 1.63 (1.10-2.42) 0.0002
207 Endometrioid 0.74 (0.53-1.04) 1.29 (0.73-2.31) 0.3904
143 Mucinous 0.95 (0.64-1.41) 1.39 (0.69-2.83) 0.5473
RUVBL1 rs13063604 0.25 1724
124 Clear cell 1.22 (0.83-1.80) 1.07 (0.48-2.40) 0.4113
1280 All 1.20 (1.03-1.40) 1.06 (0.85-1.31) 0.207
596 Serous 1.35 (1.10-1.64) 1.14 (0.86-1.52) 0.0677
194 Endometrioid 1.25 (0.90-1.74) 1.24 (0.79-1.94) 0.236
147 Mucinous 0.91 (0.64-1.31) 0.70 (0.40-1.24) 0.1882
RUVBL1 rs3732402 0.4 2382
114 Clear cell 1.00 (0.67-1.49) 0.61 (0.31-1.20) 0.2799
1645 All 1.08 (0.93-1.26) 0.86 (0.72-1.03) 0.1081
769 Serous 0.97 (0.80-1.17) 0.74 (0.58-0.93) 0.009
256 Endometrioid 1.12 (0.83-1.53) 0.74 (0.50-1.09) 0.1777
175 Mucinous 1.04 (0.70-1.53) 1.25 (0.81-1.93) 0.371
RUVBL1 rs7650365 0.46 2672
155 Clear cell 1.08 (0.73-1.60) 0.93 (0.58-1.48) 0.7821
1787 All 1.05 (0.93-1.19) 0.97 (0.76-1.23) 0.8219
845 Serous 1.11 (0.95-1.31) 1.04 (0.77-1.41) 0.3458
RUVBL1 rs4857836 0.2 2993
278 Endometrioid 1.05 (0.80-1.37) 1.38 (0.89-2.14) 0.2742
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Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
195 Mucinous 0.85 (0.62-1.16) 0.76 (0.40-1.44) 0.1432
165 Clear cell 0.89 (0.63-1.24) 0.91 (0.49-1.69) 0.5199
1733 All 0.97 (0.84-1.11) 0.93 (0.63-1.37) 0.5613
820 Serous 0.99 (0.82-1.18) 0.57 (0.31-1.06) 0.2966
269 Endometrioid 1.14 (0.86-1.52) 2.09 (1.16-3.78) 0.0286
186 Mucinous 0.86 (0.60-1.23) 0.62 (0.19-2.00) 0.1981
RUVBL1 rs9821568 0.15 2911
161 Clear cell 0.68 (0.45-1.02) 0.85 (0.30-2.38) 0.0967
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with
common homozygous; Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened
OR are statistically significant or do not cross 1.
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Appendix IV-P: Haplotype-specific risks of RUVBL1 on ovarian
cancer susceptibility
Gene Haplotype Freq (%) Histology OR (95% CI) P-value
All 0.96 (0.86-1.07) 0.491
Serous 0.76 (0.62-0.93) 0.0315
Endometrioid 0.75 (0.54-1.05) 0.137
Mucinous 1.22 (0.83-1.79) 0.3395
RUVBL1 h000100 48
Clear cell 0.9 (0.6-1.38) 0.624
All 0.98 (0.84-1.15) 0.833
Serous 0.86 (0.64-1.17) 0.429
Endometrioid 1.61 (1.03-2.52) 0.0465
Mucinous 0.59 (0.32-1.11) 0.1085
RUVBL1 h001011 14.5
Clear cell 0.605 (0.32-1.17) 0.1645
All 0.91 (0.77-1.07) 0.247
Serous 1.22 (0.9-1.67) 0.3585
Endometrioid 1.43 (0.89-2.32) 0.1805
Mucinous 1.23 (0.7-2.18) 0.485
RUVBL1 h000000 13.3
Clear cell 1.51 (0.85-2.75) 0.165
All 1.15 (0.97-1.36) 0.114
Serous 1.44 (1.04-1.98) 0.027
Endometrioid 0.79 (0.45-1.39) 0.401
Mucinous 0.91 (0.48-1.75) 0.751
RUVBL1 h011010 11.7
Clear cell 1.32 (0.7-2.51) 0.395
All 1.17 (0.99-1.4) 0.071
Serous 1.4 (0.99-2) 0.1915
Endometrioid 0.95 (0.55-1.67) 0.8565
Mucinous 0.96 (0.49-1.9) 0.7185
RUVBL1 h111000 9.8
Clear cell 1.02 (0.51-2.1) 0.74
All 0.99 (0.54-1.8) 0.963
Serous 0.98 (0.69-1.38) 0.892
Endometrioid 0.89 (0.49-1.6) 0.69
Mucinous 0.89 (0.46-1.75) 0.746
RUVBL1 Rare 0.8
Clear cell 1.06 (0.54-2.07) 0.861
SNP order in haplotypes is 5’ to 3’ of RUVBL1: rs9860614, rs13063604, rs3732402, rs7650365,
rs4857836, rs9821568.
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Appendix IV-Q: Genotype specific ratios of STAG3 tSNPs on ovarian cancer susceptibility
Gene tSNP MAF No.controls
No.
cases Histology HetOR (95% CI) HomOR (95% CI) P-trend
1787 All 1.03 (0.90-1.17) 1.06 (0.80-1.40) 0.6327
846 Serous 1.03 (0.88-1.22) 1.06 (0.74-1.52) 0.6639
279 Endometrioid 0.98 (0.75-1.28) 1.22 (0.71-2.11) 0.695
194 Mucinous 0.83 (0.60-1.15) 0.79 (0.37-1.67) 0.2541
STAG3 rs11762932 0.22 2965
164 Clear cell 1.29 (0.93-1.79) 1.01 (0.46-2.23) 0.2781
1295 All 0.97 (0.81-1.15) 0.96 (0.78-1.19) 0.6593
549 Serous 0.95 (0.75-1.20) 0.87 (0.66-1.16) 0.2436
212 Endometrioid 0.98 (0.69-1.40) 1.02 (0.67-1.54) 0.8107
143 Mucinous 1.11 (0.71-1.73) 0.90 (0.52-1.55) 0.9446
STAG3 rs2246713 0.47 1765
130 Clear cell 1.02 (0.66-1.58) 1.16 (0.70-1.92) 0.5676
1784 All 0.86 (0.76-0.98) 0.92 (0.73-1.16) 0.0692
843 Serous 0.84 (0.71-0.99) 0.77 (0.56-1.05) 0.0177
278 Endometrioid 0.79 (0.61-1.04) 0.92 (0.57-1.48) 0.2456
194 Mucinous 1.23 (0.90-1.68) 1.27 (0.74-2.18) 0.1363
STAG3 rs1637001 0.26 2967
165 Clear cell 1.02 (0.73-1.41) 0.61 (0.29-1.28) 0.4137
MAF – minor allele frequency; Het – heterozygous; Hom – homozygous; OR – odds ratio; CI – confidence interval; § compared with common homozygous;
Emboldened tSNP and histology names, and P-values are statistically associated with susceptibility; emboldened OR are statistically significant or do not cross
1.
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Appendix IV-R: Haplotype-specific risks of STAG3 on ovarian cancer
susceptibility
Gene Haplotype Freq (%) Histology OR (95% CI) P-value
All 1.06 (0.96-1.16) 0.257
Serous 1.12 (1.01-1.25) 0.039
Endometrioid 1.06 (0.89-1.27) 0.523
Mucinous 0.97 (0.79-1.2) 0.805
STAG3 h000 50.7
Clear cell 1 (0.8-1.25) 0.996
All 0.94 (0.85-1.05) 0.29
Serous 0.88 (0.78-1) 0.046
Endometrioid 0.89 (0.73-1.09) 0.251
Mucinous 1.22 (0.97-1.53) 0.084
STAG3 h011 26.8
Clear cell 0.89 (0.69-1.16) 0.401
All 1.03 (0.92-1.16) 0.627
Serous 1.05 (0.92-1.2) 0.48
Endometrioid 1.03 (0.83-1.28) 0.765
Mucinous 0.87 (0.66-1.13) 0.297
STAG3 h110 20.5
Clear cell 1.16 (0.89-1.51) 0.285
SNP order in haplotypes is 5’ to 3’ of STAG3: rs11762932, rs2246713, rs1637001
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Appendix V: Genotype distributions of tagging SNPs in candidate genes analysed with AML test
Number of cases Number of controls
Pathway Gene/cytoband SNP Study
AA Aa aa Total AA Aa aa Total
BCAC 2q22.1 rs4954956 GEOCS 171 129 20 320 240 156 25 421
BCAC 2q22.1 rs4954956 MALOVA 224 158 29 411 686 440 69 1195
BCAC 2q22.1 rs4954956 SEARCH 414 262 39 715 466 323 64 853
BCAC 5q11.2 rs889312 GEOCS 166 129 25 320 202 174 45 421
BCAC 5q11.2 rs889312 MALOVA 225 178 31 434 616 485 86 1187
BCAC 5q11.2 rs889312 SEARCH 378 286 55 719 447 341 64 852
BCAC 8q24.21 rs13281615 GEOCS 97 167 57 321 138 204 79 421
BCAC 8q24.21 rs13281615 MALOVA 162 193 67 422 462 557 170 1189
BCAC 8q24.21 rs13281615 SEARCH 267 337 111 715 281 439 134 854
BCAC 8q24.21 rs6983267 GEOCS 77 157 85 319 125 206 90 421
BCAC 8q24.21 rs6983267 MALOVA 100 156 73 329 311 572 285 1168
BCAC 8q24.21 rs6983267 SEARCH 210 370 136 716 224 423 203 850
BCAC 8q24.21 rs9283954 GEOCS 250 65 6 321 340 79 2 421
BCAC 8q24.21 rs9283954 MALOVA 290 80 4 374 927 209 13 1149
BCAC 8q24.21 rs9283954 SEARCH 582 124 8 714 683 158 9 850
BCAC 11p15.5 rs2107425 GEOCS 156 124 39 319 170 204 48 422
BCAC 11p15.5 rs2107425 MALOVA 226 157 50 433 558 518 114 1190
BCAC 11p15.5 rs2107425 SEARCH 385 263 60 708 390 376 85 851
BCAC 12p11.22 rs7313833 GEOCS 138 147 35 320 194 174 53 421
BCAC 12p11.22 rs7313833 MALOVA 187 191 45 423 527 505 152 1184
BCAC 12p11.22 rs7313833 SEARCH 315 308 94 717 397 372 83 852
BCAC FLJ41481 rs4666451 GEOCS 107 161 49 317 146 209 65 420
BCAC FLJ41481 rs4666451 MALOVA 153 195 74 422 417 584 198 1199
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Number of cases Number of controls
Pathway Gene/cytoband SNP Study
AA Aa aa Total AA Aa aa Total
BCAC FLJ41481 rs4666451 SEARCH 260 336 119 715 306 409 135 850
BCAC HCN1 rs981782 GEOCS 103 150 67 320 136 204 80 420
BCAC HCN1 rs981782 MALOVA 98 192 93 383 327 577 258 1162
BCAC HCN1 rs981782 SEARCH 180 381 155 716 233 404 213 850
BCAC LOC100131885 rs2981582 GEOCS 117 161 42 320 149 205 69 423
BCAC LOC100131885 rs2981582 MALOVA 169 188 73 430 469 537 183 1189
BCAC LOC100131885 rs2981582 SEARCH 296 314 103 713 302 420 132 854
BCAC LSP1 rs3817198 GEOCS 140 151 31 322 226 162 35 423
BCAC LSP1 rs3817198 MALOVA 195 183 48 426 606 460 101 1167
BCAC LSP1 rs3817198 SEARCH 313 306 90 709 380 381 84 845
BCAC TOX3 rs12443621 GEOCS 63 186 72 321 100 211 110 421
BCAC TOX3 rs12443621 MALOVA 156 190 69 415 395 561 232 1188
BCAC TOX3 rs12443621 SEARCH 214 352 143 709 237 425 186 848
Cell cycle CCND1 rs602652 GEOCS 93 153 70 316 121 217 85 423
Cell cycle CCND1 rs602652 MALOVA 108 206 123 437 364 590 263 1217
Cell cycle CCND1 rs602652 SEARCH 193 381 141 715 257 418 178 853
Cell cycle CCND1 rs3862792 GEOCS 302 19 0 321 402 19 0 421
Cell cycle CCND1 rs3862792 MALOVA 414 18 0 432 1130 64 0 1194
Cell cycle CCND1 rs3862792 SEARCH 688 30 0 718 803 50 0 853
Cell cycle CCND1 rs603965 GEOCS 97 151 73 321 129 217 79 425
Cell cycle CCND1 rs603965 MALOVA 117 202 118 437 365 578 242 1185
Cell cycle CCND1 rs603965 SEARCH 212 368 138 718 269 427 158 854
Cell cycle CCND1 rs3212879 GEOCS 87 144 85 316 101 211 108 420
Cell cycle CCND1 rs3212879 MALOVA 145 206 90 441 324 608 285 1217
Cell cycle CCND1 rs3212879 SEARCH 206 355 154 715 236 419 199 854
Cell cycle CCND1 rs3212891 GEOCS 91 151 79 321 118 211 95 424
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Cell cycle CCND1 rs3212891 MALOVA 153 203 79 435 356 589 253 1198
Cell cycle CCND1 rs3212891 SEARCH 228 354 137 719 245 428 181 854
Cell cycle CCND1 rs678653 GEOCS 108 145 50 303 138 195 60 393
Cell cycle CCND1 rs678653 MALOVA 202 191 50 443 538 538 145 1221
Cell cycle CCND1 rs678653 SEARCH 302 321 96 719 341 390 123 854
Cell cycle CCND1 rs7178 GEOCS 279 41 1 321 369 49 5 423
Cell cycle CCND1 rs7178 MALOVA 359 78 5 442 1040 168 7 1215
Cell cycle CCND1 rs7178 SEARCH 596 119 2 717 732 120 1 853
Cell cycle CCND2 rs3217795 GEOCS 277 44 2 323 356 66 6 428
Cell cycle CCND2 rs3217795 MALOVA 365 76 2 443 1026 188 4 1218
Cell cycle CCND2 rs3217795 SEARCH 601 115 3 719 709 140 5 854
Cell cycle CCND2 rs3217805 GEOCS 120 158 44 322 171 183 73 427
Cell cycle CCND2 rs3217805 MALOVA 152 224 65 441 435 589 197 1221
Cell cycle CCND2 rs3217805 SEARCH 252 343 100 695 299 405 150 854
Cell cycle CCND2 rs3217820 GEOCS 127 154 41 322 181 185 59 425
Cell cycle CCND2 rs3217820 MALOVA 195 192 56 443 532 532 156 1220
Cell cycle CCND2 rs3217820 SEARCH 247 314 81 642 361 378 113 852
Cell cycle CCND2 rs3217852 GEOCS 194 113 14 321 250 147 23 420
Cell cycle CCND2 rs3217852 MALOVA 252 158 25 435 702 438 76 1216
Cell cycle CCND2 rs3217852 SEARCH 422 261 35 718 493 310 49 852
Cell cycle CCND2 rs3217862 GEOCS 224 93 3 320 308 104 12 424
Cell cycle CCND2 rs3217862 MALOVA 308 116 11 435 850 332 34 1216
Cell cycle CCND2 rs3217862 SEARCH 503 186 26 715 566 263 24 853
Cell cycle CCND2 rs3217863 GEOCS 267 47 6 320 331 85 6 422
Cell cycle CCND2 rs3217863 MALOVA 340 77 5 422 1018 176 5 1199
Cell cycle CCND2 rs3217863 SEARCH 615 96 6 717 725 119 7 851
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Cell cycle CCND2 rs3217869 GEOCS 118 152 52 322 170 174 84 428
Cell cycle CCND2 rs3217869 MALOVA 152 215 76 443 446 564 206 1216
Cell cycle CCND2 rs3217869 SEARCH 268 322 128 718 298 430 126 854
Cell cycle CCND2 rs3217901 GEOCS 105 165 50 320 124 225 72 421
Cell cycle CCND2 rs3217901 MALOVA 136 208 97 441 386 590 240 1216
Cell cycle CCND2 rs3217901 SEARCH 214 382 122 718 294 394 164 852
Cell cycle CCND2 rs3217906 GEOCS 190 112 19 321 246 153 23 422
Cell cycle CCND2 rs3217906 MALOVA 227 170 31 428 661 457 79 1197
Cell cycle CCND2 rs3217906 SEARCH 392 283 43 718 472 319 63 854
Cell cycle CCND2 rs3217916 GEOCS 165 142 17 324 238 148 38 424
Cell cycle CCND2 rs3217916 MALOVA 249 163 21 433 602 494 103 1199
Cell cycle CCND2 rs3217916 SEARCH 361 297 61 719 440 342 72 854
Cell cycle CCND2 rs3217925 GEOCS 174 133 13 320 255 141 27 423
Cell cycle CCND2 rs3217925 MALOVA 265 154 16 435 628 475 84 1187
Cell cycle CCND2 rs3217925 SEARCH 390 277 48 715 468 323 60 851
Cell cycle CCND2 rs3217926 GEOCS 119 155 48 322 157 192 78 427
Cell cycle CCND2 rs3217926 MALOVA 174 204 66 444 477 569 174 1220
Cell cycle CCND2 rs3217926 SEARCH 274 342 102 718 332 375 146 853
Cell cycle CCND2 rs3217933 GEOCS 182 122 20 324 242 164 18 424
Cell cycle CCND2 rs3217933 MALOVA 221 180 34 435 662 458 76 1196
Cell cycle CCND2 rs3217933 SEARCH 389 294 36 719 479 309 66 854
Cell cycle CCND2 rs3217936 GEOCS 151 147 24 322 218 162 47 427
Cell cycle CCND2 rs3217936 MALOVA 210 197 32 439 512 559 139 1210
Cell cycle CCND2 rs3217936 SEARCH 320 322 75 717 386 372 94 852
Cell cycle CCND3 Rs1410492 GEOCS 181 125 17 323 251 142 34 427
Cell cycle CCND3 Rs1410492 MALOVA 245 173 24 442 708 423 86 1217
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Cell cycle CCND3 Rs1410492 SEARCH 398 265 51 714 478 333 35 846
Cell cycle CCND3 rs3218092 GEOCS 212 96 13 321 261 130 32 423
Cell cycle CCND3 rs3218092 MALOVA 265 149 17 431 783 363 46 1192
Cell cycle CCND3 rs3218092 SEARCH 492 208 16 716 569 257 27 853
Cell cycle CCND3 Rs2479717 GEOCS 160 139 16 315 244 150 31 425
Cell cycle CCND3 Rs2479717 MALOVA 224 173 45 442 667 454 96 1217
Cell cycle CCND3 Rs2479717 SEARCH 382 276 57 715 414 352 81 847
Cell cycle CCND3 Rs1051130 GEOCS 81 173 65 319 112 203 110 425
Cell cycle CCND3 Rs1051130 MALOVA 118 215 110 443 373 540 298 1211
Cell cycle CCND3 Rs1051130 SEARCH 213 362 138 713 235 398 219 852
Cell cycle CCND3 rs9529 GEOCS 149 152 20 321 221 168 34 423
Cell cycle CCND3 rs9529 MALOVA 242 162 37 441 633 456 110 1199
Cell cycle CCND3 rs9529 SEARCH 381 281 57 719 423 340 90 853
Cell cycle CCND3 rs3218110 GEOCS 184 123 15 322 246 152 24 422
Cell cycle CCND3 rs3218110 MALOVA 250 157 31 438 684 443 79 1206
Cell cycle CCND3 rs3218110 SEARCH 382 295 42 719 503 308 43 854
Cell cycle CCND3 rs3218114 GEOCS 225 87 10 322 274 126 22 422
Cell cycle CCND3 rs3218114 MALOVA 279 147 17 443 812 356 48 1216
Cell cycle CCND3 rs3218114 SEARCH 496 207 16 719 576 252 26 854
Cell cycle CCNE1 rs997669 GEOCS 120 154 48 322 172 204 50 426
Cell cycle CCNE1 rs997669 MALOVA 151 218 73 442 436 601 180 1217
Cell cycle CCNE1 rs997669 SEARCH 259 349 108 716 331 389 134 854
Cell cycle CCNE1 rs3218036 GEOCS 147 146 26 319 207 183 33 423
Cell cycle CCNE1 rs3218036 MALOVA 192 193 54 439 545 546 114 1205
Cell cycle CCNE1 rs3218036 SEARCH 325 310 83 718 414 355 84 853
Cell cycle CCNE1 rs3218038 GEOCS 287 33 2 322 377 48 1 426
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Cell cycle CCNE1 rs3218038 MALOVA 418 22 0 440 1160 58 0 1218
Cell cycle CCNE1 rs3218038 SEARCH 660 56 1 717 784 68 1 853
Cell cycle CCNE1 rs3218076 GEOCS 164 130 26 320 205 185 37 427
Cell cycle CCNE1 rs3218076 MALOVA 211 203 28 442 614 512 92 1218
Cell cycle CCNE1 rs3218076 SEARCH 370 291 57 718 445 352 55 852
Cell cycle CDK2 Rs2069408 GEOCS 167 128 27 322 194 190 43 427
Cell cycle CDK2 Rs2069408 MALOVA 189 202 46 437 522 549 145 1216
Cell cycle CDK2 Rs2069408 SEARCH 332 300 85 717 369 388 96 853
Cell cycle CDK2 Rs1045435 GEOCS 266 56 1 323 367 57 2 426
Cell cycle CDK2 Rs1045435 MALOVA 356 82 3 441 996 209 13 1218
Cell cycle CDK2 Rs1045435 SEARCH 583 123 12 718 708 144 1 853
Cell cycle CDK4 rs2270777 GEOCS 87 180 53 320 141 217 68 426
Cell cycle CDK4 rs2270777 MALOVA 138 231 70 439 379 626 207 1212
Cell cycle CDK4 rs2270777 SEARCH 238 347 133 718 289 419 145 853
Cell cycle CDK4 rs2069506 GEOCS 155 134 34 323 211 164 50 425
Cell cycle CDK4 rs2069506 MALOVA 214 178 51 443 507 556 144 1207
Cell cycle CDK4 rs2069506 SEARCH 321 305 88 714 396 363 91 850
Cell cycle CDK6 rs8179 GEOCS 200 106 15 321 265 139 14 418
Cell cycle CDK6 rs8179 MALOVA 264 150 22 436 721 420 56 1197
Cell cycle CDK6 rs8179 SEARCH 447 230 31 708 508 280 37 825
Cell cycle CDK6 rs2285332 GEOCS 180 117 22 319 208 177 37 422
Cell cycle CDK6 rs2285332 MALOVA 264 151 24 439 681 450 66 1197
Cell cycle CDK6 rs2285332 SEARCH 414 263 41 718 495 298 51 844
Cell cycle CDK6 rs42046 GEOCS 152 142 27 321 212 168 26 406
Cell cycle CDK6 rs42046 MALOVA 216 188 31 435 626 492 86 1204
Cell cycle CDK6 rs42046 SEARCH 383 279 48 710 448 328 60 836
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Cell cycle CDK6 rs3731348 GEOCS 273 44 1 318 372 46 2 420
Cell cycle CDK6 rs8 GEOCS 203 102 9 314 277 127 10 414
Cell cycle CDK6 rs3731348 MALOVA 384 42 1 427 1049 139 4 1192
Cell cycle CDK6 rs8 MALOVA 255 162 26 443 736 428 55 1219
Cell cycle CDK6 rs3731348 SEARCH 631 86 1 718 761 86 6 853
Cell cycle CDK6 rs8 SEARCH 412 269 35 716 543 276 29 848
Cell cycle CDK6 rs2237570 GEOCS 264 54 2 320 329 87 6 422
Cell cycle CDK6 rs2237570 MALOVA 344 91 3 438 946 240 13 1199
Cell cycle CDK6 rs2237570 SEARCH 572 134 10 716 652 182 13 847
Cell cycle CDK6 rs3731343 GEOCS 111 153 59 323 156 191 77 424
Cell cycle CDK6 rs3731343 MALOVA 126 205 111 442 335 622 264 1221
Cell cycle CDK6 rs3731343 SEARCH 184 380 155 719 238 427 189 854
Cell cycle CDK6 rs3757823 GEOCS 242 77 5 324 341 84 3 428
Cell cycle CDK6 rs3757823 MALOVA 368 71 4 443 956 247 9 1212
Cell cycle CDK6 rs3757823 SEARCH 578 137 4 719 713 134 8 855
Cell cycle CDK6 rs2079147 GEOCS 69 165 90 324 95 224 108 427
Cell cycle CDK6 rs2079147 MALOVA 116 215 107 438 300 628 287 1215
Cell cycle CDK6 rs2079147 SEARCH 191 372 156 719 238 417 199 854
Cell cycle CDK6 rs2282991 GEOCS 274 46 1 321 330 84 4 418
Cell cycle CDK6 rs2282991 MALOVA 342 77 3 422 935 215 9 1159
Cell cycle CDK6 rs2282991 SEARCH 580 116 10 706 659 157 11 827
Cell cycle CDK6 rs4729049 GEOCS 263 59 3 325 351 75 2 428
Cell cycle CDK6 rs4729049 MALOVA 360 74 4 438 975 225 16 1216
Cell cycle CDK6 rs4729049 SEARCH 574 139 6 719 692 154 9 855
Cell cycle CDK6 rs445 GEOCS 235 78 7 320 331 87 8 426
Cell cycle CDK6 rs445 MALOVA 370 70 2 442 985 224 9 1218
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Cell cycle CDK6 rs445 SEARCH 595 120 4 719 703 144 6 853
Cell cycle CDK6 rs992519 GEOCS 235 78 6 319 308 107 8 423
Cell cycle CDK6 rs992519 MALOVA 320 111 9 440 935 262 22 1219
Cell cycle CDK6 rs992519 SEARCH 533 171 14 718 625 210 19 854
Cell cycle CDKN1A rs762624 GEOCS 149 142 29 320 206 180 40 426
Cell cycle CDKN1A rs762624 MALOVA 230 171 36 437 673 463 70 1206
Cell cycle CDKN1A rs762624 SEARCH 385 281 52 718 458 327 66 851
Cell cycle CDKN1A rs2395655 GEOCS 103 163 52 318 164 192 66 422
Cell cycle CDKN1A rs2395655 MALOVA 161 203 78 442 484 567 166 1217
Cell cycle CDKN1A rs2395655 SEARCH 274 327 117 718 331 374 143 848
Cell cycle CDKN1A rs3176331 GEOCS 241 77 4 322 324 95 5 424
Cell cycle CDKN1A rs3176331 MALOVA 325 93 13 431 911 263 22 1196
Cell cycle CDKN1A rs3176331 SEARCH 545 161 12 718 642 192 18 852
Cell cycle CDKN1A rs3176336 GEOCS 100 154 66 320 141 199 82 422
Cell cycle CDKN1A rs3176336 MALOVA 179 203 62 444 461 577 178 1216
Cell cycle CDKN1A rs3176336 SEARCH 272 334 111 717 318 385 147 850
Cell cycle CDKN1A rs3176343 GEOCS 279 43 0 322 380 41 1 422
Cell cycle CDKN1A rs3176343 MALOVA 405 36 1 442 1101 113 1 1215
Cell cycle CDKN1A rs3176343 SEARCH 639 79 1 719 758 94 2 854
Cell cycle CDKN1A rs1801270 GEOCS 259 56 3 318 334 80 5 419
Cell cycle CDKN1A rs1801270 MALOVA 394 49 0 443 1046 147 3 1196
Cell cycle CDKN1A rs1801270 SEARCH 619 95 2 716 725 118 5 848
Cell cycle CDKN1A rs3176352 GEOCS 158 131 32 321 213 173 37 423
Cell cycle CDKN1A rs3176352 MALOVA 236 162 39 437 680 442 79 1201
Cell cycle CDKN1A rs3176352 SEARCH 388 278 53 719 460 328 64 852
Cell cycle CDKN1A rs1059234 GEOCS 263 55 4 322 338 82 5 425
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Cell cycle CDKN1A rs1059234 MALOVA 394 48 1 443 1053 147 4 1204
Cell cycle CDKN1A rs1059234 SEARCH 624 92 2 718 733 114 5 852
Cell cycle CDKN1A rs6457937 GEOCS 307 18 0 325 401 26 0 427
Cell cycle CDKN1A rs6457937 MALOVA 414 25 0 439 1148 66 0 1214
Cell cycle CDKN1A rs6457937 SEARCH 686 33 0 719 812 42 0 854
Cell cycle CDKN1B rs3759217 GEOCS 225 88 9 322 314 101 8 423
Cell cycle CDKN1B rs3759217 MALOVA 345 90 8 443 958 243 14 1215
Cell cycle CDKN1B rs3759217 SEARCH 546 167 5 718 671 169 14 854
Cell cycle CDKN1B rs34330 GEOCS 189 122 14 325 249 154 26 429
Cell cycle CDKN1B rs34330 MALOVA 262 144 28 434 703 417 66 1186
Cell cycle CDKN1B rs34330 SEARCH 413 259 37 709 470 330 52 852
Cell cycle CDKN1B rs2066827 GEOCS 189 118 14 321 239 152 33 424
Cell cycle CDKN1B rs2066827 MALOVA 249 165 28 442 660 468 79 1207
Cell cycle CDKN1B rs2066827 SEARCH 449 235 34 718 476 314 63 853
Cell cycle CDKN1B rs34329 GEOCS 140 149 33 322 179 186 57 422
Cell cycle CDKN1B rs34329 MALOVA 212 191 37 440 590 513 112 1215
Cell cycle CDKN1B rs34329 SEARCH 337 312 70 719 402 380 72 854
Cell cycle CDKN1B rs3093736 GEOCS 305 17 0 322 406 17 0 423
Cell cycle CDKN1B rs3093736 MALOVA 409 32 1 442 1119 94 3 1216
Cell cycle CDKN1B rs3093736 SEARCH 675 43 1 719 794 60 0 854
Cell cycle CDKN1B rs7330 GEOCS 112 157 54 323 154 194 78 426
Cell cycle CDKN1B rs7330 MALOVA 177 194 71 442 468 562 190 1220
Cell cycle CDKN1B rs7330 SEARCH 260 338 121 719 297 427 129 853
Cell cycle CDKN1B rs1420023 GEOCS 271 48 3 322 342 77 2 421
Cell cycle CDKN1B rs1420023 MALOVA 346 83 7 436 969 229 15 1213
Cell cycle CDKN1B rs1420023 SEARCH 565 144 8 717 667 173 12 852
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Cell cycle CDKN2A Rs3217992 GEOCS 119 157 45 321 158 200 68 426
Cell cycle CDKN2A Rs3217992 MALOVA 206 182 48 436 514 567 136 1217
Cell cycle CDKN2A Rs3217992 SEARCH 282 351 84 717 343 399 104 846
Cell cycle CDKN2A Rs3218005 GEOCS 252 59 5 316 345 69 3 417
Cell cycle CDKN2A Rs3218005 MALOVA 346 79 5 430 979 215 11 1205
Cell cycle CDKN2A Rs3218005 SEARCH 588 117 10 715 702 142 7 851
Cell cycle CDKN2A Rs2811712 GEOCS 254 61 5 320 349 73 3 425
Cell cycle CDKN2A Rs2811712 MALOVA 347 88 8 443 966 239 14 1219
Cell cycle CDKN2A Rs2811712 SEARCH 584 119 13 716 681 162 7 850
Cell cycle CDKN2A Rs3218020 GEOCS 123 154 38 315 166 178 56 400
Cell cycle CDKN2A Rs3218020 MALOVA 226 175 39 440 565 539 110 1214
Cell cycle CDKN2A Rs3218020 SEARCH 303 332 77 712 377 377 95 849
Cell cycle CDKN2A rs3731197 GEOCS 110 157 52 319 147 192 83 422
Cell cycle CDKN2A rs3731197 MALOVA 175 208 60 443 488 561 156 1205
Cell cycle CDKN2A rs3731197 SEARCH 274 328 112 714 331 410 111 852
Cell cycle CDKN2A Rs3731211 GEOCS 164 128 29 321 215 177 33 425
Cell cycle CDKN2A Rs3731211 MALOVA 228 181 31 440 646 476 86 1208
Cell cycle CDKN2A Rs3731211 SEARCH 395 269 51 715 443 353 55 851
Cell cycle CDKN2A Rs3731222 GEOCS 235 84 2 321 303 114 8 425
Cell cycle CDKN2A Rs3731222 MALOVA 343 92 8 443 944 252 23 1219
Cell cycle CDKN2A Rs3731222 SEARCH 532 170 14 716 641 194 18 853
Cell cycle CDKN2A rs4074785 GEOCS 258 55 8 321 331 82 9 422
Cell cycle CDKN2A rs4074785 MALOVA 362 67 2 431 990 192 7 1189
Cell cycle CDKN2A rs4074785 SEARCH 565 146 8 719 699 149 5 853
Cell cycle CDKN2A rs3731239 GEOCS 139 152 32 323 201 171 49 421
Cell cycle CDKN2A rs3731239 MALOVA 146 225 70 441 461 577 180 1218
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Cell cycle CDKN2A rs3731239 SEARCH 283 332 99 714 319 419 110 848
Cell cycle CDKN2A rs3731249 GEOCS 301 18 2 321 397 22 1 420
Cell cycle CDKN2A rs3731249 MALOVA 405 30 0 435 1094 98 1 1193
Cell cycle CDKN2A rs3731249 SEARCH 685 22 1 708 804 33 2 839
Cell cycle CDKN2A rs11515 GEOCS 227 82 12 321 316 104 6 426
Cell cycle CDKN2A rs11515 MALOVA 304 127 9 440 870 321 25 1216
Cell cycle CDKN2A rs11515 SEARCH 544 157 17 718 624 214 12 850
Cell cycle CDKN2A rs3088440 GEOCS 261 55 6 322 329 89 9 427
Cell cycle CDKN2A rs3088440 MALOVA 367 67 2 436 1024 186 5 1215
Cell cycle CDKN2A rs3088440 SEARCH 567 143 7 717 695 150 3 848
Cell cycle CDKN2A rs3731257 GEOCS 173 131 18 322 230 160 32 422
Cell cycle CDKN2A rs3731257 MALOVA 266 154 20 440 684 449 72 1205
Cell cycle CDKN2A rs3731257 SEARCH 413 265 40 718 451 350 48 849
Cell cycle CDKN2B rs3217986 GEOCS 259 56 8 323 335 83 9 427
Cell cycle CDKN2B rs3217986 MALOVA 367 71 2 440 1009 197 7 1213
Cell cycle CDKN2B rs3217986 SEARCH 568 140 7 715 696 145 5 846
Cell cycle CDKN2B rs1063192 GEOCS 120 146 53 319 165 189 68 422
Cell cycle CDKN2B rs1063192 MALOVA 119 212 110 441 351 591 274 1216
Cell cycle CDKN2B rs1063192 SEARCH 221 376 119 716 245 440 168 853
Cell cycle CDKN2B rs3218009 GEOCS 255 51 5 311 324 79 4 407
Cell cycle CDKN2B rs3218009 MALOVA 317 111 13 441 859 339 21 1219
Cell cycle CDKN2B rs3218009 SEARCH 544 161 12 717 648 187 17 852
Cell cycle CDKN2B rs3218012 GEOCS 89 156 75 320 114 198 110 422
Cell cycle CDKN2B rs3218012 MALOVA 170 199 67 436 418 586 203 1207
Cell cycle CDKN2B rs3218012 SEARCH 208 358 142 708 267 426 155 848
Cell cycle CDKN2C Rs12855 GEOCS 254 64 4 322 354 72 2 428
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Cell cycle CDKN2C Rs12855 MALOVA 353 84 5 442 967 234 16 1217
Cell cycle CDKN2C Rs12855 SEARCH 597 114 7 718 697 152 5 854
Cell cycle CDKN2C rs3176459 GEOCS 128 148 38 314 188 184 44 416
Cell cycle CDKN2C rs3176459 MALOVA 201 194 42 437 590 489 134 1213
Cell cycle CDKN2C rs3176459 SEARCH 321 312 82 715 362 375 114 851
Cell cycle CDKN2D rs1465702 GEOCS 294 27 1 322 375 47 0 422
Cell cycle CDKN2D rs1465702 MALOVA 406 36 0 442 1118 83 5 1206
Cell cycle CDKN2D rs1465702 SEARCH 646 72 1 719 786 66 1 853
Cell cycle CDKN2D rs3218222 GEOCS 185 113 23 321 207 174 34 415
Cell cycle CDKN2D rs3218222 MALOVA 273 149 19 441 720 424 63 1207
Cell cycle CDKN2D rs3218222 SEARCH 391 268 47 706 502 295 40 837
Cell cycle RB1 rs1981434 GEOCS 163 133 21 317 203 181 30 414
Cell cycle RB1 rs1981434 MALOVA 210 183 40 433 586 494 115 1195
Cell cycle RB1 rs1981434 SEARCH 370 282 61 713 438 349 64 851
Cell cycle RB1 rs2854345 GEOCS 206 104 11 321 280 135 8 423
Cell cycle RB1 rs2854345 MALOVA 288 133 19 440 757 396 61 1214
Cell cycle RB1 rs2854345 SEARCH 470 217 28 715 575 235 33 843
Cell cycle RB1 rs399413 GEOCS 169 130 23 322 210 188 29 427
Cell cycle RB1 rs399413 MALOVA 123 124 26 273 367 282 62 711
Cell cycle RB1 rs399413 SEARCH 380 280 59 719 452 340 59 851
Cell cycle RB1 rs4151540 GEOCS 173 124 21 318 216 179 24 419
Cell cycle RB1 rs4151540 MALOVA 228 164 42 434 572 502 114 1188
Cell cycle RB1 rs4151540 SEARCH 379 287 51 717 453 341 54 848
Cell cycle RB1 rs4151551 GEOCS 265 52 4 321 365 56 2 423
Cell cycle RB1 rs4151551 MALOVA 357 74 3 434 998 202 12 1212
Cell cycle RB1 rs4151551 SEARCH 590 120 7 717 707 138 7 852
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Cell cycle RB1 rs2854344 GEOCS 282 25 3 310 360 52 5 417
Cell cycle RB1 rs2854344 MALOVA 240 39 4 283 608 107 3 718
Cell cycle RB1 rs2854344 SEARCH 633 73 5 711 717 121 2 840
Cell cycle RB1 rs425834 GEOCS 299 20 2 321 380 42 0 422
Cell cycle RB1 rs425834 MALOVA 404 31 1 436 1136 59 3 1198
Cell cycle RB1 rs425834 SEARCH 668 44 3 715 800 48 1 849
Cell cycle RB1 rs4151611 GEOCS 296 23 2 321 375 46 2 423
Cell cycle RB1 rs4151611 MALOVA 385 42 3 430 1089 114 2 1205
Cell cycle RB1 rs4151611 SEARCH 657 55 0 712 770 74 4 848
Cell cycle RB1 rs4151620 GEOCS 231 79 0 310 311 83 5 399
Cell cycle RB1 rs4151620 MALOVA 215 62 2 279 547 157 11 715
Cell cycle RB1 rs4151620 SEARCH 527 182 2 711 635 196 13 844
Cell cycle RB1 rs3092904 GEOCS 186 114 20 320 229 171 20 420
Cell cycle RB1 rs3092904 MALOVA 140 113 27 280 373 285 64 722
Cell cycle RB1 rs3092904 SEARCH 399 273 45 717 472 327 52 851
Cell cycle RB1 rs4151636 GEOCS 294 20 1 315 372 47 2 421
Cell cycle RB1 rs4151636 MALOVA 399 37 0 436 1109 107 1 1217
Cell cycle RB1 rs4151636 SEARCH 650 64 2 716 772 77 2 851
Cell cycle STK15 rs732417 GEOCS 271 43 1 315 351 64 4 419
Cell cycle STK15 rs732417 MALOVA 315 52 3 370 770 108 2 880
Cell cycle STK15 rs732417 SEARCH 589 117 6 712 717 118 5 840
Cell cycle STK15 rs1047972 GEOCS 216 94 9 319 286 127 14 427
Cell cycle STK15 rs1047972 MALOVA 298 99 11 408 735 260 21 1016
Cell cycle STK15 rs1047972 SEARCH 485 207 20 712 566 246 31 843
Cell cycle STK15 rs2273535 GEOCS 185 99 20 304 271 112 15 398
Cell cycle STK15 rs2273535 MALOVA 167 126 22 315 391 239 46 676
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Cell cycle STK15 rs2273535 SEARCH 436 250 28 714 524 285 34 843
Cell cycle STK15 rs8173 GEOCS 161 116 18 295 229 155 22 406
Cell cycle STK15 rs8173 MALOVA 209 128 24 361 509 339 37 885
Cell cycle STK15 rs8173 SEARCH 373 271 38 682 458 314 40 812
DNA repair BRCA1 rs799917 GEOCS 119 151 36 306 178 177 44 399
DNA repair BRCA1 rs799917 MALOVA 173 176 50 399 436 393 99 928
DNA repair BRCA1 rs799917 SEARCH 316 325 68 709 388 350 92 830
DNA repair BRCA1 rs1799950 GEOCS 276 41 1 318 376 50 0 426
DNA repair BRCA1 rs1799950 SEARCH 633 85 0 718 745 100 4 849
DNA repair BRIP rs11871785 GEOCS 131 149 39 319 165 191 67 356
DNA repair BRIP rs11871785 MALOVA 195 203 46 444 535 538 144 1073
DNA repair BRIP rs11871785 SEARCH 274 343 98 715 346 396 106 742
DNA repair BRIP rs1557720 GEOCS 120 139 63 322 175 193 56 368
DNA repair BRIP rs1557720 MALOVA 89 135 52 276 245 347 118 592
DNA repair BRIP rs1557720 SEARCH 259 352 108 719 315 403 135 718
DNA repair BRIP rs11652980 GEOCS 292 25 2 319 374 49 0 423
DNA repair BRIP rs11652980 MALOVA 404 38 1 443 1120 98 1 1218
DNA repair BRIP rs11652980 SEARCH 637 76 1 714 773 76 4 849
DNA repair BRIP rs2191249 GEOCS 191 108 20 319 239 155 33 394
DNA repair BRIP rs2191249 MALOVA 158 98 19 275 398 251 51 649
DNA repair BRIP rs2191249 SEARCH 413 269 37 719 463 318 62 781
DNA repair BRIP rs16945628 GEOCS 147 140 34 321 191 177 55 368
DNA repair BRIP rs16945628 MALOVA 195 186 60 441 534 546 131 1080
DNA repair BRIP rs16945628 SEARCH 348 302 69 719 377 372 105 749
DNA repair BRIP rs2191248 GEOCS 138 141 41 320 202 174 45 376
DNA repair BRIP rs2191248 MALOVA 183 205 47 435 453 602 155 1055
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DNA repair BRIP rs2191248 SEARCH 295 317 102 714 381 392 78 773
DNA repair BRIP rs16945643 GEOCS 266 47 6 319 357 62 4 419
DNA repair BRIP rs16945643 MALOVA 360 77 3 440 1019 189 4 1208
DNA repair BRIP rs16945643 SEARCH 617 93 2 712 716 133 2 849
DNA repair BRIP rs6504074 GEOCS 170 115 37 322 225 156 40 381
DNA repair BRIP rs6504074 MALOVA 137 103 19 259 340 258 52 598
DNA repair BRIP rs6504074 SEARCH 412 264 37 713 457 325 65 782
DNA repair BRIP rs2378908 GEOCS 241 70 7 318 318 91 10 409
DNA repair BRIP rs2378908 MALOVA 198 73 3 274 564 137 10 701
DNA repair BRIP rs2378908 SEARCH 509 170 16 695 625 214 13 839
DNA repair BRIP rs4988344 GEOCS 227 85 9 321 309 103 15 412
DNA repair BRIP rs4988344 MALOVA 188 81 8 277 526 174 12 700
DNA repair BRIP rs4988344 SEARCH 491 198 28 717 592 241 20 833
DNA repair BRIP rs9908659 GEOCS 131 146 43 320 191 172 59 363
DNA repair BRIP rs9908659 MALOVA 169 203 67 439 405 615 192 1020
DNA repair BRIP rs9908659 SEARCH 269 333 117 719 341 401 112 742
DNA repair BRIP rs4968451 GEOCS 225 87 9 321 306 103 14 409
DNA repair BRIP rs4968451 MALOVA 306 121 13 440 877 310 25 1187
DNA repair BRIP rs4968451 SEARCH 489 201 26 716 588 247 19 835
DNA repair BRIP rs2048718 GEOCS 91 155 74 320 131 195 95 326
DNA repair BRIP rs2048718 MALOVA 118 215 96 429 352 632 225 984
DNA repair BRIP rs2048718 SEARCH 234 333 143 710 247 428 177 675
DNA repair KU70 rs132788 GEOCS 144 140 30 314 211 173 37 421
DNA repair KU70 rs132788 MALOVA 153 169 33 355 356 375 91 822
DNA repair KU70 rs132788 SEARCH 306 302 105 713 364 369 106 839
DNA repair NBS1 rs1063045 GEOCS 145 137 39 321 169 201 54 424
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DNA repair NBS1 rs1063045 MALOVA 197 185 42 424 479 454 108 1041
DNA repair NBS1 rs1063045 SEARCH 295 334 79 708 365 373 102 840
DNA repair NBS1 rs1805794 GEOCS 140 131 33 304 163 174 52 389
DNA repair NBS1 rs1805794 MALOVA 196 176 39 411 484 437 109 1030
DNA repair NBS1 rs1805794 SEARCH 303 327 78 708 369 372 107 848
DNA repair NBS1 rs709816 GEOCS 128 123 54 305 157 165 71 393
DNA repair NBS1 rs709816 MALOVA 173 199 53 425 429 470 132 1031
DNA repair NBS1 rs709816 SEARCH 278 342 98 718 336 388 125 849
DNA repair NBS1 rs1061302 GEOCS 137 131 34 302 159 178 50 387
DNA repair NBS1 rs1061302 MALOVA 156 144 32 332 390 346 82 818
DNA repair NBS1 rs1061302 SEARCH 302 325 72 699 367 364 99 830
DNA repair RAD51 rs1801320 GEOCS 266 52 4 322 363 61 1 425
DNA repair RAD51 rs1801320 MALOVA 315 44 2 361 725 88 7 820
DNA repair RAD51 rs1801320 SEARCH 629 84 3 716 745 100 2 847
DNA repair RAD51 rs1801321 GEOCS 117 144 56 317 151 193 74 418
DNA repair RAD51 rs1801321 MALOVA 139 166 73 378 279 330 112 721
DNA repair RAD51 rs1801321 SEARCH 216 359 142 717 273 433 141 847
DNA repair RAD52 rs11226 GEOCS 75 169 75 319 122 210 89 421
DNA repair RAD52 rs11226 MALOVA 119 203 97 419 311 489 232 1032
DNA repair RAD52 rs11226 SEARCH 217 358 136 711 269 374 197 840
DNA repair XRCC2 UNKNOWN GEOCS 286 29 0 315 369 45 4 418
DNA repair XRCC2 UNKNOWN MALOVA 303 28 2 333 627 66 1 694
DNA repair XRCC2 UNKNOWN SEARCH 634 78 4 716 755 89 3 847
DNA repair XRCC2 rs3218384* GEOCS 204 103 12 319 277 134 14 425
DNA repair XRCC2 rs3218384* MALOVA 237 134 21 392 522 316 49 887
DNA repair XRCC2 rs3218384* SEARCH 426 258 31 715 509 301 38 848
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DNA repair XRCC2 rs3218536 GEOCS 257 53 1 311 334 70 5 409
DNA repair XRCC2 rs3218536 MALOVA 275 35 0 310 467 67 2 536
DNA repair XRCC2 rs3218536 SEARCH 620 94 2 716 704 129 9 842
DNA repair XRCC3 rs1799794 GEOCS 201 111 9 321 269 136 18 423
DNA repair XRCC3 rs1799794 MALOVA 285 131 8 424 684 316 42 1042
DNA repair XRCC3 rs1799794 SEARCH 454 242 20 716 552 261 29 842
DNA repair XRCC3 rs1799796 GEOCS 156 130 35 321 195 185 41 421
DNA repair XRCC3 rs1799796 MALOVA 200 164 60 424 459 440 127 1026
DNA repair XRCC3 rs1799796 SEARCH 320 314 82 716 386 381 85 852
DNA repair XRCC3 rs861539 GEOCS 123 112 31 266 131 177 40 348
DNA repair XRCC3 rs861539 MALOVA 138 166 49 353 335 377 134 846
DNA repair XRCC3 rs861539 SEARCH 284 334 95 713 318 404 108 830
Mismatch repair MLH1 rs1800734 GEOCS 178 114 21 313 246 145 28 419
Mismatch repair MLH1 rs1800734 MALOVA 182 77 9 268 449 211 27 687
Mismatch repair MLH1 rs1800734 SEARCH 457 225 36 718 532 285 34 851
Mismatch repair MLH1 rs1540354 GEOCS 213 94 12 319 286 124 12 422
Mismatch repair MLH1 rs1540354 MALOVA 172 91 12 275 444 222 30 696
Mismatch repair MLH1 rs1540354 SEARCH 469 215 27 711 566 245 31 842
Mismatch repair MLH1 rs1799977 GEOCS 167 114 30 311 209 147 47 403
Mismatch repair MLH1 rs1799977 SEARCH 340 300 66 706 424 333 78 835
Mismatch repair MLH1 rs2286939 GEOCS 107 149 62 318 127 205 86 418
Mismatch repair MLH1 rs2286939 MALOVA 82 139 60 281 260 359 160 779
Mismatch repair MLH1 rs2286939 SEARCH 208 369 142 719 251 421 182 854
Mismatch repair MLH3 rs7303 GEOCS 74 132 102 308 101 198 103 402
Mismatch repair MLH3 rs7303 MALOVA 87 119 58 264 189 322 154 665
Mismatch repair MLH3 rs7303 SEARCH 179 366 164 709 241 399 199 839
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Mismatch repair MLH3 rs175080 GEOCS 120 132 58 310 129 202 81 412
Mismatch repair MLH3 rs175080 MALOVA 78 127 68 273 214 345 166 725
Mismatch repair MLH3 rs175080 SEARCH 206 373 134 713 249 406 189 844
Mismatch repair MSH2 rs4952887 GEOCS 262 48 5 315 347 72 3 422
Mismatch repair MSH2 rs4952887 MALOVA 227 43 3 273 574 118 7 699
Mismatch repair MSH2 rs4952887 SEARCH 611 95 8 714 699 146 9 854
Mismatch repair MSH2 rs13425206 GEOCS 284 35 2 321 394 30 1 425
Mismatch repair MSH2 rs13425206 MALOVA 417 21 1 439 1133 82 2 1217
Mismatch repair MSH2 rs13425206 SEARCH 667 46 2 715 781 64 4 849
Mismatch repair MSH2 rs3771274 GEOCS 121 143 50 314 160 194 70 424
Mismatch repair MSH2 rs3771274 MALOVA 85 140 46 271 244 349 108 701
Mismatch repair MSH2 rs3771274 SEARCH 261 348 110 719 306 411 136 853
Mismatch repair MSH2 rs1981928 GEOCS 177 120 24 321 224 159 42 425
Mismatch repair MSH2 rs1981928 MALOVA 138 115 22 275 384 281 60 725
Mismatch repair MSH2 rs1981928 SEARCH 393 274 51 718 455 330 66 851
Mismatch repair MSH2 rs2059520 GEOCS 151 134 34 319 186 181 58 425
Mismatch repair MSH2 rs2059520 MALOVA 110 125 40 275 311 314 85 710
Mismatch repair MSH2 rs2059520 SEARCH 304 326 88 718 364 377 105 846
Mismatch repair MSH2 rs2303428 GEOCS 266 48 1 315 330 72 4 406
Mismatch repair MSH2 rs2303428 MALOVA 231 46 6 283 626 154 7 787
Mismatch repair MSH2 rs2303428 SEARCH 592 124 3 719 692 147 15 854
Mismatch repair MSH3 rs6151662 GEOCS 290 30 1 321 383 43 0 426
Mismatch repair MSH3 rs6151662 MALOVA 391 43 1 435 1057 122 4 1183
Mismatch repair MSH3 rs6151662 SEARCH 630 87 1 718 747 93 12 852
Mismatch repair MSH3 rs40139 GEOCS 104 160 56 320 118 197 102 417
Mismatch repair MSH3 rs40139 MALOVA 95 136 46 277 270 343 143 756
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Mismatch repair MSH3 rs40139 SEARCH 213 369 136 718 301 392 160 853
Mismatch repair MSH3 rs26282 GEOCS 167 121 27 315 237 141 28 406
Mismatch repair MSH3 rs26282 MALOVA 149 109 18 276 386 296 49 731
Mismatch repair MSH3 rs26282 SEARCH 380 284 53 717 444 338 69 851
Mismatch repair MSH3 rs26779 GEOCS 121 154 47 322 175 171 74 420
Mismatch repair MSH3 rs26779 MALOVA 161 209 69 439 442 569 196 1207
Mismatch repair MSH3 rs26779 SEARCH 259 343 112 714 287 429 123 839
Mismatch repair MSH3 rs33008 GEOCS 171 129 18 318 224 166 36 426
Mismatch repair MSH3 rs33008 MALOVA 145 112 20 277 365 285 59 709
Mismatch repair MSH3 rs33008 SEARCH 360 300 56 716 463 316 69 848
Mismatch repair MSH3 rs10079641 GEOCS 271 48 3 322 350 64 8 422
Mismatch repair MSH3 rs10079641 MALOVA 365 63 6 434 1009 180 8 1197
Mismatch repair MSH3 rs10079641 SEARCH 579 133 5 717 708 127 16 851
Mismatch repair MSH3 rs184967 GEOCS 219 93 6 318 319 91 10 420
Mismatch repair MSH3 rs184967 MALOVA 204 66 7 277 514 186 17 717
Mismatch repair MSH3 rs184967 SEARCH 505 186 19 710 585 241 20 846
Mismatch repair MSH3 rs2897298 GEOCS 232 82 7 321 328 84 9 421
Mismatch repair MSH3 rs2897298 MALOVA 342 85 2 429 945 227 7 1179
Mismatch repair MSH3 rs2897298 SEARCH 541 162 12 715 646 186 18 850
Mismatch repair MSH3 rs26279 GEOCS 142 151 28 321 242 151 34 427
Mismatch repair MSH3 rs26279 MALOVA 151 104 23 278 403 289 54 746
Mismatch repair MSH3 rs26279 SEARCH 364 268 70 702 417 336 82 835
Mismatch repair MSH3 rs2112416 GEOCS 225 82 9 316 289 122 12 423
Mismatch repair MSH3 rs2112416 MALOVA 195 75 8 278 525 169 15 709
Mismatch repair MSH3 rs2112416 SEARCH 550 151 15 716 649 188 16 853
Mismatch repair MSH6 rs3136245 GEOCS 209 97 16 322 266 140 21 427
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Mismatch repair MSH6 rs3136245 MALOVA 181 84 5 270 435 211 37 683
Mismatch repair MSH6 rs3136245 SEARCH 454 241 23 718 538 275 37 850
Mismatch repair MSH6 rs3136272 GEOCS 136 152 34 322 196 184 43 423
Mismatch repair MSH6 rs3136272 MALOVA 171 177 65 413 445 557 156 1158
Mismatch repair MSH6 rs3136272 SEARCH 303 319 93 715 334 398 112 844
Mismatch repair MSH6 rs1800932 GEOCS 206 99 16 321 291 122 13 426
Mismatch repair MSH6 rs1800932 MALOVA 187 82 8 277 506 191 26 723
Mismatch repair MSH6 rs1800932 SEARCH 471 220 28 719 560 253 39 852
Mismatch repair MSH6 rs2348244 GEOCS 227 67 9 303 287 91 13 391
Mismatch repair MSH6 rs2348244 MALOVA 201 65 2 268 523 164 15 702
Mismatch repair MSH6 rs2348244 SEARCH 501 193 14 708 614 206 27 847
Mismatch repair MSH6 rs3136317 GEOCS 204 104 10 318 294 114 15 423
Mismatch repair MSH6 rs3136317 MALOVA 308 128 5 441 849 360 9 1218
Mismatch repair MSH6 rs3136317 SEARCH 475 220 22 717 581 243 25 849
Mismatch repair MSH6 rs1800935 GEOCS 163 131 27 321 228 171 27 426
Mismatch repair MSH6 rs1800935 MALOVA 135 119 23 277 384 291 72 747
Mismatch repair MSH6 rs1800935 SEARCH 366 289 63 718 427 350 76 853
Mismatch repair MSH6 rs2020911 GEOCS 111 154 54 319 158 195 71 424
Mismatch repair MSH6 rs2020911 MALOVA 118 120 34 272 271 310 97 678
Mismatch repair MSH6 rs2020911 SEARCH 259 355 101 715 315 392 141 848
Mismatch repair PMS1 rs3762545 GEOCS 194 109 14 317 257 146 19 422
Mismatch repair PMS1 rs3762545 MALOVA 167 98 8 273 474 237 34 745
Mismatch repair PMS1 rs3762545 SEARCH 488 206 24 718 540 278 33 851
Mismatch repair PMS1 rs5742981 GEOCS 299 23 0 322 387 32 2 421
Mismatch repair PMS1 rs5742981 MALOVA 233 28 1 262 924 101 3 1028
Mismatch repair PMS1 rs5742981 SEARCH 676 40 0 716 792 57 1 850
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Mismatch repair PMS1 rs5741593 GEOCS 291 31 0 322 373 46 1 420
Mismatch repair PMS1 rs5741593 MALOVA 378 58 2 438 1037 170 8 1215
Mismatch repair PMS1 rs5741593 SEARCH 625 75 2 702 705 104 3 812
Mismatch repair PMS1 rs1233291 GEOCS 169 132 20 321 220 174 31 425
Mismatch repair PMS1 rs1233291 MALOVA 137 114 22 273 352 294 58 704
Mismatch repair PMS1 rs1233291 SEARCH 414 260 41 715 443 348 57 848
Mismatch repair PMS1 rs1233255 GEOCS 194 111 13 318 270 131 23 424
Mismatch repair PMS1 rs1233255 MALOVA 149 81 7 237 413 193 31 637
Mismatch repair PMS1 rs1233255 SEARCH 465 223 28 716 530 277 37 844
Mismatch repair PMS1 rs1233258 GEOCS 167 130 21 318 217 164 40 421
Mismatch repair PMS1 rs1233258 MALOVA 137 113 28 278 330 320 57 707
Mismatch repair PMS1 rs1233258 SEARCH 394 260 55 709 447 328 66 841
Mismatch repair PMS1 rs256571 GEOCS 284 36 1 321 371 49 2 422
Mismatch repair PMS1 rs256571 MALOVA 378 60 0 438 1074 134 4 1212
Mismatch repair PMS1 rs256571 SEARCH 636 79 1 716 741 107 2 850
Mismatch repair PMS1 rs256563 GEOCS 250 65 5 320 318 96 7 421
Mismatch repair PMS1 rs256563 MALOVA 335 86 6 427 916 265 15 1196
Mismatch repair PMS1 rs256563 SEARCH 578 136 4 718 650 183 12 845
Mismatch repair PMS2 rs7797466 GEOCS 186 117 13 316 285 115 14 414
Mismatch repair PMS2 rs7797466 MALOVA 161 94 15 270 470 202 28 700
Mismatch repair PMS2 rs7797466 SEARCH 490 201 28 719 580 248 26 854
Mismatch repair PMS2 rs2345060 GEOCS 191 112 20 323 243 154 29 426
Mismatch repair PMS2 rs2345060 MALOVA 159 110 10 279 411 256 43 710
Mismatch repair PMS2 rs2345060 SEARCH 403 278 36 717 479 324 48 851
Mismatch repair PMS2 rs2286680 GEOCS 227 84 8 319 320 97 8 425
Mismatch repair PMS2 rs2286680 MALOVA 198 77 3 278 577 158 15 750
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Mismatch repair PMS2 rs2286680 SEARCH 546 157 16 719 632 205 14 851
Mismatch repair PMS2 rs12112229 GEOCS 173 117 20 310 231 151 24 406
Mismatch repair PMS2 rs12112229 MALOVA 152 105 15 272 408 246 46 700
Mismatch repair PMS2 rs12112229 SEARCH 399 263 55 717 442 351 46 839
Mismatch repair PMS2 rs1805321 GEOCS 117 143 62 322 142 205 79 426
Mismatch repair PMS2 rs1805321 MALOVA 100 126 51 277 230 346 127 703
Mismatch repair PMS2 rs1805321 SEARCH 249 347 122 718 270 436 145 851
Mismatch repair PMS2 rs2228006 GEOCS 231 84 6 321 308 116 3 427
Mismatch repair PMS2 rs2228006 MALOVA 324 103 7 434 898 288 20 1206
Mismatch repair PMS2 rs2228006 SEARCH 509 184 19 712 615 211 19 845
OCAC ABL1 rs2855192 GEOCS 232 77 13 322 333 85 5 423
OCAC ABL1 rs2855192 MALOVA 328 98 5 431 929 249 21 1199
OCAC ABL1 rs2855192 SEARCH 550 151 16 717 624 217 7 848
OCAC BRCA2 rs144848 GEOCS 173 128 20 321 217 189 21 427
OCAC BRCA2 rs144848 MALOVA 227 158 35 420 540 399 81 1020
OCAC BRCA2 rs144848 SEARCH 379 283 56 718 443 337 67 847
OCAC CDC2 rs2448343 GEOCS 122 152 40 314 169 203 46 418
OCAC CDC2 rs2448343 MALOVA 181 184 54 419 522 479 158 1159
OCAC CDC2 rs2448343 SEARCH 297 329 89 715 339 381 123 843
OCAC CDK7 rs12656449 GEOCS 282 36 2 320 356 61 4 421
OCAC CDK7 rs12656449 MALOVA 356 75 3 434 988 206 11 1205
OCAC CDK7 rs12656449 SEARCH 581 132 4 717 705 139 6 850
OCAC CHR8-P3 rs7000448 GEOCS 121 163 36 320 164 199 57 420
OCAC CHR8-P3 rs7000448 MALOVA 167 208 58 433 458 546 176 1180
OCAC CHR8-P3 rs7000448 SEARCH 284 344 91 719 359 387 107 853
OCAC DESP-1979 rs16901979 GEOCS 295 26 1 322 385 37 1 423
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OCAC DESP-1979 rs16901979 MALOVA 401 29 0 430 1073 81 1 1155
OCAC DESP-1979 rs16901979 SEARCH 666 44 1 711 798 51 1 850
OCAC E2F2 rs760607 GEOCS 103 156 60 319 146 189 66 401
OCAC E2F2 rs760607 MALOVA 191 181 49 421 489 520 150 1159
OCAC E2F2 rs760607 SEARCH 270 341 105 716 325 407 118 850
OCAC E2F3 rs7760528 GEOCS 152 132 36 320 185 185 50 420
OCAC E2F3 rs7760528 MALOVA 194 186 46 426 572 502 126 1200
OCAC E2F3 rs7760528 SEARCH 340 311 65 716 404 348 93 845
OCAC KU70 rs132788 GEOCS 144 140 30 314 211 173 37 421
OCAC KU70 rs132788 MALOVA 153 169 33 355 356 375 91 822
OCAC KU70 rs132788 SEARCH 306 302 105 713 364 369 106 839
OCAC LIG4 rs1805386 GEOCS 207 96 13 316 296 108 11 415
OCAC LIG4 rs1805386 MALOVA 321 97 13 431 839 330 36 1205
OCAC LIG4 rs1805386 SEARCH 478 215 22 715 615 210 21 846
OCAC PGR rs10895068 GEOCS 294 27 0 321 382 41 0 423
OCAC PGR rs10895068 MALOVA 372 51 1 424 997 136 7 1140
OCAC PGR rs10895068 SEARCH 638 77 2 717 760 86 4 850
OCAC PGR rs1042838 GEOCS 220 98 4 322 306 102 15 423
OCAC PGR rs1042838 MALOVA 295 92 10 397 884 233 21 1138
OCAC PGR rs1042838 SEARCH 490 187 28 705 629 191 27 847
OCAC PGR rs608995 GEOCS 170 136 15 321 228 165 31 424
OCAC PGR rs608995 MALOVA 270 142 25 437 754 390 58 1202
OCAC PGR rs608995 SEARCH 418 249 50 717 521 280 46 847
OCAC TGFB1 rs1982073 GEOCS 125 143 46 314 166 189 58 413
OCAC TGFB1 rs1982073 SEARCH 281 329 102 712 326 393 130 849
OCAC TNRC9 rs3803662 GEOCS 152 142 27 321 187 189 44 420
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OCAC TNRC9 rs3803662 MALOVA 244 160 22 426 649 427 81 1157
OCAC TNRC9 rs3803662 SEARCH 401 258 50 709 464 329 57 850
OCAC TP53 rs1042522 GEOCS 171 128 19 318 230 171 21 422
OCAC TP53 rs1042522 MALOVA 231 154 38 423 569 375 79 1023
OCAC TP53 rs1042522 SEARCH 406 263 49 718 463 328 55 846
OCAC TP53 rs1625895 GEOCS 242 75 2 319 308 106 3 417
OCAC TP53 rs1625895 MALOVA 303 82 3 388 720 147 14 881
OCAC TP53 rs1625895 SEARCH 537 151 14 702 639 183 16 838
OCAC TP53 rs9894946 GEOCS 219 96 5 320 285 133 4 422
OCAC TP53 rs9894946 MALOVA 312 116 9 437 900 288 26 1214
OCAC TP53 rs9894946 SEARCH 514 179 20 713 629 194 26 849
OCAC VDR rs10735810 GEOCS 118 136 65 319 158 200 63 421
OCAC VDR rs10735810 MALOVA 159 208 57 424 475 545 163 1183
OCAC VDR rs10735810 SEARCH 274 341 103 718 332 383 136 851
OCAC XRCC5 rs16855489 GEOCS 121 153 48 322 152 209 63 424
OCAC XRCC5 rs16855489 MALOVA 148 218 69 435 428 586 195 1209
OCAC XRCC5 rs16855489 SEARCH 277 347 95 719 344 394 113 851
AA – common homozygous; Aa – heterozygous; aa – rare homozygous; the distributions for oncogenes and MMCT-18 candidates are tabulated in
Appendices II-A and II-B, respectively.
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Appendix VI: Genotype-specific risks of all SNPs analysed with AML method
Pathway /
Group Gene/cytoband SNP
Call rate
(%)** Cases Controls HetOR (95% CI) HomOR (95% CI)
P-trend
unadj
P-trend
adj.‡
BCAC§ 2q22.1 rs4954956 98 1446 2469 1.02 (0.89-1.18) 0.94 (0.71-1.25) 0.9634 0.9651
BCAC§ 5q11.2 rs889312 98 1473 2460 0.98 (0.85-1.12) 0.92 (0.71-1.18) 0.5136 0.533
BCAC§ 8q24.21 rs10505477 98 1456 2459 0.97 (0.83-1.14) 0.86 (0.71-1.04) 0.1166 0.1342
BCAC§ 8q24.21 rs10808556 98 1462 2453 1.15 (0.99-1.33) 1.20 (0.99-1.46) 0.0446 0.0552
BCAC§ 8q24.21 rs13254738 97 1458 2451 0.98 (0.85-1.13) 0.91 (0.73-1.13) 0.4202 0.4416
BCAC§ 8q24.21 rs13281615 98 1458 2464 0.93 (0.81-1.08) 0.98 (0.80-1.20) 0.6699 0.6841
BCAC§ 8q24.21 rs6983267 95 1364 2439 0.96 (0.82-1.13) 0.88 (0.72-1.07) 0.1965 0.2171
BCAC§ 8q24.21 rs6983561 97 1444 2456 0.97 (0.75-1.27) 1.86 (0.31-11.15) 0.9962 0.9964
BCAC§ 8q24.21 rs9283954 95 1409 2420 1.06 (0.89-1.26) 1.33 (0.71-2.50) 0.3346 0.3565
BCAC§ 11p15.5 rs2107425 98 1460 2463 0.71 (0.62-0.82) 0.88 (0.70-1.10) 0.0012 0.002
BCAC§ 12p11.22 rs7313833 98 1460 2457 1.08 (0.94-1.24) 1.08 (0.87-1.34) 0.3209 0.3434
BCAC§ FLJ41481 rs4666451 98 1454 2469 0.96 (0.83-1.11) 1.03 (0.85-1.25) 0.926 0.9294
BCAC§ HCN1 rs981782 96 1419 2432 1.12 (0.96-1.32) 1.05 (0.87-1.27) 0.5399 0.5582
BCAC§ LOC100131885 rs2981582 98 1463 2466 0.88 (0.76-1.02) 0.89 (0.73-1.09) 0.1381 0.157
BCAC§ LSP1 rs3817198 97 1457 2435 1.16 (1.01-1.34) 1.40 (1.11-1.75) 0.0016 0.0026
BCAC§ TOX3 rs12443621 97 1445 2457 0.96 (0.82-1.12) 0.83 (0.69-1.01) 0.0752 0.0894
Cell cycle CCND1 rs602652 99 1468 2493 1.13 (0.97-1.32) 1.24 (1.03-1.49) 0.0235 0.0307
Cell cycle CCND1 rs3862792 98 1471 2468 0.83 (0.61-1.13) 0.91 (0.76-1.08) 0.2311 0.2531
Cell cycle CCND1 rs603965 98 1476 2464 1.06 (0.91-1.23) 1.28 (1.06-1.55) 0.013 0.0178
Cell cycle CCND1 rs3212879 99 1472 2491 0.85 (0.73-0.99) 0.82 (0.68-0.99) 0.0321 0.0409
Cell cycle CCND1 rs3212891 98 1475 2476 0.86 (0.74-1.00) 0.83 (0.69-1.00) 0.0376 0.0472
Cell cycle CCND1 rs678653 98 1465 2468 0.94 (0.81-1.08) 0.93 (0.76-1.15) 0.3791 0.4012
Cell cycle CCND1 rs7178 99 1480 2491 1.24 (1.04-1.49) 1.24 (0.50-3.04) 0.0211 0.0278
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Cell cycle CCND2 rs3217795 99 1485 2500 1.00 (0.84-1.20) 0.71 (0.28-1.76) 0.819 0.8272
Cell cycle CCND2 rs3217805 99 1458 2502 1.08 (0.93-1.25) 0.86 (0.70-1.05) 0.3599 0.3824
Cell cycle CCND2 rs3217820 97 1407 2497 1.12 (0.97-1.29) 1.01 (0.82-1.25) 0.4954 0.5152
Cell cycle CCND2 rs3217852 99 1474 2488 0.99 (0.86-1.14) 0.86 (0.64-1.15) 0.4711 0.4917
Cell cycle CCND2 rs3217862 99 1470 2493 0.93 (0.80-1.08) 0.94 (0.62-1.40) 0.3481 0.3708
Cell cycle CCND2 rs3217863 98 1459 2472 0.99 (0.83-1.20) 1.49 (0.75-2.93) 0.6464 0.6615
Cell cycle CCND2 rs3217869 99 1483 2498 1.01 (0.87-1.16) 1.05 (0.87-1.28) 0.6306 0.6465
Cell cycle CCND2 rs3217901 99 1479 2489 1.10 (0.95-1.28) 1.03 (0.85-1.25) 0.5991 0.616
Cell cycle CCND2 rs3217906 98 1467 2473 1.05 (0.91-1.20) 0.97 (0.74-1.28) 0.7711 0.7813
Cell cycle CCND2 rs3217916 98 1476 2477 1.01 (0.88-1.16) 0.75 (0.58-0.97) 0.1541 0.1739
Cell cycle CCND2 rs3217925 98 1470 2461 0.98 (0.86-1.13) 0.72 (0.54-0.96) 0.1078 0.1248
Cell cycle CCND2 rs3217926 99 1484 2500 1.05 (0.91-1.21) 0.90 (0.74-1.10) 0.5268 0.5461
Cell cycle CCND2 rs3217933 98 1478 2474 1.13 (0.99-1.30) 1.01 (0.76-1.33) 0.241 0.2632
Cell cycle CCND2 rs3217936 99 1478 2489 1.02 (0.89-1.17) 0.77 (0.61-0.97) 0.1303 0.1489
Cell cycle CCND3 rs1410492 99 1479 2490 1.08 (0.94-1.24) 1.06 (0.80-1.40) 0.3187 0.3415
Cell cycle CCND3 rs3218092 98 1468 2468 1.02 (0.89-1.18) 0.74 (0.51-1.06) 0.4626 0.4833
Cell cycle CCND3 rs2479717 99 1472 2489 1.05 (0.91-1.20) 0.98 (0.76-1.25) 0.7947 0.804
Cell cycle CCND3 rs1051130 99 1475 2488 1.13 (0.96-1.31) 0.87 (0.72-1.05) 0.2 0.2215
Cell cycle CCND3 rs9529 99 1481 2475 1.00 (0.87-1.15) 0.79 (0.62-1.02) 0.1898 0.2109
Cell cycle CCND3 rs3218110 99 1479 2482 1.11 (0.97-1.28) 1.11 (0.83-1.47) 0.145 0.1644
Cell cycle CCND3 rs3218114 99 1484 2492 1.01 (0.88-1.17) 0.78 (0.53-1.13) 0.5375 0.5565
Cell cycle CCNE1 rs997669 99 1480 2497 1.10 (0.95-1.27) 1.14 (0.93-1.39) 0.1414 0.1607
Cell cycle CCNE1 rs3218036 99 1476 2481 1.07 (0.93-1.23) 1.27 (1.01-1.59) 0.0458 0.0567
Cell cycle CCNE1 rs3218038 99 1479 2497 0.97 (0.76-1.25) 1.90 (0.32-11.42) 0.9863 0.987
Cell cycle CCNE1 rs3218076 99 1480 2497 1.02 (0.89-1.17) 1.02 (0.79-1.33) 0.7375 0.7492
Cell cycle CDK2 rs2069408 99 1476 2496 0.90 (0.78-1.03) 0.89 (0.71-1.11) 0.1327 0.1515
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Cell cycle CDK2 rs1045435 99 1482 2497 1.11 (0.94-1.33) 1.87 (0.92-3.82) 0.0735 0.0879
Cell cycle CDK4 rs2270777 99 1477 2491 1.07 (0.92-1.24) 1.07 (0.88-1.30) 0.4203 0.442
Cell cycle CDK4 rs2069506 99 1480 2482 0.94 (0.82-1.08) 1.00 (0.81-1.24) 0.6775 0.6915
Cell cycle CDK6 rs8179 97 1465 2440 0.96 (0.84-1.11) 1.07 (0.78-1.48) 0.9164 0.9202
Cell cycle CDK6 rs2285332 98 1476 2463 0.92 (0.80-1.06) 0.88 (0.66-1.17) 0.1799 0.2006
Cell cycle CDK6 rs42046 97 1466 2446 1.07 (0.93-1.23) 1.07 (0.82-1.39) 0.3659 0.3881
Cell cycle CDK6 rs3731348 98 1463 2465 1.08 (0.88-1.32) 0.39 (0.11-1.39) 0.9009 0.9054
Cell cycle CDK6 rs8 99 1473 2481 1.17 (1.02-1.35) 1.44 (1.04-1.99) 0.0039 0.0059
Cell cycle CDK6 rs2237570 98 1474 2468 0.89 (0.76-1.06) 0.71 (0.38-1.33) 0.1015 0.1182
Cell cycle CDK6 rs3731343 99 1484 2499 1.04 (0.89-1.21) 1.09 (0.90-1.31) 0.3637 0.3863
Cell cycle CDK6 rs3757823 99 1486 2495 1.05 (0.89-1.24) 1.09 (0.53-2.23) 0.534 0.553
Cell cycle CDK6 rs2079147 99 1481 2496 1.01 (0.86-1.18) 1.01 (0.84-1.22) 0.9246 0.928
Cell cycle CDK6 rs2282991 96 1449 2404 0.85 (0.71-1.01) 0.86 (0.44-1.69) 0.0626 0.0753
Cell cycle CDK6 rs4729049 99 1482 2499 1.01 (0.85-1.19) 0.86 (0.44-1.69) 0.9082 0.9125
Cell cycle CDK6 rs445 99 1481 2497 0.99 (0.83-1.17) 0.89 (0.44-1.78) 0.7706 0.7809
Cell cycle CDK6 rs992519 99 1477 2496 1.05 (0.90-1.22) 0.99 (0.62-1.59) 0.6382 0.6538
Cell cycle CDKN1A rs762624 99 1475 2483 1.06 (0.92-1.21) 1.11 (0.86-1.44) 0.3019 0.3247
Cell cycle CDKN1A rs2395655 99 1478 2487 1.12 (0.97-1.29) 1.18 (0.97-1.43) 0.0692 0.083
Cell cycle CDKN1A rs3176331 98 1471 2472 1.01 (0.86-1.18) 1.14 (0.70-1.85) 0.7129 0.7255
Cell cycle CDKN1A rs3176336 99 1481 2488 0.98 (0.85-1.14) 0.94 (0.77-1.14) 0.5351 0.5541
Cell cycle CDKN1A rs3176343 99 1483 2491 1.03 (0.83-1.28) 0.78 (0.14-4.37) 0.8189 0.8272
Cell cycle CDKN1A rs1801270 98 1477 2463 0.91 (0.75-1.11) 0.53 (0.19-1.50) 0.1987 0.22
Cell cycle CDKN1A rs3176352 98 1477 2476 1.03 (0.89-1.18) 1.17 (0.91-1.50) 0.2978 0.3205
Cell cycle CDKN1A rs1059234 99 1483 2481 0.90 (0.74-1.09) 0.73 (0.29-1.83) 0.2182 0.2401
Cell cycle CDKN1A rs6457937 99 1483 2495 0.97 (0.72-1.30) 0.90 (0.76-1.08) 0.8263 0.8342
Cell cycle CDKN1B rs3759217 99 1483 2492 1.15 (0.98-1.34) 1.04 (0.60-1.79) 0.1301 0.1487
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Cell cycle CDKN1B rs34330 98 1468 2467 0.94 (0.81-1.08) 0.90 (0.67-1.20) 0.2774 0.3
Cell cycle CDKN1B rs2066827 99 1481 2484 0.88 (0.77-1.01) 0.68 (0.51-0.90) 0.0035 0.0053
Cell cycle CDKN1B rs34329 99 1481 2491 1.01 (0.88-1.16) 0.96 (0.76-1.21) 0.8616 0.868
Cell cycle CDKN1B rs3093736 99 1483 2493 0.94 (0.72-1.23) 1.53 (0.25-9.44) 0.7519 0.763
Cell cycle CDKN1B rs7330 99 1484 2499 0.95 (0.82-1.09) 1.01 (0.83-1.23) 0.8981 0.9028
Cell cycle CDKN1B rs1420023 99 1475 2486 0.95 (0.81-1.13) 1.08 (0.59-1.97) 0.7146 0.7272
Cell cycle CDKN2A rs3217992 99 1474 2489 0.96 (0.83-1.10) 0.91 (0.74-1.13) 0.3764 0.3987
Cell cycle CDKN2A rs3218005 98 1461 2473 1.04 (0.87-1.24) 1.63 (0.87-3.05) 0.2853 0.3079
Cell cycle CDKN2A rs2811712 99 1479 2494 0.97 (0.82-1.15) 1.91 (1.08-3.37) 0.4497 0.4709
Cell cycle CDKN2A rs3218020 98 1467 2463 0.99 (0.86-1.14) 0.93 (0.74-1.17) 0.6253 0.6412
Cell cycle CDKN2A rs3731197 99 1476 2479 1.02 (0.88-1.17) 1.07 (0.87-1.30) 0.5644 0.5824
Cell cycle CDKN2A rs3731211 99 1476 2484 0.95 (0.83-1.09) 1.06 (0.82-1.37) 0.8613 0.8676
Cell cycle CDKN2A rs3731222 99 1480 2497 1.01 (0.87-1.19) 0.82 (0.50-1.36) 0.8169 0.8252
Cell cycle CDKN2A rs4074785 98 1471 2464 1.04 (0.88-1.24) 1.30 (0.68-2.47) 0.4466 0.4677
Cell cycle CDKN2A rs3731239 99 1478 2487 1.08 (0.94-1.24) 1.08 (0.88-1.33) 0.324 0.3468
Cell cycle CDKN2A rs3731249 98 1464 2452 0.86 (0.64-1.16) 1.03 (0.23-4.67) 0.3584 0.3806
Cell cycle CDKN2A rs11515 99 1479 2492 1.00 (0.86-1.16) 1.53 (0.98-2.41) 0.3809 0.4032
Cell cycle CDKN2A rs3088440 99 1475 2490 1.02 (0.86-1.21) 1.33 (0.65-2.70) 0.6122 0.6287
Cell cycle CDKN2A rs3731257 99 1480 2476 0.89 (0.78-1.03) 0.80 (0.60-1.07) 0.0452 0.056
Cell cycle CDKN2B rs3217986 99 1478 2486 1.04 (0.88-1.24) 1.23 (0.64-2.37) 0.4832 0.5035
Cell cycle CDKN2B rs1063192 99 1476 2491 1.01 (0.87-1.17) 0.98 (0.81-1.19) 0.8927 0.8976
Cell cycle CDKN2B rs3218009 98 1469 2478 0.93 (0.80-1.09) 1.25 (0.77-2.02) 0.7664 0.7768
Cell cycle CDKN2B rs3218012 98 1464 2477 0.96 (0.83-1.12) 0.96 (0.79-1.16) 0.6371 0.6526
Cell cycle CDKN2C rs12855 99 1482 2499 0.98 (0.83-1.17) 1.30 (0.68-2.51) 0.8688 0.8748
Cell cycle CDKN2C rs3176459 98 1466 2480 1.06 (0.92-1.22) 0.93 (0.75-1.16) 0.9162 0.92
Cell cycle CDKN2D rs1465702 99 1483 2481 1.12 (0.89-1.41) 0.65 (0.13-3.33) 0.4518 0.4729
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Cell cycle CDKN2D rs3218222 98 1468 2459 0.97 (0.85-1.12) 1.04 (0.78-1.38) 0.9412 0.9439
Cell cycle RB1 rs1981434 98 1463 2460 0.97 (0.85-1.12) 1.01 (0.79-1.30) 0.8937 0.8985
Cell cycle RB1 rs2854345 99 1476 2480 1.02 (0.88-1.17) 1.02 (0.73-1.43) 0.8221 0.8301
Cell cycle RB1 rs399413 82 1314 1989 1.02 (0.88-1.19) 1.15 (0.88-1.51) 0.3906 0.4093
Cell cycle RB1 rs4151540 98 1469 2455 0.91 (0.79-1.04) 1.03 (0.80-1.33) 0.5165 0.5358
Cell cycle RB1 rs4151551 99 1472 2487 1.08 (0.90-1.29) 1.16 (0.58-2.31) 0.3718 0.3941
Cell cycle RB1 rs2854344 82 1304 1975 0.73 (0.59-0.91) 1.84 (0.78-4.32) 0.0552 0.0653
Cell cycle RB1 rs425834 98 1472 2469 1.04 (0.80-1.37) 2.59 (0.71-9.43) 0.3967 0.4186
Cell cycle RB1 rs4151611 98 1463 2476 0.87 (0.69-1.10) 1.03 (0.33-3.23) 0.2988 0.3214
Cell cycle RB1 rs4151620 81 1300 1958 1.12 (0.95-1.33) 0.22 (0.08-0.62) 0.9699 0.9711
Cell cycle RB1 rs3092904 82 1317 1993 0.96 (0.83-1.12) 1.09 (0.82-1.45) 0.953 0.9549
Cell cycle RB1 rs4151636 99 1467 2489 0.87 (0.69-1.10) 0.81 (0.19-3.43) 0.2213 0.2432
Cell cycle STK15 rs732417 88 1397 2139 1.12 (0.92-1.35) 1.32 (0.55-3.15) 0.2128 0.2324
Cell cycle STK15 rs1047972 93 1439 2286 0.97 (0.83-1.13) 0.90 (0.60-1.35) 0.5405 0.5583
Cell cycle STK15 rs2273535 81 1333 1917 1.15 (0.99-1.34) 1.20 (0.87-1.66) 0.0515 0.0611
Cell cycle STK15 rs8173 86 1338 2103 1.01 (0.88-1.17) 1.29 (0.94-1.76) 0.2747 0.2945
DNA repair BRCA1 rs799917 89 1414 2157 1.16 (1.01-1.34) 1.09 (0.87-1.37) 0.1299 0.1467
DNA repair BRCA1 rs1799950 58 1036 1275 1.04 (0.81-1.34) 0.30 (0.03-2.72) 0.9818 0.9823
DNA repair BRIP rs11871785 99 1478 2488 1.05 (0.91-1.21) 0.96 (0.78-1.18) 0.9737 0.9749
DNA repair BRIP rs1557720 82 1317 1987 1.06 (0.91-1.24) 1.17 (0.95-1.45) 0.1434 0.1596
DNA repair BRIP rs11652980 99 1476 2495 1.02 (0.82-1.28) 1.17 (0.31-4.44) 0.7972 0.8064
DNA repair BRIP rs2191249 82 1313 1970 0.94 (0.81-1.09) 0.76 (0.56-1.02) 0.0798 0.0921
DNA repair BRIP rs16945628 99 1481 2488 0.93 (0.81-1.06) 0.90 (0.73-1.12) 0.2309 0.2531
DNA repair BRIP rs2191248 98 1469 2482 1.00 (0.87-1.15) 1.20 (0.97-1.49) 0.2147 0.2364
DNA repair BRIP rs16945643 99 1471 2486 0.97 (0.81-1.17) 1.83 (0.76-4.38) 0.8358 0.8433
DNA repair BRIP rs6504074 80 1294 1918 0.94 (0.81-1.09) 0.85 (0.65-1.12) 0.208 0.2257
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DNA repair BRIP rs2378908 81 1287 1982 1.10 (0.93-1.30) 1.18 (0.70-2.00) 0.2122 0.2303
DNA repair BRIP rs4988344 82 1315 1992 1.09 (0.93-1.28) 1.43 (0.94-2.18) 0.0777 0.09
DNA repair BRIP rs9908659 99 1478 2488 0.98 (0.85-1.14) 1.08 (0.88-1.32) 0.6005 0.6174
DNA repair BRIP rs4968451 99 1477 2489 1.06 (0.91-1.23) 1.38 (0.93-2.06) 0.1459 0.1653
DNA repair BRIP rs2048718 98 1459 2482 0.94 (0.81-1.10) 1.04 (0.86-1.25) 0.8081 0.8167
DNA repair NBS1 rs1063045 94 1453 2305 0.99 (0.86-1.15) 0.93 (0.74-1.16) 0.5945 0.6107
DNA repair NBS1 rs1805794 92 1423 2267 1.00 (0.87-1.16) 0.85 (0.68-1.07) 0.3049 0.3262
DNA repair NBS1 rs709816 93 1448 2273 1.03 (0.89-1.19) 0.96 (0.78-1.18) 0.8746 0.88
DNA repair NBS1 rs1061302 84 1333 2035 1.02 (0.88-1.18) 0.89 (0.70-1.12) 0.5305 0.5469
DNA repair RAD51 rs1801320 87 1399 2092 1.08 (0.88-1.33) 1.51 (0.60-3.76) 0.3156 0.3357
DNA repair RAD51 rs1801321 85 1412 1986 1.02 (0.87-1.18) 1.21 (0.99-1.48) 0.0985 0.1127
DNA repair RAD52 rs11226 93 1449 2293 1.17 (1.00-1.37) 1.03 (0.85-1.24) 0.6166 0.6321
DNA repair XRCC2 XRCC212 83 1364 1959 0.95 (0.75-1.20) 1.03 (0.35-2.98) 0.6961 0.7074
DNA repair XRCC2 rs3218384 89 1426 2160 1.00 (0.86-1.15) 0.99 (0.72-1.38) 0.9722 0.9734
DNA repair XRCC2 rs3218536 78 1337 1787 0.88 (0.72-1.08) 0.23 (0.07-0.79) 0.0364 0.0439
DNA repair XRCC3 rs1799794 94 1461 2307 1.07 (0.93-1.24) 0.66 (0.44-0.98) 0.6996 0.7122
DNA repair XRCC3 rs1799796 94 1461 2299 0.92 (0.80-1.06) 1.12 (0.90-1.39) 0.8358 0.8429
DNA repair XRCC3 rs861539 84 1332 2024 0.91 (0.78-1.06) 0.91 (0.73-1.14) 0.2705 0.2898
Mismatch MLH1 rs1800734 81 1299 1957 0.95 (0.82-1.11) 1.07 (0.76-1.49) 0.8455 0.8513
Mismatch MLH1 rs1540354 81 1305 1960 1.05 (0.90-1.23) 1.10 (0.76-1.60) 0.4616 0.4789
Mismatch MLH1 rs1799977 56 1017 1238 1.07 (0.90-1.28) 0.96 (0.72-1.28) 0.8334 0.8379
Mismatch MLH1 rs2286939 84 1318 2051 1.05 (0.89-1.23) 0.98 (0.80-1.20) 0.9276 0.9304
Mismatch MLH3 rs7303 79 1281 1906 1.03 (0.87-1.22) 1.08 (0.89-1.32) 0.4363 0.4537
Mismatch MLH3 rs175080 82 1296 1981 0.97 (0.82-1.14) 0.89 (0.73-1.10) 0.2971 0.3161
Mismatch MSH2 rs4952887 82 1302 1975 0.82 (0.67-1.00) 1.24 (0.63-2.44) 0.1534 0.1698
Mismatch MSH2 rs13425206 99 1475 2491 0.94 (0.73-1.22) 1.06 (0.33-3.39) 0.698 0.7113
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Mismatch MSH2 rs3771274 82 1304 1978 1.02 (0.88-1.20) 1.01 (0.81-1.25) 0.8708 0.8757
Mismatch MSH2 rs1981928 83 1314 2001 1.00 (0.86-1.16) 0.88 (0.67-1.15) 0.5225 0.5388
Mismatch MSH2 rs2059520 82 1312 1981 1.03 (0.88-1.19) 1.00 (0.80-1.26) 0.884 0.8885
Mismatch MSH2 rs2303428 84 1317 2047 0.90 (0.75-1.08) 0.59 (0.28-1.24) 0.1071 0.1217
Mismatch MSH3 rs6151662 98 1474 2461 1.02 (0.82-1.26) 0.27 (0.08-0.92) 0.4541 0.475
Mismatch MSH3 rs40139 83 1315 2026 1.17 (1.00-1.38) 0.96 (0.78-1.17) 0.9751 0.976
Mismatch MSH3 rs26282 82 1308 1988 1.02 (0.88-1.19) 1.01 (0.76-1.33) 0.8299 0.8364
Mismatch MSH3 rs26779 98 1475 2466 1.00 (0.87-1.16) 0.98 (0.80-1.19) 0.8493 0.8561
Mismatch MSH3 rs33008 82 1227 1829 0.77 (0.32-1.87) 0.85 (0.35-2.07) 0.8039 0.8113
Mismatch MSH3 rs10079641 98 1473 2470 1.10 (0.92-1.32) 0.67 (0.36-1.28) 0.7589 0.7696
Mismatch MSH3 rs184967 92 1305 1983 1.01 (0.86-1.18) 1.04 (0.65-1.65) 0.8937 0.8978
Mismatch MSH3 rs2897298 98 1465 2450 1.10 (0.94-1.29) 0.87 (0.50-1.52) 0.4274 0.4487
Mismatch MSH3 rs26279 82 1301 2008 1.08 (0.93-1.25) 1.10 (0.85-1.42) 0.2922 0.3114
Mismatch MSH3 rs2112416 82 1310 1985 0.99 (0.83-1.16) 1.14 (0.71-1.83) 0.8772 0.8819
Mismatch MSH6 rs3136245 81 1310 1960 0.98 (0.84-1.14) 0.68 (0.47-0.99) 0.1573 0.1739
Mismatch MSH6 rs3136272 97 1450 2425 0.92 (0.80-1.06) 1.02 (0.83-1.26) 0.7715 0.7815
Mismatch MSH6 rs1800932 83 1317 2001 1.09 (0.93-1.28) 1.01 (0.70-1.45) 0.4088 0.4273
Mismatch MSH6 rs2348244 80 1279 1940 1.07 (0.90-1.26) 0.65 (0.40-1.05) 0.727 0.7369
Mismatch MSH6 rs3136317 99 1476 2490 1.10 (0.95-1.27) 1.08 (0.70-1.68) 0.227 0.2491
Mismatch MSH6 rs1800935 83 1316 2026 1.04 (0.90-1.20) 1.03 (0.79-1.33) 0.6797 0.6916
Mismatch MSH6 rs2020911 81 1306 1950 1.05 (0.90-1.22) 0.90 (0.72-1.12) 0.5504 0.5658
Mismatch PMS1 rs3762545 83 1308 2018 0.94 (0.81-1.10) 0.81 (0.56-1.18) 0.2317 0.2505
Mismatch PMS1 rs5742981 90 1300 2299 0.94 (0.72-1.23) 0.36 (0.04-3.10) 0.4592 0.4783
Mismatch PMS1 rs5741593 97 1462 2447 0.87 (0.71-1.07) 0.63 (0.20-2.00) 0.1275 0.1457
Mismatch PMS1 rs1233291 82 1309 1977 0.89 (0.77-1.03) 0.84 (0.63-1.12) 0.08 0.0924
Mismatch PMS1 rs1233255 79 1271 1905 1.03 (0.88-1.21) 0.79 (0.55-1.13) 0.6249 0.6378
Appendices
456
Pathway /
Group Gene/cytoband SNP
Call rate
(%)** Cases Controls HetOR (95% CI) HomOR (95% CI)
P-trend
unadj
P-trend
adj.‡
Mismatch PMS1 rs1233258 82 1305 1969 0.91 (0.79-1.06) 0.94 (0.72-1.22) 0.3118 0.3307
Mismatch PMS1 rs256571 99 1475 2484 1.02 (0.83-1.25) 0.41 (0.09-1.97) 0.8635 0.8697
Mismatch PMS1 rs256563 98 1456 2446 2.50 (0.99-6.33) 2.15 (0.84-5.48) 0.04 0.05
Mismatch PMS2 rs7797466 82 1305 1968 1.18 (1.01-1.38) 1.38 (0.96-2.00) 0.0108 0.0142
Mismatch PMS2 rs2345060 82 1319 1987 1.02 (0.88-1.18) 0.82 (0.59-1.12) 0.5412 0.557
Mismatch PMS2 rs2286680 83 1316 2026 1.09 (0.92-1.28) 1.13 (0.68-1.88) 0.2972 0.3165
Mismatch PMS2 rs12112229 81 1299 1945 0.95 (0.82-1.10) 1.15 (0.86-1.54) 0.8827 0.8872
Mismatch PMS2 rs1805321 82 1317 1980 0.85 (0.73-1.00) 0.93 (0.75-1.14) 0.2586 0.2775
Mismatch PMS2 rs2228006 98 1467 2478 1.01 (0.87-1.18) 1.24 (0.77-2.00) 0.5728 0.5905
MMCT-18* AIFM2 rs2394655 75 1037 1983 1.11 (0.83-1.49) 0.52 (0.06-4.50) 0.6144 0.6282
MMCT-18* AIFM2 rs7908957 74 1017 1939 0.84 (0.70-1.02) 1.16 (0.67-2.02) 0.2381 0.2529
MMCT-18* AIFM2 rs1053495 67 958 1741 0.91 (0.72-1.16) 0.44 (0.14-1.32) 0.1832 0.1945
MMCT-18* AIFM2 rs2894111 74 1046 1925 0.96 (0.81-1.12) 0.75 (0.56-1.01) 0.1055 0.1173
MMCT-18* AIFM2 rs2394656 39 440 1134 0.88 (0.69-1.12) 0.80 (0.41-1.55) 0.2354 0.2415
MMCT-18* AIFM2 rs6480440 39 422 1140 1.01 (0.79-1.29) 0.90 (0.56-1.44) 0.7992 0.8026
MMCT-18* AIFM2 rs2280201 76 1041 1996 1.04 (0.87-1.26) 0.81 (0.44-1.50) 0.96 0.9614
MMCT-18* AIFM2 rs10999147 76 1049 2017 1.10 (0.89-1.36) 0.73 (0.19-2.82) 0.4693 0.4866
MMCT-18* AIFM2 rs3750772 75 1027 1995 1.04 (0.81-1.33) 0.99 (0.25-3.90) 0.7791 0.787
MMCT-18* AIFM2 rs4295944 76 1047 2008 0.99 (0.84-1.17) 1.08 (0.87-1.34) 0.5842 0.5978
MMCT-18* AIFM2 rs2394644 34 600 745 1.05 (0.81-1.37) 0.78 (0.35-1.74) 0.9997 0.9997
MMCT-18* AIFM2 rs10999152 64 908 1672 1.17 (0.98-1.41) 1.11 (0.70-1.75) 0.1151 0.1279
MMCT-18* AKTIP rs9931702 40 441 1150 0.95 (0.74-1.22) 0.90 (0.66-1.24) 0.5203 0.528
MMCT-18* AKTIP rs17801966 31 348 898 0.92 (0.69-1.24) 0.90 (0.32-2.53) 0.5794 0.5836
MMCT-18* AKTIP rs7189819 75 1034 1980 0.89 (0.76-1.04) 0.82 (0.63-1.06) 0.066 0.0754
MMCT-18* AKTIP rs3743772 38 413 1093 0.88 (0.60-1.28) 1.74 (0.29-10.48) 0.6778 0.6817
MMCT-18* AXIN2 rs11868547 65 847 1764 0.95 (0.78-1.16) 0.92 (0.73-1.16) 0.463 0.4768
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MMCT-18* AXIN2 rs7591 74 1041 1921 1.12 (0.95-1.33) 1.04 (0.82-1.32) 0.461 0.4769
MMCT-18* AXIN2 rs4074947 74 1043 1946 1.09 (0.92-1.28) 0.98 (0.66-1.45) 0.5141 0.5294
MMCT-18* AXIN2 rs7210356 76 1047 2019 1.11 (0.92-1.34) 0.84 (0.41-1.71) 0.443 0.4606
MMCT-18* AXIN2 rs11655966 36 594 832 0.98 (0.79-1.23) 1.03 (0.68-1.57) 0.9882 0.9884
MMCT-18* AXIN2 rs4541111 35 594 830 1.24 (0.96-1.60) 1.10 (0.82-1.49) 0.5038 0.511
MMCT-18* AXIN2 rs4791171 67 950 1735 1.08 (0.91-1.28) 1.20 (0.89-1.60) 0.1827 0.1976
MMCT-18* AXIN2 rs11079571 36 603 831 1.08 (0.86-1.37) 1.68 (0.87-3.25) 0.1748 0.1831
MMCT-18* AXIN2 rs3923087 75 1041 1961 1.03 (0.87-1.21) 1.37 (0.95-1.98) 0.2081 0.2255
MMCT-18* AXIN2 rs3923086 75 1039 1990 1.01 (0.86-1.20) 1.13 (0.91-1.42) 0.329 0.3467
MMCT-18* CASP5 rs518604 76 1041 2029 1.11 (0.93-1.33) 1.27 (1.02-1.58) 0.032 0.0387
MMCT-18* CASP5 rs523104 75 1017 2006 0.92 (0.77-1.10) 0.89 (0.71-1.11) 0.2633 0.2803
MMCT-18* CASP5 rs3181328 75 1039 1981 0.98 (0.79-1.21) 0.63 (0.32-1.26) 0.3921 0.4072
MMCT-18* CASP5 rs17446518 34 574 805 0.82 (0.62-1.08) 1.55 (0.56-4.30) 0.3641 0.3707
MMCT-18* CASP5 rs9651713 74 1029 1959 1.02 (0.84-1.24) 1.39 (0.67-2.90) 0.5982 0.6117
MMCT-18* CASP5 rs3181175 76 1046 2001 0.91 (0.77-1.07) 1.14 (0.74-1.76) 0.5699 0.5832
MMCT-18* CASP5 rs3181174 76 1044 2006 0.85 (0.68-1.06) 0.93 (0.35-2.47) 0.1687 0.1814
MMCT-18* CASP5 rs2282657 67 958 1739 0.97 (0.82-1.15) 1.01 (0.78-1.32) 0.9472 0.9488
MMCT-18* CASP5 rs507879 75 1038 1957 1.04 (0.85-1.27) 1.05 (0.85-1.31) 0.6488 0.6603
MMCT-18* FILIP1 rs796977 40 437 1166 1.11 (0.88-1.40) 1.28 (0.91-1.81) 0.1458 0.1548
MMCT-18* FILIP1 rs793477 66 944 1705 0.92 (0.76-1.12) 0.72 (0.37-1.40) 0.2396 0.2528
MMCT-18* FILIP1 rs793446 76 1045 1997 1.06 (0.90-1.26) 1.10 (0.88-1.38) 0.359 0.3766
MMCT-18* FILIP1 rs3921767 75 1040 1956 1.10 (0.88-1.37) 0.74 (0.26-2.13) 0.5993 0.613
MMCT-18* FILIP1 rs17338680 77 1046 2027 1.05 (0.87-1.28) 0.70 (0.37-1.32) 0.8847 0.8887
MMCT-18* FILIP1 rs9864437 76 1047 2009 0.95 (0.80-1.11) 1.15 (0.83-1.60) 0.9395 0.9417
MMCT-18* FILIP1 rs6788750 57 711 1593 0.99 (0.82-1.21) 0.91 (0.70-1.18) 0.523 0.5341
MMCT-18* FILIP1 rs12494994 75 1038 1971 1.13 (0.95-1.33) 0.98 (0.63-1.52) 0.3168 0.3352
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Pathway /
Group Gene/cytoband SNP
Call rate
(%)** Cases Controls HetOR (95% CI) HomOR (95% CI)
P-trend
unadj
P-trend
adj.‡
MMCT-18* RBBP8 rs7239066 76 1040 1993 0.81 (0.67-0.98) 1.20 (0.62-2.32) 0.1062 0.117
MMCT-18* RBBP8 rs11082221 76 1038 1991 1.00 (0.74-1.34) 1.23 (0.29-5.24) 0.9388 0.942
MMCT-18* RBBP8 rs4474794 74 1033 1947 0.93 (0.79-1.10) 0.95 (0.75-1.21) 0.5173 0.5318
MMCT-18* RBBP8 rs9304261 31 346 888 1.08 (0.82-1.40) 0.66 (0.38-1.15) 0.5163 0.5212
MMCT-18* RGC32 rs10467472 74 1045 1943 1.04 (0.87-1.26) 1.24 (0.70-2.17) 0.4527 0.4696
MMCT-18* RGC32 rs3783194 68 956 1762 1.00 (0.82-1.22) 1.75 (0.85-3.59) 0.4929 0.5077
MMCT-18* RGC32 rs11618371 76 1047 2009 1.04 (0.85-1.26) 1.40 (0.70-2.80) 0.4719 0.489
MMCT-18* RGC32 rs9532824 75 1051 1949 0.88 (0.71-1.10) 0.42 (0.14-1.24) 0.0912 0.1003
MMCT-18* RGC32 rs995845 76 1040 1995 1.01 (0.86-1.19) 1.16 (0.85-1.58) 0.4767 0.493
MMCT-18* RGC32 rs9594551 74 1043 1929 0.95 (0.80-1.14) 1.20 (0.70-2.06) 0.9182 0.921
MMCT-18* RGC32 rs975590 75 1033 1994 1.00 (0.85-1.18) 0.76 (0.53-1.08) 0.3487 0.3652
MMCT-18* RUVBL1 rs9860614 76 1039 2012 1.04 (0.86-1.25) 1.43 (0.83-2.45) 0.3153 0.3344
MMCT-18* RUVBL1 rs13063604 34 564 785 1.23 (0.98-1.56) 1.54 (1.00-2.39) 0.016 0.0181
MMCT-18* RUVBL1 rs3732402 76 1045 2005 1.24 (1.05-1.46) 1.17 (0.93-1.48) 0.0554 0.0649
MMCT-18* RUVBL1 rs7650365 75 1009 2010 1.17 (0.97-1.40) 0.87 (0.70-1.09) 0.2912 0.3085
MMCT-18* RUVBL1 rs4857836 77 1049 2031 1.08 (0.93-1.27) 1.13 (0.83-1.54) 0.2526 0.2708
MMCT-18* RUVBL1 rs9821568 75 1028 1971 1.02 (0.86-1.22) 1.10 (0.65-1.85) 0.6988 0.7092
MMCT-18* STAG3 rs11762932 76 1047 2007 0.96 (0.82-1.13) 1.00 (0.71-1.41) 0.7446 0.7533
MMCT-18* STAG3 rs2246713 35 591 824 0.88 (0.68-1.14) 0.89 (0.66-1.20) 0.4251 0.4329
MMCT-18* STAG3 rs1637001 76 1047 2005 0.83 (0.71-0.97) 0.88 (0.65-1.18) 0.0512 0.0592
OCAC§ 11q13.2 rs7931342 98 1466 2474 0.94 (0.80-1.11) 0.93 (0.77-1.12) 0.4153 0.4369
OCAC§ 17q22 rs7501993 97 1454 2456 0.90 (0.78-1.05) 1.02 (0.84-1.24) 0.8645 0.8706
OCAC§ 17q24.3 rs1859962 97 1446 2464 1.01 (0.86-1.19) 0.98 (0.81-1.18) 0.8063 0.815
OCAC§ 3p12.1 rs2660753 96 1437 2428 1.14 (0.96-1.36) 1.53 (0.80-2.94) 0.0628 0.0755
OCAC§ 8q24.21 rs7000448 98 1472 2453 1.09 (0.95-1.26) 0.96 (0.78-1.19) 0.8229 0.8308
OCAC§ Xp11.22 rs5945619 98 1457 2479 1.00 (0.87-1.15) 1.08 (0.88-1.33) 0.56 0.5781
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Pathway /
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Call rate
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P-trend
unadj
P-trend
adj.‡
OCAC§ ABL1 rs2855192 98 1470 2470 0.98 (0.84-1.15) 1.76 (1.07-2.88) 0.3501 0.3726
OCAC§ BRCA2 rs144848 93 1459 2294 0.94 (0.82-1.08) 1.03 (0.79-1.33) 0.6796 0.6929
OCAC§ CDC2 rs2448343 96 1448 2420 1.04 (0.90-1.20) 0.95 (0.77-1.17) 0.839 0.8462
OCAC§ CDK7 rs12656449 98 1471 2476 1.02 (0.85-1.22) 0.75 (0.34-1.66) 0.9306 0.9338
OCAC§ CRCAC rs10795668 96 1428 2417 1.02 (0.89-1.17) 0.92 (0.73-1.16) 0.7112 0.7235
OCAC§ CRCAC rs16892766 96 1439 2425 1.17 (0.98-1.41) 0.91 (0.42-1.95) 0.1575 0.177
OCAC§ CTBP2 rs12769019 56 996 1259 0.94 (0.79-1.12) 1.24 (0.91-1.69) 0.6017 0.6116
OCAC§ DESP-1979 rs16901979 97 1463 2428 0.98 (0.75-1.27) 0.96 (0.16-5.86) 0.8539 0.8605
OCAC§ DNMT3A rs13420827 98 1462 2473 0.96 (0.83-1.11) 1.13 (0.82-1.56) 0.9359 0.9388
OCAC§ DPYD rs1801265 97 1464 2444 1.00 (0.87-1.15) 1.05 (0.76-1.45) 0.8433 0.8503
OCAC§ E2F2 rs760607 96 1251 2109 2.94 (1.38-6.23) 2.91 (1.37-6.15) 0.8924 0.8972
OCAC§ E2F3 rs7760528 98 1462 2465 1.03 (0.90-1.18) 0.92 (0.74-1.16) 0.7598 0.7704
OCAC§ EHBP1 rs2710646 95 1454 2355 0.94 (0.81-1.08) 1.32 (0.95-1.83) 0.7223 0.7342
OCAC§ ESR1 rs712221 97 1445 2454 1.08 (0.93-1.25) 1.12 (0.92-1.37) 0.2115 0.233
OCAC§ ESR1 rs9322336 98 1453 2464 0.81 (0.70-0.93) 0.73 (0.52-1.02) 0.0013 0.0021
OCAC§ FANCE rs2395626 98 1460 2480 1.06 (0.91-1.23) 0.98 (0.81-1.18) 0.971 0.9723
OCAC§ 5q35.3 SNP4 95 1461 2370 1.04 (0.90-1.20) 1.02 (0.83-1.25) 0.7217 0.7336
OCAC§ 5q35.3 SNP3 95 1462 2371 0.96 (0.82-1.12) 0.90 (0.74-1.09) 0.2835 0.3055
OCAC§ 5q35.3 SNP2 95 1467 2359 0.96 (0.84-1.11) 0.75 (0.56-1.00) 0.1085 0.1251
OCAC§ 5q35.3 SNP1 97 1475 2411 0.92 (0.80-1.06) 0.82 (0.58-1.14) 0.1207 0.1384
OCAC§ GALNTL2 rs2271077 98 1460 2479 0.96 (0.77-1.21) 0.97 (0.24-3.97) 0.7433 0.7546
OCAC§ 11p15.5 SNP3 96 1457 2396 0.87 (0.75-1.01) 0.85 (0.61-1.17) 0.0503 0.0616
OCAC§ 11p15.5 SNP2 96 1459 2407 1.20 (1.02-1.40) 1.20 (1.00-1.44) 0.0473 0.0581
OCAC§ 11p15.5 SNP1 97 1473 2402 0.84 (0.73-0.97) 0.86 (0.60-1.22) 0.0243 0.0314
OCAC§ IL18 rs1834481 97 1449 2435 0.89 (0.77-1.02) 0.77 (0.59-1.01) 0.0227 0.0295
OCAC§ JAZF1 rs10486567 96 1456 2408 1.00 (0.87-1.14) 1.09 (0.83-1.45) 0.7233 0.7352
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P-trend
unadj
P-trend
adj.‡
OCAC§ KLK3 rs2735839 98 1459 2481 0.92 (0.79-1.08) 1.38 (0.90-2.11) 0.9525 0.9547
OCAC§ KU70 rs132788 86 1382 2082 1.04 (0.90-1.21) 1.08 (0.87-1.36) 0.4333 0.4522
OCAC§ LIG4 rs1805386 98 1462 2466 1.08 (0.93-1.26) 1.24 (0.85-1.83) 0.1498 0.1693
OCAC§ LMTK2 rs6465657 97 1439 2454 0.94 (0.80-1.09) 1.00 (0.83-1.21) 0.9184 0.9221
OCAC§ MSMB rs10993994 98 1454 2473 1.03 (0.89-1.19) 1.08 (0.88-1.32) 0.4583 0.479
OCAC§ MTHFD1 rs1950902 97 1451 2458 0.97 (0.84-1.12) 0.89 (0.62-1.27) 0.4952 0.515
OCAC§ MTHFS rs17284990 96 1418 2416 0.98 (0.85-1.13) 1.06 (0.79-1.44) 0.9714 0.9727
OCAC§ NRIP1 rs2822986 98 1458 2458 1.03 (0.89-1.18) 0.89 (0.71-1.10) 0.5123 0.5317
OCAC§ PGR rs10895068 97 1462 2413 1.00 (0.81-1.24) 0.49 (0.13-1.80) 0.7231 0.7351
OCAC§ PGR rs1042838 95 1424 2408 1.25 (1.07-1.46) 1.09 (0.73-1.64) 0.0161 0.0215
OCAC§ PGR rs608995 98 1475 2473 1.08 (0.94-1.24) 1.12 (0.84-1.48) 0.2427 0.265
OCAC§ SLC22A3 rs9364554 96 1449 2390 1.07 (0.93-1.24) 1.19 (0.94-1.51) 0.1223 0.1399
OCAC§ TGFB1 rs1982073 57 1026 1262 0.98 (0.82-1.17) 0.95 (0.74-1.23) 0.7069 0.7146
OCAC§ TNRC9 rs3803662 97 1456 2427 0.94 (0.82-1.08) 0.85 (0.65-1.11) 0.1849 0.2055
OCAC§ TP53 rs2287498 98 1459 2471 1.03 (0.86-1.24) 2.20 (0.95-5.08) 0.3145 0.3371
OCAC§ TP53 rs1042522 93 1459 2291 0.97 (0.84-1.11) 1.11 (0.85-1.45) 0.8221 0.8297
OCAC§ TP53 rs12951053 96 1428 2430 1.03 (0.86-1.24) 1.48 (0.71-3.11) 0.4635 0.4838
OCAC§ TP53 rs1625895 88 1409 2136 1.05 (0.89-1.24) 0.85 (0.48-1.51) 0.8096 0.8173
OCAC§ TP53 rs9894946 99 1470 2485 1.09 (0.94-1.27) 1.02 (0.65-1.58) 0.3293 0.3519
OCAC§ TYMS rs495139 97 1433 2469 1.09 (0.94-1.26) 0.93 (0.76-1.14) 0.8128 0.8212
OCAC§ 12q13.11 SNP1 98 1461 2455 1.06 (0.92-1.23) 1.06 (0.86-1.29) 0.4679 0.4884
OCAC§ 6p21.1 SNP1 97 1475 2418 1.07 (0.91-1.25) 1.17 (0.97-1.41) 0.0943 0.1102
OCAC§ XRCC5 rs16855489 99 1476 2484 1.05 (0.91-1.21) 1.02 (0.83-1.25) 0.7089 0.7217
Oncogene BRAF rs10487888 99 1480 2481 1.02 (0.87-1.19) 0.88 (0.73-1.07) 0.2443 0.2666
Oncogene BRAF rs1733832 80 1149 2043 1.07 (0.85-1.34) 3.40 (0.97-11.92) 0.2404 0.2585
Oncogene BRAF rs1267622 97 1458 2443 0.96 (0.83-1.10) 0.83 (0.62-1.12) 0.2461 0.2682
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unadj
P-trend
adj.‡
Oncogene BRAF rs13241719 83 1304 2032 1.05 (0.91-1.22) 0.89 (0.69-1.14) 0.7355 0.7455
Oncogene BRAF rs17695623 96 1441 2434 1.24 (0.61-2.51) 1.28 (0.62-2.64) 0.8847 0.8898
Oncogene BRAF rs17161747 98 1473 2467 1.19 (0.96-1.47) 1.38 (0.52-3.62) 0.094 0.11
Oncogene BRAF rs17623382 97 1465 2439 0.98 (0.83-1.15) 1.01 (0.59-1.74) 0.8527 0.8593
Oncogene BRAF rs6944385 98 1471 2464 1.15 (0.99-1.35) 0.98 (0.61-1.57) 0.1463 0.1657
Oncogene ERBB2 rs2952155 98 1463 2462 1.01 (0.87-1.15) 1.13 (0.84-1.52) 0.5785 0.596
Oncogene ERBB2 rs2952156 98 1470 2473 1.00 (0.87-1.14) 1.17 (0.90-1.52) 0.4481 0.4691
Oncogene ERBB2 rs1801200 97 1455 2434 1.06 (0.92-1.22) 1.07 (0.80-1.42) 0.4236 0.4449
Oncogene KRAS rs12305513 99 1483 2472 0.89 (0.75-1.06) 0.83 (0.42-1.62) 0.1668 0.1872
Oncogene KRAS rs12822857 97 1465 2446 1.01 (0.86-1.18) 0.99 (0.82-1.19) 0.9441 0.9467
Oncogene KRAS rs10842508 98 1476 2469 0.97 (0.84-1.11) 0.99 (0.75-1.31) 0.7587 0.7694
Oncogene KRAS rs12579073 97 1460 2442 0.96 (0.82-1.12) 0.94 (0.78-1.14) 0.5369 0.5555
Oncogene KRAS rs10842513 97 1469 2421 0.98 (0.82-1.17) 0.84 (0.40-1.75) 0.6988 0.7118
Oncogene KRAS rs4623993 79 1140 2030 1.05 (0.88-1.24) 1.17 (0.73-1.89) 0.4498 0.4669
Oncogene KRAS rs6487464 98 1470 2448 1.03 (0.89-1.19) 1.02 (0.84-1.24) 0.7956 0.8047
Oncogene KRAS rs10842514 98 1473 2442 0.96 (0.83-1.12) 1.12 (0.93-1.35) 0.3125 0.335
Oncogene KRAS rs11047917 98 1465 2456 0.88 (0.71-1.08) 1.22 (0.42-3.50) 0.311 0.3335
Oncogene NMI rs394884 95 1412 2390 1.07 (0.92-1.26) 0.99 (0.53-1.86) 0.4338 0.4544
Oncogene NMI rs11551174 79 1150 2040 0.98 (0.77-1.24) 1.24 (0.45-3.42) 0.9861 0.9866
Oncogene NMI rs289831 96 1422 2403 1.07 (0.87-1.33) 0.84 (0.40-1.79) 0.5856 0.6026
Oncogene NMI rs3771886 98 1464 2465 1.00 (0.87-1.16) 1.15 (0.95-1.40) 0.2006 0.2219
Oncogene NMI rs11683487 83 1172 2149 0.78 (0.66-0.93) 0.85 (0.70-1.04) 0.0668 0.0782
Oncogene NMI rs2113509 97 1459 2452 1.09 (0.93-1.28) 1.05 (0.59-1.85) 0.3195 0.342
Oncogene PIK3CA rs2865084 80 1154 2046 1.14 (0.89-1.45) 0.91 (0.26-3.17) 0.356 0.3744
Oncogene PIK3CA rs7621329 97 1466 2424 1.02 (0.88-1.18) 1.18 (0.79-1.76) 0.557 0.575
Oncogene PIK3CA rs1517586 96 1429 2434 0.89 (0.74-1.06) 0.77 (0.39-1.51) 0.143 0.1618
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unadj
P-trend
adj.‡
Oncogene PIK3CA rs2699905 97 1445 2439 0.99 (0.86-1.14) 1.04 (0.82-1.32) 0.8746 0.8802
Oncogene PIK3CA rs7641889 98 1478 2463 0.87 (0.71-1.07) 1.22 (0.51-2.91) 0.297 0.3196
Oncogene PIK3CA rs7651265 97 1449 2435 0.91 (0.77-1.08) 1.33 (0.73-2.42) 0.5891 0.606
Oncogene PIK3CA rs7640662 98 1475 2472 1.06 (0.91-1.23) 0.88 (0.57-1.37) 0.7612 0.7719
Oncogene PIK3CA rs2677760 97 1451 2446 0.99 (0.84-1.16) 1.08 (0.90-1.30) 0.4223 0.4436
‡ Adjusted for population stratification
* GEOCS not done
**Call rate bases on total number of samples analysed.
§ candidate genes identified from the Breast Cancer Association Consortium (BCAC) and Ovarian Cancer Association Consortium (OCAC);
Emboldened P-values are significant at the 5% level. The P-trend looks for a trend between the OR and the heterozygous (Het); and rare homozygous (Hom) when compared
with the common homozygous; the P-heterogeneity (P-het) does not assume a correlation with increasing number of rare allele.enboldened odds ratios (OR) do not cross 1.
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Appendix VII-A: Univariate and multivariate Cox regression results of BRAF tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1680 All 1 (0.89-1.12) 0.972 0.94 (0.82-1.07) 0.357 6
804 Serous 1.05 (0.9-1.21) 0.549 0.9 (0.8-1.1) 0.468 14
251 Endometrioid 0.97 (0.67-1.39) 0.852 0.87 (0.59-1.28) 0.466 10
180 Mucinous 1.1 (0.68-1.78) 0.71 1.01 (0.65-1.59) 0.95 8
BRAF rs10487888 0.46
95 Clear cell 0.74 (0.43-1.28) 0.277 1 (0.54-1.84) 0.999 35
1159 All 1.01 (0.79-1.29) 0.936 1.28 (0.96-1.72) 0.095 27
525 Serous 0.99 (0.72-1.37) 0.966 1.2 (0.8-1.8) 0.291 21
182 Endometrioid 1.03 (0.51-2.08) 0.94 1.67 (0.76-3.69) 0.201 62
135 Mucinous 0.93 (0.39-2.25) 0.879 0.92 (0.38-2.22) 0.856 1
BRAF rs1733832 0.07
94 Clear cell 1.72 (0.66-4.46) 0.264 1.67 (0.52-5.36) 0.389 3
1751 All 1.12 (0.99-1.27) 0.077 1.19 (1.03-1.38) 0.02 6
831 Serous 1.03 (0.87-1.22) 0.727 1.2 (1-1.4) 0.134 17
268 Endometrioid 1.07 (0.72-1.59) 0.733 1.1 (0.71-1.71) 0.655 3
187 Mucinous 1.08 (0.64-1.82) 0.764 0.89 (0.54-1.49) 0.663 18
BRAF rs1267622 0.23
123 Clear cell 1.27 (0.7-2.3) 0.429 1 (0.51-1.98) 0.997 21
1602 All 0.97 (0.85-1.1) 0.606 0.79 (0.67-0.93) 0.004 19
733 Serous 0.94 (0.79-1.12) 0.507 0.8 (0.6-0.9) 0.006 15
246 Endometrioid 0.77 (0.49-1.21) 0.258 0.79 (0.48-1.29) 0.339 3
176 Mucinous 0.99 (0.58-1.69) 0.98 1.05 (0.63-1.74) 0.852 6
BRAF rs13241719 0.31
135 Clear cell 1.12 (0.59-2.15) 0.723 1.4 (0.64-3.06) 0.404 25
1744 All 1.16 (0.94-1.43) 0.174 0.98 (0.76-1.27) 0.89 16
829 Serous 0.93 (0.7-1.23) 0.601 0.9 (0.6-1.2) 0.472 3
BRAF rs17695623 0.07
264 Endometrioid 1.23 (0.61-2.49) 0.569 0.98 (0.43-2.22) 0.955 20
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
186 Mucinous 0.78 (0.21-2.97) 0.721 0.29 (0.07-1.25) 0.098 63
132 Clear cell 1.77 (0.82-3.84) 0.146 1.31 (0.57-3.04) 0.523 26
1771 All 0.83 (0.66-1.05) 0.119 0.84 (0.65-1.1) 0.209 1
847 Serous 0.77 (0.57-1.03) 0.079 0.8 (0.6-1.1) 0.146 4
272 Endometrioid 0.97 (0.45-2.06) 0.928 1.29 (0.61-2.7) 0.506 33
191 Mucinous 0.99 (0.38-2.56) 0.981 1.64 (0.61-4.46) 0.329 66
BRAF rs17161747 0.06
134 Clear cell 0.83 (0.28-2.42) 0.734 1.01 (0.29-3.51) 0.986 22
1764 All 1.08 (0.92-1.28) 0.333 0.98 (0.81-1.19) 0.874 9
841 Serous 1.09 (0.89-1.35) 0.408 1 (0.8-1.2) 0.935 8
270 Endometrioid 0.73 (0.36-1.49) 0.382 0.74 (0.35-1.53) 0.413 1
186 Mucinous 1.54 (0.83-2.87) 0.17 1.86 (0.96-3.58) 0.065 21
BRAF rs17623382 0.12
133 Clear cell 0.74 (0.33-1.69) 0.479 0.5 (0.17-1.45) 0.201 32
1758 All 1.19 (1.03-1.38) 0.021 1.25 (1.05-1.5) 0.013 5
840 Serous 0.97 (0.79-1.2) 0.804 1.1 (0.9-1.3) 0.516 13
268 Endometrioid 1.31 (0.84-2.07) 0.235 1.43 (0.87-2.35) 0.156 9
187 Mucinous 0.83 (0.4-1.73) 0.614 0.76 (0.36-1.62) 0.477 8
BRAF rs6944385 0.14
124 Clear cell 2.22 (1.18-4.17) 0.014 1.93 (0.95-3.92) 0.07 13
1786 All 0.89 (0.79-1.01) 0.076 0.84 (0.72-0.97) 0.018 6
724 Serous 0.97 (0.82-1.14) 0.708 0.9 (0.7-1) 0.115 7
246 Endometrioid 0.9 (0.61-1.34) 0.611 0.87 (0.57-1.34) 0.532 3
169 Mucinous 0.94 (0.56-1.58) 0.82 1.18 (0.7-1.98) 0.528 26
BRAF rs1267622,rs6944385; AA 73.3*
126 Clear cell 0.79 (0.44-1.43) 0.434 1 (0.51-1.98) 0.999 27
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated with
survival; emboldened HR are statistically significant. * Haplotype frequency
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Appendix VII-B: Univariate and multivariate Cox regression results of BRAF haplotypes
Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.98 (0.85-1.13) 0.76 1.09 (0.92-1.3) 0.335 11
Serous 1.06 (0.89-1.28) 0.502 0.4 (0.1-1.5) 0.16 62
Endometrioid 1.24 (0.79-1.95) 0.358 1.06 (0.63-1.79) 0.819 15
Mucinous 1.09 (0.6-1.98) 0.767 0.93 (0.49-1.76) 0.812 15
BRAF h10000000 22.9
Clear cell 0.63 (0.31-1.31) 0.217 0.87 (0.39-1.91) 0.723 38
All 0.95 (0.81-1.1) 0.493 0.8 (0.66-0.95) 0.014 16
Serous 0.95 (0.79-1.16) 0.633 1.1 (0.9-1.4) 0.415 16
Endometrioid 0.88 (0.54-1.42) 0.591 0.88 (0.53-1.48) 0.629 0
Mucinous 0.63 (0.31-1.28) 0.204 0.62 (0.32-1.23) 0.173 2
BRAF h10010000 18.8
Clear cell 1.38 (0.61-3.08) 0.438 2.38 (0.92-6.15) 0.074 72
All 0.94 (0.81-1.1) 0.443 1 (0.84-1.19) 0.962 6
Serous 0.98 (0.81-1.18) 0.813 1 (0.8-1.3) 0.944 2
Endometrioid 0.99 (0.63-1.55) 0.952 0.98 (0.61-1.56) 0.917 1
Mucinous 0.84 (0.43-1.65) 0.618 1.31 (0.61-2.86) 0.49 56
BRAF h00000000 16.4
Clear cell 1.24 (0.62-2.45) 0.542 0.93 (0.4-2.19) 0.874 25
All 1.1 (0.94-1.3) 0.238 1 (0.83-1.21) 0.96 9
Serous 1.12 (0.91-1.37) 0.296 0.8 (0.6-1) 0.037 29
Endometrioid 0.74 (0.36-1.5) 0.401 0.74 (0.36-1.54) 0.425 0
Mucinous 1.5 (0.81-2.8) 0.199 1.91 (0.96-3.78) 0.065 27
BRAF h10010010 12.2
Clear cell 0.79 (0.35-1.75) 0.557 0.62 (0.23-1.7) 0.351 22
All 0.97 (0.79-1.2) 0.804 1.09 (0.86-1.39) 0.48 12
Serous 1.11 (0.86-1.44) 0.426 0.8 (0.6-1.1) 0.161 28
BRAF h00100000 8.7
Endometrioid 0.86 (0.42-1.74) 0.669 0.78 (0.36-1.65) 0.511 9
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Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
Mucinous 1.4 (0.64-3.07) 0.4 1.1 (0.46-2.61) 0.833 21
Clear cell 0.18 (0.02-1.32) 0.092 0.19 (0.03-1.28) 0.087 6
All 1.21 (1-1.46) 0.055 1.43 (1.14-1.8) 0.002 18
Serous 1.1 (0.85-1.42) 0.483 0.9 (0.7-1.3) 0.636 18
Endometrioid 1.3 (0.71-2.4) 0.393 2.04 (1.05-3.99) 0.036 57
Mucinous 0.81 (0.33-1.99) 0.652 0.9 (0.38-2.1) 0.804 11
BRAF h01100001 7.1
Clear cell 1.86 (0.84-4.13) 0.127 1.92 (0.74-4.96) 0.179 3
All 1.17 (0.95-1.44) 0.147 1.01 (0.79-1.3) 0.933 14
Serous 0.94 (0.71-1.24) 0.66 1.3 (1-1.7) 0.099 38
Endometrioid 1.2 (0.59-2.44) 0.611 0.95 (0.42-2.16) 0.896 21
Mucinous 0.77 (0.23-2.61) 0.672 0.37 (0.1-1.36) 0.133 52
BRAF h00101001 7
Clear cell 1.72 (0.79-3.75) 0.171 1.32 (0.57-3.05) 0.523 23
All 0.84 (0.67-1.05) 0.128 0.85 (0.65-1.11) 0.232 1
Serous 0.77 (0.58-1.04) 0.091 1 (0.8-1.3) 0.807 30
Endometrioid 0.97 (0.45-2.07) 0.935 1.3 (0.62-2.73) 0.486 34
Mucinous 1.04 (0.41-2.59) 0.941 1.66 (0.62-4.45) 0.314 60
BRAF h00000100 6.2
Clear cell 0.82 (0.28-2.46) 0.729 1.01 (0.29-3.57) 0.985 23
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, BRAF: rs10487888, rs1733832, rs1267622,
rs13241719, rs17695623, rs17161747, rs17623382, rs6944385.
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Appendix VII-C: Univariate and multivariate Cox regression results of ERBB2 tSNPs
Univariate Multivariate§
Gene tSNP MAF Cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1667 All 1.05 (0.92-1.2) 0.451 1.11 (0.95-1.3) 0.184 6
795 Serous 1.14 (0.96-1.35) 0.127 1.2 (1-1.5) 0.061 5
250 Endometrioid 1.22 (0.8-1.86) 0.358 1.2 (0.79-1.84) 0.396 2
177 Mucinous 1.11 (0.64-1.92) 0.705 0.83 (0.46-1.47) 0.517 25
ERBB2 rs2952155 0.24
135 Clear cell 1.11 (0.6-2.06) 0.73 0.97 (0.45-2.06) 0.933 13
1766 All 1.06 (0.94-1.2) 0.323 1.09 (0.94-1.26) 0.235 3
840 Serous 1.12 (0.96-1.31) 0.154 1.1 (1-1.4) 0.118 2
269 Endometrioid 1.27 (0.85-1.89) 0.239 1.24 (0.8-1.91) 0.337 2
186 Mucinous 1.08 (0.64-1.84) 0.77 0.81 (0.45-1.46) 0.489 25
ERBB2 rs2952156 0.3
134 Clear cell 1.04 (0.58-1.84) 0.906 0.88 (0.42-1.85) 0.731 15
1766 All 0.92 (0.81-1.05) 0.216 1.02 (0.87-1.19) 0.818 11
847 Serous 1.04 (0.88-1.22) 0.635 1.1 (0.9-1.3) 0.372 6
263 Endometrioid 0.81 (0.53-1.22) 0.309 0.74 (0.47-1.19) 0.217 9
188 Mucinous 1.26 (0.7-2.27) 0.448 1.19 (0.64-2.21) 0.586 6
ERBB2 rs1801200 0.23
136 Clear cell 0.9 (0.5-1.64) 0.738 1.41 (0.71-2.78) 0.328 57
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated with
survival; emboldened HR are statistically significant.
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Appendix VII-D: Univariate and multivariate Cox regression results of ERBB2 haplotypes
Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1.02 (0.91-1.14) 0.745 0.95 (0.83-1.09) 0.458 7
Serous 0.92 (0.79-1.06) 0.224 0.9 (0.2-3.6) 0.928 2
Endometrioid 0.98 (0.68-1.4) 0.892 1.06 (0.7-1.6) 0.795 8
Mucinous 0.81 (0.46-1.44) 0.483 1.06 (0.58-1.93) 0.85 31
ERBB2 h000 51.2
Clear cell 1.08 (0.63-1.85) 0.789 0.92 (0.51-1.68) 0.793 15
All 1.12 (0.95-1.31) 0.171 1.14 (0.94-1.38) 0.171 2
Serous 1.18 (0.97-1.44) 0.103 1 (0.7-1.3) 0.767 15
Endometrioid 1.55 (0.9-2.67) 0.111 1.57 (0.9-2.73) 0.111 1
Mucinous 0.96 (0.5-1.86) 0.911 0.71 (0.35-1.44) 0.343 26
ERBB2 h110 18.4
Clear cell 1.16 (0.56-2.42) 0.684 0.99 (0.38-2.55) 0.978 15
All 0.9 (0.77-1.05) 0.181 0.98 (0.81-1.18) 0.835 9
Serous 1.02 (0.84-1.24) 0.853 1.2 (0.9-1.4) 0.179 18
Endometrioid 0.73 (0.44-1.21) 0.222 0.62 (0.34-1.13) 0.12 15
Mucinous 1.21 (0.59-2.47) 0.604 1.32 (0.61-2.82) 0.479 9
ERBB2 h001 17.7
Clear cell 0.87 (0.43-1.74) 0.686 1.45 (0.69-3.03) 0.327 67
All 1 (0.8-1.25) 0.982 0.95 (0.74-1.21) 0.682 5
Serous 0.94 (0.73-1.21) 0.622 1.1 (0.9-1.3) 0.562 17
Endometrioid 1.14 (0.45-2.88) 0.776 0.75 (0.26-2.13) 0.588 34
Mucinous 1.19 (0.4-3.57) 0.753 1.24 (0.41-3.77) 0.699 4
ERBB2 h010 6.5
Clear cell 0.8 (0.23-2.74) 0.722 0.58 (0.13-2.56) 0.47 28
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, ERBB2: rs2952155, rs2952156, rs1801200.
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Appendix VII-E: Univariate and multivariate Cox regression results of KRAS tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1788 All 1.01 (0.84-1.22) 0.879 0.98 (0.79-1.23) 0.878 3
852 Serous 0.92 (0.73-1.17) 0.498 0.9 (0.7-1.2) 0.662 2
272 Endometrioid 1.39 (0.77-2.52) 0.272 1 (0.49-2.03) 0.998 28
Mucinous 1.99 (0.92-4.28) 0.079 1.39 (0.62-3.11) 0.418 30
KRAS rs12305513 0.09
132 Clear cell 0.9 (0.37-2.19) 0.824 0.5 (0.18-1.36) 0.175 44
1751 All 1 (0.9-1.11) 0.959 1.03 (0.91-1.17) 0.622 3
835 Serous 0.96 (0.83-1.1) 0.517 1 (0.9-1.2) 0.898 4
268 Endometrioid 0.96 (0.66-1.38) 0.821 1.01 (0.67-1.5) 0.976 5
166 Mucinous 0.99 (0.65-1.52) 0.976 0.94 (0.59-1.53) 0.816 5
KRAS rs12822857 0.47
136 Clear cell 0.93 (0.54-1.6) 0.796 0.89 (0.47-1.7) 0.726 4
1776 All 0.97 (0.86-1.1) 0.683 1 (0.86-1.17) 0.966 3
841 Serous 0.94 (0.8-1.1) 0.429 1 (0.8-1.2) 0.967 6
273 Endometrioid 1.03 (0.7-1.52) 0.879 0.99 (0.64-1.54) 0.965 4
190 Mucinous 1.7 (0.96-3.02) 0.071 1.26 (0.64-2.47) 0.503 26
KRAS rs10842508 0.24
135 Clear cell 0.97 (0.53-1.77) 0.919 0.65 (0.27-1.54) 0.329 33
1765 All 0.96 (0.86-1.07) 0.417 0.97 (0.85-1.09) 0.583 1
836 Serous 0.92 (0.8-1.06) 0.253 0.9 (0.8-1.1) 0.407 2
269 Endometrioid 0.7 (0.49-1) 0.053 0.74 (0.5-1.1) 0.138 6
190 Mucinous 0.99 (0.65-1.53) 0.981 1.24 (0.77-2) 0.367 25
KRAS rs12579073 0.48
137 Clear cell 0.86 (0.51-1.43) 0.554 0.89 (0.49-1.6) 0.694 3
1770 All 1.18 (0.98-1.42) 0.08 1.25 (1.01-1.55) 0.039 6
846 Serous 1.38 (1.09-1.75) 0.008 1.3 (1-1.6) 0.091 6
271 Endometrioid 1.19 (0.67-2.1) 0.552 1.47 (0.79-2.74) 0.227 24
KRAS rs10842513 0.09
187 Mucinous 0.7 (0.29-1.69) 0.432 0.74 (0.29-1.87) 0.521 6
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
132 Clear cell 2.02 (1-4.1) 0.052 1.71 (0.81-3.58) 0.156 15
1748 All 0.93 (0.8-1.09) 0.378 0.96 (0.8-1.16) 0.676 3
834 Serous 0.89 (0.73-1.08) 0.236 0.9 (0.7-1.1) 0.306 1
242 Endometrioid 0.83 (0.51-1.36) 0.463 0.93 (0.55-1.56) 0.782 12
187 Mucinous 1.79 (1.02-3.15) 0.044 1.56 (0.83-2.93) 0.163 13
KRAS rs4623993 0.16
136 Clear cell 0.93 (0.46-1.89) 0.835 1.18 (0.46-3.01) 0.732 27
1763 All 1 (0.9-1.12) 0.933 1.03 (0.9-1.16) 0.688 3
836 Serous 0.97 (0.84-1.12) 0.694 1 (0.8-1.1) 0.795 3
243 Endometrioid 0.77 (0.53-1.13) 0.189 0.93 (0.61-1.41) 0.74 21
192 Mucinous 0.99 (0.65-1.52) 0.978 0.92 (0.59-1.45) 0.734 7
KRAS rs6487464 0.39
134 Clear cell 0.94 (0.56-1.59) 0.823 1.24 (0.68-2.27) 0.484 32
1757 All 0.95 (0.85-1.06) 0.339 0.93 (0.82-1.05) 0.216 2
835 Serous 0.96 (0.84-1.1) 0.594 1 (0.9-1.1) 0.82 4
243 Endometrioid 1.09 (0.77-1.55) 0.623 0.94 (0.64-1.37) 0.748 14
188 Mucinous 1.04 (0.66-1.64) 0.88 1.18 (0.69-2.01) 0.536 13
KRAS rs10842514 0.45
118 Clear cell 0.71 (0.42-1.21) 0.21 0.65 (0.35-1.19) 0.162 8
1476 All 1 (0.79-1.25) 0.982 1.03 (0.81-1.32) 0.805 3
685 Serous 0.88 (0.66-1.17) 0.373 1 (0.7-1.3) 0.832 14
231 Endometrioid 0.64 (0.2-2.06) 0.455 0.61 (0.19-1.99) 0.409 5
163 Mucinous 0.72 (0.18-2.82) 0.634 0.77 (0.23-2.57) 0.677 7
KRAS rs11047917 0.06
117 Clear cell 1.95 (0.83-4.6) 0.128 2.34 (0.89-6.17) 0.085 20
1717 All 0.89 (0.71-1.11) 0.289 0.86 (0.65-1.14) 0.3 3
698 Serous 0.86 (0.64-1.16) 0.32 0.8 (0.6-1.1) 0.233 7
238 Endometrioid 0.76 (0.39-1.48) 0.417 0.82 (0.4-1.7) 0.592 8
162 Mucinous 1.3 (0.54-3.14) 0.556 0.98 (0.32-2.98) 0.97 25
KRAS rs4623993,rs12579073; TC 11.6*
119 Clear cell 0.73 (0.28-1.88) 0.513 0.88 (0.22-3.5) 0.856 21
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1730 All 1.03 (0.91-1.17) 0.653 1.05 (0.91-1.22) 0.488 2
714 Serous 1.01 (0.86-1.18) 0.904 1 (0.8-1.2) 0.996 1
243 Endometrioid 0.87 (0.56-1.38) 0.563 1.01 (0.61-1.66) 0.973 16
164 Mucinous 0.61 (0.33-1.13) 0.114 0.71 (0.36-1.4) 0.322 16
KRAS rs12822857,rs10842508; AC 24.4*
121 Clear cell 1.06 (0.61-1.86) 0.826 1.32 (0.68-2.55) 0.409 25
1715 All 0.95 (0.85-1.06) 0.366 0.92 (0.81-1.04) 0.194 3
711 Serous 0.95 (0.83-1.1) 0.494 1 (0.8-1.1) 0.521 5
239 Endometrioid 1.03 (0.72-1.48) 0.868 0.88 (0.59-1.31) 0.527 15
164 Mucinous 1 (0.62-1.59) 0.983 1.02 (0.59-1.77) 0.934 2
KRAS rs12822857,rs10842514; GT 38.3*
120 Clear cell 0.82 (0.45-1.48) 0.508 0.96 (0.46-2.01) 0.916 17
1689 All 1.01 (0.89-1.15) 0.824 0.97 (0.83-1.12) 0.659 4
695 Serous 1.13 (0.96-1.33) 0.133 1.1 (0.9-1.3) 0.331 3
236 Endometrioid 1.32 (0.86-2.01) 0.201 1.2 (0.76-1.91) 0.436 9
164 Mucinous 0.82 (0.48-1.43) 0.49 0.65 (0.37-1.17) 0.152 21
KRAS
rs12822857,
rs12579073,
rs6487464; GAC
44.5*
129 Clear cell 0.97 (0.52-1.83) 0.931 1.03 (0.46-2.29) 0.942 6
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated with
survival; emboldened HR are statistically significant.
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Appendix VII-F: Univariate and multivariate Cox regression results of KRAS haplotypes
Univariate Multivariate§Gene Haplotype Freq (%) Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1 (0.9-1.11) 0.989 0.96 (0.85-1.09) 0.542 4
Serous 1.05 (0.91-1.2) 0.519 0.3 (0-1.9) 0.198 71
Endometrioid 1.06 (0.74-1.52) 0.755 1 (0.67-1.48) 0.995 6
Mucinous 1 (0.65-1.52) 0.988 1.04 (0.65-1.68) 0.857 4
KRAS
(haplotype
block 1)
h100 52.7
Clear cell 0.99 (0.58-1.69) 0.98 1.03 (0.55-1.92) 0.928 4
All 1.03 (0.91-1.17) 0.591 1.07 (0.92-1.24) 0.382 4
Serous 1.03 (0.87-1.2) 0.75 0.9 (0.7-1) 0.084 13
Endometrioid 0.88 (0.56-1.38) 0.583 1.02 (0.62-1.67) 0.95 16
Mucinous 0.65 (0.37-1.16) 0.147 0.77 (0.41-1.46) 0.422 18
KRAS
(haplotype
block 1)
h000 22.8
Clear cell 1.04 (0.59-1.81) 0.902 1.28 (0.67-2.44) 0.463 23
All 0.95 (0.82-1.1) 0.466 0.99 (0.83-1.18) 0.889 4
Serous 0.94 (0.78-1.13) 0.504 1 (0.9-1.2) 0.774 6
Endometrioid 0.89 (0.56-1.43) 0.631 0.99 (0.59-1.66) 0.971 11
Mucinous 1.29 (0.67-2.49) 0.448 1.02 (0.46-2.24) 0.964 21
KRAS
(haplotype
block 1)
h001 15.5
Clear cell 1.02 (0.5-2.11) 0.949 1.22 (0.49-3.05) 0.676 20
All 1.04 (0.86-1.26) 0.692 1.02 (0.82-1.28) 0.838 2
Serous 0.94 (0.74-1.2) 0.644 1 (0.8-1.2) 0.944 6
Endometrioid 1.43 (0.79-2.57) 0.238 1.04 (0.51-2.11) 0.916 27
Mucinous 2.01 (0.94-4.3) 0.07 1.38 (0.62-3.07) 0.424 31
KRAS
(haplotype
block 1)
h101 8.9
Clear cell 0.9 (0.37-2.19) 0.823 0.49 (0.18-1.37) 0.174 46
All 0.96 (0.84-1.09) 0.495 0.92 (0.79-1.08) 0.322 4
Serous 1.03 (0.87-1.22) 0.702 1 (0.7-1.4) 0.988 3
Endometrioid 1.23 (0.82-1.85) 0.324 1.03 (0.65-1.64) 0.883 16
Mucinous 0.77 (0.43-1.39) 0.387 0.66 (0.33-1.28) 0.218 14
KRAS
(haplotype
block 2)
h000010 34.5
Clear cell 0.65 (0.32-1.33) 0.238 0.53 (0.22-1.26) 0.15 18
KRAS
(haplotype
h100100 13.8 All 1.05 (0.87-1.25) 0.617 1.06 (0.85-1.31) 0.613 1
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Univariate Multivariate§Gene Haplotype Freq (%) Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
Serous 1.13 (0.9-1.43) 0.293 0.9 (0.8-1.1) 0.376 20
Endometrioid 0.49 (0.24-1) 0.05 0.59 (0.27-1.32) 0.2 20
Mucinous 0.71 (0.25-2.04) 0.521 1.06 (0.32-3.5) 0.926 49
Clear cell 0.32 (0.09-1.16) 0.082 0.26 (0.04-1.81) 0.172 19
All 0.92 (0.75-1.11) 0.375 0.91 (0.71-1.16) 0.429 1
Serous 0.89 (0.69-1.15) 0.367 1 (0.6-1.7) 0.908 12
Endometrioid 0.83 (0.45-1.52) 0.552 0.93 (0.49-1.77) 0.821 12
Mucinous 1.12 (0.49-2.57) 0.787 0.91 (0.33-2.53) 0.861 19
KRAS
(haplotype
block 2)
h101100 11.8
Clear cell 0.74 (0.31-1.77) 0.505 0.84 (0.25-2.79) 0.771 14
All 0.96 (0.83-1.12) 0.625 0.95 (0.81-1.12) 0.556 1
Serous 0.9 (0.74-1.08) 0.255 0.9 (0.6-1.3) 0.479 0
Endometrioid 0.86 (0.51-1.45) 0.571 0.82 (0.47-1.43) 0.481 5
Mucinous 1.32 (0.79-2.22) 0.288 1.79 (1.03-3.13) 0.04 36
KRAS
(haplotype
block 2)
h100010 10.7
Clear cell 0.95 (0.47-1.91) 0.881 0.87 (0.39-1.93) 0.723 8
All 1.27 (0.99-1.62) 0.056 1.24 (0.93-1.66) 0.15 2
Serous 1.69 (1.21-2.36) 0.002 0.9 (0.6-1.3) 0.523 47
Endometrioid 1.21 (0.59-2.48) 0.599 1.53 (0.72-3.23) 0.269 26
Mucinous 0.66 (0.17-2.55) 0.55 0.48 (0.11-2.12) 0.33 27
KRAS
(haplotype
block 2)
h010000 5.9
Clear cell 2.81 (0.95-8.33) 0.062 2.29 (0.71-7.45) 0.167 19
All 0.89 (0.67-1.18) 0.412 0.83 (0.59-1.17) 0.283 7
Serous 0.89 (0.62-1.28) 0.536 1.3 (0.9-1.9) 0.203 46
Endometrioid 1.1 (0.41-2.94) 0.848 0.72 (0.18-2.91) 0.644 35
Mucinous 0.84 (0.28-2.59) 0.767 0.87 (0.27-2.77) 0.814 4
KRAS
(haplotype
block 2)
h100000 4.9
Clear cell 1.04 (0.33-3.28) 0.95 0.91 (0.25-3.28) 0.885 13
All 0.96 (0.7-1.31) 0.794 1.06 (0.73-1.54) 0.759 10
Serous 0.81 (0.53-1.25) 0.352 1.1 (0.8-1.4) 0.528 36
Endometrioid 0.43 (0.09-2.11) 0.296 0.52 (0.12-2.23) 0.377 21
Mucinous 0.06 (0-24.2) 0.355 0.11 (0-32.59) 0.451 83
KRAS
(haplotype
block 2)
h100101 4.1
Clear cell 1.84 (0.67-5.03) 0.236 2.37 (0.73-7.7) 0.15 29
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Univariate Multivariate§Gene Haplotype Freq (%) Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1.03 (0.82-1.29) 0.813 1.05 (0.83-1.34) 0.669 2
Serous 1.09 (0.81-1.45) 0.577 1 (0.6-1.6) 0.865 8
Endometrioid 1.67 (0.85-3.28) 0.134 1.48 (0.72-3.06) 0.287 11
Mucinous 0.43 (0.13-1.43) 0.171 0.42 (0.14-1.31) 0.134 2
KRAS
(haplotype
block 2)
h000100 3.7
Clear cell 1.11 (0.46-2.66) 0.811 1.21 (0.48-3.05) 0.685 9
All 1.02 (0.79-1.31) 0.902 1.05 (0.79-1.41) 0.722 3
Serous 0.87 (0.62-1.21) 0.411 1.1 (0.8-1.5) 0.631 26
Endometrioid 0.99 (0.44-2.18) 0.971 1.21 (0.52-2.82) 0.652 22
Mucinous 3.24 (1.55-6.74) 0.002 2.74 (1.27-5.9) 0.01 15
KRAS
(haplotype
block 2)
h001100 3.7
Clear cell 2.42 (0.6-9.66) 0.212 3.42 (0.65-18) 0.146 41
All 1.26 (0.87-1.82) 0.219 1.18 (0.78-1.77) 0.44 6
Serous 0.96 (0.61-1.53) 0.872 1 (0.9-1.2) 0.956 4
Endometrioid 2.47 (0.84-7.23) 0.099 1.55 (0.52-4.65) 0.433 37
Mucinous 6.59 (1.37-31.62) 0.018 2.57 (0.5-13.28) 0.26 61
KRAS
(haplotype
block 2)
h000000 2.6
Clear cell 1.53 (0.32-7.36) 0.593 0.67 (0.09-4.97) 0.698 56
All 1.07 (0.77-1.5) 0.686 1.28 (0.9-1.82) 0.177 20
Serous 1.07 (0.71-1.64) 0.738 0.9 (0.7-1.2) 0.427 16
Endometrioid 1.87 (0.57-6.12) 0.302 2.03 (0.56-7.32) 0.282 9
Mucinous 0.76 (0.22-2.63) 0.663 1.05 (0.3-3.71) 0.934 38
KRAS
(haplotype
block 2)
h110000 2.3
Clear cell 1.84 (0.72-4.72) 0.202 1.43 (0.56-3.65) 0.459 22
All 1.1 (0.8-1.5) 0.57 1.07 (0.79-1.46) 0.66 3
Serous 1.03 (0.72-1.47) 0.884 1.2 (0.7-1.8) 0.515 17
Endometrioid 0.91 (0.23-3.62) 0.889 1.29 (0.32-5.12) 0.722 42
Mucinous 1.82 (0.44-7.61) 0.411 2.47 (0.57-10.6) 0.225 36
KRAS
(haplotype
block 2)
Rare 1.7
Clear cell 1.37 (0.26-7.1) 0.708 2.22 (0.37-13.1) 0.38 62
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, KRAS -block 1: rs12305513, rs12822857, rs10842508;
KRAS -block 2: rs12579073, rs10842513, rs4623993, rs6487464, rs10842514, rs11047917.
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Appendix VII-G: Univariate and multivariate Cox regression results of NMI tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1708 All 1.04 (0.88-1.22) 0.655 1 (0.82-1.21) 0.975 4
809 Serous 0.97 (0.79-1.19) 0.771 1 (0.8-1.2) 0.934 3
260 Endometrioid 1.09 (0.63-1.87) 0.768 1.26 (0.73-2.15) 0.404 16
184 Mucinous 1.33 (0.64-2.76) 0.443 0.73 (0.32-1.65) 0.452 45
NMI rs394884 0.14
95 Clear cell 0.37 (0.13-1.06) 0.063 0.47 (0.13-1.63) 0.232 27
1159 All 0.9 (0.67-1.19) 0.457 1.02 (0.73-1.43) 0.901 13
524 Serous 1.03 (0.71-1.49) 0.887 1 (0.6-1.5) 0.92 3
185 Endometrioid 1.38 (0.67-2.85) 0.382 0.84 (0.37-1.9) 0.675 39
133 Mucinous 1.03 (0.42-2.55) 0.942 0.95 (0.33-2.7) 0.918 8
NMI rs11551174 0.06
132 Clear cell 0.9 (0.26-3.09) 0.867 1.26 (0.35-4.5) 0.726 40
1665 All 1.02 (0.86-1.21) 0.8 1.01 (0.83-1.23) 0.933 1
792 Serous 0.92 (0.74-1.13) 0.425 1 (0.8-1.2) 0.8 9
258 Endometrioid 1.19 (0.67-2.12) 0.562 1.28 (0.71-2.31) 0.404 8
176 Mucinous 0.9 (0.38-2.13) 0.809 0.53 (0.18-1.55) 0.246 41
NMI rs289831 0.12
132 Clear cell 0.46 (0.16-1.32) 0.149 0.61 (0.17-2.16) 0.447 33
1764 All 1.02 (0.91-1.13) 0.749 1.02 (0.9-1.16) 0.789 0
843 Serous 1.02 (0.89-1.17) 0.76 1.1 (0.9-1.2) 0.42 8
266 Endometrioid 0.94 (0.64-1.37) 0.741 0.81 (0.54-1.23) 0.332 14
191 Mucinous 1.23 (0.79-1.91) 0.353 1.08 (0.66-1.75) 0.771 12
NMI rs3771886 0.43
107 Clear cell 1.07 (0.64-1.78) 0.798 1.51 (0.81-2.82) 0.194 41
1464 All 0.98 (0.88-1.09) 0.683 0.94 (0.83-1.08) 0.397 4
713 Serous 1 (0.87-1.16) 0.971 0.9 (0.8-1.1) 0.343 10
NMI rs11683487 0.44
227 Endometrioid 0.98 (0.69-1.4) 0.91 1.06 (0.72-1.56) 0.785 8
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
154 Mucinous 0.77 (0.49-1.22) 0.265 1.12 (0.68-1.85) 0.659 45
138 Clear cell 1.15 (0.67-1.96) 0.614 0.7 (0.36-1.37) 0.304 39
1776 All 1.03 (0.88-1.22) 0.685 1 (0.82-1.21) 0.986 3
843 Serous 0.95 (0.78-1.17) 0.65 1 (0.8-1.2) 0.931 5
272 Endometrioid 1.11 (0.63-1.96) 0.722 1.17 (0.66-2.08) 0.591 5
190 Mucinous 1.1 (0.54-2.24) 0.788 0.68 (0.3-1.54) 0.36 38
NMI rs2113509 0.13
126 Clear cell 0.45 (0.16-1.31) 0.146 0.6 (0.17-2.1) 0.424 33
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated
with survival; emboldened HR are statistically significant.
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Appendix VII-H: Univariate and multivariate Cox regression results of NMI haplotypes
Univariate Multivariate§Gene Haplotype Freq (%) Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.97 (0.87-1.08) 0.573 0.98 (0.86-1.11) 0.744 1
Serous 1 (0.87-1.15) 0.99 1.4 (0.9-2.3) 0.131 40
Endometrioid 1.01 (0.71-1.42) 0.964 1.13 (0.77-1.66) 0.532 12
Mucinous 0.8 (0.51-1.25) 0.328 1.12 (0.68-1.83) 0.662 40
NMI h00001 44.3
Clear cell 1.11 (0.66-1.87) 0.696 0.71 (0.37-1.36) 0.301 36
All 1.03 (0.92-1.16) 0.64 1.01 (0.88-1.16) 0.864 2
Serous 1 (0.86-1.16) 0.979 1.1 (0.9-1.3) 0.55 10
Endometrioid 0.87 (0.57-1.32) 0.515 0.86 (0.54-1.36) 0.524 1
Mucinous 1.22 (0.76-1.96) 0.418 1.1 (0.65-1.87) 0.72 10
NMI h00010 35
Clear cell 1.27 (0.76-2.14) 0.366 1.6 (0.87-2.95) 0.133 26
All 1.03 (0.87-1.22) 0.755 1.01 (0.83-1.23) 0.932 2
Serous 0.96 (0.78-1.18) 0.707 1 (0.7-1.5) 0.924 4
Endometrioid 1.05 (0.59-1.87) 0.875 1.22 (0.68-2.2) 0.5 16
Mucinous 1.07 (0.52-2.19) 0.852 0.66 (0.29-1.5) 0.319 38
NMI h10100 12.3
Clear cell 0.45 (0.15-1.31) 0.145 0.59 (0.17-2.1) 0.419 31
All 0.9 (0.68-1.19) 0.44 1 (0.71-1.39) 0.978 11
Serous 1.07 (0.75-1.54) 0.7 1 (0.9-1.2) 0.664 7
Endometrioid 1.22 (0.57-2.59) 0.61 0.72 (0.31-1.71) 0.46 41
Mucinous 0.99 (0.4-2.49) 0.991 0.94 (0.34-2.62) 0.904 5
NMI h01010 5.6
Clear cell 1.05 (0.35-3.13) 0.933 1.56 (0.52-4.73) 0.43 49
All 1.16 (0.83-1.62) 0.397 1.07 (0.74-1.56) 0.712 8
Serous 1.11 (0.69-1.76) 0.674 1 (0.8-1.2) 0.903 10
Endometrioid 1.66 (0.51-5.37) 0.4 0.8 (0.25-2.59) 0.715 52
Mucinous 1.21 (0.42-3.44) 0.722 1.02 (0.34-3.03) 0.968 16
NMI Rare 1.9
Clear cell 0.35 (0.04-2.93) 0.333 0.39 (0.04-3.37) 0.39 11
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, NMI: rs394884, rs11551174, rs289831,
rs3771886, rs11683487.
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Appendix VII-I: Univariate and multivariate Cox regression results of PIK3CA tSNPs
Univariate Multivariate§
Gene tSNP MAF Cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1164 All 1 (0.75-1.33) 0.984 0.87 (0.61-1.24) 0.449 13
520 Serous 0.93 (0.64-1.34) 0.69 0.7 (0.4-1.1) 0.086 25
183 Endometrioid 1.76 (0.87-3.55) 0.117 1.29 (0.6-2.76) 0.514 27
99 Mucinous 0.81 (0.25-2.65) 0.722 1.73 (0.36-8.28) 0.495 114
PIK3CA rs2865084 0.06
94 Clear cell 0.79 (0.1-5.98) 0.819 - - -
1749 All 1.11 (0.96-1.27) 0.159 1.05 (0.89-1.24) 0.591 5
834 Serous 1.05 (0.89-1.25) 0.555 1 (0.8-1.2) 0.807 5
268 Endometrioid 1.39 (0.91-2.13) 0.122 1.37 (0.86-2.17) 0.186 1
186 Mucinous 1.34 (0.7-2.57) 0.384 1.23 (0.6-2.53) 0.569 8
PIK3CA rs7621329 0.17
134 Clear cell 1.68 (0.83-3.37) 0.147 1.48 (0.64-3.43) 0.358 12
1739 All 1.1 (0.92-1.32) 0.311 0.96 (0.76-1.21) 0.725 13
827 Serous 1.13 (0.9-1.41) 0.294 0.9 (0.7-1.2) 0.691 20
267 Endometrioid 0.67 (0.34-1.34) 0.263 1.21 (0.56-2.59) 0.628 81
183 Mucinous 0.73 (0.31-1.71) 0.463 0.7 (0.27-1.83) 0.467 4
PIK3CA rs1517586 0.1
135 Clear cell 1.29 (0.53-3.13) 0.57 1.24 (0.37-4.16) 0.727 4
1741 All 0.98 (0.87-1.1) 0.703 0.92 (0.79-1.06) 0.246 6
825 Serous 1 (0.85-1.16) 0.95 0.9 (0.7-1) 0.152 10
266 Endometrioid 0.98 (0.68-1.42) 0.917 1.09 (0.74-1.6) 0.668 11
184 Mucinous 0.73 (0.39-1.37) 0.326 1.07 (0.53-2.15) 0.857 47
PIK3CA rs2699905 0.26
136 Clear cell 0.86 (0.49-1.51) 0.598 0.99 (0.48-2.07) 0.983 15
1779 All 1.14 (0.92-1.4) 0.229 1.06 (0.83-1.35) 0.639 7
845 Serous 1.09 (0.85-1.4) 0.497 1.1 (0.9-1.5) 0.343 1
PIK3CA rs7641889 0.06
273 Endometrioid 1.1 (0.53-2.28) 0.791 1.42 (0.66-3.04) 0.367 29
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Univariate Multivariate§
Gene tSNP MAF Cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
192 Mucinous 0.91 (0.26-3.1) 0.876 0.61 (0.18-2.08) 0.434 33
136 Clear cell 2.03 (0.85-4.85) 0.111 1.31 (0.47-3.64) 0.607 35
1794 All 1.07 (0.9-1.26) 0.449 1.02 (0.83-1.24) 0.868 5
828 Serous 1.05 (0.85-1.29) 0.678 1.1 (0.8-1.3) 0.651 5
267 Endometrioid 0.97 (0.56-1.67) 0.913 0.98 (0.54-1.8) 0.958 1
189 Mucinous 1.66 (0.79-3.46) 0.179 1.02 (0.47-2.21) 0.952 39
PIK3CA rs7651265 0.1
135 Clear cell 2.25 (1.06-4.79) 0.035 1.99 (0.85-4.7) 0.115 12
1765 All 0.88 (0.75-1.04) 0.133 0.88 (0.73-1.06) 0.169 0
842 Serous 0.91 (0.74-1.12) 0.374 0.9 (0.7-1.1) 0.311 1
268 Endometrioid 1.1 (0.71-1.71) 0.668 0.86 (0.55-1.35) 0.516 22
188 Mucinous 0.58 (0.24-1.37) 0.215 0.95 (0.38-2.38) 0.914 64
PIK3CA rs7640662 0.15
134 Clear cell 0.7 (0.33-1.52) 0.374 1.07 (0.42-2.71) 0.889 53
1762 All 0.97 (0.87-1.08) 0.545 1 (0.88-1.14) 0.973 3
836 Serous 0.92 (0.81-1.05) 0.23 1 (0.9-1.2) 0.851 9
268 Endometrioid 0.98 (0.67-1.42) 0.896 0.92 (0.63-1.35) 0.676 6
189 Mucinous 1.17 (0.67-2.05) 0.572 1.11 (0.62-2) 0.727 5
PIK3CA rs2677760 0.49
125 Clear cell 1.1 (0.66-1.84) 0.703 0.99 (0.51-1.9) 0.964 10
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated
with survival; emboldened HR are statistically significant.
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Appendix VII-J: Univariate and multivariate Cox regression results of PIK3CA haplotypes
Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.97 (0.87-1.08) 0.539 1.01 (0.89-1.14) 0.911 4
Serous 0.95 (0.79-1.16) 0.633 0.6 (0.4-1.1) 0.094 37
Endometrioid 1 (0.69-1.45) 0.99 0.98 (0.67-1.41) 0.894 2
Mucinous 1.17 (0.67-2.04) 0.582 1.1 (0.61-1.98) 0.748 6
PIK3CA h00000001 48.3
Clear cell 1.1 (0.65-1.84) 0.73 0.98 (0.5-1.89) 0.942 11
All 0.9 (0.77-1.06) 0.206 0.91 (0.75-1.09) 0.301 1
Serous 0.93 (0.75-1.14) 0.461 1.2 (1-1.6) 0.104 29
Endometrioid 1.18 (0.75-1.86) 0.467 0.97 (0.6-1.57) 0.911 18
Mucinous 0.69 (0.31-1.56) 0.376 1.12 (0.47-2.67) 0.796 62
PIK3CA h00010010 15.2
Clear cell 0.68 (0.31-1.49) 0.34 0.97 (0.38-2.48) 0.945 43
All 1.07 (0.88-1.29) 0.501 1.16 (0.93-1.43) 0.183 8
Serous 1.24 (0.98-1.56) 0.078 0.9 (0.8-1.1) 0.438 27
Endometrioid 0.72 (0.36-1.46) 0.362 0.8 (0.41-1.56) 0.511 11
Mucinous 1.05 (0.46-2.4) 0.911 0.74 (0.3-1.82) 0.506 30
PIK3CA h00000000 9.6
Clear cell 0.57 (0.21-1.54) 0.266 0.49 (0.13-1.79) 0.281 14
All 1.05 (0.87-1.26) 0.609 0.95 (0.75-1.19) 0.647 10
Serous 1.08 (0.86-1.35) 0.494 0.9 (0.7-1.1) 0.416 17
Endometrioid 0.64 (0.32-1.28) 0.21 1.23 (0.57-2.63) 0.6 92
Mucinous 0.73 (0.31-1.73) 0.479 0.78 (0.3-2.03) 0.604 7
PIK3CA h00110000 9.6
Clear cell 1.17 (0.48-2.85) 0.734 1.14 (0.34-3.84) 0.838 3
All 1.11 (0.9-1.36) 0.332 1.05 (0.82-1.34) 0.7 5
Serous 1.06 (0.83-1.37) 0.636 1 (0.7-1.5) 0.978 6
Endometrioid 1.02 (0.49-2.09) 0.966 1.32 (0.62-2.81) 0.466 29
PIK3CA h01001100 6.5
Mucinous 0.99 (0.3-3.31) 0.991 0.66 (0.2-2.2) 0.497 33
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Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
Clear cell 2.03 (0.85-4.85) 0.112 1.31 (0.47-3.64) 0.608 35
All 1.1 (0.86-1.42) 0.444 1.12 (0.83-1.5) 0.463 2
Serous 1.06 (0.78-1.45) 0.701 1.1 (0.9-1.5) 0.365 4
Endometrioid 2.19 (1.1-4.37) 0.026 1.7 (0.81-3.55) 0.157 22
Mucinous 0.76 (0.24-2.46) 0.651 1.52 (0.33-7.08) 0.59 100
PIK3CA h11000000 4.9
Clear cell 0.38 (0.04-3.48) 0.394 0.44 (0.05-4.05) 0.47 16
All 1.01 (0.77-1.33) 0.943 1.06 (0.76-1.46) 0.739 5
Serous 1.05 (0.73-1.51) 0.782 0.9 (0.7-1.2) 0.532 14
Endometrioid 0.98 (0.43-2.23) 0.967 0.67 (0.23-1.98) 0.467 32
Mucinous 2.25 (0.98-5.17) 0.057 1.55 (0.65-3.68) 0.323 31
PIK3CA h01000100 4
Clear cell 1.61 (0.55-4.69) 0.387 2.74 (0.84-8.98) 0.095 70
All 1.01 (0.71-1.43) 0.97 0.7 (0.44-1.12) 0.133 31
Serous 0.99 (0.65-1.52) 0.971 1 (0.7-1.4) 0.8 1
Endometrioid 0.78 (0.21-2.81) 0.699 0.65 (0.17-2.44) 0.525 17
Mucinous 0.08 (0-166.25) 0.524 0.23 (0-282.55) 0.687 188
PIK3CA Rare 1.6
Clear cell 1.2 (0.13-10.66) 0.872 - - -
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, PIK3CA: rs2865084, rs7621329, rs1517586,
rs2699905, rs7641889, rs7651265, rs7640662, rs2677760.
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Appendix VIII-A: Univariate and multivariate Cox regression results of AIFM2 tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1751 All 1.04 (0.78-1.39) 0.788 1 (0.72-1.4) 0.986 4
827 Serous 0.97 (0.68-1.39) 0.878 0.91 (0.61-1.36) 0.652 6
269 Endometrioid 0.22 (0.03-1.56) 0.129 0.32 (0.04-2.35) 0.262 45
189 Mucinous 4.88 (1.96-12.15) 0.001 3.05 (1.03-8.98) 0.043 38
AIFM2 rs2394655 0.04
150 Clear cell 1.08 (0.55-2.11) 0.824 1.27 (0.6-2.73) 0.532 18
1719 All 0.97 (0.81-1.15) 0.731 0.92 (0.74-1.14) 0.445 5
817 Serous 0.83 (0.65-1.05) 0.126 0.85 (0.64-1.13) 0.276 2
264 Endometrioid 0.67 (0.36-1.25) 0.212 0.64 (0.32-1.27) 0.203 4
184 Mucinous 1.61 (0.96-2.73) 0.073 1.2 (0.7-2.03) 0.507 25
AIFM2 rs7908957 0.13
159 Clear cell 1.24 (0.86-1.77) 0.244 1.18 (0.74-1.88) 0.482 5
1697 All 1.03 (0.82-1.29) 0.794 0.96 (0.73-1.27) 0.799 7
790 Serous 0.99 (0.75-1.32) 0.968 0.94 (0.67-1.33) 0.738 5
267 Endometrioid 0.54 (0.2-1.44) 0.218 0.66 (0.24-1.78) 0.408 22
185 Mucinous 2.47 (1.25-4.9) 0.01 1.32 (0.59-2.99) 0.5 47
AIFM2 rs1053495 0.07
156 Clear cell 1.01 (0.63-1.64) 0.956 1.03 (0.56-1.91) 0.914 2
1770 All 0.99 (0.87-1.13) 0.914 0.97 (0.83-1.13) 0.678 2
835 Serous 0.88 (0.74-1.04) 0.145 0.87 (0.72-1.07) 0.186 1
276 Endometrioid 1.06 (0.72-1.56) 0.766 1.2 (0.76-1.89) 0.434 13
192 Mucinous 1.59 (1.03-2.46) 0.036 1.37 (0.85-2.19) 0.194 14
AIFM2 rs2894111 0.28
164 Clear cell 1.04 (0.8-1.37) 0.753 1.04 (0.76-1.43) 0.8 0
913 All 1.01 (0.87-1.17) 0.929 0.94 (0.79-1.14) 0.542 7
506 Serous 0.89 (0.73-1.08) 0.244 0.96 (0.76-1.21) 0.736 8
AIFM2 rs2394656 0.19
136 Endometrioid 0.96 (0.61-1.53) 0.88 0.9 (0.53-1.55) 0.707 6
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
85 Mucinous 2.01 (1.19-3.4) 0.009 1.31 (0.76-2.26) 0.326 35
78 Clear cell 1.11 (0.82-1.51) 0.509 1.06 (0.73-1.55) 0.743 5
422 All 0.99 (0.86-1.13) 0.835 1 (0.85-1.17) 0.973 1
261 Serous 0.88 (0.73-1.04) 0.14 0.87 (0.71-1.07) 0.191 1
254 Endometrioid 1 (0.66-1.51) 0.998 1.23 (0.77-1.96) 0.397 23
180 Mucinous 1.41 (0.9-2.21) 0.13 1.43 (0.88-2.32) 0.145 1
AIFM2 rs6480440 0.24
145 Clear cell 1.1 (0.81-1.49) 0.546 1.15 (0.82-1.61) 0.425 5
1313 All 0.93 (0.77-1.11) 0.392 0.95 (0.77-1.17) 0.617 2
556 Serous 0.81 (0.63-1.03) 0.08 0.87 (0.66-1.13) 0.296 7
216 Endometrioid 1.44 (0.84-2.45) 0.182 2.03 (1.13-3.65) 0.018 41
146 Mucinous 0.93 (0.49-1.78) 0.833 2.02 (0.96-4.24) 0.065 117
AIFM2 rs2280201 0.12
150 Clear cell 1.01 (0.71-1.45) 0.94 0.86 (0.56-1.33) 0.496 15
1285 All 0.95 (0.77-1.17) 0.597 0.91 (0.71-1.18) 0.477 4
600 Serous 1.03 (0.79-1.33) 0.842 0.93 (0.69-1.26) 0.653 10
260 Endometrioid 0.79 (0.37-1.66) 0.532 0.65 (0.28-1.52) 0.319 18
183 Mucinous 0.63 (0.23-1.69) 0.359 0.78 (0.29-2.14) 0.636 24
AIFM2 rs10999147 0.09
151 Clear cell 0.92 (0.59-1.43) 0.699 0.89 (0.51-1.57) 0.686 3
1743 All 0.89 (0.70-1.14) 0.363 1.01 (0.77-1.33) 0.919 13
831 Serous 0.78 (0.58-1.05) 0.101 0.98 (0.71-1.36) 0.922 26
266 Endometrioid 1.14 (0.56-2.34) 0.712 1.57 (0.77-3.21) 0.215 38
0 Mucinous 0.76 (0.18-3.18) 0.71 0.62 (0.08-4.65) 0.646 18
AIFM2 rs3750772 0.06
0 Clear cell 1 (0.59-1.7) 0.995 0.98 (0.53-1.8) 0.938 2
1335 All 0.93 (0.83-1.04) 0.209 0.92 (0.8-1.05) 0.198 1
567 Serous 0.97 (0.84-1.13) 0.708 0.9 (0.76-1.07) 0.23 7
220 Endometrioid 1.13 (0.8-1.6) 0.485 1.05 (0.72-1.53) 0.801 7
AIFM2 rs4295944 0.42
149 Mucinous 0.93 (0.6-1.43) 0.743 0.99 (0.56-1.75) 0.964 6
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
133 Clear cell 0.78 (0.6-1.02) 0.073 0.81 (0.6-1.08) 0.145 4
1324 All 1.10 (0.93-1.30) 0.26 1.06 (0.87-1.29) 0.581 4
561 Serous 1.02 (0.83-1.26) 0.843 1.09 (0.85-1.39) 0.506 7
218 Endometrioid 1.74 (1.07-2.82) 0.025 1.67 (0.98-2.87) 0.061 4
149 Mucinous 0.46 (0.17-1.25) 0.129 0.68 (0.24-1.9) 0.462 48
AIFM2 rs2394644 0.13
133 Clear cell 1.12 (0.8-1.58) 0.507 0.97 (0.64-1.46) 0.883 13
1618 All 1.05 (0.91-1.22) 0.509 1.1 (0.93-1.31) 0.276 5
760 Serous 1.07 (0.89-1.29) 0.451 1.18 (0.96-1.46) 0.12 10
251 Endometrioid 1.16 (0.74-1.82) 0.521 1.19 (0.73-1.93) 0.488 3
170 Mucinous 0.48 (0.21-1.06) 0.071 0.69 (0.29-1.66) 0.408 44
AIFM2 rs10999152 0.18
153 Clear cell 1.06 (0.77-1.45) 0.719 1.08 (0.75-1.54) 0.69 2
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated
with survival; emboldened HR are statistically significant.
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Appendix VIII-B: Univariate and multivariate Cox regression results of AIFM2 haplotypes
Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.98 (0.87-1.12) 0.849 1.01 (0.87-1.17) 0.905 3
Serous 1.10 (0.93-1.30) 0.255 1.07 (0.88-1.3) 0.486 3
Endometrioid 0.91 (0.62-1.33) 0.614 0.8 (0.51-1.23) 0.308 12
Mucinous 0.62 (0.4-0.96) 0.032 0.76 (0.49-1.19) 0.235 23
AIFM2
(haplotype
block 1)
h0000000 69
Clear cell 0.95 (0.73-1.24) 0.726 0.96 (0.71-1.32) 0.822 1
All 0.90 (0.71-1.13) 0.348 1 (0.77-1.3) 0.98 11
Serous 0.80 (0.60-1.08) 0.149 0.86 (0.62-1.19) 0.352 7
Endometrioid 1.51 (0.81-2.8) 0.191 2.76 (1.36-5.59) 0.005 83
Mucinous 0.88 (0.37-2.12) 0.776 1.98 (0.69-5.7) 0.204 125
AIFM2
(haplotype
block 1)
h0001011 7
Clear cell 0.87 (0.52-1.47) 0.602 0.86 (0.48-1.56) 0.626 1
All 1.03 (0.75-1.41) 0.855 0.92 (0.62-1.38) 0.697 11
Serous 0.99 (0.65-1.51) 0.967 1.18 (0.72-1.93) 0.514 19
Endometrioid 1.33 (0.55-3.24) 0.532 0.87 (0.29-2.66) 0.811 35
Mucinous 1.98 (0.66-5.92) 0.222 0.65 (0.18-2.34) 0.51 67
AIFM2
(haplotype
block 1)
h0001100 4
Clear cell 0.88 (0.44-1.78) 0.719 0.94 (0.42-2.07) 0.871 7
All 1.02 (0.76-1.38) 0.879 0.99 (0.7-1.41) 0.957 3
Serous 0.91 (0.62-1.32) 0.612 0.82 (0.53-1.27) 0.379 10
Endometrioid 0.34 (0.07-1.71) 0.191 0.5 (0.1-2.58) 0.408 47
Mucinous 4.87 (1.95-12.17) 0.001 3.02 (1.02-8.91) 0.045 38
AIFM2
(haplotype
block 1)
h1111110 4
Clear cell 1.15 (0.58-2.27) 0.69 1.57 (0.71-3.48) 0.27 37
All 1.19 (0.85-1.65) 0.311 1.12 (0.75-1.68) 0.58 6
Serous 1.33 (0.90-1.98) 0.153 1 (0.6-1.67) 0.997 25
AIFM2
(haplotype
block 1)
h0001010 3
Endometrioid 0.83 (0.27-2.53) 0.741 0.86 (0.22-3.3) 0.821 4
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Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
Mucinous 1.09 (0.29-4.05) 0.901 0.93 (0.24-3.65) 0.919 15
Clear cell 0.96 (0.4-2.32) 0.923 1.12 (0.46-2.73) 0.802 17
All 1.01 (0.72-1.40) 0.973 0.91 (0.61-1.36) 0.635 10
Serous 0.91 (0.58-1.42) 0.675 1.06 (0.64-1.78) 0.814 16
Endometrioid 0.71 (0.22-2.29) 0.564 0.63 (0.19-2.06) 0.445 11
Mucinous 1.08 (0.35-3.33) 0.898 2.12 (0.65-6.92) 0.215 96
AIFM2
(haplotype
block 1)
h0101111 3
Clear cell 1.46 (0.78-2.72) 0.236 1 (0.44-2.24) 0.994 32
All 1.07 (0.75-1.52) 0.715 1.11 (0.71-1.74) 0.649 4
Serous 1.25 (0.79-1.98) 0.337 1.53 (0.87-2.69) 0.142 22
Endometrioid 0.91 (0.25-3.3) 0.886 0.81 (0.22-2.98) 0.756 11
Mucinous 1.02 (0.31-3.35) 0.973 0.55 (0.16-1.87) 0.339 46
AIFM2
(haplotype
block 1)
h0111110 3
Clear cell 0.92 (0.44-1.9) 0.816 0.95 (0.36-2.51) 0.925 3
All 1.02 (0.81-1.30) 0.853 0.97 (0.72-1.3) 0.824 5
Serous 0.81 (0.58-1.12) 0.207 0.84 (0.56-1.26) 0.4 4
Endometrioid 1.39 (0.72-2.68) 0.331 1.54 (0.76-3.13) 0.231 11
Mucinous 2.08 (0.89-4.86) 0.091 1.78 (0.68-4.63) 0.237 14
AIFM2
(haplotype
block 1)
Rare 8
Clear cell 1.15 (0.72-1.84) 0.559 1.08 (0.62-1.89) 0.788 6
All 0.95 (0.84-1.07) 0.386 0.93 (0.81-1.07) 0.322 2
Serous 1.00 (0.86-1.16) 0.989 0.93 (0.78-1.11) 0.431 7
Endometrioid 1.15 (0.79-1.67) 0.473 1.11 (0.74-1.67) 0.599 3
Mucinous 1.01 (0.65-1.58) 0.948 1.05 (0.59-1.89) 0.862 4
AIFM2
(haplotype
block 2)
h00100 38
Clear cell 0.77 (0.58-1.02) 0.066 0.79 (0.58-1.07) 0.127 3
All 1.03 (0.91-1.16) 0.627 1.05 (0.91-1.2) 0.539 2
Serous 0.97 (0.83-1.13) 0.696 0.99 (0.83-1.18) 0.873 2
Endometrioid 0.86 (0.6-1.25) 0.431 0.94 (0.63-1.4) 0.771 9
AIFM2
(haplotype
block 2)
h00000 35
Mucinous 1.72 (1.03-2.88) 0.038 1.25 (0.65-2.39) 0.498 27
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Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
Clear cell 1.17 (0.89-1.53) 0.251 1.17 (0.86-1.57) 0.313 0
All 1.15 (0.93-1.42) 0.207 1.05 (0.81-1.36) 0.699 9
Serous 1.18 (0.90-1.54) 0.236 1.17 (0.85-1.6) 0.336 1
Endometrioid 1.61 (0.89-2.9) 0.116 1.34 (0.68-2.65) 0.401 17
Mucinous 0.57 (0.19-1.76) 0.331 0.76 (0.25-2.31) 0.623 33
AIFM2
(haplotype
block 2)
h00011 7
Clear cell 0.96 (0.59-1.56) 0.873 0.93 (0.52-1.66) 0.817 3
All 1.07 (0.79-1.45) 0.651 1.21 (0.86-1.71) 0.279 13
Serous 1.18 (0.79-1.75) 0.414 1.37 (0.89-2.11) 0.155 16
Endometrioid 0.27 (0.05-1.34) 0.11 0.33 (0.07-1.51) 0.153 22
Mucinous 0.47 (0.11-1.97) 0.304 1.31 (0.29-5.91) 0.725 179
AIFM2
(haplotype
block 2)
h00001 4
Clear cell 1.77 (1-3.12) 0.05 2.29 (1.23-4.28) 0.009 29
All 1.06 (0.74-1.53) 0.735 1.05 (0.68-1.64) 0.819 1
Serous 1.13 (0.74-1.75) 0.569 1.12 (0.68-1.85) 0.645 1
Endometrioid 0.58 (0.1-3.52) 0.558 0.55 (0.1-3) 0.49 5
Mucinous 1.22 (0.3-4.92) 0.778 0.93 (0.23-3.69) 0.918 24
AIFM2
(haplotype
block 2)
h10000 3
Clear cell 0.71 (0.28-1.78) 0.461 0.78 (0.23-2.65) 0.694 10
All 1.14 (0.56-2.33) 0.722 0.8 (0.31-2.07) 0.642 30
Serous 0.78 (0.26-2.33) 0.652 1 (0.26-3.84) 0.995 28
Endometrioid 2.73 (0.35-21.44) 0.34 1.01 (0-274.28) 0.998 63
Mucinous 0.13 (0-25.3) 0.452 0.21 (0-137.26) 0.638 62
AIFM2
(haplotype
block 2)
h00010 2
Clear cell 1.84 (0.59-5.67) 0.291 0.89 (0.22-3.54) 0.864 52
All 0.93 (0.64-1.35) 0.702 1.16 (0.77-1.74) 0.476 25
Serous 0.73 (0.45-1.17) 0.188 1.04 (0.63-1.73) 0.879 42
Endometrioid 2.74 (1.07-7.04) 0.036 5.31 (2.04-13.8) 0.001 94
Mucinous - - - 1 -
AIFM2
(haplotype
block 2)
h01011 2
Clear cell 1 (0.43-2.36) 0.992 0.62 (0.22-1.73) 0.36 38
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Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1.09 (0.70-1.70) 0.702 0.92 (0.52-1.62) 0.76 16
Serous 1.16 (0.67-1.99) 0.599 0.98 (0.5-1.91) 0.945 16
Endometrioid 0.73 (0.12-4.39) 0.733 0.67 (0.11-3.95) 0.66 8
Mucinous - - - - -
AIFM2
(haplotype
block 2)
h10011 2
Clear cell 1.36 (0.57-3.26) 0.49 1.28 (0.39-4.24) 0.688 6
All 0.78 (0.49-1.23) 0.285 0.72 (0.41-1.24) 0.233 8
Serous 0.91 (0.49-1.70) 0.77 0.63 (0.3-1.29) 0.206 31
Endometrioid 1.06 (0.35-3.22) 0.921 0.64 (0.14-3) 0.573 40
Mucinous 0.25 (0.02-2.94) 0.27 0.41 (0.03-5.59) 0.507 64
AIFM2
(haplotype
block 2)
h10100 2
Clear cell 0.8 (0.31-2.05) 0.645 0.62 (0.19-2.03) 0.432 23
All 0.89 (0.64-1.23) 0.476 0.99 (0.67-1.46) 0.96 11
Serous 0.89 (0.59-1.34) 0.577 1.06 (0.68-1.66) 0.786 19
Endometrioid 0.54 (0.16-1.83) 0.322 0.65 (0.2-2.17) 0.486 20
Mucinous 1.13 (0.27-4.84) 0.866 0.99 (0.13-7.52) 0.989 12
AIFM2
(haplotype
block 2)
Rare 4
Clear cell 1.03 (0.49-2.15) 0.937 1.57 (0.68-3.66) 0.293 52
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, AIFM2 - block 1: rs2394655, rs7908957, rs1053495,
rs2894111, rs2394656, rs6480440, rs2280201. AIFM2 -block 2: rs10999147, rs3750772, rs4295944, rs2394644, rs10999152.
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Appendix VIII-C: Univariate and multivariate Cox regression results of AKTIP tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
917 All 1.07 (0.96-1.20) 0.229 1 (0.88-1.14) 0.981 7
506 Serous 1.10 (0.95-1.26) 0.213 0.98 (0.84-1.16) 0.843 11
137 Endometrioid 0.93 (0.65-1.32) 0.675 0.99 (0.68-1.46) 0.974 6
86 Mucinous 0.99 (0.62-1.6) 0.981 0.87 (0.5-1.5) 0.605 12
AKTIP rs9931702 0.44
79 Clear cell 1.03 (0.81-1.3) 0.821 1.07 (0.82-1.41) 0.608 4
828 All 0.97 (0.82-1.14) 0.695 0.99 (0.82-1.2) 0.91 2
450 Serous 0.93 (0.75-1.14) 0.477 0.92 (0.72-1.17) 0.475 1
125 Endometrioid 0.9 (0.52-1.54) 0.692 0.96 (0.54-1.69) 0.88 7
0 Mucinous 1.42 (0.73-2.77) 0.299 1.62 (0.75-3.51) 0.222 14
AKTIP rs17801966 0.15
78 Clear cell 0.95 (0.67-1.33) 0.762 1.04 (0.71-1.53) 0.845 9
1745 All 1.12 (1.00-1.27) 0.056 1.02 (0.88-1.18) 0.764 9
825 Serous 1.17 (1.01-1.36) 0.036 1.05 (0.88-1.26) 0.552 10
271 Endometrioid 0.92 (0.61-1.38) 0.685 0.89 (0.56-1.41) 0.618 3
186 Mucinous 0.83 (0.49-1.43) 0.51 0.72 (0.39-1.33) 0.295 13
AKTIP rs7189819 0.3
163 Clear cell 1.13 (0.88-1.45) 0.324 1.07 (0.8-1.43) 0.665 5
413 All 0.95 (0.74-1. 23) 0.709 0.9 (0.67-1.23) 0.52 5
256 Serous 0.92 (0.67-1.27) 0.63 0.94 (0.66-1.33) 0.708 2
199 Endometrioid 0.4 (0.1-1.6) 0.195 0.27 (0.04-2.03) 0.205 33
143 Mucinous 0.62 (0.15-2.47) 0.494 0.84 (0.2-3.58) 0.816 35
AKTIP rs3743772 0.07
109 Clear cell 1.11 (0.68-1.79) 0.678 1.07 (0.62-1.86) 0.81 4
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated
with survival; emboldened HR are statistically significant.
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Appendix VIII-D: Univariate and multivariate Cox regression results of AKTIP haplotypes
Univariate Multivariate§Gene Haplotype† Freq (%) Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.93 (0.83-1.04) 0.196 1 (0.88-1.13) 0.957 8
Serous 0.91 (0.79-1.05) 0.199 1 (0.85-1.18) 0.954 10
Endometrioid 1.05 (0.74-1.5) 0.784 1 (0.68-1.47) 0.993 5
Mucinous 0.98 (0.61-1.56) 0.927 1.07 (0.63-1.83) 0.797 9
AKTIP h0000 54
Clear cell 1 (0.79-1.26) 0.983 1.02 (0.79-1.33) 0.866 2
All 0.94 (0.75-1.18) 0.59 0.97 (0.74-1.26) 0.791 3
Serous 0.85 (0.64-1.14) 0.292 0.8 (0.57-1.12) 0.195 6
Endometrioid 1.36 (0.67-2.74) 0.392 1.52 (0.75-3.1) 0.247 12
Mucinous 1.69 (0.78-3.65) 0.183 1.77 (0.75-4.18) 0.192 5
AKTIP h1100 8
Clear cell 0.8 (0.47-1.36) 0.404 0.95 (0.5-1.77) 0.863 19
All 1.01 (0.78-1.30) 0.965 1.01 (0.75-1.36) 0.95 0
Serous 1.00 (0.74-1.36) 0.998 1.01 (0.72-1.41) 0.97 1
Endometrioid 0.41 (0.12-1.4) 0.153 0.34 (0.07-1.56) 0.165 17
Mucinous 0.84 (0.22-3.15) 0.795 1.09 (0.28-4.32) 0.898 30
AKTIP h1101 5
Clear cell 1.17 (0.67-2.05) 0.573 1.38 (0.76-2.5) 0.294 18
All 1.09 (0.97-1.24) 0.15 1 (0.87-1.16) 0.957 8
Serous 1.15 (0.99-1.34) 0.072 1.03 (0.86-1.23) 0.773 10
Endometrioid 0.94 (0.62-1.41) 0.757 0.96 (0.61-1.51) 0.863 2
Mucinous 0.76 (0.43-1.35) 0.352 0.62 (0.32-1.2) 0.154 18
AKTIP h1010 3
Clear cell 1.07 (0.84-1.38) 0.575 1.07 (0.79-1.43) 0.671 0
All 1.12 (0.82-1.53) 0.46 1.07 (0.73-1.57) 0.732 4
Serous 1.14 (0.75-1.74) 0.528 1.34 (0.82-2.18) 0.243 18
Endometrioid 1.45 (0.55-3.84) 0.453 1.28 (0.4-4.05) 0.675 12
Mucinous 1.42 (0.58-3.49) 0.442 1.5 (0.5-4.51) 0.473 6
AKTIP Rare 2
Clear cell 0.75 (0.38-1.51) 0.425 0.31 (0.1-0.97) 0.043 59
SNP order in haplotypes, 5’ to 3’, ATKIP: rs9931702, rs17801966, rs7189819, rs3743772.
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Appendix VIII-E: Univariate and multivariate Cox regression results of AXIN2 tSNPs
Univariate Multivariate§Gene tSNP MAF No. cases Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
919 All 0.97 (0.86-1.08) 0.553 0.94 (0.83-1.08) 0.381 3
509 Serous 0.90 (0.78-1.04) 0.171 0.9 (0.76-1.06) 0.212 0
136 Endometrioid 0.91 (0.64-1.29) 0.602 0.89 (0.61-1.29) 0.525 2
85 Mucinous 1.18 (0.74-1.88) 0.492 1.11 (0.71-1.73) 0.655 6
AXIN2 rs11868547 0.48
81 Clear cell 1.04 (0.81-1.34) 0.772 1 (0.74-1.35) 0.983 4
1779 All 1.06 (0.94-1.19) 0.347 1.03 (0.9-1.18) 0.706 3
838 Serous 1.10 (0.95-1.28) 0.215 1.06 (0.9-1.26) 0.478 4
277 Endometrioid 1.14 (0.8-1.62) 0.463 1.2 (0.81-1.78) 0.364 5
195 Mucinous 1.12 (0.71-1.77) 0.618 1 (0.64-1.55) 0.985 11
AXIN2 rs7591 0.38
165 Clear cell 0.93 (0.73-1.2) 0.596 1.03 (0.76-1.38) 0.86 11
1775 All 1.06 (0.92-1.22) 0.417 1.05 (0.89-1.24) 0.53 1
840 Serous 1.07 (0.89-1.28) 0.482 1.06 (0.86-1.31) 0.586 1
276 Endometrioid 1.06 (0.7-1.62) 0.775 1.19 (0.74-1.93) 0.47 12
192 Mucinous 1.44 (0.91-2.28) 0.124 1.39 (0.88-2.19) 0.158 3
AXIN2 rs4074947 0.22
163 Clear cell 1.01 (0.75-1.35) 0.96 1.02 (0.72-1.44) 0.915 1
1777 All 0.99 (0.82-1.19) 0.922 0.91 (0.73-1.14) 0.409 8
838 Serous 1.02 (0.81-1.29) 0.836 0.92 (0.7-1.2) 0.523 10
277 Endometrioid 1.01 (0.56-1.84) 0.962 1.15 (0.59-2.23) 0.687 14
193 Mucinous 0.61 (0.26-1.41) 0.248 0.6 (0.24-1.53) 0.287 2
AXIN2 rs7210356 0.11
165 Clear cell 0.98 (0.65-1.47) 0.91 1.06 (0.64-1.76) 0.827 8
1301 All 1.00 (0.88-1.13) 0.971 1.02 (0.88-1.19) 0.753 2
552 Serous 0.98 (0.83-1.16) 0.847 1 (0.83-1.21) 0.998 2
213 Endometrioid 1.25 (0.85-1.86) 0.256 1.44 (0.94-2.19) 0.091 15
144 Mucinous 0.71 (0.42-1.2) 0.204 0.72 (0.42-1.25) 0.242 1
AXIN2 rs11655966 0.27
130 Clear cell 0.98 (0.76-1.27) 0.885 1.13 (0.84-1.52) 0.41 15
AXIN2 rs4541111 0.48 1297 All 1.05 (0.94-1.17) 0.423 1.08 (0.94-1.23) 0.285 3
Appendices
492
Univariate Multivariate§Gene tSNP MAF No. cases Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
554 Serous 1.16 (1.00-1.34) 0.043 1.15 (0.97-1.35) 0.108 1
214 Endometrioid 1.07 (0.76-1.51) 0.685 1.07 (0.74-1.55) 0.712 0
141 Mucinous 0.75 (0.45-1.24) 0.261 0.96 (0.6-1.53) 0.859 28
128 Clear cell 0.91 (0.71-1.18) 0.493 0.98 (0.73-1.32) 0.917 8
1185 All 1.06 (0.94-1.20) 0.349 1 (0.86-1.16) 0.988 6
539 Serous 1.11 (0.95-1.30) 0.176 1.04 (0.87-1.26) 0.649 6
180 Endometrioid 1.05 (0.72-1.52) 0.8 1.1 (0.73-1.66) 0.642 5
133 Mucinous 0.94 (0.57-1.54) 0.806 1.01 (0.61-1.67) 0.973 7
AXIN2 rs4791171 0.3
111 Clear cell 1.06 (0.8-1.39) 0.686 1.07 (0.77-1.5) 0.686 1
839 All 1.05 (0.90-1.22) 0.527 0.98 (0.81-1.18) 0.804 7
326 Serous 1.11 (0.91-1.34) 0.301 1.07 (0.85-1.35) 0.558 4
137 Endometrioid 1.12 (0.71-1.77) 0.612 1.1 (0.65-1.86) 0.721 2
104 Mucinous 1.12 (0.68-1.82) 0.662 0.88 (0.51-1.51) 0.634 21
AXIN2 rs11079571 0.17
83 Clear cell 0.86 (0.61-1.23) 0.42 0.98 (0.65-1.49) 0.932 14
1780 All 1.05 (0.92-1.21) 0.477 1.05 (0.88-1.25) 0.614 0
843 Serous 1.11 (0.93-1.33) 0.25 1.16 (0.93-1.44) 0.181 5
275 Endometrioid 1.2 (0.81-1.79) 0.359 1.26 (0.8-1.97) 0.314 5
193 Mucinous 1.12 (0.67-1.89) 0.659 1.12 (0.65-1.91) 0.689 0
AXIN2 rs3923087 0.22
164 Clear cell 0.94 (0.69-1.27) 0.664 0.84 (0.57-1.23) 0.368 11
1753 All 0.98 (0.87-1.1) 0.689 0.99 (0.86-1.14) 0.896 1
833 Serous 1.05 (0.91-1.21) 0.535 1.09 (0.91-1.3) 0.345 4
267 Endometrioid 0.88 (0.61-1.26) 0.474 0.92 (0.62-1.36) 0.666 5
188 Mucinous 0.79 (0.48-1.29) 0.347 1.04 (0.64-1.7) 0.859 32
AXIN2 rs3923086 0.42
163 Clear cell 1.01 (0.79-1.3) 0.92 0.87 (0.64-1.18) 0.379 14
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated
with survival; emboldened HR are statistically significant.
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Appendix VIII-F: Univariate and multivariate Cox regression results of AXIN2 haplotypes
Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI)e P-value
Diff HR
(%)
All 0.95 (0.85-1.07) 0.407 0.93 (0.81-1.06) 0.291 2
Serous 0.90 (0.78-1.04) 0.164 0.9 (0.76-1.06) 0.205 0
Endometrioid 0.89 (0.63-1.25) 0.508 0.83 (0.57-1.19) 0.313 7
Mucinous 1.21 (0.75-1.95) 0.431 1.11 (0.71-1.75) 0.653 8
AXIN2
(haplotype
block 1)
h100000 46
Clear cell 1.02 (0.8-1.3) 0.884 1 (0.75-1.34) 0.985 2
All 0.95 (0.79-1.14) 0.592 1.09 (0.89-1.34) 0.406 15
Serous 1.04 (0.82-1.33) 0.755 1.1 (0.84-1.44) 0.475 6
Endometrioid 0.93 (0.55-1.57) 0.785 0.93 (0.53-1.62) 0.791 0
Mucinous 0.61 (0.29-1.27) 0.184 1.04 (0.45-2.38) 0.928 70
AXIN2
(haplotype
block 1)
h000001 14
Clear cell 1 (0.68-1.47) 0.998 1.02 (0.66-1.56) 0.931 2
All 0.92 (0.71-1.19) 0.537 0.95 (0.68-1.32) 0.756 3
Serous 0.99 (0.71-1.39) 0.962 0.99 (0.66-1.49) 0.971 0
Endometrioid 1.02 (0.49-2.14) 0.951 1.11 (0.47-2.6) 0.812 9
Mucinous 0.74 (0.26-2.09) 0.57 1.06 (0.37-3.08) 0.912 43
AXIN2
(haplotype
block 1)
h011011 6
Clear cell 0.87 (0.5-1.53) 0.629 1.06 (0.53-2.11) 0.874 22
All 1.09 (0.86-1.38) 0.484 1.12 (0.85-1.47) 0.414 3
Serous 1.15 (0.86-1.55) 0.344 1.23 (0.89-1.72) 0.213 7
Endometrioid 1.46 (0.78-2.73) 0.235 1.24 (0.62-2.5) 0.54 15
Mucinous 0.58 (0.17-2) 0.385 0.28 (0.06-1.23) 0.091 52
AXIN2
(haplotype
block 1)
h010011 5
Clear cell 0.88 (0.5-1.53) 0.648 1.3 (0.72-2.37) 0.388 48
All 1.06 (0.77-1.44) 0.728 1.21 (0.85-1.72) 0.299 14
Serous 0.84 (0.53-1.31) 0.435 1.04 (0.64-1.69) 0.867 24
AXIN2
(haplotype
block 1)
h011010 4
Endometrioid 1.24 (0.41-3.74) 0.707 2.57 (0.82-8) 0.104 107
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Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI)e P-value
Diff HR
(%)
Mucinous 1.8 (0.56-5.82) 0.324 1.39 (0.35-5.63) 0.64 23
Clear cell 1.25 (0.75-2.1) 0.389 1.39 (0.77-2.49) 0.272 11
All 1.00 (0.78-1.29) 0.976 0.94 (0.71-1.25) 0.681 6
Serous 1.01 (0.74-1.39) 0.934 0.97 (0.69-1.37) 0.853 4
Endometrioid 1.08 (0.43-2.69) 0.874 1.47 (0.58-3.73) 0.412 36
Mucinous 1 (0.42-2.38) 0.995 0.75 (0.29-1.94) 0.55 25
AXIN2
(haplotype
block 1)
Rare 6
Clear cell 0.94 (0.56-1.55) 0.801 0.6 (0.31-1.18) 0.139 36
All 0.98 (0.87-1.10) 0.697 0.99 (0.86-1.14) 0.881 1
Serous 0.91 (0.78-1.05) 0.179 0.9 (0.76-1.08) 0.258 1
Endometrioid 1.1 (0.78-1.57) 0.583 1.03 (0.7-1.51) 0.893 6
Mucinous 1.3 (0.83-2.06) 0.256 1.21 (0.79-1.85) 0.387 7
AXIN2
(haplotype
block 2)
h0000 54
Clear cell 0.95 (0.74-1.21) 0.659 0.99 (0.73-1.33) 0.933 4
All 0.97 (0.81-1.17) 0.773 1.08 (0.87-1.33) 0.491 11
Serous 1.09 (0.86-1.37) 0.475 1.22 (0.95-1.58) 0.124 12
Endometrioid 0.61 (0.31-1.19) 0.149 0.61 (0.29-1.26) 0.18 0
Mucinous 0.72 (0.37-1.4) 0.337 1.02 (0.48-2.16) 0.963 42
AXIN2
(haplotype
block 2)
h0001 14
Clear cell 1.05 (0.72-1.54) 0.795 0.84 (0.53-1.32) 0.442 20
All 1.06 (0.90-1.26) 0.466 0.99 (0.8-1.22) 0.934 7
Serous 1.13 (0.91-1.41) 0.262 1.12 (0.87-1.45) 0.389 1
Endometrioid 1.13 (0.69-1.86) 0.621 1.09 (0.61-1.93) 0.771 4
Mucinous 1.23 (0.69-2.19) 0.485 1.04 (0.51-2.1) 0.918 15
AXIN2
(haplotype
block 2)
h1111 12
Clear cell 0.86 (0.58-1.29) 0.467 0.86 (0.53-1.41) 0.555 0
All 0.89 (0.70-1.13) 0.324 0.82 (0.62-1.09) 0.177 8
Serous 0.86 (0.63-1.16) 0.32 0.77 (0.54-1.08) 0.125 10
Endometrioid 0.66 (0.3-1.47) 0.31 0.74 (0.31-1.77) 0.499 12
AXIN2
(haplotype
block 2)
h1001 7
Mucinous 0.57 (0.18-1.8) 0.337 0.83 (0.22-3.18) 0.784 46
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Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI)e P-value
Diff HR
(%)
Clear cell 1.35 (0.83-2.19) 0.229 1.45 (0.79-2.65) 0.226 7
All 0.99 (0.78-1.25) 0.921 1.04 (0.78-1.38) 0.781 5
Serous 1.06 (0.78-1.43) 0.717 1.06 (0.74-1.52) 0.746 0
Endometrioid 1.24 (0.67-2.32) 0.49 1.35 (0.7-2.58) 0.367 9
Mucinous 0.89 (0.38-2.08) 0.792 2.39 (0.95-6.02) 0.065 169
AXIN2
(haplotype
block 2)
h1011 7
Clear cell 0.9 (0.53-1.52) 0.69 0.7 (0.35-1.4) 0.314 22
All 1.32 (0.92-1.91) 0.137 1.06 (0.68-1.65) 0.8 20
Serous 1.39 (0.90-2.13) 0.135 1.08 (0.65-1.8) 0.76 22
Endometrioid 0.98 (0.15-6.31) 0.981 1.07 (0.16-7.29) 0.942 9
Mucinous 0.82 (0.14-4.76) 0.822 0.22 (0.03-1.55) 0.13 73
AXIN2
(haplotype
block 2)
h1000 2
Clear cell 1.39 (0.6-3.24) 0.442 2.2 (0.92-5.28) 0.077 58
All 1.09 (0.82-1.45) 0.548 1.13 (0.81-1.57) 0.483 4
Serous 1.05 (0.72-1.53) 0.813 1.11 (0.74-1.67) 0.619 6
Endometrioid 1.37 (0.58-3.24) 0.472 1.72 (0.71-4.16) 0.231 26
Mucinous 0.75 (0.24-2.37) 0.623 0.37 (0.1-1.33) 0.128 51
AXIN2
(haplotype
block 2)
Rare 4
Clear cell 1.16 (0.65-2.07) 0.61 1.63 (0.83-3.19) 0.156 41
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, AXIN2 - block 1: rs11868547, rs7591,
rs4074947, rs7210356, rs11655966, rs4541111. AXIN2 - block 2: rs4791171, rs11079571, rs3923087, rs3923086.
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Appendix VIII-G: Univariate and multivariate Cox regression results of CASP5 tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
438 All 1.13 (1.00-1.27) 0.042 1.08 (0.95-1.24) 0.243 4
270 Serous 1.16 (1.00-1.34) 0.047 1.11 (0.93-1.31) 0.257 4
56 Endometrioid 1.14 (0.79-1.65) 0.485 1.06 (0.74-1.53) 0.74 7
42 Mucinous 0.89 (0.58-1.39) 0.612 0.7 (0.42-1.18) 0.182 21
CASP5 rs518604 0.46
32 Clear cell 1.14 (0.88-1.47) 0.321 1.12 (0.84-1.49) 0.455 2
824 All 0.90 (0.80-1.02) 0.105 0.91 (0.78-1.04) 0.173 1
320 Serous 0.85 (0.73 – 1.00) 0.049 0.9 (0.75-1.08) 0.254 6
131 Endometrioid 0.82 (0.55-1.22) 0.322 0.88 (0.59-1.32) 0.529 7
102 Mucinous 1.16 (0.73-1.85) 0.531 1.18 (0.7-2) 0.531 2
CASP5 rs523104 0.46
81 Clear cell 1 (0.77-1.29) 0.971 0.95 (0.71-1.28) 0.742 5
829 All 1.08 (0.89-1.32) 0.421 1.09 (0.86-1.38) 0.497 1
319 Serous 1.16 (0.91-1.49) 0.232 1 (0.75-1.34) 0.983 14
255 Endometrioid 1.28 (0.66-2.51) 0.465 1.32 (0.64-2.7) 0.455 3
102 Mucinous 0.62 (0.26-1.46) 0.272 0.86 (0.35-2.11) 0.745 39
CASP5 rs3181328 0.09
83 Clear cell 0.99 (0.65-1.51) 0.971 1.29 (0.77-2.18) 0.334 30
803 All 0.83 (0.68-1.01) 0.067 0.96 (0.77-1.2) 0.723 16
311 Serous 0.92 (0.72-1.17) 0.485 1 (0.76-1.3) 0.977 9
130 Endometrioid 0.72 (0.35-1.51) 0.389 0.96 (0.45-2.04) 0.921 33
97 Mucinous 0.34 (0.11-1.08) 0.068 0.58 (0.17-1.94) 0.377 71
CASP5 rs17446518 0.11
147 Clear cell 0.73 (0.47-1.14) 0.165 0.74 (0.45-1.22) 0.237 1
1730 All 0.85 (0.70-1.04) 0.111 0.88 (0.71-1.11) 0.285 4
819 Serous 0.96 (0.76-1.22) 0.748 0.95 (0.72-1.26) 0.728 1
CASP5 rs9651713 0.11
269 Endometrioid 0.93 (0.53-1.63) 0.791 0.89 (0.48-1.67) 0.715 4
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
183 Mucinous 0.37 (0.13-1.03) 0.056 0.56 (0.2-1.6) 0.282 51
162 Clear cell 0.77 (0.49-1.23) 0.275 0.81 (0.48-1.38) 0.441 5
1282 All 0.94 (0.81-1.09) 0.393 0.93 (0.78-1.11) 0.413 1
597 Serous 1.06 (0.89-1.27) 0.514 1.07 (0.87-1.32) 0.495 1
194 Endometrioid 0.78 (0.48-1.26) 0.313 0.62 (0.35-1.09) 0.095 21
147 Mucinous 0.4 (0.19-0.86) 0.019 0.5 (0.22-1.15) 0.102 25
CASP5 rs3181175 0.19
115 Clear cell 0.94 (0.68-1.32) 0.732 0.92 (0.62-1.37) 0.682 2
1780 All 1.11 (0.90-1.37) 0.316 1.02 (0.8-1.31) 0.876 8
840 Serous 1.20 (0.92-1.55) 0.174 1.2 (0.9-1.61) 0.209 0
278 Endometrioid 0.66 (0.29-1.47) 0.306 0.34 (0.11-1.07) 0.064 48
183 Mucinous 0.65 (0.23-1.84) 0.42 0.54 (0.17-1.79) 0.318 17
CASP5 rs3181174 0.07
165 Clear cell 1.27 (0.83-1.94) 0.268 1.24 (0.73-2.11) 0.434 2
852 All 0.94 (0.83-1.06) 0.329 0.94 (0.81-1.09) 0.442 0
462 Serous 1.10 (0.95-1.28) 0.216 1.12 (0.93-1.34) 0.247 2
128 Endometrioid 0.82 (0.55-1.22) 0.327 0.78 (0.5-1.2) 0.254 5
80 Mucinous 0.75 (0.47-1.19) 0.224 0.92 (0.57-1.48) 0.735 23
CASP5 rs2282657 0.35
73 Clear cell 0.76 (0.57-1) 0.049 0.68 (0.48-0.96) 0.029 11
1768 All 0.94 (0.83-1.06) 0.298 0.94 (0.81-1.08) 0.385 0
835 Serous 1.07 (0.92-1.24) 0.403 1.05 (0.87-1.25) 0.621 2
276 Endometrioid 0.78 (0.52-1.17) 0.226 0.81 (0.52-1.26) 0.351 4
194 Mucinous 0.9 (0.59-1.38) 0.627 1.04 (0.63-1.69) 0.89 16
CASP5 rs507879 0.46
164 Clear cell 0.83 (0.64-1.07) 0.145 0.77 (0.57-1.03) 0.079 7
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated
with survival; emboldened HR are statistically significant.
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Appendix VIII-H: Univariate and multivariate Cox regression results of CASP5 haplotypes
Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P -value
Diff HR
(%)
All 0.86 (0.77-0.97) 0.014 0.89 (0.78-1.03) 0.116 3
Serous 0.81 (0.70-0.94) 0.006 0.89 (0.75-1.06) 0.202 10
Endometrioid 0.81 (0.55-1.19) 0.278 0.86 (0.58-1.28) 0.466 6
Mucinous 1.29 (0.83-1.99) 0.261 1.35 (0.81-2.25) 0.248 5
CASP5
(haplotype
block 1)
h010 45
Clear cell 0.93 (0.72-1.2) 0.573 0.9 (0.68-1.2) 0.489 3
All 1.12 (1.00-1.26) 0.05 1.08 (0.94-1.24) 0.289 4
Serous 1.14 (0.99-1.32) 0.077 1.09 (0.92-1.29) 0.339 4
Endometrioid 1.14 (0.79-1.64) 0.486 1.04 (0.72-1.49) 0.847 9
Mucinous 0.99 (0.62-1.59) 0.965 0.79 (0.45-1.37) 0.401 20
CASP5
(haplotype
block 1)
h100 42
Clear cell 1.11 (0.86-1.44) 0.422 1.09 (0.81-1.46) 0.561 2
All 1.04 (0.85-1.28) 0.679 1.02 (0.8-1.31) 0.863 2
Serous 1.14 (0.88-1.46) 0.324 0.96 (0.71-1.29) 0.765 16
Endometrioid 1.13 (0.56-2.28) 0.741 1.13 (0.53-2.41) 0.747 0
Mucinous 0.62 (0.26-1.47) 0.282 0.9 (0.37-2.19) 0.811 45
CASP5
(haplotype
block 1)
h001 9
Clear cell 0.93 (0.6-1.45) 0.762 1.16 (0.67-1.99) 0.599 25
All 1.04 (0.63-1.73) 0.871 1.19 (0.68-2.09) 0.549 14
Serous 1.26 (0.68-2.35) 0.459 1.31 (0.68-2.53) 0.413 4
Endometrioid 0.94 (0.16-5.71) 0.949 1.32 (0.21-8.15) 0.764 40
Mucinous 1.19 (0.28-5.06) 0.817 3.31 (0.72-15.19) 0.124 178
CASP5
(haplotype
block 1)
h000 2
Clear cell 0.42 (0.09-2.03) 0.28 0.24 (0.03-2) 0.186 43
All 1.05 (0.63-1.76) 0.852 1.05 (0.45-2.42) 0.914 0
Serous 1.34 (0.69-2.59) 0.387 1.94 (0.61-6.18) 0.261 45
Endometrioid 1.3 (0.2-8.49) 0.783 2.74 (0.43-17.66) 0.288 111
CASP5
(haplotype
block 1)
h110 2
Mucinous 0.29 (0.04-2.25) 0.236 0.28 (0.04-2.15) 0.223 3
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Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P -value
Diff HR
(%)
Clear cell 1.43 (0.47-4.39) 0.533 1.34 (0.26-6.88) 0.723 6
All 4.56 (1.71-12.12) 0.002 11.73 (4.14-33.28) 8.85x10-
5
157
Serous 2.80 (0.70-11.25) 0.146 16.8 (3.39-83.24) 0.001 500
Endometrioid 11.54 (1.26-105.63) 0.03 6.52 (0.77-54.93) 0.085 44
Mucinous - - - - -
CASP5
(haplotype
block 1)
Rare 4
Clear cell 3.82 (0.63-23.06) 0.144 9.13 (1.57-52.94) 0.014 139
All 1.08 (0.96-1.22) 0.223 1.02 (0.79-1.31) 0.896 6
Serous 0.93 (0.80-1.09) 0.385 0.94 (0.67-1.31) 0.697 1
Endometrioid 0.93 (0.49-1.76) 0.816 1.15 (0.56-2.32) 0.706 24
Mucinous 1.42 (0.71-2.87) 0.324 1.23 (0.59-2.57) 0.588 13
CASP5
(haplotype
block 2)
h000000 47
Clear cell 1.17 (0.79-1.74) 0.431 1.16 (0.71-1.9) 0.542 1
All 1.02 (0.87-1.20) 0.821 1.01 (0.83-1.23) 0.916 1
Serous 1.11 (0.91-1.35) 0.298 1.08 (0.86-1.36) 0.493 3
Endometrioid 1.05 (0.63-1.77) 0.847 1.17 (0.66-2.07) 0.583 11
Mucinous 1.69 (0.92-3.1) 0.089 1.64 (0.85-3.15) 0.139 3
CASP5
(haplotype
block 2)
h000011 13
Clear cell 0.62 (0.4-0.97) 0.034 0.57 (0.34-0.97) 0.037 8
All 1.14 (0.91-1.43) 0.251 1 (0.76-1.32) 0.998 12
Serous 1.16 (0.88-1.54) 0.29 1.15 (0.83-1.58) 0.408 1
Endometrioid 0.74 (0.31-1.77) 0.498 0.34 (0.1-1.13) 0.079 54
Mucinous 0.74 (0.25-2.17) 0.588 0.56 (0.17-1.87) 0.347 24
CASP5
(haplotype
block 2)
h001111 7
Clear cell 1.3 (0.85-1.99) 0.224 1.3 (0.76-2.22) 0.343 0
All 0.93 (0.69-1.25) 0.615 1.13 (0.81-1.58) 0.479 22
Serous 0.91 (0.63-1.31) 0.61 1.06 (0.7-1.61) 0.786 16
Endometrioid 1.18 (0.46-3.07) 0.73 1.51 (0.59-3.86) 0.384 28
Mucinous 0.35 (0.05-2.55) 0.297 0.46 (0.06-3.39) 0.444 31
CASP5
(haplotype
block 2)
h100000 6
Clear cell 0.84 (0.45-1.58) 0.595 1.04 (0.52-2.08) 0.922 24
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Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P -value
Diff HR
(%)
All 0.5 (0.26-0.98) 0.042 0.73 (0.34-1.58) 0.424 46
Serous 0.69 (0.30-1.55) 0.366 0.92 (0.37-2.28) 0.856 33
Endometrioid 0.26 (0.02-3.18) 0.294 0.53 (0.04-6.45) 0.619 104
Mucinous - - - - -
CASP5
(haplotype
block 2)
h100011 3
Clear cell 0.64 (0.18-2.36) 0.507 0.34 (0.07-1.78) 0.202 47
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, CASP5 (block 1): rs518604, rs523104, rs3181328. CASP5 (block 2):
rs17446518, rs9651713, rs3181175, rs3181174, rs2282657, rs507879.
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Appendix VIII-I: Univariate and multivariate Cox regression results of FILIP1L tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
437 All 0.94 (0.84-1.06) 0.328 0.94 (0.81-1.08) 0.38 0
269 Serous 1.03 (0.89-1.19) 0.692 1.01 (0.84-1.2) 0.948 2
56 Endometrioid 1.1 (0.75-1.61) 0.636 1.09 (0.74-1.62) 0.654 1
43 Mucinous 0.66 (0.41-1.06) 0.084 0.63 (0.37-1.08) 0.094 5
FILIP1L rs796977 0.33
31 Clear cell 0.84 (0.64-1.1) 0.216 0.82 (0.6-1.11) 0.196 2
1653 All 0.97 (0.81-1.15) 0.717 1.03 (0.84-1.26) 0.774 6
771 Serous 1.11 (0.90-1.36) 0.337 1.1 (0.87-1.38) 0.43 1
257 Endometrioid 0.78 (0.41-1.46) 0.432 0.9 (0.48-1.7) 0.75 15
175 Mucinous 1.01 (0.51-2.02) 0.976 0.97 (0.4-2.36) 0.955 4
FILIP1L rs793477 0.13
155 Clear cell 0.62 (0.39-0.99) 0.047 0.68 (0.4-1.17) 0.162 10
1773 All 0.96 (0.85-1.07) 0.461 1.04 (0.9-1.19) 0.628 8
838 Serous 1.02 (0.88-1.18) 0.816 1.08 (0.91-1.28) 0.399 6
274 Endometrioid 1.08 (0.74-1.59) 0.69 1.15 (0.77-1.71) 0.501 6
194 Mucinous 0.65 (0.41-1.03) 0.065 0.57 (0.33-0.99) 0.046 12
FILIP1L rs793446 0.41
164 Clear cell 0.97 (0.76-1.25) 0.83 0.99 (0.74-1.32) 0.932 2
1773 All 1.03 (0.83-1.29) 0.786 1.39 (1.07-1.81) 0.014 35
840 Serous 0.98 (0.71-1.34) 0.895 1.28 (0.89-1.84) 0.186 31
276 Endometrioid 0.99 (0.5-1.93) 0.967 1.23 (0.59-2.57) 0.576 24
191 Mucinous 1.03 (0.45-2.34) 0.949 1.09 (0.44-2.73) 0.849 6
FILIP1L rs3921767 0.07
166 Clear cell 1.29 (0.88-1.89) 0.196 1.59 (0.99-2.58) 0.057 23
1786 All 0.96 (0.80-1.15) 0.675 0.99 (0.81-1.22) 0.932 3
574 Serous 0.99 (0.78-1.27) 0.944 0.98 (0.74-1.29) 0.866 1
FILIP1L rs17338680 0.11
221 Endometrioid 1.1 (0.69-1.76) 0.688 1.21 (0.76-1.93) 0.414 10
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
184 Mucinous 1.82 (0.93-3.58) 0.083 1.21 (0.58-2.54) 0.606 34
133 Clear cell 0.86 (0.57-1.3) 0.479 0.82 (0.51-1.31) 0.408 5
1786 All 0.96 (0.84-1.09) 0.515 0.93 (0.8-1.09) 0.366 3
843 Serous 1.03 (0.88-1.20) 0.708 1 (0.84-1.2) 0.964 3
278 Endometrioid 1.07 (0.69-1.68) 0.752 0.97 (0.6-1.57) 0.892 9
195 Mucinous 0.45 (0.25-0.82) 0.009 0.46 (0.23-0.91) 0.027 2
FILIP1L rs9864437 0.22
165 Clear cell 0.89 (0.66-1.2) 0.455 0.87 (0.63-1.2) 0.396 2
1414 All 1.00 (0.89-1.13) 0.944 0.94 (0.81-1.08) 0.363 6
710 Serous 0.97 (0.84-1.13) 0.727 0.92 (0.77-1.1) 0.368 5
226 Endometrioid 1.05 (0.71-1.55) 0.803 0.92 (0.62-1.39) 0.703 12
140 Mucinous 0.95 (0.58-1.56) 0.843 0.86 (0.48-1.56) 0.62 9
FILIP1L rs6788750 0.41
131 Clear cell 0.96 (0.75-1.24) 0.778 0.98 (0.73-1.32) 0.889 2
1273 All 0.96 (0.82-1.12) 0.573 1.1 (0.92-1.32) 0.277 15
594 Serous 0.93 (0.75-1.15) 0.514 1.05 (0.82-1.33) 0.705 13
193 Endometrioid 1 (0.65-1.53) 0.986 1.16 (0.75-1.8) 0.512 16
145 Mucinous 1.36 (0.75-2.5) 0.313 1.16 (0.62-2.18) 0.65 15
FILIP1L rs12494994 0.18
113 Clear cell 1.1 (0.81-1.5) 0.525 1.13 (0.8-1.61) 0.486 3
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated
with survival; emboldened HR are statistically significant.
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Appendix VIII-J: Univariate and multivariate Cox regression results of FILIP1L haplotypes
Univariate Multivariate§Gene Haplotype† Freq (%) Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1.06 (0.94-1.19) 0.333 0.95 (0.83-1.09) 0.49 10
Serous 0.95 (0.82-1.10) 0.485 0.89 (0.75-1.06) 0.211 6
Endometrioid 0.98 (0.67-1.42) 0.904 0.88 (0.59-1.32) 0.542 10
Mucinous 1.37 (0.91-2.07) 0.129 1.58 (0.94-2.65) 0.086 15
FILIP1L
(haplotype
block 1)
h00000 47
Clear cell 1.21 (0.95-1.55) 0.117 1.16 (0.87-1.54) 0.316 4
All 0.96 (0.84-1.09) 0.52 0.94 (0.8-1.1) 0.424 2
Serous 1.03 (0.89-1.21) 0.667 0.94 (0.67-1.31) 0.697 9
Endometrioid 1.12 (0.71-1.78) 0.618 1 (0.61-1.63) 0.998 11
Mucinous 0.42 (0.22-0.78) 0.006 0.44 (0.21-0.9) 0.024 5
FILIP1L
(haplotype
block 1)
h10100 21
Clear cell 0.88 (0.65-1.19) 0.419 0.88 (0.64-1.22) 0.447 0
All 0.97 (0.81-1.16) 0.728 1.02 (0.83-1.25) 0.839 5
Serous 1.09 (0.88-1.34) 0.427 1.08 (0.86-1.36) 0.516 1
Endometrioid 0.83 (0.44-1.56) 0.562 0.92 (0.49-1.74) 0.799 11
Mucinous 0.97 (0.48-1.97) 0.937 0.95 (0.39-2.32) 0.911 2
FILIP1L
(haplotype
block 1)
h01000 12
Clear cell 0.62 (0.38-0.99) 0.048 0.67 (0.39-1.16) 0.156 8
All 0.96 (0.80-1.15) 0.651 0.99 (0.8-1.23) 0.94 3
Serous 0.99 (0.77-1.27) 0.919 1.02 (0.85-1.22) 0.834 3
Endometrioid 1.1 (0.69-1.76) 0.693 1.21 (0.76-1.93) 0.418 10
Mucinous 1.82 (0.93-3.59) 0.082 1.22 (0.58-2.54) 0.605 33
FILIP1L
(haplotype
block 1)
h10101 11
Clear cell 0.87 (0.58-1.31) 0.505 0.82 (0.51-1.32) 0.415 6
All 1.02 (0.81-1.27) 0.871 1.36 (1.04-1.77) 0.024 33
Serous 0.95 (0.69-1.30) 0.742 1.22 (0.85-1.76) 0.283 28
Endometrioid 1 (0.5-2) 0.996 1.22 (0.58-2.55) 0.604 22
Mucinous 1.01 (0.44-2.31) 0.977 1.08 (0.43-2.69) 0.877 7
FILIP1L
(haplotype
block 1)
h00110 7
Clear cell 1.29 (0.88-1.89) 0.197 1.61 (0.99-2.6) 0.053 25
All 1.00 (0.63-1.58) 0.991 0.98 (0.54-1.79) 0.955 2FILIP1L
(haplotype
block 1)
Rare 2
Serous 0.76 (0.36-1.62) 0.479 0.98 (0.73-1.3) 0.876 29
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Univariate Multivariate§Gene Haplotype† Freq (%) Histology HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
Endometrioid 0.65 (0.14-2.92) 0.574 0.72 (0.15-3.54) 0.691 11
Mucinous 1.12 (0.17-7.37) 0.903 0.81 (0.11-6.26) 0.843 28
Clear cell 1.57 (0.77-3.18) 0.211 1.73 (0.78-3.83) 0.177 10
All 1.01 (0.90-1.14) 0.894 0.94 (0.81-1.08) 0.385 7
Serous 0.97 (0.84-1.13) 0.719 1.06 (0.83-1.34) 0.652 9
Endometrioid 1.01 (0.68-1.49) 0.97 0.9 (0.6-1.34) 0.592 11
Mucinous 0.96 (0.6-1.54) 0.857 0.84 (0.47-1.51) 0.571 13
FILIP1L
(haplotype
block 2)
h010 41
Clear cell 0.96 (0.75-1.24) 0.781 1 (0.74-1.34) 0.989 4
All 0.96 (0.84-1.09) 0.506 0.94 (0.8-1.09) 0.42 2
Serous 1.03 (0.89-1.21) 0.668 0.92 (0.77-1.1) 0.371 11
Endometrioid 1.08 (0.69-1.69) 0.727 0.97 (0.6-1.57) 0.902 10
Mucinous 0.45 (0.25-0.82) 0.009 0.46 (0.23-0.91) 0.026 2
FILIP1L
(haplotype
block 2)
h100 22
Clear cell 0.88 (0.65-1.18) 0.385 0.87 (0.63-1.21) 0.407 1
All 1.10 (0.94-1.28) 0.223 1.11 (0.92-1.33) 0.292 1
Serous 1.07 (0.87-1.31) 0.506 0.64 (0.26-1.55) 0.321 40
Endometrioid 0.87 (0.53-1.44) 0.594 0.98 (0.59-1.64) 0.946 13
Mucinous 1.72 (1.09-2.72) 0.019 1.96 (1.15-3.33) 0.013 14
FILIP1L
(haplotype
block 2)
h000 19
Clear cell 1.13 (0.82-1.58) 0.456 1.09 (0.74-1.6) 0.664 4
All 0.96 (0.82-1.11) 0.563 1.11 (0.93-1.33) 0.24 16
Serous 0.93 (0.75-1.15) 0.494 1.09 (0.85-1.38) 0.505 17
Endometrioid 1.03 (0.68-1.57) 0.89 1.19 (0.78-1.84) 0.42 16
Mucinous 1.47 (0.81-2.69) 0.208 1.26 (0.66-2.41) 0.476 14
FILIP1L
(haplotype
block 2)
h001 17
Clear cell 1.08 (0.79-1.46) 0.627 1.12 (0.79-1.59) 0.535 4
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, FILIP1L -block 1: rs796977, rs793477, rs793446,
rs3921767, rs17338680. FILIP1L - block 2: rs9864437, rs6788750, rs12494994.
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Appendix VIII-K: Univariate and multivariate Cox regression results of RBBP8 tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1272 All 1.14 (0.96-1.35) 0.147 1.02 (0.83-1.24) 0.875 11
594 Serous 1.04 (0.83-1.30) 0.743 0.93 (0.72-1.19) 0.555 11
188 Endometrioid 1.21 (0.67-2.19) 0.524 1 (0.54-1.85) 0.997 17
144 Mucinous 0.95 (0.49-1.86) 0.884 0.79 (0.36-1.71) 0.543 17
RBBP8 rs7239066 0.11
115 Clear cell 1.35 (0.95-1.93) 0.098 1.35 (0.91-2) 0.135 0
1748 All 1.29 (0.99-1.68) 0.055 1.09 (0.8-1.46) 0.593 16
826 Serous 1.08 (0.77-1.51) 0.664 0.92 (0.62-1.36) 0.67 15
253 Endometrioid 1.69 (0.72-3.95) 0.228 1.3 (0.51-3.33) 0.587 23
176 Mucinous 1.23 (0.43-3.54) 0.698 0.54 (0.16-1.84) 0.327 56
RBBP8 rs11082221 0.04
151 Clear cell 1.67 (1.01-2.75) 0.044 1.54 (0.93-2.54) 0.092 8
1764 All 0.85 (0.75-0.95) 0.007 0.86 (0.74-0.99) 0.034 1
829 Serous 0.88 (0.75-1.02) 0.098 0.85 (0.71-1.01) 0.065 3
271 Endometrioid 0.8 (0.53-1.19) 0.265 0.86 (0.56-1.31) 0.479 7
193 Mucinous 0.67 (0.42-1.05) 0.079 0.83 (0.51-1.36) 0.465 24
RBBP8 rs4474794 0.36
165 Clear cell 0.91 (0.71-1.18) 0.484 0.98 (0.73-1.32) 0.899 8
346 All 0.83 (0.71-0.95) 0.009 0.83 (0.7-0.99) 0.038 0
215 Serous 0.87 (0.72-1.05) 0.143 0.82 (0.66-1.02) 0.073 6
44 Endometrioid 0.87 (0.56-1.35) 0.536 0.99 (0.62-1.6) 0.982 14
33 Mucinous 0.61 (0.35-1.05) 0.074 0.81 (0.44-1.49) 0.497 33
RBBP8 rs9304261 0.22
21 Clear cell 0.84 (0.62-1.13) 0.242 0.86 (0.61-1.22) 0.401 2
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically
associated with survival; emboldened HR are statistically significant.
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Appendix VIII-L: Univariate and multivariate Cox regression results of RBBP8 haplotypes
Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1.16 (1.03-1.31) 0.015 1.17 (1.01-1.34) 0.032 1
Serous 1.12 (0.97-1.30) 0.134 0.02 (0-27735) 0.589 98
Endometrioid 1.26 (0.85-1.86) 0.257 1.15 (0.76-1.75) 0.511 9
Mucinous 1.57 (1-2.47) 0.05 1.22 (0.75-2) 0.422 22
RBBP8 h0000 62
Clear cell 1.06 (0.83-1.35) 0.659 1 (0.75-1.32) 0.98 6
All 0.81 (0.71-0.94) 0.005 0.82 (0.69-0.98) 0.029 1
Serous 0.84 (0.70-1.02) 0.079 0.99 (0.53-1.85) 0.976 18
Endometrioid 0.83 (0.53-1.3) 0.422 0.94 (0.58-1.52) 0.789 13
Mucinous 0.64 (0.37-1.08) 0.096 0.86 (0.48-1.53) 0.614 34
RBBP8 h0011 23
Clear cell 0.85 (0.64-1.13) 0.261 0.87 (0.63-1.22) 0.429 2
All 0.99 (0.78-1.26) 0.941 0.93 (0.7-1.22) 0.588 6
Serous 1.00 (0.73-1.36) 0.99 0.81 (0.65-1) 0.054 19
Endometrioid 0.85 (0.38-1.88) 0.689 0.78 (0.35-1.73) 0.548 8
Mucinous 0.87 (0.36-2.13) 0.762 1.15 (0.45-2.93) 0.771 32
RBBP8 h1010 7
Clear cell 1.05 (0.63-1.75) 0.841 1.03 (0.57-1.87) 0.928 2
All 1.26 (0.97-1.65) 0.086 1.04 (0.77-1.42) 0.789 17
Serous 1.06 (0.76-1.49) 0.725 0.92 (0.77-1.11) 0.403 13
Endometrioid 1.43 (0.56-3.63) 0.457 1.02 (0.36-2.89) 0.974 29
Mucinous 1.27 (0.45-3.63) 0.651 0.55 (0.16-1.85) 0.333 57
RBBP8 h1110 4
Clear cell 1.64 (0.99-2.72) 0.057 1.51 (0.91-2.5) 0.111 8
All 0.60 (0.39-0.93) 0.022 0.75 (0.45-1.25) 0.275 25
Serous 0.75 (0.41-1.36) 0.347 1.2 (1.01-1.42) 0.041 60
Endometrioid 0.35 (0.08-1.56) 0.169 0.54 (0.12-2.46) 0.429 54
RBBP8 h0010 3
Mucinous 0.56 (0.13-2.31) 0.419 1.03 (0.15-7.23) 0.976 84
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Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
Clear cell 0.7 (0.31-1.58) 0.388 0.78 (0.28-2.18) 0.637 11
All 1.24 (0.72-2.15) 0.436 1.34 (0.71-2.52) 0.366 8
Serous 1.10 (0.57-2.12) 0.786 1.08 (0.86-1.36) 0.493 2
Endometrioid 2.48 (0.32-19.53) 0.388 11.36 (1.27-101.18) 0.029 358
Mucinous - - - - -
RBBP8 Rare 1
Clear cell 1.37 (0.44-4.31) 0.587 1.5 (0.47-4.83) 0.493 9
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, RBBP8: rs7239066, rs11082221, rs4474794, rs9304261.
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Appendix VIII-M: Univariate and multivariate Cox regression results of RGC32 tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1769 All 0.94 (0.79-1.12) 0.486 0.99 (0.8-1.22) 0.922 5
839 Serous 0.91 (0.72-1.15) 0.447 0.95 (0.73-1.24) 0.693 4
273 Endometrioid 1.08 (0.62-1.88) 0.78 1.4 (0.78-2.52) 0.259 30
191 Mucinous 1.12 (0.64-1.97) 0.688 1.19 (0.62-2.29) 0.591 6
RGC32 rs10467472 0.13
164 Clear cell 0.97 (0.69-1.38) 0.88 0.72 (0.45-1.13) 0.151 26
1690 All 0.95 (0.79-1.14) 0.567 1.11 (0.9-1.36) 0.342 17
788 Serous 1.11 (0.88-1.41) 0.359 1.44 (1.12-1.86) 0.005 30
264 Endometrioid 1.09 (0.65-1.84) 0.742 1.12 (0.61-2.05) 0.713 3
184 Mucinous 0.63 (0.29-1.35) 0.232 0.64 (0.24-1.73) 0.38 2
RGC32 rs3783194 0.11
155 Clear cell 0.81 (0.55-1.19) 0.282 0.76 (0.5-1.16) 0.202 6
1771 All 1.01 (0.84-1.20) 0.931 0.96 (0.79-1.18) 0.72 5
835 Serous 1.00 (0.81-1.25) 0.968 0.94 (0.73-1.21) 0.63 6
275 Endometrioid 0.88 (0.49-1.6) 0.677 0.8 (0.41-1.57) 0.522 9
193 Mucinous 1.22 (0.58-2.56) 0.598 0.93 (0.42-2.05) 0.862 24
RGC32 rs11618371 0.11
164 Clear cell 0.98 (0.67-1.44) 0.918 1.1 (0.72-1.69) 0.65 12
1782 All 1.18 (0.95-1.46) 0.137 1.12 (0.86-1.46) 0.386 5
841 Serous 1.19 (0.90-1.57) 0.233 1.06 (0.75-1.48) 0.75 11
276 Endometrioid 0.6 (0.27-1.3) 0.193 0.45 (0.18-1.14) 0.093 25
196 Mucinous 1.62 (0.81-3.23) 0.169 1.75 (0.82-3.76) 0.149 8
RGC32 rs9532824 0.07
150 Clear cell 1.69 (1.07-2.67) 0.023 1.45 (0.86-2.42) 0.162 14
1274 All 0.96 (0.85-1.08) 0.488 1.13 (0.93-1.38) 0.218 18
595 Serous 1.03 (0.88-1.21) 0.682 1.25 (0.97-1.61) 0.082 21
RGC32 rs995845 0.2
193 Endometrioid 1.55 (0.93-2.6) 0.093 1.8 (1.03-3.14) 0.039 16
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
146 Mucinous 1.09 (0.58-2.03) 0.797 0.75 (0.36-1.54) 0.43 31
112 Clear cell 0.94 (0.66-1.34) 0.716 1.04 (0.69-1.56) 0.851 11
1766 All 0.97 (0.83-1.13) 0.697 0.92 (0.77-1.11) 0.377 5
833 Serous 1.02 (0.84-1.24) 0.813 0.92 (0.74-1.15) 0.488 10
275 Endometrioid 0.94 (0.55-1.59) 0.811 0.74 (0.4-1.34) 0.317 21
193 Mucinous 1.23 (0.67-2.29) 0.505 1.24 (0.68-2.28) 0.482 1
RGC32 rs9594551 0.15
163 Clear cell 0.78 (0.55-1.11) 0.167 0.94 (0.63-1.42) 0.776 21
1749 All 1.06 (0.92-1.21) 0.407 0.98 (0.84-1.16) 0.837 8
828 Serous 1.05 (0.88-1.25) 0.571 0.95 (0.78-1.15) 0.574 10
268 Endometrioid 0.77 (0.49-1.22) 0.266 0.6 (0.35-1.01) 0.056 22
188 Mucinous 1.68 (0.99-2.87) 0.056 1.62 (0.91-2.9) 0.102 4
RGC32 rs975590 0.23
161 Clear cell 1.13 (0.84-1.52) 0.421 1.22 (0.86-1.73) 0.262 8
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated with
survival; emboldened HR are statistically significant.
Appendices
510
Appendix VIII-N: Univariate and multivariate Cox regression results of RGC32 haplotypes
Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 0.96 (0.84-1.1) 0.56 0.92 (0.79-1.07) 0.283 4
Serous 0.94 (0.81-1.1) 0.46 0.91 (0.76-1.08) 0.265 3
Endometrioid 1 (0.68-1.47) 0.986 0.96 (0.62-1.47) 0.838 4
Mucinous 0.88 (0.56-1.38) 0.586 0.83 (0.51-1.37) 0.476 6
RGC32 h0000000 41.5
Clear cell 0.65 (0.37-1.14) 0.131 0.82 (0.45-1.52) 0.534 26
All 1.1 (0.82-1.48) 0.525 0.97 (0.69-1.38) 0.873 12
Serous 1.12 (0.79-1.57) 0.522 1.04 (0.71-1.54) 0.826 7
Endometrioid 1.24 (0.55-2.8) 0.604 0.73 (0.29-1.88) 0.518 41
Mucinous 1.69 (0.62-4.63) 0.304 2.46 (0.88-6.89) 0.086 46
RGC32 h0000011 4.9
Clear cell 0.59 (0.14-2.59) 0.485 0.8 (0.17-3.66) 0.773 36
All 1.05 (0.86-1.29) 0.611 1.03 (0.82-1.3) 0.785 2
Serous 1.01 (0.79-1.28) 0.959 1 (0.76-1.3) 0.975 1
Endometrioid 1.36 (0.81-2.29) 0.244 1.54 (0.9-2.64) 0.118 13
Mucinous 0.77 (0.32-1.82) 0.546 0.74 (0.3-1.79) 0.5 4
RGC32 h0000100 10.4
Clear cell 1.42 (0.6-3.36) 0.424 1.4 (0.45-4.37) 0.561 1
All 1.11 (0.86-1.43) 0.434 1.06 (0.78-1.43) 0.73 5
Serous 1.13 (0.83-1.53) 0.442 1.06 (0.74-1.51) 0.752 6
Endometrioid 0.65 (0.29-1.47) 0.303 0.51 (0.19-1.33) 0.168 22
Mucinous 1.6 (0.77-3.3) 0.208 1.54 (0.69-3.42) 0.289 4
RGC32 h0001001 6.7
Clear cell 1.83 (0.63-5.28) 0.267 1.02 (0.23-4.54) 0.977 44
All 1.03 (0.84-1.26) 0.791 0.94 (0.74-1.18) 0.575 9
Serous 1.01 (0.8-1.28) 0.928 0.94 (0.73-1.22) 0.646 7
RGC32 h0010011 7.8
Endometrioid 0.93 (0.48-1.81) 0.84 0.9 (0.43-1.88) 0.775 3
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Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
Mucinous 1.06 (0.47-2.41) 0.89 0.81 (0.35-1.89) 0.627 24
Clear cell 1.01 (0.47-2.17) 0.989 1.23 (0.5-3.05) 0.649 22
All 1.01 (0.83-1.23) 0.93 1.29 (1.03-1.62) 0.024 28
Serous 1.13 (0.89-1.42) 0.324 1.5 (1.16-1.94) 0.002 33
Endometrioid 1.23 (0.69-2.2) 0.476 1.34 (0.72-2.49) 0.364 9
Mucinous 0.65 (0.3-1.4) 0.271 0.64 (0.24-1.71) 0.37 2
RGC32 h0100100 10.8
Clear cell 0.94 (0.47-1.88) 0.866 0.95 (0.45-2.01) 0.884 1
All 0.98 (0.76-1.25) 0.843 1.01 (0.76-1.34) 0.935 3
Serous 0.88 (0.65-1.2) 0.418 0.89 (0.63-1.25) 0.487 1
Endometrioid 0.94 (0.46-1.93) 0.875 1.2 (0.58-2.48) 0.626 28
Mucinous 1.45 (0.68-3.12) 0.338 1.57 (0.64-3.82) 0.322 8
RGC32 h1000000 8.1
Clear cell 1.65 (0.77-3.56) 0.201 1.59 (0.51-4.94) 0.421 4
All 0.97 (0.69-1.36) 0.863 1.46 (0.98-2.19) 0.063 51
Serous 1.06 (0.71-1.59) 0.767 1.48 (0.92-2.39) 0.109 40
Endometrioid 1.42 (0.55-3.64) 0.469 1.9 (0.72-5.04) 0.196 34
Mucinous 0.81 (0.29-2.23) 0.686 0.75 (0.17-3.23) 0.695 7
RGC32 h1000100 4.1
Clear cell 0.61 (0.14-2.6) 0.501 0.57 (0.14-2.23) 0.415 7
All 0.67 (0.41-1.1) 0.114 0.49 (0.27-0.9) 0.022 27
Serous 0.72 (0.42-1.24) 0.234 0.56 (0.29-1.06) 0.073 22
Endometrioid 0.35 (0.05-2.56) 0.298 0.09 (0-9.19) 0.312 74
Mucinous 0.77 (0.1-6.16) 0.809 1.31 (0.17-10.38) 0.796 70
RGC32 Rare
Clear cell 0.82 (0.13-5.14) 0.832 0.64 (0.1-4.06) 0.639 22
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, RGC32: rs10467472, rs3783194,
rs11618371, rs9532824, rs995845, rs9594551, rs975590.
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Appendix VIII-O: Univariate and multivariate Cox regression results of RUVBL1 tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1777 All 1.07 (0.91-1.27) 0.404 0.97 (0.79-1.19) 0.789 9
839 Serous 1.03 (0.83-1.29) 0.772 1.04 (0.8-1.34) 0.789 1
276 Endometrioid 1.19 (0.71-1.98) 0.516 1.19 (0.71-2.01) 0.504 0
193 Mucinous 1.01 (0.53-1.93) 0.981 0.64 (0.27-1.5) 0.306 37
RUVBL1 rs9860614 0.12
162 Clear cell 1.11 (0.79-1.56) 0.555 0.81 (0.53-1.24) 0.335 27
1266 All 1.08 (0.95-1.23) 0.248 0.99 (0.85-1.16) 0.925 8
537 Serous 1.04 (0.88-1.23) 0.626 1.02 (0.84-1.24) 0.862 2
207 Endometrioid 1.3 (0.88-1.9) 0.186 1.2 (0.78-1.85) 0.397 8
143 Mucinous 0.75 (0.44-1.28) 0.286 0.75 (0.41-1.38) 0.358 0
RUVBL1 rs13063604 0.25
124 Clear cell 1.08 (0.81-1.43) 0.609 0.82 (0.58-1.14) 0.24 24
1280 All 1.00 (0.89-1.13) 0.977 0.92 (0.8-1.07) 0.275 8
596 Serous 0.97 (0.83-1.14) 0.729 0.91 (0.76-1.1) 0.326 6
194 Endometrioid 0.98 (0.68-1.43) 0.931 1.07 (0.71-1.62) 0.743 9
147 Mucinous 0.8 (0.51-1.26) 0.344 0.87 (0.53-1.43) 0.58 9
RUVBL1 rs3732402 0.4
114 Clear cell 1.06 (0.82-1.39) 0.645 0.91 (0.67-1.24) 0.556 14
1645 All 1.03 (0.92-1.15) 0.64 1.06 (0.92-1.22) 0.429 3
769 Serous 1.07 (0.92-1.24) 0.388 1.09 (0.91-1.3) 0.341 2
256 Endometrioid 0.9 (0.61-1.34) 0.615 0.81 (0.52-1.28) 0.377 10
175 Mucinous 1.2 (0.79-1.83) 0.393 0.87 (0.55-1.39) 0.567 28
RUVBL1 rs7650365 0.46
155 Clear cell 1.03 (0.81-1.31) 0.824 1.1 (0.84-1.44) 0.486 7
1787 All 0.98 (0.86-1.12) 0.758 0.81 (0.67-0.98) 0.03 17
845 Serous 1.01 (0.86-1.19) 0.879 0.75 (0.59-0.95) 0.018 26
RUVBL1 rs4857836 0.2
278 Endometrioid 1.12 (0.67-1.88) 0.66 0.92 (0.52-1.61) 0.762 18
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Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
195 Mucinous 0.8 (0.42-1.55) 0.513 0.9 (0.42-1.95) 0.797 13
165 Clear cell 0.97 (0.68-1.38) 0.863 0.84 (0.55-1.28) 0.406 13
1733 All 0.89 (0.76-1.05) 0.179 0.91 (0.74-1.11) 0.336 2
820 Serous 0.92 (0.75-1.14) 0.45 0.88 (0.68-1.12) 0.292 4
269 Endometrioid 0.49 (0.27-0.9) 0.021 0.65 (0.35-1.2) 0.172 33
186 Mucinous 0.64 (0.31-1.35) 0.244 1.1 (0.47-2.6) 0.824 72
RUVBL1 rs9821568 0.15
161 Clear cell 1.13 (0.82-1.55) 0.447 1.37 (0.94-1.98) 0.098 21
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated
with survival; emboldened HR are statistically significant.
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Appendix VIII-P: Univariate and multivariate Cox regression results of RUVBL1 haplotypes
Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
All 0.95 (0.76-1.2) 0.682 1.04 (0.81-1.34) 0.751 9
Serous 0.89 (0.68-1.17) 0.405 0.97 (0.72-1.31) 0.855 9
Endometrioid 1.89 (0.97-3.68) 0.061 1.65 (0.84-3.25) 0.149 13
Mucinous 0.95 (0.42-2.15) 0.91 1.76 (0.75-4.15) 0.195 85
RUVBL1 h000000 13.3
Clear cell 0.8 (0.31-2.06) 0.646 0.86 (0.33-2.23) 0.754 7
All 1.08 (0.92-1.26) 0.367 1.11 (0.93-1.32) 0.246 3
Serous 1.11 (0.92-1.33) 0.279 1.12 (0.92-1.38) 0.259 1
Endometrioid 0.76 (0.46-1.26) 0.282 0.76 (0.44-1.32) 0.329 0
Mucinous 1.58 (0.93-2.7) 0.09 1.05 (0.58-1.88) 0.88 34
RUVBL1 h000100 48
Clear cell 1.23 (0.62-2.43) 0.561 1.45 (0.73-2.91) 0.292 18
All 0.99 (0.58-1.69) 0.984 1.29 (0.62-2.69) 0.499 30
Serous 1.34 (0.72-2.48) 0.351 1.72 (0.73-4.07) 0.216 28
Endometrioid 0.21 (0.04-1.09) 0.063 0.47 (0.08-2.73) 0.398 124
Mucinous 2.34 (0.33-16.57) 0.394 2.8 (0.24-32.22) 0.408 20
RUVBL1 h001011 14.5
Clear cell 0.28 (0.02-4.97) 0.382 1.18 (0.06-23.01) 0.912 321
All 1.15 (0.91-1.46) 0.234 1.05 (0.81-1.36) 0.715 9
Serous 1.11 (0.85-1.45) 0.457 1.05 (0.78-1.41) 0.738 5
Endometrioid 1.93 (0.94-3.97) 0.073 1.35 (0.61-2.96) 0.456 30
Mucinous 0.6 (0.23-1.58) 0.302 0.77 (0.28-2.1) 0.616 28
RUVBL1 h011010 11.7
Clear cell 1.35 (0.48-3.78) 0.573 0.77 (0.22-2.66) 0.676 43
All 1.02 (0.8-1.3) 0.855 0.95 (0.73-1.25) 0.724 7RUVBL1 h111000 9.8
Serous 1.03 (0.77-1.36) 0.862 1.02 (0.75-1.39) 0.885 1
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Univariate Multivariate§
Gene Haplotype Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
Endometrioid 1.07 (0.49-2.33) 0.869 1.19 (0.53-2.7) 0.676 11
Mucinous 0.97 (0.42-2.2) 0.934 0.63 (0.23-1.72) 0.368 35
Clear cell 0.69 (0.21-2.24) 0.539 0.27 (0.04-1.74) 0.17 61
All 0.82 (0.51-1.33) 0.429 0.93 (0.56-1.55) 0.789 13
Serous 0.88 (0.51-1.53) 0.655 0.96 (0.54-1.69) 0.877 9
Endometrioid 1.43 (0.44-4.66) 0.553 1.47 (0.44-4.89) 0.525 3
Mucinous 0.05 (0-62.52) 0.405 0.02 (0-2257451) 0.674 60
RUVBL1 Rare
Clear cell 0.54 (0.07-4.06) 0.549 1.37 (0.17-11.14) 0.769 154
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, RUVBL1: rs9860614, rs13063604, rs3732402, rs7650365,
rs4857836, rs9821568.
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Appendix VIII-Q: Univariate and multivariate Cox regression results of STAG3 tSNPs
Univariate Multivariate§
Gene tSNP MAF No. cases Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
1787 All 0.95 (0.83-1.09) 0.482 0.92 (0.78-1.09) 0.342 3
846 Serous 1.00 (0.84-1.18) 0.985 0.94 (0.77-1.14) 0.533 6
279 Endometrioid 0.87 (0.56-1.34) 0.52 0.86 (0.52-1.42) 0.557 1
194 Mucinous 0.8 (0.45-1.39) 0.421 0.87 (0.44-1.75) 0.702 9
STAG3 rs11762932 0.22
164 Clear cell 0.9 (0.66-1.21) 0.473 0.98 (0.7-1.37) 0.893 9
1295 All 1.07 (0.95-1.19) 0.268 1.06 (0.93-1.21) 0.412 1
549 Serous 1.17 (1.02-1.35) 0.03 1.11 (0.95-1.31) 0.188 5
212 Endometrioid 0.94 (0.65-1.37) 0.749 0.96 (0.63-1.47) 0.866 2
143 Mucinous 0.87 (0.56-1.36) 0.544 0.99 (0.61-1.61) 0.972 14
STAG3 rs2246713 0.47
130 Clear cell 1 (0.79-1.27) 0.992 1 (0.76-1.32) 0.983 0
1784 All 1.11 (0.97-1.26) 0.119 1.1 (0.95-1.28) 0.198 1
843 Serous 1.20 (1.02-1.42) 0.029 1.15 (0.95-1.38) 0.157 4
278 Endometrioid 1.15 (0.79-1.68) 0.472 1.15 (0.75-1.74) 0.524 0
194 Mucinous 0.97 (0.59-1.58) 0.904 1.01 (0.64-1.61) 0.966 4
STAG3 rs1637001 0.26
165 Clear cell 1.03 (0.78-1.35) 0.852 0.96 (0.7-1.31) 0.777 7
HR: Hazard ratio; CI: confidence interval; MAF- minor allele frequency; §: adjusted for clinical factors; emboldened histology names are statistically associated
with survival; emboldened HR are statistically significant.
Appendices
517
Appendix VIII-R: Univariate and multivariate Cox regression results of STAG3 haplotypes
Univariate Multivariate§
Gene Haplotype† Freq (%) Histology
HR (95% CI) P-value HR (95% CI) P-value
Diff HR
(%)
All 1.11 (0.98-1.26) 0.1 0.88 (0.66-1.18) 0.381 21
Serous 1.21 (1.03-1.43) 0.021 0.76 (0.23-2.51) 0.654 37
Endometrioid 1.09 (0.74-1.6) 0.678 1.07 (0.7-1.64) 0.758 2
Mucinous 0.98 (0.6-1.6) 0.932 1.01 (0.64-1.61) 0.953 3
STAG3 h011 27
Clear cell 1.05 (0.8-1.38) 0.708 0.98 (0.72-1.35) 0.914 7
All 0.96 (0.84-1.11) 0.599 1 (0.77-1.28) 0.977 4
Serous 1.02 (0.86-1.21) 0.846 1.04 (0.71-1.54) 0.834 2
Endometrioid 0.82 (0.52-1.3) 0.405 0.83 (0.5-1.39) 0.482 1
Mucinous 0.75 (0.42-1.36) 0.347 0.81 (0.39-1.69) 0.573 8
STAG3 h110 21
Clear cell 0.93 (0.69-1.25) 0.624 1 (0.71-1.41) 0.998 8
All 0.96 (0.86-1.07) 0.468 1.38 (0.96-1.99) 0.085 44
Serous 0.88 (0.76-1.01) 0.077 0.9 (0.76-1.08) 0.267 2
Endometrioid 0.97 (0.68-1.39) 0.872 0.95 (0.63-1.44) 0.821 2
Mucinous 1.2 (0.78-1.84) 0.405 1.06 (0.66-1.71) 0.798 12
STAG3 h000 5
Clear cell 1.06 (0.83-1.35) 0.646 1.06 (0.8-1.41) 0.669 0
All 0.76 (0.45-1.27) 0.296 0.9 (0.46-1.77) 0.762 18
Serous 0.52 (0.21-1.29) 0.159 0.95 (0.68-1.34) 0.771 83
Endometrioid 2.2 (0.88-5.52) 0.093 2.83 (1.01-7.95) 0.048 29
Mucinous 1 (0.14-7.16) 0.998 1.45 (0.19-10.86) 0.717 45
STAG3 Rare 2
Clear cell 0.55 (0.2-1.49) 0.239 0.55 (0.17-1.75) 0.31 0
†: ‘0’= common allele and ‘1’= rare allele; §: adjusted for clinical factors; SNP order in haplotypes, 5’ to 3’, STAG3: rs11762932, rs2246713, rs1637001
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Appendix IX-A: Call rates and concordance of WGA samples vs gDNA genotyped with TaqMan
gDNA
(n=95) GenomePlex (n=90) GenomiPhi (n=95) PEP (n=95) REPLI-g (n=95)SNP MAF
Call rate Call rate Discord Call rate Discord Call rate Discord Call rate Discord
rs602652 0.44 99% 99% 0% 90% 0% 100% 0% 83% 1%
rs3217805 0.42 100% 99% 0% 93% 0% 100% 0% 87% 0%
rs3217869 0.41 95% 96% 0% 93% 0% 100% 0% 79% 1%
rs2079147 0.48 94% 99% 0% 96% 0% 99% 0% 80% 0%
rs10487888 0.47 98% 94% 0% 100% 0% 88% 0% 99% 2%
Average 97% 97% 0% 94% 0% 97% 0% 82% 1%
Discord: discordance rate, the proportion of genotypes which were the same where both gDNA (non-amplified genomic DNA) and WGA method
had calls. Bold rates failed quality control of call rate >90%; discordance <2%. Average call rate of assays that passed.
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Appendix IX-B: Call rates of assays genotyped on iPLEX (by
amplification method)
SNP MAF Genomic GenomePlex GenomiPhi PEP REPLI-g
rs10487888 0.47 94 (98%) 90 (100%) 95 (100%) 84 (88%) 95 (100%)
rs10842514 0.44 66 (96%) 75 (83%) 78 (82.1%) 2 (2%) 78 (82%)
rs11047898 0.01 96 (100%) 90 (100%) 95 (100%) 71 (75%) 95 (100%)
rs11047917 0.06 94 (98%) 90 (100%) 95 (100%) 80 (84%) 94 (99%)
rs11551174 0.06 90 (94%) 90 (100%) 94 (98.9%) 87 (92%) 95 (100%)
rs12305513 0.1 94 (98%) 90 (100%) 94 (98.9%) 39 (41%) 94 (99%)
rs12822857 0.48 89 (93%) 89 (99%) 95 (100%) 3 (3%) 93 (98%)
rs17161747 0.05 94 (98%) 90 (100%) 95 (100%) 37 (39%) 94 (99%)
rs17191185 0.04 90 (94%) 90 (100%) 95 (100%) 94 (99%) 95 (100%)
rs1733832 0.06 88 (92%) 89 (99%) 95 (100%) 86 (90%) 95 (100%)
rs17623382 0.12 82 (85%) 88 (98%) 94 (98.9%) 10 (11%) 94 (99%)
rs17695623 0.13 94 (98%) 90 (100%) 95 (100%) 79 (83%) 94 (99%)
rs1801200 0.23 95 (99%) 90 (100%) 94 (98.9%) 95 (100%) 94 (99%)
rs2161841 0.28 95 (99%) 90 (100%) 93 (97.9%) 80 (84%) 95 (100%)
rs2699905 0.26 94 (98%) 89 (99%) 95 (100%) 90 (95%) 95 (100%)
rs2865084 0.05 91 (95%) 90 (100%) 95 (100%) 94 (99%) 94 (99%)
rs2952155 0.26 95 (99%) 90 (100%) 95 (100%) 95 (100%) 93 (98%)
rs2952156 0.3 94 (98%) 90 (100%) 95 (100%) 94 (99%) 95 (100%)
rs3771882 0.43 94 (98%) 90 (100%) 94 (98.9%) 84 (88%) 95 (100%)
rs3771886 0.41 92 (96%) 89 (99%) 95 (100%) 32 (34%) 95 (100%)
rs3854012 0.28 94 (98%) 90 (100%) 95 (100%) 95 (100%) 95 (100%)
rs453226 0.15 94 (98%) 90 (100%) 95 (100%) 59 (62%) 95 (100%)
rs4623993 0.16 90 (94%) 90 (100%) 95 (100%) 56 (59%) 94 (99%)
rs6978734 0.01 95 (99%) 90 (100%) 95 (100%) 94 (99%) 95 (100%)
Average 84 (88%) 83 (92%) 87 (91%) 64 (67%) 86 (91%)
N=95 (GenomePlex =90)
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Appendix IX-C: Discordance rates on iPLEX (by WGA method)
GenomePlex Genomi-Phi PEP REPLI-gAssay No. called Discordance No. called Discordance No. called Discordance No. called Discordance
rs10487888 88 0 (0%) 94 0 (0%) 82 11 (13.4%) 93 2 (2.2%)
rs10842514 60 0 (0%) 65 0 (0%) Fail 63 0 (0%)
rs11047917 88 0 (0%) 94 0 (0%) 78 1 (1.3%) 93 2 (2.2%)
rs11551174 87 2 (2.3%) 89 1 (1.2%) 83 0 (0%) 90 2 (2.2%)
rs12305513 88 0 (0%) 94 0 (0%) 37 1 (2.7%) 93 1 (1.1%)
rs12822857 82 0 (0%) 89 0 (0%) Fail 86 1 (1.2%)
rs17161747 88 0 (0%) 94 0 (0%) 35 0 (0%) 92 0 (0%)
rs17191185 85 0 (0%) 90 0 (0%) 88 0 (0%) 89 0 (0%)
rs1733832 81 0 (0%) 88 0 (0%) 77 0 (0%) 87 0 (0%)
rs17623382 74 1 (1.4%) 82 1 (1.2%) Fail 80 2 (2.5%)
rs1801200 89 1 (1.1%) 94 0 (0%) 94 2 (2.1%) 93 1 (1.08%)
rs2161841 89 0 (0%) 93 0 (0%) 79 1 (1.3%) 94 0 (0%)
rs2699905 87 1 (1.2%) 94 0 (0%) 88 1 (1.1%) 93 2 (2.2%)
rs2865084 85 0 (0%) 91 0 (0%) 89 0 (0%) 89 0 (0%)
rs2952155 89 0 (0%) 95 0 (0%) 94 0 (0%) 93 1 (1.1%)
rs2952156 88 0 (0%) 94 0 (0%) 92 0 (0%) 92 0 (0%)
rs3771882 89 0 (0%) 93 0 (0%) 82 0 (0%) 93 1 (1.1%)
rs3771886 85 0 (0%) 92 0 (0%) 31 6 (19.4%) 91 1 (1.1%)
rs3854012 88 0 (0%) 94 0 (0%) 93 0 (0%) 93 2 (2.2%)
rs453226 89 0 (0%) 94 0 (0%) 57 0 (0%) 93 0 (0%)
rs4623993 84 0 (0%) 90 0 (0%) 51 0 (0%) 88 2 (2.3%)
rs6978734 89 0 (0%) 95 0 (0%) 93 0 (0%) 94 0 (0%)
Discordance rate, the proportion of genotypes which were different where the sample had a genotype in both gDNA and the WGA method. Bold pass rates less
than 90% or failed in only one method and discordance 2% or more
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Appendix IX-D: Call rates of SNPs genotyped on SNPlex (by WGA
method)
SNP MAF Genomic GenomePlex GenomiPhi REPLI-g
rs1419755 0.08 91 (96.8%) 87 (92.6%) Fail Fail
rs1569244 0.17 Fail Fail Fail Fail
rs354893 0.21 92 (97.9%) 90 (95.7%) Fail 86 (91.5%)
rs729673 0.34 90 (95.7%) Fail 81 (86.2%) 85 (90.4%)
rs751340 0.41 92 (97.9%) 87 (92.6%)* Fail 87 (92.6%)
rs1323001 0.33 91 (96.8%) 89 (94.7%) 80 (85.1%) 86 (91.5%)
rs1115261 0.44 92 (97.9%) Fail Fail 85 (90.4%)
rs1323881 0.20 Fail Fail Fail 86 (91.5%)
rs1507213 0.46 91 (96.8%) Fail Fail 86 (91.5%)
rs1425151 0.24 91 (96.8%) Fail 80 (85.1%) 86 (91.5%)
HCV2059319 0.31 Fail Fail Fail Fail
rs2286216 0.22 92 (97.9%) 89 (94.7%)* Fail Fail
rs220860 0.22 Fail 88 (93.6%) Fail 86 (91.5%)
rs1016146 0.31 92 (97.9%) 89 (94.7%) Fail 85 (90.4%)
rs1548543 0.34 Fail Fail Fail 84 (89.4%)
rs1980408 0.23 Fail Fail Fail 86 (91.5%)
rs1861606 0.29 91 (96.8%) Fail Fail 85 (90.4%)
HCV2962785 0.11 Fail Fail Fail Fail
rs705681 0.48 92 (97.9%) Fail Fail Fail
rs1007106 0.34 Fail 90 (95.7%) Fail 87 (92.6%)
rs984071 0.33 90 (95.7%) Fail Fail 85 (90.4%)
rs992690 0.16 92 (97.9%) Fail Fail 86 (91.5%)
rs1520483 0.38 89 (94.7%) Fail Fail 86 (91.5%)
rs1569125 0.32 91 (96.8%) Fail Fail Fail
rs288423 0.34 92 (97.9%) Fail 79 (84%) 87 (92.6%)
rs963014 0.40 Fail Fail Fail Fail
rs238196 0.10 Fail Fail Fail 87 (92.6%)
rs961495 0.18 92 (97.9%) Fail 81 (86.2%) 86 (91.5%)
rs1388276 0.27 91 (96.8%) Fail 79 (84%) 87 (92.6%)
rs748573 0.22 Fail Fail Fail 86 (91.5%)
rs1457947 0.42 Fail Fail Fail Fail
rs927221 0.12 92 (97.9%) 85 (90.4%) 81 (86.2%) 87 (92.6%)
rs1378324 0.12 92 (97.9%) Fail Fail 84 (89.4%)
rs1570903 0.44 Fail Fail Fail Fail
rs893613 0.48 90 (95.7%) Fail Fail 85 (90.4%)
rs1597695 0.39 Fail Fail Fail 87 (92.6%)
rs954779 0.18 Fail Fail Fail 79 (84%)
rs879253 0.47 92 (97.9%) Fail Fail 87 (92.6%)
rs1156404 0.47 90 (95.7%) Fail Fail 86 (91.5%)
rs1460239 0.46 90 (95.7%) Fail Fail 86 (91.5%)
rs1334334 0.24 Fail 89 (94.7%) Fail 87 (92.6%)
HCV8879897 0.46 Fail Fail Fail Fail
rs1713423 0.47 91 (96.8%) 86 (91.5%)* Fail 86 (91.5%)
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SNP MAF Genomic GenomePlex GenomiPhi REPLI-g
rs1035089 0.42 Fail Fail Fail Fail
rs794108 0.46 92 (97.9%) Fail 81 (86.2%) 87 (92.6%)
rs1925643 0.30 Fail 89 (94.7%) Fail Fail
rs995178 0.41 92 (97.9%) 89 (94.7%) 80 (85.1%) 86 (91.5%)
rs1129167 0.31 92 (97.9%) Fail Fail 87 (92.6%)
Based on auto-called results; * Failed after checking clusters.
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Appendix IX-E: Discordance rates of WGA-DNA on SNPlex (auto-call
genotypes)
GenomePlex GenomiPhi REPLI-gSNP MAF
No. called Discord. No. called Discord. No. called Discord
rs1419755 0.08 86 4 (4.7%) Fail Fail
rs354893 0.21 90 1 (1.1%) Fail 85 3 (3.5%)
rs729673 0.34 Fail 78 1 (1.3%) 82 3 (3.7%)
rs751340 0.41 83 43 (52%) Fail 86 4 (4.7%)
rs1323001 0.33 88 0 (0%) 78 0 (0%) 84 4 (4.8%)
rs1115261 0.44 Fail Fail 86 2 (2.3%)
rs1507213 0.46 Fail Fail 84 2 (2.4%)
rs1425151 0.24 Fail 78 0 (0%) 84 4 (4.8%)
rs2286216 0.22 89 78 (88%) Fail Fail
rs1016146 0.31 Fail Fail 84 3 (3.6%)
rs1861606 0.29 Fail Fail 83 2 (2.4%)
rs705681 0.48 Fail Fail Fail
rs984071 0.33 Fail Fail 82 5 (6.1%)
rs992690 0.16 Fail Fail 85 2 (2.4%)
rs1520483 0.38 Fail Fail 82 2 (2.4%)
rs1569125 0.32 Fail Fail Fail
rs288423 0.34 Fail 78 2(2.6%) 86 2 (2.3%)
rs961495 0.18 Fail 80 1 (1.3%) 85 1 (1.2%)
rs1388276 0.27 Fail 77 0 (0%) 85 3 (3.5%)
rs927221 0.12 85 27 (32%) 80 1 (1.3%) 86 5 (5.8%)
rs1378324 0.12 Fail Fail 83 4 (4.8%)
rs893613 0.48 Fail Fail 82 3 (3.7%)
rs879253 0.47 Fail Fail 86 1 (1.2%)
rs1156404 0.47 Fail Fail 83 3 (3.6%)
rs1460239 0.46 Fail Fail 83 1 (1.2%)
rs1713423 0.47 85 62 (73%) Fail 84 5 (6%)
rs794108 0.46 Fail 80 0 (0%) 86 3 (3.5%)
rs995178 0.41 89 2 (2.3%) 79 0 (0%) 85 4 (4.7%)
rs1129167 0.31 Fail Fail 86 5 (5.8%)
N=94 (90 for GenomePlex): Discordance rate, the proportion of genotypes which were different where
the sample had a genotype in both gDNA and the WGA method. Bold pass rates less than 90% or
failed in only one method and discordance 2% or more.
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Appendix IX-F: Types of discordances found with SNPlex (by WGA
method)
GenomePlex GenomiPhi REPLI-g
SNP MAF
Dropout Miscall Dropout Miscall Dropout Miscall
rs1419755 0.08 0 4 Fail
Fail
Fail
Failrs354893 0.21 1 0 Fail 1 2
rs729673 0.34 Fail 1 0 3 0
rs751340 0.41 Fail Fail 2 2
rs1323001 0.33 0 0 0 0 1 3
rs1115261 0.44 Fail Fail 1 1
rs1507213 0.46 Fail Fail 0 2
rs1425151 0.24 Fail 0 0 1 3
rs2286216 0.22 0 0 Fail 2 1
rs1016146 0.31 Fail Fail 1 1
rs1861606 0.29 Fail Fail 2 3
rs705681 0.48 Fail Fail 1 1
rs984071 0.33 Fail Fail 1 1
rs992690 0.16 Fail 2 0 2 0
rs1520483 0.38 Fail 1 0 1 0
rs1569125 0.32 Fail 0 0 0 3
rs288423 0.34 0 0 1 0 2 3
rs961495 0.18 Fail Fail 1 3
rs1388276 0.27 Fail Fail 1 2
rs927221 0.12 Fail Fail 1 0
rs1378324 0.12 Fail Fail 1 2
rs893613 0.48 Fail Fail 0 1
rs879253 0.47 Fail Fail 0 5
rs1156404 0.47 Fail 0 0 0 3
rs1460239 0.46 1 1 0 0 0 4
rs1713423 0.47 Fail Fail 0 5
Total 2 5 5 0 25 51
Discord: discordance rate, the proportion of genotypes which were the same where both gDNA (non-
amplified genomic DNA) and WGA method had calls. Bold rates failed quality control of call rate
>90%; discordance <2%. Average call rate of assays that passed.
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Appendix IX-G: Call rates of polymorphisms genotyped on OpenArray
(by WGA method)
SNP MAF Genomic GenomePlex Genomi-Phi REPLI-g
rs11209026 0.07 85 (91.4%) 85 (91.4%) 81 (87.1%) 78 (83.9%)
rs28665122 UK 81 (87.1%) Fail Fail 59 (63.4%)
rs6920220 0.18 90 (96.8%) 79 (84.9%) Fail 72 (77.4%)
rs10499194 0.18 91 (97.8%) 76 (81.7%) 82 (88.2%) 75 (80.6%)
rs7517847 0.5 90 (96.8%) 80 (86%) 83 (89.2%) 76 (81.7%)
rs12722489 0.16 90 (96.8%) 88 (94.6%) 84 (90.3%) 79 (84.9%)
rs13119723 0.15 89 (95.7%) Fail 82 (88.2%) 72 (77.4%)
rs6855911 0.31 91 (97.8%) 82 (88.2%) 84 (90.3%) 81 (87.1%)
rs2241880 0.46 89 (95.7%) Fail 81 (87.1%) 71 (76.3%)
rs12150220 0.47 91 (97.8%) Fail 84 (90.3%) 72 (77.4%)
rs2066845 0.02 84 (90.3%) Fail 85 (91.4%) Fail
rs1048990 0.12 91 (97.8%) 84 (90.3%) 86 (92.5%) 80 (86%)
rs1063857 0.34 91 (97.8%) 81 (87.1%) 83 (89.2%) 80 (86%)
rs216320 0.09 92 (98.9%) 87 (93.5%) 86 (92.5%) 80 (86%)
rs8177374 0.14 90 (96.8%) Fail 85 (91.4%) 79 (84.9%)
rs2476601 0.14 92 (98.9%) 86 (92.5%) 80 (86%) 80 (86%)
rs6822844 0.2 92 (98.9%) 82 (88.2%) 86 (92.5%) 79 (84.9%)
rs3761847 0.48 91 (97.8%) 78 (83.9%) 77 (82.8%) 66 (71%)
rs2233406 0.27 89 (95.7%) 82 (88.2%) 82 (88.2%) 74 (79.6%)
rs3138053 0.26 91 (97.8%) 80 (86%) 86 (92.5%) 73 (78.5%)
rs1050152 0.46 92 (98.9%) 86 (92.5%) 86 (92.5%) 79 (84.9%)
rs3087243 0.46 88 (94.6%) 82 (88.2%) 82 (88.2%) 76 (81.7%)
rs6897932 0.24 90 (96.8%) Fail 87 (93.5%) 81 (87.1%)
rs1990760 0.39 92 (98.9%) 85 (91.4%) 79 (84.9%) 76 (81.7%)
rs2076756 0.35 91 (97.8%) 80 (86%) 78 (83.9%) 77 (82.8%)
rs6502867 0.28 92 (98.9%) 80 (86%) 85 (91.4%) 78 (83.9%)
rs4965373 UK 92 (98.9%) Fail 80 (86%) 74 (79.6%)
rs8025174 UK 90 (96.8%) Fail Fail Fail
rs4790797 UK 89 (95.7%) 76 (81.7%) 72 (77.4%) 78 (83.9%)
rs41295061 UK 89 (95.7%) 85 (91.4%) 86 (92.5%) 79 (84.9%)
rs11597367 UK 89 (95.7%) Fail Fail Fail
rs10487888 0.47 91 (97.8%) 81 (87.1%) 85 (91.4%) 79 (84.9%)
N=93; PEP amplified DNA failed for all the assays. UK is unknown
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Appendix IX-H: Discordance rates of polymorphisms genotyped on
OpenArray (by WGA method)
GenomePlex GenomiPhi REPLI-g
Assay
No. called Discord No. called Discord No. called Discord
rs11209026 80 1 (1.3%) 76 1 (1.3%) 74 3 (4.1%)
rs28665122 Fail Fail 51 9 (17.7%)
rs6920220 76 3 (4%) Fail 69 7 (10.1%)
rs10499194 76 2 (2.6%) 81 1 (1.2%) 74 4 (5.4%)
rs7517847 79 4 (5.1%) 81 2 (2.5%) 74 7 (9.5%)
rs12722489 86 3 (3.5%) 82 4 (4.9%) 78 6 (7.7%)
rs13119723 Fail 79 1 (1.3%) 70 5 (7.1%)
rs6855911 81 3 (3.7%) 83 4 (4.8%) 80 8 (10%)
rs2241880 Fail 78 2 (2.6%) 70 5 (7.1%)
rs12150220 Fail 83 2 (2.4%) 72 5 (6.9%)
rs2066845 Fail 77 13 (17%) Fail
rs1048990 83 1 (1.2%) 85 1 (1.2%) 79 4 (5.1%)
rs1063857 80 1 (1.3%) 82 2 (2.4%) 79 4 (5.1%)
rs216320 87 1 (1.2%) 86 1 (1.2%) 80 1 (1.3%)
rs8177374 Fail 83 0 (0%) 77 4 (5.2%)
rs2476601 Fail 80 1 (1.3%) 80 1 (1.3%)
rs6822844 82 0 (0%) 86 1 (1.2%) 79 3 (3.8%)
rs3761847 77 3 (3.9%) 76 3 (4%) 65 9 (14%)
rs2233406 80 2 (2.5%) 79 2 (2.5%) 72 6 (8. 3%)
rs3138053 80 3 (3.8%) 85 1 (1.2%) 73 3 (4.1%)
rs1050152 86 4 (4.7%) 86 1 (1.2%) 79 4 (5.1%)
rs3087243 80 4 (5%) 79 3 (3.8%) 74 5 (6.8%)
rs6897932 Fail 85 8 (9.4%) 79 9 (11%)
rs1990760 85 3 (3.5%) 79 0 (0%) 76 6 (7.9%)
rs2076756 80 3 (3.8%) 78 1 (1.3%) 76 4 (5.3%)
rs6502867 80 2 (2.5%) 85 1 (1.2%) 78 2 (2.6%)
rs4965373 Fail 80 4 (5%) 74 4 (5.4%)
rs4790797 73 1 (1.4%) 69 2 (2.9%) 75 22 (29%)
rs41295061 82 2 (2.4%) 83 2 (2.4%) 76 2 (2.6%)
rs10487888 80 3 (3.8%) 84 2 (2.4%) 78 5 (6.4%)
rs8025174 and rs11597367 failed for all the WGA methods. Discord: discordance rate, the proportion
of genotypes which were the same where both gDNA (non-amplified genomic DNA) and WGA
method had calls. Bold rates failed quality control of call rate >90%; discordance <2%. Average call
rate of assays that passed.
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Appendix IX-I: Types of discordances on OpenArray
GenomePlex GenomiPhi REPLI-g
Assay
Dropout Miscall Dropout Miscall Dropout Miscall
rs11209026 0 1 0 1 2 1
rs28665122 Fail Fail 8 1
rs6920220 1 3 Fail 2 5
rs10499194 0 2 0 1 3 1
rs7517847 0 4 0 2 4 3
rs12722489 1 2 0 4 3 3
rs13119723 Fail 0 1 2 3
rs6855911 2 1 0 4 5 5
rs2241880 Fail 0 2 1 3
rs12150220 Fail 0 2 3 1
rs2066845 Fail 13 0 Fail
rs1048990 0 1 0 1 3 1
rs1063857 0 1 1 1 1 4
rs216320 0 1 0 1 0 1
rs8177374 Fail 0 0 2 2
rs2476601 Fail 0 1 0 1
rs6822844 0 0 0 1 0 3
rs3761847 1 2 1 2 7 2
rs2233406 0 2 0 2 4 1
rs3138053 2 1 0 1 2 1
rs1050152 0 4 0 1 2 2
rs3087243 1 3 0 3 0 5
rs6897932 Fail 0 8 4 5
rs1990760 2 1 0 0 5 1
rs2076756 0 3 0 1 2 2
rs6502867 1 1 0 1 1 1
rs4965373 Fail 0 4 2 2
rs4790797 0 1 0 2 1 21
rs41295061 0 2 0 2 0 2
rs10487888 1 2 0 2 3 2
Total 12 38 15 51 72 85
Dropout- allele dropout
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Appendix IX-J: Reproducibility of genotyping on OpenArray - comparison of duplicates
Genomic GenomePlex Genomi-Phi REPLI-g
SNP
Call rate Discord Call rate Discord Call rate Discord Call rate Discord
rs11209026 10 (83.3%) 1 (10%) 11 (91.7%) 0 (0%) 10 (83.3%) 0 (0%) 10 (83.3%) 1 (10%)
rs28665122 10 (83.3%) 1 (10%) Fail Fail Fail
rs6920220 9 (75%) 0 (0%) 11 (91.7%) 0 (0%) Fail 10 (83.3%) 1 (10%)
rs10499194 12 (100%) 0 (0%) Fail 11 (91.7%) 0 (0%) 11 (91.7%) 1 (9.1%)
rs7517847 11 (91.7%) 0 (0%) 11 (91.7%) 0 (0%) 12 (100%) 1 (8.3%) 9 (75%) 1 (11.1%)
rs12722489 12 (100%) 0 (0%) 11 (91.7%) 0 (0%) 12 (100%) 0 (0%) 9 (75%) 1 (11.1%)
rs13119723 11 (91.7%) 0 (0%) Fail 12 (100%) 0 (0%) 8 (66.7%) 0 (0%)
rs6855911 12 (100%) 0 (0%) 11 (91.7%) 0 (0%) 11 (91.7%) 1 (9.1%) 11 (91.7%) 0 (0%)
rs2241880 9 (75%) 0 (0%) Fail 10 (83.3%) 0 (0%) 7 (58.3%) 1 (14.3%)
rs12150220 11 (91.7%) 0 (0%) Fail 12 (100%) 0 (0%) 11 (91.7%) 2 (18.2%)
rs1048990 11 (91.7%) 0 (0%) 11 (91.7%) 0 (0%) 12 (100%) 0 (0%) 10 (83.3%) 0 (0%)
rs1063857 12 (100%) 0 (0%) 12 (100%) 0 (0%) 12 (100%) 0 (0%) 11 (91.7%) 2 (18.2%)
rs216320 11 (91.7%) 0 (0%) 12 (100%) 0 (0%) 12 (100%) 0 (0%) 10 (83.3%) 0 (0%)
rs8177374 12 (100%) 0 (0%) Fail 12 (100%) 0 (0%) 9 (75%) 0 (0%)
rs2476601 12 (100%) 0 (0%) 11 (91.7%) 0 (0%) 10 (83.3%) 0 (0%) 10 (83.3%) 0 (0%)
rs6822844 12 (100%) 0 (0%) 9 (75%) 0 (0%) 12 (100%) 0 (0%) 10 (83.3%) 0 (0%)
rs3761847 11 (91.7%) 0 (0%) 10 (83.3%) 0 (0%) 9 (75%) 0 (0%) 8 (66.7%) 0 (0%)
rs2233406 12 (100%) 1 (8.3%) 12 (100%) 0 (0%) 11 (91.7%) 0 (0%) 9 (75%) 2 (22.2%)
rs3138053 10 (83.3%) 0 (0%) Fail 12 (100%) 0 (0%) Fail
rs1050152 12 (100%) 0 (0%) 12 (100%) 0 (0%) 12 (100%) 0 (0%) 11 (91.7%) 0 (0%)
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Genomic GenomePlex Genomi-Phi REPLI-g
SNP
Call rate Discord Call rate Discord Call rate Discord Call rate Discord
rs3087243 9 (75%) 0 (0%) 12 (100%) 0 (0%) 10 (83.3%) 0 (0%) 8 (66.7%) 0 (0%)
rs6897932 11 (91.7%) 1 (9.1%) Fail 11 (91. 7%) 0 (0%) 10 (83.3%) 1 (10%)
rs1990760 11 (91.7%) 0 (0%) 10 (83.3%) 0 (0%) 11 (91. 7%) 0 (0%) 11 (91.7%) 0 (0%)
rs2076756 11 (91.7%) 1 (9.1%) 10 (83.3%) 0 (0%) 9 (75%) 0 (0%) Fail
rs6502867 11 (91.7%) 0 (0%) 9 (75%) 0 (0%) 11 (91. 7%) 0 (0%) 9 (75%) 1 (11.1%)
rs4965373 10 (83.3%) 0 (0%) Fail 11 (91. 7%) 0 (0%) 10 (83.3%) 1 (10%)
rs4790797 9 (75%) 0 (0%) Fail 8 (66. 7%) 0 (0%) 9 (75%) 4 (44.4%)
rs41295061 11 (91.7%) 0 (0%) 11 (91.7%) 0 (0%) 11 (91. 7%) 0 (0%) 11 (91.7%) 0 (0%)
rs10487888 11 (91.7%) 0 (0%) 10 (83.3%) 0 (0%) 11 (91. 7%) 0 (0%) 11 (91.7%) 1 (9.1%)
Average 90.8% 5 (1.6%) 206
(90.4%)
0 (0%) 299 (90%) 2 (0.67) 253 (81.1%) 20 (8.03%)
Discord: discordance rate, the proportion of genotypes which were the same where both gDNA (non-amplified genomic DNA) and WGA method had calls.
Bold rates failed quality control of call rate >90%; discordance <2%. Average call rate of assays that passed.
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Appendix X-K: iPLEX gold vs Illumina genome-wide association data
(based on SEARCH and UKOPS cases only)
SEARCH UKOPS
SNP
MAF
Total no. of
genotypes Discord. (%)
Total no. of
genotypes Discord. (%)
rs6788750 0.47 493 2 (0.4%) 469 17 (3.6%)
rs7650365 0.48 811 4 (0.5%) 452 12 (2.7%)
rs2280201 0.08 821 0 (0%) 471 7 (1.5%)
rs2394644 0.13 823 1 (0.1%) 479 7 (1.5%)
rs3181175 0.21 834 4 (0.5%) Fail
rs3783194 0.14 835 4 (0.5%) 486 6 (1.2%)
rs3923086 0.39 818 3 (0.4%) 473 20 (4.2%)
rs793477 0.12 817 7 (0.9%) 468 14 (3%)
rs12494994 0.2 829 1 (0.1%) Fail
rs9860614 0.16 832 8 (1%) 489 7 (1.4%)
rs10999147 0.08 835 2 (0.2%) Fail
rs3181328 0.06 820 1 (0.1%) 464 7 (1.5%)
rs2282657 0.35 832 2 (0.2%) 489 13 (2.7%)
rs7189819 0.33 815 1 (0.1%) 471 30 (6.4%)
rs4541111 0.44 814 0 (0%) 460 20 (4.4%)
rs4791171 0.3 828 1 (0.1%) Fail
Discord- discordance; bold: discordance rate >2%
